Healthy Extracts Inc. - Form 10-K SEC filing

0001096906-24-000706.txt : 20240401 0001096906-24-000706.hdr.sgml : 20240401 20240401170438 ACCESSION NUMBER: 0001096906-24-000706 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 96 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240401 DATE AS OF CHANGE: 20240401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHY EXTRACTS INC. CENTRAL INDEX KEY: 0001630176 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 472594704 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55572 FILM NUMBER: 24810696 BUSINESS ADDRESS: STREET 1: 7375 COMMERCIAL WAY STREET 2: SUITE 125 CITY: HENDERSON STATE: NV ZIP: 89011 BUSINESS PHONE: 702-505-0471 MAIL ADDRESS: STREET 1: 7375 COMMERCIAL WAY STREET 2: SUITE 125 CITY: HENDERSON STATE: NV ZIP: 89011 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHLY EXTRACTS INC. DATE OF NAME CHANGE: 20210219 FORMER COMPANY: FORMER CONFORMED NAME: GREY CLOAK TECH INC. DATE OF NAME CHANGE: 20150108 10-K 1 hyex-20231231.htm HEALTHY EXTRACTS INC. - FORM 10-K SEC FILING Healthy Extracts Inc. - Form 10-K SEC filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-K

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2023

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from_____________ to _____________.

Commission file number 000-55572

Healthy Extracts Inc.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of

incorporation or organization)

47-2594704

(I.R.S. Employer

Identification No.)

7375 Commercial Way, Suite 125

Henderson, NV

(Address of principal executive offices)

89011

(Zip Code)

Registrant’s telephone number, including area code (720) 463-1004

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

None

N/A

None

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, par value $0.001

(Title of class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S. C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes ☐ No ☒

The aggregate market value of the voting and non-voting common equity held by non-affiliates as of April 1, 2024 was $18,465,134, based on the closing price of $6.23 on June 30, 2023.

As of April 1, 2024, there were 2,963,906 shares of common stock, par value $0.001, issued and outstanding.

Documents Incorporated by Reference

None.

HEALTHY EXTRACTS INC.

FORM 10-K ANNUAL REPORT

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023

TABLE OF CONTENTS

PART I

ITEM 1	BUSINESS	1
ITEM 1A	RISK FACTORS	22
ITEM 1B	UNRESOLVED STAFF COMMENTS	40
ITEM 1C	CYBERSECURITY	40
ITEM 2	PROPERTIES	41
ITEM 3	LEGAL PROCEEDINGS	41
ITEM 4	MINE SAFETY DISCLOSURES	41

PART II

ITEM 5	MARKET FOR REGISTRANT ’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES	42
ITEM 6	RESERVED	43
ITEM 7	MANAGEMENT ’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	44
ITEM 7A	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	49
ITEM 8	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA	50
ITEM 9	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	51
ITEM 9A	CONTROLS AND PROCEDURES	51
ITEM 9B	OTHER INFORMATION	53
ITEM 9C	DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS	53

PART III

ITEM 10	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE	54
ITEM 11	EXECUTIVE COMPENSATION	59
ITEM 12	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	61
ITEM 13	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE	63
ITEM 14	PRINCIPAL ACCOUNTING FEES AND SERVICES	66

PART IV

ITEM 15	EXHIBITS AND FINANCIAL STATEMENT SCHEDULES	66
ITEM 16	FORM 10-K SUMMARY	70

PART I

Cautionary Statement Regarding Forward Looking Statements

This Annual Report includes forward-looking statements within the meaning of the Securities Exchange Act of 1934 (the “Exchange Act”). These statements are based on management’s beliefs and assumptions, and on information currently available to management. Forward-looking statements include the information concerning possible or assumed future results of operations of the Company set forth under the heading “Management’s Discussion and Analysis of Financial Condition or Plan of Operation.” Forward-looking statements also include statements in which words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “consider” or similar expressions are used.

Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions. The Company’s future results and shareholder values may differ materially from those expressed in these forward-looking statements. Readers are cautioned not to put undue reliance on any forward-looking statements.

ITEM 1 – BUSINESS

Our Business

We are a platform for acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals. Our proprietary and patented products target select high-growth categories within the multibillion-dollar nutraceuticals market, such as heart, brain and immune health.

Nutraceuticals are generally considered to be substances that beyond their nutritional value can be used to achieve a benefit for an existing physiological condition or provide protection against potential ailments. Our current principal geographic markets are customers in the United States looking for nutraceutical products focused on their own heart and brain health and immune support. Our products have not been evaluated by the U.S. Food and Drug Administration (“FDA”) or any similar regulatory body for safety and efficacy.

The primary philosophy behind nutraceuticals is the focus on prevention and the body’s ability to use natural rather than artificially derived substances to treat disease or dysfunction — or as the Greek physician and father of modern medicine Hippocrates famously espoused, “Let food be your Medicine.”

Today, the role of nutraceuticals in human health and wellbeing has become one of the most active and important areas of scientific investigation, with the latest findings presenting wide-ranging implications for consumers, health care providers, regulators, nutritional supplement producers and distributors. Our mission is to acquire or create products with health and performance benefits that have mass consumer appeal.

Guided by this mission, our first two acquisitions (in 2019 and 2020, respectively) formed our current operating subsidiaries, Bergamet NA, LLC (“Bergamet”), which offers nutraceutical heart and immune health products, and Ultimate Brain Nutrients, LLC (“UBN”), which offers nutraceutical products for brain health.

Based on published research from third-party sources, we believe our Bergamet products have been shown to support heart health, support immune response, and address metabolic syndrome. Our UBN brain health formulations have been in development for more than 20 years, over which time its effects have been supported by third-party research studies.

1

Our Markets

The overall nutraceutical market is growing at a 7.8% compounded annual growth rate (“CAGR”) and is expected to reach $441 billion by 2026, according to ReportLinker. Driving this growth are multiple factors, including changing lifestyles, growing consumer desire to move away from expensive prescription medicine and undesirable side effects, aging population and increased life expectancy. Our current principal geographic markets are customers in the United States looking for nutraceutical products focused on their own heart and brain health and immune support.

A growing self-care trend is also driving strong demand for nutraceuticals. Given increasingly hectic lifestyles, and the lack of time for preparing and consuming the required nutrients through a regular diet, the desire to replenish or augment essential nutrients with nutraceuticals is also increasing.

Our BergaMet all-natural Citrus Bergamot SuperFruitTM formulations address an expanding global heart health ingredients market that is projected to grow at a 4.6% CAGR to reach $55.3 billion by 2027, according to ResearchAndMarkets. This growth is largely being driven by concerns about cardiovascular disease, which remains the leading cause of premature death globally according to the World Health Organization.

Our UBN products tap the fast-growing market for brain health, which is growing at a 9.4% CAGR to reach $15.7 billion by 2030, according to Grandview Research. This market is being driven in part by the rise in the aging adult population in North America and Europe, with consumers increasingly using brain health supplements to prevent or treat mental conditions such as memory loss or dementia, or to improve mental cognition, energy and focus.

Our UBN RELIEF product for migraine suffers also address a huge market opportunity, with an estimated 39 million people suffering from migraine headaches in the U.S. and 1 billion worldwide, according to the American Migraine Foundation.

Our Competitive Strengths

We believe the following our are competitive strengths:

High Gross Margins. We have high gross margin categories, with our gross margin ranging from 60% to 80%, depending on product and market channel.

Nutraceutical Delivery System. Through our exclusive U.S. and Canada licensing and manufacturing agreement with Gelteq Pty Ltd. (“Gelteq”), a third party global leader in ingestible gel technology, we believe we are able to offer a gel-pack delivery system that our competition in North America cannot provide. Gelteq provides a customizable platform for supplement delivery, in that each gel formulation is tailored to solve a particular problem and deliver a specific outcome.

2

Higher BPF Content. As the leading North American provider of the world’s highest strength Citrus Bergamot SuperFruit, our heart and immune products have specific advantages. For example, our BergaMet PRO+ product has 47% Bergamot Polyphenolic Fraction Gold (“BPF Gold”) potency as compared to our closest competitor at only 38% BPF. BPF is an extract derived from the fruit’s juice, peel, and pulp, is comprised of five polyphenols (Naringin, Neohesperidin, Brutieridin, Melitidin, and Neoeriocitrin), and its potency is determined by the concentration of these five polyphenols achieved during the extraction process. The potency of BPF is widely compared by Bergamot users in making their purchase decisions because a higher potency may lead to greater benefits, and is generally considered more desirable in the marketplace.

Backed by published research from third-parties, our citrus bergamot has been shown to support heart health, support immune response, and address metabolic syndrome.

Our Competitive Challenges

We compete with other manufacturers, distributors and marketers of vitamins, minerals, herbs, and other nutritional supplements both within and outside the U.S. The nutritional supplement industry is highly competitive, and we expect the level of competition to remain high. Our ability to scale our business and grow our revenue depends on our ability to maintain the value and reputation of our brands in the face of this competition.

The nutritional supplement industry is highly fragmented and competition for the sale of nutritional supplements comes from many sources. Such products are sold primarily through retailers (drug store chains, supermarkets, and mass market discount retailers), health and natural food stores, and direct sales channels (network marketing and internet sales).

The nutritional supplement industry is highly competitive, and we expect the level of competition to remain high over the near term. We do not believe it is possible to accurately estimate the total number or size of our competitors. The nutritional supplement industry has undergone some consolidation in the recent past and we expect that trend may continue in the near term.

We have a limited operating history in our current business, we are not profitable, and we do not expect to be profitable in the near future. There is no assurance our future operations will result in revenues sufficient to obtain or sustain profitability.

We face intense competition from competitors that are larger, more established and that possess greater resources than we do, and if we are unable to compete effectively, we may be unable to gain sufficient market share to sustain profitability. If our competitor’s market nutritional supplement products that are less expensive, safer or otherwise more appealing than our current and potential products, or that reach the market before our current and potential products, we may not achieve operational or financial success. The market may choose to continue utilizing existing products for any number of reasons, including familiarity with or pricing of these existing products. The failure of any of our products to compete with products marketed by our competitors would impair our ability to generate revenue, which would have a material adverse effect on our future business, financial condition, results of operations, and cash flows. Our competitors may:

·develop and market products that are less expensive, safer, or otherwise more appealing than our products;

·commercialize competing products before we or our partners can launch our products; and

3

·initiate or withstand substantial price competition more successfully than we can.

Our Financial Condition and Ability to Continue as a Going Concern

Our net loss from inception to December 31, 2023 was $18,399,673, and we had only very limited cash resources at December 31, 2023 of $19,441. Our financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Our auditor’s report reflects that our ability to continue as a going concern is dependent upon our ability to raise additional capital from the sale of common stock and, ultimately, the achievement of significant operating revenues. If we are unable to continue as a going concern, our business will fail and stockholders will lose their investment in our company. Even after competition of this offering, we will be required to seek additional capital to fund future growth and expansion. No assurance can be given that such financing will be available or, if available, that it will be on commercially favorable terms. Moreover, financing will likely be dilutive to our stockholders.

Future Anticipated Growth Drivers

New Sales Channels and Product Launches

In order to drive continued sales growth and leverage our growing customer base, we are planning to expand our product portfolio to include supplements that support gut health (the balance between helpful and harmful bacteria and yeast in the digestive system) as well as introduce more products in gel-pack format. Our gut health products are ready to be manufactured but have not yet been introduced to the market.

We plan to further expand our sales channels as well as our portfolio of natural formulations for heart and brain health and other indications.

Strategic Acquisitions

The market for nutraceutical products is highly fragmented, which create many acquisition opportunities. As part of our primary mission, we will continue to evaluate potential acquisition opportunities that could expand our product portfolio and benefit from our marketing strength and multi-channel distribution.

Employees

On the Healthy Extracts holding company level, our employees are comprised of our company’s two officers, each of which is a full-time employee. Our BergaMet subsidiary has two full-time employees. Our UBN subsidiary currently does not have its own employees since it uses outside contract help on an as-needed basis, with management provided by our officers.

We anticipate all of our employees will continue to work for us for the foreseeable future. We plan to hire appropriate personnel on an as-needed basis and utilize the services of independent contractors as needed.

4

Corporate History

We were incorporated on December 19, 2014 in the State of Nevada.

On February 4, 2019, we acquired BergaMet NA, LLC, a Delaware limited liability company (“BergaMet”). BergaMet is a wholly-owned subsidiary through which we conduct our nutraceuticals business. As a result of the acquisition, Jay Decker became our majority shareholder. The shares of common stock issued in the acquisition were equal to approximately 80.1% of our outstanding common stock immediately following the closing.

On April 3, 2020, we acquired Ultimate Brain Nutrients, LLC, a Delaware limited liability company (“UBN”). UBN is a wholly-owned subsidiary through which we conduct our plant-based neuro-products business. As a result of the acquisition, Jay Decker became a significantly larger shareholder. The shares of common stock issued in the acquisition were equal to approximately 42.5% of our outstanding common stock immediately following the closing.

Corporate Information

Our corporate headquarters are located at 7375 Commercial Way, Suite 125, Henderson, NV 89011, and our telephone number is (702) 463-1004. Our websites are www.healthyextractsinc.com, www.bergametna.com, and www.tryubn.com. Information contained on our websites is not incorporated into, and does not constitute any part of, this annual report.

Recent Developments

Reverse Stock Split

On August 21, 2023, our majority shareholders approved by written consent, declared it advisable and in our best interest, to amend our Articles of Incorporation to (a) effect a reverse split of our outstanding Common Stock within a range of 1-for-25 to 1-for-150, the exact ratio and timing to be determined by our board of directors (“Board”) no later than December 31, 2023, and (b) reduce our authorized common stock to fifty million (50,000,000) shares. On August 22, 2023, our Board of Directors approved the same stock split range and decrease in authorized common stock. On December 29, 2023, we effectuated a 1-for-120 reverse split of our common stock and decreased our authorized common stock to fifty million (50,000,000) shares. Unless specifically provided otherwise herein, all share numbers and prices in this Annual Report reflect the effectiveness of the 1-for-120 reverse stock split of our Common Stock.

Summary of Risk Factors

There are a number of risks related to our business and our common stock that you should consider. You should carefully consider all the information presented in the section titled “Risk Factors” in this Annual Report. Some of the principal risks related to our business include the following:

•We rely on a single supplier relationship for licensing and manufacturing, and the termination of that agreement could have material effect on the cost of our products and the manufacturing of our finished goods.

•We have a limited operating history in our current business, we are not profitable, and we do not expect to be profitable in the near future. There is no assurance our future operations will result in revenues sufficient to obtain or sustain profitability. If we cannot generate sufficient revenues to operate profitably, we may suspend or cease operations.

5

•We answered a warning letter from the FDA in November 2022 regarding one of our products.

•Our success is linked to the size and growth rate of the vitamins, minerals and supplements market and an adverse change in the size or growth rate of that market could have a material adverse effect on us;

•Our success depends on our ability to maintain the value and reputation of our brands;

•We may fail to attract, acquire or retain customers at our current or anticipated future growth rate, or may fail to do so in a cost-effective manner, which would adversely affect our business, financial condition and results of operations;

•If we are unable to anticipate customer preferences and successfully develop new and innovative products in a timely manner or effectively manage the introduction of new or enhanced products, then our business may be adversely affected;

•We are highly dependent upon consumers’ perception of the safety, quality, and efficacy of our products as well as similar products distributed by other companies in our industry, and adverse publicity and negative public perception regarding particular ingredients or products or our industry in general could limit our ability to increase revenue and grow our business;

•We face intense competition from competitors that are larger, more established and that possess greater resources than we do, and if we are unable to compete effectively, we may be unable to gain sufficient market share to sustain profitability;

•Because we depend on outside suppliers with whom we do not have long-term agreements for raw materials, we may be unable to obtain adequate supplies of raw materials for our products at favorable prices or at all, which could result in product shortages and back orders for our products, with a resulting loss of sales and profitability;

•A disruption in the service, a significant increase in the cost of our primary delivery and shipping services for our products or a significant disruption at shipping ports could adversely affect our business;

•We will require additional financing in the future, and we can provide no assurance that such funding will be available on terms that are acceptable to us, or at all.

•One of our shareholders and his adult children will continue to own a significant percentage of our Common Stock and will maintain the ability to substantially influence all matters submitted to stockholders for approval.

•We are dependent upon our lenders for financing to execute our business strategy and meet our liquidity needs, and the lack of adequate financing could negatively impact our business;

6

•We and our suppliers are subject to numerous laws and regulations that apply to the manufacturing and sale of nutritional supplements, and compliance with these laws and regulations, as they currently exist or as modified in the future, may increase our costs, limit or eliminate our ability to sell certain products, subject us or our suppliers to the risk of enforcement action, or otherwise adversely affect our business, results of operations and financial condition; and

•Our success is dependent on the accuracy, reliability, and proper use of sophisticated and dependable information processing systems and management information technology and any interruption in these systems could have a material adverse effect on our business, financial condition and results of operations.

These and other risks are more fully described in the section titled “Risk Factors” in this Annual Report. If any of these risks actually occurs, our business, financial condition, results of operations, cash flows and prospects could be materially and adversely affected. As a result, you could lose all or part of your investment in our common stock.

As used in this annual report, the term “success” generally means (unless the specific context requires otherwise) our ability to establish and grow our brand, scale our manufacturing, marketing and sales activities, integrate acquired products or internally develop new products, grow our revenues and, ultimately, establish cash flow positive and profitable operations.

Overview

Our current principal geographic markets are customers in the United States looking for nutraceutical products focused on their own heart and brain health and immune support. Our products have not been evaluated by the FDA or any similar regulatory body for safety and efficacy.

The term “nutraceutical” is derived from the combination of the words “nutrient,” which means a nourishing food component, and “pharmaceutical,” meaning a medical drug. The term was coined in 1989 by Stephen DeFelice, founder and chairman of the Foundation for Innovation in Medicine.

Nutraceuticals are generally considered to be substances that beyond their nutritional value can be used to achieve a benefit for an existing physiological condition or provide protection against potential ailments. Nutraceuticals may be used to improve health, delay the aging process, help prevent chronic disease, increase life expectancy, or support the structure or function of the body.

In the U.S., nutraceutical products are regulated as drugs, food ingredients and dietary supplements. The term is not defined the same in all countries but is usually defined as a product isolated from foods and generally sold in medicinal forms not usually associated with food.

The primary philosophy behind nutraceuticals is the focus on prevention and the body’s ability use natural rather artificially derived substances to treat disease or dysfunction — or as the Greek physician and father of modern medicine Hippocrates famously espoused, “Let food be your Medicine.”

7

for consumers, health care providers, regulators, nutritional supplement producers and distributors. Our mission is to acquire or create products with health and performance benefits that have mass consumer appeal.

Guided by this mission, our first two acquisitions (in 2019 and 2020, respectively) formed our current operating subsidiaries, Bergamet, which offers nutraceutical heart and immune health products, and UBN, which offers nutraceutical products for brain health.

Our Products

Heart & Immune Health

Our products which are intended to promote heart and immune health have been developed by our BergaMet subsidiary. Bergamot Polyphenolic Fraction Gold (“BPF”) is the active ingredient in these products, and our 47% BPF Bergamet products are currently the only heart health supplements distributed in North America that contain Citrus Bergamot SuperFruit. This exclusive superfruit is of the bergamot orange family, a fragrant citrus fruit about the size of a common orange but with a yellow or green color similar to a lime, depending on its ripeness.

Our Citrus Bergamot SuperFruit varietal, with its 47% BPF, has a high concentration of polyphenols and flavonoids of the citrus bergamia or bergamot orange fruit species. BPF is comprised of five polyphenols (Naringin, Neohesperidin, Brutieridin, Melitidin, and Neoeriocitrin).

BergaMet currently holds the rights to distribute Citrus Bergamot SuperFruit 47% BPF products in the online and direct to consumer channels in the U.S. and Canada pursuant to a supply agreement with H&AD S.r.L., an Italian limited company, which we entered into on January 1, 2019 and amended on November 1, 2021. The supply agreement has a term of five years and is renewable for up to four additional and successive three-year terms. Through 2023, we have paid H&AD a total of approximately $1.2 million for BPF product. The agreement is mutually exclusive in that (i) we cannot purchase BPF from any third-party, sell or distribute any similar product in the territory, sell the product outside the territory, or produce the product ourselves, and (ii) H&AD will not supply or sell the product to any third-party in the territory. Each party may terminate the agreement upon a breach by the other party.

Bergamot is a rare citrus fruit native to the Calabrian region of Southern Italy. Due to the fruit’s sensitivity to certain weather and soil conditions, this region accounts for 80 percent of the worldwide production of bergamot. Bergamot has been used for decades in the Calabrian regions for its beneficial effects in promoting overall health, particularly in support of cholesterol, cardiovascular, and metabolic health.

Citrus bergamot contains five antioxidant polyphenols in unusually concentrated amounts, which are believed to help protect the human body’s trillions of cells from free radical damage. The juice and albedo of bergamot has a profile of flavanoid and glycosides, such as neoeriocitrin, neohesperidin, naringin, rutin, neodesmin, rhoifolin, and poncirin.

Naringin has been shown to be beneficial in animal models of atherosclerosis, while neoeriocitrin and rutin have been found to exhibit a strong capacity to prevent low-density lipoprotein (“LDL”) from

8

oxidation. Importantly, bergamot juice is rich in brutieridine and melitidine with an ability to inhibit HMG-CoA reductase, which inhibits the liver’s ability to produce LDL, resulting in reduced cholesterol levels in liver cells.

Bergamot Products

We develop, manufacture and distribute bergamot-based products in tablet and capsule form under the following brands:

·BergaMet Pro+

·BergaMet Mega+O

·BergaMet HERHEART

·BergaMet Cholesterol Command

·BergaMet SPORTSHEART

·BergaMet CLINICAL IMMUNE

All of our BergaMet products are vegan friendly, non-GMO and gluten-free, and produced and tested by certified U.S. facilities, all as represented to us by our supplier, H&AD. Our HerHeart, Cholesterol Command, and Pro+ products are vegan, non-GMO, and gluten-free, as represented to us by our supplier, Norax Supplements.

In published research from third-party sources, our Citrus Bergamot has been shown to support heart health, support immune response and address metabolic syndrome. Our Citrus Bergamot has also been shown to naturally reduce cholesterol by lowering LDL and increasing high-density lipoprotein (“HDL”).

According to the CDC, nearly 94 million U.S. adults aged 20 years or older have high cholesterol levels that puts them at risk of heart disease. Every year an estimated 35 million people are prescribed statins to lower cholesterol, according to drugs.com, but these drugs can cause numerous negative side effects.

A peer-reviewed study demonstrated that the naturally-derived, bergamot polyphenolic fraction (BPF) contained in our Citrus Bergamot can significantly enhance the beneficial effects of rosuvastatin, one of the most prescribed drugs for reducing cardiometabolic risk.

9

Brain Health

Our UBN subsidiary develops plant-based health technology neuro-products that have been shown to improve brain health, including memory, cognition, focus and neuro-energy. UBN's mission is to naturally create better lifestyles with superior health technology and products.

UBN’s KETONOMICS® proprietary formulations, which are intended to enhance brain activity, focus, headache and cognitive behavior, provide many sales and intellectual property licensing opportunities.

UBN’s all-natural, sugar-free and caffeine-free proprietary formulations are the result of 20 years of scientific research by third-parties and are positioned to provide consumer neuro-products that are natural brain solutions.

UBN’s KETONOMICS® supplementation has also been studied in sports physiology, with specific regard to its potential benefits for competitive performance and endurance.

UBN offers several proprietary products, with four patent-pending formulations and two patents issued covering brain activity, focus, headache and cognitive behavior.

UBN Products

We have launched four brain health products based upon our proprietary Fuel4Thought® (F4T®) formulations. These brain health products are sold under the following product labels:

·UBN ACTIVATE: a proprietary natural formulation that has been demonstrated to increase key brain activity by as much as 46%. This product is sold direct-to-consumer via our UBN website, either as a singular sale or monthly subscription.

·UBN RELIEF: intended for migraine sufferers, this proprietary, patent-pending natural formulation has been shown to provide relief from symptoms often associated with migraine headaches, while also increasing brain and cognitive activation. This product is sold direct-to consumer on our website as singular sale or monthly subscription, as well as sold in the retail marketplace.

·Brain Activate - Gel, a proprietary gel pack formulation which was launched in collaboration with and under the brand name of our top brand influencer, Whitney Johns. The concentrated natural gel formulation provides the perfect “brain food” for sustained mental energy and attention without added sugars. It is sold direct-to-consumer on whitneyjohns.com as a singular sale or by subscription. The gel packs are developed by Gelteq, a global leader in ingestible gel technology. Gelteq gels offer a super-convenient way to consume substances that have a positive impact on mental skills (sometimes referred to as “nootropics”) and other nutrients.

·Brain Activate - ENERGY Gel: a proprietary gel pack nootropic formulation with caffeine. It is specially formulated to support focus, memory, cognition, mood and brain health, as well as reduce brain fog and support natural sleep patterns. The product was developed and launched in collaboration with Whitney Johns, and is sold direct-to-consumer on whitneyjohns.com as a singular sale or monthly subscription.

10

Our F4T® formulation includes C8 MCT (derived from coconut extract), Nuementix (spearmint), FloraGLO, and highly concentrated medium chain triglycerides, F4T® MCT, which are derived from our patented extraction process. F4T® C8 MCTs have been shown to elevate the level of ketones in the brain. “C8” refers to the eight-carbon chain that characterizes this specific fatty acid. As a result, manufacturers have taken to purifying MCT oil derived from coconuts so it contains only caprylic acid. That's because caprylic acid (C8) seems to be the most metabolically active medium-chain fatty acid.

The F4T® formulation also includes a proprietary blend of other key ingredients, including a naturally sourced nootropic spearmint extract that is demonstrated to support mental focus during the day without disrupting sleep at night and a protective antioxidant found naturally in the body that helps the brain function optimally and promotes better mood and sleep habits. It also includes a natural marigold extract that is scientifically shown to block blue light and replenish lutein, which is critical for optimum eye health. The antioxidant function comes from the Neumentix that contains a combination of polyphenols from Kemin’s proprietary spearmint extract. The complex contains rosmarinic, salvianolic, lithospermic and caftaric acids (and more) that act as antioxidants in the brain. The formulation has been in development for more than 20 years, over which time it has gained support by third-party research studies.

The above EEG brain scan images are from a study that showed a 46% increase in brain activation after a subject consumed our active ingredients. The concentrated formulation provides the perfect “brain food” for sustained mental energy and attention. There can be no assurance that our formulations will produce the same results as this study using just our active ingredients.

The brain activation described above is measured by electroencephalographic (EEG) electrodes placed on the surface of the skull overlying the major anatomic lobes of the brain (frontal, parietal, temporal, occipital). The activation is measured in microvolts of energy and reflects brain physiological function; the higher the voltage, the higher the functional activity. Functional magnetic resonance imaging (fMRI) of the brain has documented correlation between performance and health tasks and the “lighting up” of the relevant brain cortex areas. Activation of the following areas correlate with the related desirable brain function: frontal lobe - cognition, integration; parietal lobe - sensory, awareness, spatial orientation; temporal lobe - motor, language, memory; occipital lobe - visual function. The subjects in our intervention groups consumed the active supplement containing our formulation of C8 MCT, Neumentix, and Floragio. In the acute study, the assessments were made 90 minutes after consumption and in the long-term study, the assessments were made 30 days after consumption. Study one (acute) had 11 subjects (8 intervention and 3 control) and study two (long term) had 18 subjects (13 intervention and 5 control). Subjects underwent EEG voltage measurement with auditory reaction time (WaviMed System) and vision and trail making testing (Senaptec Sensory Station). Trail making testing (“TMT”), while not using sample sizes believed to be statistically significant, is one of the most widely used tests for cognitive impairment, is believed to measure several functions, particularly cognitive flexibility, alternating attention, sequencing, visual search,

11

and motor speed. Brain activation improved in 20 of the 21 intervention group subjects with voltage increases ranging from no change to 200%, average 46% increase. This activation level correlated positively with improvements in reaction time, vision and trail making tests. Parameter changes were statistically significant with a strong improvement trend for the auditory reaction time measures. The tests were conducted by Dr. Neil Wolkodoff in a strict prospective, randomized manner. The results were double blinded with regard to intervention versus placebo group results and all data was deposited into a blind pool until completion of the trials when the results were unblinded and statistically analyzed. An independent third party transposed the EEG voltage readings into a computer generated “brain image” for peer reviewed publication purposes. No caffeine, steroids or other stimulants were consumed by any study subjects.

We are in the development phase for new products focused on Alzheimer’s disease and dementia. We are finalizing development of additional non-FDA approved, brain health products which focus on dementia and Alzheimer’s disease. We expect to have our development processes completed in 2024.

Gel-Pack Exclusive Licensing and Manufacturing Agreement

In August 2021, we signed an exclusive U.S. and Canada licensing and manufacturing agreement with Gelteq, a third party developer of ingestible gel technology, under which we agreed to develop and manufacture an advanced oral delivery system for our plant-based heart, immune and brain health formulations. The agreement has a three-year term and can be terminated by either party in the event of a breach, and contains a minimum order amount of 500,000 units of product (of which 250,000 units must have been purchased during the first 12 months). The agreement is mutually exclusive in that Gelteq is to be the exclusive manufacturer of all gel products that contain bergamot by us in the territory, and that they will not manufacture gels containing bergamot for any other company in the territory. Finally, we paid Gelteq a license fee of $150,000 and 5% of the total price of products purchased by us.

Through this agreement we secured the exclusive rights to use Gelteq’s gelification process in the U.S. and Canada for the development and marketing of natural ingestible gels that contain our Citrus Bergamot or UBN ingredients. Among the many benefits, we believe our new exclusive gel pack format will make our products easier and more convenient to consume.

Citrus Bergamot has been traditionally taken in tablet form which presents several drawbacks. Tablets require a liquid to facilitate swallowing or prevent choking (which still may occur), and proper digestion and absorption can sometimes be challenging. The liquid extract form of Bergamot is typically not preferred due to its unpleasant bitter taste.

The proprietary ingredients used in in our UBN product line are typically available in powder form, with this requiring it be mixed with a liquid in a separate container. This can be messy and inconvenient for today’s on-the-go lifestyles. In contrast, a single-serving, gel pack containing our health-promoting formulations can be easily consumed anytime, anywhere with no liquid or mixing required.

We also believe this gel-based oral delivery technology can be superior to pills, tablets, powders and other delivery methods in terms of greater bioavailability, targeted release times and pleasant taste, while reducing the risk of choking.

12

We have launched two gel pack products using our patent-protected Fuel4Thought® (F4T®) formulation with Whitney Johns, including Brain Activate - Gel (without caffeine) and Brain Activate - ENERGY Gel. We plan to next introduce heart and immune health gel packs that exclusively feature Citrus Bergamot SuperFruit in 2024.

Our Markets

The overall nutraceutical market is growing at a 7.8% CAGR and is expected to reach $441 billion by 2026, according to ReportLinker. Driving this growth are multiple factors, including changing lifestyles, growing consumer desire to move away from expensive prescription medicine and undesirable side effects, aging population and increased life expectancy. Our current principal geographic markets are customers in the United States looking for nutraceutical products focused on their own heart and brain health and immune support.

Our BergaMet all-natural Citrus Bergamot SuperFruit formulations address an expanding global heart health ingredients market that is projected to grow at a 4.6% CAGR to reach $55.3 billion by 2027, according to ResearchAndMarkets. This growth is largely being driven by concerns about cardiovascular disease, which remains the leading cause of premature death globally according to the World Health Organization.

Our UBN products tap the fast-growing market for brain health, which is growing at a 9.4% CAGR to reach $15.7 billion by 2030, according to Grandview Research. This market is being driven in part by

13

the rise in the aging adult population in North America and Europe, with consumers increasingly using brain health supplements to prevent or treat mental conditions such as memory loss or dementia, or to improve mental cognition, energy and focus.

Americans consume unhealthy energy shots and drinks every day, with this alone generating over $12.5 billion per year in industry sales. Within this growing market, UBN is advancing its position to meet rising consumer demand for healthy options backed by third-party research studies. Our KETONOMICS® proprietary formulations have been proven to naturally elevate brain energy and function, including memory, cognition and focus.

We anticipate launching a gut health gel pack. The new gut health product will allow us to address a large and expanding global gut health market that is growing at a 7.9% CAGR to reach nearly $72 billion by 2027, according to Fortune Business Insights. Our gut health products are ready to be manufactured but have not yet been introduced to the market. Gut health is the balance between helpful and harmful bacteria and yeast in the digestive system.

Go-to-Market Strategy

Our approach to the market has been to implement a multi-channel marketing strategy that includes major eCommerce websites, distributors, white and private label, direct-to-consumer, influencer and affiliate programs, and traditional retail marketplaces.

As a key part of our multi-channel strategy, Amazon.com has been generating strong sales, particularly with its popular ‘Subscribe & Save’ option helping to further expand our recurring revenue stream. Amazon complements our direct-to-consumer channel on our BergaMet and UBN websites that offer a subscription-based option. Last year our Citrus Bergamot SuperFruit formulations also became available for purchased on Walmart.com.

In the third quarter of 2022, we launched our premium Citrus Bergamot SuperFruit heart health supplement, BergaMet PRO+, on Fullscript.com, the nation’s leading care delivery platform for integrative

14

medicine. This made BergaMet PRO+ available to the more than 70,000 healthcare professionals and their more than 5 million patients on the Fullscript care platform.

The Fullscript launch followed the entry of our natural formulations for brain health into the retail marketplace through Natural Grocers stores nationwide. Natural Grocers is the nation's largest family-operated organic and natural grocery retailer. The retailer also provides extensive free nutrition education programs that help consumers make informed nutritional health choices. The initial two products sold by Natural Grocers where our Ultimate Brain Nutrients (UBN) ACTIVATE and UBN RELIEF.

Influencer Program

We introduced our influencer program in the Fall of 2021 as a cost-effective and efficient way to expand our sales, brand awareness and market share. According to the social commerce platform Poshmark, about 41% of consumers discover new brands from influencers and 33% through social media marketing.

We believe our influencer program is ideally suited for influencers who have more than 500,000 followers in the health and wellness, sports and healthcare markets, and particularly those who would like to enhance their personal brand with unlimited revenue potential. Through this program, qualified influencers can easily introduce their own personally branded nutraceutical products, with Healthy Extracts providing the backend of product development, manufacturing, distribution, order fulfillment and customer service.

As our first major influencer under this program, we teamed with popular fitness coach and entrepreneur, Whitney Johns. Whitney is an accomplished fitness athlete, model, personal trainer and nutrition advocate who has garnerd more than a million followers across Instagram, Facebook, TikTok, Twitter, and YouTube. Some of her popularity is due to her personalized diet and fitness program, Find Your Fit with Whit, which helps individuals from all walks of life achieve their personal nutritional and fitness goals. We entered into a Private Label Agreement with her on October 11, 2021, pursuant to which we granted her the exclusive right to private label our Ultimate Brain Nutrients ACTIVATE and BergaMet NA sports performance and hormone balancing products in the field of female fitness, and granted her the right of first refusal for private label rights on any new products and technology in the field. We have also developed our gut health and ACTIVATE gel pack products with her, which are ready to manufacture but which have not been introduced to the market yet. The agreement is for three years and was subsequently verbally amended for us to pay her a flat monthly fee of $4,000 instead of the sales and volume-based compensation model in the original agreement. The agreement can be terminated by either party on 90 days’ written notice. Through September 30, 2023, we have paid her a total of $38,000 under this agreement². We also granted her RSU’s for 500,000 shares of our common stock with a purchase price of $0.01 per share. The verbal amendment will be in place until otherwise agreed between the parties.

Whitney Johns’ new product line of brain, physical performance and women’s hormone health products are based upon our proven all-natural Citrus Bergamot SuperFruit and Ultimate Brain Nutrients formulations. This means they are also vegan-friendly, non-GMO, gluten-free and organic, and made in a certified U.S. facility. Moreover, they are supported by published research from third-party sources, which helps influencers like Whitney to provide their full-throated endorsement of our proprietary formulations.

The first Whitney products have included Whitney Johns Nutrition BRAIN ACTIVATE (in powder and gel format), ACTIVE for enhanced physical performance, and WOMEN’S HORMONE SUPPORT. These products are available from whitneyjohns.com as well as on Whitney’s Amazon.com store, with both channels offering subscription options.

² NTD: update to 12/31/23

15

Future Growth Drivers

New Sales Channels and Product Launches

In order to drive continued sales growth and leverage our growing customer base, we are planning to expand our product portfolio to include supplements that support gut health as well as introduce more products in gel-pack format. We anticipate this to include a new Whitney Johns gut health gel-pack as well as a new gel pack option for our Ultimate Brain Nutrients RELIEF.

We plan to further expand our sales channels as well as our portfolio of natural formulations for heart and brain health and other indications.

Strategic Acquisitions

Intellectual Property

Patents

We have filed formulation patent applications related to general brain health as well as patents particularly focused on migraine headaches. The platform includes general utility patents with additional disclosure of methods of manufacture as indicated below. Categories of ingredients are listed in both the independent (standalone) and the dependent (successor claims with specifics, variations and limitations) claims. “Comprising” language is utilized wherever it is allowed by the U.S. Patent and Trademark Office

16

(PTO) whereby the patented formulation includes but is not limited to the elements listed in the claim. Markush groups and claims are used so that categories can include alternative ingredients from a selected group that share structural similarities or common functions. Expiration dates for issued patents are listed, expiration for pending patents will be 17 years after the date of issuance, and all patents are in the United States.

Prophylaxis and Mitigation of Migraine Headaches Using Medium Chain Triglycerides, Ketone Ester, and Other Ketogenic Sources. Filed January 10, 2018 (PTO Application No. 15/743,448); pending approval. “Parent Patent” related to migraine headaches and covers the methods of reducing frequency of migraine onset and symptoms as well as augmenting the effects of pharmaceutical and non-pharmaceutical inventions. Includes techniques of providing adequate levels of dietary ketogenic MCT. The invention provides a mixture of caprylic and capric acids; these triglycerides may either be enriched or purified with coconut oil. Relates to Activate product line.

Prophylaxis and Mitigation of Migraine Headaches Using Medium Chain Triglycerides, Ketone Ester, and Other Ketogenic Sources. Filed April 22, 2019 (PTO Application No. 16/501,502); pending approval. “Divisional” filing from the “Parent” to address restriction requirements and identifies additional distinct claims. Relates to preventing, arresting or reducing the frequency and severity of a migraine headache. Additional filing September 30, 2020 (PTO Application No. 17/011/650); pending approval. This composition is comprised of a dietary ketone wherein this unique ingredient is intended to address migraines with disclosure of a related method of manufacture. The supplement manufacturing method also contains ketogenic MCT in combination with a pharmaceutical agent. Relates to the Activate product line.

Compositions of Medium Chain Triglycerides and Plant-Based Nutrients for Brain Health. Filed December 19, 2018 (PTO Application No. 16/350,663); response to PTO comments September 9, 2019; written amendment acknowledged; pending approval. Relates to enhancement of metabolic energy pathways to improve attention, cognition, memory, analytical and executive functions. Formulation categories include medium chain triglycerides (MCT), polyphenol-rich phytonutrients, brain carotenoid antioxidants, dietary vitamins and minerals and miscellaneous nutrients. Relates to Activate and BergaMet product lines.

Compositions of Ketogenic Sources, Micronutrients and Phytochemicals for Prophylaxis and Mitigation of Migraine Headache. Patent issued December 10, 2019 (Patent No. 10,500,182). Expiration December 10, 2036. This “Continuation-in-Part” filing from the “Parent” repeats a portion of the original specifications but adds subject matter not previously disclosed. Relates to preventing, arresting or reducing the frequency and severity of a migraine with disclosure of the method of manufacture. The comprehensive composition of categories includes ketogenic sources, phytonutrients, vitamins, mineral co-factors, antioxidants and miscellaneous nutrients. Relates to the Activate product line.

Compositions of Ketogenic Agents, Cannabinoids, Plant-Derived Substances and Micronutrients. Patent issued February 9, 2021 (U.S. Patent No. 10,912,758). Expiration February 9, 2038. Relates to modulation of metabolic pathways to benefit human performance, endurance and cardiometabolic health as well as improving cognition, executive function and women’s health. Formulation categories include ketogenic agents, cannabinoids, polyphenols, dietary nutrients, antioxidants and mineral co-factors. Relates to Activate and BergaMet product lines. Contains ability to include hemp-derived cannabinoids in unique product formulations whenever allowable under federal law.

Qualified Health Claim (QHC)

We filed a QHC petition for Fuel for migraine health with the Center for Food Safety and Nutrition

17

of the FDA in July 2019. The preponderance of third-party scientific evidence to support the claim has been submitted. The FDA acknowledged that our petition met the requirements under 21 CFR 101.70 and was submitted in the proper legal format. In light of increased administrative burdens from the COVID-19 pandemic, the FDA has requested extended decision delays to which we agreed. A final decision is now expected before the end of 2023.

Trademark

A trademark owned by us that supports the entire brain health product platform is: KETONOMICS. The trademark received registration approval April 29, 2014 (Registration Number 4523135) and will not expire while it is in commercial use. This Service Mark has broad application in the “Goods and Services” category and covers: “Medical and scientific research in the field of brain metabolism and physiological metabolism; Product development in the field of brain metabolism and physiological metabolism; Research and development and consultation related thereto in the field of brain metabolism and physiological metabolism; Research and development of new products; Scientific research consulting in the field of brain metabolism and physiological metabolism.”

Competition

We compete with other manufacturers, distributors and marketers of vitamins, minerals, herbs, and other nutritional supplements both within and outside the U.S.

The competitive landscape is similar to other supplements. Our higher percentage of BPF Gold 47% distinguishes us as a high-quality competitor. We promote our products consistently with online marketing.

Our key competitor is Ortho Molecular, who distributors through medical offices. We are priced similarly to their product. They sell a 38% BPF product.

Our key competitors on digital marketing and Amazon are Doublewood, Secrets, Naomi, and Jarrow. Doublewood, Jarrow, and Naomi are priced higher or similar. Secrets uses a lower quality citrus bergamot and are considered a price and low-quality competitor. We intend to distinguish ourselves from these competitors through better digital marketing and brand loyalty.

We have high gross margin categories, with our gross margin ranging from 60% to 80%, depending on product and market channel.

Based upon our exclusive U.S. and Canadian licensing and manufacturing agreement with Gelteq, we believe we are able to offer a gel-pack delivery system that our competition in North America cannot provide. Gelteq is a customizable platform for supplement delivery, in that each gel formulation is tailored to solve a particular problem and deliver a specific outcome.

18

As the exclusive North American provider of H&AD’s Citrus Bergamot SuperFruit, our heart and immune products have several advantages. For example, our BergaMet PRO+ product has 47% BPF Gold potency as compared to the closest competitor at only 38% BPF. BPF is an extract derived from the fruit’s juice, peel, and pulp, is comprised of five polyphenols (Naringin, Neohesperidin, Brutieridin, Melitidin, and Neoeriocitrin), and its potency is determined by the concentration of these five polyphenols achieved during the extraction process. The potency of BPF is widely compared by Bergamot users in making their purchase decisions because a higher potency may lead to greater benefits, and is generally considered more desirable in the marketplace.

Backed by published research from third-party sources, our citrus bergamot has been shown to support heart health, support immune response, and address metabolic syndrome.

Employees

Governmental Controls, Approval and Licensing Requirements

Our products have not been evaluated by the FDA or any similar regulatory body for safety and efficacy.

Federal laws related to the advertising, distribution and sale of health supplements.

We expect that the formulation, manufacturing, packaging, labeling, advertising, distribution and sale (hereafter, “sale” or “sold” may be used to signify all of these activities) of our vitamin and nutritional supplement products will be subject to regulation by one or more federal agencies, primarily the FDA and the Federal Trade Commission (“FTC”), and to a lesser extent the Consumer Product Safety Commission (“CPSC”), the United States Department of Agriculture, and the Environmental Protection Agency. Our activities are also regulated by various governmental agencies for the states and localities in which our products are sold, as well as by governmental agencies in certain countries outside the United States in which our products are sold. Among other matters, regulation by the FDA and the FTC is concerned with product safety and claims made with respect to a product’s ability to provide health-related benefits. Specifically, the FDA, under the Federal Food, Drug, and Cosmetic Act (“FDCA”), regulates the formulation, manufacturing, packaging, labeling, distribution, and sale of food, including dietary supplements and over-the-counter (“OTC”) drugs. The FTC regulates the advertising of these products. The National Advertising Division (“NAD”) of the Council of Better Business Bureaus oversees an industry-sponsored, self-regulatory system that permits competitors to resolve disputes over advertising claims. The NAD has no enforcement authority of its own, but may refer matters that appear to violate the FTC Act or the FDCA to the FTC or the FDA for further action, as appropriate.

19

All of the nutritional supplement products that we plan to sell are classified as dietary supplements. The FDA’s revision of nutrition labeling requirements also affects the nutrition labeling of certain dietary supplements. Our affected manufacturers may have revised labels on some of their dietary supplements to comply with the new requirements. Our manufacturers review our labels prior to each product run to assure compliance. Moreover, these manufacturers may need to reformulate their products to maintain eligibility for certain marketing claims.

The Dietary Supplement Health and Education Act (“DSHEA”) was enacted in 1994, amending the FDCA. Among other things, DSHEA prevents the FDA from regulating dietary ingredients in dietary supplements as “food additives” and allows the use of statements of nutritional support on product labels and in labeling. DSHEA establishes a statutory class of “dietary supplements,” which includes vitamins, minerals, herbs, amino acids and other dietary ingredients for human use to supplement the diet. Dietary ingredients marketed in the United States before October 15, 1994 may be marketed without the submission of a “new dietary ingredient” (“NDI”) premarket notification to the FDA. Dietary ingredients not marketed in the United States before October 15, 1994 may require the submission, at least 75 days before marketing, of an NDI notification containing information establishing that the ingredient is reasonably expected to be safe for its intended use. The FDA has issued final regulations under DSHEA.

As required by Section 113(b) of the Food Safety Modernization Act, the FDA published in July 2011 a draft guidance document clarifying when the FDA believes a dietary ingredient is an NDI, when a manufacturer or distributor must submit an NDI premarket notification to the FDA, the evidence necessary to document the safety of an NDI and the methods for establishing the identity of an NDI. Industry strongly objected to several aspects of the draft guidance. In 2016, the FDA issued revised draft guidance on what constitutes an NDI and NDI notification requirements. Regardless of whether the FDA finalizes this draft guidance, the FDA has recently acted more aggressively to remove ingredients from the market that the FDA views as unlawful dietary ingredients. This trend, if it continues, may limit the dietary supplement market. Several bills to amend DSHEA in ways that would make this law less favorable to consumers and industry have been proposed in Congress. We are very careful to assure all of the ingredients we utilized are not a “new NDI” and meets the FDA draft guidance.

The FDA issued a Final Rule on GMPs for dietary supplements on June 22, 2007. The GMPs cover manufacturers and holders of finished dietary supplement products, including dietary supplement products manufactured outside the United States that are imported for sale into the United States. Among other things, the new GMPs: (a) require identity testing on all incoming dietary ingredients, (b) call for a “scientifically valid system” for ensuring finished products meet all specifications, (c) include requirements related to process controls, including statistical sampling of finished batches for testing and requirements for written procedures and (d) require extensive recordkeeping. We have reviewed the GMPs and have taken steps to ensure compliance. While we believe we are in compliance, there can be no assurance that our operations or those of our suppliers will be in compliance in all respects at all times. Additionally, there is a potential risk of increased audits as the FDA and other regulators seek to ensure compliance with the GMPs.

On December 22, 2006, Congress passed the Dietary Supplement and Nonprescription Drug Consumer Protection Act, which went into effect on December 22, 2007. The law requires, among other things, that companies that manufacture or distribute nonprescription drugs or dietary supplements report serious adverse events allegedly associated with their products to the FDA and institute recordkeeping requirements for all adverse events (serious and non-serious). There is a risk that consumers, the press and government regulators could misinterpret reported serious adverse events as evidence of causation by the ingredient or product complained of, which could lead to additional regulations, banned ingredients or products, increased insurance costs and a potential increase in product liability litigation, among other things.

20

All states regulate foods and drugs under laws that generally parallel federal statutes. We are also subject to state consumer health and safety regulations, such as the California Safe Drinking Water and Toxic Enforcement Act of 1986 (“Proposition 65”). Violation of Proposition 65 may result in substantial monetary penalties and compliance with Proposition 65 is a major focus. Contemplated changes in the Proposition 65 labeling requirements could potentially lead to substantial costs. Current legislation in Massachusetts regarding restrictions on weight loss and sports nutrition products could also impact the marketing of dietary supplements generally. Further, state attorneys general have pressured industry to adopt DNA testing for herbal-based products to assure plant identity, and have taken other actions relating to dietary ingredient status. It is uncertain whether these efforts will have a material impact on the dietary supplement market.

On November 14, 2022, BergaMet NA, LLC, our subsidiary, received a warning letter from the FDA regarding claims we allegedly make about our Cholesterol Command product. Specifically, the warning letter related to claims on our website, Facebook page, and the webpage of a retailer claim that the products are intended for use in the cure, mitigation, treatment, or prevention of disease because they reduce cholesterol or are an anti-inflammatory. On December 1, 2022, we responded to the warning letter notifying the FDA that we had hired a third-party to review our advertising and revise portions of our website, Facebook page, and online product listings. This was the only warning letter we received from the FDA to date, and we are awaiting their response. There can be no assurance that the FDA will not pursue this action further. If the FDA were to pursue this action, we may have to cease selling our Cholesterol Command product. Any action brought by the FDA (or any ramifications of such action, including, without limitation, a required withdrawal of Cholesterol Command from the market) would have a material adverse effect on our reputation, sales efforts and results of operations.

Currently, our products are only distributed in the United States. If we distribute products in Canada or elsewhere in the future, we will go through the appropriate approval process.

Description of Property

We do not currently own, lease or use any office space as we operate on a virtual basis. However, we lease warehouse facilities under an operating lease that expires in 2025. Prior to February 4, 2022, we leased a warehouse facility on a month-to-month basis. Our rent obligations for 2023 through 2025 are as follows: 2023 - $65,335, 2024 - $69,635, and 2025 - $5,822. Total rent for the year ended December 31, 2022 and 2023 was $63,745 and $65,335.

21

ITEM 1A. – RISK FACTORS.

As a smaller reporting company, we are not required to provide a statement of risk factors. Nonetheless, we are voluntarily providing risk factors herein.

Any investment in our common stock is speculative and involves a high degree of risk. You should consider carefully the risk factors related to our business described below, together with the other information and financial statements contained in this annual report, before you decide to buy our common stock. There are numerous and varied risks, known and unknown, that may prevent us from achieving our goals. If one or more of these risks actually occurs, our business will suffer, and as a result our financial condition or results of operations will be adversely affected. In this case, the market price of our common stock could decline, and you could lose all or part of your investment in our common stock.

Risk Factors Related to our Business

We rely on a single supplier relationship for licensing and manufacturing, and the termination of that agreement could have material effect on the cost of our products and the manufacturing of our finished goods.

In August 2021, we signed an exclusive U.S. and Canada licensing and manufacturing agreement with Gelteq, a developer of ingestible gel technology, under which we agreed to develop and manufacture an advanced oral delivery system for our plant-based heart, immune and brain health formulations. Through this agreement we secured the exclusive rights to use Gelteq’s gelification process in the U.S. and Canada for the development and marketing of natural ingestible gels that contain our Citrus Bergamot or UBN ingredients. In the event either party terminates that agreement, our ability to obtain and manufacture our products will be interrupted, and we may not be able to find a replacement at the same cost.

We were incorporated on December 19, 2014, but we have changed our business focus with the acquisition of BergaMet in 2019 and UBN in 2020. We have not fully developed our current business operations and have not yet to generate significant revenue from such operations. Our ability to continue as a going concern is dependent upon our ability to further establish and then grow our business and to obtain adequate financing in order to reach profitable levels of operations. In that regard we have no proven history of performance, earnings or success.

Our net loss from inception to December 31, 2023, was ($18,399,673). Based on our cash position of $19,441 as of December 31, 2023, we have a pressing need to raise additional capital from the sale of our stock or debt (including but also following this offering). Such funding may not be available, or may be available only on terms which are not beneficial and/or acceptable to us.

Our ability to achieve profitability and positive cash flow in the future is dependent upon our ability to attract new customers who will buy our nutritional supplement products and services, and our ability to generate sufficient revenue through the sale of those products and services.

Based upon current plans, we expect to incur operating losses in future periods because we will be incurring expenses that may exceed revenues. We cannot guarantee that we will be successful in generating

22

sufficient revenues in the future. In the event we cannot generate sufficient revenues and/or secure additional financing, we may be forced to cease operations.

Our success is linked to the size and growth rate of the vitamin, mineral and supplement market and an adverse change in the size or growth rate of that market could have a material adverse effect on us.

An adverse change in size or growth rate of the vitamin, mineral and supplement market could have a material adverse effect on us. Underlying market conditions are subject to change based on economic conditions, consumer preferences and other factors that are beyond our control, including media attention and scientific research, which may be positive or negative. In addition, the vitamin, mineral and supplement market is heavily saturated, and the demand for and market acceptance of new products and services in the market is uncertain. While we predict that the overall vitamin, mineral and supplement market will continue to grow, it is difficult to predict the future growth rates, if any, to the size of our market. We cannot assure you that our market will continue to develop, that the public’s interest in personalized health and wellness will continue, or that our products and services will become widely adopted. If our market does not further develop, develops more slowly than expected, or becomes saturated with competitors, or if our products and services do not achieve market acceptance, our business, financial condition, and operating results could be adversely affected.

We are highly dependent upon consumers’ perception of the safety and quality of our products and if we fail to maintain adequate quality standards for our products and services, or if our products become subject to regulatory investigations, our business may be adversely affected and our reputation harmed.

Our products, including nutritional supplements, may contain defects or may not perform as intended. These defects could result in a product recall, market withdrawal, negative publicity or other events that would result in harm to our reputation, loss of customers or revenue, health and safety issues for our customers, product liability claims, refunds, order cancellations, or lack of market acceptance of our products and services. Any such defects, errors, or vulnerabilities would require us to take remedial action, which could require us to allocate significant customer support resources to address any such problems. Further, if we make acquisitions, we may encounter difficulties in integrating acquired technologies into our services and in augmenting those technologies to meet the quality standards that are consistent with our brand and reputation.

Our agreements with customers, distribution partners, and other third parties may include indemnification provisions under which we agree to indemnify or otherwise be liable to them for losses suffered or incurred in connection with any such defects or errors of our products or services, or other liabilities relating to or arising from our products or services. Some of these indemnity agreements provide for uncapped liability for which we would be responsible, and some indemnity provisions survive termination or expiration of the applicable agreement. Large indemnity payments could harm our business, financial condition, and results of operations. Although we attempt to contractually limit our liability with respect to such indemnity obligations, we are not always successful and may still incur substantial liability related to such claims. In addition, although we carry general liability insurance, our insurance against this liability may not be adequate to cover a potential claim, and such coverage may not be available to us on acceptable terms, or at all. Any dispute with a customer or other third party with respect to such obligations could have adverse effects on our relationship with such customer or other third party, our reputation, or demand for our platform. Any of the foregoing could adversely affect our business, financial condition, and results of operations.

23

Negative public perception may also arise from regulatory actions or investigations, regardless of whether those investigations involve us. We are highly dependent upon consumers’ perception of the safety and quality of our products as well as similar products distributed by other companies. Thus, the mere publication of reports asserting that such products may be harmful or adverse public reports or other media attention regarding the safety, efficacy and quality of nutritional supplements in general, or our products specifically, or associating the consumption of nutritional supplements with illness, questioning the benefits of nutritional supplements in general, or our products specifically, or claiming that such products do not perform as marketed, labeled and advertised, could have a material adverse effect on us, regardless of whether these reports are scientifically supported. Any such adverse public reports or other media attention could arise even if the adverse effects associated with such products resulted from consumers’ failure to consume such products as directed and the content of such public reports and other media attention may be beyond our control. Publicity related to nutritional supplements may also result in increased regulatory scrutiny of our industry. Adverse publicity may have a material adverse effect on our business, financial condition, results of operations and cash flows. There can be no assurance of future favorable scientific results and media attention or of the absence of unfavorable or inconsistent findings.

Our success depends on our ability to maintain the value and reputation of our brands.

We believe that our customers associate our name with quality products and services and that the strength of our brands is important to attracting and retaining customers. We rely on our trusted brands to differentiate our products and services from those of our competitors in a crowded and saturated market for nutritional supplements. Maintaining, protecting, and enhancing our brands depends largely on the success of our marketing efforts, ability to provide consistent, high-quality products, services, features, content and support. We believe that the importance of our brands will increase as competition further intensifies. Accordingly, brand promotion activities aimed at bolstering our brands may require substantial expenditures. Our brands could be harmed if we fail to achieve these objectives or if our public image were to be tarnished by negative publicity. Our brands could be harmed if we fail to achieve these objectives or if our public image were to be tarnished by negative publicity. Our brands could also be harmed if any of our influencers receive negative publicity, or if our products and services do not perform as intended.

We may fail to attract, acquire or retain customers at our current or anticipated future growth rate, or may fail to do so in a cost-effective manner, which would adversely affect our business, financial condition and results of operations.

Our continued growth depends, in part, on our ability to attract, acquire and retain customers in a cost-effective manner. Numerous factors, however, may impede our ability to attract, acquire or retain customers, including our failure to attract, effectively train, retain, and motivate sales and marketing personnel, our failure to educate customers and health professionals about the benefits of our products, our failure to develop or expand relationships with our suppliers, our inability to convert initial adoption into ongoing recurring revenue and our failure to provide customer support once products are delivered.

We rely on internet search engines, lead generators, and social networking sites to help drive traffic to our website and the sale of our products, and if we fail to appear prominently in the search results or fail to drive traffic through paid advertising, our traffic and product sales would decline and our business would be adversely affected.

We depend in part on internet search engines (such as Google), lead generators, and social networking sites (such as Facebook) to drive traffic to our website and the sale of our products. Our ability to maintain and increase the number of visitors directed to our website is not entirely within our control. Our competitors may increase their search engine optimization efforts and outbid us for placement on various sites or search terms on various search engines, resulting in their websites receiving a higher search

24

result page ranking than ours. Additionally, internet search engines could revise their methodologies in a way that would adversely affect our search result rankings. If internet search engines modify their search algorithms in ways that are detrimental to us, if sites refuse to display any or all of our products in certain geographic markets, or if our competitors’ efforts are more successful than ours, overall growth in our customer base could slow or our customer base could decline. Our website has experienced fluctuations in search result rankings in the past, and we anticipate similar fluctuations in the future. Any reduction in the number of users directed to our website through internet search engines, lead generators, or social networking sites could harm our business and operating results.

Our success depends, in part, on our existing customers continuing to purchase our products. Our customers have no obligation to purchase our products, and in the normal course of business, some customers may decide to purchase less or none of our products. If we acquire fewer customers than expected, or fewer customers purchase our existing products or try our new products, then our business, financial condition and results of operations may be adversely affected. Our business depends on the effectiveness of our advertising and marketing programs, including the strength of our social media presence, to attract and retain customers.

Our business success depends on our ability to attract and retain customers. Our ability to attract and retain customers depends significantly on the effectiveness of our advertising and marketing practices. From time-to-time, we use the success stories of our customers, and utilize brand ambassadors, spokespersons and social media influencers, including in some cases celebrities, in our advertising and marketing programs to communicate on a personal level with consumers. Any actions taken by these individuals that harm their personal reputation or image, or their decision to stop using our services and products, could have an adverse impact on the advertising and marketing campaigns in which they are featured. We and our brand ambassadors, spokespersons and social media influencers also use social media channels as a means of communicating with customers. Unauthorized or inappropriate use of these channels could result in harmful publicity or negative consumer experiences, which could have an adverse impact on the effectiveness of our marketing in these channels. In addition, substantial negative commentary by others on social media platforms could have an adverse impact on our reputation and ability to attract and retain customers. If our advertising and marketing campaigns do not generate a sufficient number of customers, our business, financial condition and results of operations will be adversely affected.

If we are unable to anticipate customer preferences and successfully develop new and innovative products in a timely manner or effectively manage the introduction of new or enhanced products, then our business may be adversely affected.

Part of our success is our ability to innovate and introduce new products focused on our consumer demands. To maintain our success and increase our customer base, we must continue to develop products with differentiated benefits and anticipate and react to changing health professional and consumer demands in a timely manner. Our products and services are subject to changing consumer preferences that cannot be predicted with certainty. If we are unable to introduce new or enhanced products in a timely manner, or our new or enhanced products are not accepted by our customers, then our competitors may introduce competitive products faster than us, which could negatively affect our rate of growth. Moreover, our new products may not receive customer acceptance because preferences could shift rapidly to alternative nutritional supplements, and our future success depends in part on our ability to anticipate and respond to these changes. Failure to anticipate and respond in a timely manner to changing customer preferences could lead to, among other things, lower sales, pricing pressure, lower gross margins, and excess inventory levels. Even if we are successful in anticipating consumer preferences, our ability to adequately react to and address them will partially depend upon our continued ability to develop and introduce innovative, high-quality product offerings. Development of new or enhanced products and services may require significant time and financial investment, which could result in increased costs and a reduction in our profit margins.

25

If we are unable to sustain pricing levels for our products, our business could be adversely affected.

The prices for our nutritional supplement products reflect their high quality, safety and benefits. If we are unable to sustain pricing levels for our products, whether due to competitive pressure or otherwise, then our gross profits could be reduced. Further, our decisions regarding the development of new products are based on assumptions about future pricing. If there is price compression in the market after these decisions are made, then it could lower our gross profits and have a negative effect on our results of operations.

Numerous manufacturers and distributors compete actively for consumers. There can be no assurance that we will be able to compete in this intensely competitive environment. In addition, nutritional supplements can be purchased in a wide variety of channels of distribution. These channels include mass market retail stores and the Internet. Because these markets generally have low barriers to entry, additional competitors could enter the market at any time. Private label products of our customers also provide competition to our products. Additional national or international companies may seek in the future to enter or to increase their presence in our distribution channels or the vitamin, mineral supplement market. Increased competition in either or both could have a material adverse effect on us.

Adverse economic conditions may harm our business.

Our business depends on global economic conditions. Unstable market conditions make it difficult for our clients and us to accurately forecast and plan future business activities, and could cause our customers to reduce or delay their spending with us. Economic downturns or unstable market conditions may cause customers to decrease their budgets, which could reduce spend on our products and adversely affect our business, financial condition and results of operations. As we explore new countries to expand our business, economic downturns or unstable market conditions in any of those countries could result in our investments not yielding the returns we anticipate.

Generally, the United States and other key international economies have been affected from time to time by falling demand for a variety of goods and services, restricted credit, poor liquidity, reduced corporate profitability, volatility in credit, equity and foreign exchange markets, bankruptcies, and overall uncertainty with respect to the economy, including with respect to tariff and trade issues. In particular, the economies of countries in Europe have been experiencing weakness associated with high sovereign debt levels, weakness in the banking sector, uncertainty over the future of the Eurozone and volatility in the value of the pound sterling and the Euro, including instability surrounding Brexit. We have operations, as well as current and potential new customers, throughout the United Kingdom and most of Europe. If economic conditions in the United Kingdom and Europe and other key markets for our platform continue to remain uncertain or deteriorate further, it could adversely affect our customers’ ability or willingness to subscribe to our platform, delay prospective customers’ purchasing decisions, reduce the value or duration of their subscriptions or affect renewal rates, all of which could harm our operating results.

Inflation or other changes in economic conditions that affect demand for nutritional supplements could adversely affect our revenue. Uncertainty about current global economic conditions poses a risk as consumers and businesses may postpone spending in response to tighter credit markets, negative financial news and/or declines in income or asset values, each of which could have a material negative effect on the

26

demand for our products. Other factors that could influence demand include conditions in the residential real estate and mortgage markets, labor and healthcare costs, access to credit, consumer confidence and other macroeconomic factors affecting consumer spending behavior. These and other economic factors could have a material adverse effect on demand for our products and on our financial condition and operating results.

Overall tightening of the labor market, increases in labor costs or any possible labor unrest may adversely affect our business and results of operations.

Our business, particularly the manufacturing of our products, requires a substantial number of personnel. Any failure to retain stable and dedicated labor by us may lead to disruption to our business operations, including the manufacturing of our products. Although we have not experienced any material labor shortage to date, we have observed an overall tightening and increasingly competitive labor market. We have experienced, and expect to continue to experience, increases in labor costs due to increases in salary, social benefits and employee headcount. We compete with other companies in our industry and other labor-intensive industries for labor, and we may not be able to offer competitive remuneration and benefits compared to them. If we are unable to manage and control our labor costs, our business, financial condition and results of operations may be materially and adversely affected.

Our operating results could be adversely affected if we are unable to accurately forecast customer demand for our products and services and adequately manage our inventory.

To ensure adequate inventory supply, we must forecast inventory needs and expenses and place orders sufficiently in advance with our suppliers, based on our estimates of future demand for particular products and services. Failure to accurately forecast our needs may result in manufacturing delays or increased costs. Our ability to accurately forecast demand could be affected by many factors, including changes in customer demand for our products and services, changes in demand for the products and services of our competitors, widespread acceptance of personalized health recommendations and nutritional supplements, unanticipated changes in general market conditions, and the weakening of economic conditions or consumer confidence in future economic conditions. This risk may be exacerbated by the fact that we may not carry a significant amount of inventory and may not be able to satisfy short-term demand increases. If we fail to accurately forecast customer demand, we may experience excess inventory levels or a shortage of products available for sale. Inventory levels in excess of customer demand may result in inventory write-downs or write-offs and the sale of excess inventory at discounted prices, which would cause our gross margins to suffer and could impair the strength and our brand. Further, lower than forecasted demand could also result in excess manufacturing capacity or reduced manufacturing efficiencies, which could result in lower margins. Conversely, if we underestimate customer demand, our suppliers and manufacturers may not be able to deliver products to meet our requirements or we may be subject to higher costs in order to secure the necessary production capacity. An inability to meet customer demand and delays in the delivery of our products to our customers could result in reputational harm and damaged customer relationships and have an adverse effect on our business, financial condition, and operating results.

We acquire ingredients for our products from foreign suppliers and may be negatively affected by the risks associated with international trade and importation issues.

We acquire ingredients for a number of our products from suppliers outside of the United States. Accordingly, the acquisition of these ingredients is subject to the risks generally associated with importing raw materials, including, among other factors, delays in shipments, changes in economic and political conditions, quality assurance, health epidemics affecting the region of such suppliers (including the COVID-19 pandemic), nonconformity to specifications or laws and regulations, tariffs, trade disputes and foreign currency fluctuations (particularly as it relates to the tariffs currently imposed on certain

27

products originating from China). While we inspect 100% of the lots received from third party suppliers, we cannot assure you that raw materials received from suppliers or finished products from manufacturers outside of the United States will conform to all specifications, laws and regulations or our internal standards. There have in the past been quality and safety issues in our industry with certain items imported from overseas. We may incur additional expenses and experience shipment delays due to preventative measures adopted by the U.S. governments, our suppliers and our company.

Ingredient and packaging costs are volatile and may rise significantly, which may negatively impact the profitability of our business.

Costs of ingredients and packaging are volatile and can fluctuate due to conditions that are difficult to predict, including global competition for resources, fluctuations in currency and exchange rates, weather conditions, natural or man-made disasters, consumer demand and changes in governmental trade and agricultural programs. Continued volatility in the prices of the core ingredients and other supplies we purchase could increase our cost of goods sold and reduce our profitability.

We do not use hedges or forward pricing for availability of any core ingredients. As such, any material upward movement in core ingredient pricing could negatively impact our margins if we are not able to pass these costs on to our consumers, or our sales if we are forced to increase its prices. If we are not successful in managing our ingredient and packaging costs, if we are unable to increase our prices to cover increased costs or if such price increases reduce our sales volumes, then such increases in costs will adversely affect our business, financial condition and results of operations.

Certain of our core ingredient contracts have minimum volume commitments that could require purchases without matching revenues during weaker sales periods. Future core ingredient prices may be impacted by new laws or regulations, suppliers’ allocations to other purchasers, interruptions in production by suppliers, natural disasters, volatility in the price of crude oil and related petrochemical products and changes in exchange rates.

A disruption in the service, a significant increase in the cost of our primary delivery and shipping services for our products or a significant disruption at shipping ports could adversely affect our business.

We use a variety of shipping services for delivery of our products to users and brick-and-mortar and online retail partners, including air carriers and ocean shipping services. We have experienced and could continue to experience increased congestion and new import and export restrictions implemented at ports on which we rely for our business. In many cases, we have had to secure alternative transportation, such as air freight, or use alternative routes, at increased costs, to run our supply chain.

In the event of any significant interruption in service by shipping providers or at airports or shipping ports, we may be unable to engage alternative suppliers or to receive or ship goods through alternate sites in order to deliver our products in a timely and cost-efficient manner. As a result, we could experience delays, increased shipping costs and lost sales as a result of missed delivery deadlines and product demand cycles. For example, at times during the COVID-19 pandemic, shipping of our products has been delayed, which has inconvenienced our users and brick-and-mortar and online retail partners. Furthermore, if the cost of delivery or shipping services were to increase significantly and the additional costs could not be covered by product pricing, our results of operations could be adversely affected.

In particular, we are dependent upon major shipping companies, including FedEx, for the shipment of our products to and from our third-party logistics partner facilities. Changes in shipping terms, or the inability of these third-party shippers to perform effectively, could affect our responsiveness to our users and brick-and-mortar and online retail partners. Increases in our shipping costs may adversely affect our

28

financial results if we are unable to pass on these higher costs to our users or brick-and-mortar and online retail partners.

We will require additional financing in the future, and we can provide no assurance that such funding will be available on terms that are acceptable to us, or at all.

We will require additional financing in the future in order to grow our business, and are faced with the risk that funding will be unavailable in sufficient amounts or on terms acceptable to us, if at all, when needed. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. To the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, your ownership interest will be diluted, and the terms of those securities may include liquidation or other preferences that materially adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to make capital expenditures, declare dividends, or otherwise conduct our business. If we are unable to obtain any funding we need on a timely basis, we may be required to significantly curtail, delay or discontinue development of new products, the commercialization of our products or expansion into new geographies, which could materially affect our business, financial condition, and results of operations.

Our competitors may develop nutritional supplement products that are less expensive, safer or otherwise more appealing, which may diminish or eliminate the commercial success of any potential product that we may commercialize.

If our competitors (most of whom are larger and have more resources than we do) develop and bring to market nutritional supplement products that are less expensive, safer or otherwise more appealing than our current and potential products, or that reach the market before our current and potential products, we may not achieve commercial success. The market may choose to continue utilizing existing products for any number of reasons, including familiarity with or pricing of these existing products. The failure of any of our products to compete with products marketed by our competitors would impair our ability to generate revenue, which would have a material adverse effect on our future business, financial condition, results of operations, and cash flows. Our competitors may:

·develop and market products that are less expensive, safer, or otherwise more appealing than our products;

·commercialize competing products before we or our partners can launch our products; and

·initiate or withstand substantial price competition more successfully than we can.

Our auditors have substantial doubt about our ability to continue as a going concern.

Our financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Our auditor’s report reflects that our ability to continue as a going concern is dependent upon our ability to raise additional capital from the sale of common stock and, ultimately, the achievement of significant operating revenues. If we are unable to continue as a going concern, our stockholders will lose their investment. We will be required to seek additional capital to fund future growth and expansion. No assurance can be given that

29

such financing will be available or, if available, that it will be on commercially favorable terms. Moreover, favorable financing may be dilutive to our stockholders.

One of our shareholders and his adult children owns a significant percentage of our Common Stock and has the ability to substantially influence all matters submitted to stockholders for approval.

One of our shareholders, Jay Decker, owns slightly less than 50% of our outstanding shares of Common Stock. For as long as Decker retains a significant ownership of our shares of Common Stock, he will be able to substantially influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, he will substantially influence the election of directors and approval of any merger, consolidation or sale of all or substantially all our assets. This concentration of voting power could delay or prevent an acquisition of us on terms that other stockholders may desire or result in management that our stockholders disagree with. In addition, Mr. Decker’s adult children own and will continue to own a significant portion of our outstanding Common Stock. See “Security Ownership of Certain Beneficial Owners and Management”.

Our current officers and directors may set salaries and perquisites in the future which we are unable to support with our current assets.

Although our officers and directors have written employment or services agreements, our officers and directors may decide to award themselves higher salaries and other benefits but all changes to these agreements will need to be approved by the Board of Directors. We do not have significant revenues, and there is no guarantee that we will have significant revenue in the near future. If we do not increase our revenues, we will be unable to support any higher salaries or other benefits for management, which may cause us to cease operations.

We may engage in strategic transactions that fail to enhance stockholder value.

From time to time, we may consider possible strategic transactions, including the potential acquisitions or licensing of products or technologies or acquisition of companies, and other alternatives with the goal of maximizing stockholder value. We may never complete a strategic transaction, and in the event that we do complete a strategic transaction, implementation of such transactions may impair stockholder value or otherwise adversely affect our business. Future strategic transactions we engage in may require us to incur additional charges or expenses. Moreover, our pending and future strategic acquisitions or other transactions may pose significant integration challenges and/or management and business disruptions, and we may not receive the anticipated benefits of such transactions, any of which could harm our results of operation and business prospects.

We may not be able to gain or sustain market acceptance for our products and services.

Failure to establish a brand and presence in the marketplace on a timely basis could adversely affect our financial condition and results of operations. Moreover, there can be no assurance that we will successfully complete our development and introduction of new products and services or that any such products and services will achieve acceptance in the marketplace. We may also fail to develop and deploy new products and services on a timely basis.

We have a significant amount of unsold inventory, which could affect our assets and our profitability.

As of December 31, 2021, we had over $1.9 million in inventory, after writing off over $400,000 in citrus bergamot bulk extract inventory for the year. We believe this is the only product in our inventory

30

that has a material risk of spoilage. The amount of our inventory exceeds our revenues for the year ended December 31, 2021. As of December 31, 2022, we had over $1.8 million in inventory, and we wrote off approximately $97,000 in inventory in 2022. As of December 31, 2023, we had over $1.6 million in inventory. Our inventory could spoil or be damaged, or we could never sell it, affecting the assets on our balance sheet as well as our future profitability. Our build-up in inventory peaked at the end of 2020 and we have been able to continue to reduce our inventory through increased sales. We do not anticipate any further inventory write-offs.

We are subject to and affected by extensive governmental regulations.

We are subject to and affected by extensive governmental regulations, including, among other things, regulations pertaining to (i) the formulation, manufacturing, packaging, labeling, distribution, importation, sale and storage of our products, and (ii) product claims and advertising (including direct claims and advertising by us, as well as claims and advertising by distributors for which we may be held responsible)

We could be found not to be in compliance with existing regulations as a result, among other things, of the ambiguous nature of certain of the regulations, the considerable interpretive and enforcement discretion given to regulators or misconduct by distributors, who are generally independent contractors over whom we have limited control. Enforcement actions that could be undertaken by state and federal regulators include product seizures, injunctions against further product distribution, requests for product recall, and possible criminal prosecution. Any assertion or determination that we or our distributors are not in compliance with existing regulations could have a material adverse effect on our revenues.

In addition, the adoption of new regulations, or changes in the interpretation of existing regulations, could have a material adverse effect on us. For example, in September 1997 the FDA) issued regulations governing the labeling and marketing of dietary supplement products.

In addition, claims made with respect to weight management, dietary supplement, personal care or other products of ours may change the regulatory status of the products. For example, it is possible that the FDA could take the position that claims made in connection with certain of our products place those products within the scope of an FDA “over-the counter” (OTC) drug monograph. OTC monographs prescribe permissible ingredients and appropriate labeling language, and require the marketer or supplier of the products to register and file annual drug listing information with the FDA.

The U.S. Federal Trade Commission (“FTC”), which exercises jurisdiction over the advertising of all our products, has in the past instituted enforcement actions against dietary supplement companies for false and misleading advertising of certain products. These enforcement actions have resulted in consent decrees and monetary payments by the companies involved. In addition, the FTC has increased its scrutiny of the use of testimonials.

We received a warning letter from the FDA in November 2022 regarding one of our products.

31

There can be no assurance that the FDA will not pursue this action further. If the FDA were to pursue this action, we may have to cease selling our Cholesterol Command product. Any action brought by the FDA (or any ramifications of such action, including, without limitation, a required withdrawal of Cholesterol Command from the market) would have a material adverse effect on our reputation, sales efforts and results of operations.

Economic uncertainties or downturns could materially adversely affect our business.

Current or future economic uncertainties or downturns could adversely affect our business and results of operations. Negative conditions in the general economy including conditions resulting from changes in gross domestic product growth, the continued sovereign debt crisis, financial and credit market fluctuations, political deadlock, natural catastrophes, warfare and terrorist attacks on the United States, Europe, the Asia Pacific region or elsewhere, could cause a decrease in business investments.

General worldwide economic conditions have experienced a significant downturn and continue to remain unstable. These conditions make it extremely difficult for us to forecast and plan future business activities accurately, and they could cause our potential customers to reevaluate their decisions to purchase our product, which could delay and lengthen our sales cycles or result in cancellations of planned purchases. Furthermore, during challenging economic times our potential customers may tighten their advertising budgets which may impact their spend on local inventory based digital marketing products. To the extent purchases of our products are perceived by potential customers to be discretionary, sales of our products may never occur. Also, customers may choose to seek other methods to achieve the benefits our products provide.

We cannot predict the timing, strength or duration of any economic slowdown, instability or recovery, generally or within any particular industry. If the economic conditions of the general economy or industries in which we operate do not improve, or worsen from present levels, our business, results of operations, financial condition and cash flows could be adversely affected.

We are dependent on the services of key personnel and failure to attract qualified management could limit our growth and negatively impact our results of operations.

We are highly dependent on the principal members of our management team, including our President, Kevin “Duke” Pitts, and our Chief Financial Officer, Robert Madden. At this time, we do not know of the availability of such experienced management personnel or how much it may cost to attract and retain such personnel. The loss of the services of any member of senior management or the inability to hire experienced technical or programing personnel could have a material adverse effect on our financial condition and results of operations.

Other companies may claim that we have infringed upon their intellectual property or proprietary rights.

We do not believe that our products and services violate third-party intellectual property rights; however, we have not had an independent party conduct a study of possible patent infringements. Nevertheless, we cannot guarantee that claims relating to violation of such rights will not be asserted by third parties. If any of our products or services are found to violate third-party intellectual property rights, we may be required to expend significant funds to re-engineer or cause to be re-engineered one or more of those products or services to avoid infringement, or seek to obtain licenses from third parties to continue offering our products and services without substantial re-engineering, and such efforts may not be successful.

32

In addition, future patents may be issued to third parties upon which our products and services may infringe. We may incur substantial costs in defending against claims under any such patents. Furthermore, parties making such claims may be able to obtain injunctive or other equitable relief, which effectively could block our ability to further develop or commercialize some or all of our products or services in the United States or abroad, and could result in the award of substantial damages against us. In the event of a claim of infringement, we may be required to obtain one or more licenses from third parties. There can be no assurance that we will be able to obtain such licenses at a reasonable cost, if at all. Defense of any lawsuit or failure to obtain any such license could be costly and have a material adverse effect on our business.

As a part of our business strategy, we have made and expect to continue to make acquisitions. These acquisitions could disrupt our operations and harm our operating results.

An element of our strategy includes expanding our product offerings and gaining access to new skills and other resources through strategic acquisitions when attractive opportunities arise. Acquiring additional businesses and the implementation of other elements of our business strategy are subject to various risks and uncertainties. Some of these factors are within our control and some are outside our control. These risks and uncertainties include, but are not limited to, the following:

• any acquisition may result in significant expenditures of cash, stock and/or management resources,

• acquired businesses may not perform in accordance with expectations,

• we may encounter difficulties and costs with the integration of the acquired businesses,

• management’s attention may be diverted from other aspects of our business,

• we may face unexpected problems entering geographic and product markets in which we have limited or no direct prior experience,

• we may lose key employees of acquired or existing businesses,

• we may incur liabilities and claims arising out of acquired businesses,

• we may be unable to obtain financing, and

• we may incur indebtedness or issue additional capital stock, which could be dilutive to holders of our common stock.

There can be no assurance that attractive acquisition opportunities will be available to us, that we will be able to obtain financing for or otherwise consummate any acquisitions or that any acquisitions which are consummated will prove to be successful. There can be no assurance that we can successfully execute all aspects of our business strategy.

Our success depends on our ability to protect our proprietary technology.

Our success depends, to a significant degree, upon the protection of our proprietary technology, and that of any licensors. Legal fees and other expenses necessary to obtain and maintain appropriate patent protection could be material. Currently, no material aspect of our business is protected by registered patents, copyrights or trademarks. Insufficient funding may inhibit our ability to obtain and maintain such

33

protection. Additionally, if we must resort to legal proceedings to enforce our intellectual property rights, the proceedings could be burdensome and expensive, and could involve a high degree of risk to our proprietary rights if we are unsuccessful in, or cannot afford to pursue, such proceedings.

We may also rely on trademarks, trade secrets and contract law to protect certain of our proprietary technology. There can be no assurance that any trademarks will be approved, that such contract will not be breached, or that if breached, we will have adequate remedies. Furthermore, there can be no assurance that any of our trade secrets will not become known or independently discovered by third parties.

Our future growth may be inhibited by the failure to implement new technologies.

Our future growth is partially tied to our ability to improve our knowledge and implementation of mobile, AI, machine learning, and other advanced technologies in a retail environment, which is a rapidly changing market. The inability to successfully implement commercially technologies in response to market conditions in a manner that is responsive to our customers’ requirements could have a material adverse effect on our business.

Our common stock is governed under The Securities Enforcement and Penny Stock Reform Act of 1990.

The Securities Enforcement and Penny Stock Reform Act of 1990 requires additional disclosure relating to the market for penny stocks in connection with trades in any stock defined as a penny stock. The Commission has adopted regulations that generally define a penny stock to be any equity security that has a market price of less than $5.00 per share, subject to certain exceptions. Such exceptions include any equity security listed on NASDAQ and any equity security issued by an issuer that has (i) net tangible assets of at least $2,000,000, if such issuer has been in continuous operation for three years; (ii) net tangible assets of at least $5,000,000, if such issuer has been in continuous operation for less than three years; or (iii) average annual revenue of at least $6,000,000, if such issuer has been in continuous operation for less than three years. Unless an exception is available, the regulations require the delivery, prior to any transaction involving a penny stock, of a disclosure schedule explaining the penny stock market and the risks associated therewith.

Risk Factors Related to Our Securities Generally

The market prices and trading volume of our shares of Common Stock may experience rapid and substantial price volatility, which could cause purchasers of our Common Stock to incur substantial losses.

The market prices and trading volume of shares of Common Stock of other small publicly traded companies with a limited number of shares available to purchasers, have experienced rapid and substantial price volatility unrelated to the financial performance of those companies. Similarly, shares of our Common Stock may experience similar rapid and substantial price volatility unrelated to our financial performance, which could cause purchasers of our Common Stock to incur substantial losses, which may be unpredictable and not bear any relationship to our business and financial performance. Extreme fluctuations in the market price of our Common Stock may occur in response to strong and atypical retail investor interest, including on social media and online forums, the direct access by retail investors to broadly available trading platforms, the amount and status of short interest in our Common Stock and our other securities, access to margin debt, trading in options and other derivatives on our shares of Common Stock and any related hedging and other trading factors:

If there is extreme market volatility and trading patterns in our Common Stock, it may create several risks for investors, including the following:

34

·the market price of our Common Stock may experience rapid and substantial increases or decreases unrelated to our operating performance or prospects, or macro or industry fundamentals;

·if our future market capitalization reflects trading dynamics unrelated to our financial performance or prospects, purchasers of our Common Stock could incur substantial losses as prices decline once the level of market volatility has abated;

·if the future market price of our Common Stock declines, purchasers of shares of Common Stock may be unable to resell such shares at or above the price at which they acquired them. We cannot assure such purchasers that the market of our Common Stock will not fluctuate or decline significantly in the future, in which case investors in this Offering could incur substantial losses.

Further, we may incur rapid and substantial increases or decreases in our Common Stock price in the foreseeable future that may not coincide in timing with the disclosure of news or developments by or affecting us. Accordingly, the market price of our Common Stock may fluctuate dramatically, and may decline rapidly, regardless of any developments in our business. Overall, there are various factors, many of which are beyond our control, that could negatively affect the market price of our Common Stock or result in fluctuations in the price or trading volume of our Common Stock, including:

·actual or anticipated variations in our annual or quarterly results of operations, including our earnings estimates and whether we meet market expectations with regard to our earnings;

·our current inability to pay dividends or other distributions;

·publication of research reports by analysts or others about us or the industry in which we operate, including the nutraceutical industry which may be unfavorable, inaccurate, inconsistent or not disseminated on a regular basis;

·changes in market valuations of similar companies;

·market reaction to any additional equity, debt or other securities that we may issue in the future, and which may or may not dilute the holdings of our existing stockholders;

·additions or departures of key personnel;

·actions by institutional or significant stockholders;

·short interest in our Common Stock or our other securities and the market response to such short interest;

·the dramatic increase in the number of individual holders of our Common Stock and their participation in social media platforms targeted at speculative investing;

·speculation in the press or investment community about our company or industries in which we operate;

·strategic actions by us or our competitors, such as acquisitions or other investments;

·legislative, administrative, regulatory or other actions affecting our business, our industry, including positions taken by the FDA;

·investigations, proceedings, or litigation that involve or affect us;

·the occurrence of any of the other risk factors included in this annual report; and

·general market and economic conditions.

35

Following the recent reverse stock split of our outstanding shares of Common Stock, we cannot assure you that the market price of our Common Stock will remain at the same level.

On December 29, 2023, we effectuated a 1-for-120 reverse stock split of our Common Stock. There can be no assurance that the market price of our Common Stock following such reverse stock split will remain at the same level. It is not uncommon for the market price of a company’s Common Stock to decline in the period following a reverse stock split. If the market price of our Common Stock declines following the effectuation of such reverse stock split, the percentage decline may be greater than would occur in the absence of a reverse stock split. In any event, other factors unrelated to the number of shares of our Common Stock outstanding, such as negative financial or operational results, could adversely affect the market price of our Common Stock.

The recent reverse stock split may decrease the liquidity of the shares of our Common Stock.

The liquidity of the shares of our Common Stock may be affected adversely by our recent reverse stock split given the reduced number of shares of our Common Stock that will be outstanding following such reverse stock split, especially if the market price of our Common Stock does not increase as a result of such reverse stock split. In addition, such reverse stock split may increase the number of stockholders who own odd lots (less than 100 shares) of our Common Stock, creating the potential for such stockholders to experience an increase in the cost of selling their shares of Common Stock and greater difficulty effecting such sales.

Following our recent reverse stock split, the resulting market price of our Common Stock may not attract new investors, including institutional investors, and may not satisfy the investing requirements of those investors. Consequently, the trading liquidity of our common stock may not improve.

Although we believe that a higher market price of our Common Stock may help generate greater or broader investor interest, there can be no assurance that the reverse stock split will result in a share price that will attract new investors, including institutional investors. In addition, there can be no assurance that the market price of our Common Stock will satisfy the investing requirements of those investors. As a result, the trading liquidity of our Common Stock may not necessarily improve.

A significant portion of our total outstanding shares of Common Stock are restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our Common Stock to drop significantly, even if our business is performing well.

Sales of a substantial number of shares of our Common Stock in the public market could occur at any time, subject to certain restrictions described below. All of the Shares will be freely tradable without restrictions or further registration under the Securities Act, except for any shares held by our affiliates as defined in Rule 144 under the Securities Act (“Rule 144”). These sales, or the perception in the market that holders of a large number of shares of our Common Stock intend to sell shares, could reduce the market price of our Common Stock. We have outstanding 2,963,906 shares of Common Stock, 597,265 of which may be resold in the public market immediately without restriction, and the rest of which may be sold pursuant to Rule 144. Also, we intend to register all shares of Common Stock that we may issue under our equity compensation plan on a registration statement on Form S-8. Upon such registration, such shares can be freely sold in the public market upon issuance, subject to the terms of applicable award agreements, volume limitations applicable to affiliates and lock-up agreements.

36

If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our Common Stock, the price of our Common Stock could decline.

The trading market for our Common Stock may rely, in part, on the research and reports that industry or financial analysts publish about us or our business. If securities analysts do not commence coverage of us, the trading price of our Common Stock could decrease. Additionally, if one or more of the analysts covering our business downgrade their evaluations of our Common Stock, the price of our Common Stock could decline. If one or more of these analysts cease to cover our Common Stock, we could lose visibility in the market for our Common Stock, which in turn could cause our Common Stock price to decline.

An active trading market for our Common Stock may not develop and you may not be able to resell your shares at or above the public offering price.

Prior to this Offering, there has been a limited public market for shares of our Common Stock. An active trading market for our Common Stock may never develop or be sustained. In the absence of an active trading market for our Common Stock, investors may not be able to sell their Common Stock at the time that they would like to sell. An inactive market may also impair our ability to raise capital by selling shares of our Common Stock and may impair our ability to acquire other companies, products or technologies by using shares of our Common Stock as consideration.

We have broad discretion in the use of our cash, and may not use it effectively.

Our management will have broad discretion in the application of our cash, and could spend it in ways that do not improve our results of operations or enhance the value of our Common Stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business or cause the price of our Common Stock to decline. Pending their use, we may invest our cash in a manner that does not produce income or that loses value.

Raising additional capital will likely cause dilution to our existing stockholders and restrict our operations.

We will likely seek to raise additional capital through a combination of public and private equity offerings and debt financings. To the extent that we raise additional capital through the sale of equity or debt securities, your ownership interest will be diluted and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or any of our product candidates, or grant licenses on terms unfavorable to us.

We will incur increased costs as a result of operating as a smaller reporting public company, and our management will be required to devote substantial time to new compliance initiatives.

As a smaller reporting public company, we will incur significant legal, accounting and other expenses. In addition, the Sarbanes-Oxley Act and rules subsequently implemented by the SEC have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel, who do not have extensive experience in operating a public company, will need to devote a substantial

37

amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance.

Pursuant to Section 404 of the Sarbanes-Oxley Act (“Section 404”), we will be required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.

Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.

We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our Common Stock will be your sole source of gain for the foreseeable future.

38

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

We have made forward-looking statements in this annual report, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business,” that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements include the information concerning our possible or assumed future results of operations, business strategies, financing plans, competitive position, industry environment, potential growth opportunities, the effects of future regulation, and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by the use of forward-looking terminology such as the words “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate” or similar expressions. These statements are only predictions and involve known and unknown risks and uncertainties, including the risks outlined under “Risk Factors” and elsewhere in this annual report.

Forward-looking statements contained in this annual report include, but are not limited to, statements about the following:

·our estimates regarding the potential market opportunity for our products;

·our ability to identify and develop new product candidates;

·our ability to identify, recruit and retain key personnel;

·our commercialization and marketing capabilities and strategy;

·the implementation of our business model, strategic plans for our business, product candidates and technology;

·the rate and degree of market acceptance and utility of our products and products in development;

·our competitive position;

·our intellectual property position and our ability to protect and enforce our intellectual property;

·our financial performance;

·developments and projections relating to our competitors and our industry;

·our ability to obtain additional funding;

·our expectations related to the use of proceeds from this Offering;

·our estimates regarding expenses, future revenue, capital requirements and needs for or ability to obtain additional financing;

·the impact of laws and regulations; and

39

·the impact that general economic conditions and the uncertainty of the U.S. and global economy, particularly the continuing COVID-19 pandemic, inflation in the U.S., globally supply chain disruptions and the sanctions imposed on Russia as a result of its invasion of Ukraine has had and will have on our industry, market, business and product candidates.

Forward-looking statements are subject to a number of significant risks, uncertainties and assumptions, including those described in “Risk Factors” and elsewhere in this annual report. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this annual report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date of this annual report. You should read this annual report and the documents that we have filed as exhibits completely and with the understanding that our actual future results may be materially different from what we expect.

Although we believe that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee future results, events, levels of activity, performance or achievement. We are not under any duty to update any of the forward-looking statements after the date of this annual report to conform these statements to actual results, unless required by law.

ITEM 1B – UNRESOLVED STAFF COMMENTS

This Item is not applicable to us as we are not an accelerated filer, a large accelerated filer, or a well-seasoned issuer; however, we are voluntarily disclosing that we have not received any written comments from the Commission staff more than 180 days before the end of our fiscal year to which this Annual Report relates regarding our periodic or current reports under the Securities Exchange Act of 1934 and that remain unresolved.

ITEM 1C – CYBERSECURITY

A consistent and holistic approach to cybersecurity is important to achieving our strategic business objectives and protecting our intellectual property. Because we sell many of our products through e-commerce platforms, we would be indirectly affected by a variety of cybersecurity threats such as ransomware and denial-of-service attacks that affect most industry sectors. Our customers, suppliers and other business partners face similar cybersecurity threats, and a cybersecurity incident impacting us or any of these entities could materially adversely affect our operations, performance and results of operations. We are continually evaluating best practices and methods to protect us from a wide range of potential threats.

The Board oversees our processes for identifying and mitigating risks, including cybersecurity risks. Our management periodically briefs the Board on our cybersecurity and information security policies and plans. In the event of an incident, we have developed an incident response plan, which sets forth the steps to be followed from incident detection and assessment to mitigation, recovery and notification and reporting, including notifying functional areas, as well as senior leadership and the Board, as appropriate.

40

We continue to evaluate our cybersecurity requirements to address the evolving cybersecurity risks that we face in an increasingly technically capable environment. Our management manages our cybersecurity policies, with the goal of preventing cybersecurity incidents, if possible, while also maintaining IT system performance and data integrity to minimize the business impact should an incident occur.

Although we take cybersecurity risks seriously, we may not be successful in preventing or mitigating a cybersecurity incident that could have a material adverse effect on us.

ITEM 2 – PROPERTIES

We do not currently own, lease or use any office space as we operate on a virtual basis. However, we lease warehouse facilities under an operating lease that expires in 2025. Prior to February 4, 2022, we leased a warehouse facility on a month-to-month basis. Our rent obligations for 2024 through 2025 are as follows: 2024 - $69,635, and 2025 - $5,822. Total rent for the year ended December 31, 2023 was $65,335.

ITEM 3 – LEGAL PROCEEDINGS

None of our officers or directors has, in the past ten years, filed bankruptcy, been convicted in a criminal proceeding or named in a pending criminal proceeding, been the subject of any order, judgment, or decree of any court permanently or temporarily enjoining him or her from any securities activities, or any other disclosable event required by Item 401(f) of Regulation S-K.

Other than as set forth above, we are not a party to or otherwise involved in any legal proceedings.

In the ordinary course of business, we are from time to time involved in various pending or threatened legal actions. The litigation process is inherently uncertain and it is possible that the resolution of such matters might have a material adverse effect upon our financial condition and/or results of operations. However, in the opinion of our management, other than as set forth herein, matters currently pending or threatened against us are not expected to have a material adverse effect on our financial position or results of operations.

ITEM 4 – MINE SAFETY DISCLOSURES

Not applicable.

41

PART II

ITEM 5 - MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Our common stock is quoted on an unsolicited basis on the OTCQB tier of the marketplace maintained by OTC Markets Group, Inc. under the symbol “HYEX.” Our stock is piggyback qualified for broker-dealer quotations. Our common stock trades on a limited or sporadic basis and should not be deemed to constitute an established public trading market. There is no assurance that there will be liquidity in the common stock.

The following table sets forth the high and low closing price for each quarter within the fiscal years ended December 31, 2023 and 2022, as provided by Nasdaq, after giving effect to the 1-for-120 reverse stock split on December 29, 2023. The information reflects prices between dealers, and does not include retail markup, markdown, or commission, and may not represent actual transactions.

Fiscal Year Ended December 31,
		Transaction Prices
	Period	High	Low
2024	First Quarter (through March 18, 2024)	$4.05	$1.03

2023	Fourth Quarter	$7.20	$3.24
	Third Quarter	$7.20	$3.60
	Second Quarter	$6.96	$5.50
	First Quarter	$7.02	$4.32

2022	Fourth Quarter	$8.28	$4.80
	Third Quarter	$8.52	$4.93
	Second Quarter	$9.12	$4.91
	First Quarter	$6.96	$3.72

Holders

As of March 18, 2024, there were 2,963,906 shares of our common stock issued and outstanding and held by approximately 119 holders of record, not including shares held in “street name” in brokerage accounts which is unknown.

Dividend Policy

We have not paid any dividends on our common stock and do not expect to do so in the foreseeable future. We intend to apply our earnings, if any, in expanding our operations and related activities. The payment of cash dividends in the future will be at the discretion of the Board of Directors and will depend

42

upon such factors as earnings levels, capital requirements, our financial condition and other factors deemed relevant by the Board of Directors.

Securities Authorized for Issuance under Equity Compensation Plans

We do not have any disclosure related to this item.

Recent Issuance of Unregistered Securities

Restricted Stock Units and Restricted Stock Awards

On December 26, 2022, we approved the Healthy Extracts Inc. 2022 Equity Incentive Plan and set aside 433,334 shares of our common stock for issuance thereunder. On December 26, 2022, we approved the grant of a total of 133,125 Restricted Stock Units on April 28, 2023 at $1.20 per share, and the grant of 300,000 Restricted Stock Awards upon our uplisting with a strike price of $0.00 to $1.20 to a total of sixteen (16) individuals.³

The issuances were exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, there was no solicitation involved in the offerings, and the parties were either sophisticated or accredited.

ITEM 6 – RESERVED

As a smaller reporting company, we are not required to provide the information required by this Item.

³ NTD: Confirm no other issuances through 12/31/23.

43

ITEM 7 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

Overview

We are a platform for acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals. Our products have not been evaluated by the FDA or any similar regulatory body for safety and efficacy. Our proprietary and patented products target select high-growth categories within the multibillion-dollar nutraceuticals market, such as heart, brain and immune health. Our mission is to acquire or create products with health and performance benefits that have mass consumer appeal.

Guided by this mission, our first two acquisitions formed our current operating subsidiaries, Bergamet, which offers nutraceutical heart and immune health products, and UBN, which offers nutraceutical products for brain health. Based on published research from third-party sources, we believe our Bergamet products have been shown to support heart health, support immune response, and address metabolic syndrome.

Our Financial Condition and Going Concern Issues

As a result of our financial condition, we have received a report from our independent registered public accounting firm for our financial statements for the years ended December 31, 2023 and 2022 that includes an explanatory paragraph describing the uncertainty as to our ability to continue as a going concern. From inception (December 19, 2014) through the end of December 31, 2023, we have incurred accumulated net losses of $18,399,673. In order to continue as a going concern, we must effectively balance many factors and generate more revenue so that we can fund our operations from our sales and revenues. If we are not able to do this, we may not be able to continue as an operating company. At our current revenue and burn rate, we have an immediate cash need, and thus we must raise capital by issuing debt or through the sale of our stock. However, there is no assurance that our existing cash flow will be adequate to satisfy our existing operating expenses and capital requirements.

Results of Operations for the Years Ended December 31, 2023 and 2022

Introduction

We had revenues of $2,485,866 for the year ended December 31, 2023, as compared to $2,251,469 for the year ended December 31, 2022, an increase of $234,397, or 10%. Our cost of revenue was $864,055 for the year ended December 31, 2023, as compared to $879,951 for the year ended December 31, 2022, a decrease of $15,896, or 2%.

44

Revenues and Net Operating Loss

Our revenues, operating expenses, and net operating loss for the years ended December 31, 2023 and 2022 were as follows:

	Year Ended December 31, 2023		Year Ended December 31, 2022		Increase/ (Decrease)

Revenue	$	2,485,866	$	2,251,469	$	234,397
Cost of Revenue		864,055		879,951		(15,896)

Operating expenses:
General and administrative		3,865,654		2,283,107		1,582,546
Total operating expenses		3,865,654		2,283,107		1,582,546

Net operating loss
Other income/(expense)		(229,088)		(71,531)		157,557

Net gain/(loss)	$	(2,472,931)	$	(983,121)	$	1,489,810

Revenues

We had revenues of $2,485,866 for the year ended December 31, 2023, as compared to $2,251,469 for the year ended December 31, 2022, an increase of $234,397, or 10%. The increase in revenues was mainly due to our increased focus on the Amazon marketplace.

Cost of Revenue

Our cost of revenue was $864,055 for the year ended December 31, 2023, as compared to $879,951 for the year ended December 31, 2022, a decrease of $15,896, or 2%, and consisted of wholesale product costs and packaging.

General and Administrative

General and administrative expense was $3,865,654 and $2,283,107 for the years ended December 31, 2023 and 2022, an increase of $1,582,546, or 69%. The increase was related to stock compensation expenses. In the year ended December 31, 2023, general and administrative expenses consisted mainly of stock based compensation of $1,494,191, consulting fees of $592,093, accounting and legal fees of $258,187 and salaries and wages of $198,554. In the year ended December 31, 2022, general and administrative expenses consisted mainly of consulting fees of $608,819, broker fees of $383,938, selling expenses of $595,318, accounting and legal fees of $145,062, and salaries and wages of $145,589.

Net Operating Gain/Loss

As a result of the items discussed above, our net operating loss was $2,243,843 and $911,590 for the years ended December 31, 2023 and 2022, respectively, an increase of $1,332,253, or 146%.

45

Other Income and Expense

Other income (expense) was $(229,088) and $(71,531) for the years ended December 31, 2023 and 2022, respectively, an increase of $157,557, or 220%. For the year ended December 31, 2023, our other income (expense) consisted of interest expenses, net of interest income of $(176,948) and change in fair value on derivative of $(52,140). For the year ended December 31, 2022, our other income (expense) consisted of interest expenses, net of interest income of $(64,690) and change in fair value on derivative of $(9,484), offset by a gain on the sale of asset of $2,643.

Net Gain/(Loss)

Our net gain (loss) for the year ended December 31, 2023 was $(2,472,931), or $0.85 per share, and our net gain (loss) for the ended December 31, 2022 was $(983,121), or $(0.34) per share, an increase of $1,489,810, or 152%.

Liquidity and Capital Resources

Introduction

During the years ended December 31, 2023 and 2022, we had negative operating cash flows. Our cash on hand as of December 31, 2023 was $19,441. Our monthly cash flow burn rate in 2023 was approximately $35,000. Although we have strong short term cash needs, as our operating expenses increase, we will face strong medium to long term cash needs. We anticipate that these needs will be satisfied through the issuance of debt or the sale of our securities until such time as our cash flows from operations will satisfy our cash flow needs.

Our cash, current assets, total assets, current liabilities, and total liabilities as of December 31, 2023 and 2022 were as follows:

	December 31, 2023		December 31, 2022		Change

Cash	$	19,441	$	65,651	$	(46,210)
Total Current Assets		1,899,678		2,043,587		(143,909)
Total Assets		2,635,014		2,781,118		(146,104)
Total Current Liabilities		1,680,424		902,788		777,636
Total Liabilities	$	1,680,424	$	902,788	$	777,636

Our cash decreased by $46,210 as of December 31, 2023 as compared to December 31, 2022. Our total current assets decreased by $143,909 because of our decrease in cash, as well as accounts receivable and inventory. Our total assets decreased by $146,104 for the same reasons.

Our current and total liabilities increased by $777,636, from $902,788 as of December 31, 2022 to $1,680,424 as of December 31, 2023. Our total liabilities as of the year ended December 31, 2023 consisted primarily of convertible debt, net of discount of $608,601, notes payable of $361,093, and accrued liabilities of $215,069.

In order to repay our obligations in full or in part when due, we will be required to raise significant capital from other sources. There is no assurance, however, that we will be successful in these efforts.

46

Cash Requirements

Our cash on hand as of December 31, 2022 was $19,441. Our monthly cash flow burn rate in 2023 was approximately $35,000. Although we have strong short term cash needs, as our operating expenses increase, we will face strong medium to long term cash needs. We anticipate that these needs will be satisfied through the sale of our securities until such time as our cash flows from operations will satisfy our cash flow needs.

Sources and Uses of Cash

Operations

Our net cash used in operating activities for the years ended December 31, 2023 and 2022 was $415,749 and $390,621, respectively, an increase of $25,128, or 6%. Our net cash used in operating activities for the year ended December 31, 2023 consisted primary of a net loss of $2,472,931, offset primarily by an adjustment for warrants issued for services of $1,639,191 and changes in inventory of $192,845. Our net cash used in operating activities for the year ended December 31, 2022 consisted of a net loss of $983,121 offset by an adjustment for warrants issued for services of $402,100, an increase in inventory of $138,838, and an increase in accounts payable of $54,048.

Investments

Our cash flow provided by (used in) investing activities for the years ended December 31, 2023 and 2022 was $zero and ($5,344), respectively.

Financing

Our net cash provided by financing activities for the years ended December 31, 2023 and 2022 was $369,539 and $239,518, respectively, an increase of $130,021, or 54%. The increase in 2023 was due primarily to proceeds from the issuance of notes payable of $713,283 and proceeds from the issuance of convertible debt of $362,963, offset by the repayment of notes payable of $657,560 and repayment of convertible debt of $110,535.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in our consolidated financial statements and related notes. Our significant accounting policies are described in Note 2 to our consolidated financial statements. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates and such differences may be material.

Management considers the following policies critical because they are both important to the portrayal of our financial condition and operating results, and they require management to make judgments and estimates about inherently uncertain matters.

47

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

Recent Accounting Pronouncements

Our management has considered all recent accounting pronouncements issued since the last audit of our financial statements. Our management believes that these recent pronouncements will not have a material effect on our financial statements.

Inventory

An allowance for inventory was established in 2018 and is evaluated each quarter to determine if all items are still sellable due to expiration dates. As of December 31, 2023 and 2022, the total of inventory which was written off as an inventory allowance was $1,611,257 and $1,914,891.

	DECEMBER 31,		DECEMBER 31,
	2023		2022
Inventory

Inventory Classes:
Raw Materials	$	1,387,426	$	1,483,764
Finished Goods		225,567		310,600
Work in process		13,290		24,764
Total inventory	$	1,626,283	$	1,819,128

Revenue Recognition

The Company applies Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) topic 606, Revenue from Contracts with Customers (ASC 606). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes all of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASC 606 requires us to identify distinct performance obligations. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. When distinct performance obligations exist, the Company allocates the contract transaction price to each distinct performance obligation. The

48

standalone selling price is used to allocate the transaction price to the separate performance obligations. The Company recognizes revenue when, or as, the performance obligation is satisfied.

Generally, revenues are recognized at the time of shipment to the customer with the price being fixed and determinable and collectability assured, provided title and risk of loss is transferred to the customer. Most of our shipping and handling costs are built into the transaction price, but if the customer asks for express shipping, the costs charged to customers are classified as sales, and the shipping and handling costs incurred are included in cost of sales.

The Company’s subsidiary, BergaMet N.A., LLC, recognizes revenue from our main source – e-commerce revenue. Here is a list of all the sales channels which include the Company’s subsidiary website channel or any other selling channel like Amazon, doctors’ offices, and walk-in sales. All of our customer sales for Healthy Extracts Inc. and Ultimate Brain Nutrients, LLC are recognized as revenue under the subsidiary of BergaMet N.A., LLC. All three divisions of the Company sell plant-based nutraceuticals to our end using customers.

The Company evaluates the criteria outlined in ASC 606-10-55, Principal versus Agent Considerations, currently we are the principal and have not engaged any agents at this time. Currently, we have not recognized any revenues under the agent considerations.

Revenue is recognized when, or as, control of a promised merchandise or service is shipped to the customer, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for transferring title of those products or services and are recorded net of and discounts or allowances. Shipping costs paid by the customer are included in revenue. Merchandise sales are fulfilled with inventory held in our warehouse in Henderson, NV. Therefore, the Company’s contracts have a single performance obligation (shipment of product).

If the Company receives a request for refund on a customer obligation, the Company will refund the full cost of the obligation due to our money back guarantee.

Revenue recognition is evaluated through the following five-step process:

1.identification of the contract with a customer;

2.identification off the performance obligations in the contract;

3.determination of the transaction price;

4.allocation of the transaction price to the performance obligations in the contract; and

5.recognition of revenue when or as a performance obligation is satisfied.

These steps are met when an order is received, a price agreed and the product shipped or delivered to that customer.

ITEM 7A – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a smaller reporting company, we are not required to provide the information required by this Item.

49

ITEM 8 - FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Report of Independent Registered Public Accounting Firm	F-1

Balance Sheets as of December 31, 2023 and 2022	F-2

Statement of Operations for the years ended December 31, 2023 and 2022	F-3

Statement of Stockholders’ Deficit for the years ended December 31, 2023 and 2022	F-4

Statement of Cash Flows for the years ended December 31, 2023 and 2022	F-5

Notes to Financial Statements	F-6 to F-22

50

Report of Independent Registered Public Accounting Firm

To the shareholders and the board of directors of Healthy Extracts Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Healthy Extracts Inc. as of December 31, 2023 and 2022, the related statements of operations, stockholders' equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.

Substantial Doubt about the Company’s Ability to Continue as a Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company’s significant operating losses raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

Critical Audit Matter

Critical audit matters are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.

We determined that there are no critical audit matters.

/S/ BF Borgers CPA PC (PCOAB ID 5041)

We have served as the Company's auditor since 2020

Lakewood, CO

April 1, 2024

F-1

HEALTHY EXTRACTS, INC.
CONSOLIDATED BALANCE SHEETS
AS OF DECEMBER 31, 2023 AND 2022
(Audited)

		DECEMBER 31	DECEMBER 31,
		2023	2022
ASSETS

CURRENT ASSETS
Cash		`$19,441`	`$65,651`
Accounts receivable		`30,440`	`105,794`
Inventory, net		`1,626,283`	`1,819,128`
Offering costs		`151,931`	`-`
Prepaid acquisition costs		`-`	`53,015`
Right of use asset, net		`71,583`	`-`
	Total current assets	`1,899,678`	`2,043,587`

Fixed assets		`3,306`	`5,501`
Patents/Trademarks		`521,881`	`521,881`
Deposit		`16,890`	`16,890`
Goodwill		`193,260`	`193,260`
	Total other assets	`735,336`	`737,531`

TOTAL ASSETS		`$2,635,014`	`$2,781,118`


LIABILITIES AND STOCKHOLDERS' EQUITY

LIABILITIES
Accounts payable		`$116,842`	`$91,316`
Accrued liabilities		`215,069`	`94,554`
Lease liabilities - current		`65,229`	`-`
Lease liabilities - long-term		`9,222`	`-`
Notes payable		`361,093`	`275,370`
Notes payable - related party		`83,366`	`866`
Convertible debt, net of discount		`608,601`	`317,284`
Accrued interest payable		`64,386`	`21,387`
Accrued interest payable - related party		`2,465`	`-`
Derivative liabilities		`154,150`	`102,011`
	Total current and total liabilities	`1,680,424`	`902,788`


STOCKHOLDERS' EQUITY
Preferred stock, $0.001 par value, 75,000,000 shares authorized, none and none shares issued and outstanding, respectively		`-`	`-`
Common stock, $0.001 par value, 50,000,000 shares authorized, 2,954,104 shares issued and outstanding as of December 31, 2023, and 2,876,437 shares issued and outstanding as of December 31, 2022, respectively		`354,492`	`345,172`
Additional paid-in capital		`18,999,770`	`17,459,899`
Accumulated deficit		`(18,399,673)`	`(15,926,742)`
	Total stockholders' equity	`954,590`	`1,878,330`

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY		`$2,635,014`	`$2,781,118`

The accompanying notes are an integral part of these audited consolidated financial statements.

F-2

HEALTHY EXTRACTS, INC.
CONSOLIDATED STATEMENT OF OPERATIONS
FOR THE YEAR ENDING DECEMBER 31, 2023 AND 2022
(Audited)

		FOR THE YEAR ENDING
		DECEMBER 31
		2023	2022

REVENUE
Revenue		`$2,485,866`	`$2,251,469`
	Net revenue	`2,485,866`	`2,251,469`

COST OF REVENUE
Cost of goods sold		`864,055`	`879,951`
	Total cost of revenue	`864,055`	`879,951`

GROSS PROFIT		`1,621,810`	`1,371,517`

OPERATING EXPENSES
Direct cost of revenue		`-`	`-`
General and administrative		`3,865,654`	`2,283,107`
Impairment of assets		`-`	`-`
	Total operating expenses	`3,865,654`	`2,283,107`

OTHER INCOME (EXPENSE)
Interest expense, net of interest income		`(176,948)`	`(64,690)`
Change in fair value on derivative		`(52,140)`	`(9,484)`
Gain on sale of asset		`-`	`2,643`

	Total other income (expense)	`(229,088)`	`(71,531)`

Net income/(loss) before income tax provision		`(2,472,931)`	`(983,121)`

NET INCOME/(LOSS)		`$(2,472,931)`	`$(983,121)`


Income/(Loss) per share - basic and diluted		`$(0.85)`	`$(0.34)`

Weighted average number of shares outstanding - basic and diluted		`2,915,410`	`2,854,290`


The accompanying notes are an integral part of these audited consolidated financial statements.

F-3

HEALTHY EXTRACTS, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)

FOR THE YEAR ENDING DECEMBER 31, 2023 AND 2022

(Audited)

Additional

Common Stock

Paid-In

Accumulated

Shares

Amount

Capital

Deficit

Total

Balance - December 31, 2021

2,819,868

$338,384

17,075,974

$(14,943,620)

$2,470,738

Cancelation of common stock for debt

(800,267)

(800)

(53,013)

-

(53,813)

Issuance of common stock for cash

507,917

508

24,888

-

25,396

Issuance of common stock for services

6,740,000

6,740

395,360

-

402,100

Issuance of common stock - Note Conversion

340,621

341

16,690

-

17,031

Net (loss) for the period

-

(983,121)

Balance - December 31, 2022

80,068

$345,173

17,459,899

$(15,926,741)

$1,878,330

Issuance of common stock for services

320,000

320

15,680

-

16,000

Fair value of restricted stock units

-

298,153

-

298,153

Fair value of options and warrants issued

-

785,038

-

785,038

Issuance of common stock-restricted stock units issued

9,000,000

9,000

441,000

-

450,000

Net (loss) for the period

-

(2,472,931)

Balance - December 31, 2023

2,954,104

354,492

18,999,770

(18,399,673)

954,590

The accompanying notes are an integral part of these audited financial statements.

F-4

HEALTHY EXTRACTS, INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
(Audited)

	FOR THE YEAR ENDING
	DECEMBER 31
	2023	2022
Cash Flows from Operating Activities:
Net Income/(Loss)	`$(2,472,931)`	`$(983,121)`

Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization	`2,195`	`878`
Warrants issued for services	`1,639,191`	`402,100`
Change in fair value on derivative liability	`52,140`	`9,484`
Changes in operating assets and liabilities:
Accounts receivable	`75,353`	`27,547`
Inventory	`192,845`	`138,838`
Offering Costs	`(151,931)`	`-`
Cost in acquisition of Hyperion/OP&M	`53,015`	`(53,015)`
Right of use asset, net	`(71,583)`	`-`
Deposits	`-`	`(16,890)`
Accounts payable	`25,526`	`54,048`
Accrued liabilities	`120,515`	`35,291`
Accrued interest payable	`42,999`	`8,337`
Accrued interest payable - related party	`2,465`	`(14,118)`
Lease liability - current	`65,229`	`-`
Lease liability - long-term	`9,222`	`-`
Net Cash used in Operating Activities	`(415,749)`	`(390,621)`

Cash Flows from Investing Activities:

Purchase of fixed assets	`-`	`(7,987)`
Gain on sale of asset	`-`	`2,643`
Cash flows provided by (used in) Investing Activities:	`-`	`(5,344)`

Cash Flows from Financing Activities:

Proceeds from issuance of common stock	`(90,000)`	`(11,386)`
Proceeds from issuance of convertible debt,	`362,963`	`463,630`
Payments for repayment of convertible debt	`(110,535)`	`(318,095)`
Proceeds from issuance of noted payable	`713,283`	`275,370`
Payments for repayment of notes payable	`(657,560)`	`-`
Proceeds from issuance of noted payable - related party	`107,500`	`-`
Payments for repayment of noted payable - related party	`(25,000)`	`(170,000)`
Loan origination fees	`68,888`	`-`
Net Cash provided by Financing Activities	`369,539`	`239,518`

Increase (decrease) in cash	`(46,210)`	`(156,447)`
Cash at beginning of period	`65,651`	`222,098`
Cash at end of period	`$19,441`	`$65,651`


The accompanying notes are an integral part of these audited consolidated financial statements.

F-5

HEALTHY EXTRACTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

Healthy Extracts Inc. (the “Company”) was incorporated in the State of Nevada on December 19, 2014 as Grey Cloak Tech Inc. On October 23, 2020, we changed our name from Grey Cloak Tech Inc. to Healthy Extracts Inc. to more accurately reflect our business. The Company has acquired BergaMet NA, LLC and Ultimate Brain Nutrients, LLC which market and sell health supplemental products.

On January 13, 2023 the Company entered into definitive agreement to acquire nutraceutical manufacturer, Hyperion, and its digital marketing affiliate, Online Publishing and Marketing. The total purchase price for the acquisitions was $1,750,000 in cash, $1,300,000 in the form of secured promissory notes, which was due in twelve months once the purchase had occurred, and $1,250,000 worth of our common stock.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying audited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying audited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of December 31, 2023 and the results of operations and cash flows for the periods presented. The results of operations for the year ended December 31, 2023 are not necessarily indicative of the operating results for the full fiscal year or any future period. These audited consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s form 10-K for the year ended December 31, 2022 filed with the SEC on March 31, 2023.

Use of Estimates

In regards to inventory write-offs and allowances, our Company determines the net realizable value by using the various factors as following: excess or slow-moving inventories (12 months or more of inventory on hand), expiration dates (within 12 months of the current reporting period), current and future product demand, production planning, and market conditions. If any of these factors are found in the reporting period, management will review each item and determine if any additional allowances or write-offs need to be made. A change in any of these variable’s factors could result in an adjustment to inventory. Management has provided for any risks in the current inventory allowance booked.

As for revenue adjustments for discounts, allowances and refunds, we treat each of these items differently. When it comes to revenue discounts, we will create the invoice for the product sold which will include any discounts given. These discounts usually happen for a short period of time for sales that we will offer around holidays. Due to the revenue being recognized once the order has shipped, less any applicable discount, we book this transaction at the net order transaction amount. In regards to allowances and refunds for revenue adjustments, due to our refund percentage is less than 1% we decided the need for an estimated adjustment for allowances and refunds was not material. If we

F-6

do receive any returned orders, we will directly book those orders as refunds the day we receive the call from the customer requesting the refund. We will book the credit memo at the full value of the customer original order.

Cash

Cash includes cash in banks, money market funds, and certificates of term deposits with maturities of less than three months from inception, which are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss in value.

Accounts Receivables

Accounts receivables are recorded at the invoice amount and do not bear interest.

Inventory

Inventories consist of health supplements held for sale in the ordinary course of business. The Company uses the weighted average cost method to value its inventories at the lower of cost and net realizable value. In pursuant to ASC 330-10-50-6, the components of inventory cost include raw materials, labor, and overhead. Additionally, the weighted average cost per unit is used as a basis to determine the cost amounts removed from inventory as the aggregate number of units expected to be delivered under each order. Finally, the net realizable value is determined by using the various factors as following: excess or slow-moving inventories (12 months or more of inventory on hand), expiration dates (within 12 months of the current reporting period), current and future product demand, production planning, and market conditions. If any of these factors are found in the reporting period, management will review each item and determine if any additional allowances or write-offs need to be made. A change in any of these variable’s factors could result in an adjustment to inventory.

An allowance for inventory was established in 2018 and is evaluated each quarter to determine if all items are still sellable due to the factors listed above. As of December 31, 2023 and December 31, 2022, the total of inventory allowance was $1,611,257 and $1,914,891. The following are the classes held in inventory as of December 31, 2023 and December 31, 2022:

	DECEMBER 31,		DECEMBER 31,
	2023		2022
Inventory

Inventory Classes:
Raw Materials	$	2,998,683	$	3,398,655
Finished Goods		225,567		310,600
Work in process		13,290		24,764
Total inventory		3,237,540		3,734,019
Inventory allowance		(1,611,257)		(1,914,891)
Total inventory, net	$	1,626,283	$	1,819,128

Property and Equipment

The Company’s property and equipment are recorded at cost and depreciated using the straight-line method over the useful lives of the assets, generally from three to seven years. Upon sale or disposal of property and equipment, the related asset cost and accumulated depreciation or amortization are removed from the respective accounts and any gain or loss is reflected in current operations.

Indefinite-Lived Intangible Assets

Indefinite-lived intangible assets established in connection with business combinations consist of patents, trademarks, and trade names. The impairment test for identifiable indefinite-lived intangible assets consists of a comparison of the estimated fair value of the intangible asset with it carrying value. If the carrying value exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. With the acquisition of Ultimate Brain Nutrients on April 3, 2020 the Company added a purchasing value of $315,604 in patents to its balance sheet.

As of December 31, 2023, the Company believes that based upon qualitative factors, no impairment of indefinite-lived intangible assets is necessary.

F-7

Goodwill

In accordance with Goodwill and Other Intangible Assets, goodwill is defined as the excess of the purchase price over the fair value assigned to individual assets acquired and liabilities assumed and is tested for impairment at the reporting unit level on an annual basis in the Company's fourth fiscal quarter or more frequently if indicators of impairment exist. The performance of the test involves a two-step process. The first step of the impairment test involves comparing the fair value of the Company's reporting units with each respective reporting unit's carrying amount, including goodwill. The fair value of reporting units is generally determined using the income approach. If the carrying amount of a reporting unit exceeds the reporting unit's fair value, the second step of the goodwill impairment test is performed to determine the amount of any impairment loss. The second step of the goodwill impairment test involves comparing the implied fair value of the reporting unit's goodwill with the carrying amount of that goodwill. No goodwill impairment indicators were present, for the goodwill listed on the books as of December 31, 2023, after working through our analysis of goodwill during the year ended December 31, 2023.

The Company has determined that the method applied represents the fair value of the asset group principally because the valuation of the intangibles with the asset group is based on the anticipated cash flows related to the revenue stream from its customers. The asset group excludes goodwill, long term non-operational assets and liabilities and cash. As such, the principal value from the asset group relates to the cash inflows from its customers and the cash outflows required to service these customers. The fair value for the asset group consists of the following:

·Fair value of net revenues: computed using the income approach. The key input to these computations is the anticipated cash inflows from customers. These valuations include 100% of the cash inflows related to the customer base, and taking cash outflows into consideration.

·Fair value of working capital (including accounts receivable, inventory, accrued expenses, and accounts payables). Due to the short-term nature of the working capital, book value has been determined to be fair value. These accounts represent either avoided future outflows (inventory, prepaids) or future cash flows (accrued expense, AP and AR) related to customer sales.

·Fair value of five years of revenue (2023 to 2027): we discounted our cash flows to the anticipated cash projected to be received. We also projected the anticipated cash outflows required to service these customers. If the asset group was to be valued as a whole, we would expect an income approach based on the revenues being generated from the customers and expenses required to service those customers, appropriately adjusted for the working capital position. The sum of these values reasonably approximates this approach.

The Company’s revenue streams align directly with the intangibles, which were recorded as a result of the BergaMet acquisition in fiscal 2019. For purposes of the Step 2 recoverability test under ASC 360 subsection 2.3., the net revenues from BergaMet customers base were used. The revenue stream fairly reflects anticipated future cash flows; accordingly, the intangibles associated with these revenue streams have been tested with the expected cash flows.

Debt with Warrants

In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations using the straight-line method. The offset to the contra-liability is recorded as either equity or liability in the Company’s consolidated balance sheets depending on the accounting treatment of the warrants. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations.

Convertible Debt – Derivative Treatment

When the Company issues debt with a conversion feature, we must first assess whether the conversion feature meets the requirements to be treated as a derivative, as follows: (a) one or more underlying’s, typically the price of our common stock; (b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; (c) no initial net investment, which typically excludes the amount borrowed; and (d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both (a) indexed to its own stock; and (b) classified in stockholders’ equity in its balance sheet.

F-8

If the conversion feature within convertible debt meets the requirements to be treated as a derivative, we estimate the fair value of the convertible debt derivative using a Black-Scholes Option-Pricing model upon the date of issuance. If the fair value of the convertible debt derivative is higher than the face value of the convertible debt, the excess is immediately recognized as interest expense. Otherwise, the fair value of the convertible debt derivative is recorded as a liability with an offsetting amount recorded as a debt discount, which offsets the carrying amount of the debt. The derivative is revalued at the end of each reporting period and any change in fair value is recorded as a gain or loss in the statement of operations. The debt discount is amortized through interest expense over the life of the debt using the straight-line method.

Revenue Recognition

Mostly, revenues are recognized at the time of shipment to the customer with the price being fixed and determinable and collectability assured, provided title and risk of loss is transferred to the customer. Most of our shipping and handling costs are built into the transaction price, but if the customer asks for express shipping, the costs charged to customers are classified as sales, and the shipping and handling costs incurred are included in cost of sales.

The Company’s subsidiary, BergaMet N.A., LLC, recognizes revenue from our main source – e-commerce revenue. Here is a list of all the sales channels which include the Company’s subsidiary website channel or any other selling channel like Amazon, doctors’ offices, and walk-in sales. All of our customer sales for Healthy Extracts, Inc. and Ultimate Brain Nutrients, LLC are recognized as revenue under the subsidiary of BergaMet N.A., LLC. All three divisions of the Company sell plant-based nutraceuticals to our end using customers.

The Company evaluates the criteria pursuant to ASC 606-10-55. Some of the different considerations that we use because of their significance are as follows: Collectability - payment has to be made prior to shipment unless the customer has agreed upon terms. Guaranties – we offer a money back to customers if they are unhappy with our products. Principal versus Agent Considerations - currently we are the principal and have not engaged an agent at this time and we have not recognized any revenues under the agent considerations.

If the Company receives a request for refund on a customer obligation, the Company will refund the full cost of the obligation due to our money back guarantee. Historically, we have done a valuation of our sales allowance account (customer returns). In 2023 our return percentage was 0.008% of sales and 2022 was 0.009% of sales. Due to the low refund percentage management decided there was not a need for an estimated adjustment for allowances and refunds due to materiality.

Revenue recognition is evaluated through the following five-step process:

6.identification of the contract with a customer;

7.identification off the performance obligations in the contract;

8.determination of the transaction price;

9.allocation of the transaction price to the performance obligations in the contract; and

10.recognition of revenue when or as a performance obligation is satisfied.

These steps are met when an order is received, a price agreed and the product shipped or delivered to that customer.

F-9

Concentration

There is no concentration of revenue for the year ended December 31, 2022 and for the year ended December 31, 2023 because the revenue was earned from multiple customers.

Income Taxes

The Company uses the liability method of accounting for income taxes under which deferred tax assets and liabilities are recognized for the future tax consequences of temporary differences between the accounting bases and the tax bases of the Company’s assets and liabilities. The deferred tax assets and liabilities are computed using enacted tax rates in effect for the year in which the temporary differences are expected to reverse.

The Company's deferred income taxes include certain future tax benefits. The Company records a valuation allowance against any portion of those deferred income tax assets when it believes, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred income tax asset will not be realized.

The Company has adopted ASC guidance regarding accounting for uncertainty in income taxes. This guidance clarifies the accounting for income taxes by prescribing the minimum recognition threshold an income tax position is required to meet before being recognized in the consolidated financial statements and applies to all income tax positions. Each income tax position is assessed using a two-step process. A determination is first made as to whether it is more likely than not that the income tax position will be sustained, based upon technical merits, upon examination by the taxing authorities. If the income tax position is expected to meet the more likely than not criteria, the benefit recorded in the consolidated financial statements equals the largest amount that is greater than 50% likely to be realized upon its ultimate settlement. At December 31, 2023 and 2022, there were no uncertain tax positions that required accrual.

Fair Value Measurements

The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

The estimated fair value of certain financial instruments, including cash and cash equivalents are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 — quoted prices in active markets for identical assets or liabilities

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

The derivative liability in connection with the conversion feature of the convertible debt, classified as a Level 3 liability, is the only financial liability measure at fair value on a recurring basis. If the convertible debt is viewed as short-term, management chooses to expense the full debt discount in the period incurred is recorded as a gain or loss in the consolidated statement of operations.

The Company measures and reports certain financial instruments as liabilities at fair value on a recurring basis. The fair value of these instruments as of December 31, 2023 and December 31, 2022 was as follows:

		Fair Value	Level 1		Level 2		Level 3
Fair Value at December 31, 2021	$	92,527		-		-	$	92,527
Derivative liability		102,011		-		-		102,011
Fair Value at December 31, 2022	$	102,011		-		-	$	102,011
Derivative liability		154,150		-		-		154,150
Fair Value at December 31, 2023	$	154,150		-		-	$	154,150

F-10

December 31, 2023

		Level 1				Level 2				Level 3				Total
Derivative liability			-				-				154,150			$	154,150

December 31, 2022

		Level 1				Level 2				Level 3				Total
Derivative liability			-				-				102,011			$	102,011

The details of derivative liability transactions for the year ended December 31, 2023 and December 31, 2022 are as follows:

The change in Level 3 financial instrument fair value is as follows:

Balance, December 31, 2021		$ 92,527
Issued during the year ended December 31, 2022		264,952
Derivative liabilities debt premium		(43,269)
Change in fair value recognized in operations		(212,199)
Converted during the year ended December 31, 2022		(0)
Balance, December 31, 2022		$ 102,011
Issued during the year ended December 31, 2023		145,067
Derivative liabilities debt discount		29,167
Change in fair value recognized in operations		(83,923)
Converted during the year ended December 31, 2023		(38,172)
Balance, December 31, 2023		$ 154,150

The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between levels during the year ending December 31, 2023 and December 31, 2022.

The Company determines the fair value of the derivative liability based on Level 3 inputs using the Black-Scholes option pricing model. The significant unobservable input assumptions that can significantly change the fair value includes common share price; amount of principal and accrued interest convertible into shares as of the conversion date, and the number of shares issuable upon conversion; expected exercise price; expected term; volatility; and risk-free interest rate.

Convertible Instruments

Convertible debt – derivative treatment

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

If the conversion feature within convertible debt meets the requirements to be treated as a derivative, we estimate the fair value of the convertible debt derivative using the Black-Sholes option pricing model upon the date of issuance. If the fair value of the convertible debt derivative is higher than the face value of the convertible debt, the excess is immediately recognized as interest expense. Otherwise, the fair value of the convertible debt derivative is recorded as a liability with an offsetting amount recorded as a debt discount, which offsets the carrying amount of the debt. If the convertible debt is viewed as short-term, management chooses to expense the full debt discount in the period incurred is recorded as a gain or loss in the consolidated statement of operations. The convertible debt derivative is revalued at the end of each reporting period and any change in fair value is recorded as a gain or loss in the consolidated statement of operations.

F-11

Convertible debt – beneficial conversion feature

The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records when necessary, any discounts, if applicable, to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts, if applicable, under these arrangements are amortized over the term of the related debt to their stated date of redemption.

Debt modifications and extinguishments

The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded under change in fair value on derivative, in the consolidated operation statements, as a gain or loss on extinguishment of the two separate liabilities. During the year ended December 31, 2023, the Company issued $388,888 of convertible debt.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 amends the guidance for revenue recognition to replace numerous, industry specific requirements and converges areas under this topic with those of the International Financial Reporting Standards. The ASU implements of five–step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract cost, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The amendments in this ASU are effective for reporting period beginning after December 15, 2016, and early adoption is prohibited. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption.

The Company’s revenues are recognized when control of the promised goods or services is transferred to our clients (upon shipment of goods) in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: (1) Identify the contract with a client; (2) Identify the performance obligations in the contract; (3) Determine the transaction price; (4) Allocate the transaction price to performance obligations in the contract; and (5) Recognize revenues when or as the Company satisfies a performance obligation.

We adopted ASC 2014-09 on January 1, 2019. Although the new revenue standard is expected to have an immaterial impact, if any, on our ongoing net income, we did implement changes to our processes related to revenue recognition and the control activities with them.

The Company leases its office and warehouse space under non-cancellable capital leases. The Company accounts for this lease in accordance with ASC 842. Right-of-use (“ROU”) assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Since our lease arrangements do not provide an implicit rate, we use our estimated incremental borrowing rate for the expected remaining lease term at commencement date in determining the present value of future lease payments.

The lease agreements do not contain any material residual value guarantees or material restrictive covenants.

Capital lease expense is recognized on a straight-line basis over the lease term. Variable lease payments are not included in the lease payments to measure the lease liability and are expensed as incurred.

Finance lease expense is comprised of both interest expense, which is recognized using the effective interest method, and amortization of the right-of-use assets. These expenses are presented consistently with the presentation of other interest expense and amortization or depreciation of similar assets.

Common area maintenance fees (or CAMs) and other charges related to leases are expensed as incurred. See Note 5 — Right-of-Use Assets and Lease Liabilities for further discussion of the Company’s lease activities.

F-12

Common Stock Purchase Warrants

The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to our own stock as defined in ASC 815-40 (“Contracts in Entity's Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside our control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification is required.

NOTE 3 – GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has generated minimal revenues from operations. Since its inception, the Company has been engaged substantially in financing activities and developing its business plan and incurring startup costs and expenses. As a result, the Company incurred accumulated net losses from Inception (December 19, 2014) through the year ended December 31, 2023 of $18,336,268. Due to our negative cash flow, the Company has substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. In addition, the Company’s development activities since inception have been financially sustained through equity financing. Management plans to keep seeking funding through debt and equity financing which are intended to mitigate the conditions that have raise substantial doubt about the entity’s ability to continue as a going concern.

NOTE 4 – RELATED PARTY

For the year ended December 31, 2023 and December 31, 2022, the Company had expenses totaling $0 and $1,000 respectively, to an officer and director for salaries, which is included in general and administrative expenses on the accompanying consolidated statement of operations.

Note	Issuance Date	Maturity Date	Interest Rate	Original Principal Amount	Balance at December 31, 2023	Balance at December 31, 2022
Unsecured debt A	March 2019, March and June 2020	No due date	0%	$866	$866	$866
Unsecured debt H	September 1, 2023	January 1, 2024	10%	$82,500	$82,500	$866
Total notes payable				$83,366	$83,366	$866
Debt discount and deferred financing costs				-	-	-
Total notes payable, net				$83,366	$83,366	$866

Unsecured debt A: On March 2, 2020, the Company received an unsecured loan of $200 from a shareholder. Additionally, during in March and June 2019, the Company received an additional loan of $666 from another shareholder. Both of these notes are unsecured and do not have a payment due date at an interest rate of 0.00%.

Unsecured debt H: On September 1, 2023, the Company received an unsecured line of credit in the principal of up to $82,500 with a loan origination fee in the amount of $7,500, which was amortized over the life of the line of credit. The net proceeds from this line of credit were $75,000. The loan is unsecured and is due for repayment on January 1, 2024. Interest will accrue at an interest rate of 10% per annum on any unpaid principal amount. If the Company defaults on the loan, the holder of the note can declare all or any portion of the unpaid balance with all accrued interest immediately due and payable. As of December 31, 2023, the outstanding principal balance of unsecured debt G totaled $75,000.

NOTE 5 – RIGHT-OF-USE ASSETS AND LEASE LIABILITIES

In February 2022, the Company entered into a lease agreement for our warehouse facilities located at 7375 Commercial Way Suite 125, Henderson, Nevada 89011 with a term of 35 month 25 days and will expire in 2025. Prior to February 4, 2022 the company was leasing a warehouse facility on a month-to-month lease. The average monthly base rent for the first 12 months is approximately $5,333. For the next 24 months of the lease, the average monthly base rent will be approximately $5,694. As part of the agreement the Company will be responsible to share any

F-13

property operating expenses estimated as $1,017 per month. Pursuant to ASC 842, the estimated operating expenses was included with the base rent and was included in the calculations of the right of use assets. The Company recorded operating lease right-of-use of $175,765 and lease liabilities for operating lease of $175,765.

Supplemental statements of operations information related to leases are as follows:

	Year Ended
	December 31, 2023
Lease Cost
Cash paid for amounts included in the measurement of lease liabilities for the first quarter 2022	$	-
Weighted average remaining lease term – operating leases (in years)		1.08
Average discount rate – operating leases		9.80%

	December 31, 2023
Operating leases
Right-of-use assets, net of amortization of $104,182	$	71,583

Short-term operating lease liabilities	$	(65,229)
Long-term operating lease liabilities		(9,222)
Total operating lease liabilities	$	(74,452)

The following table summarizes the future undiscounted cash payments reconciled to the lease liability:

Year Ending	Operating Leases
2022 (remaining eleven months)	$	-
2023		-
2024		69,635
2025		5,822
2026 and thereafter		-
Total lease payments	$	75,457
Less: Imputed interest/present value discount	$	(1,005)
Present value of lease liabilities	$	74,452

NOTE 6 – NOTES PAYABLE

As of December 31, 2023, the Company had the following:

Note	Issuance Date	Maturity Date	Interest Rate		Original Principal Amount	Balance at December 31, 2023	Balance at December 31, 2022
Unsecured debt B	February 22, 2022	February 15, 2023	10%	$	200,000	-	75,370
Secured debt C	October 7, 2022	October 7, 2023	12.99%		200,000	-	200,000
Unsecured debt D	March 20, 2023	August 17, 2024	10%		330,000	166,486	-
Secured debt E	May 19, 2023	May 18, 2024	12.99%		131,000	-	-
Secured debt F	July 26, 2023	May 18, 2024	12.99%		196,000	110,399	-
Secured debt G	December 19, 2023	December 18, 2024	10%		94,600	92,526	-
Total notes payable				$	1,151,600	369,411	$275,370
Debt discount and deferred financing costs					-	-	-
Total notes payable, net				$	1,151,600	369,411	$275,370

F-14

Unsecured debt B: On February 22, 2022, the Company received an unsecured loan in the principal of $200,000 with a loan origination fee in the amount of $20,000, which was fully expensed as interest expense in this period. The net proceeds from this loan were $180,000. The loan is unsecured and the initial payment of $17,804 was due on April 22, 2022. There will be ten monthly payments due on the 22nd day of each following month, beginning on May 22, 2022 through Feb 15, 2023. During fourth quarter of 2022, the note holder agreed to forgo two months of payments and add them to the back end of the note, which extended the due date of the note to April 25, 2023. Interest will accrue at an interest rate of 10% per annum on any unpaid principal amount. If the Company defaults on the loan, the default interest will increase to 16% per annum. During 2022, the Company made a total in principal payments of $124,630 towards unsecured debt B. During 2023, the Company has made additional principal payments towards unsecured debt B totaling $75,370 which settled the entire principal balance in full. As of December 31, 2023, the principal balance of the note was paid off.

Secured debt C: On October 7, 2022, the Company agreed to a secured loan by any consigned inventory held at fulfillment centers and any rights, title or interest in their account. The principal loan amount was $200,000 and will have a loan term of twelve months with an annual interest rate of 12.99%, with a default rate of 14.99%. The first three months of payment will be interest only payments of $2,165 and the remaining nine payments will be principal and interest payments of $23,442. Interest payments will begin November 8, 2022 and Installment payments, including principal and interest, will begin February 8, 2023. During 2023, the Company has made principal payments totaling $200,000 towards the secured debt C which settled the entire principal balance in full. As of December 31, 2023 the principal balance of secured debt C was paid off.

Unsecured debt D: On March 20, 2023, the Company received an unsecured loan in the principal of $330,000 with a loan origination fee in the amount of $30,000, which was fully expensed as interest expense in this period. The net proceeds from this loan were $300,000. The loan is unsecured and the initial payment of $23,359 will be due on June 17, 2023. There will be fourteen monthly payments due on the 17th day of each following month, beginning on July 17, 2023 through August 17, 2024. Interest will accrue at an interest rate of 10% per annum on any unpaid principal amount. If the Company defaults on the loan, the default interest will increase to 16% per annum. During 2023, the Company made a total in principal payments of $163,514 towards the unsecured debt D. As of December 31, 2023, the outstanding principal balance of unsecured debt D totaled $166,486.

Secured debt E: On May 19, 2023, the Company agreed to a secured loan by any consigned inventory held at fulfillment centers and any rights, title or interest in their account. The principal loan amount was $131,000 and will have a loan term of twelve months with an annual interest rate of 12.99%, with a default rate of 14.99%. The first payment of principal and interest will be $11,700 and will be due June 19, 2023 with an additional eleven payments due each 19th of the month. During 2023, the Company has made principal payments totaling $10,282 towards the secured debt E. As of December 31, 2023 the principal balance of secured debt E was paid off.

Secured debt F: On July 26, 2023, the Company agreed to a secured loan by any consigned inventory held at fulfillment centers and any rights, title or interest in their account. The principal loan amount was $196,000 and will have a loan term of twelve months with an annual interest rate of 12.99%, with a default rate of 14.99%. The first payment of principal and interest will be $17,505 and will be due August 26, 2023 with an additional eleven payments due each 26th of the month. During 2023, the Company has made principal payments totaling $85,601 towards the secured debt F. As of December 31, 2023 the principal balance of secured debt E was $110,399.

Secured debt G: On December 19, 2023, the Company agreed to a secured loan by any rights, title or interest in their account. The principal loan amount was $86,000 and will have a loan term of twelve months. The note has a cost of funds equal to 10% of the loan amount or $8,600 and will be due upon acceptance of the loan amount. A total of $283 of the interest has been expensed in 2023. Payment will be made daily at a repayment rate of 14% of daily sales. and will be due December 21, 2023 and will continue until full amount owed is paid. During 2023, the Company has made principal payments totaling $2,074 towards the secured debt E. As of December 31, 2023 the principal balance of secured debt E was $92,526.

F-15

NOTE 7 – CONVERTIBLE DEBT

As of December 31, 2023, the Company had the following convertible debt outstanding:

Note	Issuance Date	Maturity Date	Interest Rate		Original Principal Amount		Balance at December 31, 2023		Balance at December 31, 2022
Convertible promissory note #1	July 28, 2016	January 19, 2017	8%	$	15,000	$	6,750	$	6,750
Convertible promissory note #2	May 25, 2022	August 5, 2023	10%		154,000		-		110,535
Convertible promissory note #3	May 12, 2022	May 1, 2023	12%		200,000		200,000		200,000
Convertible promissory note #4	January 24, 2023	April 24, 2024	0%		388,888		401,851		-
Total notes payable				$	757,888	$	608,601	$	317,285
Debt discount and deferred financing costs					-		-		-
Total notes payable, net				$	757,888	$	608,601	$	317,285

Convertible promissory note #1:

On July 28, 2016, the Company executed the convertible promissory note #1 in the principal amount of $15,000, which is in default but management has not been able to make contact with this party, due to them living out of the country. The due date for this note was January 19, 2017 at an interest rate of 8%, with a default interest rate of 18%. We have calculated the derivative liability as if it is in default (but the note’s default interest rate stays the same at 8%) and will still accrue appropriate interest until the note is fully satisfied or converted into the Company’s common stock. The conversion option for this note coverts at a 54% discount to the market price based on the lowest trading prices in the last 20 days trading period. The outstanding balance on convertible promissory note #1 as of December 31, 2023 was $6,750.

The fair value of the derivative as of December 31, 2023 was determined to be $21,185 using the Black-Scholes option pricing model based on the following assumptions: common share price of $0.06 per share; expected exercise price of $0.0169 per share; volatility of 133%; expected dividend yield of zero; and annual risk-free interest rate of 5.44%. The derivatives are classified as liabilities as they represent an obligation to deliver a variable number of shares of common stock in the future and are therefore required to be initially and subsequently measured at fair value each reporting period. The Company originally recorded a derivative liability in the amount of $9,649. The fair value of the derivative liability is remeasured each reporting period using the Black-Scholes option pricing model, and the change in fair value is recorded as an adjustment to the derivative liabilities account with the unrealized gains or losses reflect in other income – change in fair value on derivative.

Convertible promissory note #2:

On May 25, 2022, the Company executed the convertible promissory note #2 in the principal amount of $154,000 with a loan origination fee in the amount of $15,400, which was fully expensed as interest expense in this period. The net proceeds from this note were $138,600. The loan is unsecured and the initial repayment of $14,488 was due on October 5, 2022. There will be ten additional monthly payments due on the 5th day of each following month, beginning on November 5, 2022 through August 5, 2023. Interest will accrual at an interest rate of 10% per annum on any unpaid principal amount. If the Company defaults on the loan, the default interest will increase to 16% per annum. During 2022, the Company has made principal payments totaling $43,465 towards the outstanding balance on convertible promissory note #2. During 2023, the Company has made additional principal payments towards convertible promissory note #2 totaling $110,535 which settled the entire principal balance in full. As of December 31, 2023, the principal balance of the note was paid off the principal balance of the note was paid off.

The fair value of the derivative was determined to be $0, due to being paid off, using the Black-Scholes option pricing model based, prior to the note being paid off, on the following assumptions: common share price of $0.06 per share; expected exercise price of $0.05 per share; volatility of 133%; expected dividend yield of zero; and annual risk-free interest rate of 5.44%. The derivatives are classified as liabilities as they represent an obligation to deliver a variable number of shares of common stock in the future and are therefore required to be initially and subsequently measured at fair value each reporting period. The Company originally recorded a derivative liability in the amount of $89,895.

F-16

The fair value of the derivative liability is remeasured each reporting period using the Black-Scholes option pricing model, and the change in fair value is recorded as an adjustment to the derivative liabilities account with the unrealized gains or losses reflect in other income – change in fair value on derivative.

Convertible promissory note #3:

On May 12, 2022, the Company executed the convertible promissory note #3 in the principal amount of $200,000. The loan is unsecured and the principal and any unpaid accrued interest shall be due and payable on May 12, 2023. Interest shall accrue at the rate of 12% per annum. The outstanding balance on convertible promissory note #3 as of December 31, 2023 was $200,000. At any time on or after July 24, 2023, the holder shall have the right, at his option, to convert the principal amount of the note, or any portion of such principal amount, plus accrued but unpaid interest into shares of the Company’s common stock. The Company has been advised the holder of convertible promissory note #3 will be converting the full value of the outstanding principal and interest in the near future. The conversion price shall be $0.05 per share.

The fair value of the derivative was determined to be $76,919 using the Black-Scholes option pricing model based on the following assumptions: common share price of $0.06 per share; expected exercise price of $0.05 per share; volatility of 133%; expected dividend yield of zero; and annual risk-free interest rate of 5.44%. The derivatives are classified as liabilities as they represent an obligation to deliver a variable number of shares of common stock in the future and are therefore required to be initially and subsequently measured at fair value each reporting period. The Company originally recorded a derivative liability in the amount of $184,011. The fair value of the derivative liability is remeasured each reporting period using the Black-Scholes option pricing model, and the change in fair value is recorded as an adjustment to the derivative liabilities account with the unrealized gains or losses reflect in other income – change in fair value on derivative.

Convertible promissory note #4:

On January 24, 2023, the Company executed the convertible promissory note #4 in the principal amount of $388,888 with a loan origination fee in the amount of $38,888, which was fully expensed as interest expense in this period, additionally there were $12,500 of legal costs and $31,500 of agent fees in which were also fully expenses in this period. The net proceeds from this loan were $306,000. The loan is unsecured and the principal and any unpaid accrued interest shall be due and payable on October 24, 2023 with an interest rate of 0%. Any unpaid balance at that time will start to accrue interest at a default rate of 20% per annum. On October 31, 2023 the note was extended to April 24, 2024 for an additional fee in the amount of $38,889. The additional fee will be amortized over the six month and in 2023 $12,962 was expensed. The outstanding balance on convertible promissory note #4 as of December 31, 2023 was $401,851. The holder shall have the right, at his option, to convert the principal amount of the note, or any portion of such principal amount, plus accrued but unpaid interest into shares of the Company’s common stock. The conversion price means ninety percent (90%) of the lowest VWAP of our common stock for the five (5) consecutive Trading Days immediately preceding the date of the issuance of a Conversion Election.

The fair value of the derivative was determined to be $56,047 using the Black-Scholes option pricing model based on the following assumptions: common share price of $0.06 per share; expected exercise price of $0.0425 per share; volatility of 133%; expected dividend yield of zero; and annual risk-free interest rate of 5.44%. The derivatives are classified as liabilities as they represent an obligation to deliver a variable number of shares of common stock in the future and are therefore required to be initially and subsequently measured at fair value each reporting period. The Company originally recorded a derivative liability in the amount of $174,234. The fair value of the derivative liability is remeasured each reporting period using the Black-Scholes option pricing model, and the change in fair value is recorded as an adjustment to the derivative liabilities account with the unrealized gains or losses reflect in other income – change in fair value on derivative.

NOTE 8 – DERIVATIVE LIABILITY

The Company evaluated the notes under the requirements of ASC 480 “Distinguishing Liabilities From Equity” (ASC 480) and concluded that the notes do not fall within the scope of ASC 480. The Company next evaluated the notes under the requirements of ASC 815 “Derivatives and Hedging Activities” and determined that the scope exception to ASC 815’s derivative accounting provisions does not apply. The Company then evaluated the embedded derivative criteria in ASC 815, and concluded that the conversion features meet all the embedded derivative criteria in ASC 815, and therefore, the conversion features meet the definition of an embedded derivative that should be separated from the notes and accounted for as a derivative liability.

F-17

The derivative liabilities were valued using a Black-Scholes option pricing model with the following average assumptions:

	December 31, 2023	Upon Issuance 2023	December 31, 2022	Upon Issuance 2022
Stock Price	$0.06	$0.048	$0.04	$ 0.043-0.066
Exercise Price	$ 0.017-0.05	$0.045	$ 0.0224-0.05	$ 0.0224-0.05
Expected Life	0	0.75	0 - 0.59	1.0 - 1.2
Volatility	133%	145%	168%	194.52 - 197.12%
Dividend Yield	0%	0%	0%	0%
Risk-Free Interest Rate	5.44%	4.57%	4.02%	0.53 - 0.61%
Convertible Notes	`595,638`	`388,888`	`317,285`	`356,000`
Total Fair Value	`$154,153`	`$174,234`	`$102,011`	`$273,906`

The expected life of the note was based on the remaining contractual term of the instruments. The Company uses the historical volatility of its Common Stock to estimate the future volatility for its Common Stock. The expected dividend yield was based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future. The risk-free interest rate was based on rates established by the Federal Reserve Bank.

Consolidated Statement of Operations – Change in fair value on derivative

During the year ended December 31, 2022, , the following transactions were recorded in the account “change in fair value on derivative”: (i) as a result of the issuance of convertible notes, the Company recorded derivative liabilities of $(264,952); (ii) the Company viewed the convertible debt derivatives as short term and thus chose to record as other income the debt premium associated with the derivative liabilities incurred during this period in the amount of $43,269; and (iii) the change in the fair value of these derivative liabilities for the year ended December 31, 2022 resulted in a gain of $212,199.

During the year ended December 31, 2023, the following transactions were recorded in the account “change in fair value on derivative”: (i) as a result of the issuance of convertible notes, the Company recorded derivative liabilities of $(145,067); (ii) the Company viewed the convertible debt derivatives as short term and thus chose to expense the debt discounts associated with the derivative liabilities incurred during this period in the amount of $(29,167); (iii) the changes in the fair value of these derivative liabilities for the year ended December 31, 2023 resulted in a gain of $83,920; and (iv) the Company recorded a gain on debt extinguishment of $38,172 to account for the extinguishment of derivative liabilities associated with the settlement or the conversion of the convertible debt accounted for as a derivative liability.

The details of derivative liability transactions for the period ended December 31, 2023 and December 31, 2022 are as follows:

The change in Level 3 financial instrument fair value is as follows:

Balance, December 31, 2021		$ 92,527
Issued during the year ended December 31, 2022		264,952
Derivative liabilities debt premium		(43,269)
Change in fair value recognized in operations		(212,199)
Converted during the year ended December 31, 2022		(0)
Balance, December 31, 2022		$ 102,011
Issued during the year ended December 31, 2023		145,067
Derivative liabilities debt discount		29,167
Change in fair value recognized in operations		(83,923)
Converted during the year ended December 31, 2023		(38,172)
Balance, December 31, 2023		$ 154,150

F-18

NOTE 9 – INCOME TAXES

The effective income tax rate for the years ended December 31, 2023 and 2022 differs from the U.S. Federal statutory rate due to the following:

	December 2023	December 2022
Federal statutory income tax rate	`$678,297`	`(166,169)`
Change in valuation allowance	`(678,297)`	`166,169`
	`$-`	`$-`

The components of the deferred tax assets and liabilities at December 31, 2023 and 2022 are as follows:

	December 2023	December 2022
Long-term deferred tax assets:
Federal net operating loss carryforwards	`678,297`	`166,169`
Valuation allowance	`(678,297)`	`(166,169)`
Net long-term deferred tax assets	`$-`	`$-`

NOTE 10 – STOCKHOLDERS’ EQUITY

Authorized Stock

The Company has authorized 75,000,000 common shares with a par value of $0.001 per share. Each common share entitles the holder to one vote on any matter on which action of the stockholders of the corporation is sought. During February 2017, the Company increased the authorized number of shares to 500,000,000. Also, the Company increased the authorized preferred stock to 75,000,000 shares and designated 25,000,000 shares of preferred stock to Series A Convertible Preferred Stock. During January 2018, the Company increased its authorized number of common shares to 1,000,000,000. During April 2018, the Company increased its authorized number of common shares to 2,500,000,000. The Board of Directors, in the future, has the authority to increase the authorized capital up to 4,000,000,000 shares based on shareholder approval. On December 29, 2023 the Company decreased its authorized number of common shares to 50,000,000.

The Company effectuated a reverse stock split of 120-for-1 as of December 29, 2023.

On October 16, 2017, the Company filed an Amended and Restated Certificate of Designation of the Rights, Preferences, Privileges and Restrictions of the Series A Convertible Preferred Stock (the “Amended Certificate”) with the Secretary of State of the State of Nevada. The Amended Certificate reduces the number of preferred shares designated as Series A Preferred Stock from 25,000,000 shares to 1,333,334 shares. The Amended Certificate also changes the conversion and voting rights of the Series A Preferred Stock. The Series A Preferred Stock is now convertible into the number of shares of our common stock equal to 0.00006% of our outstanding common stock upon conversion. The voting rights of the Series A Preferred Stock are now equal to the number of shares of common stock into which the Series A Preferred Stock may convert.

As of December 31, 2023, there are no outstanding shares of preferred stock. All the preferred stock was converted in common stock on February 4, 2019.

Common Share Issuances

During the months ended March 31, 2023, the Company issued 320,000 shares of common stock. During the months ended June 30, 2023, the Company did not issue any shares of common stock. During the months ended September 30, 2023, the Company issued 9,000,000 shares of common stock for the Restricted Stock Units which were executed. The holders paid the Company $0.01 for each share of common stock and the value of each share was $0.05. There were no shares issued during the fourth quarter 2023.

There were no shares issued during the fourth quarter 2022. During the third quarter 2022, the Company issued 340,000 shares of common stock for consulting fees along with issuing 340,621 shares of common stock to convert an outstanding note payable to a shareholder. On May 19, 2022, the Company issued 4,400,000 shares of common stock for broker and consulting fees. On April 22 and 25, 2022, the Company issued 2,000,000 shares of common stock for broker and funding fees. On February 4, 2022, the Company issued 507,917 shares of common stock in a direct security purchase agreement. On January 10, 2022, the Company cancelled 200,267 shares of common stock. Further, on March 4, 2022, the Company cancelled 600,000 shares of common stock.

F-19

Warrant Issuances

During the month ending March 31, 2023, the Company issued 61,846 warrants to 2 unrelated parties at a per share price of $5.6592. On February 2, 2022, the Company issued 16,667 warrants to an individual at a per share price of $6.00. As of December 31, 2023, there were 195,180 warrants outstanding, of which 195,180 warrants are fully vested.

			Weighted-
		Weighted-	Average
		Average	Remaining	Aggregate
		Exercise	Contractual	Intrinsic
	Warrants	Price	Life (Years)	Value

Outstanding at December 31, 2022	133,333	$7.22	2.17	-
Granted	61,846	6.00	1.11	-
Forfeited	-	-	-	-
Exercised	-	-	-	-
Outstanding at December 31, 2023	195,180	$6.83	1.17	$ -

Vested and expected to vest at December 31, 2023	195,180	$6.83		$ -

Exercisable at December 31, 2023	195,180	$6.83		$ -

At December 31, 2023, the intrinsic value of these stock warrants was $0 as the exercise price of these stock warrants were greater than the market price.

Stock Issued for Services

On March 6, 2023, the Company issued 320,000 shares of common stock for consulting fees at a per share price of $0.05.

On September 13, 2022, the Company issued 340,000 shares of common stock for consulting fees at a per share price of $0.05. During the period ending June 30, 2022, the Company issued 6,400,000 shares of common stock for broker, consulting, and funding fees at a per share price of $0.05.

Share Conversion Agreements

All of the holders of the Company’s Series A Convertible Preferred Stock (the “Preferred Holders”) entered into a Preferred Stock Conversion Agreement. Pursuant to the Conversion Agreements, the Preferred Holders converted their shares of preferred stock into common stock, effective as of the Exchange. As a result, no shares of the Company’s Series A Convertible Preferred Stock are outstanding. An aggregate of 15,592,986 shares of common stock were issued to the Preferred Holders. The Preferred Holders agreed to convert each share of Series A Convertible Preferred Stock into eighteen (18) shares of common stock and agreed to retire a total of 467,057 shares of Series A Convertible Preferred Stock. The Company cancelled the retired shares.

Omnibus Stock Grant and Option Plan

On December 31, 2021, the Company approved stock option agreements in the amount of 7,500,000 shares with a strike price of $0.05 to twenty-one individuals. These options are immediately vest and will expire in five years.

F-20

The following summary of options activity for the year ended December 31, 2023 is presented below:

			Weighted-
		Weighted-	Average
		Average	Remaining	Aggregate
		Exercise	Contractual	Intrinsic
	Options	Price	Life (Years)	Value

Outstanding at December 31, 2022	32,083	$6.00	2.13	38,500
Granted	6,250	6.00	3.42	7,500
Forfeited	-	-	-	-
Exercised	-	-	-	-
Outstanding at December 31, 2023	38,333	$6.00	2.34	$46,000

Vested and expected to vest at December 31, 2023	38,333	$6.00		$46,000
Exercisable at December 31, 2023	38,333	$6.00		$46,000

At December 31, 2023, the intrinsic value of these stock options was $46,000 as the exercise price of these stock options were less than the market price.

On December 26, 2022, the Company canceled 101,250 stock options with a strike price of $6.00.

The following summary of restricted stock units’ activity for the three months ended December 31, 2023 is presented below:

			Weighted-
			Weighted-
			Average
			Grant Date
	Shares		Fair Value

Non-vested at December 31, 2022		-		-
Granted		133,125		6.00
Vested		(74,167)		6.00
Forfeited		-		-
Non-vested at December 31, 2023		58,958		6.00

The total fair value of restricted stock units vested during the three months ended September 30, 2023 was $445,000 and is included in selling, general and administrative expenses in the accompanying consolidation statements of operations. As of December 31, 2023, the amount of unvested compensation related to issuances of restricted stock units’ fair value was $423,910. This amount will be amortized and expensed over the life of the contract and will be included in selling, general and administrative expenses in the accompanying consolidation statements of operations.

The fair value of share options, units, and warrants are estimated using the Black-Scholes option pricing method based on the following weighted-average assumptions:

	Year Ending December 31,
	2023			2022
Risk-free interest rate		5.18	%		2.75	%
Average expected term (years)		4.7 years			4.75 years
Expected volatility		106.5	%		194.8	%
Expected dividend yield		-			-

F-21

NOTE 11 – BUSINESS SEGMENT INFORMATION

As of December 31, 2023, the Company operated in two reportable segments (Corporate and Health Supplements) supported by a corporate group which conducts activities that are non-segment specific. The following table presents selected financial information about the Company’s reportable segments for the year ended December 31, 2023.

	CONSOLIDATED	HEALTH SUPPLEMENTS		CORPORATE
		BergaMet	UBN
Revenue	2,485,866	2,485,866	-	-
Cost of Revenue	813,614	813,614	-	-
Long-lived Assets	732,030	193,260	538,771	-
Gain (Loss) Before Income Tax	(2,422,489)	(219,975)	(5,113)	(2,197,401)
Identifiable Assets	1,676,724	1,676,724	-	-
Depreciation and Amortization	2,195	2,195	-	-

As of December 31, 2022, the Company operated in two reportable segments (Corporate and Health Supplements) supported by a corporate group which conducts activities that are non-segment specific. The following table presents selected financial information about the Company’s reportable segments for the year ended December 31, 2022.

	CONSOLIDATED	HEALTH SUPPLEMENTS		CORPORATE
		BergaMet	UBN
Revenue	2,251,469	2,251,469	-	-
Less Selling Fees
Cost of Revenue	783,141	783,141	-	-
Long-lived Assets	732,030	193,260	538,771	-
Gain (Loss) Before Income Tax	(983,121)	(164,625)	(358)	(818,138)
Identifiable Assets	1,819,128	1,819,128	-	-
Depreciation and Amortization	878	878	-	-

Currently, all of our customers are located in the United States of American and Canada. Our revenues to our customers are not material to our overall total sales. Our largest customers, Natural Grocers and Emerson Ecologics, LLC, account for less than 1% of our total sales in the year ending 2023 and 2022.

NOTE 12 – SUBSEQUENT EVENTS

The key terms for the 15,975,000 RSU are as follows: the effective grant date for all RSU’s is April 28, 2023. Each of the RSU’s will have a purchase price of $0.01 (prior to the reverse split). 8,900,000 of the RSU’s had an expiration date of June 30, 2023 and are all immediately vested once granted. All of the 8,900,000 shares of common stock were issued on July 5, 2023. 7,075,000 of the RSU’s will have an expiration date of March 31, 2024 and will vest on January 1, 2024. Any of the RSU will be forfeited without any payment or consideration by the holder. The RSU’s comply with Section 409A.

The Company has verbally agreed with the borrower of unsecured debt H to extend the due date to July 1, 2024.

The definitive agreement to be acquired for Hyperion, and its digital marketing affiliate, Online Publishing and Marketing expired on the anniversary date of the agreement. When new funding is acquired, further discussions will occur.

The Company evaluated its December 31, 2023 financial statements for subsequent events through March 11, 2024, the date the financial statements were available to be issued.

F-22

ITEM 9 - CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

There are no events required to be disclosed under this Item.

ITEM 9A - CONTROLS AND PROCEDURES

(a) Disclosure Controls and Procedures

We conducted an evaluation, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of December 31, 2023, to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities Exchange Commission’s rules and forms, including to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of December 31, 2023, our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses identified and described in Item 9A(b).

Our principal executive officers do not expect that our disclosure controls or internal controls will prevent all error and all fraud. Although our disclosure controls and procedures were designed to provide reasonable assurance of achieving their objectives and our principal executive officers have determined that our disclosure controls and procedures are effective at doing so, a control system, no matter how well conceived and operated, can provide only reasonable, not absolute assurance that the objectives of the system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented if there exists in an individual a desire to do so. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

(b) Management Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act, as amended, as a process designed by, or under the supervision of, our principal executive and principal financial officer and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States and includes those policies and procedures that:

·Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and any disposition of our assets;

·Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and

·Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect all misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2023. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework. Based on this assessment, Management identified the following two material weaknesses that have caused management to conclude that, as of December 31, 2023, our disclosure controls and procedures, and our internal control over financial reporting, were not effective at the reasonable assurance level:

1. We do not have written documentation of our internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act. Management evaluated the impact of our failure to have written documentation of our internal controls and procedures on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

2. We do not have sufficient segregation of duties within accounting functions, which is a basic internal control. Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. Management evaluated the impact of our failure to have segregation of duties on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

To address these material weaknesses, management performed additional analyses and other procedures to ensure that the financial statements included herein fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented. Accordingly, we believe that the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented.

This Annual Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to the rules of the Securities and Exchange Commission that permit us to provide only our management’s report in this Annual Report.

(c) Remediation of Material Weaknesses

To remediate the material weakness in our documentation, evaluation and testing of internal controls we plan to engage a third-party firm to assist us in remedying this material weakness once resources become available.

We also intend to remedy our material weakness with regard to insufficient segregation of duties by hiring additional employees in order to segregate duties in a manner that establishes effective internal controls once resources become available.

(d) Changes in Internal Control over Financial Reporting

No change in our system of internal control over financial reporting occurred during the period covered by this report, fourth quarter of the fiscal year ended December 31, 2023, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B – OTHER INFORMATION

None.

ITEM 9C – DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

None.

PART III

ITEM 10 – DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The following table sets forth the names, ages, and biographical information of each of our current directors and executive officers, and the positions held by each person, and the date such person became a director or executive officer. Our executive officers are elected annually by the Board of Directors. The directors serve one-year terms until their successors are elected. The executive officers serve terms of one year or until their death, resignation or removal by the Board of Directors. Family relationships among any of the directors and officers are described below.

Name	Age		Position(s)

Kevin “Duke” Pitts		64	President, Director (2018)

Robert Madden		51	Secretary, Chief Financial Officer (2022)

William Bossung		64	Director (2014)

Bill Croyle		71	Director (2019)

Kevin “Duke” Pitts, age 64, was appointed to our Board of Directors on September 28, 2018, and as our President on September 24, 2019. Mr. Pitts is a proven leader who has 30 years of senior management experience within a technology-driven industry. Mr. Pitts has been the President and Owner of Envision Enterprises, a consumer electronic integration business, where he has worked since 2007. Earlier in his career, Mr. Pitts served as the Director of Direct Marketing at Dish Network, the well-known satellite television provider. His deep experience in senior management and marketing will be of great value to us.

Robert Madden, age 51, was appointed as our Secretary and Chief Financial Officer on June 2, 2022. Mr. Madden has been working in the accounting industry for over 30 years. From 1990 to 2012 he worked for several companies starting as a staff accountant, then assistant controller position, finally the company controller position. During that time, he worked in the wholesale apparel, advertising, television, and special event industries. From 2012 to 2015, he took a sabbatical and lived overseas volunteering for different NGO’s and non-profit organizations. During the sabbatical, he volunteered for a British NGO, worked as their CFO, and was the driving force in getting the organization registered with 2 foreign nations. In 2016, he moved back to the United States and started an accounting consulting business. From 2016 to the present, he was hired to fill either a Controller or CFO position for several private and public companies, including United Concerts from 2016 through 2018, Bakken Water Transportation Services, Inc. from 2019 to the present, Geopulse Exploration, Inc. from 2016 through 2019, and Humatech, Inc. from 2021 to the present. He graduated from the University of Utah with a bachelor’s degree in accounting and from Westminster College with an MBA with a certificate of accounting.

William Bossung, age 64, has served as a member of the Board of Directors since our inception, and was our Secretary and Chief Financial Officer from our inception until June 2, 2022. Mr. Bossung has a diverse background in Corporate Finance, Insurance and accounting. From 2003 to August 2006 Mr. Bossung was co-founder of BCF Technology, an insurance software company that was ultimately sold to Vertafore in August of 2006. During January 2012 Mr. Bossung co-founded Splash Beverage Group, (SBEV) a beverage distribution company that distributes both alcohol and non-alcohol products. The company’s products are sold in over 25,000 retail locations Mr. Bossung is the managing partner of Bishop Equity Partners LLC, a small boutique private equity firm that invests in both private and public companies. From 1997 to 2002 Mr. Bossung was the Director of Corporate Finance of Chadmoore Wireless Group, the company was engaged in the business of wireless communications utilizing 800 MHZ frequencies. Chadmoore aggregated over 5500 Specialized Mobile

Radio licenses from the Federal Communications Commission, the licenses were acquired by Nextel, then merged into the Sprint PCS wireless network. Mr. Bossung currently holds an Insurance License and earned a bachelor’s degree in accounting and finance from Bloomsburg State University. Our founders believed that Mr. Bossung’s broad experience in corporate financing and accounting, dating back to 2003, made him an attractive candidate to serve on our board of directors.

Bill Croyle, age 71, was appointed to our Board of Directors on September 24, 2019. Mr. Croyle is a private investor and an accomplished Senior Executive with more than 40 years of success across the IT, energy, manufacturing, telecommunications, venture capital, and finance industries. His broad areas of expertise include mergers and acquisitions, negotiations, service contracts and delivery, executive development and mentoring, and managing complexities. Since 2009 Bill has been a founder, owner or executive of EnTX Group, Impact Legacy Partners, FB Oilfield Special Tools and Western Energy Advisors. He is Chairman of the Colorado Chapter of the Marine Corps Scholarship Foundation, and he has served on the boards of Hill City Silica LLC, the University of Colorado Advocates program, the Association for Corporate Growth/Denver, and the Denver Consulting Alliance. Bill served in the Marine Corps 1972-1974. Mr. Croyle holds Certificates in Energy Finance and Management from the University of Denver and International Trade from World Trade Center Denver. He graduated from the University of California, Santa Barbara, with a BA in History and minor in French. Our directors believed that Mr. Croyle’s experience as a business founder and finance certifications made him an attractive candidate to serve on our board of directors.

Family Relationships

There are no family relationships between any of our officers or directors.

Other Directorships; Director Independence

Other than as set forth above, none of our officers and directors are directors of any company with a class of securities registered pursuant to section 12 of the Exchange Act or subject to the requirements of section 15(d) of such Act or any company registered as an investment company under the Investment Company Act of 1940.

For purposes of determining director independence, we have applied the definitions set out in NYSE Rule 303A.02. The OTCQB on which shares of our common stock are quoted does not have any director independence requirements. The NYSE American definition of “Independent Director” means a person that has no material relationship with the company (either directly or as a partner, shareholder or officer of an organization that has a relationship with the company). According to the NYSE American definition, Mr. Bossung and Mr. Croyle are independent directors.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934 requires our directors and executive officers and persons who own more than ten percent of a registered class of our equity securities to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other equity securities. Officers, directors and greater than ten percent shareholders are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file.

Except as set forth below, to our knowledge, none of our officers, directors, or beneficial owners of more than ten percent of our common stock failed to file on a timely basis reports required by section 16(a) of the Exchange Act during the most recent fiscal or prior fiscal year.

Board Committees

Our Board of Directors maintains separate audit, nominating and compensation committees. The members of all three committees are only our two independent directors, William Bossung and Bill Croyle

Audit Committee. Our audit committee consists of two independent directors. The members of the audit committee are William Bossung and Bill Croyle. The audit committee will consist exclusively of directors who are financially literate. In addition, Mr. Bossung is considered an “audit committee financial expert” as defined by the SEC’s rules and regulations. The audit committee responsibilities include:

·Review and reassess the adequacy of the Audit Committee Charter annually and submit the Charter to the Board for approval.

·Review our annual audited financial statements and any reports or other financial information as the Committee may request, including, without limitation, any material submitted to any governmental body, or the public, including any certification, report, opinion or review rendered by the registered public accountants. Discuss major issues and significant changes regarding accounting and auditing principles and practices as well as the adequacy of internal controls that could significantly affect our financial statements.

·Review any reports to management prepared by the internal auditing department, together with management’s response. Review with management and the registered public accountants significant financial reporting issues and judgments made in connection with the preparation of our financial statements.

·Review with management and the registered public accountants our annual report on Form 10-K and our quarterly report on Form 10-Q prior to its filing or prior to the release of earnings. The chair of the Committee may represent the entire Committee for purposes of these reviews.

·Review our major financial risk exposures and the steps management has taken to monitor and control such exposures.

·Establish procedures for the receipt, retention, and treatment of complaints received by us regarding accounting, internal accounting controls, or auditing matters; and the confidential, anonymous submission by our employees of concerns regarding questionable accounting or auditing matters.

·The Committee shall be directly responsible for the appointment, compensation, and oversight of the work of our registered public accounting firm. The Committee shall monitor the independence and effectiveness and approve the fees and other compensation to be paid to the registered public accountants. On an annual basis, the Committee should review and discuss with the accountants all significant relationships the accountants have with us to confirm the accountants’ independence.

·Meet with the registered public accountants to review the scope, accuracy, completeness and overall quality of the annual financial statements.

·Receive from the registered public accountants the information they are required to communicate to the Committee under generally accepted auditing standards, including, without limitation a formal written statement delineating all relationships between the registered public accountants and us, consistent with Independence Standards Board Standard No. 1, engage in a dialogue with the registered public accountants with respect to any disclosed relationships or services that may impact the objectivity and independence of the registered public accountants, and recommend that the Board take

appropriate action to enhance the independence of the registered public accountants, and reapprove all auditing services (which may entail providing comfort letters in connection with securities underwritings) and all non-audit services as provided for under Section 202 of Sarbanes-Oxley Act of 2002.

·In consultation with the registered public accountants, review the integrity of our financial reporting processes, both internal and external.

·Meet with management and the registered public accountants to review the planning and staffing of the audit.

·Discuss with the registered public accountants the matters required to be discussed by Statement on Auditing Standards No. 61, as modified or amended, relating to the conduct of the audit.

·Review with the registered public accountants any problems or difficulties the accountants may have encountered and any management letter provided by the accountants and our response to that letter. Such review should include any difficulties encountered in the course of the audit work, including any restrictions on the scope of activities or access to required information, and any changes required in the planned scope of the audit.

·make regular reports to the Board of Directors. The Committee shall also prepare the report required by the rules of the Securities and Exchange Commission to be included our annual proxy statement.

Compensation Committee. Our compensation committee consists of two independent directors. The members of the audit committee are William Bossung and Bill Croyle. The compensation committee responsibilities include:

·Review the competitiveness of our executive compensation programs to ensure (a) the attraction and retention of executives, (b) the motivation of executives to achieve our business objectives, and (c) the alignment of the interests of key leadership with the long-term interests of our shareholders. Assist the Board in establishing CEO annual goals and objectives.

·Review trends in executive compensation, oversee the development of new compensation plans, and, when necessary, approve the revision of existing plans.

·Review and approve the compensation structure for executives.

·Oversee an evaluation of the performance of our executive officers and approve the annual compensation, including salary, bonus, incentive and equity compensation, for the executive officers. Review and approve compensation packages for new executive officers and termination packages for executive officers.

·Review and make recommendations concerning long-term incentive compensation plans, including the use of equity-based plans.

·Periodically review the compensation paid to non-employee directors and make recommendations to the Board for any adjustments. No member of the Committee will act to fix his or her own compensation except for uniform compensation to directors for their services as a director.

·Review periodic reports from management on matters relating to our compensation practices.

·Produce an annual report of the Compensation Committee on executive compensation for our annual proxy statement in compliance with and to the extent required by applicable Securities and Exchange Commission rules and regulations and any relevant listing authority.

·Obtain or perform an annual evaluation of the Committee’s performance and make applicable recommendations about, among other things, changes to the charter of the Committee.

Nominating Committee. Our nominating committee consists of two independent directors. The

members of the nominating committee are William Bossung and Bill Croyle. The nominating committee responsibilities include screening and recommending to the full Board director candidates for nomination. The Nominating and Governance Committee will consider stockholder recommendations for candidates for the board of directors, although we do not currently have a process for security holders to send communications to the Board.

During the fiscal years ended December 31, 2023 and 2022, the Board of Directors met as necessary.

Involvement in Certain Legal Proceedings

Other than as set forth above, we are not a party to or otherwise involved in any legal proceedings.

Code of Ethics

We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. The full text of our code of business conduct and ethics will be posted on our corporate website and is filed as an exhibit to this registration statement. We intend to disclose future amendments to certain provisions of our code of business conduct and ethics, or waivers of these provisions, on our corporate website or in filings under the Exchange Act.

ITEM 11 - EXECUTIVE COMPENSATION

Narrative Disclosure of Executive Compensation

Pitts Independent Contractor Agreement

On October 1, 2019, we entered into an Independent Contractor Agreement with Kevin “Duke” Pitts. Pursuant to this agreement, Mr. Pitts has agreed to serve as our President and Chief Executive Officer in exchange for $120,000 per year. The agreement had an expiration date of December 31, 2021, but has been extended indefinitely since then.

Madden Consulting Agreement

Effective June 1, 2022, we entered into a Consulting Agreement with Robert Madden. Pursuant to the agreement, Madden has agreed to serve as our Chief Financial Officer and Secretary in exchange for $42,000 per year. The agreement is effective for one year, and will automatically renew for successive one-year terms.

Summary Compensation Table

The following table sets forth information with respect to compensation earned by our President and our Secretary and Chief Financial Officer for the years ended December 31, 2023 and 2022.

Name and Principal Position	Year	Salary ($)	Bonus ($)	Stock Awards ($)	Option Awards ($)	Non-Equity Incentive Plan Compensation ($)	Nonqualified Deferred Compensation ($)	All Other ($)	Total ($)

Kevin “Duke” Pitts	2023	120,000	-0-	-0-	-0-	-0-	-0-	-0-	120,000
President	2022	110,000	-0-	-0-	-0-	-0-	-0-	-0-	110,000

William Bossung (1)
Secretary and CFO	2022	-0-	-0-	-0-	-0-	-0-	-0-	-0-	-0-

Robert Madden (1)	2023	62,500	-0-	-0-	-0-	-0-	-0-	-0-	62,500
Secretary and CFO	2022	38,500	-0-	-0-	-0-	-0-	-0-	-0-	38,500

(1)Mr. Bossung resigned as our Secretary and Chief Financial Officer effective June 2, 2022, and was replaced by Robert Madden.

Director Compensation

For the years ended December 31, 2023 and 2022, none of the members of our Board of Directors received compensation for his service as a director.

Outstanding Equity Awards at Fiscal Year-End

On June 10, 2020, our Board of Directors approved the Grey Cloak Tech, Inc. 2020 Omnibus Stock Grant and Option Plan and set aside 208,334 shares of our common stock for issuance thereunder. Pursuant to the plan, officers, directors, key employees and certain consultants may be granted stock options (including incentive stock options and non-qualified stock options), restricted stock awards, unrestricted stock awards, or performance stock awards. As of December 31, 2021, we have awarded an aggregate of 162,500 options to twenty-five (25) individuals at an exercise price of $6.00 per share.

On December 26, 2022, we canceled 101,250 of the options and, on that same date, we approved the Healthy Extracts Inc. 2022 Equity Incentive Plan and set aside 433,334 shares of our common stock for issuance thereunder. On December 26, 2022, we approved the grant of a total of 133,125 Restricted Stock Units on April 28, 2023 at $1.20 per share, and the grant of 300,000 Restricted Stock Awards upon our uplisting with a strike price of $0.00 to $1.20 to a total of sixteen (16) individuals.

ITEM 12 - SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The following table sets forth, as of March 18, 2024, certain information with respect to our equity securities owned of record or beneficially by (i) each of our Officers and Directors; (ii) each person who owns beneficially more than 10% of each class of our outstanding equity securities; and (iii) all Directors and Executive Officers as a group.

Name and Address (1)	Common Stock Beneficial Ownership	Percentage of Common Stock Beneficial Ownership (2)

Kevin “Duke” Pitts (3)(5)	218,584	6.93%

William Bossung (3)(6)	53,452	1.81%

Bill Croyle (3)(4)(7)	12,197	<1%

Robert Madden (3)(8)	50,000	1.66%

Jay Decker (9)	1,480,395	49.49%

Shelton Decker (10)	209,447	7.06%

Logan Decker (11)	219,031	7.36%

All Officers and Directors as a Group (4 Persons)	334,234	10.16%

	(1)	Unless otherwise indicated, the address of the shareholder is c/o Healthy Extracts Inc.

	(2)	Unless otherwise indicated, based on 2,954,104 shares of common stock issued and outstanding. Shares of common stock subject to convertible preferred stock and options or warrants currently exercisable, or exercisable or convertible within 60 days, are deemed outstanding for purposes of computing the percentage of the person holding such options or warrants, but are not deemed outstanding for purposes of computing the percentage of any other person.

	(3)	Indicates one of our officers or directors.

	(4)	Includes 5,531 shares of common stock held by BMJ Estate Matters, LLC, of which Mr. Croyle is the controlling party.

	(5)	Includes 200,000 Restricted Stock Awards that have not vested.

	(6)	Includes 208 Restricted Stock Units that have not vested.

	(7)	Includes 2,500 Restricted Stock Units that have not vested.

	(8)	Includes 50,000 Restricted Stock Awards that have not vested.

	(9)	Includes warrants to acquire 37,500 shares of common stock at $6.00 per share. Jay Decker disclaims any ownership of securities held by his adult sons.

	(10)	Shelton Decker is the adult son of Jay Decker. Includes warrants to acquire 12,500 shares of common stock at $6.00 per share.

	(11)	Logan Decker is the adult son of Jay Decker. Includes warrants to acquire 12,500 shares of common stock at $6.00 per share and 8,750 Restricted Stock Units that have vested and 834 Restricted Stock Units that have not vested.

The issuer is not aware of any person who owns of record, or is known to own beneficially, five percent or more of the outstanding securities of any class of the issuer, other than as set forth above. There are no classes of stock other than common stock issued or outstanding.

There are no current arrangements which will result in a change in control.

ITEM 13 - CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

Pitts Independent Contractor Agreement

Madden Consulting Agreement

Jay Decker Transactions

We have entered into numerous transactions with Jay Decker, our majority shareholder, as follows:

BergaMet Acquisition

On February 4, 2019, we acquired BergaMet NA, LLC, a Delaware limited liability company (“BergaMet”). BergaMet is a wholly-owned subsidiary through which we conduct our nutraceuticals business. As a result of the acquisition, Jay Decker became our majority shareholder upon our issuance to him of 711,216 shares of our common stock. The shares of common stock issued in the acquisition were equal to approximately 80.1% of our outstanding common stock immediately following the closing.

Ultimate Brain Nutrients, LLC Acquisition

On April 3, 2020, we acquired Ultimate Brain Nutrients, LLC, a Delaware limited liability company (“UBN”). UBN is a wholly-owned subsidiary through which we conduct our plant-based neuro-products business. As a result of the acquisition, Jay Decker became a significantly larger shareholder upon our issuance to him of 374,234 shares of our common stock. The shares of common stock issued in the acquisition were equal to approximately 42.5% of our outstanding common stock immediately following the closing.

Note Conversion Agreements and Advance Conversion Agreements

Effective April 13, 2020, we entered into a total of eighteen (18) agreements (16 Note Conversion Agreements and 2 Advance Conversion Agreements) whereby an aggregate of $1,508,408 in outstanding principal and accrued interest was converted into an aggregate of 327,074 shares of our common stock. The conversion price was either $3.60 per share or $6.00 per share, depending on the individual agreement. The conversions included notes and advances held by our officers and directors and our largest shareholder, as follows:

Name	Aggregate Principal and Interest	Aggregate Shares
Jay W. Decker	$1,282,231	278,484
William Bossung	$65,677	18,243
First Capital Properties LLC	$16,180	4,494
Shelton S. Decker	$33,717	6,518
Logan B. Decker	$33,717	6,518
Kevin Pitts	$51,255	8,543
Innovation Group Holdings, LLC	$25,627	4,271

Note Conversion Agreements

Effective September 2, 2020, we entered into five (5) Note Conversion Agreements whereby an aggregate of $1,791,383 in outstanding principal and accrued interest was converted into an aggregate of 298,564 shares of our common stock. The conversion price was $6.00 per share. The conversions included a note held by our largest shareholder, as follows:

Name:	No. of Shares
Jay W. Decker	256,125
Genuine Partners	14,105
Dan Bishop	18,334
James Knox	8,334
Matthew Dee Grabau	1,667
Total	298,564

Securities Purchase Agreements

Effective October 15, 2020, we entered into four (4) Securities Purchase Agreements whereby we sold and issued 49,167 shares of our common stock at $6.00 per share for aggregate consideration of $295,000. The purchasers included our officers and directors and our largest shareholder, as follows:

Name	Aggregate Principal and Interest	Aggregate Shares
Jay W. Decker	$100,000	16,667
Shelton S. Decker	$50,000	8,334
Logan B. Decker	$50,000	8,334
Dr. Gerald Haase	$95,000	15,834
Total	$295,000	49,167

Securities Purchase Agreements

On February 10, 2021, and effective December 29, 2020, we entered into Securities Purchase Agreements with Shelton Decker and Logan Decker for the purchase and sale of an aggregate of 16,667 shares of our common stock at $6.00 per share, as follows:

Name:	No. of Shares
Logan Decker	8,334
Jay Decker	8,334
Total	16,667

Promissory Notes

On February 10, 2021, we issued promissory notes to Jay Decker dated December 14, 2020 and December 21, 2020 in the principal amount of $100,000 and $70,000 respectively.

On January 20, 2022, we issued a promissory note to Jay Decker in the principal amount of $185,000. In conjunction therewith and on the same date, we issued to Jay Decker warrants to purchase 16,667 shares of our common stock at an exercise price of $6.00 per share.

On June 24, 2022, we entered into a Note Conversion Agreement with Jay Decker whereby Decker converted $17,000 in principal and $31.07 in interest on an outstanding convertible note into 2,838 shares of our common stock at a conversion price of $6.00 per share.

Warrants

On February 10, 2021, but effective December 21, 2020, we issued warrants to purchase an aggregate of 62,500 shares of our common stock, at an exercise price of $6.00 per share, as follows (the “Warrants”), for consulting services rendered:

Name:	No. of Warrants
Jay Decker	37,500
Logan Decker	12,500
Shelton Decker	12,500
Total	62,500

Restricted Stock Units and Restricted Stock Awards

On December 26, 2022, we approved the grant of a total of 133,125 Restricted Stock Units at $1.20 per share, and the grant of 300,000 Restricted Stock Awards upon our uplisting with a strike price of $0.00 to $1.20 to a total of sixteen (16) individuals. On April 28, 2023 the RSU’s were granted and issued. Bill Croyle received 6,667 of the RSU’s and William Bossung received 20,834 of the RSU’s. Kevin Pitts received 200,000 of the RSA’s and Robert Madden received 50,000 of the RSA’s.

Director Independence

For purposes of determining director independence, we have applied the definitions set out in NYSE Rule 303A.02. The OTCQB on which shares of common stock are quoted does not have any director independence requirements. The NYSE American definition of “Independent Director” means a person that has no material relationship with the company (either directly or as a partner, shareholder or officer of an organization that has a relationship with the company). According to the NYSE American definition, Mr. Bossung and Mr. Croyle are independent directors.

ITEM 14 – PRINCIPAL ACCOUNTING FEES AND SERVICES

BF Borgers CPA PC was our independent registered public accounting firm for the years ended December 31, 2023 and 2022.

Audit and Non-Audit Fees

The following table presents fees for professional services rendered by our independent registered public accounting firm for the audit of our annual financial statements for the years ended December 31, 2023 and 2022.

	Years Ended December 31,
	2023		2022
Audit Fees (1)	$	120,500	$	71,500
Audit Related Fees		—		—
Tax Fees		2,505		—
All Other Fees		—		—
Total	$	123,005	$	71,500

(1) Audit fees were principally for audit and review services.

Of the fees described above for the years ended December 31, 2023 and 2022, all were approved by the entire Board of Directors.

PART IV

ITEM 15 – EXHIBIT AND FINANCIAL STATEMENT SCHEDULES

(a)(1) Financial Statements

The following financial statements are filed as part of this report:

Report of Independent Registered Public Accounting Firm	F-1

Balance Sheets as of December 31, 2023 and 2022	F-2

Statement of Operations for the years ended December 31, 2023 and 2022	F-3

Statement of Stockholders’ Deficit for the years ended December 31, 2023 and 2022	F-4

Statement of Cash Flows for the years ended December 31, 2023 and 2022	F-5

Notes to Financial Statements	F-6 to F-24

(a)(2) Financial Statement Schedules

We do not have any financial statement schedules required to be supplied under this Item.

(a)(3) Exhibits

Refer to (b) below.

(b) Exhibits

Exhibit No.	Description
3.1 (11)	Articles of Incorporation of Grey Cloak Tech Inc.

3.2 (11)	Certificate of Amendment of Articles of Incorporation

3.3 (1)	Bylaws of Grey Cloak Tech Inc.

10.1 (11)	Supply Agreement with H&AD S.r.L. dated January 1, 2019, as amended

10.2 (3)	Share Exchange Agreement dated February 4, 2019 by and among Grey Cloak Tech Inc., BergaMet NA, LLC, and the Members of BergaMet

10.3 (4)	Independent Contractor Agreement by and between the Company and Kevin “Duke” Pitts, dated October 1, 2019

10.4 (5)	Share Exchange Agreement with Ultimate Brain Nutrients, LLC and its members

10.5 (6)	Securities Purchase Agreement dated March 18, 2021

10.6 (6)	Promissory Note dated March 18, 2021

10.7 (11)	Licensing Agreement with Gelteq Ptd Ltd.

10.8 (12)	Private Label Agreement with Whitney Johns, Inc. dated October 11, 2021

10.9 (11)	Lease Agreement for warehouse and distribution facility dated January 20, 2022

10.10 (7)	Common Stock Purchase Warrant dated February 10, 2022

10.11 (7)	Promissory Note dated February 22, 2022

10.12 (8)	Securities Purchase Agreement dated May 25, 2022

10.13 (8)	Convertible Promissory Note dated May 25, 2022

10.14 (11)	Consulting Agreement with Robert Madden

10.15 (9)	Loan Agreement with Amazon Capital Services, Inc. entered into on October 7, 2022

10.16 (10)	Acquisition Agreement with Hyperion, L.L.C. and Online Publishing & Marketing, LLC dated January 13, 2023

10.17 (10)	Securities Purchase Agreement dated January 24, 2023

10.18 (10)	10% OID Promissory Note dated January 24, 2023

10.19 (10)	Common Stock Purchase Warrant dated January 24, 2023

10.20 (13)	First Amendment to 10% OID Promissory Note


10.21 (13)	First Amendment to 10% OID Promissory Note

14.1 (11)	Code of Ethics

23.1*		Consent of BF Borgers CPA PC, independent registered public accounting firm

101.INS		XBRL Instance Document

101.SCH		XBRL Schema Document

101.CAL		XBRL Calculation Linkbase Document

101.DEF		XBRL Definition Linkbase Document

101.LAB		XBRL Labels Linkbase Document

101.PRE		XBRL Presentation Linkbase Document

107 (11)		Filing Fee Table

* Filed herewith

(1)	Incorporated by reference from our Registration Statement on Form S-1 dated and filed with the Commission on March 6, 2015.

(2)	Incorporated by reference from our Annual Report on Form 10-K dated and filed with the Commission on February 19, 2021.

(3)	Incorporated by reference from our Quarterly Report on Form 10-Q dated and filed with the Commission on May 28, 2020.

(4)	Incorporated by reference from our Regulation A Offering Statement on Form 1-A dated and filed with the Commission on May 7, 2021.

(5)	Incorporated by reference from our Current Report on Form 8-K filed with the Commission on April 8, 2020

(6)	Incorporated by reference from our Current Report on Form 8-K filed with the Commission on March 19, 2021

(7)	Incorporated by reference from our Current Report on Form 8-K filed with the Commission on March 2, 2022.

(8)	Incorporated by reference from our Current Report on Form 8-K filed with the Commission on June 7, 2022.

(9)	Incorporated by reference from our Quarterly Report on Form 10-Q dated and filed with the Commission on November 8, 2022.

(10)	Incorporated by reference from our Current Report on Form 8-K filed with the Commission on January 26, 2023.

(11)	Previously filed.


(12)	Incorporated by reference from our Annual Report on Form 10-K filed with the Commission on March 31, 2023.

(13)	Incorporated by reference from our Current Report on Form 8-K filed with the Commission on November 8, 2023.

ITEM 16 – 10-K SUMMARY

The issuer has elected not to provide a 10-K Summary.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Healthy Extracts Inc.


`Dated:`April 1, 2024		/s/ Kevin “Duke” Pitts
	By:	Kevin “Duke” Pitts
	Its:	President

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

`Dated:`April 1, 2024		/s/ Kevin “Duke” Pitts
	By:	Kevin “Duke” Pitts
	Its:	President




`Dated:`April 1, 2024		/s/ Robert Madden
	By:	Robert Madden
	Its:	Chief Financial Officer, Secretary,
		and Principal Accounting Officer

EX-31.1 2 hyex_ex31z1.htm CERTIFICATION

EXHIBIT 31.1

Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer

I, Kevin “Duke” Pitts, certify that:

I have reviewed this Annual Report on Form 10-K of Healthy Extracts Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exhibit Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

`Dated:`April 1, 2024		/s/ Kevin “Duke” Pitts
	By:	Kevin “Duke” Pitts
		President

EX-31.2 3 hyex_ex31z2.htm CERTIFICATION

EXHIBIT 31.2

Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer

I, Robert Madden, certify that:

I have reviewed this Annual Report on Form 10-K of Healthy Extracts Inc.;

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

`Dated:`April 1, 2024		/s/ Robert Madden
	By:	Robert Madden
		Chief Financial Officer

EX-32.1 4 hyex_ex32z1.htm CERTIFICATION

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Healthy Extracts Inc. (the “Company”) on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Kevin “Duke” Pitts, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

`Dated:`April 1, 2024	/s/ Kevin “Duke” Pitts
	By: Kevin “Duke” Pitts
	Its: President

A signed original of this written statement required by Section 906 has been provided to Healthy Extracts Inc. and will be retained by Healthy Extracts Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 hyex_ex32z2.htm CERTIFICATION

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Healthy Extracts Inc. (the “Company”) on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Robert Madden, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

`Dated:`April 1, 2024	/s/ Robert Madden
	By: Robert Madden
	Its: Chief Financial Officer

EX-101.CAL 6 hyex-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 hyex-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 hyex-20231231_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Restricted Stock Units Represents the Restricted Stock Units, during the indicated time period. Maximum Convertible Promissory Note 3 Represents the Convertible Promissory Note 3, during the indicated time period. Inventory {1} Inventory Policies NOTE 3 - GOING CONCERN Proceeds from issuance of noted payable Deposits {1} Deposits Fair value of restricted stock units Represents the monetary amount of Fair value of vested restricted stock units, during the indicated time period. Total current and total liabilities Total current and total liabilities Cash Entity Incorporation, State or Country Code Segments Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Total Fair Value Represents the monetary amount of Total Fair Value, during the indicated time period. Convertible Notes Payable Derivative Financial Instruments, Liabilities Unsecured Debt A Represents the Unsecured Debt A, during the indicated time period. Salary and Wage, Excluding Cost of Good and Service Sold Indefinite-Lived Intangible Assets Proceeds from issuance of common stock Accrued interest payable - related party {1} Accrued interest payable - related party Cash Flows from Operating Activities Cancelation of common stock for debt Represents the monetary amount of Cancelation of common stock for debt, during the indicated time period. REVENUE Patents/Trademarks Entity Voluntary Filers Entity Address, Address Line One Stockholders' Equity, Reverse Stock Split Federal net operating loss carryforwards Secured Debt 4 Represents the Secured Debt 4, during the indicated time period. Unsecured Debt 2 Represents the Unsecured Debt 2, during the indicated time period. Lessee, Operating Lease, Discount Rate Debt Instrument, Interest Rate, Effective Percentage Debt Instrument [Axis] Convertible Debt, Issued Represents the monetary amount of Convertible Debt, Issued, during the indicated time period. Schedule of Effective Income Tax Rate Reconciliation Long-Term Debt, Type [Axis] Tables/Schedules Payments for repayment of convertible debt Payments for repayment of convertible debt Represents the monetary amount of Payments for repayment of convertible debt, during the indicated time period. Net Cash used in Operating Activities Net Cash used in Operating Activities Issuance of common stock for cash {1} Issuance of common stock for cash Equity Component Goodwill Auditor Firm ID Amendment Flag Entity Common Stock, Shares Outstanding Entity Tax Identification Number Less Selling Fees Represents the monetary amount of Less Selling Fees, during the indicated time period. Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Stock Price Represents the per-share monetary value of Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Stock Price, during the indicated time period. Secured Debt 1 Represents the Secured Debt 1, during the indicated time period. Operating Leases, Future Minimum Payments Due Operating Lease, Liability Operating Lease, Liability Average monthly base rent, first 12 months Convertible Debt, Converted Represents the monetary amount of Convertible Debt, Converted, during the indicated time period. Patents Recent Accounting Pronouncements NOTE 7 - CONVERTIBLE DEBT Purchase of fixed assets Purchase of fixed assets Warrants issued for services Fair value of options and warrants issued Represents the monetary amount of Fair value of unvested restricted stock units, during the indicated time period. Statement [Line Items] General and administrative Preferred Stock, Shares Issued Derivative liabilities Notes payable Fixed assets Offering costs Document Fiscal Period Focus Entity Current Reporting Status Entity Address, City or Town UBN Represents the UBN, during the indicated time period. Income Tax Expense (Benefit) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Convertible Promissory Note 2 Represents the Convertible Promissory Note 2, during the indicated time period. Unsecured Debt 1 Represents the Unsecured Debt 1, during the indicated time period. Convertible Debt, Change In Fair Value Recognized In Operations Represents the monetary amount of Convertible Debt, Change In Fair Value Recognized In Operations, during the indicated time period. Warrants Represents the Warrants, during the indicated time period. Goodwill {1} Goodwill NOTE 9 - INCOME TAXES NOTE 8 - DERIVATIVE LIABILITY Cash flows provided by (used in) Investing Activities Cash flows provided by (used in) Investing Activities Right of use asset, net {1} Right of use asset, net Represents the monetary amount of Increase Decrease In Right of Use Asset, Net, during the indicated time period. CONSOLIDATED STATEMENT OF CASH FLOWS Issuance of common stock for services {1} Issuance of common stock for services Issuance of common stock for cash Statement OTHER INCOME (EXPENSE) CONSOLIDATED STATEMENT OF OPERATIONS Preferred Stock, Par or Stated Value Per Share Additional paid-in capital Total other assets Total other assets Local Phone Number Long-lived Assets Segments [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Preferred Stock Class of Stock [Axis] Valuation allowance Valuation allowance Minimum Secured Debt 3 Represents the Secured Debt 3, during the indicated time period. 2023 {1} 2023 Original Principal Amount Stock Issuances [Axis] Represents the description of Stock Issuances, during the indicated time period. Debt with Warrants Represents the textual narrative disclosure of Debt with Warrants Policy, during the indicated time period. NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Payments for repayment of noted payable - related party Payments for repayment of noted payable - related party Cash Flows from Investing Activities Offering Costs Represents the monetary amount of Increase Decrease in offering costs, during the indicated time period. Net income/(loss) before income tax provision Net income/(loss) before income tax provision Revenue STOCKHOLDERS' EQUITY Accrued interest payable - related party Represents the monetary amount of Accrued interest payable - related party, as of the indicated date. CONSOLIDATED BALANCE SHEETS CONSOLIDATED BALANCE SHEETS - Parenthetical Entity Well-known Seasoned Issuer Entity Address, State or Province Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price 2025 {1} 2025 Operating Lease, Weighted Average Remaining Lease Term Schedule of Segment Reporting Information, by Segment March 31, 2023 Represents the March 31, 2023, during the indicated time period. Scenario [Axis] Schedule of Share-based Compensation, Stock Options, Activity Omnibus Stock Grant and Option Plan Represents the Omnibus Stock Grant and Option Plan, during the indicated time period. Schedule of Change in Fair Value on Derivative Represents the textual narrative disclosure of Schedule of Change in Fair Value on Derivative, during the indicated time period. Schedule of Debt Accounts Receivables NOTE 11 - BUSINESS SEGMENT INFORMATION NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES Depreciation and amortization Represents the monetary amount of Depreciation and Amortization, during the indicated time period. Equity Components [Axis] Common Stock, Shares, Issued Common stock, $0.001 par value, 50,000,000 shares authorized, 2,954,104 shares issued and outstanding as of December 31, 2023, and 2,876,437 shares issued and outstanding as of December 31, 2022, respectively Accrued interest payable Accounts payable Entity File Number Document Transition Report Document Period End Date Consolidated Represents the Consolidated, during the indicated time period. Cancelation Of Common Stock For Deb tShares2 Represents the Cancelation Of Common Stock For Deb tShares2 (number of shares), during the indicated time period. Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Statistical Measurement [Axis] Upon Issuance Represents the Upon Issuance, during the indicated time period. Receivable with Imputed Interest, Discount Receivable with Imputed Interest, Discount Debt Instrument, Name Scenario Schedule of Nonvested Restricted Stock Units Activity Notes Cost in acquisition of Hyperion/OP&M Cost in acquisition of Hyperion/OP&M Issuance of common stock for services Accounts receivable CURRENT ASSETS Entity Shell Company Document Financial Statement Error Correction Weighted Average Remaining Contractual Life (Years) Represents the Weighted Average Remaining Contractual Life (Years), during the indicated time period. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Net long-term deferred tax assets Fair Value by Liability Class Liability Class [Axis] Convertible Promissory Note 4 Represents the Convertible Promissory Note 4, during the indicated time period. March 31, 2022 Represents the March 31, 2022, during the indicated time period. Share Options, Units, and Warrants Represents the Share Options, Units, and Warrants, during the indicated time period. Income Taxes NOTE 12 - SUBSEQUENT EVENTS Gain on sale of asset {1} Gain on sale of asset Lease liability - long-term Represents the monetary amount of Increase Decrease In Operating Lease Liability - Noncurrent, during the indicated time period. Income/(Loss) per share - basic and diluted Represents the per-share monetary value of Loss per share - basic and diluted, during the indicated time period. Common Stock, Shares Authorized Preferred Stock, Shares Outstanding Lease liabilities - current Accrued liabilities Document Annual Report StockIssued During Period Shares Issued For Services4 Represents the StockIssued During Period Shares Issued For Services4 (number of shares), during the indicated time period. Series A Preferred Stock Class of Stock Change in valuation allowance Gain (Loss) on Derivative Liabilities 2025 Average monthly base rent, next 24 months Represents the monetary amount of Capital Leases, Contingent Rental Payments Due, Next 24 months, as of the indicated date. Finite-Lived Intangible Assets, Major Class Name Schedule of Deferred Tax Assets and Liabilities Convertible Instruments NOTE 4 - RELATED PARTY Lease liability - current Represents the monetary amount of Increase Decrease In Operating Lease Liability - Current, during the indicated time period. Accounts receivable {1} Accounts receivable Issuance of common stock-restricted stock units issued Represents the monetary amount of Issuance of common stock-restricted stock units issued, during the indicated time period. EX-101.PRE 9 hyex-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 10 hyex-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000490 - Disclosure - NOTE 11 - BUSINESS SEGMENT INFORMATION: Schedule of Segment Reporting Information, by Segment (Tables) link:presentationLink link:definitionLink link:calculationLink 000400 - Disclosure - NOTE 6 - NOTES PAYABLE: Schedule of Debt (Tables) link:presentationLink link:definitionLink link:calculationLink 000660 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:definitionLink link:calculationLink 000140 - Disclosure - NOTE 8 - DERIVATIVE LIABILITY link:presentationLink link:definitionLink link:calculationLink 000570 - Disclosure - NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES (Details) link:presentationLink link:definitionLink link:calculationLink 000220 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Accounts Receivables (Policies) link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:definitionLink link:calculationLink 000310 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Income Taxes (Policies) link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - NOTE 7 - CONVERTIBLE DEBT link:presentationLink link:definitionLink link:calculationLink 000210 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash (Policies) link:presentationLink link:definitionLink link:calculationLink 000470 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Nonvested Restricted Stock Units Activity (Tables) link:presentationLink link:definitionLink link:calculationLink 000150 - Disclosure - NOTE 9 - INCOME TAXES link:presentationLink link:definitionLink link:calculationLink 000700 - Disclosure - NOTE 11 - BUSINESS SEGMENT INFORMATION: Schedule of Segment Reporting Information, by Segment (Details) link:presentationLink link:definitionLink link:calculationLink 000520 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Indefinite-Lived Intangible Assets (Details) link:presentationLink link:definitionLink link:calculationLink 000250 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Indefinite-Lived Intangible Assets (Policies) link:presentationLink link:definitionLink link:calculationLink 000240 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Property and Equipment (Policies) link:presentationLink link:definitionLink link:calculationLink 000270 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Debt with Warrants (Policies) link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - NOTE 3 - GOING CONCERN link:presentationLink link:definitionLink link:calculationLink 000680 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Nonvested Restricted Stock Units Activity (Details) link:presentationLink link:definitionLink link:calculationLink 000610 - Disclosure - NOTE 8 - DERIVATIVE LIABILITY: Assumptions Used Textblock (Details) link:presentationLink link:definitionLink link:calculationLink 000630 - Disclosure - NOTE 8 - DERIVATIVE LIABILITY: Schedule of Change in Fair Value on Derivative (Details) link:presentationLink link:definitionLink link:calculationLink 000550 - Disclosure - NOTE 4 - RELATED PARTY (Details) link:presentationLink link:definitionLink link:calculationLink 000430 - Disclosure - NOTE 8 - DERIVATIVE LIABILITY: Schedule of Change in Fair Value on Derivative (Tables) link:presentationLink link:definitionLink link:calculationLink 000160 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 000560 - Disclosure - NOTE 4 - RELATED PARTY: Schedule of Debt (Details) link:presentationLink link:definitionLink link:calculationLink 000460 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Share-based Compensation, Stock Options, Activity (Tables) link:presentationLink link:definitionLink link:calculationLink 000590 - Disclosure - NOTE 6 - NOTES PAYABLE: Schedule of Debt (Details) link:presentationLink link:definitionLink link:calculationLink 000540 - Disclosure - NOTE 3 - GOING CONCERN (Details) link:presentationLink link:definitionLink link:calculationLink 000530 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:definitionLink link:calculationLink 000290 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Revenue Recognition (Policies) link:presentationLink link:definitionLink link:calculationLink 000650 - Disclosure - NOTE 9 - INCOME TAXES: Schedule of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 000170 - Disclosure - NOTE 11 - BUSINESS SEGMENT INFORMATION link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES link:presentationLink link:definitionLink link:calculationLink 000640 - Disclosure - NOTE 9 - INCOME TAXES: Schedule of Effective Income Tax Rate Reconciliation (Details) link:presentationLink link:definitionLink link:calculationLink 000360 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory: Schedule of Inventory (Tables) link:presentationLink link:definitionLink link:calculationLink 000410 - Disclosure - NOTE 7 - CONVERTIBLE DEBT: Schedule of Debt (Tables) link:presentationLink link:definitionLink link:calculationLink 000510 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory: Schedule of Inventory (Details) link:presentationLink link:definitionLink link:calculationLink 000480 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY: Assumptions Used Textblock (Tables) link:presentationLink link:definitionLink link:calculationLink 000600 - Disclosure - NOTE 7 - CONVERTIBLE DEBT: Schedule of Debt (Details) link:presentationLink link:definitionLink link:calculationLink 000440 - Disclosure - NOTE 9 - INCOME TAXES: Schedule of Effective Income Tax Rate Reconciliation (Tables) link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS link:presentationLink link:definitionLink link:calculationLink 000260 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Goodwill (Policies) link:presentationLink link:definitionLink link:calculationLink 000390 - Disclosure - NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES: Lessee, Operating Lease, Disclosure (Tables) link:presentationLink link:definitionLink link:calculationLink 000190 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis of Presentation (Policies) link:presentationLink link:definitionLink link:calculationLink 000370 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables) link:presentationLink link:definitionLink link:calculationLink 000350 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Common Stock Purchase Warrants (Policies) link:presentationLink link:definitionLink link:calculationLink 000450 - Disclosure - NOTE 9 - INCOME TAXES: Schedule of Deferred Tax Assets and Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 000280 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Convertible Debt - Derivative Treatment (Policies) link:presentationLink link:definitionLink link:calculationLink 000670 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Share-based Compensation, Stock Options, Activity (Details) link:presentationLink link:definitionLink link:calculationLink 000320 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements (Policies) link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 000060 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 000300 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Concentration (Policies) link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - CONSOLIDATED BALANCE SHEETS - Parenthetical link:presentationLink link:definitionLink link:calculationLink 000380 - Disclosure - NOTE 4 - RELATED PARTY: Schedule of Debt (Tables) link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - NOTE 4 - RELATED PARTY link:presentationLink link:definitionLink link:calculationLink 000230 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory (Policies) link:presentationLink link:definitionLink link:calculationLink 000330 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Convertible Instruments (Policies) link:presentationLink link:definitionLink link:calculationLink 000620 - Disclosure - NOTE 8 - DERIVATIVE LIABILITY (Details) link:presentationLink link:definitionLink link:calculationLink 000180 - Disclosure - NOTE 12 - SUBSEQUENT EVENTS link:presentationLink link:definitionLink link:calculationLink 000200 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Use of Estimates (Policies) link:presentationLink link:definitionLink link:calculationLink 000500 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory (Details) link:presentationLink link:definitionLink link:calculationLink 000420 - Disclosure - NOTE 8 - DERIVATIVE LIABILITY: Assumptions Used Textblock (Tables) link:presentationLink link:definitionLink link:calculationLink 000690 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY: Assumptions Used Textblock (Details) link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - NOTE 6 - NOTES PAYABLE link:presentationLink link:definitionLink link:calculationLink 000580 - Disclosure - NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES: Lessee, Operating Lease, Disclosure (Details) link:presentationLink link:definitionLink link:calculationLink 000340 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Recent Accounting Pronouncements (Policies) link:presentationLink link:definitionLink link:calculationLink GRAPHIC 11 hyex10k_1.jpg IMAGE begin 644 hyex10k_1.jpg M_]C_X 02D9)1@ ! 0 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **S=4U_2-$3=J6HV]MD9"R.-Q^B]37/#XI^$C.8EU"1L'&\6[ M[?SQ42J0CNS.56G#XI)'9T5B:?XO\/:K+Y5GJUL\G0(S;"?H&QFMNJC)2U3N M5&<9*\7<****904444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!7DGQ"^*,EA<3:+H#@3QG9/>==A[JGOZGM^M=1\3?$TGAKPE(UL^V]NV^SP$ M=5R#N8?0?J17S?4UR8FLX^[$\_&XAP]R.Y::>:]E>XN99)IG.6>1BS M'ZDU)#D-M4=:@4;!@5=M,%"Q_"N)J0$$>]9QJSIOFBS&G7J4I]0JJK!2/J\+75> MDIH;(XCB=R,A037F$/QMTJ>>.)=)OY]?5YA=?&O2K6ZG@; M2KUC$[(2&3!P<>OM6F?B]X1VG%UY@$X\LJ-H)P GS/4?@FR\ W&A._B:X2._\]@ 9I%^3 QPO'7-3*K4 M]HXIV(E7JNJX1:7J=?\ \+QTG'_((OO^^D_QKU"WE%Q;13*"!(@< ]LC->56 MF@?":^O(;6VN4EGF<)&@N9I>,?&=IX-M;6:ZMIKC[0Y15B(!&!DGFJ_@[Q[:>,[B[BM;&XM_LRJS-* M00VY.G_ -O;3^L M^SZ?\ ]/U[5XM T.[U6:)Y8[9-[(F,GD#C/UKSS_ (7CI/\ T"+[_OI/\:]$ MUS1[?7]&N=+NGD2"X 5S$0&P"#QD'TKR?QK\,] \->$[S5+>XOFGCV+&))%* MDE@.<+Z$TZSJ+6.Q>(=:/O0V1J?\+QTG_H$7W_?2?XU=TCXP:7J^J0V*:9>1 MM)N.]BI"@*6)X/H*\C\$:!#XF\5VNF7+2+;NKM(8R P 4GC(/?%>NK\--!\+ M07>LV]Q>-+;6DY ED4KS&P.0%'8UE3G6FN;H<]&KB*BYKZ%:U^-.F7EW!;1: M1>^9-(L:Y9.I.!W]Z]/KY%TBXCM-8L+F8D10W$^3?%WPIY$G ME75QYFT[?]';KCBJH5[I\[+PV*YD_:,S&^-VDI*T9TF]R&*YW)Z_6KNM_%FS MT#6+C3;W1KT30GJ&7# \AAST(KP:SC^U:E;QN?\ 6S*K?BPS_.O=?BSX1_M? M1!K%G'F]L$^< 3]3T _ MPI_692BE'<;QDI0C&'Q,]_\ "/BM?%UC+>PZ=<6MLC[$>8C]X>^,>E=%FJUA M8VVF6$%C9Q"*W@0)&@[ 58KLBFEKN>A!-17,]10#W9L'_ M -!%>6(<.#7J7QUMY8]9TB\Q^Z>W>('W5L_^S"O*4;<,UY>(3]HSP\6G[65R MV"#T.:GA+19([]JH*2K CM5X'(!'0UR21P35M"S'+O."*DJF'\LAO2I1^,](@0G/VI M)"0,\(=Q_05],5ZN7IJ#/>RE-4Y>IE>)Y5@\*:O(Y^5;.7/_ 'P:^7-&TYM7 MUJQTU7*&YF2+->$ M?A]XITWQ?I5[>:4T5O!<*\CF:,[1ZX#9J\1!RG'30UQ=.4ZD4EH:UY\$DM+& MXN?[=9O)C:3;]FQG )Q][VKRS285NM8L(&)"RW$:$CT+ 5]5ZW'<2Z!J,=I' MYMR]M(L29 W,5( R?>O!] ^&GBJ#Q#ILMWI3PV\=S&\DGG1G:H8$G ;VJ*U% M*2Y$9XC#*,HJG$;\7CGX@W'/2WB_E6GX+^%]AXI\,P:K-J5Q#)([J8XT4@;6 M([U)X^\">)]:\;:A?V.F-/:R;/+D\Y!D!%!X+9Z@U@1_#OQW$@2/3;A%'\*W M: ?^AU+B_:-N-T9N+5:4I0;1Z1I'P>T[2-8L]1CU6ZD>UF6949%PQ4YP:Y7X MT>(/M>L6VAPOF*S7S9L'K(PX'X+_ .A5DVG@3QW!>V\TNFW;QQR*[)]L3Y@# MDC[]%S\._&NL:W)=WNELC7=QOED,T9"!FY/WN@!_2G)MPY8P:N7-R=-PA!JX M[P7XTT3PWX8^*?A;K2>([L:#I)?3"5,.)E&, MJ,CYFSP<]:4Z52*76W8FK0K1C'K;L7_C=*LVI:))&VZ-[9V4CH02.:V/@@\4 M>AZJ7=%)NEZD#^$5SFO^"_&>LV6B*^D2-)96(MG!GCZJ[8/WO[NVL/\ X5AX MR_Z K?\ ?^+_ .*IWFJO.HL?-4C7]JH-GTF+B$G FCS_ +PKB/B](J?#ZY5C M@O/$JCU.[/\ (&O+M+^&OBZ#6+&:71V2..XC=V,T? # D\-7J_Q0T/4O$'A2 M.STNV-Q<"Z20H&5?E"L";;]FQNVJ3C[ MWM5/P1X \3Z5XTTR^O\ 2FBM89&:1S+&=ORD#@-GKBO9/$4-Q<^&=4M[2+S; MB:UDCCCR!N9E( R>.]9T:"<&YK4PP^&3IMSCJ?+WA^ W7B32X!UDNXE_-Q7U MF0""" 0>"#7S]X9^'/BNR\4:5=76E-%;P749^[9^Z/H!_7UKS7Q9X \5:IXMU6^M=(=[>>X9HV\Z,;E['!:O9_"UC/IGA M32K&Z39/!:HDBY!PP'(XJ:$&JC;1.%I-5I-KT-:BEI*[3T1<44E% !12BDH M6DI:* 4444 )12BDH 6DHI: #-%%% !1110!R/Q'\+MXI\)S6\"@WMN?/M_ M]I@#E?Q&1]<5\Q#=&S*RD$'!!X(-?9=>6_$+X5C7)I=8T+9%J+_--;L<).?4 M'LWZ'VKFKT>;WD<6*P[G[T=SPI7#<5(KNOW6(I+VPO=)O&MK^UEMIT.#'*I4 M_P#UZB$H]*\]Q/)E![%Q7+KD]:&D$?/4^E4UDE+!4R2QP%49S7IG@CX5:CK$ M\5_K\3VFG@AO)?Y99AZ8ZJ/KSZ>M$*,I.R"GAY3E:)O?!KP[,?/\1W<>U64P MV@(ZC/S-^F!^->OU';V\-K;QV]O$D4,:A41!@*!T %25ZM*FJ<>5'O4:2I04 M$5-2U"+3+,W,P9EW*@5< EF( &20!R>I(%.LKMKN-V>WF@='*%9 .>AR",@C M!'(^G4&FZC:RWEH8H94C?(/[R/>CCNK+W!^HJ'1M,.E6LD9=&:60RE8DV1H2 M "$7)P.,]>I)[UH5[W-Y"0ZU;7$.F2HLFW421#D=/D9^?P4U'J>N#3;AXEL; MBY\J'SYFA9 (TR1D[F&?NGIGI4&EZ#<6+64<]Y'-:Z>I6V18=K./F.U#5X[#3X+L02W' MGND<4<>T,Q?I]X@#\34L5^QTV2\N;26V\M69HG9&; _W21^M,U33O[2AACW1 M 13++MEB\Q6P#@$9'<@_A3C8EM)ELMT49DC9-T,6U5R#R%R?7UIE>]=E72]= M_M*:.)]/N;0RP>?$9C&0Z<<_*QQ]X=<=:OPW:3W-S JL#;LJLQZ$E0W'X$51 MT_P]8:3?_:;"&*V5H!$\<484.0(^FVLBO#$(<.=I)4.V<$*<= " M<#-6-1T"RU74(KF^BCN(XH7B6&6,,H+%3NY[_+C\:0OWG+YERPO8M1L(;R$, M(Y5W*'&"/K27U_%8"W,JL1/.L"[>Q;H3[<4[3[7[#IUM9^89/(B6/>>K;1C/ MZ5'?Z?'J#6HE*F.&;S6C9 P?Y6 !S[MG\*9?OY ME^UM/',D@8A4"$;5VYP1UZ_WC5N]T^:YO[.\@N5B>V$@VO&75MP YP1TQ^M M7GJ)K.JG1M/>]-G/C4[!-4TV:RE;$H8R+ )RW&W!8KCZ\5;/ )QGVJC:Z7!9ZC/=0I'&)8TCV) M&%QM+'.1USN_2KU XWMJ8^F:W-J5[/;'2;RV^SOY6I.FH0OJ'V(;O.\D3'T"YQ^>:JR:_:17-_ XD5[,*6R!APP'W>><$@'T)]Z MFM](M;75)+Z")(F>%8=D:!1@,3GCZ_I6=>>%8;P2DW4B/)>?:2RJ/N_)NC^A MV#\0#VI"E[2VAJWVH)8^2OEO--._EQ11XW.<$GJ0 22:+"_6^2;]S)#+#( M8I(Y ,JV >Q((((((]:CU&QFN7M[BUG6&ZMV9HS(F]&RI!# $''T/:GZ?9-9 MI,TLQFGGE,LKXVC. .P %,KWN;R)+*[CO[**ZB!$BMC< M/]FG>UM7V3W"[=L9[\$Y(&1D@?R-2Z/ITVE:?!9-<)-#!&(T(B*MQW)W'/Y" MJLVASRBYM/MB#3+F1I)8C%F3YCEE#9P%)SVSR<&D)N?*K;FC?7R6,<>8Y)I9 M7\N**,#<[8)QS@#@$Y)[4MG=-=1NSVTUNZ.4*2@?F""00<]14.I6$MVUO/;3 M+#=6S%HF=-ZG(((89'!SV(/%,T;2AI%O/&'C8S3&4K%$(T3( PHR>./UIC][ MF\A+37+>]EAABCE\]R_F1D#,&P[3OYXYX'KVXS6G5*STY+._U"[5@6O9%D8; M0-NU%7&>_P!W/XU=H'&]O>"BBB@H**** "BBB@ HHHH J7^F6&J0^3?V5O=1 M_P!V:,.!],]*YV;X9^#9G5FT*!2O]QW0'Z@'FNMHJ7%/=$N$9;HR=,\,:%HS M;].TFTMG_OI$-W_?76M:BBFDEL-)+8****8PHHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B 6BB@ HHHH *!110 4444 %%%% '__V0$! end GRAPHIC 12 hyex10k_2.jpg IMAGE begin 644 hyex10k_2.jpg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hyex10k_3.jpg IMAGE begin 644 hyex10k_3.jpg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end GRAPHIC 14 hyex10k_4.jpg IMAGE begin 644 hyex10k_4.jpg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end GRAPHIC 15 hyex10k_5.jpg IMAGE begin 644 hyex10k_5.jpg M_]C_X 02D9)1@ ! 0 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH ***;(<1.?0&@#SVZ^,6@07L]K%;7D[1,RED4 ';UQ MD^U9/_"^]#,A0:1J'!//R^F?6O'K-@]]=R'H9)^?SK'4?Z3)]6_]!H ^BD^, MVB-"96L+Y<<$;5)_G7=:+J]KK^C6VJ698V]PFY-PP1VYKY;; T_..2X_]!%? M07PL/_%M])'HC#_QXT =C1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %0W3;;.=O2-C^AJ:N;\9>+-&\+:2YU:\%N;F-TA&T MDLVT\=YW?P^HIEDKZC M=N+8KU8_,<=5Q0(Z&9P--!_VQ_Z"*^@/A+)YGP\L1_<>1?\ QXU\[W(*6!MV MFA\P'IO]@/Z5[+\'/&&B'0K;PV;U?[5\V5A#M/(SG@].E SUJBBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\X^+/P_U'Q[8 MZ=#I]U;0&UD9W,V>X$+'UVG(Y^E ' MRAXW^'.I^ 8;.6_NK6X6Z9E7R"3@CUS6)H^K1Z?*7>W9\C' KNOBQH7AG1K; M3'\-ZNU\\CN)5-[]HV@#CN<5Y_ITNJI(?L43.WH$#4".GT#S?%OB2VTBT @F MN6(5Y8QM'&>:]5\!_!W6?"_CB#7+N_LI8(@X*1 [CD8]*\M\$:??ZIXWL+;6 MC=6MG(Y\V4'RMO'][M7TCX2M/#'A^2?3=(UI+FXN'\QHI;X329 [#.10,ZVB MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIKNL:,[D*JC))["@!EQ<0V MEN\]Q*D42#+.YP *\N\0_&FSLI6AT6Q-Z5)'G2G:A^@ZFN3\=^,Y_$^I/:VT MC+I<+8C4<>8?[Q_I7 WERD#^3$GFSG^$=!]:0TCL9_C;XQ$C-'#8*O9?*)Q^ MM53\??%T1PUIIS?6-A_6N(.G7]T=TLVP?W5X I/^$><]9*O^ M@?IO_?+?XTA_:%\5]K#3!_P!O\:X*7P[-_ +CTM=- M'_;-O\:Y7QC\1-8\_6N9UQ=U^3CK M2';0ZC2E74[!9[E@>([CPGXI76;*"*2X@9@%E)*G/'-;OA\&+3 MHT/I7+:OI\EMJ$ORD(S%@: L>I)^T7XA ^?1].8_5Q_6GC]HS73Q_8FG?]]/ M_C7CBQ$G%7(+!FYW)^-,5CUQ/V@?$4W":/IZ^^7/]:F'QK\53?=M-/3Z(Q_K M7E\-E*.!<(H]A5Z/3GD'_'])^ I%6/0)/B]XQ?[K6D?T@!_G6EI7QNU6W<)J MVG07,>>7ARC ?3I7ETFD7"#=%>RY]S55KBYM/EO4WQ_\]%'(H ^L?#/C#1_% MEJ9=.N 9%_UD#\2)]1Z>];U?'NGZE=Z3?0ZEIEPT4R'OL?45]/>!_%D' MC#P[%?H EPA\NXB'\#C^AZTQ-'24444""BBB@ HHHH *Y#XEZJ=)\#7KHQ62 M?$"$'!^8\_H#77UYQ\:@?^$(B8=%O$)_)J 1X7//K6#H]["LY M:>3]Y+R6/K5O7I,:)@?Q. :Y=2*0VST5=KK\I&*-H'>N3TW59(L(S9 ]:Z6& MZ2XCRIYH&61GUIXSZU6$N.*>LH]: )J,&F"3WIX:@!OE%NIJC/H\A:'X?DU2%&N)?*A) 2W@.T(/0XZGZT$MG*-8Z@%S]DE(]AFJ#3;6* ML"&'4$8%'6JTESDX!JI)<$\9JK-<" M*(L30 NHZB((B >37*S3L[,Q.6/>I+JY:XE+$\=JJ,>:$2V:&A?\AF'Z$_I7 MK/PAC\WXDPM_SS@E;],?UKR;0?\ D*J?16_E7KWP2'F?$&=O[EFY_4"@:V/H MNBBBF(**** "BBB@ KC?BJF_X::U[1!OR85V5#[ZZ\(Z?J[ZUI5G [,MNUW&=T;$D8!SU-4,Y,>%8EUN/3)=06.25 T;; M"=Q/:MG3_A__ &AL-MJB.K%U#>61\R]1^==?;> /$D^)?"FC6EQ87NF:G8W-P8HY[89(DD/^(H&C B\#W<,.FF>[ M6-[IG$J%?]0J\Y-(?#%LJ7?GZHJ-;,-X$9/RG[I_&NR\5:3XJT!M-^U7=E.= M2G\CS%A/[AFP,'UJQ<_#CQ!([QK9! MYP@:$1$2*0=O7\*X^SU2^TUE^S3E0IW*IY /KB@+7/1G\6_9KMKF]E57C'*L M74EQ<.7FD;0&=MSR;3C&5RBGY14M]>8!C4\FLHN/ M44(38C'%1TK,#WIN13$:FA_\?S'TC->R? (>9XPU:3^[9X_-UKQ?3/,_TEHO MO"+C\Z]J_9SC)U;7)&^\(8U_-O\ ZU(?0^@Z***8@HHHH **** "N;^(">9\ M/M=7&?\ 0W/Z5TE8_BN,2^$=80C(-G+_ .@F@#XXM3NTJY7_ *9U019O[+8A M(_*SDOG#?2K6FMNMKE/]@UG!H/L14@^?NX/.,5+)GK8F;_D$P?\ 79_Y"OY*@/YH)*C/X511U$WB[PU$NOW,&I65U<"S431/+^[E95/ MRJ/3Z51\/:YX9\1:#X+M5FTRTO);.=GC6>,,.!T^E CN%\2>$_ M%5A?6B>)5>:'4$O8VNP(PA#9VKGJO!K6U/QAIEF_B2]L=5LWG6")X )0=[!> M@]?2N9O/$UE9_#C1O$R^&M(:XOITC>(PC:H)QD5W,^C0RZSI\,6D:%_9DT.Z MY22,";=VV#N*0T<5XV\1Z)K'PK62PGMXY[F9)Y+57&Y7/WN/K7BQ*DX!R3Z5 M]+Z1H^C?V?9>3I<"1_;G0*\(W 9/!K$\37265_);1R^&C#]KBB%LD0^TJ"P_ M6@:9Y(OA.ULM/@O/$NJ_V3]IYM[<0F25E_OE?X5JY8CP_P"&8=0O;7Q'%J-S M+:O!;10PLC*S<;B3TP*]IUCPS8ZQ\0]/U:)8Y9[ >3>P/@CRV7*-@U3T+5K7 M4]>\3Z?+H6FI'I.?*981E^#UH"Y\XJ.,#)..W-5;F?8AVY/N*^A?#WBC2=?T M9IX(M&TGQ [[&%S;_NG4'@ GU'O7DWQ5M]3TCQ2YETZTTY+R'/\ H;;HIQW8 M ]#0%SG] O)K/0M>O("@N$6$([(&*Y?G&:IMXKUHCFZ3_ORG^%2:5QX5\0?2 M#_T.NKT7PQILWAG2+K4--A>2\NE4S1W&"D6>2XSU/08IDG$GQ/JS'FX3_OTO M^%-_X2+4V8;IU/(_Y9+_ (5WK>&- AU"_ANX+:(++%' /-8!@V>G/4X'/2LS M5/#FC6NB7,T,(5(H%>&Z-P"SS%L&,K[4#,:X 37-4( 4;%. ,#D UZQ^SD"U M[X@D_AVQ#]37DFJMY6I:J?\ 9C'_ (Z*]E_9OC_XE^O2XZRQ#/X&@#W2BBB@ M HHHH **** "L_74\SP]J2?WK64?^.FM"JNI#.E7@]8'_P#030!\/:8VVZE3 MU5A4 BM_L#2&4>?NP$SVI]J=FJ'_ 'F'\Z3*C3G'VC+;\"''3WS29$[V0K?\ M@F'_ *ZO_(5NMXXU ^$K#P_'#%%'8SB>*X4G?N!)'\ZPC_R"8?\ KJ_\A584 MRCT";XP:]+JUEJ(MK59+:)HG7DB8'KG\JKZQ\3]0U/1+K2;33++3;>Z.9S;# ME_7\ZX4TE SKKGQW?7?@W3O#3VL"VUC*LB2@G3XVZP!&1I=D DQF^\W).?\:KW7QENKJ9Y M&\,Z.9V(;SO+)?/KGUKS#?D8JQ:P;VW$<4BM#T2T^*&MKXQF\2K;0+-/ L$M MN"?+8+T/UI-.^(>H:5J>M:A'9V[R:MGS58G"<8XKC_EC3FHRY92>U '2Z3\2 M;O0-&.DSZ58:G9A_,C2Z3)C.<\$>]7#!$/DC7T% M9=ZV6(JG0A,W-+_Y%;Q!](/_ $.KY6,HT4)DQM;)R!41T&/_GXO/_ !Z8C1?Q;936[I-HZ;BJ!65NA! MR3SZU%=^)-/O-,EM5TA89I-H$B-P"#UQ[BJ1T*/_ )[W?_@"](NB1A@?.N^# M_P ^3T 3Z\<:GJ ]7C'_ (X*]U_9TCV^%]6DQ]ZZ4?DM>":O,MQ>74J*ZJTH M #KM;A0.1VKZ%_9[CV^"+Q_[UXWZ 4 >NT444 %%%% !1110 5%<()+65#T9 M"/TJ6CJ,4 ?"$H\G6)5Z;9F'ZFI727^Q]WV>,1[S^]S\QY]*E\00_9_%>HQ? MW+N0?^/&LQV(=TW' ;IGBDT3*-[%EO\ D$P_]=7_ )"JR@G. 3]!5AO^03#_ M -=G_D*TM%N;&S@=KF0AYG"$*,X3OGVY_2E)V5R:DW"-TKF+M+'"@DGL!FD* M-NV[6W>F.:U=.D@MKV[3SD3=&R0S'H#G@U1F>6&[W_:1)(N/WB'/ZT7UL)3; MDU8@V,OWE89]1BI%#9Q@Y],5;U6Z^TZB727?$-NWT''-66NUC\1?:H2'C#C. M!P5Q@T7=MA*?RJUJU[8WUA]FMICNMBH3*X#CH<>M1SO33<2KR]WW7K^"Z7,DB2=_N M.$'<@XJ9HV$1VHQ [@5I).?^$?C@,Q,GFG:WTG7)8)7BD$$>&0X/ MWQ5+^TM:9 XN[XH>C!FP:M:7_P @/7O^N$?_ *&*[W0F?1_"VEP2K?K(UPEQ M<1O;[U:/=\JH>P.<^] 'G!O];W$&YOL@9(RW2H_[3U;R_,^V7>S.-V]L9^M> MKW>LQ6E_>7QL+R2&ZGBCC/EE2I#D$<_RZ&LW5M1230=3=;:[\I+=K5K4VX6- M)0V3+GL<$&@#CM?RUXSL2681DD]SY:U]"? !=OP^E/\ >O'_ )"OGW7Q^]'T MC_\ 1:U]&? A-GPS@;'WKF0_J* /3**** "BBB@ HHHH **** /BCQS#]G\> MZU'TQ>R?^A&J=Y;S?V.)6BM_+63AP/GP2>I[].E;GQ1A$?Q)UL 8S=,WYFN: MNK6\%J;EMWV1I,+\_&[Z4 1M_P @F'_KL_\ (56%:+6%V-)B/D-@2,2>.F!5 M:*REEMC.&C5=VU0S89SZ*._6@"OVIM:BZ'>-*L:&%L@EF60%4QUW'MU'YU&N MCWS0R3K$&BC=D=@>A R: *0'&*LVZA?F-6$T:Y\NX=Y+>/R%5G5Y,'!Z8]:G MAT:]E60A8UV$@*SX+D#)"^IQS0"(?-+\#I5VUA[D4TZ1>6@CDGCVHZ*ZL#D$ M'I5^!,"D4/ VJ:S;\_+BM6086LF\&2:0S(<>U6V\.P#_F$:Y^.R@#17QGJLT!>>SL)9F96,KN1R"2OR].,UGZKXTU M&>RDTZ>UM526,B4Q?QD@#=GL>!4)T"'_ *!6L_\ CE-_L&$_\PK6/_': #Q" M,2)[HA_\<6OI3X)Q^7\+M./]YY&_\>KYIU^5I9$9K>2W(4+YF0#(2V73E M21M)7TXXJ>?Q)+/I#V @1-TS3"53\P).<9]*CDN9=5U!KJ;J0!CT H!&C#>W MD]DMM-+NA#!@I'0@8XJU#'Q4%M%TXK22/"TBRI*, UFS1[LUL3)G-4)TP#2 MP;A<9%5*T+E>35 C!IHEFSHTCQZ)KS1NR-Y$?*G!^^*R&O;C_GZG_P"_K?XU MJZ5_R =?_P"N$7_HP5ZE#_9Z66F2QZ,\TC6Y:&)+=+3=0TNS9+%XUDNS,JBV"F49R%Y]P161XIW MIX;OC;:?Y"2SHTF^% 8_E.]0P_VL=* ,/Q8";N#)))MHB2?]P5]2?#1/+^&^ MA+_T[ _J:^9O$T(;4(@>UK#_ .BUKZC\"Q>3X$T5!VM$/YC-)#9T-%%%,044 M44 %%%% !1110!\N?&J+;XWOCZ[#_P".BO/-1D5K"-!;L"NW,K8QT/3_ #VK MTWXVQ_\ %979]40_^.UYKJ\=FEC:-%+(9WC4M&P/'7)],=,8I#*#_P#(,A_Z MZM_(5-;7=K%8I#+ 9'\\.Y'&4&.*@66!K(0R&0.KEAM (.15_2;+2[J(&^NF MA<2'@?Q+C@#T.:8BZ;[23/M#Q[S&X6Y\CY8R3E05[X'&:J>=IQTY#N7[4BF, MH8S\YWYWY],<8IL>GV1@@EEEV1NZ*TN_)Y;##;[#O5S^RK(3JBX:38[&(S # M ;"G=[CG% %/5I+2XU!7LR"A1=VU=JAN^!Z5;LH=J#UJ@((EOY4A;=$KX5NN M170VMJ0H:12 >B@_>@#&OK6-%5EG5MW3((K)D@D4G*Y'JO-=%J-J$2,%O-PG"KQCZ MUB":19@JCRQTV@8S0)EO2?\ D!:__P!<(O\ T,5>TOQS=Z-;6J6]E;O-;0F" M.63)^4ON/'OTIGAD&Z&I6G]ES7BS0J)1#($V8;())]ZMR:! I(/AG4 ?>]6F M(KWOCN>\BBC_ +/@C$=PLZ_,3C#;L+ZUIO]B08_P"1>OO_ +6@#5\1KG55'_3K!_Z+6OJ'PBN MSP=HZ^EG%_Z"*^8=9>2;5F,UJUJXBC7R7;)4! !D_05]1^&EV^%M*7TM(O\ MT$4D-FK1113$%%%% !1110 4444 ?-_QN3_BKISZPH?TKS/7!=KI.GK(8/LP MC4Q[3EB3GKW'TKU7XX)CQ43ZVZ?UKQ_5M/DMX;>Y9XRDD:X"MD\^U(?0RJ** M*8A13U4>E,%31#+ 4 :^F0JB^!GK_P#6JE$!LB2- M4"KA3QR/>M.$?:I2,?-G ?M^-(HO!G#(58[MHZ5;0QK')YP#-CJO;-0.IMW9 M1DGH7_PIH)$+>A(% !*(TX8.#U#*V,=: ,:\B;R"&#;U;CW!K.3>DH\X>9M!(3&2/J:VC-Y0>*) MB2RGYO?VK$^T2*KEI#ASL_#O0)[%[3"TVAZ]Y:M'F&/Y>V=XK%FM[DL5*2E@ M.",G\*V="^2QUKS'.U$A)S[2BN^N[RUB6WM[&*2=II9!+Y$'^JSRQW>O3BF2 M>3V&FWNI:E;V%O&_VBX<(@;(R:W-:\$:AH^ER:BM[;7EO#+Y,YMY"3$_H,D=LCI[5K>.;VVG\'WL4LZ7$YO/,A^R0F M-47/_+3U..] S'U]L:V!_P!.\'_HM:^I-!79X>TU?2UC_P#017R7XDN_+\3- M&<_ZBW _[]K7UOHW_(#T_P#Z]H__ $$4D-EVBBBF(**** "BBB@ HHHH ^?/ MC@/^*G4^MLO]:\AUOR!:V2I;-',(P7D*8#CM@]Z]A^.0QXDC/_3L/YFO&-7N M[FX%O%+/(\<<0"(6X7'H*0^AE5LZ++I\KBVO;>/<3\LA[^QK&HH:NK&52G[2 M+C>QZ-#H.EN>;*/'XUNZ?X0TJ>)9!:19+[2.?E]Z\[TWQ-J%K"L"K'+CA2_7 MZ5OV?BS56]<=;^(-2>V$T=O&^1D@9X [UHIXAU 0AS @ MR ><_C1[.I_3%#"8M;O_ ,F.ICT*R^T2IY";AG/^U4H\-V.4C\B/#KO]A7,K MXDO?*\WRX\8QGGDTX^(K_P"SB3R8^&VGKQ3]G4_IG0L-B5N__)CH/^$8T]PI M$,.&SCKU'45%)X9LGMXU,4+1MR ,\'&<5B1Z_?.P62*),G )S@^U5IO$=[$A M)@5CG (! _.CV=3^F2\-B>__ ),6+G0=/@G(^QH&4XK@_&.GP6MW;);1I#$4 M)/.!G-=#/XDU (SO;Q\G:O7DUS.MS7.K7*&[B6%HQ@,.F.^:JG":FFWH+!87 M%T\1SU)7CKUN1:<4C\/:S)_K'$41)Z#B08K4N/B1?W%LUO<6$!0G<5B8QGM@ M9'TZ]ZP=.U-;+[=!/!#&5IOL,'GL<,X8X*@D@8^IJK?^-I]1TB;3YK*+$H4;]Y^0C R!^%91U'3O\ MH"Q#_MLU"ZCIV?\ D#1'_MLU S8\6<^+6 _YY6X_\AK7V-IB[-)LU/:!!_XZ M*^-KF9]9\1&^>)(MS1J(U.0 H 'Z"OLVU&+. >D:_P J2&34444Q!1110 44 M44 %%%% 'S]\=SC7H3_TZC^9KQ"].X0G_IF*]L^/C;==M_>U'\S7B%SRD/\ MN?UI#Z%:BB@4R26,D8(."#UK7L6<-NWMN/?-9*#H*V+)?EI,I)&O:RRQ,"CL MN!C@]O2NA\YPL95VE4+D#L*YZ 5L6OSH%W[67[I_I2'9&@+EY;55)5?G/;C- M.6ZVP_O(AGS.2.QQZ5&&B99$D4Y'.X\'\J7I"X/TJG+/*226SWP>:+#LBM>3O M++*@#1KWV=/UKGM1PBD+)YC-]YO;TK7NY'E)+'\!P*QKM?E- TDC'D=* MFD%7M*TZ'4(;C>^V1"NS+8'O3),:E7[P^M=+<^';*SFL8Y+QW^T.4D<* J\ M@C\ZIZMI-MI\:O#-)(6D&W.,%#R#GUXH T].7%_"/61/YBOLN#_CWC_W1_*O MC?3^=3MQ_P!-$_F*^R8O]2G^Z*2&Q]%%%,04444 %%%% !1110!\\_M <:]: M>]J/_0C7B,WW(O\ =_K7M_[0*YURS.?^7;_V8UXC/]V+_=/\Z0RM2CK24Y1S M3$31CYA6U:#Y16/"/FK;MAA128T:4 K1BZ5GP5H1GB@HN138X=0ZXQSUJ=9H M(@=J%P1]UC5):?0(669I!C 51T"U7<<5)3'H S;@=:RKH?*:V+@=:R;D?*:0 MS,MVB6Y'GQJZ$$$,<8XZU>T:/3W*PWJPAQN([ ('88JMJMG8VL4 M1LYQ(6D^8"7=MXZ8_K5FTO\ 1HW8SVP( M(YA%G)3(/YU]O:YH=CXATN2POXM\3\@C@J>Q!]:\AN/V<[*:624>(K@,Q)YM MPG*.:]WD_9MG#'RO$<9';=;D?UJK)^SCJZ_P"JUVS;_>C84"/& MH!\WXUMV_05Z*/V>_$41^74K!_\ OH?TJ=/@=XGC_P"7BQ;_ +:'_"D-'"0' MBKT9XKM$^#/BA!]^S/\ VU_^M4J_"+Q0HZ6A_P"VM [G&H:D)XKLE^$_BA?X M+7_O\*?_ ,*I\3X^Y:_]_A0!P^:8QKN?^%3^)\_=M/\ O]1_PJ3Q,?\ GT'_ M &UH \ZGZ&LFXZ&O5W^#OB9QC?9C_MI_]:JLGP0\329_TBQ'_;0_X4!<\6N. M&-0U[,W[/?B&7EM4L$_[Z/\ 2GI^SEK)^_KED/HC'^E,EGB1[TJ??7ZBO=(_ MV;;PG][XBA'^[ 3_ %K4M/V;]/1@;KQ!]?8P& !Z5Q/@[X8Z-X/O)+Z)Y+N];(6:8#Y%]%']:[>DAL****8@H MHHH **** "BL&[\66-GXRL/#$D,YO+V!IXY% \L*N<@G.<\'M5>_\;Z=I_BF M?0)H+DW,.GOJ#2*J[/+7.0.<[N/3\: .FHKSC2OC)HNI7&GK-I.LV%KJ$ODV MMY=6P$,CYQ@,&/>M>^^(^BZ=X\@\(W*7*7DP7;.5'E!F&54G.)[.^\6ZIXGR6XN/,DXVIC/-]:-Q\4M*MX->D?3M2W:((C=1^6@;#^@+=N^<4 =U17/:WXQTW0 MO"D?B&999K641^4D(!>0OC: "0,\^M4?%WQ#TKP9:V$VHVUY(UX"PB@16>-0 M 2S D8 SCO0!U]%<_KOBI=%TBUU*#2-3U6*XP573H/-95(R&(R,"N9TOXP:? MJMEC45Q7ACXBIXIO+>*V\,^(+: MVN$+I>W-J%@( S]\,>O:M#Q3XXTCPF]O;W0N+F_N?]196D?F32>X7T^M '2T M5R_AGQM;>);Z>Q.E:KIEY#'YI@U&V,3%,XR.2.M=,'1B0K*2.H!H =17->$O M%9\42:RAL_LW]G7SVF?,W>9M_BZ#'TJ+Q?X[LO!]QIUM/I^H7]SJ#,D$-C$' M=B,=B1Z]J .JHKF?"?CC2_%Z7:VL5U:75FP6YM+R/RY8B>F1DUTBNK_=8-CT M.: '450U?4UTO1;_ %!5$QM('F,8;&[:"<9[=*K>&=<'B+PSINKM"+=KV$2" M'?NVY[9XS0!L4444 %%%% 'E'C2\M]!^-/A76=3D%MIK6DUN;F3A%?YN&/;J M/SK*O-0M/$GQ3\0:GI$Z7=A9>&IH);F$[HRY!(4,.#P?T->QWNGV6IVQMK^T M@NH#R8YXPZG\#Q3+32=-T^S>TLM/M;:V<$-##"J(V>N0!B@#Y@L+Q[3P7X7O M3XFL]7-E>I)#X9,:AT;>>ZG<3W&X8YKT+6_#Y\4_$_Q78H3%>#2K6XM).\4Z M\H<]N>/QKU*S\*^'M.N5N;+0M,MIUZ2PVB(P_$#-7TL;..^DODM85NY%"/.( MP'91T!;J0* /(_A9K;^(?B3XDU":,Q7+6%I'<(1C;*B[7'_?0-.\7:AJNM_% M>.UT?05UV'0;1A-;FZ6!5EF!&2S<'Y>,?6O5[;2M.LKNXN[6QMH+FY.9YHHE M5Y3_ +1 R?QIUOI]E:7%Q<6UI!#/<-NFDCC"M*?5B.2?K0!X+I3:K<_!OQ?X M.EMGBU72)#FU#AV$1.[G $LZQ@/(!T#-U/XU6@\.Z);7YOX-'L(KPG M)N$MD63/^\!F@#@I?^3C;?\ [ K_ /H0K/\ #.G0ZQ\1/B9ILX!CN0D39[94 MC->K'3[(Z@-0-I!]M">6+CRQY@7^[NZX]J(-.LK6[GNK>S@BN+@@S2I&%>3' M3<1R?QH \"\+W-QXEO?"O@6[5BV@WS6^D:;:7T]];Z?:PW<_^NGCA57D_WF R M?QI]GIUEIPE%E9P6PE?$G^_>?SKV:WTVQLY;B6VL[>&2Y;=.T<04RGU8@< MGZTV'2--M["2QAT^UCLY-Q>!(5$;9ZY7&#GO0!Y9\(;UET_289O'UG>HUIMC MT,1PK)"?3<#O./<4NMWMMX;^-TVHZS,+*VU#2A;V.H2J#'#(.N2>!^/K7H]E MX5\/:;=+=6.A:9;7"?=EAM$1A]"!FKU[I]EJ5L;>_M(+J ]8YXPZG\#0!X?; M>+O$S?\ ":Z?;^*QX@2QTGSK6\MK>-,.2 2NSJ0">YK)^'&G20^*_#^HVOB' MP^LMQ_Q\V]G_W.\0:#>>#_! MWBCQ'XC>+4]5UB2%)X[1GAAC (4#/WMO3/TQ7'^&9[[0M8\3V^A7FFLW]@23 MHFBSR30B0$8(WDDR >E?2UQ;P7=N]OA!ZU2LM!T?39%DL M=*L;614,8:"W5"%)R1D#IGM0!XYX:MO!ZO-*U1YO$%UH<[7R?:6=G;9E MS(I)P0>G3\:I_"]@_BW0X_$PRPTM&\/G.(L<[\#O)_A]*]NM_#VBVAN#;:18 M0FY4K.8[=%\T'J&P.1]:?_8FE8LQ_9EGBRYM?W"_N/\ GRAPHIC 16 hyex10k_6.jpg IMAGE begin 644 hyex10k_6.jpg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end GRAPHIC 17 hyex10k_7.jpg IMAGE begin 644 hyex10k_7.jpg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hyex10k_8.jpg IMAGE begin 644 hyex10k_8.jpg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htm IDEA: XBRL DOCUMENT v3.24.1

Document and Entity Information - USD ($)
12 Months Ended

Dec. 31, 2023

Apr. 01, 2024

Jun. 30, 2023

Details

Registrant CIK 0001630176

Fiscal Year End --12-31

Document Type 10-K

Document Annual Report true

Document Period End Date Dec. 31, 2023

Document Transition Report false

Entity File Number 000-55572

Entity Registrant Name Healthy Extracts Inc.

Entity Incorporation, State or Country Code NV

Entity Tax Identification Number 47-2594704

Entity Address, Address Line One 7375 Commercial Way

Entity Address, Address Line Two Suite 125

Entity Address, City or Town Henderson

Entity Address, State or Province NV

Entity Address, Postal Zip Code 89011

City Area Code 720

Local Phone Number 463-1004

Entity Well-known Seasoned Issuer No

Entity Voluntary Filers No

Entity Current Reporting Status Yes

Entity Interactive Data Current Yes

Entity Filer Category Non-accelerated Filer

Entity Small Business true

Entity Emerging Growth Company false

Document Financial Statement Error Correction false

Entity Shell Company false

Entity Public Float $ 18,465,134

Entity Common Stock, Shares Outstanding 2,963,906

Amendment Flag false

Document Fiscal Year Focus 2023

Document Fiscal Period Focus FY

Auditor Name BF Borgers CPA PC

Auditor Firm ID 5041

Auditor Location Lakewood, CO

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
PCAOB issued Audit Firm Identifier
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-K
-Number 249
-Section 310

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 20-F
-Number 249
-Section 220
-Subsection f

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 40-F
-Number 249
-Section 240
-Subsection f
+ Details

Name: dei_AuditorFirmId

Namespace Prefix: dei_

Data Type: dei:nonemptySequenceNumberItemType

Balance Type: na

Period Type: duration

X

- References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-K
-Number 249
-Section 310

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 20-F
-Number 249
-Section 220
-Subsection f

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 40-F
-Number 249
-Section 240
-Subsection f
+ Details

Name: dei_AuditorLocation

Namespace Prefix: dei_

Data Type: dei:internationalNameItemType

Balance Type: na

Period Type: duration

X

- References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-K
-Number 249
-Section 310

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 20-F
-Number 249
-Section 220
-Subsection f

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 40-F
-Number 249
-Section 240
-Subsection f
+ Details

Name: dei_AuditorName

Namespace Prefix: dei_

Data Type: dei:internationalNameItemType

Balance Type: na

Period Type: duration

X

- Definition
Area code of city
+ References
No definition available.
+ Details

Name: dei_CityAreaCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as an annual report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-K
-Number 249
-Section 310

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 20-F
-Number 249
-Section 220
-Subsection f

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 40-F
-Number 249
-Section 240
-Subsection f
+ Details

Name: dei_DocumentAnnualReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates whether any of the financial statement period in the filing include a restatement due to error correction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-K
-Number 229
-Section 402
-Subsection w

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-K
-Number 249
-Section 310

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 20-F
-Number 249
-Section 220
-Subsection f

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 40-F
-Number 249
-Section 240
-Subsection f
+ Details

Name: dei_DocumentFinStmtErrorCorrectionFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as a transition report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Forms 10-K, 10-Q, 20-F
-Number 240
-Section 13
-Subsection a-1
+ Details

Name: dei_DocumentTransitionReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine2

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the state or province.
+ References
No definition available.
+ Details

Name: dei_EntityAddressStateOrProvince

Namespace Prefix: dei_

Data Type: dei:stateOrProvinceItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.
+ References
No definition available.
+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityTaxIdentificationNumber

Namespace Prefix: dei_

Data Type: dei:employerIdItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 405
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Local phone number for entity.
+ References
No definition available.
+ Details

Name: dei_LocalPhoneNumber

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R2.htm IDEA: XBRL DOCUMENT v3.24.1

CONSOLIDATED BALANCE SHEETS - USD ($)

Dec. 31, 2023

Dec. 31, 2022

CURRENT ASSETS

Cash $ 19,441 $ 65,651

Accounts receivable 30,440 105,794

Inventory, net 1,626,283 1,819,128

Offering costs 151,931 0

Prepaid acquisition costs 0 53,015

Right of use asset, net 71,583 0

Total current assets 1,899,678 2,043,587

Fixed assets 3,306 5,501

Patents/Trademarks 521,881 521,881

Deposit 16,890 16,890

Goodwill 193,260 193,260

Total other assets 735,336 737,531

TOTAL ASSETS 2,635,014 2,781,118

LIABILITIES

Accounts payable 116,842 91,316

Accrued liabilities 215,069 94,554

Lease liabilities - current 65,229 0

Lease liabilities - long-term 9,222 0

Notes payable 361,093 275,370

Notes payable - related party 83,366 866

Convertible debt, net of discount 608,601 317,284

Accrued interest payable 64,386 21,387

Accrued interest payable - related party 2,465 0

Derivative liabilities 154,150 102,011

Total current and total liabilities 1,680,424 902,788

STOCKHOLDERS' EQUITY

Preferred stock, $0.001 par value, 75,000,000 shares authorized, none and none shares issued and outstanding, respectively 0 0

Common stock, $0.001 par value, 50,000,000 shares authorized, 2,954,104 shares issued and outstanding as of December 31, 2023, and 2,876,437 shares issued and outstanding as of December 31, 2022, respectively 354,492 345,172

Additional paid-in capital 18,999,770 17,459,899

Accumulated deficit (18,399,673) (15,926,742)

Total stockholders' equity 954,590 1,878,330

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 2,635,014 $ 2,781,118

X

- Definition
Represents the monetary amount of Accrued interest payable - related party, as of the indicated date.
+ References
No definition available.
+ Details

Name: fil_AccruedInterestPayableRelatedParty

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Represents the monetary amount of Notes payable - related party, as of the indicated date.
+ References
No definition available.
+ Details

Name: fil_NotesPayableRelatedParty

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481990/310-10-45-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481990/310-10-45-9
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The capitalized costs incurred (excluded from amortization), as of the date of the balance sheet, to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-10.(c)(7)(ii))
-SubTopic 10
-Topic 932
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479664/932-10-S99-1
+ Details

Name: us-gaap_AcquisitionCostsCumulative

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481231/810-10-45-25

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(8))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481231/810-10-45-25

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483467/210-10-45-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 45
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480555/946-210-45-21

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-SubTopic 210
-Topic 946
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480555/946-210-45-20
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_ConvertibleNotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 340
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.A)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1
+ Details

Name: us-gaap_DeferredOfferingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_DepositsAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13(Column G)(Footnote 8))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13(Column G))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5A
-Subparagraph (SX 210.12-13A(Column E))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483466/210-20-50-3

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483444/210-20-55-22

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483444/210-20-55-10

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-10
+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483154/926-20-50-5

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details

Name: us-gaap_FiniteLivedPatentsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482548/350-20-55-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482598/350-20-45-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483467/210-10-45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481231/810-10-45-25

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483467/210-10-45-5

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7

Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(10))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details

Name: us-gaap_OtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(21))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of accumulated undistributed earnings (deficit).
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-11

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(17))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 22 R3.htm IDEA: XBRL DOCUMENT v3.24.1

CONSOLIDATED BALANCE SHEETS - Parenthetical - $ / shares

Dec. 31, 2023

Dec. 31, 2022

CONSOLIDATED BALANCE SHEETS

Preferred Stock, Par or Stated Value Per Share $ 0.001 $ 0.001

Preferred Stock, Shares Authorized 75,000,000 75,000,000

Preferred Stock, Shares Issued 0 0

Preferred Stock, Shares Outstanding 0 0

Common Stock, Par or Stated Value Per Share $ 0.001 $ 0.001

Common Stock, Shares Authorized 50,000,000 50,000,000

Common Stock, Shares, Issued 2,954,104 2,876,437

Common Stock, Shares, Outstanding 2,954,104 2,876,437

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R4.htm IDEA: XBRL DOCUMENT v3.24.1

CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)
12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

REVENUE

Revenue $ 2,485,866 $ 2,251,469

Net revenue 2,485,866 2,251,469

COST OF REVENUE

Cost of goods sold 864,055 879,951

Total cost of revenue 864,055 879,951

GROSS PROFIT 1,621,810 1,371,517

OPERATING EXPENSES

Direct cost of revenue 0 0

General and administrative 3,865,654 2,283,107

Impairment of assets 0 0

Total operating expenses 3,865,654 2,283,107

OTHER INCOME (EXPENSE)

Interest expense, net of interest income (176,948) (64,690)

Change in fair value on derivative (52,140) (9,484)

Gain on sale of asset 0 2,643

Total other income (expense) (229,088) (71,531)

Net income/(loss) before income tax provision (2,472,931) (983,121)

NET INCOME/(LOSS) $ (2,472,931) $ (983,121)

Income/(Loss) per share - basic and diluted $ (0.85) $ (0.34)

Weighted average number of shares outstanding - basic and diluted 2,915,410 2,854,290

X

- Definition
Represents the monetary amount of Direct cost of revenue, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_DirectCostOfRevenue

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the per-share monetary value of Loss per share - basic and diluted, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_LossPerShareBasicAndDiluted

Namespace Prefix: fil_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the Weighted average number of shares outstanding - basic and diluted (number of shares), during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate cost of goods produced and sold and services rendered during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostOfRevenueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of other assets.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_GainLossOnSaleOfOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482099/360-10-50-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482130/360-10-45-4
+ Details

Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net amount of operating interest income (expense).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.10)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details

Name: us-gaap_InterestIncomeExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherIncomeAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-11

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480767/946-205-45-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(16))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 19
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481231/810-10-45-19

Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 29: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 33: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4J
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J

Reference 34: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4K
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-2

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of sales-type lease revenue.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482964/270-10-50-6A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479773/842-30-50-5
+ Details

Name: us-gaap_SalesTypeLeaseRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(7)(c)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(7)(c)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(7)(c)(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(7)(c)(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5A
-Subparagraph (SX 210.12-13A(Column F))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A
+ Details

Name: us-gaap_UnrealizedGainLossOnDerivatives

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 24 R5.htm IDEA: XBRL DOCUMENT v3.24.1

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)

Common Stock

Additional Paid-in Capital

Retained Earnings

Total

Equity, Attributable to Parent, Beginning Balance at Dec. 31, 2021 $ 338,384 $ 17,075,974 $ (14,943,620) $ 2,470,738

Shares, Outstanding, Beginning Balance at Dec. 31, 2021 2,819,868

Cancelation of common stock for debt $ (800) (53,013) 0 (53,813)

Cancelation of common stock for debt (800,267)

Issuance of common stock for cash $ 508 24,888 0 25,396

Issuance of common stock for cash 507,917

Issuance of common stock for services $ 6,740 395,360 0 402,100

Issuance of common stock for services 6,740,000

Issuance of common stock - Note Conversion $ 341 16,690 0 17,031

Issuance of common stock-Note Conversion, shares 340,621

Net Income/(Loss) $ 0 0 (983,121) (983,121)

Equity, Attributable to Parent, Ending Balance at Dec. 31, 2022 $ 345,173 17,459,899 (15,926,741) 1,878,330

Shares, Outstanding, Ending Balance at Dec. 31, 2022 80,068

Cancelation of common stock for debt (200,267)

Issuance of common stock for cash 507,917

Issuance of common stock for services $ 320 15,680 0 16,000

Issuance of common stock-Note Conversion, shares 340,621

Net Income/(Loss) $ 0 0 (2,472,931) (2,472,931)

Equity, Attributable to Parent, Ending Balance at Dec. 31, 2023 $ 354,492 18,999,770 (18,399,673) 954,590

Shares, Outstanding, Ending Balance at Dec. 31, 2023 2,954,104

Issuance of common stock for services 320,000

Fair value of restricted stock units $ 0 298,153 0 298,153

Fair value of options and warrants issued 0 785,038 0 785,038

Issuance of common stock-restricted stock units issued $ 9,000 $ 441,000 $ 0 $ 450,000

Issuance of common stock-restricted stock units issued 9,000,000

X

- Definition
Represents the monetary amount of Cancelation of common stock for debt, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_CancelationOfCommonStockForDebt

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the Cancelation of common stock for debt, Shares (number of shares), during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_CancelationOfCommonStockForDebtShares

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the monetary amount of Fair value of unvested restricted stock units, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_FairValueOfUnvestedRestrictedStockUnits

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the monetary amount of Fair value of vested restricted stock units, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_FairValueOfVestedRestrictedStockUnits

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the monetary amount of Issuance of common stock-Note Conversion, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_IssuanceOfCommonStockNoteConversion

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the Issuance of common stock-Note Conversion, shares (number of shares), during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_IssuanceOfCommonStockNoteConversionShares

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the monetary amount of Issuance of common stock-restricted stock units issued, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_IssuanceOfCommonStockRestrictedStockUnitsIssued

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the Issuance of common stock-restricted stock units issued, shares (number of shares), during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_IssuanceOfCommonStockRestrictedStockUnitsIssuedShares

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the Issuance of common stock for services (number of shares), during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_StockissuedDuringPeriodSharesIssuedForServices

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-11

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480767/946-205-45-4

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 25 R6.htm IDEA: XBRL DOCUMENT v3.24.1

CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)
12 Months Ended 108 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2023

Cash Flows from Operating Activities

Net Income/(Loss) $ (2,472,931) $ (983,121) $ 18,336,268

Adjustments to reconcile net loss to net cash

Depreciation and amortization 2,195 878

Warrants issued for services 1,639,191 402,100

Change in fair value on derivative liability 52,140 9,484

Changes in operating assets and liabilities

Accounts receivable 75,353 27,547

Inventory 192,845 138,838

Offering Costs (151,931) 0

Cost in acquisition of Hyperion/OP&M 53,015 (53,015)

Right of use asset, net (71,583) 0

Deposits 0 (16,890)

Accounts payable 25,526 54,048

Accrued liabilities 120,515 35,291

Accrued interest payable 42,999 8,337

Accrued interest payable - related party 2,465 (14,118)

Lease liability - current 65,229 0

Lease liability - long-term 9,222 0

Net Cash used in Operating Activities (415,749) (390,621)

Cash Flows from Investing Activities

Purchase of fixed assets 0 (7,987)

Gain on sale of asset 0 2,643

Cash flows provided by (used in) Investing Activities 0 (5,344)

Cash Flows from Financing Activities

Proceeds from issuance of common stock (90,000) (11,386)

Proceeds from issuance of convertible debt 362,963 463,630

Payments for repayment of convertible debt (110,535) (318,095)

Proceeds from issuance of noted payable 713,283 275,370

Payments for repayment of notes payable (657,560) 0

Proceeds from issuance of noted payable - related party 107,500 0

Payments for repayment of noted payable - related party (25,000) (170,000)

Loan origination fees 68,888 0

Net Cash provided by Financing Activities 369,539 239,518

Increase (decrease) in cash (46,210) (156,447)

Cash at beginning of period 65,651 222,098

Cash at end of period $ 19,441 $ 65,651 $ 19,441

X

- Definition
Represents the monetary amount of Depreciation and Amortization, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_DepreciationAndAmortization1

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the monetary amount of Increase Decrease in offering costs, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_IncreaseDecreaseInOfferingCosts

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the monetary amount of Increase Decrease In Operating Lease Liability - Current, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_IncreaseDecreaseInOperatingLeaseLiabilityCurrent

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the monetary amount of Increase Decrease In Operating Lease Liability - Noncurrent, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_IncreaseDecreaseInOperatingLeaseLiabilityNoncurrent

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the monetary amount of Increase Decrease In Right of Use Asset, Net, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_IncreaseDecreaseInRightOfUseAssetNet

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the monetary amount of Payments for repayment of convertible debt, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_PaymentsForRepaymentOfConvertibleDebt

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the monetary amount of Proceeds from issuance of notes payable - related party, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_ProceedsFromIssuanceOfNotesPayableRelatedParty

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482913/230-10-50-8

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-24

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-24

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-SubTopic 230
-Topic 830
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481877/830-230-45-1
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-8

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 230
-Section 45
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481160/942-230-45-1
+ Details

Name: us-gaap_IncreaseDecreaseInDeposits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInInterestPayableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-24

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Cash inflow associated with loan origination (the process when securing a mortgage for a piece of real property) or lease origination.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-12
+ Details

Name: us-gaap_ProceedsFromLoanOriginations1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromRepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-12
+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details

Name: us-gaap_RepaymentsOfRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(7)(c)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(7)(c)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(7)(c)(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(7)(c)(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5A
-Subparagraph (SX 210.12-13A(Column F))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A
+ Details

Name: us-gaap_UnrealizedGainLossOnDerivatives

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 26 R7.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS
12 Months Ended

Dec. 31, 2023

Notes

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS
NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

Healthy Extracts Inc. (the “Company”) was incorporated in the State of Nevada on December 19, 2014 as Grey Cloak Tech Inc. On October 23, 2020, we changed our name from Grey Cloak Tech Inc. to Healthy Extracts Inc. to more accurately reflect our business. The Company has acquired BergaMet NA, LLC and Ultimate Brain Nutrients, LLC which market and sell health supplemental products.

On January 13, 2023 the Company entered into definitive agreement to acquire nutraceutical manufacturer, Hyperion, and its digital marketing affiliate, Online Publishing and Marketing. The total purchase price for the acquisitions was $1,750,000 in cash, $1,300,000 in the form of secured promissory notes, which was due in twelve months once the purchase had occurred, and $1,250,000 worth of our common stock.

X

- Definition
The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 235
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//235/tableOfContent

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 275
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//275/tableOfContent

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//205/tableOfContent
+ Details

Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R8.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended

Dec. 31, 2023

Notes

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying audited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying audited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of December 31, 2023 and the results of operations and cash flows for the periods presented. The results of operations for the year ended December 31, 2023 are not necessarily indicative of the operating results for the full fiscal year or any future period. These audited consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s form 10-K for the year ended December 31, 2022 filed with the SEC on March 31, 2023.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

In regards to inventory write-offs and allowances, our Company determines the net realizable value by using the various factors as following: excess or slow-moving inventories (12 months or more of inventory on hand), expiration dates (within 12 months of the current reporting period), current and future product demand, production planning, and market conditions. If any of these factors are found in the reporting period, management will review each item and determine if any additional allowances or write-offs need to be made. A change in any of these variable’s factors could result in an adjustment to inventory. Management has provided for any risks in the current inventory allowance booked.

As for revenue adjustments for discounts, allowances and refunds, we treat each of these items differently. When it comes to revenue discounts, we will create the invoice for the product sold which will include any discounts given. These discounts usually happen for a short period of time for sales that we will offer around holidays. Due to the revenue being recognized once the order has shipped, less any applicable discount, we book this transaction at the net order transaction amount. In regards to allowances and refunds for revenue adjustments, due to our refund percentage is less than 1% we decided the need for an estimated adjustment for allowances and refunds was not material. If we

do receive any returned orders, we will directly book those orders as refunds the day we receive the call from the customer requesting the refund. We will book the credit memo at the full value of the customer original order.

Cash

Cash includes cash in banks, money market funds, and certificates of term deposits with maturities of less than three months from inception, which are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss in value.

Accounts Receivables

Accounts receivables are recorded at the invoice amount and do not bear interest.

Inventory

Inventories consist of health supplements held for sale in the ordinary course of business. The Company uses the weighted average cost method to value its inventories at the lower of cost and net realizable value. In pursuant to ASC 330-10-50-6, the components of inventory cost include raw materials, labor, and overhead. Additionally, the weighted average cost per unit is used as a basis to determine the cost amounts removed from inventory as the aggregate number of units expected to be delivered under each order. Finally, the net realizable value is determined by using the various factors as following: excess or slow-moving inventories (12 months or more of inventory on hand), expiration dates (within 12 months of the current reporting period), current and future product demand, production planning, and market conditions. If any of these factors are found in the reporting period, management will review each item and determine if any additional allowances or write-offs need to be made. A change in any of these variable’s factors could result in an adjustment to inventory.

An allowance for inventory was established in 2018 and is evaluated each quarter to determine if all items are still sellable due to the factors listed above. As of December 31, 2023 and December 31, 2022, the total of inventory allowance was $1,611,257 and $1,914,891. The following are the classes held in inventory as of December 31, 2023 and December 31, 2022:

DECEMBER 31,

DECEMBER 31,

2023

2022

Inventory

Inventory Classes:

Raw Materials

$

2,998,683

$

3,398,655

Finished Goods

225,567

310,600

Work in process

13,290

24,764

Total inventory

3,237,540

3,734,019

Inventory allowance

(1,611,257)

(1,914,891)

Total inventory, net

$

1,626,283

$

1,819,128

Property and Equipment

The Company’s property and equipment are recorded at cost and depreciated using the straight-line method over the useful lives of the assets, generally from three to seven years. Upon sale or disposal of property and equipment, the related asset cost and accumulated depreciation or amortization are removed from the respective accounts and any gain or loss is reflected in current operations.

Indefinite-Lived Intangible Assets

Indefinite-lived intangible assets established in connection with business combinations consist of patents, trademarks, and trade names. The impairment test for identifiable indefinite-lived intangible assets consists of a comparison of the estimated fair value of the intangible asset with it carrying value. If the carrying value exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. With the acquisition of Ultimate Brain Nutrients on April 3, 2020 the Company added a purchasing value of $315,604 in patents to its balance sheet.

As of December 31, 2023, the Company believes that based upon qualitative factors, no impairment of indefinite-lived intangible assets is necessary.

Goodwill

In accordance with Goodwill and Other Intangible Assets, goodwill is defined as the excess of the purchase price over the fair value assigned to individual assets acquired and liabilities assumed and is tested for impairment at the reporting unit level on an annual basis in the Company's fourth fiscal quarter or more frequently if indicators of impairment exist. The performance of the test involves a two-step process. The first step of the impairment test involves comparing the fair value of the Company's reporting units with each respective reporting unit's carrying amount, including goodwill. The fair value of reporting units is generally determined using the income approach. If the carrying amount of a reporting unit exceeds the reporting unit's fair value, the second step of the goodwill impairment test is performed to determine the amount of any impairment loss. The second step of the goodwill impairment test involves comparing the implied fair value of the reporting unit's goodwill with the carrying amount of that goodwill. No goodwill impairment indicators were present, for the goodwill listed on the books as of December 31, 2023, after working through our analysis of goodwill during the year ended December 31, 2023.

The Company has determined that the method applied represents the fair value of the asset group principally because the valuation of the intangibles with the asset group is based on the anticipated cash flows related to the revenue stream from its customers. The asset group excludes goodwill, long term non-operational assets and liabilities and cash. As such, the principal value from the asset group relates to the cash inflows from its customers and the cash outflows required to service these customers. The fair value for the asset group consists of the following:

·Fair value of net revenues: computed using the income approach. The key input to these computations is the anticipated cash inflows from customers. These valuations include 100% of the cash inflows related to the customer base, and taking cash outflows into consideration.

·Fair value of working capital (including accounts receivable, inventory, accrued expenses, and accounts payables). Due to the short-term nature of the working capital, book value has been determined to be fair value. These accounts represent either avoided future outflows (inventory, prepaids) or future cash flows (accrued expense, AP and AR) related to customer sales.

·Fair value of five years of revenue (2023 to 2027): we discounted our cash flows to the anticipated cash projected to be received. We also projected the anticipated cash outflows required to service these customers. If the asset group was to be valued as a whole, we would expect an income approach based on the revenues being generated from the customers and expenses required to service those customers, appropriately adjusted for the working capital position. The sum of these values reasonably approximates this approach.

The Company’s revenue streams align directly with the intangibles, which were recorded as a result of the BergaMet acquisition in fiscal 2019. For purposes of the Step 2 recoverability test under ASC 360 subsection 2.3., the net revenues from BergaMet customers base were used. The revenue stream fairly reflects anticipated future cash flows; accordingly, the intangibles associated with these revenue streams have been tested with the expected cash flows.

Debt with Warrants

In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations using the straight-line method. The offset to the contra-liability is recorded as either equity or liability in the Company’s consolidated balance sheets depending on the accounting treatment of the warrants. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations.

Convertible Debt – Derivative Treatment

When the Company issues debt with a conversion feature, we must first assess whether the conversion feature meets the requirements to be treated as a derivative, as follows: (a) one or more underlying’s, typically the price of our common stock; (b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; (c) no initial net investment, which typically excludes the amount borrowed; and (d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both (a) indexed to its own stock; and (b) classified in stockholders’ equity in its balance sheet.

If the conversion feature within convertible debt meets the requirements to be treated as a derivative, we estimate the fair value of the convertible debt derivative using a Black-Scholes Option-Pricing model upon the date of issuance. If the fair value of the convertible debt derivative is higher than the face value of the convertible debt, the excess is immediately recognized as interest expense. Otherwise, the fair value of the convertible debt derivative is recorded as a liability with an offsetting amount recorded as a debt discount, which offsets the carrying amount of the debt. The derivative is revalued at the end of each reporting period and any change in fair value is recorded as a gain or loss in the statement of operations. The debt discount is amortized through interest expense over the life of the debt using the straight-line method.

Revenue Recognition

The Company applies Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) topic 606, Revenue from Contracts with Customers (ASC 606). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes all of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASC 606 requires us to identify distinct performance obligations. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. When distinct performance obligations exist, the Company allocates the contract transaction price to each distinct performance obligation. The standalone selling price is used to allocate the transaction price to the separate performance obligations. The Company recognizes revenue when, or as, the performance obligation is satisfied.

Mostly, revenues are recognized at the time of shipment to the customer with the price being fixed and determinable and collectability assured, provided title and risk of loss is transferred to the customer. Most of our shipping and handling costs are built into the transaction price, but if the customer asks for express shipping, the costs charged to customers are classified as sales, and the shipping and handling costs incurred are included in cost of sales.

The Company’s subsidiary, BergaMet N.A., LLC, recognizes revenue from our main source – e-commerce revenue. Here is a list of all the sales channels which include the Company’s subsidiary website channel or any other selling channel like Amazon, doctors’ offices, and walk-in sales. All of our customer sales for Healthy Extracts, Inc. and Ultimate Brain Nutrients, LLC are recognized as revenue under the subsidiary of BergaMet N.A., LLC. All three divisions of the Company sell plant-based nutraceuticals to our end using customers.

The Company evaluates the criteria pursuant to ASC 606-10-55. Some of the different considerations that we use because of their significance are as follows: Collectability - payment has to be made prior to shipment unless the customer has agreed upon terms. Guaranties – we offer a money back to customers if they are unhappy with our products. Principal versus Agent Considerations - currently we are the principal and have not engaged an agent at this time and we have not recognized any revenues under the agent considerations.

Revenue is recognized when, or as, control of a promised merchandise or service is shipped to the customer, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for transferring title of those products or services and are recorded net of and discounts or allowances. Shipping costs paid by the customer are included in revenue. Merchandise sales are fulfilled with inventory held in our warehouse in Henderson, NV. Therefore, the Company’s contracts have a single performance obligation (shipment of product).

If the Company receives a request for refund on a customer obligation, the Company will refund the full cost of the obligation due to our money back guarantee. Historically, we have done a valuation of our sales allowance account (customer returns). In 2023 our return percentage was 0.008% of sales and 2022 was 0.009% of sales. Due to the low refund percentage management decided there was not a need for an estimated adjustment for allowances and refunds due to materiality.

Revenue recognition is evaluated through the following five-step process:

6.identification of the contract with a customer;

7.identification off the performance obligations in the contract;

8.determination of the transaction price;

9.allocation of the transaction price to the performance obligations in the contract; and

10.recognition of revenue when or as a performance obligation is satisfied.

These steps are met when an order is received, a price agreed and the product shipped or delivered to that customer.

Concentration

There is no concentration of revenue for the year ended December 31, 2022 and for the year ended December 31, 2023 because the revenue was earned from multiple customers.

Income Taxes

The Company uses the liability method of accounting for income taxes under which deferred tax assets and liabilities are recognized for the future tax consequences of temporary differences between the accounting bases and the tax bases of the Company’s assets and liabilities. The deferred tax assets and liabilities are computed using enacted tax rates in effect for the year in which the temporary differences are expected to reverse.

The Company's deferred income taxes include certain future tax benefits. The Company records a valuation allowance against any portion of those deferred income tax assets when it believes, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred income tax asset will not be realized.

The Company has adopted ASC guidance regarding accounting for uncertainty in income taxes. This guidance clarifies the accounting for income taxes by prescribing the minimum recognition threshold an income tax position is required to meet before being recognized in the consolidated financial statements and applies to all income tax positions. Each income tax position is assessed using a two-step process. A determination is first made as to whether it is more likely than not that the income tax position will be sustained, based upon technical merits, upon examination by the taxing authorities. If the income tax position is expected to meet the more likely than not criteria, the benefit recorded in the consolidated financial statements equals the largest amount that is greater than 50% likely to be realized upon its ultimate settlement. At December 31, 2023 and 2022, there were no uncertain tax positions that required accrual.

Fair Value Measurements

The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

The estimated fair value of certain financial instruments, including cash and cash equivalents are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 — quoted prices in active markets for identical assets or liabilities

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

The derivative liability in connection with the conversion feature of the convertible debt, classified as a Level 3 liability, is the only financial liability measure at fair value on a recurring basis. If the convertible debt is viewed as short-term, management chooses to expense the full debt discount in the period incurred is recorded as a gain or loss in the consolidated statement of operations.

The Company measures and reports certain financial instruments as liabilities at fair value on a recurring basis. The fair value of these instruments as of December 31, 2023 and December 31, 2022 was as follows:

Fair Value

Level 1

Level 2

Level 3

Fair Value at December 31, 2021

$

92,527

-

-

$

92,527

Derivative liability

102,011

-

-

102,011

Fair Value at December 31, 2022

$

102,011

-

-

$

102,011

Derivative liability

154,150

-

-

154,150

Fair Value at December 31, 2023

$

154,150

-

-

$

154,150

December 31, 2023

Level 1

Level 2

Level 3

Total

Derivative liability

-

-

154,150

$

 154,150

December 31, 2022

Level 1

Level 2

Level 3

Total

Derivative liability

-

-

 102,011

$

 102,011

The details of derivative liability transactions for the year ended December 31, 2023 and December 31, 2022 are as follows:

The change in Level 3 financial instrument fair value is as follows:

Balance, December 31, 2021

$ 92,527

Issued during the year ended December 31, 2022

264,952

Derivative liabilities debt premium

(43,269)

Change in fair value recognized in operations

(212,199)

Converted during the year ended December 31, 2022

(0)

Balance, December 31, 2022

$ 102,011

Issued during the year ended December 31, 2023

145,067

Derivative liabilities debt discount

29,167

Change in fair value recognized in operations

(83,923)

Converted during the year ended December 31, 2023

(38,172)

Balance, December 31, 2023

$ 154,150

The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between levels during the year ending December 31, 2023 and December 31, 2022.

The Company determines the fair value of the derivative liability based on Level 3 inputs using the Black-Scholes option pricing model. The significant unobservable input assumptions that can significantly change the fair value includes common share price; amount of principal and accrued interest convertible into shares as of the conversion date, and the number of shares issuable upon conversion; expected exercise price; expected term; volatility; and risk-free interest rate.

Convertible Instruments

Convertible debt – derivative treatment

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

If the conversion feature within convertible debt meets the requirements to be treated as a derivative, we estimate the fair value of the convertible debt derivative using the Black-Sholes option pricing model upon the date of issuance. If the fair value of the convertible debt derivative is higher than the face value of the convertible debt, the excess is immediately recognized as interest expense. Otherwise, the fair value of the convertible debt derivative is recorded as a liability with an offsetting amount recorded as a debt discount, which offsets the carrying amount of the debt. If the convertible debt is viewed as short-term, management chooses to expense the full debt discount in the period incurred is recorded as a gain or loss in the consolidated statement of operations. The convertible debt derivative is revalued at the end of each reporting period and any change in fair value is recorded as a gain or loss in the consolidated statement of operations.

Convertible debt – beneficial conversion feature

The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records when necessary, any discounts, if applicable, to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts, if applicable, under these arrangements are amortized over the term of the related debt to their stated date of redemption.

Debt modifications and extinguishments

The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded under change in fair value on derivative, in the consolidated operation statements, as a gain or loss on extinguishment of the two separate liabilities. During the year ended December 31, 2023, the Company issued $388,888 of convertible debt.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 amends the guidance for revenue recognition to replace numerous, industry specific requirements and converges areas under this topic with those of the International Financial Reporting Standards. The ASU implements of five–step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract cost, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The amendments in this ASU are effective for reporting period beginning after December 15, 2016, and early adoption is prohibited. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption.

The Company’s revenues are recognized when control of the promised goods or services is transferred to our clients (upon shipment of goods) in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: (1) Identify the contract with a client; (2) Identify the performance obligations in the contract; (3) Determine the transaction price; (4) Allocate the transaction price to performance obligations in the contract; and (5) Recognize revenues when or as the Company satisfies a performance obligation.

We adopted ASC 2014-09 on January 1, 2019. Although the new revenue standard is expected to have an immaterial impact, if any, on our ongoing net income, we did implement changes to our processes related to revenue recognition and the control activities with them.

The Company leases its office and warehouse space under non-cancellable capital leases. The Company accounts for this lease in accordance with ASC 842. Right-of-use (“ROU”) assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Since our lease arrangements do not provide an implicit rate, we use our estimated incremental borrowing rate for the expected remaining lease term at commencement date in determining the present value of future lease payments.

The lease agreements do not contain any material residual value guarantees or material restrictive covenants.

Capital lease expense is recognized on a straight-line basis over the lease term. Variable lease payments are not included in the lease payments to measure the lease liability and are expensed as incurred.

Finance lease expense is comprised of both interest expense, which is recognized using the effective interest method, and amortization of the right-of-use assets. These expenses are presented consistently with the presentation of other interest expense and amortization or depreciation of similar assets.

Common area maintenance fees (or CAMs) and other charges related to leases are expensed as incurred. See Note 5 — Right-of-Use Assets and Lease Liabilities for further discussion of the Company’s lease activities.

Common Stock Purchase Warrants

The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to our own stock as defined in ASC 815-40 (“Contracts in Entity's Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside our control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification is required.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483426/235-10-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 235
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//235/tableOfContent
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R9.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 3 - GOING CONCERN
12 Months Ended

Dec. 31, 2023

Notes

NOTE 3 - GOING CONCERN
NOTE 3 – GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has generated minimal revenues from operations. Since its inception, the Company has been engaged substantially in financing activities and developing its business plan and incurring startup costs and expenses. As a result, the Company incurred accumulated net losses from Inception (December 19, 2014) through the year ended December 31, 2023 of $18,336,268. Due to our negative cash flow, the Company has substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. In addition, the Company’s development activities since inception have been financially sustained through equity financing. Management plans to keep seeking funding through debt and equity financing which are intended to mitigate the conditions that have raise substantial doubt about the entity’s ability to continue as a going concern.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 40
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//205-40/tableOfContent
+ Details

Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R10.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 4 - RELATED PARTY
12 Months Ended

Dec. 31, 2023

Notes

NOTE 4 - RELATED PARTY
NOTE 4 – RELATED PARTY

For the year ended December 31, 2023 and December 31, 2022, the Company had expenses totaling $0 and $1,000 respectively, to an officer and director for salaries, which is included in general and administrative expenses on the accompanying consolidated statement of operations.

Note

Issuance Date

Maturity Date

Interest Rate

Original
Principal
Amount

Balance at
December
31, 2023

Balance at
December
31, 2022

Unsecured debt A

March 2019, March and June 2020

No due date

0%

$866

$866

$866

Unsecured debt H

September 1, 2023

January 1, 2024

10%

$82,500

$82,500

$866

Total notes payable

$83,366

$83,366

$866

Debt discount and deferred financing costs

-

-

-

Total notes payable, net

$83,366

$83,366

$866

Unsecured debt A: On March 2, 2020, the Company received an unsecured loan of $200 from a shareholder. Additionally, during in March and June 2019, the Company received an additional loan of $666 from another shareholder. Both of these notes are unsecured and do not have a payment due date at an interest rate of 0.00%.

Unsecured debt H: On September 1, 2023, the Company received an unsecured line of credit in the principal of up to $82,500 with a loan origination fee in the amount of $7,500, which was amortized over the life of the line of credit. The net proceeds from this line of credit were $75,000. The loan is unsecured and is due for repayment on January 1, 2024. Interest will accrue at an interest rate of 10% per annum on any unpaid principal amount. If the Company defaults on the loan, the holder of the note can declare all or any portion of the unpaid balance with all accrued interest immediately due and payable. As of December 31, 2023, the outstanding principal balance of unsecured debt G totaled $75,000.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R11.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES
12 Months Ended

Dec. 31, 2023

Notes

NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES
NOTE 5 – RIGHT-OF-USE ASSETS AND LEASE LIABILITIES

In February 2022, the Company entered into a lease agreement for our warehouse facilities located at 7375 Commercial Way Suite 125, Henderson, Nevada 89011 with a term of 35 month 25 days and will expire in 2025. Prior to February 4, 2022 the company was leasing a warehouse facility on a month-to-month lease. The average monthly base rent for the first 12 months is approximately $5,333. For the next 24 months of the lease, the average monthly base rent will be approximately $5,694. As part of the agreement the Company will be responsible to share any

property operating expenses estimated as $1,017 per month. Pursuant to ASC 842, the estimated operating expenses was included with the base rent and was included in the calculations of the right of use assets. The Company recorded operating lease right-of-use of $175,765 and lease liabilities for operating lease of $175,765.

Supplemental statements of operations information related to leases are as follows:

Year Ended

December 31, 2023

Lease Cost

Cash paid for amounts included in the measurement of lease liabilities for the first quarter 2022

$

 -

Weighted average remaining lease term – operating leases (in years)

1.08

Average discount rate – operating leases

9.80%

December 31, 2023

Operating leases

Right-of-use assets, net of amortization of $104,182

$

71,583

Short-term operating lease liabilities

$

(65,229)

Long-term operating lease liabilities

(9,222)

Total operating lease liabilities

$

(74,452)

The following table summarizes the future undiscounted cash payments reconciled to the lease liability:

Year Ending

Operating Leases

2022 (remaining eleven months)

$

 -

2023

 -

2024

69,635

2025

5,822

2026 and thereafter

 -

Total lease payments

$

75,457

Less: Imputed interest/present value discount

$

(1,005)

Present value of lease liabilities

$

74,452

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 840
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//840/tableOfContent
+ Details

Name: us-gaap_LeasesOfLesseeDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R12.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 6 - NOTES PAYABLE
12 Months Ended

Dec. 31, 2023

Notes

NOTE 6 - NOTES PAYABLE
NOTE 6 – NOTES PAYABLE

As of December 31, 2023, the Company had the following:

Note

Issuance Date

Maturity Date

Interest Rate

Original Principal Amount

Balance at December 31, 2023

Balance at December 31, 2022

Unsecured debt B

February 22, 2022

February 15, 2023

10%

$

200,000

-

75,370

Secured debt C

October 7, 2022

October 7, 2023

12.99%

200,000

-

200,000

Unsecured debt D

March 20, 2023

August 17, 2024

10%

330,000

166,486

-

Secured debt E

May 19, 2023

May 18, 2024

12.99%

131,000

-

-

Secured debt F

July 26, 2023

May 18, 2024

12.99%

196,000

110,399

-

Secured debt G

December 19, 2023

December 18, 2024

10%

94,600

92,526

-

Total notes payable

$

1,151,600

369,411

$275,370

Debt discount and deferred financing costs

-

-

-

Total notes payable, net

$

1,151,600

369,411

$275,370

Unsecured debt B: On February 22, 2022, the Company received an unsecured loan in the principal of $200,000 with a loan origination fee in the amount of $20,000, which was fully expensed as interest expense in this period. The net proceeds from this loan were $180,000. The loan is unsecured and the initial payment of $17,804 was due on April 22, 2022. There will be ten monthly payments due on the 22nd day of each following month, beginning on May 22, 2022 through Feb 15, 2023. During fourth quarter of 2022, the note holder agreed to forgo two months of payments and add them to the back end of the note, which extended the due date of the note to April 25, 2023. Interest will accrue at an interest rate of 10% per annum on any unpaid principal amount. If the Company defaults on the loan, the default interest will increase to 16% per annum. During 2022, the Company made a total in principal payments of $124,630 towards unsecured debt B. During 2023, the Company has made additional principal payments towards unsecured debt B totaling $75,370 which settled the entire principal balance in full. As of December 31, 2023, the principal balance of the note was paid off.

Secured debt C: On October 7, 2022, the Company agreed to a secured loan by any consigned inventory held at fulfillment centers and any rights, title or interest in their account. The principal loan amount was $200,000 and will have a loan term of twelve months with an annual interest rate of 12.99%, with a default rate of 14.99%. The first three months of payment will be interest only payments of $2,165 and the remaining nine payments will be principal and interest payments of $23,442. Interest payments will begin November 8, 2022 and Installment payments, including principal and interest, will begin February 8, 2023. During 2023, the Company has made principal payments totaling $200,000 towards the secured debt C which settled the entire principal balance in full. As of December 31, 2023 the principal balance of secured debt C was paid off.

Unsecured debt D: On March 20, 2023, the Company received an unsecured loan in the principal of $330,000 with a loan origination fee in the amount of $30,000, which was fully expensed as interest expense in this period. The net proceeds from this loan were $300,000. The loan is unsecured and the initial payment of $23,359 will be due on June 17, 2023. There will be fourteen monthly payments due on the 17th day of each following month, beginning on July 17, 2023 through August 17, 2024. Interest will accrue at an interest rate of 10% per annum on any unpaid principal amount. If the Company defaults on the loan, the default interest will increase to 16% per annum. During 2023, the Company made a total in principal payments of $163,514 towards the unsecured debt D. As of December 31, 2023, the outstanding principal balance of unsecured debt D totaled $166,486.

Secured debt E: On May 19, 2023, the Company agreed to a secured loan by any consigned inventory held at fulfillment centers and any rights, title or interest in their account. The principal loan amount was $131,000 and will have a loan term of twelve months with an annual interest rate of 12.99%, with a default rate of 14.99%. The first payment of principal and interest will be $11,700 and will be due June 19, 2023 with an additional eleven payments due each 19th of the month. During 2023, the Company has made principal payments totaling $10,282 towards the secured debt E. As of December 31, 2023 the principal balance of secured debt E was paid off.

Secured debt F: On July 26, 2023, the Company agreed to a secured loan by any consigned inventory held at fulfillment centers and any rights, title or interest in their account. The principal loan amount was $196,000 and will have a loan term of twelve months with an annual interest rate of 12.99%, with a default rate of 14.99%. The first payment of principal and interest will be $17,505 and will be due August 26, 2023 with an additional eleven payments due each 26th of the month. During 2023, the Company has made principal payments totaling $85,601 towards the secured debt F. As of December 31, 2023 the principal balance of secured debt E was $110,399.

Secured debt G: On December 19, 2023, the Company agreed to a secured loan by any rights, title or interest in their account. The principal loan amount was $86,000 and will have a loan term of twelve months. The note has a cost of funds equal to 10% of the loan amount or $8,600 and will be due upon acceptance of the loan amount. A total of $283 of the interest has been expensed in 2023. Payment will be made daily at a repayment rate of 14% of daily sales. and will be due December 21, 2023 and will continue until full amount owed is paid. During 2023, the Company has made principal payments totaling $2,074 towards the secured debt E. As of December 31, 2023 the principal balance of secured debt E was $92,526.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for short-term debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent
+ Details

Name: us-gaap_ShortTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R13.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 7 - CONVERTIBLE DEBT
12 Months Ended

Dec. 31, 2023

Notes

NOTE 7 - CONVERTIBLE DEBT
NOTE 7 – CONVERTIBLE DEBT

As of December 31, 2023, the Company had the following convertible debt outstanding:

Note

Issuance Date

Maturity Date

Interest Rate

Original Principal Amount

Balance at December 31, 2023

Balance at December 31, 2022

Convertible promissory note #1

July 28, 2016

January 19, 2017

8%

$

15,000

$

6,750

$

6,750

Convertible promissory note #2

May 25, 2022

August 5, 2023

10%

154,000

-

110,535

Convertible promissory note #3

May 12, 2022

May 1, 2023

12%

200,000

200,000

200,000

Convertible promissory note #4

January 24, 2023

April 24, 2024

0%

388,888

401,851

 -

Total notes payable

$

757,888

$

608,601

$

317,285

Debt discount and deferred financing costs

 -

 -

 -

Total notes payable, net

$

757,888

$

608,601

$

317,285

Convertible promissory note #1:

On July 28, 2016, the Company executed the convertible promissory note #1 in the principal amount of $15,000, which is in default but management has not been able to make contact with this party, due to them living out of the country. The due date for this note was January 19, 2017 at an interest rate of 8%, with a default interest rate of 18%. We have calculated the derivative liability as if it is in default (but the note’s default interest rate stays the same at 8%) and will still accrue appropriate interest until the note is fully satisfied or converted into the Company’s common stock. The conversion option for this note coverts at a 54% discount to the market price based on the lowest trading prices in the last 20 days trading period. The outstanding balance on convertible promissory note #1 as of December 31, 2023 was $6,750.

The fair value of the derivative as of December 31, 2023 was determined to be $21,185 using the Black-Scholes option pricing model based on the following assumptions: common share price of $0.06 per share; expected exercise price of $0.0169 per share; volatility of 133%; expected dividend yield of zero; and annual risk-free interest rate of 5.44%. The derivatives are classified as liabilities as they represent an obligation to deliver a variable number of shares of common stock in the future and are therefore required to be initially and subsequently measured at fair value each reporting period. The Company originally recorded a derivative liability in the amount of $9,649. The fair value of the derivative liability is remeasured each reporting period using the Black-Scholes option pricing model, and the change in fair value is recorded as an adjustment to the derivative liabilities account with the unrealized gains or losses reflect in other income – change in fair value on derivative.

Convertible promissory note #2:

On May 25, 2022, the Company executed the convertible promissory note #2 in the principal amount of $154,000 with a loan origination fee in the amount of $15,400, which was fully expensed as interest expense in this period. The net proceeds from this note were $138,600. The loan is unsecured and the initial repayment of $14,488 was due on October 5, 2022. There will be ten additional monthly payments due on the 5th day of each following month, beginning on November 5, 2022 through August 5, 2023. Interest will accrual at an interest rate of 10% per annum on any unpaid principal amount. If the Company defaults on the loan, the default interest will increase to 16% per annum. During 2022, the Company has made principal payments totaling $43,465 towards the outstanding balance on convertible promissory note #2. During 2023, the Company has made additional principal payments towards convertible promissory note #2 totaling $110,535 which settled the entire principal balance in full. As of December 31, 2023, the principal balance of the note was paid off the principal balance of the note was paid off.

The fair value of the derivative was determined to be $0, due to being paid off, using the Black-Scholes option pricing model based, prior to the note being paid off, on the following assumptions: common share price of $0.06 per share; expected exercise price of $0.05 per share; volatility of 133%; expected dividend yield of zero; and annual risk-free interest rate of 5.44%. The derivatives are classified as liabilities as they represent an obligation to deliver a variable number of shares of common stock in the future and are therefore required to be initially and subsequently measured at fair value each reporting period. The Company originally recorded a derivative liability in the amount of $89,895.

The fair value of the derivative liability is remeasured each reporting period using the Black-Scholes option pricing model, and the change in fair value is recorded as an adjustment to the derivative liabilities account with the unrealized gains or losses reflect in other income – change in fair value on derivative.

Convertible promissory note #3:

On May 12, 2022, the Company executed the convertible promissory note #3 in the principal amount of $200,000. The loan is unsecured and the principal and any unpaid accrued interest shall be due and payable on May 12, 2023. Interest shall accrue at the rate of 12% per annum. The outstanding balance on convertible promissory note #3 as of December 31, 2023 was $200,000. At any time on or after July 24, 2023, the holder shall have the right, at his option, to convert the principal amount of the note, or any portion of such principal amount, plus accrued but unpaid interest into shares of the Company’s common stock. The Company has been advised the holder of convertible promissory note #3 will be converting the full value of the outstanding principal and interest in the near future. The conversion price shall be $0.05 per share.

The fair value of the derivative was determined to be $76,919 using the Black-Scholes option pricing model based on the following assumptions: common share price of $0.06 per share; expected exercise price of $0.05 per share; volatility of 133%; expected dividend yield of zero; and annual risk-free interest rate of 5.44%. The derivatives are classified as liabilities as they represent an obligation to deliver a variable number of shares of common stock in the future and are therefore required to be initially and subsequently measured at fair value each reporting period. The Company originally recorded a derivative liability in the amount of $184,011. The fair value of the derivative liability is remeasured each reporting period using the Black-Scholes option pricing model, and the change in fair value is recorded as an adjustment to the derivative liabilities account with the unrealized gains or losses reflect in other income – change in fair value on derivative.

Convertible promissory note #4:

On January 24, 2023, the Company executed the convertible promissory note #4 in the principal amount of $388,888 with a loan origination fee in the amount of $38,888, which was fully expensed as interest expense in this period, additionally there were $12,500 of legal costs and $31,500 of agent fees in which were also fully expenses in this period. The net proceeds from this loan were $306,000. The loan is unsecured and the principal and any unpaid accrued interest shall be due and payable on October 24, 2023 with an interest rate of 0%. Any unpaid balance at that time will start to accrue interest at a default rate of 20% per annum. On October 31, 2023 the note was extended to April 24, 2024 for an additional fee in the amount of $38,889. The additional fee will be amortized over the six month and in 2023 $12,962 was expensed. The outstanding balance on convertible promissory note #4 as of December 31, 2023 was $401,851. The holder shall have the right, at his option, to convert the principal amount of the note, or any portion of such principal amount, plus accrued but unpaid interest into shares of the Company’s common stock. The conversion price means ninety percent (90%) of the lowest VWAP of our common stock for the five (5) consecutive Trading Days immediately preceding the date of the issuance of a Conversion Election.

The fair value of the derivative was determined to be $56,047 using the Black-Scholes option pricing model based on the following assumptions: common share price of $0.06 per share; expected exercise price of $0.0425 per share; volatility of 133%; expected dividend yield of zero; and annual risk-free interest rate of 5.44%. The derivatives are classified as liabilities as they represent an obligation to deliver a variable number of shares of common stock in the future and are therefore required to be initially and subsequently measured at fair value each reporting period. The Company originally recorded a derivative liability in the amount of $174,234. The fair value of the derivative liability is remeasured each reporting period using the Black-Scholes option pricing model, and the change in fair value is recorded as an adjustment to the derivative liabilities account with the unrealized gains or losses reflect in other income – change in fair value on derivative.

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 33 R14.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 8 - DERIVATIVE LIABILITY
12 Months Ended

Dec. 31, 2023

Notes

NOTE 8 - DERIVATIVE LIABILITY
NOTE 8 – DERIVATIVE LIABILITY

The Company evaluated the notes under the requirements of ASC 480 “Distinguishing Liabilities From Equity” (ASC 480) and concluded that the notes do not fall within the scope of ASC 480. The Company next evaluated the notes under the requirements of ASC 815 “Derivatives and Hedging Activities” and determined that the scope exception to ASC 815’s derivative accounting provisions does not apply. The Company then evaluated the embedded derivative criteria in ASC 815, and concluded that the conversion features meet all the embedded derivative criteria in ASC 815, and therefore, the conversion features meet the definition of an embedded derivative that should be separated from the notes and accounted for as a derivative liability.

The derivative liabilities were valued using a Black-Scholes option pricing model with the following average assumptions:

December 31, 2023

Upon Issuance 2023

December 31, 2022

Upon Issuance 2022

Stock Price

$0.06

$0.048

$0.04

$ 0.043-0.066

Exercise Price

$ 0.017-0.05

$0.045

$ 0.0224-0.05

$ 0.0224-0.05

Expected Life

0

0.75

0 - 0.59

1.0 - 1.2

Volatility

133%

145%

168%

194.52 - 197.12%

Dividend Yield

0%

0%

0%

0%

Risk-Free Interest Rate

5.44%

4.57%

4.02%

0.53 - 0.61%

Convertible Notes

595,638

388,888

317,285

356,000

Total Fair Value

$154,153

$174,234

$102,011

$273,906

The expected life of the note was based on the remaining contractual term of the instruments. The Company uses the historical volatility of its Common Stock to estimate the future volatility for its Common Stock. The expected dividend yield was based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future. The risk-free interest rate was based on rates established by the Federal Reserve Bank.

Consolidated Statement of Operations – Change in fair value on derivative

During the year ended December 31, 2022, , the following transactions were recorded in the account “change in fair value on derivative”: (i) as a result of the issuance of convertible notes, the Company recorded derivative liabilities of $(264,952); (ii) the Company viewed the convertible debt derivatives as short term and thus chose to record as other income the debt premium associated with the derivative liabilities incurred during this period in the amount of $43,269; and (iii) the change in the fair value of these derivative liabilities for the year ended December 31, 2022 resulted in a gain of $212,199.

During the year ended December 31, 2023, the following transactions were recorded in the account “change in fair value on derivative”: (i) as a result of the issuance of convertible notes, the Company recorded derivative liabilities of $(145,067); (ii) the Company viewed the convertible debt derivatives as short term and thus chose to expense the debt discounts associated with the derivative liabilities incurred during this period in the amount of $(29,167); (iii) the changes in the fair value of these derivative liabilities for the year ended December 31, 2023 resulted in a gain of $83,920; and (iv) the Company recorded a gain on debt extinguishment of $38,172 to account for the extinguishment of derivative liabilities associated with the settlement or the conversion of the convertible debt accounted for as a derivative liability.

The details of derivative liability transactions for the period ended December 31, 2023 and December 31, 2022 are as follows:

The change in Level 3 financial instrument fair value is as follows:

Balance, December 31, 2021

$ 92,527

Issued during the year ended December 31, 2022

264,952

Derivative liabilities debt premium

(43,269)

Change in fair value recognized in operations

(212,199)

Converted during the year ended December 31, 2022

(0)

Balance, December 31, 2022

$ 102,011

Issued during the year ended December 31, 2023

145,067

Derivative liabilities debt discount

29,167

Change in fair value recognized in operations

(83,923)

Converted during the year ended December 31, 2023

(38,172)

Balance, December 31, 2023

$ 154,150

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for other liabilities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20,24)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_OtherLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R15.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 9 - INCOME TAXES
12 Months Ended

Dec. 31, 2023

Notes

NOTE 9 - INCOME TAXES
NOTE 9 – INCOME TAXES

The effective income tax rate for the years ended December 31, 2023 and 2022 differs from the U.S. Federal statutory rate due to the following:

December 2023

December 2022

Federal statutory income tax rate

$678,297

(166,169)

Change in valuation allowance

(678,297)

166,169

$-

$-

The components of the deferred tax assets and liabilities at December 31, 2023 and 2022 are as follows:

December 2023

December 2022

Long-term deferred tax assets:

Federal net operating loss carryforwards

678,297

166,169

Valuation allowance

(678,297)

(166,169)

Net long-term deferred tax assets

$-

$-

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R16.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 10 - STOCKHOLDERS' EQUITY
12 Months Ended

Dec. 31, 2023

Notes

NOTE 10 - STOCKHOLDERS' EQUITY
NOTE 10 – STOCKHOLDERS’ EQUITY

Authorized Stock

The Company has authorized 75,000,000 common shares with a par value of $0.001 per share. Each common share entitles the holder to one vote on any matter on which action of the stockholders of the corporation is sought. During February 2017, the Company increased the authorized number of shares to 500,000,000. Also, the Company increased the authorized preferred stock to 75,000,000 shares and designated 25,000,000 shares of preferred stock to Series A Convertible Preferred Stock. During January 2018, the Company increased its authorized number of common shares to 1,000,000,000. During April 2018, the Company increased its authorized number of common shares to 2,500,000,000. The Board of Directors, in the future, has the authority to increase the authorized capital up to 4,000,000,000 shares based on shareholder approval. On December 29, 2023 the Company decreased its authorized number of common shares to 50,000,000.

The Company effectuated a reverse stock split of 120-for-1 as of December 29, 2023.

On October 16, 2017, the Company filed an Amended and Restated Certificate of Designation of the Rights, Preferences, Privileges and Restrictions of the Series A Convertible Preferred Stock (the “Amended Certificate”) with the Secretary of State of the State of Nevada. The Amended Certificate reduces the number of preferred shares designated as Series A Preferred Stock from 25,000,000 shares to 1,333,334 shares. The Amended Certificate also changes the conversion and voting rights of the Series A Preferred Stock. The Series A Preferred Stock is now convertible into the number of shares of our common stock equal to 0.00006% of our outstanding common stock upon conversion. The voting rights of the Series A Preferred Stock are now equal to the number of shares of common stock into which the Series A Preferred Stock may convert.

As of December 31, 2023, there are no outstanding shares of preferred stock. All the preferred stock was converted in common stock on February 4, 2019.

Common Share Issuances

During the months ended March 31, 2023, the Company issued 320,000 shares of common stock. During the months ended June 30, 2023, the Company did not issue any shares of common stock. During the months ended September 30, 2023, the Company issued 9,000,000 shares of common stock for the Restricted Stock Units which were executed. The holders paid the Company $0.01 for each share of common stock and the value of each share was $0.05. There were no shares issued during the fourth quarter 2023.

There were no shares issued during the fourth quarter 2022. During the third quarter 2022, the Company issued 340,000 shares of common stock for consulting fees along with issuing 340,621 shares of common stock to convert an outstanding note payable to a shareholder. On May 19, 2022, the Company issued 4,400,000 shares of common stock for broker and consulting fees. On April 22 and 25, 2022, the Company issued 2,000,000 shares of common stock for broker and funding fees. On February 4, 2022, the Company issued 507,917 shares of common stock in a direct security purchase agreement. On January 10, 2022, the Company cancelled 200,267 shares of common stock. Further, on March 4, 2022, the Company cancelled 600,000 shares of common stock.

Warrant Issuances

During the month ending March 31, 2023, the Company issued 61,846 warrants to 2 unrelated parties at a per share price of $5.6592. On February 2, 2022, the Company issued 16,667 warrants to an individual at a per share price of $6.00. As of December 31, 2023, there were 195,180 warrants outstanding, of which 195,180 warrants are fully vested.

Weighted-

Weighted-

Average

Average

Remaining

Aggregate

Exercise

Contractual

Intrinsic

Warrants

Price

Life (Years)

Value

Outstanding at December 31, 2022

133,333

$7.22

2.17

 -

Granted

61,846

6.00

1.11

 -

Forfeited

 -

 -

 -

 -

Exercised

 -

 -

 -

 -

Outstanding at December 31, 2023

195,180

$6.83

1.17

$ -

Vested and expected to vest at December 31, 2023

195,180

$6.83

$ -

Exercisable at December 31, 2023

195,180

$6.83

$ -

At December 31, 2023, the intrinsic value of these stock warrants was $0 as the exercise price of these stock warrants were greater than the market price.

Stock Issued for Services

On March 6, 2023, the Company issued 320,000 shares of common stock for consulting fees at a per share price of $0.05.

On September 13, 2022, the Company issued 340,000 shares of common stock for consulting fees at a per share price of $0.05. During the period ending June 30, 2022, the Company issued 6,400,000 shares of common stock for broker, consulting, and funding fees at a per share price of $0.05.

Share Conversion Agreements

All of the holders of the Company’s Series A Convertible Preferred Stock (the “Preferred Holders”) entered into a Preferred Stock Conversion Agreement. Pursuant to the Conversion Agreements, the Preferred Holders converted their shares of preferred stock into common stock, effective as of the Exchange. As a result, no shares of the Company’s Series A Convertible Preferred Stock are outstanding. An aggregate of 15,592,986 shares of common stock were issued to the Preferred Holders. The Preferred Holders agreed to convert each share of Series A Convertible Preferred Stock into eighteen (18) shares of common stock and agreed to retire a total of 467,057 shares of Series A Convertible Preferred Stock. The Company cancelled the retired shares.

Omnibus Stock Grant and Option Plan

On December 31, 2021, the Company approved stock option agreements in the amount of 7,500,000 shares with a strike price of $0.05 to twenty-one individuals. These options are immediately vest and will expire in five years.

The following summary of options activity for the year ended December 31, 2023 is presented below:

Weighted-

Weighted-

Average

Average

Remaining

Aggregate

Exercise

Contractual

Intrinsic

Options

Price

Life (Years)

Value

Outstanding at December 31, 2022

32,083

$6.00

2.13

38,500

Granted

6,250

6.00

3.42

7,500

Forfeited

 -

 -

 -

 -

Exercised

 -

 -

 -

 -

Outstanding at December 31, 2023

38,333

$6.00

2.34

$46,000

Vested and expected to vest at December 31, 2023

38,333

$6.00

$46,000

Exercisable at December 31, 2023

38,333

$6.00

$46,000

At December 31, 2023, the intrinsic value of these stock options was $46,000 as the exercise price of these stock options were less than the market price.

On December 26, 2022, the Company canceled 101,250 stock options with a strike price of $6.00.

The following summary of restricted stock units’ activity for the three months ended December 31, 2023 is presented below:

Weighted-

Weighted-

Average

Grant Date

Shares

Fair Value

Non-vested at December 31, 2022

-

-

Granted

133,125

6.00

Vested

(74,167)

6.00

Forfeited

-

-

Non-vested at December 31, 2023

58,958

6.00

The total fair value of restricted stock units vested during the three months ended September 30, 2023 was $445,000 and is included in selling, general and administrative expenses in the accompanying consolidation statements of operations. As of December 31, 2023, the amount of unvested compensation related to issuances of restricted stock units’ fair value was $423,910. This amount will be amortized and expensed over the life of the contract and will be included in selling, general and administrative expenses in the accompanying consolidation statements of operations.

The fair value of share options, units, and warrants are estimated using the Black-Scholes option pricing method based on the following weighted-average assumptions:

Year Ending December 31,

2023

2022

Risk-free interest rate

5.18

%

2.75

%

Average expected term (years)

4.7 years

4.75 years

Expected volatility

106.5

%

194.8

%

Expected dividend yield

-

-

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R17.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 11 - BUSINESS SEGMENT INFORMATION
12 Months Ended

Dec. 31, 2023

Notes

NOTE 11 - BUSINESS SEGMENT INFORMATION
NOTE 11 – BUSINESS SEGMENT INFORMATION

As of December 31, 2023, the Company operated in two reportable segments (Corporate and Health Supplements) supported by a corporate group which conducts activities that are non-segment specific. The following table presents selected financial information about the Company’s reportable segments for the year ended December 31, 2023.

CONSOLIDATED

HEALTH SUPPLEMENTS

CORPORATE

BergaMet

UBN

Revenue

2,485,866

2,485,866

-

-

Cost of Revenue

813,614

813,614

-

-

Long-lived Assets

732,030

193,260

538,771

-

Gain (Loss) Before Income Tax

(2,422,489)

(219,975)

(5,113)

(2,197,401)

Identifiable Assets

1,676,724

1,676,724

-

-

Depreciation and Amortization

2,195

2,195

-

-

As of December 31, 2022, the Company operated in two reportable segments (Corporate and Health Supplements) supported by a corporate group which conducts activities that are non-segment specific. The following table presents selected financial information about the Company’s reportable segments for the year ended December 31, 2022.

CONSOLIDATED

HEALTH SUPPLEMENTS

CORPORATE

BergaMet

UBN

Revenue

2,251,469

2,251,469

-

-

Less Selling Fees

Cost of Revenue

783,141

783,141

-

-

Long-lived Assets

732,030

193,260

538,771

-

Gain (Loss) Before Income Tax

(983,121)

(164,625)

(358)

(818,138)

Identifiable Assets

1,819,128

1,819,128

-

-

Depreciation and Amortization

878

878

-

-

Currently, all of our customers are located in the United States of American and Canada. Our revenues to our customers are not material to our overall total sales. Our largest customers, Natural Grocers and Emerson Ecologics, LLC, account for less than 1% of our total sales in the year ending 2023 and 2022.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//280/tableOfContent

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-26

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-34

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R18.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 12 - SUBSEQUENT EVENTS
12 Months Ended

Dec. 31, 2023

Notes

NOTE 12 - SUBSEQUENT EVENTS
NOTE 12 – SUBSEQUENT EVENTS

The key terms for the 15,975,000 RSU are as follows: the effective grant date for all RSU’s is April 28, 2023. Each of the RSU’s will have a purchase price of $0.01 (prior to the reverse split). 8,900,000 of the RSU’s had an expiration date of June 30, 2023 and are all immediately vested once granted. All of the 8,900,000 shares of common stock were issued on July 5, 2023. 7,075,000 of the RSU’s will have an expiration date of March 31, 2024 and will vest on January 1, 2024. Any of the RSU will be forfeited without any payment or consideration by the holder. The RSU’s comply with Section 409A.

The Company has verbally agreed with the borrower of unsecured debt H to extend the due date to July 1, 2024.

The definitive agreement to be acquired for Hyperion, and its digital marketing affiliate, Online Publishing and Marketing expired on the anniversary date of the agreement. When new funding is acquired, further discussions will occur.

The Company evaluated its December 31, 2023 financial statements for subsequent events through March 11, 2024, the date the financial statements were available to be issued.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//855/tableOfContent

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483399/855-10-50-2
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R19.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis of Presentation (Policies)
12 Months Ended

Dec. 31, 2023

Policies

Basis of Presentation
Basis of Presentation

The accompanying audited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying audited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of December 31, 2023 and the results of operations and cash flows for the periods presented. The results of operations for the year ended December 31, 2023 are not necessarily indicative of the operating results for the full fiscal year or any future period. These audited consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s form 10-K for the year ended December 31, 2022 filed with the SEC on March 31, 2023.

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R20.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Use of Estimates (Policies)
12 Months Ended

Dec. 31, 2023

Policies

Use of Estimates
Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

In regards to inventory write-offs and allowances, our Company determines the net realizable value by using the various factors as following: excess or slow-moving inventories (12 months or more of inventory on hand), expiration dates (within 12 months of the current reporting period), current and future product demand, production planning, and market conditions. If any of these factors are found in the reporting period, management will review each item and determine if any additional allowances or write-offs need to be made. A change in any of these variable’s factors could result in an adjustment to inventory. Management has provided for any risks in the current inventory allowance booked.

As for revenue adjustments for discounts, allowances and refunds, we treat each of these items differently. When it comes to revenue discounts, we will create the invoice for the product sold which will include any discounts given. These discounts usually happen for a short period of time for sales that we will offer around holidays. Due to the revenue being recognized once the order has shipped, less any applicable discount, we book this transaction at the net order transaction amount. In regards to allowances and refunds for revenue adjustments, due to our refund percentage is less than 1% we decided the need for an estimated adjustment for allowances and refunds was not material. If we

do receive any returned orders, we will directly book those orders as refunds the day we receive the call from the customer requesting the refund. We will book the credit memo at the full value of the customer original order.

X

- References
No definition available.
+ Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-9

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-12

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-8
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R21.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash (Policies)
12 Months Ended

Dec. 31, 2023

Policies

Cash
Cash

Cash includes cash in banks, money market funds, and certificates of term deposits with maturities of less than three months from inception, which are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss in value.

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482913/230-10-50-1
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R22.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Accounts Receivables (Policies)
12 Months Ended

Dec. 31, 2023

Policies

Accounts Receivables
Accounts Receivables

Accounts receivables are recorded at the invoice amount and do not bear interest.

X

- References
No definition available.
+ Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for accounts receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481962/310-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481569/310-20-50-1

Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 11B
-Subparagraph (b)
-SubTopic 10
-Topic 310
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481962/310-10-50-1

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-SubTopic 10
-Topic 310
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481962/310-10-50-6

Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Subparagraph (d)
-SubTopic 10
-Topic 310
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481962/310-10-50-15
+ Details

Name: us-gaap_TradeAndOtherAccountsReceivablePolicy

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R23.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory (Policies)
12 Months Ended

Dec. 31, 2023

Policies

Inventory
Inventory

Inventories consist of health supplements held for sale in the ordinary course of business. The Company uses the weighted average cost method to value its inventories at the lower of cost and net realizable value. In pursuant to ASC 330-10-50-6, the components of inventory cost include raw materials, labor, and overhead. Additionally, the weighted average cost per unit is used as a basis to determine the cost amounts removed from inventory as the aggregate number of units expected to be delivered under each order. Finally, the net realizable value is determined by using the various factors as following: excess or slow-moving inventories (12 months or more of inventory on hand), expiration dates (within 12 months of the current reporting period), current and future product demand, production planning, and market conditions. If any of these factors are found in the reporting period, management will review each item and determine if any additional allowances or write-offs need to be made. A change in any of these variable’s factors could result in an adjustment to inventory.

An allowance for inventory was established in 2018 and is evaluated each quarter to determine if all items are still sellable due to the factors listed above. As of December 31, 2023 and December 31, 2022, the total of inventory allowance was $1,611,257 and $1,914,891. The following are the classes held in inventory as of December 31, 2023 and December 31, 2022:

DECEMBER 31,

DECEMBER 31,

2023

2022

Inventory

Inventory Classes:

Raw Materials

$

2,998,683

$

3,398,655

Finished Goods

225,567

310,600

Work in process

13,290

24,764

Total inventory

3,237,540

3,734,019

Inventory allowance

(1,611,257)

(1,914,891)

Total inventory, net

$

1,626,283

$

1,819,128

X

- Definition
Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483489/210-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483426/235-10-50-4

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 912
-SubTopic 330
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482105/912-330-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 330
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//330/tableOfContent

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 330
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483080/330-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 330
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483080/330-10-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 6
-Subparagraph (a)
-SubTopic 10
-Topic 270
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482989/270-10-45-6
+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 43 R24.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Property and Equipment (Policies)
12 Months Ended

Dec. 31, 2023

Policies

Property and Equipment
Property and Equipment

The Company’s property and equipment are recorded at cost and depreciated using the straight-line method over the useful lives of the assets, generally from three to seven years. Upon sale or disposal of property and equipment, the related asset cost and accumulated depreciation or amortization are removed from the respective accounts and any gain or loss is reflected in current operations.

X

- References
No definition available.
+ Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 10
-Topic 360
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482099/360-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8)(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-SubTopic 360
-Topic 958
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480321/958-360-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-SubTopic 360
-Topic 958
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480321/958-360-50-1
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R25.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Indefinite-Lived Intangible Assets (Policies)
12 Months Ended

Dec. 31, 2023

Policies

Indefinite-Lived Intangible Assets
Indefinite-Lived Intangible Assets

Indefinite-lived intangible assets established in connection with business combinations consist of patents, trademarks, and trade names. The impairment test for identifiable indefinite-lived intangible assets consists of a comparison of the estimated fair value of the intangible asset with it carrying value. If the carrying value exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. With the acquisition of Ultimate Brain Nutrients on April 3, 2020 the Company added a purchasing value of $315,604 in patents to its balance sheet.

As of December 31, 2023, the Company believes that based upon qualitative factors, no impairment of indefinite-lived intangible assets is necessary.

X

- Definition
Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.
+ References
No definition available.
+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 45 R26.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Goodwill (Policies)
12 Months Ended

Dec. 31, 2023

Policies

Goodwill
Goodwill

In accordance with Goodwill and Other Intangible Assets, goodwill is defined as the excess of the purchase price over the fair value assigned to individual assets acquired and liabilities assumed and is tested for impairment at the reporting unit level on an annual basis in the Company's fourth fiscal quarter or more frequently if indicators of impairment exist. The performance of the test involves a two-step process. The first step of the impairment test involves comparing the fair value of the Company's reporting units with each respective reporting unit's carrying amount, including goodwill. The fair value of reporting units is generally determined using the income approach. If the carrying amount of a reporting unit exceeds the reporting unit's fair value, the second step of the goodwill impairment test is performed to determine the amount of any impairment loss. The second step of the goodwill impairment test involves comparing the implied fair value of the reporting unit's goodwill with the carrying amount of that goodwill. No goodwill impairment indicators were present, for the goodwill listed on the books as of December 31, 2023, after working through our analysis of goodwill during the year ended December 31, 2023.

The Company has determined that the method applied represents the fair value of the asset group principally because the valuation of the intangibles with the asset group is based on the anticipated cash flows related to the revenue stream from its customers. The asset group excludes goodwill, long term non-operational assets and liabilities and cash. As such, the principal value from the asset group relates to the cash inflows from its customers and the cash outflows required to service these customers. The fair value for the asset group consists of the following:

·Fair value of net revenues: computed using the income approach. The key input to these computations is the anticipated cash inflows from customers. These valuations include 100% of the cash inflows related to the customer base, and taking cash outflows into consideration.

·Fair value of working capital (including accounts receivable, inventory, accrued expenses, and accounts payables). Due to the short-term nature of the working capital, book value has been determined to be fair value. These accounts represent either avoided future outflows (inventory, prepaids) or future cash flows (accrued expense, AP and AR) related to customer sales.

·Fair value of five years of revenue (2023 to 2027): we discounted our cash flows to the anticipated cash projected to be received. We also projected the anticipated cash outflows required to service these customers. If the asset group was to be valued as a whole, we would expect an income approach based on the revenues being generated from the customers and expenses required to service those customers, appropriately adjusted for the working capital position. The sum of these values reasonably approximates this approach.

The Company’s revenue streams align directly with the intangibles, which were recorded as a result of the BergaMet acquisition in fiscal 2019. For purposes of the Step 2 recoverability test under ASC 360 subsection 2.3., the net revenues from BergaMet customers base were used. The revenue stream fairly reflects anticipated future cash flows; accordingly, the intangibles associated with these revenue streams have been tested with the expected cash flows.

X

- Definition
Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//350-20/tableOfContent
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R27.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Debt with Warrants (Policies)
12 Months Ended

Dec. 31, 2023

Policies

Debt with Warrants
Debt with Warrants

In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations using the straight-line method. The offset to the contra-liability is recorded as either equity or liability in the Company’s consolidated balance sheets depending on the accounting treatment of the warrants. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations.

X

- Definition
Represents the textual narrative disclosure of Debt with Warrants Policy, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_DebtWithWarrantsPolicyTextBlock

Namespace Prefix: fil_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 47 R28.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Convertible Debt - Derivative Treatment (Policies)
12 Months Ended

Dec. 31, 2023

Policies

Convertible Debt - Derivative Treatment
Convertible Debt – Derivative Treatment

When the Company issues debt with a conversion feature, we must first assess whether the conversion feature meets the requirements to be treated as a derivative, as follows: (a) one or more underlying’s, typically the price of our common stock; (b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; (c) no initial net investment, which typically excludes the amount borrowed; and (d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both (a) indexed to its own stock; and (b) classified in stockholders’ equity in its balance sheet.

If the conversion feature within convertible debt meets the requirements to be treated as a derivative, we estimate the fair value of the convertible debt derivative using a Black-Scholes Option-Pricing model upon the date of issuance. If the fair value of the convertible debt derivative is higher than the face value of the convertible debt, the excess is immediately recognized as interest expense. Otherwise, the fair value of the convertible debt derivative is recorded as a liability with an offsetting amount recorded as a debt discount, which offsets the carrying amount of the debt. The derivative is revalued at the end of each reporting period and any change in fair value is recorded as a gain or loss in the statement of operations. The debt discount is amortized through interest expense over the life of the debt using the straight-line method.

X

- Definition
Represents the textual narrative disclosure of Convertible Debt - Derivative Treatment Policy, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_ConvertibleDebtDerivativeTreatmentPolicyTextBlock

Namespace Prefix: fil_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R29.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Revenue Recognition (Policies)
12 Months Ended

Dec. 31, 2023

Policies

Revenue Recognition
Revenue Recognition

The Company applies Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) topic 606, Revenue from Contracts with Customers (ASC 606). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes all of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASC 606 requires us to identify distinct performance obligations. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. When distinct performance obligations exist, the Company allocates the contract transaction price to each distinct performance obligation. The standalone selling price is used to allocate the transaction price to the separate performance obligations. The Company recognizes revenue when, or as, the performance obligation is satisfied.

Mostly, revenues are recognized at the time of shipment to the customer with the price being fixed and determinable and collectability assured, provided title and risk of loss is transferred to the customer. Most of our shipping and handling costs are built into the transaction price, but if the customer asks for express shipping, the costs charged to customers are classified as sales, and the shipping and handling costs incurred are included in cost of sales.

The Company’s subsidiary, BergaMet N.A., LLC, recognizes revenue from our main source – e-commerce revenue. Here is a list of all the sales channels which include the Company’s subsidiary website channel or any other selling channel like Amazon, doctors’ offices, and walk-in sales. All of our customer sales for Healthy Extracts, Inc. and Ultimate Brain Nutrients, LLC are recognized as revenue under the subsidiary of BergaMet N.A., LLC. All three divisions of the Company sell plant-based nutraceuticals to our end using customers.

The Company evaluates the criteria pursuant to ASC 606-10-55. Some of the different considerations that we use because of their significance are as follows: Collectability - payment has to be made prior to shipment unless the customer has agreed upon terms. Guaranties – we offer a money back to customers if they are unhappy with our products. Principal versus Agent Considerations - currently we are the principal and have not engaged an agent at this time and we have not recognized any revenues under the agent considerations.

Revenue is recognized when, or as, control of a promised merchandise or service is shipped to the customer, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for transferring title of those products or services and are recorded net of and discounts or allowances. Shipping costs paid by the customer are included in revenue. Merchandise sales are fulfilled with inventory held in our warehouse in Henderson, NV. Therefore, the Company’s contracts have a single performance obligation (shipment of product).

If the Company receives a request for refund on a customer obligation, the Company will refund the full cost of the obligation due to our money back guarantee. Historically, we have done a valuation of our sales allowance account (customer returns). In 2023 our return percentage was 0.008% of sales and 2022 was 0.009% of sales. Due to the low refund percentage management decided there was not a need for an estimated adjustment for allowances and refunds due to materiality.

Revenue recognition is evaluated through the following five-step process:

6.identification of the contract with a customer;

7.identification off the performance obligations in the contract;

8.determination of the transaction price;

9.allocation of the transaction price to the performance obligations in the contract; and

10.recognition of revenue when or as a performance obligation is satisfied.

These steps are met when an order is received, a price agreed and the product shipped or delivered to that customer.

X

- References
No definition available.
+ Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483426/235-10-50-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (e)
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R30.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Concentration (Policies)
12 Months Ended

Dec. 31, 2023

Policies

Concentration
Concentration

There is no concentration of revenue for the year ended December 31, 2022 and for the year ended December 31, 2023 because the revenue was earned from multiple customers.

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480981/942-825-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-1
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 50 R31.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Income Taxes (Policies)
12 Months Ended

Dec. 31, 2023

Policies

Income Taxes
Income Taxes

The Company uses the liability method of accounting for income taxes under which deferred tax assets and liabilities are recognized for the future tax consequences of temporary differences between the accounting bases and the tax bases of the Company’s assets and liabilities. The deferred tax assets and liabilities are computed using enacted tax rates in effect for the year in which the temporary differences are expected to reverse.

The Company's deferred income taxes include certain future tax benefits. The Company records a valuation allowance against any portion of those deferred income tax assets when it believes, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred income tax asset will not be realized.

The Company has adopted ASC guidance regarding accounting for uncertainty in income taxes. This guidance clarifies the accounting for income taxes by prescribing the minimum recognition threshold an income tax position is required to meet before being recognized in the consolidated financial statements and applies to all income tax positions. Each income tax position is assessed using a two-step process. A determination is first made as to whether it is more likely than not that the income tax position will be sustained, based upon technical merits, upon examination by the taxing authorities. If the income tax position is expected to meet the more likely than not criteria, the benefit recorded in the consolidated financial statements equals the largest amount that is greater than 50% likely to be realized upon its ultimate settlement. At December 31, 2023 and 2022, there were no uncertain tax positions that required accrual.

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(h)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-9

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482525/740-10-45-25

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482525/740-10-45-28

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 19
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-19

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-20
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 51 R32.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements (Policies)
12 Months Ended

Dec. 31, 2023

Policies

Fair Value Measurements
Fair Value Measurements

The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

The estimated fair value of certain financial instruments, including cash and cash equivalents are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 — quoted prices in active markets for identical assets or liabilities

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

The derivative liability in connection with the conversion feature of the convertible debt, classified as a Level 3 liability, is the only financial liability measure at fair value on a recurring basis. If the convertible debt is viewed as short-term, management chooses to expense the full debt discount in the period incurred is recorded as a gain or loss in the consolidated statement of operations.

The Company measures and reports certain financial instruments as liabilities at fair value on a recurring basis. The fair value of these instruments as of December 31, 2023 and December 31, 2022 was as follows:

Fair Value

Level 1

Level 2

Level 3

Fair Value at December 31, 2021

$

92,527

-

-

$

92,527

Derivative liability

102,011

-

-

102,011

Fair Value at December 31, 2022

$

102,011

-

-

$

102,011

Derivative liability

154,150

-

-

154,150

Fair Value at December 31, 2023

$

154,150

-

-

$

154,150

December 31, 2023

Level 1

Level 2

Level 3

Total

Derivative liability

-

-

154,150

$

 154,150

December 31, 2022

Level 1

Level 2

Level 3

Total

Derivative liability

-

-

 102,011

$

 102,011

The details of derivative liability transactions for the year ended December 31, 2023 and December 31, 2022 are as follows:

The change in Level 3 financial instrument fair value is as follows:

Balance, December 31, 2021

$ 92,527

Issued during the year ended December 31, 2022

264,952

Derivative liabilities debt premium

(43,269)

Change in fair value recognized in operations

(212,199)

Converted during the year ended December 31, 2022

(0)

Balance, December 31, 2022

$ 102,011

Issued during the year ended December 31, 2023

145,067

Derivative liabilities debt discount

29,167

Change in fair value recognized in operations

(83,923)

Converted during the year ended December 31, 2023

(38,172)

Balance, December 31, 2023

$ 154,150

The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between levels during the year ending December 31, 2023 and December 31, 2022.

The Company determines the fair value of the derivative liability based on Level 3 inputs using the Black-Scholes option pricing model. The significant unobservable input assumptions that can significantly change the fair value includes common share price; amount of principal and accrued interest convertible into shares as of the conversion date, and the number of shares issuable upon conversion; expected exercise price; expected term; volatility; and risk-free interest rate.

X

- Definition
Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 52 R33.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Convertible Instruments (Policies)
12 Months Ended

Dec. 31, 2023

Policies

Convertible Instruments
Convertible Instruments

Convertible debt – derivative treatment

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

If the conversion feature within convertible debt meets the requirements to be treated as a derivative, we estimate the fair value of the convertible debt derivative using the Black-Sholes option pricing model upon the date of issuance. If the fair value of the convertible debt derivative is higher than the face value of the convertible debt, the excess is immediately recognized as interest expense. Otherwise, the fair value of the convertible debt derivative is recorded as a liability with an offsetting amount recorded as a debt discount, which offsets the carrying amount of the debt. If the convertible debt is viewed as short-term, management chooses to expense the full debt discount in the period incurred is recorded as a gain or loss in the consolidated statement of operations. The convertible debt derivative is revalued at the end of each reporting period and any change in fair value is recorded as a gain or loss in the consolidated statement of operations.

Convertible debt – beneficial conversion feature

The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records when necessary, any discounts, if applicable, to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts, if applicable, under these arrangements are amortized over the term of the related debt to their stated date of redemption.

Debt modifications and extinguishments

The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded under change in fair value on derivative, in the consolidated operation statements, as a gain or loss on extinguishment of the two separate liabilities. During the year ended December 31, 2023, the Company issued $388,888 of convertible debt.

X

- Definition
Disclosure of accounting policy for its derivative instruments and hedging activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 815
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480434/815-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(n))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480434/815-10-50-1

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480434/815-10-50-4

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480434/815-10-50-7
+ Details

Name: us-gaap_DerivativesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 53 R34.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Recent Accounting Pronouncements (Policies)
12 Months Ended

Dec. 31, 2023

Policies

Recent Accounting Pronouncements
Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 amends the guidance for revenue recognition to replace numerous, industry specific requirements and converges areas under this topic with those of the International Financial Reporting Standards. The ASU implements of five–step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract cost, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The amendments in this ASU are effective for reporting period beginning after December 15, 2016, and early adoption is prohibited. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption.

The Company’s revenues are recognized when control of the promised goods or services is transferred to our clients (upon shipment of goods) in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: (1) Identify the contract with a client; (2) Identify the performance obligations in the contract; (3) Determine the transaction price; (4) Allocate the transaction price to performance obligations in the contract; and (5) Recognize revenues when or as the Company satisfies a performance obligation.

We adopted ASC 2014-09 on January 1, 2019. Although the new revenue standard is expected to have an immaterial impact, if any, on our ongoing net income, we did implement changes to our processes related to revenue recognition and the control activities with them.

The Company leases its office and warehouse space under non-cancellable capital leases. The Company accounts for this lease in accordance with ASC 842. Right-of-use (“ROU”) assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Since our lease arrangements do not provide an implicit rate, we use our estimated incremental borrowing rate for the expected remaining lease term at commencement date in determining the present value of future lease payments.

The lease agreements do not contain any material residual value guarantees or material restrictive covenants.

Capital lease expense is recognized on a straight-line basis over the lease term. Variable lease payments are not included in the lease payments to measure the lease liability and are expensed as incurred.

Finance lease expense is comprised of both interest expense, which is recognized using the effective interest method, and amortization of the right-of-use assets. These expenses are presented consistently with the presentation of other interest expense and amortization or depreciation of similar assets.

Common area maintenance fees (or CAMs) and other charges related to leases are expensed as incurred. See Note 5 — Right-of-Use Assets and Lease Liabilities for further discussion of the Company’s lease activities.

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 54 R35.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Common Stock Purchase Warrants (Policies)
12 Months Ended

Dec. 31, 2023

Policies

Common Stock Purchase Warrants
Common Stock Purchase Warrants

The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to our own stock as defined in ASC 815-40 (“Contracts in Entity's Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside our control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification is required.

X

- Definition
Represents the textual narrative disclosure of Common Stock Purchase Warrants Policy Textblock, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_CommonStockPurchaseWarrantsPolicyTextblockTextBlock

Namespace Prefix: fil_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 55 R36.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory: Schedule of Inventory (Tables)
12 Months Ended

Dec. 31, 2023

Tables/Schedules

Schedule of Inventory

DECEMBER 31,

DECEMBER 31,

2023

2022

Inventory

Inventory Classes:

Raw Materials

$

2,998,683

$

3,398,655

Finished Goods

225,567

310,600

Work in process

13,290

24,764

Total inventory

3,237,540

3,734,019

Inventory allowance

(1,611,257)

(1,914,891)

Total inventory, net

$

1,626,283

$

1,819,128

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483489/210-10-50-1
+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 56 R37.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables)
12 Months Ended

Dec. 31, 2023

Tables/Schedules

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

Fair Value

Level 1

Level 2

Level 3

Fair Value at December 31, 2021

$

92,527

-

-

$

92,527

Derivative liability

102,011

-

-

102,011

Fair Value at December 31, 2022

$

102,011

-

-

$

102,011

Derivative liability

154,150

-

-

154,150

Fair Value at December 31, 2023

$

154,150

-

-

$

154,150

December 31, 2023

Level 1

Level 2

Level 3

Total

Derivative liability

-

-

154,150

$

 154,150

December 31, 2022

Level 1

Level 2

Level 3

Total

Derivative liability

-

-

 102,011

$

 102,011

The details of derivative liability transactions for the year ended December 31, 2023 and December 31, 2022 are as follows:

The change in Level 3 financial instrument fair value is as follows:

Balance, December 31, 2021

$ 92,527

Issued during the year ended December 31, 2022

264,952

Derivative liabilities debt premium

(43,269)

Change in fair value recognized in operations

(212,199)

Converted during the year ended December 31, 2022

(0)

Balance, December 31, 2022

$ 102,011

Issued during the year ended December 31, 2023

145,067

Derivative liabilities debt discount

29,167

Change in fair value recognized in operations

(83,923)

Converted during the year ended December 31, 2023

(38,172)

Balance, December 31, 2023

$ 154,150

X

- Definition
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 57 R38.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 4 - RELATED PARTY: Schedule of Debt (Tables)
12 Months Ended

Dec. 31, 2023

Related Party

Schedule of Debt

Note

Issuance Date

Maturity Date

Interest Rate

Original
Principal
Amount

Balance at
December
31, 2023

Balance at
December
31, 2022

Unsecured debt A

March 2019, March and June 2020

No due date

0%

$866

$866

$866

Unsecured debt H

September 1, 2023

January 1, 2024

10%

$82,500

$82,500

$866

Total notes payable

$83,366

$83,366

$866

Debt discount and deferred financing costs

-

-

-

Total notes payable, net

$83,366

$83,366

$866

X

- Definition
Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfDebtTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=fil_RelatedParty1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 58 R39.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES: Lessee, Operating Lease, Disclosure (Tables)
12 Months Ended

Dec. 31, 2023

Tables/Schedules

Lessee, Operating Lease, Disclosure
Supplemental statements of operations information related to leases are as follows:

Year Ended

December 31, 2023

Lease Cost

Cash paid for amounts included in the measurement of lease liabilities for the first quarter 2022

$

 -

Weighted average remaining lease term – operating leases (in years)

1.08

Average discount rate – operating leases

9.80%

December 31, 2023

Operating leases

Right-of-use assets, net of amortization of $104,182

$

71,583

Short-term operating lease liabilities

$

(65,229)

Long-term operating lease liabilities

(9,222)

Total operating lease liabilities

$

(74,452)

The following table summarizes the future undiscounted cash payments reconciled to the lease liability:

Year Ending

Operating Leases

2022 (remaining eleven months)

$

 -

2023

 -

2024

69,635

2025

5,822

2026 and thereafter

 -

Total lease payments

$

75,457

Less: Imputed interest/present value discount

$

(1,005)

Present value of lease liabilities

$

74,452

X

- Definition
Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 840
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481440/840-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 840
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481418/840-10-55-40

Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 840
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481501/840-20-50-1

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482425/460-10-50-4

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 840
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481501/840-20-50-2
+ Details

Name: us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 59 R40.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 6 - NOTES PAYABLE: Schedule of Debt (Tables)
12 Months Ended

Dec. 31, 2023

Notes Payable, Other Payables

Schedule of Debt

Note

Issuance Date

Maturity Date

Interest Rate

Original Principal Amount

Balance at December 31, 2023

Balance at December 31, 2022

Unsecured debt B

February 22, 2022

February 15, 2023

10%

$

200,000

-

75,370

Secured debt C

October 7, 2022

October 7, 2023

12.99%

200,000

-

200,000

Unsecured debt D

March 20, 2023

August 17, 2024

10%

330,000

166,486

-

Secured debt E

May 19, 2023

May 18, 2024

12.99%

131,000

-

-

Secured debt F

July 26, 2023

May 18, 2024

12.99%

196,000

110,399

-

Secured debt G

December 19, 2023

December 18, 2024

10%

94,600

92,526

-

Total notes payable

$

1,151,600

369,411

$275,370

Debt discount and deferred financing costs

-

-

-

Total notes payable, net

$

1,151,600

369,411

$275,370

X

- Definition
Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfDebtTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 60 R41.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 7 - CONVERTIBLE DEBT: Schedule of Debt (Tables)
12 Months Ended

Dec. 31, 2023

Convertible Debt

Schedule of Debt

Note

Issuance Date

Maturity Date

Interest Rate

Original Principal Amount

Balance at December 31, 2023

Balance at December 31, 2022

Convertible promissory note #1

July 28, 2016

January 19, 2017

8%

$

15,000

$

6,750

$

6,750

Convertible promissory note #2

May 25, 2022

August 5, 2023

10%

154,000

-

110,535

Convertible promissory note #3

May 12, 2022

May 1, 2023

12%

200,000

200,000

200,000

Convertible promissory note #4

January 24, 2023

April 24, 2024

0%

388,888

401,851

 -

Total notes payable

$

757,888

$

608,601

$

317,285

Debt discount and deferred financing costs

 -

 -

 -

Total notes payable, net

$

757,888

$

608,601

$

317,285

X

- Definition
Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfDebtTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 61 R42.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 8 - DERIVATIVE LIABILITY: Assumptions Used Textblock (Tables)
12 Months Ended

Dec. 31, 2023

Tables/Schedules

Assumptions Used Textblock

December 31, 2023

Upon Issuance 2023

December 31, 2022

Upon Issuance 2022

Stock Price

$0.06

$0.048

$0.04

$ 0.043-0.066

Exercise Price

$ 0.017-0.05

$0.045

$ 0.0224-0.05

$ 0.0224-0.05

Expected Life

0

0.75

0 - 0.59

1.0 - 1.2

Volatility

133%

145%

168%

194.52 - 197.12%

Dividend Yield

0%

0%

0%

0%

Risk-Free Interest Rate

5.44%

4.57%

4.02%

0.53 - 0.61%

Convertible Notes

595,638

388,888

317,285

356,000

Total Fair Value

$154,153

$174,234

$102,011

$273,906

X

- Definition
Represents the textual narrative disclosure of Schedule of Assumptions Used for Derivative Liabilities Table, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_ScheduleOfAssumptionsUsedForDerivativeLiabilitiesTblTextBlock

Namespace Prefix: fil_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 62 R43.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 8 - DERIVATIVE LIABILITY: Schedule of Change in Fair Value on Derivative (Tables)
12 Months Ended

Dec. 31, 2023

Tables/Schedules

Schedule of Change in Fair Value on Derivative

The change in Level 3 financial instrument fair value is as follows:

Balance, December 31, 2021

$ 92,527

Issued during the year ended December 31, 2022

264,952

Derivative liabilities debt premium

(43,269)

Change in fair value recognized in operations

(212,199)

Converted during the year ended December 31, 2022

(0)

Balance, December 31, 2022

$ 102,011

Issued during the year ended December 31, 2023

145,067

Derivative liabilities debt discount

29,167

Change in fair value recognized in operations

(83,923)

Converted during the year ended December 31, 2023

(38,172)

Balance, December 31, 2023

$ 154,150

X

- Definition
Represents the textual narrative disclosure of Schedule of Change in Fair Value on Derivative, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_ScheduleOfChangeInFairValueOnDerivativeTextBlock

Namespace Prefix: fil_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 63 R44.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 9 - INCOME TAXES: Schedule of Effective Income Tax Rate Reconciliation (Tables)
12 Months Ended

Dec. 31, 2023

Tables/Schedules

Schedule of Effective Income Tax Rate Reconciliation

December 2023

December 2022

Federal statutory income tax rate

$678,297

(166,169)

Change in valuation allowance

(678,297)

166,169

$-

$-

X

- Definition
Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Paragraph 12
-Section 50
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-12
+ Details

Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 64 R45.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 9 - INCOME TAXES: Schedule of Deferred Tax Assets and Liabilities (Tables)
12 Months Ended

Dec. 31, 2023

Tables/Schedules

Schedule of Deferred Tax Assets and Liabilities

December 2023

December 2022

Long-term deferred tax assets:

Federal net operating loss carryforwards

678,297

166,169

Valuation allowance

(678,297)

(166,169)

Net long-term deferred tax assets

$-

$-

X

- Definition
Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Paragraph 2
-Section 50
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-2
+ Details

Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 65 R46.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Share-based Compensation, Stock Options, Activity (Tables)
12 Months Ended

Dec. 31, 2023

Warrants

Schedule of Share-based Compensation, Stock Options, Activity

Weighted-

Weighted-

Average

Average

Remaining

Aggregate

Exercise

Contractual

Intrinsic

Warrants

Price

Life (Years)

Value

Outstanding at December 31, 2022

133,333

$7.22

2.17

 -

Granted

61,846

6.00

1.11

 -

Forfeited

 -

 -

 -

 -

Exercised

 -

 -

 -

 -

Outstanding at December 31, 2023

195,180

$6.83

1.17

$ -

Vested and expected to vest at December 31, 2023

195,180

$6.83

$ -

Exercisable at December 31, 2023

195,180

$6.83

$ -

Omnibus Stock Grant and Option Plan

Schedule of Share-based Compensation, Stock Options, Activity
The following summary of options activity for the year ended December 31, 2023 is presented below:

Weighted-

Weighted-

Average

Average

Remaining

Aggregate

Exercise

Contractual

Intrinsic

Options

Price

Life (Years)

Value

Outstanding at December 31, 2022

32,083

$6.00

2.13

38,500

Granted

6,250

6.00

3.42

7,500

Forfeited

 -

 -

 -

 -

Exercised

 -

 -

 -

 -

Outstanding at December 31, 2023

38,333

$6.00

2.34

$46,000

Vested and expected to vest at December 31, 2023

38,333

$6.00

$46,000

Exercisable at December 31, 2023

38,333

$6.00

$46,000

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: fil_StockIssuancesAxis=fil_WarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: fil_StockIssuancesAxis=fil_OmnibusStockGrantAndOptionPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 66 R47.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Nonvested Restricted Stock Units Activity (Tables)
12 Months Ended

Dec. 31, 2023

Tables/Schedules

Schedule of Nonvested Restricted Stock Units Activity

Weighted-

Weighted-

Average

Grant Date

Shares

Fair Value

Non-vested at December 31, 2022

-

-

Granted

133,125

6.00

Vested

(74,167)

6.00

Forfeited

-

-

Non-vested at December 31, 2023

58,958

6.00

X

- Definition
Tabular disclosure of the changes in outstanding nonvested restricted stock units.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 67 R48.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 10 - STOCKHOLDERS' EQUITY: Assumptions Used Textblock (Tables)
12 Months Ended

Dec. 31, 2023

Share Options, Units, and Warrants

Assumptions Used Textblock

Year Ending December 31,

2023

2022

Risk-free interest rate

5.18

%

2.75

%

Average expected term (years)

4.7 years

4.75 years

Expected volatility

106.5

%

194.8

%

Expected dividend yield

-

-

X

- Definition
Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (k)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1
+ Details

Name: us-gaap_ScheduleOfAssumptionsUsedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: fil_StockIssuancesAxis=fil_ShareOptionsUnitsAndWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 68 R49.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 11 - BUSINESS SEGMENT INFORMATION: Schedule of Segment Reporting Information, by Segment (Tables)
12 Months Ended

Dec. 31, 2023

March 31, 2023

Schedule of Segment Reporting Information, by Segment

CONSOLIDATED

HEALTH SUPPLEMENTS

CORPORATE

BergaMet

UBN

Revenue

2,485,866

2,485,866

-

-

Cost of Revenue

813,614

813,614

-

-

Long-lived Assets

732,030

193,260

538,771

-

Gain (Loss) Before Income Tax

(2,422,489)

(219,975)

(5,113)

(2,197,401)

Identifiable Assets

1,676,724

1,676,724

-

-

Depreciation and Amortization

2,195

2,195

-

-

March 31, 2022

Schedule of Segment Reporting Information, by Segment

CONSOLIDATED

HEALTH SUPPLEMENTS

CORPORATE

BergaMet

UBN

Revenue

2,251,469

2,251,469

-

-

Less Selling Fees

Cost of Revenue

783,141

783,141

-

-

Long-lived Assets

732,030

193,260

538,771

-

Gain (Loss) Before Income Tax

(983,121)

(164,625)

(358)

(818,138)

Identifiable Assets

1,819,128

1,819,128

-

-

Depreciation and Amortization

878

878

-

-

X

- Definition
Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-25

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
+ Details

Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_StatementScenarioAxis=fil_March312023Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementScenarioAxis=fil_March312022Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 69 R50.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory (Details) - USD ($)

Dec. 31, 2023

Dec. 31, 2022

Details

Inventory Allowances $ 1,611,257 $ 1,914,891

X

- Definition
Represents the monetary amount of Inventory Allowances, as of the indicated date.
+ References
No definition available.
+ Details

Name: fil_InventoryAllowances

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 70 R51.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory: Schedule of Inventory (Details) - USD ($)

Dec. 31, 2023

Dec. 31, 2022

Details

Raw Materials $ 2,998,683 $ 3,398,655

Finished Goods 225,567 310,600

Work in process 13,290 24,764

Total inventory 3,237,540 3,734,019

Inventory allowance (1,611,257) (1,914,891)

Inventory, net $ 1,626,283 $ 1,819,128

X

- Definition
Represents the monetary amount of Inventory Allowances, as of the indicated date.
+ References
No definition available.
+ Details

Name: fil_InventoryAllowances

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_InventoryFinishedGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_InventoryGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483467/210-10-45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_InventoryWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 71 R52.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Indefinite-Lived Intangible Assets (Details) - USD ($)

Dec. 31, 2023

Dec. 31, 2022

Patents/Trademarks $ 521,881 $ 521,881

Patents

Patents/Trademarks $ 315,604 $ 315,604

X

- Definition
Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details

Name: us-gaap_FiniteLivedPatentsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 72 R53.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)
12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Fair Value, Inputs, Level 3

Derivative liabilities $ 154,150 $ 102,011 $ 92,527

Increase (Decrease) in Derivative Liabilities 154,150 102,011

Derivative liabilities 154,150 102,011 $ 92,527

Increase (Decrease) in Derivative Liabilities 154,150 102,011

Convertible Debt, Issued 145,067 264,952

Derivative liabilities debt premium 29,167 (43,269)

Convertible Debt, Change In Fair Value Recognized In Operations (83,923) (212,199)

Convertible Debt, Converted $ (38,172) $ 0

X

- Definition
Represents the monetary amount of Convertible Debt, Change In Fair Value Recognized In Operations, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_ConvertibleDebtChangeInFairValueRecognizedInOperations

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the monetary amount of Convertible Debt, Converted, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_ConvertibleDebtConverted

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the monetary amount of Convertible Debt, Issued, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_ConvertibleDebtIssued

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the monetary amount of Derivative liabilities debt premium, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_DerivativeLiabilitiesDebtPremium

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13(Column G)(Footnote 8))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13(Column G))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5A
-Subparagraph (SX 210.12-13A(Column E))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483466/210-20-50-3

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483444/210-20-55-22

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483444/210-20-55-10

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-10
+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInDerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 73 R54.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 3 - GOING CONCERN (Details) - USD ($)
12 Months Ended 108 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2023

Details

Net Income/(Loss) $ (2,472,931) $ (983,121) $ 18,336,268

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 74 R55.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 4 - RELATED PARTY (Details) - USD ($)

Dec. 31, 2023

Dec. 31, 2022

Details

Salary and Wage, Excluding Cost of Good and Service Sold $ 0 $ 1,000

X

- Definition
Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.
+ References
No definition available.
+ Details

Name: us-gaap_SalariesWagesAndOfficersCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 75 R56.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 4 - RELATED PARTY: Schedule of Debt (Details) - USD ($)

Dec. 31, 2023

Dec. 31, 2022

Notes payable $ 361,093 $ 275,370

Related Party

Original Principal Amount 83,366

Due to Related Parties 83,366 866

Notes payable $ 83,366 866

Unsecured Debt A | Related Party

Debt Instrument, Interest Rate, Effective Percentage 0.00%

Original Principal Amount $ 866

Due to Related Parties $ 866 866

Unsecured Debt H | Related Party

Debt Instrument, Interest Rate, Effective Percentage 10.00%

Original Principal Amount $ 82,500

Due to Related Parties $ 82,500 $ 866

X

- Definition
Represents the monetary amount of Due to Related Parties, as of the indicated date.
+ References
No definition available.
+ Details

Name: fil_DueToRelatedParties

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482900/835-30-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-6
+ Details

Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
This is the result of the principal amount outstanding of total loans managed or securitized less securitized loans and loans that are in the process of being securitized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Subparagraph (a)
-Paragraph 4
-SubTopic 20
-Topic 860
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481326/860-20-50-4
+ Details

Name: us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=fil_RelatedParty1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=fil_UnsecuredDebtAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=fil_UnsecuredDebtHMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 76 R57.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES (Details)

Dec. 31, 2023

USD ($)

Details

Average monthly base rent, first 12 months $ 5,333

Average monthly base rent, next 24 months $ 5,694

X

- Definition
Represents the monetary amount of Capital Leases, Contingent Rental Payments Due, Next 24 months, as of the indicated date.
+ References
No definition available.
+ Details

Name: fil_CapitalLeasesContingentRentalPaymentsDueNext24Months

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due based upon the occurrence of an event specified in the contractual terms.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 840
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481161/840-30-50-1
+ Details

Name: us-gaap_CapitalLeasesContingentRentalPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 77 R58.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES: Lessee, Operating Lease, Disclosure (Details) - USD ($)
12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Details

Lease, Cost $ 0

Operating Lease, Weighted Average Remaining Lease Term 1 year 29 days

Lessee, Operating Lease, Discount Rate 9.80%

Right-of-use assets, net of amortization $ 71,583

Lease liabilities - current 65,229 $ 0

Lease liabilities - long-term (9,222) $ 0

Operating Lease, Liability (74,452)

2023 0

2023 0

2025 69,635

2025 5,822

Operating Leases, Future Minimum Payments Due 75,457

Receivable with Imputed Interest, Discount (1,005)

Operating Lease, Liability $ 74,452

X

- Definition
Represents the monetary amount of Right-of-use assets, net of amortization, as of the indicated date.
+ References
No definition available.
+ Details

Name: fil_RightOfUseAssetsNetOfAmortization

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of lease cost recognized by lessee for lease contract.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 53
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479589/842-20-55-53

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details

Name: us-gaap_LeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Discount rate used by lessee to determine present value of operating lease payments.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147478964/842-20-50-3
+ Details

Name: us-gaap_LesseeOperatingLeaseDiscountRate

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 53
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479589/842-20-55-53

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 840
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481418/840-10-55-40

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 840
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481501/840-20-50-2
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 840
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481418/840-10-55-40

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 840
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481501/840-20-50-2
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 840
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481418/840-10-55-40

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 840
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481501/840-20-50-2
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 840
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481418/840-10-55-40

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 840
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481501/840-20-50-2
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 840
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481418/840-10-55-40

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 840
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481501/840-20-50-2
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Disclosure of the unamortized amount of the discount on the note or receivable which is deducted from the face amount of the receivable or loan. The discount or premium is the difference between the present value and the face amount.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
+ Details

Name: us-gaap_ReceivableWithImputedInterestDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 78 R59.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 6 - NOTES PAYABLE: Schedule of Debt (Details) - USD ($)

Dec. 31, 2023

Dec. 31, 2022

Notes payable $ 361,093 $ 275,370

Notes Payable, Other Payables

Original Principal Amount 1,151,600

Due to Related Parties 369,411 275,370

Notes payable $ 369,411 275,370

Unsecured Debt 1 | Notes Payable, Other Payables

Debt Instrument, Interest Rate, Effective Percentage 10.00%

Original Principal Amount $ 200,000

Due to Related Parties $ 0 75,370

Secured Debt 1 | Notes Payable, Other Payables

Debt Instrument, Interest Rate, Effective Percentage 12.99%

Original Principal Amount $ 200,000

Due to Related Parties $ 0 200,000

Unsecured Debt 2 | Notes Payable, Other Payables

Debt Instrument, Interest Rate, Effective Percentage 10.00%

Original Principal Amount $ 330,000

Due to Related Parties $ 166,486 0

Secured Debt 2 | Notes Payable, Other Payables

Debt Instrument, Interest Rate, Effective Percentage 12.99%

Original Principal Amount $ 131,000

Due to Related Parties $ 0 0

Secured Debt 3 | Notes Payable, Other Payables

Debt Instrument, Interest Rate, Effective Percentage 12.99%

Original Principal Amount $ 196,000

Due to Related Parties $ 110,399 0

Secured Debt 4 | Notes Payable, Other Payables

Debt Instrument, Interest Rate, Effective Percentage 10.00%

Original Principal Amount $ 94,600

Due to Related Parties $ 92,526 $ 0

X

- Definition
Represents the monetary amount of Due to Related Parties, as of the indicated date.
+ References
No definition available.
+ Details

Name: fil_DueToRelatedParties

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482900/835-30-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-6
+ Details

Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
This is the result of the principal amount outstanding of total loans managed or securitized less securitized loans and loans that are in the process of being securitized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Subparagraph (a)
-Paragraph 4
-SubTopic 20
-Topic 860
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481326/860-20-50-4
+ Details

Name: us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=fil_UnsecuredDebt1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=fil_SecuredDebt1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=fil_UnsecuredDebt2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=fil_SecuredDebt2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=fil_SecuredDebt3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=fil_SecuredDebt4Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 79 R60.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 7 - CONVERTIBLE DEBT: Schedule of Debt (Details) - USD ($)

Dec. 31, 2023

Dec. 31, 2022

Notes payable $ 361,093 $ 275,370

Convertible Debt

Original Principal Amount 757,888

Due to Related Parties 608,601 317,285

Notes payable $ 608,601 317,285

Convertible Promissory Note 1 | Convertible Debt

Debt Instrument, Interest Rate, Effective Percentage 8.00%

Original Principal Amount $ 15,000

Due to Related Parties $ 6,750 6,750

Convertible Promissory Note 2 | Convertible Debt

Debt Instrument, Interest Rate, Effective Percentage 10.00%

Original Principal Amount $ 154,000

Due to Related Parties $ 0 110,535

Convertible Promissory Note 3 | Convertible Debt

Debt Instrument, Interest Rate, Effective Percentage 12.00%

Original Principal Amount $ 200,000

Due to Related Parties $ 200,000 200,000

Convertible Promissory Note 4 | Convertible Debt

Debt Instrument, Interest Rate, Effective Percentage 0.00%

Original Principal Amount $ 388,888

Due to Related Parties $ 401,851 $ 0

X

- Definition
Represents the monetary amount of Due to Related Parties, as of the indicated date.
+ References
No definition available.
+ Details

Name: fil_DueToRelatedParties

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482900/835-30-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-6
+ Details

Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
This is the result of the principal amount outstanding of total loans managed or securitized less securitized loans and loans that are in the process of being securitized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Subparagraph (a)
-Paragraph 4
-SubTopic 20
-Topic 860
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481326/860-20-50-4
+ Details

Name: us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=fil_ConvertiblePromissoryNote1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=fil_ConvertiblePromissoryNote2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=fil_ConvertiblePromissoryNote3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=fil_ConvertiblePromissoryNote4Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 80 R61.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 8 - DERIVATIVE LIABILITY: Assumptions Used Textblock (Details) - USD ($)
3 Months Ended 12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2023

Dec. 31, 2022

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 4 years 8 months 12 days 4 years 9 months

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate 106.50% 194.80%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0.00% 0.00%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 5.18% 2.75%

Derivative Financial Instruments, Liabilities

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Stock Price $ 0.06 $ 0.04

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 0 years 0 years

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate 133.00% 168.00%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0.00% 0.00%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 5.44% 4.02%

Convertible Notes Payable $ 595,638 $ 317,285 $ 595,638 $ 317,285

Total Fair Value $ 154,153 $ 102,011

Derivative Financial Instruments, Liabilities | Minimum

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price $ 0.017 $ 0.0224 $ 0.017 $ 0.0224

Derivative Financial Instruments, Liabilities | Maximum

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price 0.05 $ 0.05 0.05 $ 0.05

Upon Issuance

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Stock Price 0.048

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price $ 0.045 $ 0.045

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 9 months 1 year

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate 145.00%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0.00% 0.00%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 4.57%

Convertible Notes Payable $ 388,888 $ 356,000 $ 388,888 $ 356,000

Total Fair Value $ 174,234 $ 273,906

Upon Issuance | Minimum

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Stock Price $ 0.043

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price $ 0.0224 $ 0.0224

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate 194.52%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 0.53%

Upon Issuance | Maximum

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Stock Price $ 0.066

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price $ 0.05 $ 0.05

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate 197.12%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 0.61%

X

- Definition
Represents the per-share monetary value of Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Stock Price, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice

Namespace Prefix: fil_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the monetary amount of Total Fair Value, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_TotalFairValue

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details

Name: us-gaap_ConvertibleNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByLiabilityClassAxis=fil_UponIssuanceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 81 R62.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 8 - DERIVATIVE LIABILITY (Details) - USD ($)
12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Details

Gain (Loss) on Derivative Liabilities $ 83,920 $ 212,199

Gain (Loss) on Extinguishment of Debt $ 38,172

X

- Definition
Amount of unrealized gain (loss) recognized in income for derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3) and still held.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details

Name: us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481303/470-50-40-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481303/470-50-40-4
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 82 R63.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 8 - DERIVATIVE LIABILITY: Schedule of Change in Fair Value on Derivative (Details) - USD ($)
12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Details

Derivative liabilities $ 154,150 $ 102,011 $ 92,527

Convertible Debt, Issued 145,067 264,952

Derivative liabilities debt premium 29,167 (43,269)

Convertible Debt, Change In Fair Value Recognized In Operations (83,923) (212,199)

Convertible Debt, Converted $ (38,172) $ 0

X

- Definition
Represents the monetary amount of Convertible Debt, Change In Fair Value Recognized In Operations, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_ConvertibleDebtChangeInFairValueRecognizedInOperations

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the monetary amount of Convertible Debt, Converted, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_ConvertibleDebtConverted

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the monetary amount of Convertible Debt, Issued, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_ConvertibleDebtIssued

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the monetary amount of Derivative liabilities debt premium, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_DerivativeLiabilitiesDebtPremium

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13(Column G)(Footnote 8))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13(Column G))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5A
-Subparagraph (SX 210.12-13A(Column E))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483466/210-20-50-3

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483444/210-20-55-22

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483444/210-20-55-10

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-10
+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 83 R64.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 9 - INCOME TAXES: Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)
12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Details

Federal statutory income tax rate $ 678,297 $ (166,169)

Change in valuation allowance (678,297) 166,169

Income Tax Expense (Benefit) $ 0 $ 0

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-10

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482659/740-20-45-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-12
+ Details

Name: us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-12
+ Details

Name: us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 84 R65.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 9 - INCOME TAXES: Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)

Dec. 31, 2023

Sep. 30, 2022

Details

Federal net operating loss carryforwards $ 678,297 $ 166,169

Valuation allowance (678,297) (166,169)

Net long-term deferred tax assets $ 0 $ 0

X

- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-2
+ Details

Name: us-gaap_DeferredTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-6

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-8
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-2
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 85 R66.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 10 - STOCKHOLDERS' EQUITY (Details) - USD ($)
3 Months Ended 12 Months Ended

Dec. 31, 2023

Mar. 31, 2023

Dec. 31, 2023

Dec. 31, 2022

Apr. 30, 2018

Jan. 31, 2018

Oct. 16, 2017

Feb. 28, 2017

Preferred Stock, Shares Authorized 75,000,000 75,000,000 75,000,000 75,000,000

Preferred Stock, Par or Stated Value Per Share $ 0.001 $ 0.001 $ 0.001

Common Stock, Shares Authorized 50,000,000 50,000,000 50,000,000 2,500,000,000 1,000,000,000 500,000,000

Stockholders' Equity, Reverse Stock Split The Company effectuated a reverse stock split of 120-for-1 as of December 29, 2023

Preferred Stock, Shares Outstanding 0 0 0

Warrants Issued 61,846

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number 195,180 195,180

Warrants Fully Vested 195,180 195,180

General and administrative $ 3,865,654 $ 2,283,107

Unvested compensation related to issuances of restricted stock units fair value $ 423,910 $ 423,910

Restricted Stock Units

General and administrative $ 445,000

Common Stock

Issuance of common stock for services 320,000 320,000

StockIssued During Period Shares Issued For Services4 340,000 340,000

Issuance of common stock-Note Conversion, shares 340,621 340,621

StockIssued During Period Shares Issued For Services3 4,400,000

Issuance of common stock for cash 507,917 507,917

Cancelation of common stock for debt (200,267) (800,267)

Cancelation Of Common Stock For Deb tShares2 (600,000)

StockIssued During Period Shares Issued For Services2 16,667

StockIssued During Period Shares Issued For Services5 6,400,000

Preferred Stock

Issuance of common stock-Share Conversion Agreements 15,592,986

Issuance of common stock-Share Conversion Agreements, Retired 467,057

Series A Preferred Stock

Preferred Stock, Shares Authorized 1,333,334 25,000,000

X

- Definition
Represents the Cancelation Of Common Stock For Deb tShares2 (number of shares), during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_CancelationOfCommonStockForDebTshares2

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the Cancelation of common stock for debt, Shares (number of shares), during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_CancelationOfCommonStockForDebtShares

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the Issuance of common stock-Note Conversion, shares (number of shares), during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_IssuanceOfCommonStockNoteConversionShares

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the Issuance of common stock-Share Conversion Agreements (number of shares), during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_IssuanceOfCommonStockShareConversionAgreements

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the Issuance of common stock-Share Conversion Agreements, Retired (number of shares), during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_IssuanceOfCommonStockShareConversionAgreementsRetired

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the Issuance of common stock for services (number of shares), during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_StockissuedDuringPeriodSharesIssuedForServices

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the StockIssued During Period Shares Issued For Services2 (number of shares), during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_StockissuedDuringPeriodSharesIssuedForServices2

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the StockIssued During Period Shares Issued For Services3 (number of shares), during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_StockissuedDuringPeriodSharesIssuedForServices3

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the StockIssued During Period Shares Issued For Services4 (number of shares), during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_StockissuedDuringPeriodSharesIssuedForServices4

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the StockIssued During Period Shares Issued For Services5 (number of shares), during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_StockissuedDuringPeriodSharesIssuedForServices5

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the monetary amount of Unvested compensation related to issuances of restricted stock units fair value, as of the indicated date.
+ References
No definition available.
+ Details

Name: fil_UnvestedCompensationRelatedToIssuancesOfRestrictedStockUnitsFairValue

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Represents the Warrants Fully Vested (number of shares), as of the indicated date.
+ References
No definition available.
+ Details

Name: fil_WarrantsFullyVested

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the Warrants Issued (number of shares), during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_WarrantsIssued

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4
+ Details

Name: us-gaap_StockholdersEquityReverseStockSplit

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: fil_StockIssuancesAxis=fil_RestrictedStockUnitsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 86 R67.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Share-based Compensation, Stock Options, Activity (Details)
12 Months Ended

Dec. 31, 2023

USD ($)

$ / shares

shares

Dec. 31, 2022

USD ($)

$ / shares

shares

Dec. 31, 2023

USD ($)

$ / shares

shares

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number | shares 195,180 195,180

Warrants

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number | shares 195,180 133,333 195,180

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price $ 6.83 $ 7.22 $ 6.83

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 1 year 2 months 1 day 2 years 2 months 1 day

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value | $ $ 0 $ 0 $ 0

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures | shares 61,846

Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price $ 6.00

Weighted Average Remaining Contractual Life (Years) 1.11

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value $ 0

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | shares 195,180 195,180

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $ 6.83 $ 6.83

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | $ $ 0 $ 0

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number | shares 195,180 195,180

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price $ 6.83 $ 6.83

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value | $ $ 0 $ 0

Omnibus Stock Grant and Option Plan

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number | shares 38,333 32,083 38,333

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price $ 6.00 $ 6.00 $ 6.00

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 2 years 4 months 2 days 2 years 1 month 17 days

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value | $ $ 46,000 $ 38,500 $ 46,000

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures | shares 6,250

Weighted Average Remaining Contractual Life (Years) 3.42

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value $ 7,500

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | shares 38,333 38,333

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $ 6.00 $ 6.00

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | $ $ 46,000 $ 46,000

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number | shares 38,333 38,333

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price $ 6.00 $ 6.00

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value | $ $ 46,000 $ 46,000

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 6.00

X

- Definition
Represents the Weighted Average Remaining Contractual Life (Years), during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_WeightedAverageRemainingContractualLifeYears

Namespace Prefix: fil_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Net number of share options (or share units) granted during the period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 718
-SubTopic 10
-Subparagraph (e)(1)
-Name Accounting Standards Codification
-Paragraph 2
-Section 50
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: fil_StockIssuancesAxis=fil_WarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: fil_StockIssuancesAxis=fil_OmnibusStockGrantAndOptionPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 87 R68.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Nonvested Restricted Stock Units Activity (Details) - Restricted Stock Units - $ / shares
12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares 58,958 0

Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price $ 6.00 $ 0

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures 133,125

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 6.00

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (74,167)

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value $ 6.00

X

- Definition
Net number of share options (or share units) granted during the period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of non-vested options outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average grant-date fair value of non-vested options outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average grant-date fair value of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: fil_StockIssuancesAxis=fil_RestrictedStockUnitsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 88 R69.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 10 - STOCKHOLDERS' EQUITY: Assumptions Used Textblock (Details)
3 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Details

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 5.18% 2.75%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 4 years 8 months 12 days 4 years 9 months

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate 106.50% 194.80%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0.00% 0.00%

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 89 R70.htm IDEA: XBRL DOCUMENT v3.24.1

NOTE 11 - BUSINESS SEGMENT INFORMATION: Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Revenue $ 2,485,866 $ 2,251,469

Total cost of revenue 864,055 879,951

Net income/(loss) before income tax provision (2,472,931) (983,121)

Depreciation and amortization 2,195 878

Consolidated

Revenue 2,485,866 2,251,469

Total cost of revenue 813,614 783,141

Long-lived Assets 732,030 732,030

Net income/(loss) before income tax provision (2,422,489) (983,121)

Identifiable Assets 1,676,724 1,819,128

Depreciation and amortization 2,195 878

BergaMet

Revenue 2,485,866 2,251,469

Total cost of revenue 813,614 783,141

Long-lived Assets 193,260 193,260

Net income/(loss) before income tax provision (219,975) (164,625)

Identifiable Assets 1,676,724 1,819,128

Depreciation and amortization 2,195 878

UBN

Revenue 0 0

Total cost of revenue 0 0

Long-lived Assets 538,771 538,771

Net income/(loss) before income tax provision (5,113) (358)

Identifiable Assets 0 0

Depreciation and amortization 0 0

Corporate Segment

Revenue 0 0

Total cost of revenue 0 0

Long-lived Assets 0 0

Net income/(loss) before income tax provision (2,197,401) (818,138)

Identifiable Assets 0 0

Depreciation and amortization $ 0 $ 0

X

- Definition
Represents the monetary amount of Depreciation and Amortization, during the indicated time period.
+ References
No definition available.
+ Details

Name: fil_DepreciationAndAmortization1

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the monetary amount of Identifiable Assets, as of the indicated date.
+ References
No definition available.
+ Details

Name: fil_IdentifiableAssets

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The aggregate cost of goods produced and sold and services rendered during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
+ Details

Name: us-gaap_NoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-11

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480767/946-205-45-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(16))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 19
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481231/810-10-45-19

Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 29: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 33: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4J
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J

Reference 34: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4K
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-2

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of sales-type lease revenue.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482964/270-10-50-6A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479773/842-30-50-5
+ Details

Name: us-gaap_SalesTypeLeaseRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=fil_ConsolidatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=fil_BergametMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=fil_UbnMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 90 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 91 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 92 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 94 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 124 248 1 false 36 0 false 4 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 000020 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 000030 - Statement - CONSOLIDATED BALANCE SHEETS - Parenthetical Sheet http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS - Parenthetical Statements 3 false false R4.htm 000040 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS Sheet http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations CONSOLIDATED STATEMENT OF OPERATIONS Statements 4 false false R5.htm 000050 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) Statements 5 false false R6.htm 000060 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS Sheet http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows CONSOLIDATED STATEMENT OF CASH FLOWS Statements 6 false false R7.htm 000070 - Disclosure - NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote1OrganizationAndDescriptionOfBusiness NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS Notes 7 false false R8.htm 000080 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 000090 - Disclosure - NOTE 3 - GOING CONCERN Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote3GoingConcern NOTE 3 - GOING CONCERN Notes 9 false false R10.htm 000100 - Disclosure - NOTE 4 - RELATED PARTY Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedParty NOTE 4 - RELATED PARTY Notes 10 false false R11.htm 000110 - Disclosure - NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilities NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES Notes 11 false false R12.htm 000120 - Disclosure - NOTE 6 - NOTES PAYABLE Notes http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayable NOTE 6 - NOTES PAYABLE Notes 12 false false R13.htm 000130 - Disclosure - NOTE 7 - CONVERTIBLE DEBT Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebt NOTE 7 - CONVERTIBLE DEBT Notes 13 false false R14.htm 000140 - Disclosure - NOTE 8 - DERIVATIVE LIABILITY Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiability NOTE 8 - DERIVATIVE LIABILITY Notes 14 false false R15.htm 000150 - Disclosure - NOTE 9 - INCOME TAXES Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote9IncomeTaxes NOTE 9 - INCOME TAXES Notes 15 false false R16.htm 000160 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquity NOTE 10 - STOCKHOLDERS' EQUITY Notes 16 false false R17.htm 000170 - Disclosure - NOTE 11 - BUSINESS SEGMENT INFORMATION Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformation NOTE 11 - BUSINESS SEGMENT INFORMATION Notes 17 false false R18.htm 000180 - Disclosure - NOTE 12 - SUBSEQUENT EVENTS Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote12SubsequentEvents NOTE 12 - SUBSEQUENT EVENTS Notes 18 false false R19.htm 000190 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis of Presentation (Policies) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesBasisOfPresentationPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis of Presentation (Policies) Policies 19 false false R20.htm 000200 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Use of Estimates (Policies) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesUseOfEstimatesPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Use of Estimates (Policies) Policies 20 false false R21.htm 000210 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash (Policies) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesCashPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash (Policies) Policies 21 false false R22.htm 000220 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Accounts Receivables (Policies) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesAccountsReceivablesPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Accounts Receivables (Policies) Policies 22 false false R23.htm 000230 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory (Policies) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesInventoryPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory (Policies) Policies 23 false false R24.htm 000240 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Property and Equipment (Policies) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Property and Equipment (Policies) Policies 24 false false R25.htm 000250 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Indefinite-Lived Intangible Assets (Policies) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesIndefiniteLivedIntangibleAssetsPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Indefinite-Lived Intangible Assets (Policies) Policies 25 false false R26.htm 000260 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Goodwill (Policies) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesGoodwillPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Goodwill (Policies) Policies 26 false false R27.htm 000270 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Debt with Warrants (Policies) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesDebtWithWarrantsPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Debt with Warrants (Policies) Policies 27 false false R28.htm 000280 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Convertible Debt - Derivative Treatment (Policies) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesConvertibleDebtDerivativeTreatmentPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Convertible Debt - Derivative Treatment (Policies) Policies 28 false false R29.htm 000290 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Revenue Recognition (Policies) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesRevenueRecognitionPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Revenue Recognition (Policies) Policies 29 false false R30.htm 000300 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Concentration (Policies) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesConcentrationPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Concentration (Policies) Policies 30 false false R31.htm 000310 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Income Taxes (Policies) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesIncomeTaxesPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Income Taxes (Policies) Policies 31 false false R32.htm 000320 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements (Policies) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements (Policies) Policies 32 false false R33.htm 000330 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Convertible Instruments (Policies) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesConvertibleInstrumentsPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Convertible Instruments (Policies) Policies 33 false false R34.htm 000340 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Recent Accounting Pronouncements (Policies) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Recent Accounting Pronouncements (Policies) Policies 34 false false R35.htm 000350 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Common Stock Purchase Warrants (Policies) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesCommonStockPurchaseWarrantsPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Common Stock Purchase Warrants (Policies) Policies 35 false false R36.htm 000360 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory: Schedule of Inventory (Tables) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesInventoryScheduleOfInventoryTables NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory: Schedule of Inventory (Tables) Tables 36 false false R37.htm 000370 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTables NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables) Tables 37 false false R38.htm 000380 - Disclosure - NOTE 4 - RELATED PARTY: Schedule of Debt (Tables) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtTables NOTE 4 - RELATED PARTY: Schedule of Debt (Tables) Tables 38 false false R39.htm 000390 - Disclosure - NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES: Lessee, Operating Lease, Disclosure (Tables) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesLesseeOperatingLeaseDisclosureTables NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES: Lessee, Operating Lease, Disclosure (Tables) Tables 39 false false R40.htm 000400 - Disclosure - NOTE 6 - NOTES PAYABLE: Schedule of Debt (Tables) Notes http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtTables NOTE 6 - NOTES PAYABLE: Schedule of Debt (Tables) Tables 40 false false R41.htm 000410 - Disclosure - NOTE 7 - CONVERTIBLE DEBT: Schedule of Debt (Tables) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtTables NOTE 7 - CONVERTIBLE DEBT: Schedule of Debt (Tables) Tables 41 false false R42.htm 000420 - Disclosure - NOTE 8 - DERIVATIVE LIABILITY: Assumptions Used Textblock (Tables) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockTables NOTE 8 - DERIVATIVE LIABILITY: Assumptions Used Textblock (Tables) Tables 42 false false R43.htm 000430 - Disclosure - NOTE 8 - DERIVATIVE LIABILITY: Schedule of Change in Fair Value on Derivative (Tables) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityScheduleOfChangeInFairValueOnDerivativeTables NOTE 8 - DERIVATIVE LIABILITY: Schedule of Change in Fair Value on Derivative (Tables) Tables 43 false false R44.htm 000440 - Disclosure - NOTE 9 - INCOME TAXES: Schedule of Effective Income Tax Rate Reconciliation (Tables) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote9IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationTables NOTE 9 - INCOME TAXES: Schedule of Effective Income Tax Rate Reconciliation (Tables) Tables 44 false false R45.htm 000450 - Disclosure - NOTE 9 - INCOME TAXES: Schedule of Deferred Tax Assets and Liabilities (Tables) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote9IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTables NOTE 9 - INCOME TAXES: Schedule of Deferred Tax Assets and Liabilities (Tables) Tables 45 false false R46.htm 000460 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Share-based Compensation, Stock Options, Activity (Tables) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityTables NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Share-based Compensation, Stock Options, Activity (Tables) Tables 46 false false R47.htm 000470 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Nonvested Restricted Stock Units Activity (Tables) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfNonvestedRestrictedStockUnitsActivityTables NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Nonvested Restricted Stock Units Activity (Tables) Tables 47 false false R48.htm 000480 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY: Assumptions Used Textblock (Tables) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityAssumptionsUsedTextblockTables NOTE 10 - STOCKHOLDERS' EQUITY: Assumptions Used Textblock (Tables) Tables 48 false false R49.htm 000490 - Disclosure - NOTE 11 - BUSINESS SEGMENT INFORMATION: Schedule of Segment Reporting Information, by Segment (Tables) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentTables NOTE 11 - BUSINESS SEGMENT INFORMATION: Schedule of Segment Reporting Information, by Segment (Tables) Tables 49 false false R50.htm 000500 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory (Details) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesInventoryDetails NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory (Details) Details http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesInventoryScheduleOfInventoryTables 50 false false R51.htm 000510 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory: Schedule of Inventory (Details) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesInventoryScheduleOfInventoryDetails NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory: Schedule of Inventory (Details) Details http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesInventoryScheduleOfInventoryTables 51 false false R52.htm 000520 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Indefinite-Lived Intangible Assets (Details) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesIndefiniteLivedIntangibleAssetsDetails NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Indefinite-Lived Intangible Assets (Details) Details http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesIndefiniteLivedIntangibleAssetsPolicies 52 false false R53.htm 000530 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Details http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTables 53 false false R54.htm 000540 - Disclosure - NOTE 3 - GOING CONCERN (Details) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote3GoingConcernDetails NOTE 3 - GOING CONCERN (Details) Details http://healthyextractsinc.com/20231231/role/idr_DisclosureNote3GoingConcern 54 false false R55.htm 000550 - Disclosure - NOTE 4 - RELATED PARTY (Details) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyDetails NOTE 4 - RELATED PARTY (Details) Details http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtTables 55 false false R56.htm 000560 - Disclosure - NOTE 4 - RELATED PARTY: Schedule of Debt (Details) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtDetails NOTE 4 - RELATED PARTY: Schedule of Debt (Details) Details http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtTables 56 false false R57.htm 000570 - Disclosure - NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES (Details) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesDetails NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES (Details) Details http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesLesseeOperatingLeaseDisclosureTables 57 false false R58.htm 000580 - Disclosure - NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES: Lessee, Operating Lease, Disclosure (Details) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesLesseeOperatingLeaseDisclosureDetails NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES: Lessee, Operating Lease, Disclosure (Details) Details http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesLesseeOperatingLeaseDisclosureTables 58 false false R59.htm 000590 - Disclosure - NOTE 6 - NOTES PAYABLE: Schedule of Debt (Details) Notes http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtDetails NOTE 6 - NOTES PAYABLE: Schedule of Debt (Details) Details http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtTables 59 false false R60.htm 000600 - Disclosure - NOTE 7 - CONVERTIBLE DEBT: Schedule of Debt (Details) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtDetails NOTE 7 - CONVERTIBLE DEBT: Schedule of Debt (Details) Details http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtTables 60 false false R61.htm 000610 - Disclosure - NOTE 8 - DERIVATIVE LIABILITY: Assumptions Used Textblock (Details) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockDetails NOTE 8 - DERIVATIVE LIABILITY: Assumptions Used Textblock (Details) Details http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockTables 61 false false R62.htm 000620 - Disclosure - NOTE 8 - DERIVATIVE LIABILITY (Details) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityDetails NOTE 8 - DERIVATIVE LIABILITY (Details) Details http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockTables 62 false false R63.htm 000630 - Disclosure - NOTE 8 - DERIVATIVE LIABILITY: Schedule of Change in Fair Value on Derivative (Details) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityScheduleOfChangeInFairValueOnDerivativeDetails NOTE 8 - DERIVATIVE LIABILITY: Schedule of Change in Fair Value on Derivative (Details) Details http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityScheduleOfChangeInFairValueOnDerivativeTables 63 false false R64.htm 000640 - Disclosure - NOTE 9 - INCOME TAXES: Schedule of Effective Income Tax Rate Reconciliation (Details) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote9IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails NOTE 9 - INCOME TAXES: Schedule of Effective Income Tax Rate Reconciliation (Details) Details http://healthyextractsinc.com/20231231/role/idr_DisclosureNote9IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationTables 64 false false R65.htm 000650 - Disclosure - NOTE 9 - INCOME TAXES: Schedule of Deferred Tax Assets and Liabilities (Details) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote9IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails NOTE 9 - INCOME TAXES: Schedule of Deferred Tax Assets and Liabilities (Details) Details http://healthyextractsinc.com/20231231/role/idr_DisclosureNote9IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTables 65 false false R66.htm 000660 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY (Details) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails NOTE 10 - STOCKHOLDERS' EQUITY (Details) Details http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityTables 66 false false R67.htm 000670 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Share-based Compensation, Stock Options, Activity (Details) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Share-based Compensation, Stock Options, Activity (Details) Details http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityTables 67 false false R68.htm 000680 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Nonvested Restricted Stock Units Activity (Details) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfNonvestedRestrictedStockUnitsActivityDetails NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Nonvested Restricted Stock Units Activity (Details) Details http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfNonvestedRestrictedStockUnitsActivityTables 68 false false R69.htm 000690 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY: Assumptions Used Textblock (Details) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityAssumptionsUsedTextblockDetails NOTE 10 - STOCKHOLDERS' EQUITY: Assumptions Used Textblock (Details) Details http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityAssumptionsUsedTextblockTables 69 false false R70.htm 000700 - Disclosure - NOTE 11 - BUSINESS SEGMENT INFORMATION: Schedule of Segment Reporting Information, by Segment (Details) Sheet http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails NOTE 11 - BUSINESS SEGMENT INFORMATION: Schedule of Segment Reporting Information, by Segment (Details) Details http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentTables 70 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate - hyex-20231231.htm 13 hyex-20231231.htm hyex-20231231.xsd hyex-20231231_cal.xml hyex-20231231_def.xml hyex-20231231_lab.xml hyex-20231231_pre.xml hyex10k_1.jpg hyex10k_2.jpg hyex10k_3.jpg hyex10k_4.jpg hyex10k_5.jpg hyex10k_6.jpg hyex10k_7.jpg hyex10k_8.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 97 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hyex-20231231.htm": { "nsprefix": "fil", "nsuri": "http://healthyextractsinc.com/20231231", "dts": { "inline": { "local": [ "hyex-20231231.htm" ] }, "schema": { "local": [ "hyex-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "hyex-20231231_cal.xml" ] }, "definitionLink": { "local": [ "hyex-20231231_def.xml" ] }, "labelLink": { "local": [ "hyex-20231231_lab.xml" ] }, "presentationLink": { "local": [ "hyex-20231231_pre.xml" ] } }, "keyStandard": 200, "keyCustom": 48, "axisStandard": 10, "axisCustom": 1, "memberStandard": 13, "memberCustom": 23, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 124, "entityCount": 1, "segmentCount": 36, "elementCount": 331, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 457, "http://xbrl.sec.gov/dei/2023": 34 }, "report": { "R1": { "role": "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation", "longName": "000010 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Y23", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R2": { "role": "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets", "longName": "000020 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "E23", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "E23", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R3": { "role": "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheetsParenthetical", "longName": "000030 - Statement - CONSOLIDATED BALANCE SHEETS - Parenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS - Parenthetical", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "E23", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "UsdPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "E23", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "unique": true } }, "R4": { "role": "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations", "longName": "000040 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS", "shortName": "CONSOLIDATED STATEMENT OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:SalesTypeLeaseRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "unique": true } }, "R5": { "role": "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "longName": "000050 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "E21_StEqComps-CommonStock", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "E21_StEqComps-CommonStock", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R6": { "role": "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows", "longName": "000060 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENT OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "unique": true } }, "R7": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote1OrganizationAndDescriptionOfBusiness", "longName": "000070 - Disclosure - NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS", "shortName": "NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R8": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPolicies", "longName": "000080 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R9": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote3GoingConcern", "longName": "000090 - Disclosure - NOTE 3 - GOING CONCERN", "shortName": "NOTE 3 - GOING CONCERN", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R10": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedParty", "longName": "000100 - Disclosure - NOTE 4 - RELATED PARTY", "shortName": "NOTE 4 - RELATED PARTY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R11": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilities", "longName": "000110 - Disclosure - NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES", "shortName": "NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R12": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayable", "longName": "000120 - Disclosure - NOTE 6 - NOTES PAYABLE", "shortName": "NOTE 6 - NOTES PAYABLE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R13": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebt", "longName": "000130 - Disclosure - NOTE 7 - CONVERTIBLE DEBT", "shortName": "NOTE 7 - CONVERTIBLE DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R14": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiability", "longName": "000140 - Disclosure - NOTE 8 - DERIVATIVE LIABILITY", "shortName": "NOTE 8 - DERIVATIVE LIABILITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R15": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote9IncomeTaxes", "longName": "000150 - Disclosure - NOTE 9 - INCOME TAXES", "shortName": "NOTE 9 - INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R16": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquity", "longName": "000160 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY", "shortName": "NOTE 10 - STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R17": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformation", "longName": "000170 - Disclosure - NOTE 11 - BUSINESS SEGMENT INFORMATION", "shortName": "NOTE 11 - BUSINESS SEGMENT INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R18": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote12SubsequentEvents", "longName": "000180 - Disclosure - NOTE 12 - SUBSEQUENT EVENTS", "shortName": "NOTE 12 - SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R19": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesBasisOfPresentationPolicies", "longName": "000190 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis of Presentation (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis of Presentation (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "19", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R20": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesUseOfEstimatesPolicies", "longName": "000200 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Use of Estimates (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Use of Estimates (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "20", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R21": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesCashPolicies", "longName": "000210 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R22": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesAccountsReceivablesPolicies", "longName": "000220 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Accounts Receivables (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Accounts Receivables (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:TradeAndOtherAccountsReceivablePolicy", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:TradeAndOtherAccountsReceivablePolicy", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R23": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesInventoryPolicies", "longName": "000230 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:InventoryPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:InventoryPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R24": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentPolicies", "longName": "000240 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Property and Equipment (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Property and Equipment (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R25": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesIndefiniteLivedIntangibleAssetsPolicies", "longName": "000250 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Indefinite-Lived Intangible Assets (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Indefinite-Lived Intangible Assets (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R26": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesGoodwillPolicies", "longName": "000260 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Goodwill (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Goodwill (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "26", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R27": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesDebtWithWarrantsPolicies", "longName": "000270 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Debt with Warrants (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Debt with Warrants (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "Y23", "name": "fil:DebtWithWarrantsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "fil:DebtWithWarrantsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R28": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesConvertibleDebtDerivativeTreatmentPolicies", "longName": "000280 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Convertible Debt - Derivative Treatment (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Convertible Debt - Derivative Treatment (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "Y23", "name": "fil:ConvertibleDebtDerivativeTreatmentPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "fil:ConvertibleDebtDerivativeTreatmentPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R29": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesRevenueRecognitionPolicies", "longName": "000290 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Revenue Recognition (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Revenue Recognition (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "29", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R30": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesConcentrationPolicies", "longName": "000300 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Concentration (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Concentration (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "30", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:ConcentrationRiskCreditRisk", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:ConcentrationRiskCreditRisk", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R31": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesIncomeTaxesPolicies", "longName": "000310 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Income Taxes (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Income Taxes (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "31", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:IncomeTaxPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:IncomeTaxPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R32": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsPolicies", "longName": "000320 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "32", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R33": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesConvertibleInstrumentsPolicies", "longName": "000330 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Convertible Instruments (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Convertible Instruments (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "33", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:DerivativesPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:DerivativesPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R34": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsPolicies", "longName": "000340 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Recent Accounting Pronouncements (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Recent Accounting Pronouncements (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "34", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R35": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesCommonStockPurchaseWarrantsPolicies", "longName": "000350 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Common Stock Purchase Warrants (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Common Stock Purchase Warrants (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "35", "firstAnchor": { "contextRef": "Y23", "name": "fil:CommonStockPurchaseWarrantsPolicyTextblockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "fil:CommonStockPurchaseWarrantsPolicyTextblockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R36": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesInventoryScheduleOfInventoryTables", "longName": "000360 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory: Schedule of Inventory (Tables)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory: Schedule of Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R37": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTables", "longName": "000370 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R38": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtTables", "longName": "000380 - Disclosure - NOTE 4 - RELATED PARTY: Schedule of Debt (Tables)", "shortName": "NOTE 4 - RELATED PARTY: Schedule of Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "Y23_LongtermDebtType-RelPty1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23_LongtermDebtType-RelPty1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R39": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesLesseeOperatingLeaseDisclosureTables", "longName": "000390 - Disclosure - NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES: Lessee, Operating Lease, Disclosure (Tables)", "shortName": "NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES: Lessee, Operating Lease, Disclosure (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R40": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtTables", "longName": "000400 - Disclosure - NOTE 6 - NOTES PAYABLE: Schedule of Debt (Tables)", "shortName": "NOTE 6 - NOTES PAYABLE: Schedule of Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "Y23_LongtermDebtType-NotesPayOtherPay", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ShortTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23_LongtermDebtType-NotesPayOtherPay", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ShortTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R41": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtTables", "longName": "000410 - Disclosure - NOTE 7 - CONVERTIBLE DEBT: Schedule of Debt (Tables)", "shortName": "NOTE 7 - CONVERTIBLE DEBT: Schedule of Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "Y23_LongtermDebtType-ConvertibleDebt", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23_LongtermDebtType-ConvertibleDebt", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R42": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockTables", "longName": "000420 - Disclosure - NOTE 8 - DERIVATIVE LIABILITY: Assumptions Used Textblock (Tables)", "shortName": "NOTE 8 - DERIVATIVE LIABILITY: Assumptions Used Textblock (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "Y23", "name": "fil:ScheduleOfAssumptionsUsedForDerivativeLiabilitiesTblTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "fil:ScheduleOfAssumptionsUsedForDerivativeLiabilitiesTblTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R43": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityScheduleOfChangeInFairValueOnDerivativeTables", "longName": "000430 - Disclosure - NOTE 8 - DERIVATIVE LIABILITY: Schedule of Change in Fair Value on Derivative (Tables)", "shortName": "NOTE 8 - DERIVATIVE LIABILITY: Schedule of Change in Fair Value on Derivative (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "Y23", "name": "fil:ScheduleOfChangeInFairValueOnDerivativeTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "fil:ScheduleOfChangeInFairValueOnDerivativeTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R44": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote9IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationTables", "longName": "000440 - Disclosure - NOTE 9 - INCOME TAXES: Schedule of Effective Income Tax Rate Reconciliation (Tables)", "shortName": "NOTE 9 - INCOME TAXES: Schedule of Effective Income Tax Rate Reconciliation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R45": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote9IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTables", "longName": "000450 - Disclosure - NOTE 9 - INCOME TAXES: Schedule of Deferred Tax Assets and Liabilities (Tables)", "shortName": "NOTE 9 - INCOME TAXES: Schedule of Deferred Tax Assets and Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R46": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityTables", "longName": "000460 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Share-based Compensation, Stock Options, Activity (Tables)", "shortName": "NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Share-based Compensation, Stock Options, Activity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "Y23_StockIssuances-Warrants", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23_StockIssuances-Warrants", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R47": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfNonvestedRestrictedStockUnitsActivityTables", "longName": "000470 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Nonvested Restricted Stock Units Activity (Tables)", "shortName": "NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Nonvested Restricted Stock Units Activity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R48": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityAssumptionsUsedTextblockTables", "longName": "000480 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY: Assumptions Used Textblock (Tables)", "shortName": "NOTE 10 - STOCKHOLDERS' EQUITY: Assumptions Used Textblock (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "Y23_StockIssuances-ShareOptionsUnitsAndWarrants", "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23_StockIssuances-ShareOptionsUnitsAndWarrants", "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R49": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentTables", "longName": "000490 - Disclosure - NOTE 11 - BUSINESS SEGMENT INFORMATION: Schedule of Segment Reporting Information, by Segment (Tables)", "shortName": "NOTE 11 - BUSINESS SEGMENT INFORMATION: Schedule of Segment Reporting Information, by Segment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "Y23_StScenario-March312023", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23_StScenario-March312023", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R50": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesInventoryDetails", "longName": "000500 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory (Details)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "E23", "name": "fil:InventoryAllowances", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true }, "uniqueAnchor": null }, "R51": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesInventoryScheduleOfInventoryDetails", "longName": "000510 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory: Schedule of Inventory (Details)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory: Schedule of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "E23", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "E23", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R52": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesIndefiniteLivedIntangibleAssetsDetails", "longName": "000520 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Indefinite-Lived Intangible Assets (Details)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Indefinite-Lived Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "E23", "name": "us-gaap:FiniteLivedPatentsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "E23_FiniteLivedIntangibleAssetsByMajorClass-Patents", "name": "us-gaap:FiniteLivedPatentsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "unique": true } }, "R53": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "longName": "000530 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "E23_FvByFvHierarchyLevel-FvInputsLevel3", "name": "us-gaap:DerivativeLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "E23_FvByFvHierarchyLevel-FvInputsLevel3", "name": "us-gaap:DerivativeLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R54": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote3GoingConcernDetails", "longName": "000540 - Disclosure - NOTE 3 - GOING CONCERN (Details)", "shortName": "NOTE 3 - GOING CONCERN (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true }, "uniqueAnchor": null }, "R55": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyDetails", "longName": "000550 - Disclosure - NOTE 4 - RELATED PARTY (Details)", "shortName": "NOTE 4 - RELATED PARTY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "D231231", "name": "us-gaap:SalariesWagesAndOfficersCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D231231", "name": "us-gaap:SalariesWagesAndOfficersCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R56": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtDetails", "longName": "000560 - Disclosure - NOTE 4 - RELATED PARTY: Schedule of Debt (Details)", "shortName": "NOTE 4 - RELATED PARTY: Schedule of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "E23", "name": "us-gaap:NotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "E23_LongtermDebtType-RelPty1", "name": "us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "unique": true } }, "R57": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesDetails", "longName": "000570 - Disclosure - NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES (Details)", "shortName": "NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "E23", "name": "us-gaap:CapitalLeasesContingentRentalPaymentsDue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "E23", "name": "us-gaap:CapitalLeasesContingentRentalPaymentsDue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R58": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesLesseeOperatingLeaseDisclosureDetails", "longName": "000580 - Disclosure - NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES: Lessee, Operating Lease, Disclosure (Details)", "shortName": "NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES: Lessee, Operating Lease, Disclosure (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:LeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "128", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:LeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "128", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R59": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtDetails", "longName": "000590 - Disclosure - NOTE 6 - NOTES PAYABLE: Schedule of Debt (Details)", "shortName": "NOTE 6 - NOTES PAYABLE: Schedule of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "E23", "name": "us-gaap:NotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "E23_LongtermDebtType-NotesPayOtherPay", "name": "us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "unique": true } }, "R60": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtDetails", "longName": "000600 - Disclosure - NOTE 7 - CONVERTIBLE DEBT: Schedule of Debt (Details)", "shortName": "NOTE 7 - CONVERTIBLE DEBT: Schedule of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "E23", "name": "us-gaap:NotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "E23_LongtermDebtType-ConvertibleDebt", "name": "us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "unique": true } }, "R61": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockDetails", "longName": "000610 - Disclosure - NOTE 8 - DERIVATIVE LIABILITY: Assumptions Used Textblock (Details)", "shortName": "NOTE 8 - DERIVATIVE LIABILITY: Assumptions Used Textblock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "Y23Q4", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "Y23_FvByLiabClass-DerivativeFinancialInstrsLiab", "name": "fil:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice", "unitRef": "UsdPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "unique": true } }, "R62": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityDetails", "longName": "000620 - Disclosure - NOTE 8 - DERIVATIVE LIABILITY (Details)", "shortName": "NOTE 8 - DERIVATIVE LIABILITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R63": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityScheduleOfChangeInFairValueOnDerivativeDetails", "longName": "000630 - Disclosure - NOTE 8 - DERIVATIVE LIABILITY: Schedule of Change in Fair Value on Derivative (Details)", "shortName": "NOTE 8 - DERIVATIVE LIABILITY: Schedule of Change in Fair Value on Derivative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "E23", "name": "us-gaap:DerivativeLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true }, "uniqueAnchor": null }, "R64": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote9IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "longName": "000640 - Disclosure - NOTE 9 - INCOME TAXES: Schedule of Effective Income Tax Rate Reconciliation (Details)", "shortName": "NOTE 9 - INCOME TAXES: Schedule of Effective Income Tax Rate Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R65": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote9IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails", "longName": "000650 - Disclosure - NOTE 9 - INCOME TAXES: Schedule of Deferred Tax Assets and Liabilities (Details)", "shortName": "NOTE 9 - INCOME TAXES: Schedule of Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "E23", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "E23", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R66": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails", "longName": "000660 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY (Details)", "shortName": "NOTE 10 - STOCKHOLDERS' EQUITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "E23", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I170228", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "unique": true } }, "R67": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails", "longName": "000670 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Share-based Compensation, Stock Options, Activity (Details)", "shortName": "NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Share-based Compensation, Stock Options, Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "E23", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "E22_StockIssuances-Warrants", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "unique": true } }, "R68": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfNonvestedRestrictedStockUnitsActivityDetails", "longName": "000680 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Nonvested Restricted Stock Units Activity (Details)", "shortName": "NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Nonvested Restricted Stock Units Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "E23_StockIssuances-RestrictedStockUnits", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "E23_StockIssuances-RestrictedStockUnits", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true, "unique": true } }, "R69": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityAssumptionsUsedTextblockDetails", "longName": "000690 - Disclosure - NOTE 10 - STOCKHOLDERS' EQUITY: Assumptions Used Textblock (Details)", "shortName": "NOTE 10 - STOCKHOLDERS' EQUITY: Assumptions Used Textblock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "Y23Q4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true }, "uniqueAnchor": null }, "R70": { "role": "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails", "longName": "000700 - Disclosure - NOTE 11 - BUSINESS SEGMENT INFORMATION: Schedule of Segment Reporting Information, by Segment (Details)", "shortName": "NOTE 11 - BUSINESS SEGMENT INFORMATION: Schedule of Segment Reporting Information, by Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "Y23", "name": "us-gaap:SalesTypeLeaseRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "Y23_StBusnSeg-Consolidated", "name": "us-gaap:SalesTypeLeaseRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "hyex-20231231.htm", "unique": true } } }, "tag": { "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r14", "r553" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r214", "r215" ] }, "fil_AccruedInterestPayableRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "AccruedInterestPayableRelatedParty", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued interest payable - related party", "documentation": "Represents the monetary amount of Accrued interest payable - related party, as of the indicated date." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r16" ] }, "us-gaap_AcquisitionCostsCumulative": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquisitionCostsCumulative", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid acquisition costs", "documentation": "The capitalized costs incurred (excluded from amortization), as of the date of the balance sheet, to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties." } } }, "auth_ref": [ "r11" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r60", "r553", "r625" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r319", "r320", "r321", "r433", "r592", "r593", "r594", "r611", "r626" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "TOTAL ASSETS", "totalLabel": "TOTAL ASSETS", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r95", "r132", "r154", "r184", "r199", "r205", "r219", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r342", "r346", "r361", "r394", "r474", "r553", "r565", "r603", "r604", "r613" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Total current assets", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r127", "r138", "r154", "r219", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r342", "r346", "r361", "r553", "r603", "r604", "r613" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r567", "r568", "r569" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r567", "r568", "r569" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r567", "r568", "r569" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesBasisOfPresentationPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "fil_BergametMember": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "BergametMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "lang": { "en-us": { "role": { "label": "BergaMet", "documentation": "Represents the BergaMet, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote1OrganizationAndDescriptionOfBusiness" ], "lang": { "en-us": { "role": { "label": "NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r54", "r79", "r80" ] }, "fil_CancelationOfCommonStockForDebTshares2": { "xbrltype": "sharesItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "CancelationOfCommonStockForDebTshares2", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Cancelation Of Common Stock For Deb tShares2", "documentation": "Represents the Cancelation Of Common Stock For Deb tShares2 (number of shares), during the indicated time period." } } }, "auth_ref": [] }, "fil_CancelationOfCommonStockForDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "CancelationOfCommonStockForDebt", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Cancelation of common stock for debt", "documentation": "Represents the monetary amount of Cancelation of common stock for debt, during the indicated time period." } } }, "auth_ref": [] }, "fil_CancelationOfCommonStockForDebtShares": { "xbrltype": "sharesItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "CancelationOfCommonStockForDebtShares", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Cancelation of common stock for debt {1}", "terseLabel": "Cancelation of common stock for debt", "documentation": "Represents the Cancelation of common stock for debt, Shares (number of shares), during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_CapitalLeasesContingentRentalPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalLeasesContingentRentalPaymentsDue", "crdr": "credit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Average monthly base rent, first 12 months", "documentation": "Amount due based upon the occurrence of an event specified in the contractual terms." } } }, "auth_ref": [ "r111" ] }, "fil_CapitalLeasesContingentRentalPaymentsDueNext24Months": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "CapitalLeasesContingentRentalPaymentsDueNext24Months", "crdr": "credit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Average monthly base rent, next 24 months", "documentation": "Represents the monetary amount of Capital Leases, Contingent Rental Payments Due, Next 24 months, as of the indicated date." } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r113", "r395", "r444", "r469", "r553", "r565", "r578" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesCashPolicies" ], "lang": { "en-us": { "role": { "label": "Cash {1}", "terseLabel": "Cash", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r27" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash at beginning of period", "periodStartLabel": "Cash at beginning of period", "periodEndLabel": "Cash at end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r25", "r76", "r150" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in cash", "totalLabel": "Increase (decrease) in cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r76" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r123", "r133", "r134", "r135", "r154", "r171", "r172", "r174", "r175", "r178", "r179", "r219", "r248", "r250", "r251", "r252", "r255", "r256", "r285", "r286", "r288", "r291", "r297", "r361", "r423", "r424", "r425", "r426", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r445", "r461", "r483", "r503", "r523", "r524", "r525", "r526", "r527", "r574", "r589", "r596" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r555", "r556", "r557", "r559", "r560", "r561", "r562", "r592", "r593", "r611", "r623", "r626" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r59" ] }, "fil_CommonStockPurchaseWarrantsPolicyTextblockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "CommonStockPurchaseWarrantsPolicyTextblockTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesCommonStockPurchaseWarrantsPolicies" ], "lang": { "en-us": { "role": { "label": "Common Stock Purchase Warrants", "documentation": "Represents the textual narrative disclosure of Common Stock Purchase Warrants Policy Textblock, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r59", "r461" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r59" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r5", "r59", "r461", "r480", "r626", "r627" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.001 par value, 50,000,000 shares authorized, 2,954,104 shares issued and outstanding as of December 31, 2023, and 2,876,437 shares issued and outstanding as of December 31, 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r59", "r397", "r553" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesConcentrationPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r53", "r117" ] }, "fil_ConsolidatedMember": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "ConsolidatedMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "lang": { "en-us": { "role": { "label": "Consolidated", "documentation": "Represents the Consolidated, during the indicated time period." } } }, "auth_ref": [] }, "fil_ConvertibleDebtChangeInFairValueRecognizedInOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "ConvertibleDebtChangeInFairValueRecognizedInOperations", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityScheduleOfChangeInFairValueOnDerivativeDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt, Change In Fair Value Recognized In Operations", "documentation": "Represents the monetary amount of Convertible Debt, Change In Fair Value Recognized In Operations, during the indicated time period." } } }, "auth_ref": [] }, "fil_ConvertibleDebtConverted": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "ConvertibleDebtConverted", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityScheduleOfChangeInFairValueOnDerivativeDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt, Converted", "documentation": "Represents the monetary amount of Convertible Debt, Converted, during the indicated time period." } } }, "auth_ref": [] }, "fil_ConvertibleDebtDerivativeTreatmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "ConvertibleDebtDerivativeTreatmentPolicyTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesConvertibleDebtDerivativeTreatmentPolicies" ], "lang": { "en-us": { "role": { "label": "Convertible Debt - Derivative Treatment", "documentation": "Represents the textual narrative disclosure of Convertible Debt - Derivative Treatment Policy, during the indicated time period." } } }, "auth_ref": [] }, "fil_ConvertibleDebtIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "ConvertibleDebtIssued", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityScheduleOfChangeInFairValueOnDerivativeDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt, Issued", "documentation": "Represents the monetary amount of Convertible Debt, Issued, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtTables" ], "lang": { "en-us": { "role": { "label": "Convertible Debt {1}", "terseLabel": "Convertible Debt", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r85", "r258", "r259", "r269", "r270", "r271", "r275", "r276", "r277", "r278", "r279", "r539", "r540", "r541", "r542", "r543" ] }, "us-gaap_ConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayable", "crdr": "credit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r12", "r97", "r621" ] }, "us-gaap_ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Convertible debt, net of discount", "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r16" ] }, "fil_ConvertiblePromissoryNote1Member": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "ConvertiblePromissoryNote1Member", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Promissory Note 1", "documentation": "Represents the Convertible Promissory Note 1, during the indicated time period." } } }, "auth_ref": [] }, "fil_ConvertiblePromissoryNote2Member": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "ConvertiblePromissoryNote2Member", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Promissory Note 2", "documentation": "Represents the Convertible Promissory Note 2, during the indicated time period." } } }, "auth_ref": [] }, "fil_ConvertiblePromissoryNote3Member": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "ConvertiblePromissoryNote3Member", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Promissory Note 3", "documentation": "Represents the Convertible Promissory Note 3, during the indicated time period." } } }, "auth_ref": [] }, "fil_ConvertiblePromissoryNote4Member": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "ConvertiblePromissoryNote4Member", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Promissory Note 4", "documentation": "Represents the Convertible Promissory Note 4, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_CorporateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "lang": { "en-us": { "role": { "label": "Corporate Segment", "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": [ "r597" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations": { "parentTag": "us-gaap_CostOfRevenue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of goods sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r70", "r388" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Total cost of revenue", "totalLabel": "Total cost of revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r71", "r154", "r219", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r361", "r603" ] }, "us-gaap_CostOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenueAbstract", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "COST OF REVENUE" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Fiscal Year End", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebt" ], "lang": { "en-us": { "role": { "label": "NOTE 7 - CONVERTIBLE DEBT", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r84", "r152", "r257", "r263", "r264", "r265", "r266", "r267", "r268", "r273", "r280", "r281", "r282" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r12", "r56", "r57", "r96", "r97", "r157", "r258", "r259", "r260", "r261", "r262", "r264", "r269", "r270", "r271", "r272", "r274", "r275", "r276", "r277", "r278", "r279", "r368", "r539", "r540", "r541", "r542", "r543", "r590" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r19", "r51", "r283", "r368" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r20", "r157", "r258", "r259", "r260", "r261", "r262", "r264", "r269", "r270", "r271", "r272", "r274", "r275", "r276", "r277", "r278", "r279", "r368", "r539", "r540", "r541", "r542", "r543", "r590" ] }, "fil_DebtWithWarrantsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "DebtWithWarrantsPolicyTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesDebtWithWarrantsPolicies" ], "lang": { "en-us": { "role": { "label": "Debt with Warrants", "documentation": "Represents the textual narrative disclosure of Debt with Warrants Policy, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_DeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredOfferingCosts", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Offering costs", "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period." } } }, "auth_ref": [ "r599" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote9IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Net long-term deferred tax assets", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r609" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote9IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Federal net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards." } } }, "auth_ref": [ "r44", "r610" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote9IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Valuation allowance", "negatedLabel": "Valuation allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r330" ] }, "us-gaap_DepositsAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositsAssets", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_OtherAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deposit", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future." } } }, "auth_ref": [ "r579" ] }, "fil_DepreciationAndAmortization1": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "DepreciationAndAmortization1", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "Represents the monetary amount of Depreciation and Amortization, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Financial Instruments, Liabilities", "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect." } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityScheduleOfChangeInFairValueOnDerivativeDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Derivative liabilities", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r139", "r140", "r360", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r475", "r477", "r478", "r514", "r515", "r516", "r518", "r519", "r520", "r521", "r533", "r624" ] }, "fil_DerivativeLiabilitiesDebtPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "DerivativeLiabilitiesDebtPremium", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityScheduleOfChangeInFairValueOnDerivativeDetails" ], "lang": { "en-us": { "role": { "label": "Derivative liabilities debt premium", "documentation": "Represents the monetary amount of Derivative liabilities debt premium, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesConvertibleInstrumentsPolicies" ], "lang": { "en-us": { "role": { "label": "Convertible Instruments", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r6", "r45", "r46", "r47", "r48", "r156" ] }, "fil_DirectCostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "DirectCostOfRevenue", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Direct cost of revenue", "documentation": "Represents the monetary amount of Direct cost of revenue, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureTextBlockAbstract", "lang": { "en-us": { "role": { "label": "Notes" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r567", "r568", "r569" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r567", "r568", "r569", "r571" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r570" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "fil_DueToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "DueToRelatedParties", "crdr": "credit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Due to Related Parties", "documentation": "Represents the monetary amount of Due to Related Parties, as of the indicated date." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Registrant CIK", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r566" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r566" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r566" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r572" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r566" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r566" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r566" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r566" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r573" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Component", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r5", "r124", "r144", "r145", "r146", "r158", "r159", "r160", "r162", "r167", "r169", "r177", "r220", "r221", "r298", "r319", "r320", "r321", "r334", "r335", "r348", "r349", "r350", "r351", "r352", "r353", "r355", "r362", "r363", "r364", "r365", "r366", "r367", "r374", "r416", "r417", "r418", "r433", "r503" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r271", "r300", "r301", "r302", "r303", "r304", "r305", "r358", "r382", "r383", "r384", "r540", "r541", "r545", "r546", "r547" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockDetails" ], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r49", "r93" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r271", "r300", "r301", "r302", "r303", "r304", "r305", "r358", "r384", "r540", "r541", "r545", "r546", "r547" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r7" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r271", "r300", "r301", "r302", "r303", "r304", "r305", "r382", "r383", "r384", "r540", "r541", "r545", "r546", "r547" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Derivative Liabilities", "documentation": "Amount of unrealized gain (loss) recognized in income for derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3) and still held." } } }, "auth_ref": [ "r359" ] }, "fil_FairValueOfUnvestedRestrictedStockUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "FairValueOfUnvestedRestrictedStockUnits", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Fair value of options and warrants issued", "documentation": "Represents the monetary amount of Fair value of unvested restricted stock units, during the indicated time period." } } }, "auth_ref": [] }, "fil_FairValueOfVestedRestrictedStockUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "FairValueOfVestedRestrictedStockUnits", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Fair value of restricted stock units", "documentation": "Represents the monetary amount of Fair value of vested restricted stock units, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r237", "r238", "r239", "r240", "r389", "r390" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r35", "r36" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_OtherAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Fixed assets", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r82", "r389" ] }, "us-gaap_FiniteLivedPatentsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedPatentsGross", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_OtherAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesIndefiniteLivedIntangibleAssetsDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Patents/Trademarks", "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights." } } }, "auth_ref": [ "r82" ] }, "us-gaap_GainLossOnSaleOfOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfOtherAssets", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Gain on sale of asset", "documentation": "Amount of gain (loss) on sale or disposal of other assets." } } }, "auth_ref": [ "r588" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r3", "r39", "r40" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r72", "r485" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_OtherAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r130", "r226", "r391", "r538", "r553", "r600", "r601" ] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesGoodwillPolicies" ], "lang": { "en-us": { "role": { "label": "Goodwill {1}", "terseLabel": "Goodwill", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": [ "r225", "r236", "r538" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "GROSS PROFIT", "totalLabel": "GROSS PROFIT", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r69", "r154", "r184", "r198", "r204", "r207", "r219", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r361", "r536", "r603" ] }, "fil_IdentifiableAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "IdentifiableAssets", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "lang": { "en-us": { "role": { "label": "Identifiable Assets", "documentation": "Represents the monetary amount of Identifiable Assets, as of the indicated date." } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Impairment of assets", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r3", "r37", "r83" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesIndefiniteLivedIntangibleAssetsPolicies" ], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets", "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENT OF OPERATIONS" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote9IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "NOTE 9 - INCOME TAXES", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r155", "r322", "r327", "r328", "r332", "r336", "r338", "r339", "r340", "r428" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote9IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r112", "r122", "r168", "r169", "r192", "r325", "r337", "r403" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesIncomeTaxesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r143", "r323", "r324", "r328", "r329", "r331", "r333", "r422" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote9IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Change in valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r608" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote9IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Federal statutory income tax rate", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r326" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts payable {1}", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts receivable {1}", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cost in acquisition of Hyperion/OP&M", "negatedLabel": "Cost in acquisition of Hyperion/OP&M", "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accrued interest payable - related party {1}", "terseLabel": "Accrued interest payable - related party", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeposits", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deposits {1}", "terseLabel": "Deposits", "documentation": "The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances." } } }, "auth_ref": [ "r26", "r52" ] }, "us-gaap_IncreaseDecreaseInDerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDerivativeLiabilities", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Derivative Liabilities", "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer)." } } }, "auth_ref": [ "r587" ] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accrued liabilities {1}", "terseLabel": "Accrued liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInterestPayableNet", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accrued interest payable {1}", "terseLabel": "Accrued interest payable", "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Inventory", "negatedLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r2" ] }, "fil_IncreaseDecreaseInOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "IncreaseDecreaseInOfferingCosts", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Offering Costs", "documentation": "Represents the monetary amount of Increase Decrease in offering costs, during the indicated time period." } } }, "auth_ref": [] }, "fil_IncreaseDecreaseInOperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "IncreaseDecreaseInOperatingLeaseLiabilityCurrent", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Lease liability - current", "documentation": "Represents the monetary amount of Increase Decrease In Operating Lease Liability - Current, during the indicated time period." } } }, "auth_ref": [] }, "fil_IncreaseDecreaseInOperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "IncreaseDecreaseInOperatingLeaseLiabilityNoncurrent", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Lease liability - long-term", "documentation": "Represents the monetary amount of Increase Decrease In Operating Lease Liability - Noncurrent, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "auth_ref": [] }, "fil_IncreaseDecreaseInRightOfUseAssetNet": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "IncreaseDecreaseInRightOfUseAssetNet", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Right of use asset, net {1}", "terseLabel": "Right of use asset, net", "documentation": "Represents the monetary amount of Increase Decrease In Right of Use Asset, Net, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest expense, net of interest income", "documentation": "The net amount of operating interest income (expense)." } } }, "auth_ref": [ "r100" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued interest payable", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r16" ] }, "fil_InventoryAllowances": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "InventoryAllowances", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesInventoryDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesInventoryScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory Allowances", "negatedLabel": "Inventory allowance", "documentation": "Represents the monetary amount of Inventory Allowances, as of the indicated date." } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesInventoryScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Finished Goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r582" ] }, "us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryGross", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesInventoryScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Total inventory", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r585" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesInventoryScheduleOfInventoryDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Inventory, net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r137", "r532", "r553" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesInventoryPolicies" ], "lang": { "en-us": { "role": { "label": "Inventory {1}", "terseLabel": "Inventory", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r114", "r129", "r136", "r222", "r223", "r224", "r387", "r534" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterials", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesInventoryScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Raw Materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r584" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcess", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesInventoryScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Work in process", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r583" ] }, "fil_IssuanceOfCommonStockNoteConversion": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "IssuanceOfCommonStockNoteConversion", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock - Note Conversion", "documentation": "Represents the monetary amount of Issuance of common stock-Note Conversion, during the indicated time period." } } }, "auth_ref": [] }, "fil_IssuanceOfCommonStockNoteConversionShares": { "xbrltype": "sharesItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "IssuanceOfCommonStockNoteConversionShares", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock-Note Conversion, shares", "documentation": "Represents the Issuance of common stock-Note Conversion, shares (number of shares), during the indicated time period." } } }, "auth_ref": [] }, "fil_IssuanceOfCommonStockRestrictedStockUnitsIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "IssuanceOfCommonStockRestrictedStockUnitsIssued", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock-restricted stock units issued", "documentation": "Represents the monetary amount of Issuance of common stock-restricted stock units issued, during the indicated time period." } } }, "auth_ref": [] }, "fil_IssuanceOfCommonStockRestrictedStockUnitsIssuedShares": { "xbrltype": "sharesItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "IssuanceOfCommonStockRestrictedStockUnitsIssuedShares", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock-restricted stock units issued {1}", "terseLabel": "Issuance of common stock-restricted stock units issued", "documentation": "Represents the Issuance of common stock-restricted stock units issued, shares (number of shares), during the indicated time period." } } }, "auth_ref": [] }, "fil_IssuanceOfCommonStockShareConversionAgreements": { "xbrltype": "sharesItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "IssuanceOfCommonStockShareConversionAgreements", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock-Share Conversion Agreements", "documentation": "Represents the Issuance of common stock-Share Conversion Agreements (number of shares), during the indicated time period." } } }, "auth_ref": [] }, "fil_IssuanceOfCommonStockShareConversionAgreementsRetired": { "xbrltype": "sharesItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "IssuanceOfCommonStockShareConversionAgreementsRetired", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock-Share Conversion Agreements, Retired", "documentation": "Represents the Issuance of common stock-Share Conversion Agreements, Retired (number of shares), during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Warrants issued for services", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r3" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesLesseeOperatingLeaseDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r371", "r552" ] }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesOfLesseeDisclosureTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilities" ], "lang": { "en-us": { "role": { "label": "NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES", "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing." } } }, "auth_ref": [ "r105" ] }, "fil_LessSellingFees": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "LessSellingFees", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "lang": { "en-us": { "role": { "label": "Less Selling Fees", "documentation": "Represents the monetary amount of Less Selling Fees, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseDiscountRate", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesLesseeOperatingLeaseDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Discount Rate", "documentation": "Discount rate used by lessee to determine present value of operating lease payments." } } }, "auth_ref": [ "r551" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r64", "r98", "r399", "r553", "r591", "r598", "r612" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Total current and total liabilities", "totalLabel": "Total current and total liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r18", "r128", "r154", "r219", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r343", "r346", "r347", "r361", "r553", "r603", "r613", "r614" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtTables", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtTables", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtTables" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r20" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtTables", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtTables", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtTables" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r20", "r38" ] }, "fil_LossPerShareBasicAndDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "LossPerShareBasicAndDiluted", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Income/(Loss) per share - basic and diluted", "documentation": "Represents the per-share monetary value of Loss per share - basic and diluted, during the indicated time period." } } }, "auth_ref": [] }, "fil_March312022Member": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "March312022Member", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentTables" ], "lang": { "en-us": { "role": { "label": "March 31, 2022", "documentation": "Represents the March 31, 2022, during the indicated time period." } } }, "auth_ref": [] }, "fil_March312023Member": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "March312023Member", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentTables" ], "lang": { "en-us": { "role": { "label": "March 31, 2023", "documentation": "Represents the March 31, 2023, during the indicated time period." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockDetails" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "auth_ref": [ "r244", "r245", "r246", "r247", "r307", "r386", "r415", "r453", "r454", "r510", "r511", "r512", "r513", "r522", "r529", "r530", "r537", "r544", "r548", "r554", "r605", "r615", "r616", "r617", "r618", "r619", "r620" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockDetails" ], "lang": { "en-us": { "role": { "label": "Minimum" } } }, "auth_ref": [ "r244", "r245", "r246", "r247", "r307", "r386", "r415", "r453", "r454", "r510", "r511", "r512", "r513", "r522", "r529", "r530", "r537", "r544", "r548", "r554", "r605", "r615", "r616", "r617", "r618", "r619", "r620" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash provided by Financing Activities", "totalLabel": "Net Cash provided by Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r149" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flows from Financing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows provided by (used in) Investing Activities", "totalLabel": "Cash flows provided by (used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r149" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flows from Investing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash used in Operating Activities", "totalLabel": "Net Cash used in Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r76", "r77", "r78" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flows from Operating Activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote3GoingConcernDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Net Income/(Loss)", "totalLabel": "NET INCOME/(LOSS)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r68", "r78", "r99", "r126", "r141", "r142", "r146", "r154", "r161", "r163", "r164", "r165", "r166", "r168", "r169", "r173", "r184", "r198", "r204", "r207", "r219", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r356", "r361", "r402", "r482", "r501", "r502", "r536", "r563", "r603" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncurrentAssets", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-lived Assets", "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets." } } }, "auth_ref": [ "r212" ] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Notes payable", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r15" ] }, "us-gaap_NotesPayableOtherPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableOtherPayablesMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtTables" ], "lang": { "en-us": { "role": { "label": "Notes Payable, Other Payables", "documentation": "A written promise to pay a note to a third party." } } }, "auth_ref": [] }, "fil_NotesPayableRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "NotesPayableRelatedParty", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Notes payable - related party", "documentation": "Represents the monetary amount of Notes payable - related party, as of the indicated date." } } }, "auth_ref": [] }, "fil_OmnibusStockGrantAndOptionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "OmnibusStockGrantAndOptionPlanMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityTables" ], "lang": { "en-us": { "role": { "label": "Omnibus Stock Grant and Option Plan", "documentation": "Represents the Omnibus Stock Grant and Option Plan, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Total operating expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesLesseeOperatingLeaseDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "negatedLabel": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r370" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesLesseeOperatingLeaseDisclosureDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Lease liabilities - current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r370" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesLesseeOperatingLeaseDisclosureDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Lease liabilities - long-term", "negatedLabel": "Lease liabilities - long-term", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r370" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Right of use asset, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r369" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesLesseeOperatingLeaseDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r372", "r552" ] }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasesFutureMinimumPaymentsDue", "crdr": "credit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesLesseeOperatingLeaseDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments Due", "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year." } } }, "auth_ref": [ "r107", "r110" ] }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "crdr": "credit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesLesseeOperatingLeaseDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "2023", "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [ "r107", "r110" ] }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "crdr": "credit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesLesseeOperatingLeaseDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "2025 {1}", "terseLabel": "2025", "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [ "r107", "r110" ] }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "crdr": "credit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesLesseeOperatingLeaseDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [ "r107", "r110" ] }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "crdr": "credit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesLesseeOperatingLeaseDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "2023 {1}", "terseLabel": "2023", "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [ "r107", "r110" ] }, "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasesOfLesseeDisclosureTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesLesseeOperatingLeaseDisclosureTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Disclosure", "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions." } } }, "auth_ref": [ "r104", "r106", "r107", "r108", "r109" ] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Total other assets", "totalLabel": "Total other assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": [ "r94", "r131", "r393", "r565" ] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndExpensesAbstract", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "OTHER INCOME (EXPENSE)" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiability" ], "lang": { "en-us": { "role": { "label": "NOTE 8 - DERIVATIVE LIABILITY", "documentation": "The entire disclosure for other liabilities." } } }, "auth_ref": [ "r17" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Total other income (expense)", "totalLabel": "Total other income (expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r73" ] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PatentsMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Patents", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r92" ] }, "fil_PaymentsForRepaymentOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "PaymentsForRepaymentOfConvertibleDebt", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments for repayment of convertible debt", "negatedLabel": "Payments for repayment of convertible debt", "documentation": "Represents the monetary amount of Payments for repayment of convertible debt, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Purchase of fixed assets", "negatedLabel": "Purchase of fixed assets", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r75" ] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PolicyTextBlockAbstract", "lang": { "en-us": { "role": { "label": "Policies" } } }, "auth_ref": [] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r555", "r556", "r559", "r560", "r561", "r562", "r623", "r626" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r58", "r285" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r58", "r461" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r58", "r285" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r58", "r461", "r480", "r626", "r627" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $0.001 par value, 75,000,000 shares authorized, none and none shares issued and outstanding, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r58", "r396", "r553" ] }, "us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrincipalAmountOutstandingOfLoansHeldInPortfolio", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Original Principal Amount", "documentation": "This is the result of the principal amount outstanding of total loans managed or securitized less securitized loans and loans that are in the process of being securitized." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of convertible debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r23" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r1" ] }, "fil_ProceedsFromIssuanceOfNotesPayableRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "ProceedsFromIssuanceOfNotesPayableRelatedParty", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of noted payable - related party", "documentation": "Represents the monetary amount of Proceeds from issuance of notes payable - related party, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromLoanOriginations1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLoanOriginations1", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Loan origination fees", "documentation": "Cash inflow associated with loan origination (the process when securing a mortgage for a piece of real property) or lease origination." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ProceedsFromNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromNotesPayable", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of noted payable", "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r23" ] }, "us-gaap_ProceedsFromRepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRepaymentsOfNotesPayable", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments for repayment of notes payable", "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Gain on sale of asset {1}", "terseLabel": "Gain on sale of asset", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r74" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Net income/(loss) before income tax provision", "totalLabel": "Net income/(loss) before income tax provision", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r126", "r141", "r142", "r148", "r154", "r161", "r168", "r169", "r184", "r198", "r204", "r207", "r219", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r341", "r344", "r345", "r356", "r361", "r392", "r401", "r432", "r482", "r501", "r502", "r536", "r549", "r550", "r564", "r586", "r603" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentPolicies" ], "lang": { "en-us": { "role": { "label": "Property and Equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r4", "r118", "r121", "r400" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r244", "r245", "r246", "r247", "r299", "r307", "r316", "r317", "r318", "r385", "r386", "r415", "r453", "r454", "r510", "r511", "r512", "r513", "r522", "r529", "r530", "r537", "r544", "r548", "r554", "r557", "r602", "r605", "r616", "r617", "r618", "r619", "r620" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement" } } }, "auth_ref": [ "r244", "r245", "r246", "r247", "r299", "r307", "r316", "r317", "r318", "r385", "r386", "r415", "r453", "r454", "r510", "r511", "r512", "r513", "r522", "r529", "r530", "r537", "r544", "r548", "r554", "r557", "r602", "r605", "r616", "r617", "r618", "r619", "r620" ] }, "us-gaap_ReceivableWithImputedInterestDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivableWithImputedInterestDiscount", "crdr": "credit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesLesseeOperatingLeaseDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Receivable with Imputed Interest, Discount", "negatedLabel": "Receivable with Imputed Interest, Discount", "documentation": "Disclosure of the unamortized amount of the discount on the note or receivable which is deducted from the face amount of the receivable or loan. The discount or premium is the difference between the present value and the face amount." } } }, "auth_ref": [ "r50" ] }, "fil_RelatedParty1Member": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "RelatedParty1Member", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtTables" ], "lang": { "en-us": { "role": { "label": "Related Party", "documentation": "Represents the Related Party, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedParty" ], "lang": { "en-us": { "role": { "label": "NOTE 4 - RELATED PARTY", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r375", "r376", "r377", "r378", "r379", "r429", "r430", "r431", "r486", "r487", "r488", "r507", "r509" ] }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfRelatedPartyDebt", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments for repayment of noted payable - related party", "negatedLabel": "Payments for repayment of noted payable - related party", "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates." } } }, "auth_ref": [ "r24" ] }, "fil_RestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "RestrictedStockUnitsMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units", "documentation": "Represents the Restricted Stock Units, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r61", "r87", "r398", "r419", "r420", "r427", "r462", "r553" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r124", "r158", "r159", "r160", "r162", "r167", "r169", "r220", "r221", "r319", "r320", "r321", "r334", "r335", "r348", "r350", "r351", "r353", "r355", "r416", "r418", "r433", "r626" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesRevenueRecognitionPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r484", "r531", "r535" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Net revenue", "totalLabel": "Net revenue", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r147", "r154", "r185", "r186", "r197", "r202", "r203", "r209", "r211", "r213", "r219", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r361", "r392", "r603" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "REVENUE" } } }, "auth_ref": [] }, "fil_RightOfUseAssetsNetOfAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "RightOfUseAssetsNetOfAmortization", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote5RightOfUseAssetsAndLeaseLiabilitiesLesseeOperatingLeaseDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Right-of-use assets, net of amortization", "documentation": "Represents the monetary amount of Right-of-use assets, net of amortization, as of the indicated date." } } }, "auth_ref": [] }, "us-gaap_SalariesWagesAndOfficersCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalariesWagesAndOfficersCompensation", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Salary and Wage, Excluding Cost of Good and Service Sold", "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [] }, "us-gaap_SalesTypeLeaseRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeLeaseRevenue", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenue", "documentation": "Amount of sales-type lease revenue." } } }, "auth_ref": [ "r176", "r373" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentTables" ], "lang": { "en-us": { "role": { "label": "Scenario" } } }, "auth_ref": [ "r170", "r308", "r575", "r595" ] }, "fil_ScheduleOfAssumptionsUsedForDerivativeLiabilitiesTblTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "ScheduleOfAssumptionsUsedForDerivativeLiabilitiesTblTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockTables" ], "lang": { "en-us": { "role": { "label": "Assumptions Used Textblock", "documentation": "Represents the textual narrative disclosure of Schedule of Assumptions Used for Derivative Liabilities Table, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityAssumptionsUsedTextblockTables" ], "lang": { "en-us": { "role": { "label": "Assumptions Used Textblock {1}", "terseLabel": "Assumptions Used Textblock", "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate." } } }, "auth_ref": [ "r306" ] }, "fil_ScheduleOfChangeInFairValueOnDerivativeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "ScheduleOfChangeInFairValueOnDerivativeTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityScheduleOfChangeInFairValueOnDerivativeTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Change in Fair Value on Derivative", "documentation": "Represents the textual narrative disclosure of Schedule of Change in Fair Value on Derivative, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtTables", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtTables", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Debt", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote9IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r91" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote9IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r90" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r357", "r358" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesInventoryScheduleOfInventoryTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventory", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r13", "r65", "r66", "r67" ] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfNonvestedRestrictedStockUnitsActivityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Nonvested Restricted Stock Units Activity", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r31", "r32", "r33", "r34" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation, Stock Options, Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r8", "r9", "r42" ] }, "fil_SecuredDebt1Member": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "SecuredDebt1Member", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Secured Debt 1", "documentation": "Represents the Secured Debt 1, during the indicated time period." } } }, "auth_ref": [] }, "fil_SecuredDebt2Member": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "SecuredDebt2Member", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Secured Debt 2", "documentation": "Represents the Secured Debt 2, during the indicated time period." } } }, "auth_ref": [] }, "fil_SecuredDebt3Member": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "SecuredDebt3Member", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Secured Debt 3", "documentation": "Represents the Secured Debt 3, during the indicated time period." } } }, "auth_ref": [] }, "fil_SecuredDebt4Member": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "SecuredDebt4Member", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Secured Debt 4", "documentation": "Represents the Secured Debt 4, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "lang": { "en-us": { "role": { "label": "Segments", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r181", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r207", "r213", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r242", "r243", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r538", "r577", "r622" ] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformation" ], "lang": { "en-us": { "role": { "label": "NOTE 11 - BUSINESS SEGMENT INFORMATION", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r180", "r181", "r182", "r183", "r184", "r196", "r201", "r205", "r206", "r207", "r208", "r209", "r210", "r213" ] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r580", "r581", "r606" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityAssumptionsUsedTextblockDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r317" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityAssumptionsUsedTextblockDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r316" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityAssumptionsUsedTextblockDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r318" ] }, "fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice": { "xbrltype": "perShareItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Stock Price", "documentation": "Represents the per-share monetary value of Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Stock Price, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r311" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r311" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfNonvestedRestrictedStockUnitsActivityDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r607" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value", "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r313" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfNonvestedRestrictedStockUnitsActivityDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r313" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r41" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r309", "r310" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r309", "r310" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r314" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r314" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r314" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r312" ] }, "fil_ShareOptionsUnitsAndWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "ShareOptionsUnitsAndWarrantsMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityAssumptionsUsedTextblockTables" ], "lang": { "en-us": { "role": { "label": "Share Options, Units, and Warrants", "documentation": "Represents the Share Options, Units, and Warrants, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityAssumptionsUsedTextblockDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r315" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r41" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r89" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "negatedLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding, Beginning Balance", "periodStartLabel": "Shares, Outstanding, Beginning Balance", "periodEndLabel": "Shares, Outstanding, Ending Balance", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayable" ], "lang": { "en-us": { "role": { "label": "NOTE 6 - NOTES PAYABLE", "documentation": "The entire disclosure for short-term debt." } } }, "auth_ref": [ "r84" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r79", "r151" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r125", "r181", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r207", "r213", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r241", "r242", "r243", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r538", "r577", "r622" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r123", "r133", "r134", "r135", "r154", "r171", "r172", "r174", "r175", "r178", "r179", "r219", "r248", "r250", "r251", "r252", "r255", "r256", "r285", "r286", "r288", "r291", "r297", "r361", "r423", "r424", "r425", "r426", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r445", "r461", "r483", "r503", "r523", "r524", "r525", "r526", "r527", "r574", "r589", "r596" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r5", "r21", "r124", "r144", "r145", "r146", "r158", "r159", "r160", "r162", "r167", "r169", "r177", "r220", "r221", "r298", "r319", "r320", "r321", "r334", "r335", "r348", "r349", "r350", "r351", "r352", "r353", "r355", "r362", "r363", "r364", "r365", "r366", "r367", "r374", "r416", "r417", "r418", "r433", "r503" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityAssumptionsUsedTextblockTables", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfNonvestedRestrictedStockUnitsActivityDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityTables", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentTables", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesIndefiniteLivedIntangibleAssetsDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtTables", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtTables", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtTables", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r158", "r159", "r160", "r177", "r388", "r421", "r445", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r464", "r465", "r466", "r467", "r468", "r470", "r471", "r472", "r473", "r475", "r476", "r477", "r478", "r479", "r481", "r484", "r485", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r503", "r558" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENT OF CASH FLOWS" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED BALANCE SHEETS", "verboseLabel": "CONSOLIDATED BALANCE SHEETS - Parenthetical" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentTables" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r170", "r308", "r575", "r576", "r595" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityAssumptionsUsedTextblockTables", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfNonvestedRestrictedStockUnitsActivityDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityTables", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentTables", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesIndefiniteLivedIntangibleAssetsDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtTables", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtTables", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote7ConvertibleDebtScheduleOfDebtTables", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r158", "r159", "r160", "r177", "r388", "r421", "r445", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r464", "r465", "r466", "r467", "r468", "r470", "r471", "r472", "r473", "r475", "r476", "r477", "r478", "r479", "r481", "r484", "r485", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r503", "r558" ] }, "fil_StockIssuancesAxis": { "xbrltype": "stringItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "StockIssuancesAxis", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityAssumptionsUsedTextblockTables", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfNonvestedRestrictedStockUnitsActivityDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityTables" ], "lang": { "en-us": { "role": { "label": "Stock Issuances [Axis]", "documentation": "Represents the description of Stock Issuances, during the indicated time period." } } }, "auth_ref": [] }, "fil_StockIssuancesDomain": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "StockIssuancesDomain", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityAssumptionsUsedTextblockTables", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfNonvestedRestrictedStockUnitsActivityDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityTables" ], "lang": { "en-us": { "role": { "label": "Stock Issuances", "documentation": "Represents the Stock Issuances, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for services {1}", "terseLabel": "Issuance of common stock for services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for cash {1}", "terseLabel": "Issuance of common stock for cash", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r5", "r58", "r59", "r87", "r423", "r503", "r524" ] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for cash", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r5", "r58", "r59", "r87", "r433", "r503", "r524", "r564" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Total stockholders' equity", "totalLabel": "Total stockholders' equity", "periodStartLabel": "Equity, Attributable to Parent, Beginning Balance", "periodEndLabel": "Equity, Attributable to Parent, Ending Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r59", "r62", "r63", "r81", "r463", "r480", "r504", "r505", "r553", "r565", "r591", "r598", "r612", "r626" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquity" ], "lang": { "en-us": { "role": { "label": "NOTE 10 - STOCKHOLDERS' EQUITY", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r86", "r153", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r298", "r354", "r506", "r508", "r528" ] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityReverseStockSplit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Reverse Stock Split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r88" ] }, "fil_StockissuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "StockissuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for services {2}", "terseLabel": "Issuance of common stock for services", "documentation": "Represents the Issuance of common stock for services (number of shares), during the indicated time period." } } }, "auth_ref": [] }, "fil_StockissuedDuringPeriodSharesIssuedForServices2": { "xbrltype": "sharesItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "StockissuedDuringPeriodSharesIssuedForServices2", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "StockIssued During Period Shares Issued For Services2", "documentation": "Represents the StockIssued During Period Shares Issued For Services2 (number of shares), during the indicated time period." } } }, "auth_ref": [] }, "fil_StockissuedDuringPeriodSharesIssuedForServices3": { "xbrltype": "sharesItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "StockissuedDuringPeriodSharesIssuedForServices3", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "StockIssued During Period Shares Issued For Services3", "documentation": "Represents the StockIssued During Period Shares Issued For Services3 (number of shares), during the indicated time period." } } }, "auth_ref": [] }, "fil_StockissuedDuringPeriodSharesIssuedForServices4": { "xbrltype": "sharesItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "StockissuedDuringPeriodSharesIssuedForServices4", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "StockIssued During Period Shares Issued For Services4", "documentation": "Represents the StockIssued During Period Shares Issued For Services4 (number of shares), during the indicated time period." } } }, "auth_ref": [] }, "fil_StockissuedDuringPeriodSharesIssuedForServices5": { "xbrltype": "sharesItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "StockissuedDuringPeriodSharesIssuedForServices5", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "StockIssued During Period Shares Issued For Services5", "documentation": "Represents the StockIssued During Period Shares Issued For Services5 (number of shares), during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote12SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "NOTE 12 - SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r380", "r381" ] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote3GoingConcern" ], "lang": { "en-us": { "role": { "label": "NOTE 3 - GOING CONCERN", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r55" ] }, "us-gaap_TableTextBlockSupplementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TableTextBlockSupplementAbstract", "lang": { "en-us": { "role": { "label": "Tables/Schedules" } } }, "auth_ref": [] }, "us-gaap_TextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TextBlockAbstract", "lang": { "en-us": { "role": { "label": "Details" } } }, "auth_ref": [] }, "fil_TotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "TotalFairValue", "crdr": "credit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockDetails" ], "lang": { "en-us": { "role": { "label": "Total Fair Value", "documentation": "Represents the monetary amount of Total Fair Value, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesAccountsReceivablesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivables", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r101", "r102", "r103", "r216", "r217", "r218" ] }, "fil_UbnMember": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "UbnMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote11BusinessSegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" ], "lang": { "en-us": { "role": { "label": "UBN", "documentation": "Represents the UBN, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_UnrealizedGainLossOnDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrealizedGainLossOnDerivatives", "crdr": "credit", "calculation": { "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfCashFlows", "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Change in fair value on derivative", "negatedLabel": "Change in fair value on derivative liability", "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period." } } }, "auth_ref": [ "r3", "r497", "r498", "r499", "r500", "r517" ] }, "fil_UnsecuredDebt1Member": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "UnsecuredDebt1Member", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Unsecured Debt 1", "documentation": "Represents the Unsecured Debt 1, during the indicated time period." } } }, "auth_ref": [] }, "fil_UnsecuredDebt2Member": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "UnsecuredDebt2Member", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote6NotesPayableScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Unsecured Debt 2", "documentation": "Represents the Unsecured Debt 2, during the indicated time period." } } }, "auth_ref": [] }, "fil_UnsecuredDebtAMember": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "UnsecuredDebtAMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Unsecured Debt A", "documentation": "Represents the Unsecured Debt A, during the indicated time period." } } }, "auth_ref": [] }, "fil_UnsecuredDebtHMember": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "UnsecuredDebtHMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote4RelatedPartyScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Unsecured Debt H", "documentation": "Represents the Unsecured Debt H, during the indicated time period." } } }, "auth_ref": [] }, "fil_UnvestedCompensationRelatedToIssuancesOfRestrictedStockUnitsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "UnvestedCompensationRelatedToIssuancesOfRestrictedStockUnitsFairValue", "crdr": "credit", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Unvested compensation related to issuances of restricted stock units fair value", "documentation": "Represents the monetary amount of Unvested compensation related to issuances of restricted stock units fair value, as of the indicated date." } } }, "auth_ref": [] }, "fil_UponIssuanceMember": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "UponIssuanceMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote8DerivativeLiabilityAssumptionsUsedTextblockDetails" ], "lang": { "en-us": { "role": { "label": "Upon Issuance", "documentation": "Represents the Upon Issuance, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesUseOfEstimatesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r28", "r29", "r30", "r115", "r116", "r119", "r120" ] }, "fil_WarrantsFullyVested": { "xbrltype": "sharesItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "WarrantsFullyVested", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Warrants Fully Vested", "documentation": "Represents the Warrants Fully Vested (number of shares), as of the indicated date." } } }, "auth_ref": [] }, "fil_WarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "WarrantsIssued", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Warrants Issued", "documentation": "Represents the Warrants Issued (number of shares), during the indicated time period." } } }, "auth_ref": [] }, "fil_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "WarrantsMember", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails", "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityTables" ], "lang": { "en-us": { "role": { "label": "Warrants", "documentation": "Represents the Warrants, during the indicated time period." } } }, "auth_ref": [] }, "fil_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted": { "xbrltype": "sharesItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_StatementConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average number of shares outstanding - basic and diluted", "documentation": "Represents the Weighted average number of shares outstanding - basic and diluted (number of shares), during the indicated time period." } } }, "auth_ref": [] }, "fil_WeightedAverageRemainingContractualLifeYears": { "xbrltype": "decimalItemType", "nsuri": "http://healthyextractsinc.com/20231231", "localname": "WeightedAverageRemainingContractualLifeYears", "presentation": [ "http://healthyextractsinc.com/20231231/role/idr_DisclosureNote10StockholdersEquityScheduleOfShareBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life (Years)", "documentation": "Represents the Weighted Average Remaining Contractual Life (Years), during the indicated time period." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(a)", "Paragraph": "4", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-10.(c)(7)(ii))", "SubTopic": "10", "Topic": "932", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-8" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "230", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481160/942-230-45-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-40/tableOfContent" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//840/tableOfContent" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481440/840-10-50-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Subparagraph": "(Note 3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481418/840-10-55-40" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481161/840-30-50-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-20/tableOfContent" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r532": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r539": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r541": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r545": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r574": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r575": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r576": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 98 0001096906-24-000706-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001096906-24-000706-xbrl.zip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�M?041@46J00'7.G=9_RCI?!&J&NAW+>&PQ@:&4 T$$4 MU9RF-LEA$M)[CRBR09K4.#;Y%1!I^^[ UO:\\OF,K),/SV;Q5$#G M2$*'TP-1IAC:'FT:S,M,<9NE7HX%HD3A:2)WXS.8+"H*#ZQZ;(*$,6HP.ZA: MS2K7Z#0-J?B!?.JF&@W8++DZ>,&A.CT\<[$?9&DB-1:.MHK-HC3#Y/!0&73+ MY[7OL FG2P&39"O(W\,TJW,,HB]!I<&G%;MS)QSL1C@*R5;!J[GHE1[]39); M^7_I:'UT/!)?_MDFEY$_C)B;_2)5,LF45CQ(G'N13(9W^6T>/VPX$PKL!/[(-#:&*7/:= U>,>@_^=WT(TD/*E1NQA+<$+5&G<6 M%/E46T]G=D&#N><'$2=RIW<23#G=)T\[7(6B79(4#NQ69VN M.DUQ5H? KN?[GL8[P="9)[-IZ$_:=#4Z5U=;W%)@"FCEZ^&!/%W?BWA'*\!5 MC8;Z54L&@DMKI3I Z8^<.E8E;VZCUC'E_W9G'#6C$K( M-MGCQ,\2,DSO:M,[NI=O%X34\2[\Z#X-4SQ(R3/6*AWA[[.ZXPP)!A3RQ4! )GNF9MV#59*\$#:K9_CZ7 MXB.^L).^:=78%L"HIQYU@Q%]@\JH1'Z,G]@/7XN-,B'FBJ*\GE7JP0 &5$KA M^W1023.S/]MDC],\2\@PGRN^Q^;S\([PE0Q2*;7LU86MFKD0PZBFZP^YX-MF M9FRAU1XG;8&68=Y6(U]@9K[Z0J6MFKD@RZBF[H_[=-N[U ;-3%]ERSU.824] MPS2N1'Z<8"&U'3&?TB8UK9K>1E"@FNH?DN3]=\ZWIG;4F19[G-H9.H8I737[ M5P*=^5S65K%J$NN91S5[3U\7W]IN*,Y&U7*?834J>H99?>#+\Q)9\REN7M^J M^5X!%ER3_W0;[7-+EC)R<%X)M5[E?1E @F$W)O"(:-&N=S0":+RR"DPK8F02_*!B !OYX!"!]4 MC-D#NAGT &ISA:Q1&7GF;%0-<4*!/A1"IF/\:B!#[C#YC6\GCUCAUK^1>6%6 MUQI580C%XJ>XH.^_=@F.CKP:R8=]8.B,B+[CCLN$=,S/OE$RQ=_RJI4CSH% , R_2P)4:.V!Q:]0&S/#S M,FFV3T2D7X?H1=UH"<&O>;3D#TK(-#VF^KD2,Z5D7-T:)64.B)WFC4L6E-&0 M7--'F1>T5Y27"+S1\^.)P[K">+#20"/PZ"B3] MF>@JY;LG2E! (\FD!GI%8\2VC49+[E[Z_H[K'2=.V)MKJ0)9^)5(!6:>LUHQ MA$FK:*JW887JJ0&-C&\B\H M,E%3PQHEHF7;1O61RA+2TTE7L7_\JD-%]: XJN56,0WQ 8I;HS)@AFW4%U<. MY;\Z7D0^$4=679&^/+!Z2O#K$#W]@S8Q(EL%8I53;O/ZUNB;"I#8J(!2;J,Q M$RA$_6F@$E+PJZ 2!@8=9)C'=>NY-+RCI:E@C9;1,6VC6I%7-3+?_*K*A(MGHJ> \VP]/G''][)C_8EV]5;0JY_:\-BH?7;WUF[G#\2- M/#)9[+ZZB^]2]W-)%"8'O^XQ8*+S"]ZRV]U0O8W60HAR(2W10:75NL\ 6(3T M/.)RUF=IA1("FE;O5TN9BBN3)- 8&1OUE-+)NF=Y]_/^<;G]ZP6;*NZ$B0V, M@$0T&R<[ZT&_M<@&?KW8(O.#/CU8G]:'WUSI-M&'S9JY$8Q1J>]WZ<=9]XS& M#[HUJ%[+N\'R[K&2N$$]U7[J00"[VMHPD'[)%K)00>2XU,_P3@4@K\J&VQ<: M13^C;Q3*8JDLVJ\PU,,G\WBLDC_$ KCP5PYEAB+8%.Y7"+HAI!/%EM,&A:%T MA:6U]^DGLKHG/ 3]9$AC&S M9?QSZFF)!NWOQJCIT4QOC(?!FJ_[PFH&UV"R2."N\-"J>0/V[0*JH(-*57TO M_Q-,G2?)='L^@/)N>E0NY<0-6F/P 0P^ (R&^N #Z'VOVJ$/X."PO92BCY.$ M;_X.E*X#TUIVB*>4=TS[V\&U,+@6!M>"PE;](9>QI3V3W:BG'JUV(_H&PWTP MW ?#'>,R.!CN:"Q#"PSWG*[7FNOJLG:( N 3M@\/RRT[&/6#43\8];T;]3_N M+_)NS[.>1D$0K6+ZY"N^[O[.2H,F?HU^>S3X:U#[;,U_9;#,?D;D8+OR>1%; M2H*[>T]W@^RP]NS9+32 '7IUL^?O_,%A2S)FNWCG"4NEA6U9^U0C YDRJD;\ MH)O4NDF/G9$Z,FS"5@UDBA JI?,AE:YOS\KE8D'FDNS=KS-AV\GTL&PNYE1, M59,ZYV J>E0Y!]/^;#5.<]LG8[3-MUN,8DV=^.I*(6=9K47@W3U*-":YB30<<-1]7]'%6K M-^1RI(Z#('+8G 2*TV>@$)*C@<))#<13MS@J#Y'!8OU@J9>^&LNN[GMN$WF! M5SUS!3 CF.>EP?-")7:3%:/W41 3]I$GK\@G2Y%\4QY$U*@:9IS-^%:C_W:( M?GVF!^45[3?SK5/MAI&(MC HU?NF^OA9M(6ZD>$Z04CKQ).R][0DO\W(VNK3HF^:E\'>'^Q]1!>. QZFP!>?]L"+#WMR;N>$.9SZ MBAT!7 [)DE%8US6<]8WWAIC/+%B3.5U0XBKW#OJR_>!>.EYVT,-,MKV1^"38 M>!!?B>_!?4.Q#&(\ :;:/BK>=_G& ,3X_I;3O'_T14@>3.]T+;\5:V^2F4:V;5W $P M\CS_:^SY4ZR;JE(];V0@W+8KIY(QJZ>TXL&]7F>YAAZ+)KZ&BR/6!8>2NL-J MYGS])%9A3AT/,O[491&KCQ(F$:68VE%X11D-Q$#^Z/MNJ1RRA6T21(Y-1/;X MCL0O/O]]S*;<%PM.J22RA6V21(Y-1)O2'8D?N5\N@:203",K:4V1*3N[G]V/!&)-E@QALQ,ECRQW2&::(V$&=)OH+'Z]G3)^=_ M?7[N.8$JT+%."TAHR5HLJQRZBC?9PYM@;]*DQM1D?NBTV5!J)$ K#!]!464YM/$#8I5S\ M1!Q957*?RF:U^UF5*FA3Q9VP&9E'G(MFSYR ]K)I:9,/_#N=-KD?MD?#]@B- MI;4;R6=/NS]_H83+2*BG:_)(/-W.R*PRDC4(WA098H!1;&.VCL(@)E(=T&A2 MHV?CN=(05 I.A0)&::57DR*O^KUKI3:LEZ@94HC,]6&GU!OTRM<5 /3599$( M0+M+ KA$I.;&;,[EX_87)/EWS*I(QK2V#;(R1J+M,/W<:V'ROC%QY[1")G+ +3US(!/%B1_^'=,%. MUL)0B._^EH]UTX:P2Z@N/G P1CMR2SZ::*%]4=NPW_.(*H3B[4>?LJ6@;DXX M:]2IJ&RY1S>?DI[!\0:2>D/"Y/&%:_B((5O& K=;CBE4IPGO9L23H6M3AX?- M7BQ0MMSC5%32,TQ%V)'@> X7QM479TGDR<)DL:!"BP7I)*F0:\&DJ@43UPP" MO/,Y^[!L>[-;W0^6N:ZF;ICYP^D7&H]5[#5@@O0H3LL"GW0I"B+9DX!.6Q5O M:*$O#=T#B_9.N?G^S (9@T!<2<((S-2A+(8969BWMCVJF5Y_ M,4/T%QL1_05A"I1KGRU#PE>2OCO1CT9C*XMBU]EJ_A =M>4)U.ILH'"_0M - M(9THNM+8:0OZ%%0OJE*X<05Y0S2ZAS/\WC1[=G$:,S&42!#*AW]WSP%/"9]+ M6)?0UJA:&T@$5AAJL.%8B@HB\W[**9O3M>.-5C*T=A*%0>@PE[+E9''M.RSX MA7CNF$U]'BY\C_J 2"LW8X-4JV/3ME%[$9$[/Z6=BU$:4"G,>(.<(=)[TFL6 M3)TGJ;;/(RX9AHY?%"4QHZ_E4!\LT+'O]OV,+A_"R>)SD(KGEV$[F5"'!IVX M53KLT9M;ANZL:>AX,7+!N1_?,R$R,:*0I290M+W-,J7D1K#UYMTG4>!!&4M4IQG$@JH/C=Y$0:C1KXGXA6PBH=@R_GG? M2N?ZWHP:'9U?B!S5Q!T]BF^7 M0@=)+]_VQSO"5Z> )"HW8X' JD.#R'D'Z1ZYQ98>$W!&E52S0&[EK+<=$I]? M&VZ(^#1:RD.D&@^*;U7O;1?M)[W0HJ8180*9L-QC^WI*$ M;GPVKR.D5#U[Y91F'HZEMRIM),!I->%:+%)(D#_8+3L)%6T2JU M3ZZB84L;L4[LY;"H1\./_6M@D/0QN_OJ_Y,X'#H?KM[.\<@U#8Y:M!\.?F43 MZ: 0'9)FAL6^I:,:&"F (_ :]33_LJ/>","WC=T3/)-P0.(]_ '=C$.C,-& MPQ$- 5#NO7B$9F1.Z*,\=_Y"PX?Q:AV%<7[..(AFZQ\!9&=6UP+)&8( R.VM MW39YSX2#W>)[;U+W.0]I$GX0/CF;_T;3&6U[!!/*>^()LUP17FXHHSJ M>M]P17FXHCQ<41ZN*$,E,:.OY1#5%>4?LB4QMT?5GJ*HR]HA"H!/>%I8=/MC.&L9SEI0^2F'LY;AK&4X:QG.6H:S M%M%%:V^F/;O3DI4['/9[#U"%W.)493F70 M&"6[IY'/GO9YH3PG"#2N"WT=) H8M/I+.,8HFU1VT4_$D;K'G;"9#"T69M/R MS EH\)GY]P'A\27G,5M'H7SJ6IA4'HW1S_.J]8NTWV^_8\1HS"N'3'N"0#3L M]DO:%66.(-WQ]ANN( .!QJ%3M17+AD1ED%I_DVWML[&P/ 0M!+XI52QD">X0 MBVWO6P(>IN:,^+2?+^+#;S.'+55>_NQO6)?$' =M^_%-L%0.W?RO_>"IE'<& M1OV@;$Z9EP"YR4D#0IG]'2&8.09Z'I>?G&]Z.#._8X0SRP B5\]PNM!L6,;M M@R!KQE^GVVHRV+/J*(TD:YG='@]RM.2#IJIHNQINSWV8TU-?H-9M9I M,%XS':%0'K&9*6V#7$%.&\S-H]R@W_FAX^T&AV)?G2N &4P5/_IW+! $L;0> MK((T*&4(/C$_;K\AX1[!^%FS'8S0J>_Y@UP1QNPSXT)F] _B?G0HN_:#TAB* M9CNS(!BF+9@1.= D48&DB@03=OE-YB>/:/ @-6ER01\8%.7U+)"O ?.HWDE6 M:;=%)^I+K74; BY@.K"T^&E_IBNY*.)"MH7M0SZ/8MZ3VO' MEN"',1/%R)WSC01[VV5WK7#WJW3<9:-Z&S4$#R>C1SOP<.(',Q D=8]>!KG= MU_(T@P7DC#"RH.$HO")B.CF>=.-%@IJG#/H F\WV@5@QM00J(C<$P-EVY;O8 MY" 0!6+O2R"7P40\GN=_E5'6U<9(E8;M'1B5X$,4?@,,Z#(1YTK;)+<\HWH# M'(6Q41A4(^9F]A.MVQF&%* S,0SI'JP+C9,IA^#^<4T_",X=SI\6/I>GV_+6 M&@E".@>8J=.2!8JE%D"([('Z"_Z1K.@'+ME6/0)H""[_%34=@J#KH,M)O<% M7!Y)J%;Y?;0BIXCDD29.FZ1"41")!*"1E E 5+")2 JWA(L]TVBZM7=B.K7I M'G0U+)*+EG%$SIP=4\G2*J.3?28^ZM+VZ.L@$5*Y^E)SC$@V.0*U6DQ=%HDL M=&,K+1J 843Z3-"V\EFY%BN6LTP4"D81S8P*ZPGFA<14&%56D09S ,C.MFER M5.L!4 @)N(4% .*I6QR56APLU@^6>NFKL>SJ<9P9$=M#*J_:Q?U_9C14YP\K M*8P961V/B+3PD'2EMYO#V14AOCH8C*+PP>,RC&P<)3@F/J3<2%5C9/I'!."!2;"GCUW!JZ6K8("0MQYAR=!0. M V;D4;YJDI"^]L X%).:-DC*" 'D*U7J588*2U6ZE@V2*N6\P>P0\,:#QC,V\/GC-O MT0NG,B)J$7WHS1 < [3?D*_Q3[ _PJ@R9OE5Q0'8&+]&L)B=2P7AQ=!FU(08 M>_*2%Z@ES>IA%F(%[@'YG:*7WUT0<_"FL@!W%>V6X)Y_0(3-79;^XLA\8F$ MWCS/%< .;)X? ,"&3VJ,%T35D*[: G815$8$D)%=Z34G29Z]U&;])M*%+#7> M#^9AT2*ZP.!ISB.RU2A7D><]_4H"]>UX52G,$@$Y _"LE1.R 87Y_F"%^1Z] M'"HC LBH94=$3,]^#SY:R-@!O +J&J> ":LXQ48V@&0DI5ZJM>NT< ME[AVZ !2Z\57\9$P>=%_Q-R1NZ*,ROL-,H?%YEHQ8%64U<(L.&/.@4/?U\V] M9B?&B%P,TS;*YLGJ.W\7A#-9J$)N=.EUFVD7LPP;1 ^0\C8L \%5NOWU;[59 M&]?8&*XCF8"FB^MWAQ"%[,K>(:P,U_R&:W[MQI0^[TCGMG <(IV;<5: TMWSL?"%T^2!VCJ-'PITE:?69SXJ]/[-QII<$-LU5YT'*4IYG1-IV MXOMSG\7;D\CQY$N5^;/>/BFQ9E1V+2%,9DUSLW(LV*0LH'.5*[+]_JP9;>V@ MC>@FQ:%8>1JI:6Y/V;=H-W,1WGLUNH27^SG.0PR!;I- MWEQ#-'AZ6)Y->W]F ZW6@MN?8_^ @XT4TUD5?=K2"9.F0VL&64MX']-=1:U; M<.<.@"+:^Z+"FA'8I61*;D&BBI:_\3Y#>/Q1ALD R"5G>B(-+8 MPKJ;X/&@#6@W!#RK,5=[VVFECW>(=.PSTM'*@.O!?V;'H*NMR/KSZAZ@OW_M MSC13=F7-^&H<8SB(VZK'VYL!IR]KSK3WYS-,:ZN_[_&<'HR"(%HE3'T6O$J7 MY[UT>;9^3%#6,;+S@#)R!\=_\];@;AZEP)_1X/-!X24=VC+X&H)[F/P@.C8_-676>H]^6181RH, MZ-F6<=:V ([!?Z+C]X(^4E?82ET/MTR_SW6P9<'7.T6ZWA6K)!/D/E-D\MN,K'T>QE?S=X4$'LF/S>X9&B>KSQU%X\P,^XTAT B/ MV;TE+3?*5>%)9G60.)'* Q'4'&.2S49OJ *SBGZOXW MBP!,,83H./' MP>>.RK)(!% 8.ADAJ+E$9-R=^T$H'_S0X9\M8P/N.:X0C?L;G\TC+KDK?__S_P%02P,$% @ D(B!6/YJ MKKN[% EA8 T !H>65X,3!K7S$N:G!GS9=G4-3-EH?_0QJR@H"$(8^2 MD30$28(R!*\B2(Z2DX0A9P04R7E !R1G&)" 6ZKP57A @$ *";!EPO H\!8B(B M,!$A,1@,)B$A)B6GH2 G(R-GH+YSBX:9D96%F1$"88,*@H!=AA["+_+?MNAV@(@8L00A\ M$ > 1P7"IP)==P.L-^LD!/W3@+\-A(=/0$@$)B8A);L)J+T-X('P\?$(\ D) M"0ANO $W?H" BI":75B!Z(Z&&9@#02,2G)!-S*E8V4&K.7$ %35W#2$AI;M+ MS\!X[SX7-P^O&$Q<0E+JX>,G2G!E%56UEUK:.KIZ^@86EE;6-K9V]F[N'IY> MWCZ^H6_?A;T/CXA,3$I&IJ1^^(C*RWK M'QB= M(*6#BJW>._P+[9]D_S6PD/\1V;^#_0?7 D".#[K9/'PJ0![ GG/GO"']OQ"? MA-;L<0R5A+U!3&L=7+$?@SA_\-+HX*QPE5,JPH.$"[>G!P6OH :5-J*/,)3_0UUR\F!G13T!B%-KX?#\S3'1DD@]ADOC3Z@!J5VU&79PIWP7(VVA6B3G4;&E-4 M"]Q2?.BK68MA4"F*6F6#8'A'L*ZCT(MT__GUEN*VPG>:!N+R%KZZ7JNLK%N, MY D+WP?NK7\:+X6TF&RI:^P$D:[9/U)@.4FW'TU;CQ(N-,GG<5.8._>=V2); MU"M'Y^N;(1]S%O>S?9W^\9U41E%S+P#/ZQZ$ ?T[UMY9[:\F=1:+>Y443,(N2"V=PULUK!O/=.-C3:N6A?:_,!CS82C_@,B ;_M M="H<7$40DN6&?N(!M&N9$0^#WCDYLC54-7S:>W4GCK]H@:0=S+7P.6C5>U/^ MF+CM&FA+PCDDGXU2R9C94;O'=L+Z"H=/6$->M^ CLJ7/4*N<7X[F .N$P'^0 MN[1XC/RCY.MI+,]U,]Q<76N?ECQHC[9R%!))(0@ M'(*_R G[J8,"=SIL]SLZEFOJK[LD9#6F\GS^8W'W8#U]Q(9;QE*I(.T93;QO43I=C MH%%D%FZ<5)^^"]&?8Q XOH8SOK* I.YZ \,ZSM;WKK=.IS(O">I_ZKVLD("- M5$L5K96HY6C.9^1C6!D6O,5G9AQ*[5,A< ^\P>=? ^-^I M?#(KYA<0!&^SM5MB5@4>G]WD#N6!Q>B'O S'45?/<[=C(HQGA23LC.MZV8(M(N M-:$F+?:45_%-?L3*.>EO>0+;VV=I/9Y-5D,J=7OED_3]Y("F=[_LH4G3%PHQ M5C(%K[+%)1.QNIFD^'L):D=,^/$TGC"DU QJ_9?;1&EX46-%ML$LYOE''R_" M&@.E_8]B48P_DXHEF2^WI[9_&'.L23\S[UPW?_)B29DS7N01./PZ)BQ+'PUCN*OF%&0C)AD&..%L91^5I[G9I?"5N> M"DCZ9._O^_"N(OELG$/FH7KW)5?G>>.497W&GL>C29][" 99T,!V;!"5B<)* M$&1L97^74&]XPJA333F#S@QKN+E]IFU*_DOB2NI0->*'IX@4ZO>/HUK5'Y?J MC^0[,V>LN/.9>P\3DSGI_?^!O0:(S]#^QA8".P\]>M!5K^]&^NDHH MM)F%8X&>@H7-[CF1P,$U$*M++5Z?MY!T45/G V"M.VZ. ME)*/.402MF7*[/@S3G_R@?!%8;UW,%9G[&J8;U"CGGPV-5Q]0;2KIW#7RG6. M[5BJ>%6 3F5_H8B'MSUVVAOR1OFQ4:(RP70-?Y_@40BO6@'K$'LKKX9K&25H MK-42,[>1S/K8KU/W@1V&^;[6]FG>XU%)BYJKL+;$BH\X)L=[^]''X;?3+XNA M4/*#]XA+P@!ADW(35*CL3C[LN4F!;L1//1F>TOZ-GX92;C=WA_&/&WPJ37>F MS'W:-6S=,LJ%83$I&K/0EG5H_*DW>U5 9W224Z#[= QB2\ST(1J4U.,]^S:0 MU;OPV6$@TL\G7TSGP(BO?]UV=&+[S7QIM\(@8NJQD;'4\SQ- \;93(+$R=ZU MC0N/M(&8O,73US9 >L"^_>^1^[1-,_QLYHI#"$9J63*0J?8V8NEIEKWP@O+Z M4FM-%+4EQ;#6&Y& [8[C6V$9O*'=#U_7^[[L=H9FN-O8AQ&D$YT6H95X M!)_8A'=Q#_*FPW$F4F>AB+&GWE^0=F1_J+$I6*YR/($Z6+8\4TB68X M6U4Q^WC>F0:'==E!%@5BIU6O;PY.O"7!"V^!C*P9@B!*G!-!)>>YRX.R+.) MM5NUVW0+D D>9'/RZ2SF;O9=L[YFR?/DRVO 9RGY<' MS,K$=5NWA9J^:Z,@!4U,AT.29-*O 5]C>BB M_C]I,I"3_(?:'*F&GO?1I!/1OHN501CWFYSEJ#(YQ>Q^2HY]2RV%C@NY1>/+ M4F(\H=IDDG=KE7;4X8KL,*/:*H=ODUHL18=COB-#KF0W%/NEN>[S-;"JYSUT M]09]#02M70-KQ&J[:B;JMO"%W[6RE'8M8VT"#GJ M+I%]OG,-L#D,U7P):Q,,U:M$&3,G2NYQ>EF(^0/M25VZI;@7XR7%9UF9)O/AN:HP]SB/\4PA,1:E"\_S>4S$9>I7?HMZ7XGCLSOF\P> M\<]G:\\&D#)WT"ELMSX/B@1\C3P:NTG.+$YVS2^J5?>Y^ $L%UYN"?\3Q=-' M<$K4"NY%!WXT!X2/Z][SSX8)BG\8_CR?;BLTT98K9&IC- MU&XS"ZE87&@-4;DT+MQZ&6=_C%9?:;);T/Z)/<7(SV?YU%VF,=452UXL3ZMW ML "'<;?E(EJO%>I:32I8PA3_QKY?D3"!3JXP6S9'!$G0GGP$0H@) M6(AA1]BP0,A9^5 /H_;T3/*$88<')%$*)5JK'2Q#-&9_3EI!=I=F+\9%*-G\ M#S(.Z?]7V3OKTJFN?I9R:"22$^3NT7Y:X7EFFK-H9T)2G0%E"?A-LAZXF]DD M]R;(U.#(E,X;O\>@,,K#<-N8?7G9+\QV<33:R:2/L'0>)V A]W'U&6_OIK@Z M80DT*MZEW56R.)NH1'Q"TN"93I+#^$Q.2F*S^A,C#54E@$8S4@TP4#/@!F@T ME(![-#=%E2XQT@ 05:)Y ;H1F/.0M7-W+9-DQ!DOU,_)_R+H] ,^$@=7GJ4] MNOV-2:0J7J$#'$(1D&IB>$BVJC=[/U5OO$ZIZ,L(K!D"W?C*,G+.:K]>H9RV MK$S'1[FQK^S6B>Q":/(U7XN-B=\)CQW1.%-UGN@!9R:[*@N _)S%7,]K*L?&%/PJ8>!5;FUGDD]Y\*-/ME3W M#6CWW7Q(*&L=$90?>?G3/*B?2#'+P0.#"&$LA>44XJMKADQ1F;RLKYZ05?71U 7L$$M(FO.Q'XD MR(O B]Q,!7GO48=GM3@\P"LP.>(2$_=A][%N;)=ZR(Z"0%_&)D2CKT;T[B8V M'/\0QJ^[XS[_0-#Q7MWOZ8\YGO#7M["JK&A1K:DO-=EALA,@FB'!>?,CVL^4 M( ;F?OEWDG,IDU95WVBL5>8E'M--&X7V&V6:&ECYS5H9/S"^FD1)9JHWUHAT M;'1;"\=O]LGS00)69YGM<1)VLB/#I&44S;S5+&^1%'TK2AI3.%FSO.^7!9WT M:&06E0P"3B,%9H^5CE7&Z.SL*.6/''>.99$'W>Q=G_*0E/,=I(AQ/!=1'1@SWI#V5X[& MMDCI\+5W:WI6T2(A/<_W_' -.#LR;'J;U1#97"T3L3,[.2?2BQL1(E>3.GNH M1^;&6WEG]+/@:?7:"\I/CC;K##+A*;(;I8[T8YL:WSZ:*+G5'=NWLW:[LI;_)R>4Q;VP2NJW< MJR#-C:*27,>'418=&AL<%6A>..7><-SAS*.TL,'=>N>2&(L'N13C!'/P<=6;5K=P$VJ$B<4A)J)-L=6WE M,4P&ZT X4D;(@%J=UXJ->B>0M-LK3Z6?RL(4MKYN6-^8NNLHXP8-#M$_#3W,V-;.$S560(V"-S[MA^9^$:4;17"IY:/Y\?< M:%[5A%!_5,*O&.Z2?R^VZ2'LF#M0M&SX]#6GYA@9DE\H:![J=K*O:3+?>IH^ M4R&D$]#\[65H" D]5W;O0VSNR\_/7CY##>ITNU&@>[W'Q"B.[,<%L^]L5106 M67"TIZ@ M4CGP4$:!)IYDY;,3/F4(>D%?H&S6E<^JW/K(,/K5KG;?CYRBQ5\ABUJ-+12O MKP';S%'IW2,.7$G#K>:XYLVE28ZI*@$3>XZ%-3Y;](^&1J1^-P))K_%&+X4- ME C&*'S5$(N ,;"C8+'W$W(27#!.KL+I-G%&6KHS=UU-E?PLW""B_-;W]7,$ MH_-"T_&(.2%NRU%HZ+>S0&->AV*C(:J8#15VMII:%L(-"*# M]KVE+6F _'._>:(4,%@'VE%A"R'F MG,G]^MJZT<\O2G^&J=33.KH_;:(J[W;[;<2Q;/%Y0))^W@A_K]U&\A ?QG84 M "C; 4*1UCUGCJ=\#?L[.4WA5)#21KMG-WD6&_ M0XK-TC(8%_,T=W/*SL"?[IE+TF," MJ!>MG[0N94613L@E6SW0D7=_8Q#=F!O@GR+<]^$'2M]T*)*[?6DW!#$*K-Q) M]-.<_P;[ZC3F"&O.3>;A9OW %J\PIO%B2X?Z6VW+Z12_A,ZPP7WWY4*V$'I+ M%[>YT!Y1^&18@K.,&<9"K%>S\@GGDWY\4A%OS$F!O%]:_]-GKLNG>F:14O[8 M!^OP1\-,E%-?,J16?$\QL$*MLN,?U5^^"DX'.\S3P9D>+=;2(C*N 2_Y&.,L M1&OK2DXD-S?WS3_E7RH.*M"SC_\C<:J#U;@&/&V[@H_'U#:LSVQ6YC_IUW#3 M5&"9QUF+P*AMVV*$NOO3MU9-(NYCY+8&HLY3-6E/;:[.GT@$?3=V,(CDR4OI M4A4(B>0N$+J9 _C_K*R;%P?-WPJZGO\W4$L#!!0 ( )"(@5AH69'8UVP M .!] - :'EE>#$P:U\R+FIP9^R[!5!6_JUE>T5-2L@BROGK-S MH:(^'?5].@Y )7A&^));"HU(S02=SI&8QS\V&X->NK(3J#Y^RL#[T2D $XN$ ME.P%.2,3,PLK&Q^_@*"0L(C,&UDY>07P6PU-+6T=73U]4S-S"TLK:QMG%UG(=" !;NY91^\%5;4TJ81LHIF<#[L)/]\G75EN^0C. M3]%.U",'4V[]B ;S#QL0#.>YB]W?3M.X991=VCELH#7[_4IQDC?!7,47%(9Y M^P'[C&R;VO(>*J[8BZ.=!!4\2K@!JH3"Q>R_T_44W3RUN(%,C]N*Z#\RN?.< MEMI,]4GN,[*M'HY.*CY^,F5_"4PLT]S4"A)-HL__L-#Z6^\M>'E'K M&]WYJ5KUI@N)XF"K"CH]DUBSJ&"M[YL$*M!,,:X-'/FNBZ"HJ-X(FHRE&!77 M2_YC+X%:O;Y!E]>^^&=W9BTI/RQYAW]? M.!7.AF=]@6O#6]53QRFL?U""".([[WU9A1DJ!K]_UUH0$6$/0P""H&MX=P@ MY.%\>L+*ZR@DM.:D?J_JA]W-]T7-:'FCFN\;'$3$-M+*X^Y\13D_85+K1S3= M.,C[]3@$:83)TG_ZC;XO@ T36%E*JYW"UR%KMKQF:: M*(U_MVA*Y)O^>RH;ZS^#5+7 '@2@:_8T!(8 M#_>V8#^I8G+%G?]^A(!^/'? M35HX10 B^&*(?O0E?)ZX(UOYSAYY>7!94"+5S"3T-R-V9-?V.F\I]VX(7#\4=A7VG@C_R61R:+HPN3<#.W*0VZ!.8@ MQJAZ^B)S^@9QUJOL(C5=(]HSOZBU,%HE]:T<:W\69)(!FK=]_\$R;AY1M85] M&=WAGP4U/7+T,)=V(H-AB21>14JERD'U!E"4[3132A,'W_28FI*[[H:E:9 J M6&*Z]V_ HB$;CPC R;#Z]PVJ/SQIIF>B_R-B5&I#G'Q;0=OR=K*.H--:V$L$ M '2" /CIQ]SJP_$1@,R;IU,XY&M#/O\7?7TR9XI=SJ.4W"O"GF1T,:R-#*M: MK<;KZ"$N'&^5).!'N0V1R$/TS"]N"H]>VB[ZS:=#75R)=8@0@.?&7307< 3@ M9JNT:(+?5LE9*4*UTNGZ_+&//1).O"$T;"$T]34]Y]@H)WRG]H1\UXB\.7I6 MH\DJ/U:P",,@IBO5FKTJGQ'H]COX/Q:1@4/H,H42F_B[Q>%KP>\]#.<&%"$V MF=:XFVQ3*_/R.O\-+*@U#;Z/8(6-VISN7M#XR\ RVE:]37QEE<01 HK*J7#C6Z4:KKM[AX?5Z4)?M1SKTMSLG,:3?_XYC@!@ MU@4]6:6$ /B0H[GPZ8C_QS^5YNOI[&I-)#.3U4-2+]VH'4< G\;?GYU5!)=I M+OZD70U\L1[SSXN-H09#\N>T#E*YOCYKW3 M%%]T _)6IVA.4ZV,+RY7;CJS<(/#=]K7!,;:=_;:3P+E84SSI+!'P<=3*Y3_ M@9V 7:L*;SB1W7.X7RK\E@_299<-&9V$K*!]$2%G9S,FV/MF_7.?\)UL33_& M@@HHZ&FC?EV0?F*L %HPP'\=R!!_]0O284#_)+!,Y;F?]W!NY^GW9I_57[I M?61/_\-7K5J2A"4G',!2XI58;)VW$';">#Y6-]X'YD_X;VTK(_,QS5E4H>1> MHCKNU&&1YV^5?$:L)OD,J'ZC4369N^+N3"GSTW00QHX,H;$Z,Y/?>2M_H_$" MMHM2DM-(UO;2VMZ1@90@QC + 6";GVR1S=^/))S?P\Y<=$AHIY M/%2@X&5GH:OII82$NK1RA"\NT3K"G@_[25>:WP;F,]\W5##<2FU.6/8 M5LTW.4AD72U'AP#H]DX%;? A064MY@_<;O1%;:0,/QK^T3Z(G2_7-2Q__"KX M-C*"[1AK27[FRZO_2K(ZB3#MLP5KU724=_&D\4SVC!J_%+SQG UO0FN3?4!9 M1C;.-(D8@VJ/VX<@D3OUX^L-C?:&MB:GB]];BYD:[^=26DJ&G2->&,2)E;K) MR )?62_.ICKWV?<4=^'EB_Q0C->;&\@@:^F.OY%]#T#Z(E30)Q6EL!?N:L+L MYC2D5(F!7JN0_-S_7;Y,H/J -Z'V3I"/HN-:E!XG?K7^@/2B[)^DV7UVW.@: M:7M"]>B-0G7-S4*J\ZF< '>&-P>,SA>;L#8=\+O1=>B M1EI >)?3<1ZQ/WN"/^/I[W3Y6#*AW$;=4;5Z%/8+:^Z3OZ$_>67??T;7&G,T MDWEQA?X( ZZUDUN&0PAU/=7I@^J%V9R7FQRY;CX=]8$6JT?8%_S0NG3DI_/% MJ5U13O7/V&YB DRI@2U"!TZ0!"<32.CG#TDGL5M&$A#>_J9Q9J%&R&7^*3R#1KG6XD'$ M/(46+ 3,?@S,10#&>";A,.BMCGJ70+VHMM%\._>YSM,9M3"<"'+[<@&17Z69 M6="W\,ZGD+#[POHIF.K V*;+$\KC>/07>I$K!PFR5%76]-6[A113MB]?VZ?= MI3)#:6YGUW$J]:WPV[D>[L[VQN4OH 8-&:(&UO:,'RI[\N==S?HV]#=![A1NO' MOS6]BP"0,_%X#)$URWYJ+^;? >[HP.G%(C5:K:E/3L&2IZU[5XWPA+WIG17T ME[HPC"K MO^D:?;[71M/>&OS<_Q4^;S8O(1)R"ZT3>W@^JX:;9:I^9#%?'@>P>&T8HU:% MT'J&J)2/]W?1FC(N^R("L*9RJPCW>(\ K%QH*4>6L&>/=RN7M*B@C^7RW(8H M1;H*JCVY4+I>@F'H*<"46MY2,F_FM,;UK^D$\SWL^=A7+0SC[>PRW[3DSX++OKQD&!G+9F&#Y0F!)K@1@!<'/9R#QNLR0R6EO% MPYN_#5EC:'+MBE3ARS=X*,-#:Y%HB[W5LN> T^ANP/5)XR_X1X-T4E4J^_W# M$^0R37>B%)4;)ES9(Y[7_!'#50NY*M S'"E$V0+&WE,J\LUERY1\*IUU[KZY6^10@O[TL:(0$V5$)5W^ M5&@?)++3QN31XF$K)7 ]@52TC!QK6L+E!N6_-=Q0\!%T=;F+?T4$G0$ M8\WJ-<7'$;[;2:)LOH&Q8Q$W;E7T"Y"$U"8L#VS"7+%)G*WK2,;+/B]T?I6: M/I8>&7F'HL_4K&',/N! MDPB A2X",)I&7-)\'++ MD0T5HWW0O,BFM,DVF)%:0/SX/O%CUG44 #F:9C9:*]\YL4EQF MG/$293LD0BJA9"TUB5WGMGJSA&\65-I;7XM"0N[[U)78M+?\/)SW%G7DUY7, M70P9M]%Y08.$]_70-2,E4T_.3 C.(C,>$;)XOZ,^-?TLC>%4RRI61^ G!6^O M%$DST9HXOCAN2]-$T\7I1R)PDO[41FTD_H\E>@3 U2:>\TN-F MO49>@1ZN;AA&$6@-90P!V/F^$B&RQUYT=8II;Y\_+Q!*;! 0X3P)[QI"#.,;!]]AC6B&:)E? )9A(' M5#JPS0R%7CS*[<36@>[(@]YD5U.51(PWO+IPGU3$<-U0?T!MZIRW&T]&IT7) MSLYZG;W!#D" C#L^#MYGIZ]%%F]7;E625PXXY@Y*0#&=*-64S, Y&$;>*8H>IMR U'MP,NB5$63 M8DRN)OSER9 6KW/DPJ%]3V7G9L;JRRUO?5\*=FC]!J_#9Q M!JTR!87/#EXM?*=BSYY)@PL]&[EJ0 "^U"*9EI_V5;F64S'%4WM1Q?GOB\+Y M=NV.Z4-T+"*3$N6Y\4YP6K0@V!Y>QGC]G^/>AWW-HWS6@:HCI6#)^_C#K;E\ MANA: S\Y\NH;7O/=*AS87-@W;CTF=U [#: ?FTYA 3QU8G\)RH"?T %VHKY? M% 7!CG"*VCXZRM6(1P<96<7!^M'">YADA@#@N043]1P$*@[)+)K(K2T M1&)5%&?73]8+5IV.G/^YNJDZX=/B6C!!'1R!-3!V>IUW+Q_Z"OIM8_B[_8U& M)[1 +6'<4%DK6.H:^OW>223\WJ!K%F)_6I?Z&VU[=3PUMF;&Z?P M3&()BU9B-:,?1\]\1LXXU;AZ.%1CULR-!V5]>8TY;@]W^KT&T4%[Z'=8F[TP MC-5^! #'*^V*Q1T%:0[/5,'C!51Y HYCM.]E6'LZG16I0A9O$AK7>/1>]6OA M:>Y(X5M7"53/S!_,L$O(P^X$(7B0X5')JQ_&,HP W.,8/&7_ BCH3.X+G&S6 M?&*S43$X2BLRM('RNE=8/4UK,[Q8.@^X&6ES3[%Z:9,!B.K8VOF6^;O-$YHK M029_[1 \\TOD9YS*KY0%S+/45=(3BG,Q=+V/\\=9/3N">+ 1M6).!IXE)7I7 M3[+,WQ$>L(/DC^)4TQXW0A66I4++92UM=#/CR$Q0GY)< .8"P,_EY!;,OW*/ MO?)DU/53>75-<"HO34MS1($ C$"ZDN#$P4]MG-3??S7Y034/[_,A>QE"/N"* M#;B,( )P\]C>UY8]]O2M2[3PA6&&C-T+"],XL*IG!?I_G-O*-(-:716\I/L] MF%]2)8L,GM!&G;:ZPCT;E*N>:F^)= ;IH?GC1TKNPA41<3WWV9,@NO!.9_1J M&O;F#.D,+Y(S7WZDMO+\Y67'/H0H90N ^D4922QE$RKA63W:JWF=0&.Z",?> M94S>\V>D8[9@.A 6W@?.MA^D7.!1[]];M*Z'N8JS#&Z.D)_@IBJ?=<(3\HU4 M+.*\F#0Z>^[[# GIK8#]"R$:@+BLZQ;ITTZD$M>N8GQ1RS#7@<]IB]FT4W MA/3<86?BNU(B +C3C^S?CMY/^PDXZKB7X82G5B,E2DP5:A AO#/ID(A]P(0#*A^Q;XQ-M MR;>)#Q(T-BV/NUWPV@MQS]OV*&IEDS.H3/&MDS^<=@\I6/)[YMCL9,*%0]? MFQ7\3\XPK),[K/NW=5T^V+L=7$OMJM#X%H5M%6*;BB6EJ)UU,=[AY-%4)\#V8@ M:W+&3PV/_0K\D=\SH[)0(+9LV7J4-J$\GSL)!:ER.6WO-_D@;C[Y]^G-<,/2 MO?80 CX)I FMIN1Z/XLV4W$<7XW5WC^KK52.,9>:<*TVO'5+;:/6ZT^CV.ZO MP:@#U,+$I:R[4M!D'X>U,#'6=>&R4Z6R'W%_1EW$VW+S?66-O,]"E.L:3S66 M%;Z,VK(E9S8,=@+'0PORGU^+G+E\WZN?II%0DW5MQZE)-;3MNTZ<#6LCUDXN MM& ?0)]OV>W_D1=#3> <%[[OI=,%044 S.:BG%4C2.O9'[Z;_%*[?XH!KK0 M *"#"I /U<=7C6$3O]><%BK*'6IQ6FAYMS'!7V%?WV+V --PA0^HW6OCV8SE M] C>U)W=?38<(<=;DZ?5S)R?3WI$Y82)P.QBY0%'\?Y: MH#7#O?:+*^>[F-.*"/F)['&7JVK_I3'N3^U&ULA7'#60KH&TY) MPBA_S]?T&@PS?C2664RY)#^'HAU _N@7U2=4VCE)UWFQN_'OUP0'A+.2'624]5ZE;MNW>2, O)HQ,MI<9A<.QV;PRS*(AFK6$AU7*=+]),/UH[#; M7F+N!#%]V%T M+-^+<0=VRF5ES&.['(#7H9NJ):(!WU>P:]]E\PWL !/48P9TW$5&W1 C5>0?*/^ M2R4+"IPZR52?.N:B*8M6H [\F8==/-\J+S7^QN^YMS7I3E-4>CM!_R64M^[< M;Q:S@4&:DK1CL-=+_?;BC2Q&FX?J:_3O7AJHGF'JD0/=SY1Q7*B?MSV0AJ[+ M"2E^,0493<<7#Z/>Y_^::3QG^%:U^>%"*R33'!4(,IEEGR%1YTI>C"7 MKBMK_07_)KV_4?ZZ7MO*JB>GQK>STK/[V<0Q ;M;N6>9/=?^]R^YKFAUH#KQ M'JP!MP4K0ENZSI=0O3P,E@YB';8VL94EPFJT+[3[O=!<-;5$Q;6[ M'J5JF\*-S>TA;(V20%*AN?#IER[O+-#,%;#[QG^7?U'="24]8E!4QNUN%2P'QOK3)DUI)7?,DSFGY&N7I[+H M3.0HR@B7\S'EA+/S$FBN^9>Z*N<;))\%*!3'.7QD)KEF+FA^IJY$FX"Q%B1Y MTEJ]4,L0&FE_Q8@*'(#F^ "<5WU?(P"3O+ 1GT4PEO25F,[D,G'U WH0W_#' M?#V[L9_B82] OUNQ47VO1RW9@DK =Q3$:K)>A0W L6E9+FM,JF^,N/ M[ ?H=K'5-&NHLP/S95UV%O?O'Q_"GA(]-7]_Y!]J-Y/37B#%<00@*_R.YYF>/5UD!M4TA-?8<*Z/;O(HEXJ04>T6*XWZ,*W5EL[K+G5= M@^0VL,1L!S?+3^MRQ*=VHS30<:/R!,VWQ9Z:1G % M:<=3AUG\AM ;"R22BVJWPI!C-I.: J "RT9;-?:V*&ZU*&Z;>^ J%CT*U3J7"/N/X_$]&:"?3XV4?EL2 MPX^T5*OG!1/O3Y7Q\GU.8@\,R*/KKUO1P1.YC";5.I8TR['):7#=PJMBOF/^ MJ%0E7OJ,O,T;/H"*I,J8NCUU[25Z5R;V@H&'B&CSL$)>RM6OQEBDEUY(HY/\ M"6SV>6717L2&>DX9*+7M32NQ>9U4FC%%T I(E(K_.RT.:P?L M*V@VL9V6R&]__B"(>XW!/FIR9-!"__9&)/^+M:#SMM2GBS.-ZFIF?N1)Z!& MR,-*(F_.*:R^FO=DH=&W6CU5B1?53VN!L?_QT?@42OQW6F5#BQ(J/E6ZQE59 MUC[-N/S'#/C3#+G3[9JVEV-VM6_\L_6F8BDH8W^S;ZYWHZ?2CPWG%.4N?N@O/!$D3RSP';G[0T"$'DCH1*0 M2'-WY!1XOMT&>5)+J7.&Z^-^YB&0L9KZ"[PA_NXN3"#"?\Y]S#*,WIX?(Q8;"1GPMRP26\%0_ M;9!,T,!<9@X0H51EL[0P!\R3WZ<["[U\+9J!.N"D/6S\5$"V4?%UQH\GV2&RRTJ : M5]L9S7P+6I=!Z+MLG[VKG*[*(OAW5L@*N3V &S3G,QY3<$^H%)3W=I9%!=- M3H7+B?L6:Z\<)N"V#@JB[RP=]\.6INFK4O#J_S0'\X */Q$U"^0(B,7/'6Z?N[H,L]-UXL.:VFRV+>O1S-O:0[CS]!4KH[^<:S#"M0XVIJ MGVU@9H/7),.E(5'OO41FSOR\XJLV,W!MY0NQ:03@5H4/='<@^'C/O^4=4DX1 M4H[2N)]YFF$%N9AQ>+BTE0>?X6:6#S*X*='SF7(TQH?YNR)*YLUTIOSTQV:9!/1/$8];)^\(CK0H^TG.:61!0Z', MT?O+PFL?Q@>ROT>O3KF/5*LT.BBDWI'+B$G+_,B3*%,Y4*F385S$$*D)!^E_ M?4TO?*!=\]O5]K6PA!,"(&*6L1CXR:;M"Y8KL3K+^0IUG<];^3SV1]ODBL"^ M*O0SV8[1)2W]G7H\?;.,XE70'7 # :B P@[HUW'C8]@UPR![:0TTL>4G:+3& MS_4)8)+U!_JSUVK[)$3Z;R7 FM#)Y5CYD)F=KU<:^;:5))^D0,>;+S8R@JLX MCY;[SFWU@AG"PF-5-__RY0JU3:;YA/:0P./68&>_.97MK_WEW!*5$B7*>KS$ M:&ZR>]PK%>%55S$L-*Y5")OP)2C!&RTPU^"/5>+/050[IH[?>DC"8C-)<^6@ MG7F:AVO69S$X,+PM62_CZ)HY9?_K4).GS@'[;1&E.Y1W4=PZ]-(84X$?@FEH M[22@+SX>D[WI5[LS*<-8L'G9H=X6.;$/W= M%L,UN2EP^T^UZRR0)PWLDF9#N8Z:ID2F?NL& :89@5&>G#EF!&3G@Y"D642X,6C+6);5F2-4,=2/)UW[F M^X'2:KTG H17OU:T4H@!\96]+H7S(16N1G% :Z<;:.\$5GAIM _9I]E!\A-V MEX;B'!]>]'/NE-)HZ!,'F]X6J'!U"_:+F_;O&(F)Z)1[_/)?LVW)/'[R[[FD MG,@DD: 8;3-,PT*[R.I(#Y7OUTLKY-=K/>E$=8BA8AOJ' MGWVJ?.@-N^$_X=_V8S\M[TU?3*I3>\%A)OI#U:S/^VQ/DA=/>BHXMJS30_.[ M1FW'0.W&:!DKKV7&EN:,M\"OAJ^I7 MJ7/0E^@S#2+OH@/J^4#8QK8\Q>?S%.]A$PU]\O7E !<(;IF>:7.;>5X9).576(2G7XS));+_DJ5J6"B2RQ*M(_!#W&QWE<7U$]F!YNB@OH2BM_K&KX$'RWF!AXM M-SCBUS0V9UCPI.>/+)HI)?3G2Y06LSFQJ=$>L\?FCCI.^4HPGZ\P%WI%XGN1 MZR>&VF:[FLOM=F7J76ZY:4RM9W>,3![JNXTB_Y E_A;W,S> S>9+&G9*U''T MZUSJ[6CM:UP=CJ@37&N' M!A[6)U!L>880BC#U)J__RK/R1F1U,=DE+GP3C1VI[BX#CA.&)*)US? MD-"T+-VH8 %S!'\WW=0K*V[ASUY4OE#*UP>_"G%N?H-INF]SM'15'M WJY$G M#4:U,KA-O@1^#(Y?M&/.Y48 UHA/$8!'I++VDX%RKBJ#QYC#C+>^F?:C[#2< M*^^\M,U/PB\Y1,X.CZ_(+BB^W/7% M.)(&?WIC*/I'?TOE5E8,A !(VG(]G+,@ %\UNA& 2_0J!*"=KJ:B(JNR-G%_ M6RL% M2ILQ$0",PA $8!?/' 'PDZ4Y#?> P+]<&]]L:D7QOI_DCWTY":5O./]-R2EE M7"0V?6W^QM(T2"U.Q43^E3>.'(XA@QFDBW4- ;A'T8.LQ.K_[*9J8<5FJ>P+ MQ"IY#2@ZXN(X.5+?G]%*Q$33FLT^4FYL"OB]=,QIKI ME>@N!-#XRQOJ38QY MYCIR-*G^"AR55]X$#Z7G>X[0-5\T>4M?NI$?T6!N[!0'&%T&S5/M))[T M> >LE*6L/#1F\"9# /[%B-I_3I1C9UKI?*8 -;AE.X9\@_ M)^3<=A[#TQC9J&%"[ MCPV15)UFJATT^KG_:1-'2-BEH?JA_A_CO,EONK3:E+BMLK;C9IU.*EH6JE7C M+B,"VHE#7X;)9"Q3;.()-@'HJ,8S/C5EBQE\(=:4-JBQ0O*HCL')-5XK;,=;I4"++$"'4+J: +11U /X3GAQ[.^?(L 'W 2C M>?C$N7>RW0Z8H_F2(G.B?B/6/(Q!YOOG%RI%?/TO^HR?-ZI= M1HG(6WJSO$C>C MDF(14NK3?G=;_=6,R26.&[Y$XQXZLE&@]H? M'X!^I7K&\S;<8G7.>>.YR7^2LDRF5$7+0_]-3/O\MVNP9I^A)ZJ50&"!NS<%Y]!07MO\K+F1QANWN2'_0*2( &0^ASS558-YUN-- M37J2986T7U\ GY!A]H=(3&]"K)D-VRPFJ\6YF\DJ_'5Y@M4QZ&FC+XG^MY@];>GF+BO]M?R>%CN_8PW%L;H:I&GUZ9I*WE?*C0F46Y06HQHE?3 M_#Q,7Z]LS9.BE =92?[?'512D&]Q_SW%:?%E2Q1J%-[9,W'X=YR:L+5@48]$ M%C5U_E6V2"25DFH;@<_&4N8<71Q3J\DY<":4XE)-9.L$IHE#3D:>$O15_E3*6@$ V?/%F_3F?/SR^MC'=#O M&DG !VRD.?7QOS\M]^_BJ=,+118H_^3ZR,,Q^Y.3.4J>)^M8O->K',@;$%=- MET>\,30:*94/=;P-/$VS(1PNO?4$Z"=G1NU0;X#+3BU/J1\EW:4,[M1N-N J*L67\^@JG9WEEB7H[ M4?MQ7R?=%SFZ=!,TDW>3E[9O/?2 2B;P;_DGI MP$2H:?/S(">?B;E:6UN*!JTW1TR#MH@U$7L,Q3]/54=S-. MR:7FY:3RL9+^3IKN0:GI^@IA_;7XT9D@*_6#1^"S^59<6^>N%-^YZ5I?B^W^ M!W&N'ZC:+6;/R!8[7)AJ70RI:HI=68VT8J'V*1M!?6->6#/9=*P3-K]5&H=A M,K'QG>1?WB5^+@*<)*( J3.+]_L/?X+7M,-?L?$%:XG*5W#K^S&/%\ZZ6%35 M-R@P7!!*'C>'##E':GE[@X",/7*^.BI6,CC[=;\PC5:IIE!SN:Q=O:T71AO' M9C-E/%T=-D[P1]%B!;*I7X8F#]QAO-](N23O&Z\!\[7*ZS3'K2I>/_BS%;W_ M!#"EOB15YU06.+DGDR"+?S#HTR\H9H1>^\R-'N;!AX9:O]L?Q ,J$D.&WP0J9> (0#ZV>L8LUIGB1&YBP&?9H0Y MEWEOS,T[5'T=TV;!!7H(@*6U=J)!O2=^F7=EY*HI?SITEZ.4OWPI?[QFZM-< M#='&YYV2G\Q^AT1P<#*?V69-R$9ORVV]6/^0&GL?NC7S:(U3B MC#)G[.@902:]7[7X:79Z75DVC&5[']22J";D;&=+(,6.FSK('&.S_P4 0 ,< M2:DJC0S-"(EK7ROX,0;BIG)F,XBXWS<,#-G;%X+>OK(0F>UA]V2J%#&;=ZT6 M3& 2_$43&0G!J$A;;,NSQ$^<[+]Z#K'H=08 MX0#R%AY=DXUL38-">"W"60I<*9-Z?.J_&A&KC_+WL!3A/J?:"!\Y8VHNS\3: MYU9<^U.^(? KV/1SX0?Z%WWL!6>XP:YS9;E$=XH.+DDX?>[/A'M!/2DR!_,X MOU,IUU%>HWB^Z/AM33G-.M+(OW"RF"05>+A,/9F% &2X[;;?[E88])+RR&^, MX!O,4=RMUR5*87QHH>:--ZPAN'LM3^)<*;VSRYXQ?8FCO-'STU;$_*J&L/^3 MW= (ID_ GU%452W=MC=)L0YRK6TM&5*>V>GB6DX59MJ+OD) Z*MB5*Y7D4 " M16[Q+V4C;"OO@RU%RJ_R>\Q\(K 9,23NF))Z1-[?_XYERGPV4$_TFK"-YZWE M-_&19[V#TH\JO"TSAYSEYF?=4$?/=[1;U)B?U#?U2;:TZ?*#^KM:$A$G-_WTT=-@%T STS2_79N.KM5T!JR %NSC2YY* MCAVFT*T>BV5@7 *S\SK+NQE"M%IK&Z31.E'_9GA MJNPH3T"(".]2ANT-&[P M,8Z']WU[]T!L"SWJ"&%PG!X-H^?6*/_4^Y[)>27"G]HNYMC>A-PIA5E[4;E6 MVBG."HQ61-:?7Y-MIFV<9162[#-O(@#2EZ-;4@R92^HKWZ"BI_:590L>3B\= MUO;L33W-'-E^E5"\\B:_9"]*\09GR\U/T+,X2,OQ:M;@<#V02M=,1@;((-MQ MH@E2[@AE_>A23[%>D+^G1 "^F-M65ZPH8@9;7Z&O$ C/R9.-N&G%K"T1/6#] M7B=B2=AIC'/[P'T3[6A 3%?4VX>_#6X;#^KZ9TP.=.=RT*#50(56N7I?/%LA=TM3Q9=5Y3-L]VL)*C*A4 MY/&$UO\V34GD1)^]@L$8CWC66%H2!M;4X1051\&SMVR<88 M;3M3W6;%YL<,36F^!4K619:#^ ,I B7O"G'WN]3#3H+D2Q3^'6JY$OOS* "A>;]-%;"X4IY3[&6CR(]UBZ\/K'A63#,-9K:Q9 AX\\\Z.?'9CX ME3I,A8AI"Y75,N/T*7\WE9;PU)):RKW3<3/.P04+8BL'Y(P<5[W. MX0>@7F'BR-JV9(!$:MJLWM@''6[OK .4GB21NJ0B?9F=KE@>)20GY(< %KZB M](3::A&O+1]GACC=O?N/ ^/]14;]#KR!,=\V8V\W@-7Y,B7=E(%:S?4-3GXR MJ+( ZCNF5*C53]MY [U?1Q1HA+)LOKN++B:2VVFK$PP-DWQGN8H?9\;*DT.S M8ZSF28'QJZP,\9UU!G--%9=1R9M5:"]5MK2VQV!*1?-/*6E?9/IGM4F=3MV7 MLBJH8]QGWA7@Y+R^C*DE3GX5:C Q1K@HDA2WTFC*#)BR/HS U9AD-X6C7\!, M?*HR(^Y[W[1$+C,_323_<^+JC'[5L1.SRDAZWQ)4)-7-#\6'4KV?;@.E1-K_ M5-A5*!7D6FT=[:#06A;1-_#'%GO8&L\>CM25EB[DT9:^F^36KJ*;??>VM\.&W3XWF: 4:F[ZYM%CESZ?2F_BO MH)8%5<&RMG%>'A2DQE/>MY9:.95RL!34MA MGGP_UMN_.A&T@4$=LSC>:U'NRO'FR[&>%)!9.OEM]H,4D1G";ME#)T5T]+J0 MOH)E5Z'7;_&:R!-Q)*XWUY^+_E!Y(."&)UR=5=4P,\T0^FX0WV8%4]ZI,7@> MU$J.R$_[#-R''_L,Y\%XSHS*ANN5!<8S[ZR=W&*&R[T<@OVPK;UL\W_75WC/Y M, XQCEPPQ/5"<"FL9*TMI:U0)>R?];?LZ_Y3/C8%%_=)(PSO'O4QC MK^MT=/VZ,[0HAV+]S*6AEN+]P@:^^,8@2B61D:+O,,N"%9MEHK:JR3Q69SJ< M!J&EP+C&&TJ=41(OY29^W/+80 8C0*92\$X.I@VH_)8T7G%%YL:U(@ M(DT.XEZL6/?!BDJ*5U7&C19[;+C,S%=Z8:2%=;P]EF!)3G??A?5U799C'CO\\HSW! MS-#C0B^UVZWIE0Z/++9B'5C&YQRW6^*[,Z[NK;0RQR=?/)+2PA$GNYRV.L]^ M6+6>9OU62MS9,5U-[%&<8(*<]( "6IM&?]9Y;C MQ69%M&J24%\,(;$^]V_Y['$_G;P:#E2CM,E&F^[8%6>3!.RRIG-'*!\%$:M) M_?M]F/]OB79;>\WDJ^7C:Y< U!>6SOY&OIYGJ;(!F_UVYJZ.^$(\D2ST<^0Z ME0EOI_9@]OWY:IJ7YA-'5\_E.%!W7SA/>9,WOAOGFQ[3R;A]6&+F-5-($I5KN$_D.T#/%:,QI_-;7SQH-A)F1)\BT[:M M\>HO$9;_S0L.SV X:QB*=++S$OGY^RO ME)'TA)/(C/YN;N&O0Y62C0^_A!B\S2S:HA[DKXV"F5L=X3'VV.49:YXYK]* M>H-O>=WKU3/#?%0*/0R4!=TG?/I#]L)#!=Y]YM2M*,R_1>D1-&(\K7&?+,<'$86?ZD* J1S?WSC*I\1/A'$SY&9XMN2DCHS+QPHK;)X\DV4D?\;56G@E)Y6:AAS<[ M#Z'R6+:3;01SRWJW8JT#"\"> EU24)23=Q:C^%K:[*)/K7.F_G#D)]PH"3;P MF'E%W?^"_V"9^APF?+H_HR>IYF"YW=[89]O3XFKW.4-B:CU.@$=10M4T$;V M?4%,,<_89@5O1:D2B3,%%8EL0ZA/YS+;E0MWZXCM]WRF\+(AV-M;?*KL7;R" M8=@-_SX(%TX9-B/N\#[D1F:GOLYQ]K& 9B*^H_WY<5\.%TS6GBX<);D\#+79 M*\T-JCFK;]4B[C=3F?C#;F58=E\9EUO:<+!KC;K6!AI[$5PI>+T3Q:E/D-#8 M_(=,:L$-C7W/Z=0ZQ>(N#_-9BS%O_0=T_;N3M;X$SL*-")YQ;D4+WK=OTUBI M>&]GZSQ65)JGQ:B*YG4#+#UNU:;/IOSXY!L+L/:)2NWT?ENOD+JD/KJ^PBD; MEV*_SWSZ8&6F.$Z&8QW;2%*ZN>$?Q4QJ&5'O6B]+'7> M-9!C;J-GO35>-;S97MS(#A@K M_9>(6=JJM_8P3TZB!5:66=SG9VK3)(L:WA&R9H+A+L#&!^'IPY[&OA4^UW+S M#T,O%&C/,4XDI^+_1,@2NV29R'HJ[?1N1_0:?ZRM KM<)4N;+5W4"S'HE!0O M9D5O/*6O!)&Q8C^=GS5J6B?0\LN%%U#./().K$0W\2\%-DNUYN'L.S2$'@B M[LQ58E-=2\K$O,!CCYK :W&58JCVK?.&W)E$RO5L6:Y:'4"8TC/B3WM?G+LP MJRGK5":=B J!#0(P9T3=.G6-28XQS$84U?^S@FOMID?TA&A_TOH^J.5M%R^# M XD<]Q1YT@9:R2L82R(;Q-.3A>:48+#">[4N><2]:#]2XHT:%HVZ)V@BX8JW M6!NB%R74*I)^$^,Z#,7S4-Z^'RAJ6"R*[!9U7F[,#/+CF.;?::N:VA9$PZ=B MI,]0H9UQ[[-SQ9JW> MJ-WP[7/IW$/*AIA:25WMNJ_T;5KID+0WRRJ$;?84Y'_Y#6ZB$J!_^%,Y M3',,;65O3E-NM4E(*;@9&U(A.=@K>HX '!DDIANX]^?[TA3NG[V_=<(Q M6@W-M77D^WJI%IERM](WKF=P6W$^JASTL:Z.CECK6')SMO2VCSU== W9H,]3 M]R,8Z_I]Y%A-8QVAU^08-J='_T=Y7!L7U?&U>)$$"F9#@&MPA$-PA M&20$"^X>9((%&V"0D #! P0([N[N[L%AD. P0'!FT D06'[O6[OO[I>MK=K: M_>]6O1^>;[>[NOL^Y_1S[ND^%]VC^XO95L\?]3+%APLW'5PA>%4;2R>4E=9ZE M_NNG376@Y@Q"1_IK4^$-N=.T8,:*1>BX1ZF_8, &3 M+E%^9J/5BKE #3IW.7\_OFNRCO GH".!>AUDQU@VRC^5&YUV/O"KVQ*2QH6! M73P86X0N)GYOQ_DAHLTX*#TE6HW%RAL$2,Y$Z4"FY?$;W%)_QI[BS?RX]JS( M@8$QYF!4_J3I^^Q-]5*:[.LM8:<5)##&6!'N+>3.*<43IDG%>1[_5KQ;[17H ML]=MR#L@R.& =W-9++9/=O!M1C.A0#/)E[QW*?'L972:O\-IY.\ F9;4Q3@' M-XVLC\.GF9(N._;AP5UF4).8D4B'QAC?4GV"B$B^7'\YD$,1&-U'0]42M74W?4J')#)!'3:Z^1<1A MO%S]A=$M([^++C;:WH1Q!5=^SV%FJN<__=G@O_/8[-5%@5ZC=PN379??'/Z MA"!8<#""-JD\'R^G*5!TW1DUF!4?XNRM\9'Q';\#:S'3O9;G^K=B#O\-V8U- M@5.DR1M:8UCO@R=CJ]7Z>6XPR]217E5CK M!_[2>[^+%X'@#5KR)597Q6"M>T G,L] M,J(8S-;5N>8I_29H)MV$U._\3:PW+9UTQ(VN0Z$QA2"DT8;G]5=5H6_>EG4^ M#8&"DJ]TD?'Q1_DICL:JAN0K&.M5QWKI%$WW).WEM!/D;'NZ9&(X5'59Z.C] M.?U\8@E=T+-@/%35"#\T2WB.$5%)Y5N48R1 +7DIWG?@-=#?LBLUG3>/^=K< MP.(E_#?=5+/IEP4M(9/'RIT!:AY;RZ@A8 V4Y[7:I_)^7!_%!#)WH>GE,PQ: MI1@<4^KS7 7!3+/N (M= ] "RH]AL;((J%?J][7C'BE2Y25C%][Q3$QTUM,? M]?RX3A^DW$+;J3ONQX,:*]AHN0C\M176XS'O@!@SG:@7B]LUB4$%7ADZX0XX M43PW&B,9E-2RVF@U5)HY$C!,:*[1ZQM;+N(L1] U7U]/LDZD^GJ.'U18PU64 MP>V3(\J%KS:'.8Z(JJ@Z+VG /A7=/BTI'5A]%XDV)_E0Q/O]6DNZL=80&>18 M \)!?9"@-.I7^LF';Y)>1[XE.[Y42O439RF^8I,NQ)RUSV:B/]J&$3Q@=VTJ M8S M52.SI_OE]Q1^U.-@_2DPP[7SUKW!B+>O:(4.ZVTA-$%+Y\I&>JKHP%LP M;UA5;?"D(WA!<58"8LML/&FX[3E>N)O1WW:I-^[78H,OGQ=BY6CK'!='WLH])%J:2E?L=<'4X;W,;.VK)3VETADR;H MC8="G ());$#C=5XOH#TD]UTAEIA,>O!).+UX!<_?;MV3711GGW<+M[M='7? MOIKW+'WS._4P[2Z_(:[]+EMB?!:99$F[23"7 DU^-*Q&O,?I]\6(*MBUT;DS M-5"RT.G5!WF&CSW@1==:I%./2PG:_O0=7%8AG8%K0*7C,'F[E=!?*!H1CIE[ M,^WU%&.)EM"P&9VR(1XI?, W^J"62LAO@SN7]RW60AE,"!E_5%6QN/>Q=]?< M_M8\)EBBGP8XS]MQ58C5_&);IE&$*M9_W);?JW0RNU1YE2!:MHH-,7 *NB4M MSQ,(;QSK40%O4W<>[\OY/[?B,YLOW]^7>%-R<:<)](;UKR-L6=[%? M"ODKBQM%FXV82*@*YZJ%K05< K(Q6L#KZL.C=P&^ P#.U3IC M,6/.3ET#OQ@B._HZOMX2.&H<,5L#PUBSO>&TFB,SM((7T+6:3_']G?P+J_A;DM5>/ES3^$&VZ;-]P%A67E(]H\/ZWJ9 M]5_CP;2?I=-,\$LN9>AD98% W$%)V?SX2&>T[:3J8GO!""5WRWZ[0%W$5O+V MJ8^OL-5M_-EH7UK;\O>$1"*N;XHI%.3.X/=Z4&6YJ7-A^(>S'8MFV,V:V[B1 MMU;R0*B;[T-%1GB%Y:=M$;!$W/& [+$2)U%(U@$CCV=3KPK25-%GFLL@"*ZS M5;,9A(,U[>XEU&#G KC.2A5+VLV\M((_.B2ZEZ1[TXCSTE#^5M])9\MR^Z5 MS>=^,&Q_;9]UKM7=JO31P]1Q5C^,)3N!CY9LT^$1S^L^7,F-2;/TX]X!3905 MNYJ34V$U0J@IL=&<<;\1,+LXP MQ/UD:#?*-;H_SD.!AZ>T:.ICU.\*NUO6.K@$XQV !SQD@R7$Q-\!7R(V_=S7 M_&CJXGIOQ1H>XUV#A]+?G@:-(=3:4'F' T'<-^+8?(OZK_GHY3R5Q[QN()-2 M1% #94Y]]\7!BR'G%NZ9$'KQC/X"U]#1C6(Y3NNFO>.]_J_2 M_"JQX##6F#$260LU,_:9G[#7,\$Q:RV_=7IK*F(S=-9NDS)#1^5XU++6#2). MT 7]'YNMTR_V[4$RJCB[IBH&AGEYJ4*3$4R*3T!F?"9XR!0EL9 (G:U$/GUY M:]:_.9T5F?86SELH6'7A51"QAI8WO0EHXY@:7:"*"CK@6U&"4//6LWGX[ZJ-84=V7;7HK%#UJ2-#MRM*E5EC\#STF(HOA/#(T5Y+6:@SS[C0+UI;+S M+D10)N=%_3HQ6I8M8/:#Z8[9D!2NL*.:FMN'#9:^E/MP^-)-QU&1CCA&MH^-J%N@$_0C* R9\#%2FNTSK%%&M( 4M*\_ JEK*F':AC?YE" MIW]:[.28F]P>ZIHU2M.V+\=#X2G MA[A-QH5LM#6L\Z5R ^EY96(#> INI9,@62HV6KI<^(<(XX1V'?/&3.<C&I* M4E9O%;![T2HAMP?W3"0J5PA?;@_RXVUNY.6__>4+&T3S?F!" M$?[MVB=IQ$()K$82_.Z]X) G-K@IF-L6E 2Q2!T1MA_L^CU:J#6A;FN49&E$ M1,L\,(=6K)O4N5<8K^Y.R;H0CN2_5;S6?SGV^+YW@^)VH&IQ.35=_$C09T#J M>71/.UESX\J#WC"+3ZY#EK?$!Z7NQ0);P=%20T9_.O5&W'DKV0BE4S;75>4/ M-MHL>^APCP7^OE^X S3;O^2UA&([?TY@A"=O29'M')9 QRB6E<'O"<9Z_9/6G>+1,P\F_M0Q1^ M5\5B;LP;(&A3FD/Z^M7$W.1!%KP$T(IXXC,7BEY=]]TJ6VH.#L)+GY73+YL[ MEO=M PLUIUBR#:?IA+4U*-0L]C@Y8((_Q P\C8Y7!_@T=89*R)]:;4;+^*+D/(5Z-HQUYKA+'72E$6J@AE 8 MGVM!K[:-"#3<;4FT/# L)U_C77CX'NQ/'HP#Q7S^.]X34U\.-,Y9*?V-!L+9 MW^R7E@,I4)J6M:J-8*JN^I/[[42I(I?WF''Z[#I\*(HQ4"BF/>!]N^W483[* M-&(C\F3P789NF&Y$IU;BU$B;WWIIHT3M@S2AZ MJOY<$N?-K!:A?/>CM#:"\%AIR@YB"($2)4 "J./<>QX=2=OI-_@TCQU7.TW( MZN)&HA4:N![+FJ?J@JGM""#4BH5A+TCD@0*-MX7=?&CMP#@LTV##G!//VJ:9\S$.-D O[G^SM[IQE4,+Y[UQVM*9:>X99PRPP"NOU418[EE[%AF?\,9VW1.FMLW-=%:!:%V-( M31:MV8G9X)YX)5?0Y% '6M,U936[6W;KF!@:RE'4E9+82:CTT+ MO -DL;;P]4P4<:1/%=?5LV2'<40K_MOW%%9CY$K\AKA;B&:=?B!UC@U!QRL# MN#H[6$D_U3VD!_1(SXAKWVI:+/73RP2Z> _\XC 2&?R' $V1;79O=RI]KO8_ M44KEORJ;4$&#GBDB;9QVZW,D%AB3O,*_X/@SMQ'TJP6UM7.(GRMC,Z$U;!E. MQV,@=.1-UC7*>]!.V0BG<;[\F%9 U]VJFZO#^H4K.&V=AG\>P._,JUJ*B3-\ M^S-,_P<@%FM7%HE$;N:1AX-=%HY[*T"V03ED#T_6_;?B.Z23=C@#$Q%2I5>! M F*^S0;'0+\25X]4>ZTQD2:9_./1M+D^\2R'->4Z[L\O2\V\-^=PD!83PQN< MBV4%'UXXC&=9W@&S9>,1NFK"P0()ZL/4)\?6TD>;-J>Y:-:GA,):WT&I(\5J ME71_O4UMMS(Z(I2K]NI.&_HXZ>T0)=TYF&[ZT'-&NJGVT(K'Z/$GIL_TWY!1 M'5:JE>-E&U)NXY\Y_8J'F2,8"Z'*\I-EF]A_<"_!:BZ=IM."4S?4R-W@*81) MXUN!U>:&P5LB^"U+:T^/ >% J."@P [Q^IBUR^03=\&SP\A4,?<(4H\=4G)U M!HP==@5=UPP<"IVB0YMIRQ_HN&RE,JC8EIG*Z6*,&" JLA_=(XBX T!UW%1J M*%QCQUF*Y]\=E*R-OII67>E.;F*^\-;]!EU=-SI9'BZ"^I(DR!DHOT7@-)DB M\^V6YH#?8W7F8Z,#.M'J85L MH(0^224Q!3.@K9Q?UH4\GQTE'BL"*XFT1;%V^F$YW<<#IR;AH>7$+$3.F5@9 M8PV"Q_BVM\Q/[@![@S]EH"6S/D7:))H2^S =!@%S\H_,62;]/Q=5JL/&IIC# MHBN&FLB*.Z ZP/9>.=UU]5C=^F$$V2JS2_(AO M,_^QK'2OO]B%&J;MZKS?D^IZZ][R] \=Q\*"G#I>W_Y>L _GJL:&L15+OOC7 M9_W^%VPY58II81B"&%48(7\:PT&G#O:E,[H,;:7*19>+W"Y3<4TBX^2=.[U] MPE2,MOHFW(L6Q--M[H!'42>KRH&SP\JA3%$O@I5,&3]%!'!&S]R8;H"(1)5; M=M/(4=C2'+>ORKR7&[J.'[_BV,:^:Z6RVB,6T'UL_KN(,X)IB7HRCHPYR37344 9I\AY(>(Z#9).X MH:,L3J%TO/N]&^Y^&@;J@$YFJTP_BKV)F!'< M*62BSEB(T%2Y:?K(=7,LB(I&HO^C_2@FBK7S#^X M#D=JA%>^W0'I,TUR.K1/0ZJ"T@_NMQX;]7]]Y>G_Q'_B/_&?^/\+.CHU%;]L M+>CJ_F2T#1J'I\>7&)'UIC]3N^HX(<8HN@/P;B/O )4[X#CZMLUA-[DOJH(H M=LR%9;6U#?XWN6 M7NQ#B>VIV\Y263FCJ9HR,MJJ? G&D$XD 1OP9G.%M[;;]J:MN/> MP+D8&PZC@/I#J:H-<9K'MMDMI$O^%O()%$&DXT)3#%^^T /JD(2?;\R]%2@ MJVW_-&/3KT*D^]1$BRHI!7,D90<3H085;^@/[E;H*?5MUSJ4J MGCO@H^ >'*,([*)Q(U_-(['(/@E".4/*PTXH/B2<>LR_<5I"D-.>84B2#!C! M7DTCTF*I[/+!TC!G0B?;A<.$)BPE^UY^9U0#02U&@7YS?Y-=5@]U@\_%X**N MV;C(Z+LYF*YUUL]*L=;IF!8+#]KS?G1&[T7[\VF'*?(548OO"3IG V68DAP_ MC\2OV1RSQA,Y@HVB7-ZU8,N[3LJKO(=";L%ITK>-9;9+_@.U'4=T6S)CD-MG M?ZE80_^=+GHUJ/Q(+[%>5MND*)P?C3BH\I==R<;I)47+8!_<^*>2/_%V7 UH M^9$K*?EVD\OZ!;&+W<1CK[!DHE]C$WW[R%:NVW/5LXAF=BK7SKT6BQG0 5#: MX[TJ$H8XUP(K=B(GZ-W]Y(<>6CHLT1N&Q@;]/CG4":BNRP6U%C3E0,8&3P;U M%D-]\FL<##3%%3YPL%-Z2&=0,WOX=C;*3S-$?OW[]:Q?T\8U-RGB8"1: #W, MX69:E/FH>:S-)DN!:OG/CV_?6L@$_6;7>0XM&J/%F=2'TQLK^%!JH=PP64N' M3<8!I@^>G-Z^D(8&.)DR\@M91- L&_$AC0JF,%MI&8Z!BD=7>4Y0-L;/0\OT M>%4Z$K!P*)4"Z1B-7D52NDBFS2NP^DQ=N KE]"&94X JB0)S=)TKWXU\I5U] M6^[/I.M?V-'= >*B3(K?6J,*JQ5C2,+IMV-@G)/6OJ?0ZXHL-O9'6 MU"J5\+'T\J2I39CN/7FA+3(N@#$+=QTG*05)C#T5H'@O"11Q1J,N\@C$3"]< MN%@R"%Z(/*>UQ5)60SDF%NT]LOXP)1 9BV>$%;92(8T$KT14/&B(52WT?$9O M\GG_K.P0TB_F%RG:0/\[U7=+-?Q< &-2PV@L&F$LK=UD^%XW4'==^,QR-WER MKFZPEDKQB#EHZ_$U8 #,9#<.M3/L[A1M+;X]D->S(FR?F;8S"+-OAGG&###9 M_R65_2Q#9OL_I ;_[X(S$!UWZ79S-GQOZL:'SJ9/M9,EI>WCAL\H#MBPA!9 M%)*I!H%>Z@E0I':10(:6-.KYAXE\GGY@J:3/2 *WHWJLWBQ*D[;2>#:(4 M>*FW\3@]%W= 6. .C_9;IL.S/T7)PF&. LO<;O-G]0GN@_)=FQD:8?X!.K(; MG#D,_%6A-3%1GNK8WLNMGOY/=%8T?FS&8($T#%;$I[D.SZ V@2LB:4R/OAM9 M>>OXY9;=!T8LS^JJM@M$-AK\GF/"I#(QU9+%"*XFL)NQ[:0_K>MK6&D\^6,,3V]AOB2,W$YT-K3)IG'!Q^5VN'*6&V M>+U]P=E*;H:'&9ES[S7';AE="_6BK]XK[!L:I(<7]*TU"2W*TXH[[Z'_-%B6 M0Z@V.&KL2<6UHX_&98^UCF&:15+A?V,$XYB"L!WH<9C]ON/^0GNQJ7"@!^-(.#C-A$:+?,AWI&"BX('[NU!HB6URFC MQ7?U'5%DR0]DRRM"$!V[9B/3,L&$Q3RW$ M]O;VBQ_9I[Q98?CTX? LFD>NJX%C*WK76 2Y= *E<&OH;-9>P3'[-<:&E3Q1 M-ZSR4OE:W+;:J":N73V)\.H=6FDKO.\ZJSZ9RNN2L+0 7^Q3LC%C;V([=;V# MU+Z*G=!3K1?/HZ=CC*6#SM.4=9,]FZN(#,_#9!H'&CIF T1]?KR[ S;$NYR% M^VVZ-)-\S^H U=K_A#ZG8'7&W4Y;C< ;13=T"C?[P- MU)9HO4SBB>R)[G_L+HHVT;:A)6U+/?+\>/4WU[@XCK[[5FBGW@7X3O/W\JJB MZZE&$=I.K0Z0=J)^Z\_*OQ-[?#?:.V=XU$! M<=I8BHN+"^:;0Y;Q5!LLDDET[K/U%"0&Z_"AOC1(EI*Z,U :YAWA00Q IT3. MCO$?011GV0RTWQ7S#;!$X^[,/D,;,R4OB-(B/"[,X^:H=2I"SPIF!40=-@92 MD]7G$ M;U$M?[[.#XKN$0(&Z,_F$'L'YH8@!INELDJS)YP0C3L@UO,.<-PW\OQ:EW+H M2Y^N+!2\(E%L]BSA>-3S?;_*JRX\"-W50#V5[/F^#/$M[1TPV,'ZU\.^M_J^ M91KO7W?_+2TW27]UY,:XU0<#N=%+\B?:Q6H@JB()%^H&EVK5@Y&U\A>*F8], M1#V:48)Y.7Q$0>K2:PIQQIG(BUB']2_SO3I<)'^\!B_+70?$F$=[O^UYV(Y- M$E9S1*0W/2QDC3K7C<)EJ"04>HC,A,<#G Y#\. L1F+UDD)8^Z;>OD]EH^[31]+06B=\@P$#0OB7>B16U]# MHKB.&<:"BK@ZRJ^@8&\:[)JW/4_-\&+S^G=6J?A0>:MA\6)9_H_G> %O*LC' M/JJR8S2AW."SWH1]U.>^ M@J]Y!^#>OR^%E;5H[TW6<'6D_]>MEJBE8>POAR+B^DIC+^$:@-[3.IB M9P6_-@?3BVS2UM4AMKG7]UE8F09S[X!5EDJZ:X7^Y(-WOM_[\,V>??YBM'FZ M-/<*]9"_F:28C;O>3(3BP!9S-=A-1G M !S[(60C8X\0$ CZ+C;;AO4OO;T 89!>T?[@'3%=F/G/A=3.[&^IF+Z<:9,W M^J05)4,%>27]@^3'3):?PX"=K]AF 0I96=KJYEIL9U@DFMKWZFN:MC'V)F08&!/J# M&HB-5QJWX^.-S+^_.&-(" -DLN2) H88!+P>:24.,IB M3I%'"9_Q.$Z&C%+ -0'L5#A*'R8DRE#$3+L=MF/N32R/J9_7GO@508&T89L>/'P5)?Q5$V#'D >-S= MM)]!TN>TP3Q%6)/X7OL4@WR[F0.0UW8)5E?((E[ED&R!U2W.D6_4"/YU$:!B M:H(:J(_7X+L8_;[A"C>_ WB>WI-!+D \ #," &B"N%V3>2,^"(;'.%2MI;7O M=[L8)10TO_,+KH@+] _08P;C8M/U!8-D@]9QYBX0H.*!)R3:_%:-T MSE IT$'"4E Z5/!(R9*]Y;=CR,/[H;!3D/13O +)O50& R]_1A1J4A[2/&1? M UX\?$ R:G?+$ZX^IYI07\WXT+PU)HH-*X>OW] %S+T?97LR[?A'4PA2_M%BRQQ=@%&ZPL?)O;JWSXO,%B6]7&L61QD"FU^L6.+J:VM M$02 9-BL=]OOB31+Z;O&.+04+RD$0NVCSLWZ?M MDFS A@'@OP"P)MY-_N_?^/K?!:-O_Y7N#Z@\M.S&V/E4,2:?B2IUS7?O[.(Z M\JR"?DK ?4Y"UN7]J0 CO]06A<1]U.W'#N?*1XZ>N1C+':F;:W>QQFA)T?@/ MLNS?MOB_^3DK04@:G[MDRGT32ZY+CP^ 1,K40FPH)7_1P%9W94@%5RDBI=#S M\XN^Q>M01RC.=%1^R6Z[F&>'H]XFQD9X!]\S8 M[T&G=8I]7<$24Z+]:.I$2OF!B">4?$-7$S@^Y?^<(UZP- [WS* V]P:Y'AI% MW[ F%S]/5F%^S8J.6N,[+ULV-%8!R=61J7O-/>TG&W(,B7(U.M^NV: Z9'"X MDK"S0F6D."V;:LC0)(26R9;K^>8_T?I<-W&N:52;+MT8>+NQ?$"4(&2E$O%Q MH$X)B;B5J+@#]K/O (YA)%R)-]KFE%AH-B;8AQ)8FFC5+[)/#C=4SL<&OQO[ MJ=$L,\S8\JG.01_Z^Z,2,4M7UZY#Z(SZ:,^@5#FTEK_PG;.CHJ_&F0IE@L3E&%:B;1(.S5'?"-FNY\R9]1(6CL MFX2XPT6.W?;:T2G^[PK8) IT*^/L/^=R$VFQTXX;KCMEW@;99>3'.L'&Q@>R M?&AJT+."DP'LO^E->?./T!?E^[U7!PN$WU^^PG\S=JWH&N%B)#<@_1FF26T> M:RV"?;A7\(=RQX^!>NB<#X3R<-T( MTQ:X%BA6=]Q4XP2=,5V0" >599D2Z%=\_R+F^"$J/ZYWX6][Z/L2)DPOEG4+ M2=S+B\S'']"GVI'8U78-^A'%MQ$ZW9<3/^!F_!K^U,LYA"4<,E$:S0'< ^A M\,]90']_E#@.;"TI,NDZY-L_V6N&Z7Y[5BT[<8XS524!<<)%UC9&*B3HOL=9 MOM*$8=T!#-UWP)S-[7<,N&["#O\ 3C13K#[)$R46_2B<5R9Y)J\@^3Q5&T,' M!II/O(R.-6+Y1@'OQQV%\\.9IDR>SB_)?P#43R&@]88;;]/[?E[?:FN^0Q*+ M^:6X> CB47<'=7_'$BGQ)QR_8LGTW_W'RH"."G2?0,MXY:_%O_D[ONOI. TT M>_$A49MDPT[%\REFFP!"PE?VT&@F9R6PFBK:9 M09A2JC]Z\.:K?]NI)9W! M4MNLK@RR+V/1G']) D+W?7E,=-1LO P:>*VZ_&EM^(WP':/O?GLQP@V[?"(Y?GZ@_3.SE/*EW ML;N5Y:1_ZM46C+<1UT6Y**%N)VWE7!BQXFDY:H)"TB$CXSYE"/J7&2#-Z)#A M"]0$:Z?H"1RJ$I/R%,1N!8URZ3NL6G=I;MN*7L[&I,Q6[_S_\3O6B,O05.M]R&\M_;?@K""](TIO6Q.%II$8!-E M\AD,6$'3\1QAPCX$1+6QU4!Q3MQ@:0>FWK+>;B*[IR.R1OD;M24CR&LM;Q>&N\3?'][*MD>[9 MCG>I";VQJ>K7T9^5"_S:(0UYGG#UAXY!+K[NN7T\>63Q;DI++2Y1T(T<%&T2 M2UG6. 0/4S/X[1F31YD]&]9H;4D'\:Y0B,KGMQ;"3R*&+I4NCS6A"LKP,@DU MIKF$ZDRVZUSKM;ACDQ P9E4G.DZYHPD57S="&CN$_\?+W>0A2+ -P6D8/OYX MF+!6A2L('J019_R F&!;@C=_I/VI#U5C,MFWYGB7P7'O+:XRF/)ZRJ^+M([DE@=AQ>1PEERR$!^ M:.:5^A9/BT*DJ]SBIQ/9[D6H@P.$_W6&&WF-20884V)1%;E24[J/YU/".4!N M-C;E;$@3<&C8+E;5W#YUB*AM\$JR&L)]^2ELGRW3XZ6$.$']U8-434:F<'*" M4E&24$0D_KYF\,KV*$'LJV^34;G>8?OW@Q).ONXS"(Y=\)I.8M2[:#EX7AVU M:K" )(F?B0]:6#8<>B20&; ?$:%K#,84D2:T2YQ=X6MI3)_56W=Z^7BX:V@C M:2.2YW:_;_;RB8$R$P?C(4E08<1/X?I5!W- M,;4QW#-,.,)+G ZA*7_ATN>FI?ZB0F+"K4P.1"4X4O\QEVI3RMQ$%(=DQTW] MH4<+<=R.;M7KH$W;K]HT2N7^G4)D":0-)9X.3,QI;T+(QTGF[]GI6[IC4!]3 MT5Z6TV^ERUR9PZRTAWO$;@Z'61>NR!1]<)@A)^5*T8J&S65JR% W1)PIEQFJ M!"I;@R1PF#&N.Z-<])1\-DK*.*_9[$9*M@[XJY]X(/*\!8GO]=+#[J-^\4EW M!R[Q)(]CH_X7CXF;#. M[4RD_FST0D==Y#CRX/0.,-(U_-=KW/^?X'_WZ[\ 4$L#!!0 ( )"(@5B[ M.R-A=G8 -=Z - :'EE>#$P:U\S+FIP9Z2Z!5R431OH?=-2@@A(@W2* M=(9XWSG?.US>_@7MGAMDK)O[7 MS$!GH:L MHR$M 0 !P< <+ ? +H O >>(2.C(",]0T%!045]AH:!BXF!CHY! MB/,2"Y>4B)R,E(B$A(+Z#1T%)3,5"0D]#P/S6S9.3DYR.CXA7G;!-QR<['\: M@4-%1<5 QR# Q"1@?TWRFOW_]0-M!UX\ Z[AAQ#@* 'X%W (+^"@70 Y3$XD MN+\>X)\'#AX!$0D9Y1DJ&CJL0BTV ^'@ "/B("$A(@(*_6"E0.(+Y!P7K.] M0WZI]!F%T@Z7W3WK[^@?&)R:GIF=FY^;7U MC)<_ M%5X@(KUF0\9YIX3RV>XE);OO,URQJ*S*#E0J#N53O"_V8VCXU)QK-&=_5/M+ ML_]GBOG]?]+LWXK]1Z]Y ,!#N8\A!> "'!S3Y_M@T:?:UA+<(\&:#.1+ ]A M,9L++['>A %?QS37KQ5.B SJ^I\V[GXCM^!%7<^)-(/XE=SH;B)V1(DFU37F M5QYZ+_(>5*" *\01KDC:R*[LOVY9%TE@7C"!GC[L(^L']#U\S8!GTS3&P5C,QM9E8C^Q! ML(:]RA148 +DX26^V815W==\DY2+MKBY[L.J)(X+_)54;:SU&>"+>@F+,ZP3 M'GI\N,U*[;Q886+*7N_]D0B8R:[R7OA+[G]:MV!B.HK^TWJ;Y=\9,DPJ3&8)$L#B?HI?/C:MLP)5RUNZ/73X(1\).&H M"N3Z&[G[/]9Y?0S[ONGL*O_%/]JP_F6C/\VS'BG ##D> C.1&8)\L-^\"B.. MA^KEWPJ(&\FZ4 YL""*($EVJLR[07.%FGRLHB1)SJO,VQ\Q'U/8?B1+CJHLV M@2P,:D5J 4LE+0,+D(62/6029G:E^@:76(8]C4(@.Y@>EK*\;,^DB@L0<.&\ M@[O_R)OWJNK^-_(P7L3UG)#9@U%Z#5REN!%ZOY#YBB5(&YC*KNI>3*^!F5D; MF,RN%E],.M!FM,^\#P:T_^H>_R2CMOV,/85\.4C>V:X9 E+@D'=-8A':N3U? M[H(H!F[-49N,7IL,8):'"WM3%(X%_.(3R&5T/8)%*4JA2)C!NXI65.=#&*S(L&"& M?IF)/%'D_,1@=_FX"X?$J_AJ3P9E/!*)S_OT?ASNL@!P1_MD*0D!>\?N&XGL MJPC'WO\E&]C3SF)%NZ?[ZPK& HE[<#],1_A8E;JQ^CU1S (TF'RZ7@S_J.A% M#\?PRTI./.)UQT&T^;=P@ M;!\URE7P5U-(QA8B!U ;:IT\.KIVN.+#_T77X4%B7G FA[WJ";+.Q;XEL>K MB#(>BY4'X-88PK1L 1C#+;59KV0O2_-0A"S56:\L+S-1QOXU:/ZD=Q08Z7'J MLJ6;DG>_D824X*7*..(/M!Y:%B[ = :<6R,*+3R'9_?*%;JCRUXZ%SF@)O7 MN9S+//PQ*. <@C1T!#F2(1>:KQ$>)+\Q]QXFS\.']S'<7TGCQ?'(&"E'=WUB M\(R]S&Y7)KP22;/2Z:'R%3WF4$-DV&54,?WH;FK-AN!(=I,N M#Q\]-L!+84>[3HGQ?5.1C?9WT=8XROC0SYH;XVD^C>+B)!T-UIBR,%NK*@]5 M8JGLB:(Z$/5;KS5AS(@T'=Q--PV@CG(DXO\[#I\H0T!A\*R&%"[S/^E'<(V#M0A^OKRX<3QPWMP(WGQ05J M_3U#\/K14\G!YJS9Z218['KLV@0).X3R8!%' KZH@H\7;R.!R[5_F.NB?NMX6M4/2X M+Q7C&9R;K@#6P2[(X_U0;,_+J8D^D(5+O\M@43PP.+GI,;E'8==K(/-)^,]H MJ[Z2FAG 6'S%N7]W/D*2E/_O/UT+@<8[\Q"'*WO(4YY,%.3FRK(J*,G-;6V MI1&W+3\>2(EF+.4]\(.<0^"2B9].1M*Q'E;2S)Z]'(\52X_51$/(,!A)1?:" M&66+%29!JU\(G%#J9Y;)<'!_"9ZTM,)/N^!TO@Y>ZYKVY#\29#>$&?O&_33D ME.7O8IMJ82P9.'?ZBB4#]%'[28JDT9XXW$U'S/V^SH&I">NY(TO'*VEO3IP? M#]X?_NFV"7_]#H%+)5YJX[<5/KJ;]H%Y*N'P[*]<4?(;6.YHVXY&\W?($;V_ M$!(^>E!!#Y&$X92[>IR2VOE%Q<:>"O4F"0]E(CY]+N*+*-F_1RQ79+/:&$>9-1['&L@[A[I MQ\WX7>Q)A>S35ND?G>_;ZG>9#8W/A*7^M:>!-@<4%IX.H#SPQ7T&G"8VHYR_>RR+J M3^ZV[C$/@CMDMJ/C"0]"#U(BC!KP(NP)K@5>?@8G8/+/"0\''Q%7).Y=9O,@ M]V/7#*#6&B"EF[C[;U4><#-6M 'K>[DIBBKKDE55PY8GEN]BH:)MOW+>@GH617O>;+E-$0E]"%8B2Y.9%--0SU7534++M[I&][0DE \UTRV62Q@" M.M)$Z2@2;_^AX;B^Q_\ MWBD.KO)GB'*T8SVV',%R<[IV(3%*.E5R4U^F/VXI3#?[886X\!"EY57M%D;I M?JQ$)5+ID1?B*Y>;*->7DP-?^V1)C[HGJH9.K3M^L76JJ-HJ+1W^.=R8X9GW M[DXC>/Q(]ZHFS,%V?Y:>[#,+B,/P7 7,/ZQR&_$5Q@%;R"%6"N^A+S<""*N2+= MFHNOL-3-.IL"<<<:\*%5"5N__E(OS'ST'H?N*6_'BO\?A8"&.9Q*QZ6%5=U)2OK8*Q M25Y.@UF7R&5Z)G>,)W$HD,<;2\,D40I0BKY4:>&2;JHD=V,;Y\\+[?%8:6(' MYETP*GV2ZHM]<1 L4KT <8\82/XDN:T<6/#D"P5@O;[P 2-CQ6# A[@U[!(* M_''!8Y%WU\K%;V]58'@]QDOVFA8*I'\[S]0B._>.AF"ZL MZI_JVMX3Y53-N%GM8LMW'/5+WE3QF]G!0H1-YW <@,!8D.: MZ7+T[K)2WF,$7Q84:K4A(X =PV,A/'"9M2]>N 7>+%X-T.!?X(&=-:R"Q! M%BLM_X (&P,&%8-/5_D(+F.M:7^-D;:_O;%,OR+_QQL"AW)00 AE2_2%=8Z7 M9"&3YEX]C]OSSZ$-^DG=MM?+_#_3S^?Q)Y0,TT7]Y'I)/=0O*Z8LN@?0/]A/ M=X_E<*&V:.W&5YG2>]>:5%P.]M-,4?L4'SV3E]2O;=0D?2>.JPA;8!11A!R@ MP.M^8;_ZSP]Q_O]YCX4;6%[AL*Q_,=H>NH:;SA8WH7O*NS:4LJ8Q:_#K'-ES80+WG.Q)T@A<][Q2Q9$Y/W8PM M"/83D^3/XJ! >=2"?BW#>.B76L%P]!5"FM^R.25Y/ZD(^G[$T&H>[;+S7A65 MECV:X\8?%,H6L=2,Y2P*VMD8H]!M;6SQM5.EHEU]LR%4)Q#AH8OYZ,&[%((? M^7)W$Y0>=TPBF9)?O0X%..2,JB8%0VSB5_M\DF1QX 3A10D$L<"6+*-!ZEQ: MPK\]:XV97R8(O7OD"#Z,'^%2S,IMIS[?:=-.Q0"$A,P04NODQ*3 FDMZ6UL+ M%%39&^64/]^U=\,,I4]SEK_TIEDI1YPNI6*AU3-OL7?[D&G!LAO"]LH ?S> M)XSZ@>,[>^H;%[+:.5$3W\:K\$Z;BN>Q.OQJS[?/EE_PD=,#^X0*$#A87/# MU-.*#W NN=*W/XA! 2K]P6PHT$>V\#00:G"6*T%U6UH$A@*]4^4;VOBY/]B1 MI4B91'2@0$2)04_-5R@P%9'G0)":5I=M;&Z2U)=@-Z(@;]$6=N(T&2)EQ5#V MJR\Z*>QGS,A8-2]*BV."-FT,::?!B&!6VFC"_/?[Y+'SS_%J4;K'Z+Z5IVR7 MY5B,@R6?&2?CI%=2[IL$[-3,)Z4G%.YWW9C=(T*WZIO8N0M(-_@E,:P(B=^U M4Z\Y;Q2-6'2Y1X2L762U>2E]^/AKZ=,/#JFURMK4< V2<+YA]\BJ'P1][-Z' MFYX[*^7EVA)50;Y(N1U'S6<]3(N\$2)RH*X;HJ[;^B:_^3VT!52*=?;OQM7[ M;F"J(LMSG!':,+U8?TW(;L>HC9)>1&3P>Q0['Y1EWO548Z4)6A_VKU]:'CR] MC:#GGUZJR/$KSXE08M22)E>2IPU#+"XW03/:73MZ$GO:((#;XDNEC! MEZ(ZDVDB8 +>_ZA5?V_I#?3X3/DRAE2T9VBS,[QC00!)W+VCH- M\54\!D"192(R=K25MOO/- +MBTCA>I"<]4D))E:6WVL;08'C%6X),_"/.THK M&\@[,.0<"O";)$%R5:[:[I#K'P8?]Y)-[Z/TL[9#ST@GZWZ:[)XC\*I_GB7* MREUFG<^46C@Y%=VAK#_!F9!L^:R^N/CD4-=B;I6MCWS2TD0GE,:*J:/?I$/U#4_]PG-OOZ;NJB!J#4P&X[TDU*/@>%YUUI^:9^'R9@AQ M$RF:C8WA B4AA0D6H4<]\GQ"0I8>DCJ^IJW[6OH2AEW?"(!5=7]<0-T@2&13 MI@)I@9GVM]Q'"+Y5((132&/;<\60*HCSV0^!Y]D$ M. +'2@:BY@;G9#%/$P;"LQ*_-M['F#US0B)$/'=YWO9D<8\N#04B+]N.R7=T M9T5\KF]#GM8\81-![J%ER@1H8U_A)LPQ+;12QIR5E:]$Q[D&M[09/5^ M*-J\"]-E"$<(9U&ET-P13K\JU4W4_92\=VO.X.+J] M:SK[3KM.G##%1G8&WY7$0D^!Q/HMKI=B \];2*/[)OG[\+7.@>N;+^>9F 3P MW+J>O:T*P_H!S-DJD>.FQ-YW>_(ZFI.AKS9(-:]+7O0\E71A)8!J)0@RYU\> M^TY>GD1,UY?F-'O9XNV<_R0 MIX$++-&96BB@+APW3,/BWJKLBMA6DY=KLT8DCG=^SI*0/R*UM]5EL38#:27RG0WVY_LG6,@/BR8R$Z MUT%]_J([X\L#=YIQ,;7BT PZ:^E0>R?WUJN74K82&RIWKX6*?2^V[ ME15A2_B^XR4KX-P'C*2W/A0UIICU;//19L!VG1Y;*L;;V(ZN.$W4OLB MX6'ASELR' JLK R>"YEV9IP_!]WO3QEJP\:'Y9/XNS58V(,S#07*PE0.#,XQ M087E'ZZ1S3/V_277!8)8:K+[NM\YJ5/]GH1-8EGJ3J^J9>E>=7L&W$E97XV& M! JA=B;/*.CWU) 6B\_?'WXVYPFVSI0*E[5M=]=X"=:Y_7W@7EI74G1GQ?SK M-7%DME"B7O-&>9WEF&.)'MF\\E=";4FYQ<8OK\[VU+GWJG(RV+E5+GA&]]TA M3CM&MP9%:T^IVVE+E^[$7Y+39#M$DC;75[KW,>)M2BH",,^D(*O9$MZI*F2/GI\D1244#4DZ.4;G6ZA41^F(C82_^CS]I80 M)JC.1M\\GQLI)= =MY'8"C$9 M?$Q1BS[G+5L^?2U.7+>1:N^NH8+!UB.;PV$-&-6Y%EE\5QS'7]5":8R6B KJ MBZD8Q?,.ID?@Z2(_?[-/?M4!!>+[2EP&-UO'^_*J*D6^@+3#'76DD, M\&*'N-$M4/6>QWU $N7;W %+"%-8C.W5<0SC^?4[,$EHOZ-D!+(:1X4>U*^. M\F-L;Q2\BYKV?;NB^*EF)JOR1K5MNCHS'[_:J0:68U(8VN/]56= M7*-K>2]#'$->=R^/\71BTJ]N>G(MGEI]D M[6'GY2M4^:6-X1Z:<#U_])3[7:*\=A*A&JU%8[Z%GS':3XWJ1$?O1G @0\.) M>NV599/-.=?+WOC1]9;WX@],7Z;IC#-<<*2^,7];1.N?:*67+JEZ]SESF&7R ME/,W18,8L8UBE]=*3^F\*\*[^$T%2Y#GC-+'"\%E:Q="N#Z*4,=+,";=&B0N M>]F\7EV!V7Y.[#3ZK>#IT@I"-,/@?K]9;?T&%$!Y_^I0>0Q]M1QW7YBQ/GE_ M1_(!LRJM4GH'Y8( A\"0Q!!O:EHCL(9>4" W3'A9BSI4ZMPZAG"0C>YN&FP_ M:6?OV40@5T W6*$1_&C4X#?1G4Q]@[HM$7_L'!4I+\\T7]+=^C:7W77PG?2Z MUA]%!WG&O'*M^@0$CI1UYMS&+#408#"*JI#ZQ MREU4(#IV73=1.D;2@,T#&_LS9T769?H3'WXVA*FE\\H"G11GRPW[ N^J&)B& M63E^-$ZRH@0:)>OI,_4T!M%XF..RB>G4?_502Z1KJSE[7F)'.H ?T"7U3O[9 M/+>/4,E[,07,_7NC2@*6C?0/6M91[)F&Z5B97+F<*UC[.+*%DNP\Q\U!I+3M M"Z$.MQHA:"^30S>X)DKV/""FOR>[)O*WY!4M/1Y*P. [D8XDE"[MK=HP_ZG> MN;KEON)@W"V-MG6+[ID?5[Q.>MK/7FM-3[T+@S_G(Z2;KBGGM*)3'E^M>B7P MI8;*L)=BX*Q'3ET!W=R6I>-!]=A8L6R8AXID1[BV)"^D)8<)S-46T[;NP#@K MH&];/2/K5N*-P"GDO:'29/9&?W&-!TF-?O4)2WL7E8"P_=!.LXY(R!_<:9"W ML2A5LG57)?5\;*];7RL+AYTPA\3:)M'N1&_6P)S(N?3J:M?MMLV4,2&[YG)? M9R6Q V5KU%U-J*/C2,V([8?@B3![3O1:SWR!<+6-<4%+Y]M89#CNMYOW:/-. MGY\U2N_6\JW).WA6:A_:4-GHWISH>ZPOK9S&TBOZU]$B7-(M-Z4P_3BF##=+ M9)=J1-3 6L_#6M^=]+$OZN =W=#7MY^L&+,LD2R(I2-YKY!MY.X,!8Z*O@<' MKR_"OR3V<.QVUBNJ/0 G UF%/?\J; MYAR[F_=[(&(E5=3>*-BDUZ.X/[3WJUI'9]:B2$8Y02GC.^E]=U?!CWMB8[41 M/./6Y0E=ZE7=M#FL/S OLZ]1%K$70C>^G?M.X.T*X\V<7/6TO?KI,/_C#1'G M%TE1[[V=PF-WM3FZR=?&=E_#=>GI;*C"W9T("RG;)L,V?]191%G1Q5(Y.!T< MS,=2]=UP=:EK_A"QTY\7."J7:\'9#=MGP(X7I_X4%2W$8)EY]NO/'F/5(XPK M*7N*H(!^%6B7MI:)M2OCG-DBX^J(#N)G87I:_57D+&N_C6-[ 9_%*2N@#]T[ MQ6WDW>>,/"\DV.37YVQS@W51GF&%5KL2V!<&]RHXK]ZS=X>T1>A@5X@*\KX: MU !*<_@$05A89]THS]AV]/H/HL94EMG POZ((I%EKFG/L]_&\"CY?E-.&0\_%^7G#1:TF0Q0X4 MJ$WM716'6^18:OG1@(<>TI#N0;6-J&!*R;E))6KPT$,_.@"Q2M1KT MGOGS8^?H$MU\?>THJ9[F:)YD@;BY+2O+T#C;EXYG/:(+5V#:^,G%QACQ:LO MH,D*A,0)/]3>>OC,=!9$RD[A;U8_9G&*2\Z1>[#VF3PFK(3?X^?'Z';S"CH5 MRA49:(>@ZW:31(MB=+D5ITGQ4ISM3;2\AP+HZ$HK^3WSG(PWIU[9;-=^[;2B MI*_*N< XYOC;V]N8S^F/YY?2XD2WV?EV5EJ9)"$OP$37Z"IV^3I1B&*\;!E1 M_*NJCU> M_#1V6>A0 FYS$4;OFNO]KBGG%!8 MVA Z&>5YSKG@+X>TN5Z^O6YWFO+[RLO2IB8O>DNQ8SDNZE:Q8+IG/ @CRR#^ MI/SIT($:HPVS)A+QE2X6^X7# *FO7UZ5>>:]3OR%%USAZ=(WBE=IOG[D?BPD MK%ES(*E3XZR&P[T]=U-Y=:2-(GNZKY]RQ]DC6Y\HT\7 :ZL@:"N0G#[S<>S% MU!.R8'3]#,TOYGZ3/2P\L)%S=CG*/&8+IW MKS&)&OF8M+0@AQ.8J>D(#>LL=3+I"[6SL8:5+HAMY+S3#]48] MF.+Q.95[F ;UG.KC?^WK"Q#IQ^7IR1I5#7HDN*XEV(:_=?.:W70LOJ_OHIUP M2CK,J0@VRV)[[%EEZF\CF&_8 >NTG-)&V ;1%K@YO0U>.=R]^/C*C#KU%(5+ M9J-3FU-QV!BU:=*ZG#("B12=LO=&QXU /W&8S\,;"LP\OIS,K.JU[*X'W]2! MG=K$O89)B;N(IG/60X;9=^3KZOW&WDM]R$O9?F@XTM-SF$?3$B[Q<@\2U+C( M1LV)\T72\!F01'3:_DFT''?GY")8ZD)76T,U$&W@5;M_#T%)?U3OG^#\C:PP MCT7N;R^,9@7AFDH9TA(9DQQJX0\703MH92(QGS='(=]#R?C5B(583!?&92PU MP#H7 -=;N'-61@.Y84W8](31)PC$VG?5A@7J>PN36:*HMOP.N6U259\HF(#*LWM-I!Z -R+K$' #9IC,G4Q+EAEU6J*9&-E6 M*> <_^DR8:.QTK=;D\,^1\VA4R-!@Q[];DGC7,CR>_"YAQ;K7$@BC>F/U*?I M'3PR?SCJLO[?2];?H:(^>#!I7-I4T MD[E2[;5DHKO933X>17],%]A47_)(="\#[V#C_C@+ M"NB2WVE$+2 N947:KYB3/AW,"/YW2>1\'&NV;8K_-"KD34Y$GM=SG4="=TCH M7?/$TSY9QH.]$,?_%#8XN(L\!M+"XCW3N^ ]IFYAGW\=N^^4@3;YZ'ZK'XK8 M5_SGU8=#?5 U?-6J5>.;]SJI]R>^/O(\);-FBY4=L$Z8;B@]L MC*=I7=R]'-XTW.,)L$QZ3617-R_L?)0A,YL='"30%+TTJR2.^QUO'0H0J R= M68>F6XJG:)!]B8J[^WDN[B'N&M$3%_2HDIU[N$Y;_VGK%1UQ237"HTT,_]NV M+LI;;1?S^3,H4!!WDM[3DB$#,Y1>_8-?L\Z:LO\$UQ2B24Y&$KP;F5B6I MSZ_Z.?/PDU*I-VAH?O)2K2U9;*-(5.,/VWRA(-9]P3=B)L>^:NZ>&K6PC&RI M%A:UJHHQ1P+P1QWH^R5(_>Y]C6ASR-=[U\V3HGRX:XBG,2=V^G=T::+$[B.J^BR6LS M9P^[)/@>9@_TOQ7.F]_'T(#7;3ZYE+&C/6PZ9H\,*DP8[ M3SL,EJLLF;.TH5O93#:8@)IN)NQ7SEIOGK"$L658G'QQ62O'V7U?&ZGO5)24 MY+1S65)S5Q&[L? ,1MOJH!3=7Y<=C"CVD$!.'2)D?C0KT,53HVVN8MAER.3% M34PD:]RYU=OT]"@/,PJ<]ZR(4)??ZJZ"#\LRWD5@RYR).VMKOK570:C/T]9[ M8UF"J:RCPX#SRMC25?/3J1N%%U.E[W^>%.EIL(%'0@#%%"H)(MIF%TX]FD7P^B1X%YO:,/#)WLC5ES6 M@>UOZ*/0XA(??5<9)%BOMT'EDF2*'8FRH5[N!(]+H;;3=!&GED=[HOSFY<1Z4\[O=Y_E]0I M@@/OJID7GC;^+P@:](>@$_4;ZG42Z]BH4"C"IS+>^%I1?M6B"7N+C+V19_#3 M+><')R-A/88?EOP3$X&KGV-8VE$](F]['[M#1(+(#FZJRN(XGBF6?W1]8,"F MT4]CA@DJH,,K-3)XL;<,!]546@V9J,NY1BS)^ M#5= @9[ XL?1%.:S*$4/>\X@<@[2W.QY1ZKL,3M!W[M)0#'674Z MN3*HV?*_=F>=,@0=I6_$:?NJ;U2H9NV251^RJ[;'C2+[<#[Y^L(U#FQNKB=+ M'W8VF<9UTL0]'ZTFR"7J2G&$RML1P"4QV0.G:5@T^#[/W80!IW% MAKP*?I0_%^[2^$AZ2U/W".;%V)^]MZUC/Q12"X>?A)199.* M.7SMN/OT)=Q\I%]<8KJP7LWY;U8RHGLXDU/B;_9UMF7>J[^Z'JY+ 2_U4CQ0 MO[K.,E:3IX@TPF_?2Y=ST;B7T1])8-.5LW0ABM5:HQ)0^/+\';GVYE?.)\-7 M8H.'M*>+/ NYS0+IBEB#/6]S"(3C!M796P/K?8ND.XJLC.KK1XOW%D J.J(! M*(T5.N@1-?.:"X(FJXZ1E8@8-Q08&6 GKJ"U<4)6?=YQ7FV;V \.A)^ +ZUS MX)_SR34*(L2T!UP+$/(+TW1/#>*:)2X7JZ%#CKUNNV7D;X>M[%.?+YJ/ZMI M,U%Z@=T9=\A[;5=S3::U]F0H]OS\SC0E%_80-9.5]%9U?KWFP M"24.RY"=HY:S)T0F@U.47K7JFO0K)?(,@<,U&HI##>G,OXI+R[#9AV\[:A!) MFQL^T$[ 5V4DY-LU8(WD:-70OF?L6M,7H>.EP"/Y$D\SM2:.,R\ZJ]$O3E)_ M>K8G%TXXE\]#]%5ZJ] (3OKYDO3!@?JIID:SQMJN?:DU4V[&L(C!P5 \ZR&/ MHZ/=0^'0.WF[FNM"J\-+)O/Q59E;]0&F&!_OV+"?1J/7RH(-IMYH%[^]OP0P MD^+5+(T0A/G/?M\X\>;"8OG%G>(W,7&_JSQDQZ"3 E*>K1A7'W'D^(8W>,QL MT*;/R#7&V92O*IUKB'-T9U!GT0T.UOO09EX3ILR16%X$[Q3E+ Z7QU0\GCLI-*]GB)_+Z(36C'!C"P#*T"CA7OC4\5;Y#7(0&?G)?Z:0]:_KBWP'&7?/I2_QFK 62YG^_9J)(;N"X54,D>US2M.>EMR/ MTH4F': UOD$C]71X0D *G6BC2P8$X7I)TL0NZJK?? E>+Y&BZH M#X@6)>4_TS ZDPC"FUIJ3HY%94E&:<"PV_HVP5FN9D/>K@\%SB%(*N0A[>L; M$L+;?"A7^7?>;"?"(5# 4UJ;W_0'9YBYD16/HM^F^,UC7;]!80DK[6WB1OBO MZMA%O53E.YS-B6H#W^]&9U(C-IS60I214$#;YE&M2L;7B93PE>VB8!"[I*?1 M=&IH936)/X#5ZI8U>E(![R/*2\K@H4!S@Y[1-U5.>-OX.J3G'B$(T=6_JKMN MU9ION\4>]<>GL('T@&;0QFM_3YWLEE^!05:)<51\=Q%?(W;T",@W/)/*7MWZ MV_B'DLO/))*V+Y8+-Y-9SCN>W*'H0($&INY6_.*RM'(D*IMY#0*"#>26$@78 M"/4D/T;[*EJ.O&UI-B9;6_;Y/I!1&:9XL: ^GCNCE6@0SH;3;B_1C>,7/ M[WFA@% QZZTTY[?0)?HA,6O5T\"L I"E6?["$>WVP@!+M1MY]YYNZ[C(*/G! MMM-/99U?!C-]D?W&-.M++)LD] 3, J8KRW%A(7JHPYLZWY 1A@GV(K0=RI*H M*R7VOHY_Y)% \]/T4%8PSYO_-:%@8T5B.94$P!<5E$PTHH+Q5;20PU-T7]XT=&1F8;MP"7[5"AWS>NS2BO?69_42:@1L?\5\>$J8X$E<--UR? MZ,W\AYG4_NPZQEM!3EM>T,*(FP+F5C=0&H6.JP9GF[])&,?@I/U;;J,.8.;&YY_Q01 M<+E2MU)]^(;J0YB+0.4N<&R9E+'.%12/>F0<.E];6BVH3!54GR^Q:!@NR96Z MB+]C0D80Q+I44BZ;S&8F3.6WMF. (W&X2'J-VG<4C2GU]=$PIEYMO.\H!4;? M1-]D;WVS]7;K7.KK[;1E;;_?,4MWH" BA%LJWA:\UY&V#L]#B<+PXR.G0^O- M%+Y"GVO)NTW#_+)ZQ"A;W]["3XD8TAV<: FF69@9L'LRFUM?N3O(!:VPJP4U M*V7I++/DSN=5Z7*_];_;*1BO25DF'S$.GJ<;(0&W$<;W.=[31< MCWVXX>>' NW4A4/I=$C=J%L@MY<+YS8^I!_*5Z1BBL')GTK M6YDSL*.-Y'J'&*C:4),LMO*Z5JSXU>_-J\)'F*$I6__L;XZ#J!3\YR2V!&\* M/276'NF**C:>"&\O5\=8*']]:W$5X;K+X-,<3'*D_Z$;]DXFU2&L\[(\J\;F M#GT)U/ADN9-"B\GM_[ T]-,O+$>$8I'_R7+7BA@B=F, X[\=&/]5_\U_*4__ M9UN<=V-T#,'M,;_.$:BT#^9KD$9$+V[\[Y&1Z^/\>K1^ !C1'AKH;F<",O&# MBOQ?FZQ9)IN5]3X,XK:_56>45,0TE^< H;ZT,WA1,8_?&EQBLY[43OJQKG 3 M(JA<&QA")5IQX,S^8EF''6MW*JK@\>.$\?3)Y<.VK"N84N-!8;AV!/F8K1T1 MPO5;Z[9)=/*-87WM%$6\EFXOT;>;67O1*S")1:\K!)%!)7[TC$G<:@/Q:W^1 MN3*60G4#I)9/ <\Y!<;/K=0%H%\&:V=6-)T6=0>X]HE:B1L[I)(M!M53S+7$ MK]V,'4B[$%<%32DR9)+X\ES(V^V4W!F\:3\;X-$/*N3"'53)F*:LB]S=C[<] MRP4'R5\1^_()(:EBE- C9BUV(0E9\#U&>;8:<8LLC'H&[%_(6WY..^M^B2*< M2#V]9)3C?>7;WNDLB-:&V!TD^="9=55DO2'3Z^LZH/JM!T(;]2UF"P].@V)+ MU6$4;^:_L-:T.[P$%DCC%L0:1;4#"+^M-J_*4MIAB\IK,R@ 6[9_#[MKMJU* M;MV1$!BLR^[W.7HQH:O!YN(:@V/U_?]"7/W/NT37?]'K%2O6NR)=SNT+ MQ;JXV#<'EO&AGSR>,XG-/&G>JR/7;H0QB4U335BKKVV^UC8-9A^$KVQ_XP%O M+C,]&=20=_)5Z)'-Y?Q9LV11<;DYFG3&L/EHCN5:1TA7&:ZSQX>O,%#81NDJ MJ$Y2WOOBT.WX;#< M5?W0CDH6:ZU-BD$1SVRS6,GY 7XI:+X&"B 7:L]T)]UQ"?&070]#N&QO(Z1U M?KRVK-%()Z^1C!1EV^ ;YN_MXI=*KPXU!Y3AZ10G67_ J7C&=-ZGO6&JE10/I3VE\A$W83$R]+T9I8VQJ:3W$ M&R6:I!P:NE<*N, $%Y-*+:$E@]$I<672U/9:NG=8Z^@=/[D37P5IJ:$HZ^!] M&<&4=\5?Q[3G6XNTEN#NC+I]H6L0;6I4[\X(3!KM,DCQ>!@<4HQ#0>3[[8 @60=B"2$5<9WHOE ^.6>H*/(VM' MM:.KDU8*#],[C^:5G>MX#S?.L#7I:R)(>_V8Z^$'Y[#^4BVA__PRTG=K 3^$ M$2&D5T3#EZ_*.7_&CG$]6'&\6?H%?ON.<6$HG3]T"(RE)#X6_MAY19_X>Z. MM&?8 >*A"5K!U'X=W(/A_]XPFM\D&XLZ,C?JTA@%\=.%DM%F/&:&G?[7/"]F M#\?5G&*K^WC$3@?XMYFF7!2?.BG\&"M-T%PW )57MGRB<]=XR-^%*:! E(LB MC&&Q'DOZC^:(2%$U!.(O,$<;CO1+RMPR3L/WB<^@ -G1Q)Z^ GQWDYBQ,;M7 M#@I*U(5+N>D;"$8+2,(38@JYPE)X:B1+^!.=V]O<;X/2')U&_MPK(/YSKV!' MC]2U]S?2_\U%@I3YW7G_FV"NE4.A+[/FX\NOVL+6AHKH/WY%#/UT'VY1EK9J M@[U[M)803"P;4/&RUU9P$:AZV=>W \QPL3S>FX9=\3D>/-1.Z>B@);MO2@I^ M\.RZ%HXK68L@<$T_4>88MI\0YU]T^]T8^@SM6TWVCFT/'Z)&4;^2Q)G%],&N MB_TP4SX8"@!>)YU+VN0!O[4Z/R-8C!FXG3-_Y9%*XKUKNL)#OU7H2JZ]^<%J M4X.HXH4A3L$#V#?L=MX&")PI+]S6=T^WOIBH#0'+S*8I.];YYWU'K-=-[>MR MHLT-67]>57G ?;>>[NM%X3TF5I*>3Y4#[9\*!G M95J>X:#3_E.X)=^"YWP?_PCI>U3QKS?.G'=DI6V=>@OQ^*6JUZO!9W<02M?D M%87)'/,5.YD[+9QU,]3Q)!BV0[.-0L5+JEHOA^$:PCK]M4.-47=UQKON31?.,G%5A M+T8"VD3%8F&7-=4,Z<'HL:=!F>X2-;9%_/U;?LTV-^VWGC=4QV%+*..%6OJZ M^^FLISU%1?LV5C1;0<;B /S[J H/;@Y-+W5I_8^#LP)ZU?/?D(WI)7H(R6JW M1/ Z4GJTX19]GI)2GC=]PU8@Z#C0+$)G#!T&K6>VFS#WUA:MWK.P?"#6))6 MM$,&LVN'-AWE=H56D/5,^)S<_^MH@>50QWOB.&KZ=A24/ _]#!B\W8HLXJUG MH!,(IY6_Y4/>LO5RY3IR!SU^6_VSE;K^SU:JB3.,\\C5V\*$KSMJA7 \J&W# M&*TP.GT__HOHS@Y^PKH"(M8)OA45CT2#5,&&H/F-MA\ MY@@("'B6?:V./,"I@F6HOF#IWGM8=M\VA0"?)N)G[RCR+M9;5X^#;( +, M&Q\1;K;V PW3<2=SO&6MG,8Y>]KP5P08*#8V!;5Z7N^5!,1TD'BITW*G_7/' MFY$*% GMHOG)&#HQWRTS](WDTU;5)$=/447X//[+3"&>-< MBYW:.1/W%(P$G+?8-KNE6;= 6<]#-6_] M=AR_L+^F,@,^V>WI[?P;VCMV;Z' =S]/7+I#*, F^E:!\+]+=[<,CD^F$DV@ MP GZ&(XEZ!S3YB;A;H*S[8HR S:N^[C:E@UV/HY#@QVUW")TOEJZ+LL/Q MYT!/:GIAH:HM/OB0LEQ.1,]M,_N"UKN9* M\CQOJA&YA7L%U$=2%$F_5)]O-R)4,L)%3FIQND]I*3MK_35LM7X^ODLR]'+9 MC47-1M!XW15\A2F&GJ)D9>RQZ6;R1I-D(T.FV,E"M>$COS+G'U4X3V&MV9?-MG[B:\ MS8KE06,TW0^_!)\-&M9G+JV,5[/6@FT4ORE.O.':; G6HU[FK)3(&>#M#]V8 MR7/T^L*:M=F<7>IDKS[1.DRW4'U@..78E-=03:.E0\Z.;8\&!;2YIGO]:V$$ M6: ADN< !9Z/*7QGI@Z_7"H,179XI"/)O-9>/D,1)IK2!(WF9@S4Q#03G_,Q MO(]Y27 =_3B:?F@$!:1^YV"E[J,-M9K876!XMOQ,OB>'L6IDR\Q#QG2K0U6U M5*W<\SUCC/&E3*.^@;4>IMWA_PY$RKO4[W_59VS;7',-[[6=7=$]]/R4[VEL MX8$(YT(!UQFMBYZEF;BG%+N=Z-?G*4-498LDD+C->]!W)[!EQTO-O?GAM)[@ MST83/B&64AA)0]]#_?A(-(KV#Y^(+.&E6<*-!GM^ M$L>2=G]\^%SG8^Z;M[Q\9O M^](5&XYGT2A^V^I!BQP9B9_MV?:2IQO.7@4[#DLJC!\[A>#%'R^5$^V[BF6' M&DF(]"[7RQ3OMY$Z0@$JY+U6*##!#G[$*RM+-ODYME2&_[1-)MZNIC%]F)>A2NFRF;?@F"T-C!IVIV7;^ M+KQ#&O"1!S9:U.K/>H.<:'Y_JD^?%@"+#I)$"VH1JOC871:H MX,E_#=O'^(H:"O@3)81>[:JH-]9/KE7+HG?5A\BRP4_ N_$)0M2&K_B69R1E MNKK!$9)5+>^*^A'DPW>=!S)#RR>=P0W]8?U]=PH6YPJ("PVW,>7B#B"J)5R- MMW4H29&HU*#J5(W2WJY/1O&[7@=$D9MQ89_?&#MT"9KBVL!6K)<<:PK/(J*? MT3CX^J[@3;N^RH W6XF !%A&G]4M,Q"1[E-(K_;FV?+2_(J;^HHA=C3B:+KJ M1CEI"7]XWTZ7M 1#=79"^_Q2;2J[=HI6F=558.L'YW9':Y]46XM?KCQ*L*G; MIJNBW\J:]>282%/JDWWC",="BZ'6;4I7M&M4?O)N#LW]@E!,GZ]GL_/["]-6 M<>&5KF4Z?K*"0VH*#*#F:RKK* YBZO'2 I'+ M(=](1GI!G>*%VGM=BVN'7&ZE@9A2/L5##]_)ZV+0:8*E^HYRL&Q^BG'"_&NW M+#5C:X'GBS>E+W,(Z< 0@YGWSP:Q"(LL00E7OR\+^\\3_7A+?:IDF:/H1BGN M H[OCG29B4Z"CVN?E4I4HJ4TD=>>G*,IRI@06U2E4H5]VX6-Y(RD)0.9KT;^)@UHXZ11.9'L7BC@K^(4 M\;R;!'>!0UB%Y2^:)]]<_> D?:\ZN:DF)W?4_2LLTS=B&U"JTS7>H"L%X^V$FN:*.[HB7OWQ*%6;^[XP M_9LCCH\J[>:+IJ?PC0;P"S09H5>6KELXV3K896Q]BT),OJ!665BL9O X1#YX M+A0H^L^115N:R#]7,SC^URQWR1J>OR(S\IZ95\Y[N5Q)M":MXL_(S;S;&(0# MZCAAL5R,SN^CVMG7P>M:V>=&.#D?%C3?WH K+D(9&60-,3[0\,N_7=S).5M' M-_L^3=BR0BF-(P5?^-[O/5F;3-WRVPII,,Z$0O+:\><+PQ<4(UA*]RHTIS3) M"^UU_Z.ZKXJ*J]G6;4*P8,$=DN#N;B$)'MS=@[MK$PB00.,!@I/@TGCC[N[: MN =W:*!I+O_>^]Q[SGV_#_=ACC56C56C:LZ:L^K[UJBJF<))U2/](TT3_RX] M1GG=I[2NC9RX:04,:URN-+@3%4!9.>U_T;1]YM42\ "/0:'T/()#IO<> WMI M-]E1[1-P,L:L?GZ:^H4ZY_SY0;->Y"2>."]*(O6-,]^'Q!: ^X2%V&9E^J<9 MR=KDH55,2+W!FB0^RD4'XLQL?E^?L5-'W8BOQJ0/UG"9M(CAQGLK/XZ\KS]$ M:@.]V%_>B3:T/!U^N?) ?Y="?]Z7CBF'1?))EOG'@FQ7-EB"DV11.:7-4F.) M0A.?*]Y%+[!=9:PD&W5@CJ1NU"]G>043]&T_Q.?1;G;\V]0% N%;KI+B_:*W MEI-%ALL=IJUD>H-H G8*@FK8CUKY+B^O'H8$C3G6S#PJ]0P-5KX'+'S[M0-L M-5BE:FYLFP [<-S9*-T0\$?VN>;;_\ MM$7-P\P&$[HY1QTO#ZHV/.*]AP-'@6->'1Q MWC&6M)1+D:=0QEX77D K#+H^HOZ'4_K_PRFQX:5]96#ZF >%IB\CZLLH:G^E MRH^J5_N\$;76J/9 L$:]\\RU(RFP9]<=T8GPG-21_!,+2UO.O@&"/8@V:3X1 M_N<6#_=YR0O*Q+^L7C2-QMXE/GL*4W!/[_R#&,>ZE\S"9!_CUZ:: T5UIIVW M4*=5(1EXV2M#V(;%8RS'A!OTI=+M-=#:5>=$C'AE[V,RM$/-_H@KSY:T=+ HS$A+NU(!6>V2'^VFU)BW[ M5?<'\L]T65NI,%O0YKQO1?'0 /^=?\-B)="FBX9,ZZ7L/DYI'B=5C.U;R(GX M)J?:W.QX=8_@S[.; 3GD.^47C[(R[JJE=%)3QBQ.\OT2X"V+$=Y)$6+<3\LZ M[&ZBWVC)9EQ3WVA0.E@8_]W['3U['$D]D7)?OVJ8 MM=XV6P6UJO/8W. UG(5R]]J-?LC@DO0^XAL;YW%.Y)XR)(U5$Q-5Q@L)3@NM MX$BR8-$7J_-Z ).2*O9A*(MPYA0L=1:1EG_\00NDMWB_!^MSZZ:&B-KB>GM: MB,47VP0]",@$F-KOPA\# @2XF@G:NLD6KI+=@;0&C\V)90!>(JS SS1\H(1E?CNNHH.YQ4MY$<.TW&5(\='1C&9O;)[7(RB"%W5\\)MLJ^PB"(1\[ M:5*NSQ6]N7KSR&PK)BXXH8BGYLD#K"X/J*-Q<-/=2I9DNJ:^]NFH7/RU!3#U MHE+2S9F^>:UFZTE8,F20$5I#!ZKH1,MG^HD"L):8+2W>O^3B@2[)\H7"R&[V MSLL.*:BT]=XW3&_42,'M!7_-7B9Q>:XO:QJ(T I!_$&-WO6U/E^Q6;-\3NK3(+Y]C@=\;3[,'F3A>!*%FPQ M$+M(+7JKG0GQ%DV'*&TN"G\7FM,L)=_Z:( S<=-/7Z1/=P3%6Q"_&!?A"HYS M_UC8YV&,;Z9LE@.2$;%VU[PL7/G?PI@O6_&LP($*J_8S7V"+_0. ^J-35E2WZ'0^7]BNWGFR_*Q/TE<#ZCP3' M4'*9CIM1VY]SH85'IZ=&S:CN$44E#P;^=0H(JY7_<]@Q!9&G[1T#29H(X.3X M32>C.Z7;S20DQ![#4AC>8K%QK+Z"W5;J5.[7S^K@"B._]DTZ=A_4M!-RS_?P M3.C'"F8; /%VN.!*1FLU3WHT/TA#FJ>/"^H_)D5OH6@^X,PL-0/K1NWY\'L^ M*374N7=>'=DZ'I>;MV4N=G_8KKYPP^@GA6-37!$Z4VG44!''%TKY$BUKN\J* MJ?ER-Y4+%-[*0MP2X>(/QO4WI:57_FIN'%Z8GGID$=(<(I'0")49,!_KSP?% M89\MUA#EZ:R>M&1=",:5;FY8IA-6J*M[Y?&X.&_DCP\\*U0>W%I% OOC@9P[ MEPM?Q0@V>AI\PU.);Q)'MA.0_;YFO-(Z6XW>7EZ4+^PQ2U/CBY3J%OJKI.^ M=!;H_U>C80*,O3+:"\F3@6_51$M%'YDT!+ S&L\W\![:IE>4?A*TMWW]KO+S?N]?2 M\^+V9)BK!@+-E3BFYA4A C>5O91V\ICX*(;99FH^80JPCUKNL^#L.ZUH&CD# M3%+:))(1Z3W;,97BHA8#/OD-(R7]3UAS)R686(DQ(3\1:'^-:0P_\;>57DIX M5H'RTNA 54@=RNO53;J70T>4Q70=^KU-$/[9'Q?>H'#JQH"9UNVD3SS::QU=$TTQ_$A==650 M+;5,&A :WU.3QM[2W:C/ S,[IY^BK&0$:0FF7!(F'"D2A67?_)I1JF7UL%BP MQ(OE MTZ71?3G!8.T+SS*"&^-X%_WF[A_L;Q:]EO3R()_-"@\3*,>O=WJQ/NO?J+5[3\I IQGBNA3?X;>$U?!6O;:#?6!SY%>6K45\, M\-Y1V_5X*7,ZE;^,3TH5***9BUH63EQ2UYFJW7=.OCL"0X_]/EN@]&]IG=2* MZGE$@24FM0>=>/1^@SS%E47(M:H;[QG^8,YGK3K!D@)A.=9:Z M]/&EW\1^#B:.M7 )LKKB_W* N=>N9^:%]_89;*IEIT=FFC:(Y(Y,Q3L1HL3. MW/+CY2HY?(]^I3;Y*16]BW&"8I=MVU04UE"9P&R;5N+WW%3.:PN'KK3@NQ7G33]7SNU&#M$JN;@;"FK M)LG52F\TQ^0 YVDUFX=/@*-QW$$/#;_2(JO3$/NY0A*UHGXO/Z# M?_9Q5?F^K)%'BJ6AW=Z>(P[=%']W0X2W]JGB<1!GCB;3R2AUKQ[;3,SL,B-+ MBB@@\1N8WEF=2DXS;//TK]"/T6E3+FGMSG$L%85PH=.WT[OL;VT5K-#4<5C M/T5Z=.B6%:AP,(S1MR]#YR,CCIM&J$T?F'_B>]5@.>Y->&[6JOHS9/7AE-3S M_4Q^ LR%QSS\MB!)5E301643#=+D2XFV=X2\3UK"M[1 1BW*U%&UC$^>#%^5 M>9V%QG@)QA;8]&]8]962M@C[7OYJ:ZV56;K7*$^31<9M1^D)8#*_R7-7\;K_ MQB&.,/FV3_+^FGYZN2SG0YE6,.!KA_ I3*N)E9Z]5H1*X+1TI@1O]"AGSSJ9 M>SS(-FXANE(LEBE!+.%EQ,N'^]F.!O- 6UMF_LH5OI7%]$W<.Q(([OWZVE!+ M^!@;]CL-XJGYYH\G#QT6]4Z0PZPW"=PY:V\]L28JM<;IMG(JJ.LB;T2'FY#XJ(EUR;BPS"84P2 H MNZ!][9KU>O[M[+7_=9T,WCOF93B^_%7Y6,O0ST)EPQIM:XA"&4M_&LY?IC^1 MH>__1#(A[TI& 2_43I\ R[%/ *ER'D$/X>A4E0=&HK\T1$=869*M+@HU[RCQ M.C<;/MJ*64OH"9T(5^1TF3.+V G.7)]=%S /4M[7JK6]2$KZ M+F8=$\@RY?/0[P7Z#HW>U3S&I'NSMQ0_J@&DLG?3[W9TJ11SJ;3IC*5P03^> M!^NVG#\>WRY^JZMZ]Y%%08L4WBLO?F^9-I^@#LM)+63U[^7Y"X-L":WA>E++ M:MF[:B=NR4;.N@R;K^XB(_@!L&2M7.[]UV_PT5PS%Y'%W&%!6E05T7R_^[ M :!BHL+9_8NUQ7>/(&'GH^'J /WS*&8:YV@WD>\D_)F2/9RD1M*0Z]+*U$-J MDNPB(G,:,F@WS6BN--O7]ZC:6$C(I)0NXL6E6\/?>6^,>*;PW;,$W3-F'NCJ M"MJ1_/GJ0K@XKH^_7-5#KQ4'O0/7+[G'#XV P:GI[4Y+(<'V*0&,5T;->'?Y7Q^?P*5Q&AP.W/DT^ PRG)'1,1^Z&F\ES\/_))=Q\L=LW] M7$T4?+R@BI+8^W/3#(.T]=)65T+[AKK";NO,:@FU2:>W-2/]VF'R^CA[;\\9 M'[VRKX#[AI_QQ*;I7$'-E+A@![CMW-XDIX?>2VJKVI#W<(LL[M!#0Z6(J-K! M5%U#_I:<;332SOOYKZE6OXJU/+?0F-J@63=:OS9RPS6M^/(JVC*5&TFT:N-D M*5->+2R_$"YUM6^Z>K-Y<1B'.SI.W3(G)K+>(!JVS LR#>G8R[C4_ZC?9"H4 M6_10"J>M/S26Y2TX'F7*^O:GA+6A3_KJW*F1%#HO3/MP#IK9WV*W]$P6N._7 ME(0D?-@Y#KHGI#>H.KTNE"BFC&LQ?X$L\]I-J-\/J%^2G)2]Z=["S]A*!"/_ MV-?4)M+Y! AZ MQ?1?1"E[]&\IC)Z)89H;AOENO;X=I:>SN'#+KDN+C6AF;, MJ?9OTK,JE\K1A^0D;2D)V%,Y]_)4_M!^?]0<Z'JWV,@NBXY8T95_M.M] M/U(X279W6I8* 2N@W3*N#S!4VW_Z MWA^D"X9'PS*C?BXNVES^JVM1=OC*@% M_SS+F9_(%!!X_1AX-YW+7Y)+= LTF5])XD?\=BF[6#%LRL+@<-7437"39YQ) MFYL)D*=?B3(P#,SBDC/O"%OW!^KO ,%&_ =M2$^ >&/)^[]/@+&VH!DQ5V?RI.JO^4$C<-QA ML']*5Y$G.AS-GJ, E$(P<.EH%D*8)73<&XBCEV3N\AS1U%K5*L"&LQK0.*YQ M6J[TI>C:0.@6+CPQ??S^D 019B(@:Z(4H//-,$"RY0..8)^;:,"*_>ZE!0M- M"HYX:3V>LM+*FT%7#]O.Z8RRTYF%R7?G*$,#T(^K7*#H33+T_D*R&_" F,J6 M/67]$H22FO<-AZ3A'$/H)K9&M_/;*FCX!TSGSWM4[?I+TW#/0&O*'S=RI*+$ M:'&:69!>CWI'WGU:,DW'OHPOM76]L"!:6!MID'U7M] *'6U%@:NV.0R\^;W! MNB[Q$0;LF&7G[#NVHL"HA>UY_1K12Z=2=@5Y% ,W^$*.CQ%KIJ\^K)I>)+F- MMKN@B5?URD("67CSUXOK[BKC[=NRMXV> &&-FRHG>L"U7 0?L&OYG/.6K?UT M\ E 7AY@D<;"^MIPLAXG!71\JB.2AV#GJNK2EOMC$*I\WJ-#;+9/E:68C@&PV.\Q=7 MP-+VC,+,DZ&D\28^"RVAH""M^'QF(^/)A==1+,D.+JCVPJMJM@)7KR()]P6% MBB2@P YQVIZ>;!SY:;+$PZDB..JS,\5J/0$JGF4B3+KB4/MR/P':5];-_C#: M (B/N:XZ^_@Y8?5!HP6O/FZ2+E25_R9:^D4-$WIY)1N09;4_ZXLV+W][LWI2@7 M]6[C,+!VT4C:)3[SG,N3SM)21Q8WQE-WX-*\/FZ]>#G/DF _[9IB#^8P+KD! M*X^:@'\\K\4/@(9U4UH[Q"'W5RA 2'J!Q'V+]K]H%G.(TK($F_S')>PM/?'$ M/O '8 E()K,<&4OX6+Y@%T%"!SBXD.X%*P<%(SPE!H'CM=3/T[ HG\X6[H]^ MS:HG0#LCW!:XX>*3_I!,<_L<@=$:=>=.TXU$V!#(R'[O[NF M"2[%1BB\YR.#AECM[,]0M%7\LE,SW;>Q3@KV8EI#@I?A[&C,< '[&E5!,D2ZCRB&YLGG@EGK]78*R6V'FF=O4WL"_":_+3E;BR;NA2M:O461JNLP%Q++8ITJ2H^. MW]DL'O* _MCEAN>]EI/(C=RO_=NB1LBM9/8<6"E^I/E"?:[3_&/?Z:AJKL / MN(1V7J^EG;(,I/'#M"S[ RZD?2^BLUM_;PH)20;]G8[MS>*ITI:9X9Q!#MTM M/Z(I)@J4> NK(\*@GZ=MB<.:,T1PMS?7V1@SQ4FNK]=G"V!NX-+/ &PRO),,N#<410 M_/'>$T!R;5.6LV<-O\UKV*G]I%O+$A:QV?<=SQ-BN*%G2IEMH2:U*<=^+:YP M7'8+GF:6BGMENIO,2?:8/=(;(L1;.QGN1$#GL07-8!D\54.\);_TGP/^4-CJ M,V9OB$Z"B(Z6ABA@-XPKOR]C;776;F&_B58X,5JFFA:4!'O4^)SL1R55?A6T MWGEYO+?4ZAJ#P1AS7P1/HA\WR#V MR%+_K?Q==<+YGGEZ_ =X7H*[TKEV+G4I3QPH]6VU# ]W3%+O*Z+\:#VS/^2JT2SYH+[(YZJ5RVR6 M2=]:YG/D657(D/NN68]OX3/JQ3+(.M\]^1Z$'7WW\2YR=9K?E^WV,=D&$6 M M),YZ@*A2+@-ZTRV>>W+-VHS?5MGZ4N1JG+,G@I:-BY$! KJ:\;#F'K4705-' MDDL@FOUGE!#5T7#Q^\UE'(ZMZ3E!7^%H'3ZWM4/*23]_5![TMKCP]D4/4_.' MVI15/1/*PR'?-('['A:UEY$D5:Q,>+,7WB1/(26'^@O=21N"[(!9O M6D5I)SLS9T=LN9;CVNLG $V+S+G.=RMADFIX/[(=TIVK)L. MVC5*9M]%6=,.%B^1>%GL(B<+GQH9-SRT2 #Z*2[O=,CL/9U1X+AL R7E&'17 MX&H[.^C+M^TT;7NWJ]A0M!SM:?!D[/?M\_N.+VJ8KQ$8]8UGH)BD"VS MFG)XDB[Y"KC]MA@XSX?XTJK0DKL.:\S:TVCQ276,+*'="G%S0P/[M?K].I@$ M&VN$]RT&8JAV]V7_:1.W'DK7@85&R?.( M[2((? 56)*Z+][W,4ZL]=Y]7_0S8T8R!WR< M5?QN'+(UWC/.3/NDC1^WM\8N:0)M'_>B.4.,==2H0WFR4T138H'[&D^ +N2B M@>"/>6SJJ)*BU<&RSGVM0,;5R AM9Z^>'<9FL;'I#I'Z(CWG1A9.9H,YO%*B70SCBR N!)3^.C'0:+ M#0)_LM;W6UW=UW)<>/VO4^#(53E$AA!7RO Q>N5XI+-MQ"RV4BQM^6XDZ I) MUG"J#!(M#JX FS<&/_[=-HPMNN+?%31!JY7RXJ@M+8TBTSS1=%"D#HK(T,DU MH4=,;R>F[<44EBX,28_&-T2(:X33;.E_*-N'<_0T%#OYCO9W'MN]*YAZ4,E@ MK<$^4(L)#,HL20L0/G=,U;A1X5;E KX[1?VX@" ZNFG*!T/A"81.^V^@TD:4 MH)B@I,GK@VA]>4E-ZR/U.?;!\-JW:BUXU9*9C M D'A8R(5_Z5^NK>WZRKM[]TW&E615Z>_U:L ]NF0&4Z./6JM7&F2TFO^R4^& M_9>>Y;;*&MZ)C27R#O0CS*X.9P,E!]THNI;DEYD:&P4_?%G%7AB086Q_QL.22P&@!O8+3]X!6*%194%UG=J^ER//Z=T\=Z5$"@T,']-K#RS M7PB7YE I+O98OY5;%5K^'$2>8"*(L(Z)Q7#49"\P3!9>;E:A_OD$@'U"MOZ2 MZ=YE&1"1?'6O4VEYG\83J*1270@O/>%#3#VS[?%]X+H*?)SZ>3I4MEJ6K"JG M>&,:)D9]31>$V2:J:S-5C>_&D[-5[W=]E*TAKUG7S(T"+#N%P$64" ML#>7:IJ:8)!ZW Z]V(2LPP+]EC[7:R?#QN_SV'R%^UO]<(7V58>]G0$,>O&! M-8EWK_),E_SJW5/K8/YYM!%M"?Z[:**6HAK"C#GW\_8%2Q_M'=Z%$$;2DVI* M=]"$F67JRV=;99;%CM_WD]($@Y<8?O6(389^EA[:@LNNK]#H9^8U0WI&IWQB MYN"!0/(#1OQC4=;,&2 D;-=7W48#+90 ;UQ!=Y4PGU U_4^P)P%(41'T0 M/Q:N:"^_U4(S[JK: M5EEWE+? ? 3I!8M^MZ)=(IQ>WQ=+19\\>1D<7:(A3+K;&INFJE)I>,_LLXD-GR'Z]I(?C$+4*\-"X,_' ]CEJ=.98 MG@"\#X,WA$^ I,#^.,%0/,%?5Z6I -=Z[OBD4]BTZ9E13X(;Z0U5,=926::_;/4 Q)"+T,')?K^F* OYW=<7J6'@9(9 MK85HNJ=:;=QX1-1#I!5!QG]'IT)7: 97XKHQLL/JHO[V#S)WE@ M_3?,:42^<:;'SCVI/G;9-?$*?,S9*4*/:NQ/LAFD,7]4XHE)>Z--CYKN_FK98)"@I+JR4YL,;6'J MT\FD502_PH7_3XV=8CZD'KML[%K11:,->8=\QFPZ>/OM8)D/@F)ED9CX5CM% M#1]#?J)8:$R8BC6O?=Y34=@;DIV1V<<%%*DRV\P4N<2@%2];NQQSC1VXRD.C MH@GQE-/Z-B?/C-5@8]VGZ4FCH288[OD)1R;5K>1W7=QZLO"=^WB^7Z3( ^H M3%QS-X/W5+M$09176*V0,Y(9'LM&CKW?%!8TZ%?Y6JQO,0$W0/-'SLJ1TER* M?\QQ]_ ZT)M&_QJ@TLJATJK?HV5B^W@TN,%UZL/92&T.?;FCO.0_XS](E;AJE"B(+=-Z1@E']AA2CL\#.KQQUI;_ M*V"%96/ 8C?HBHFVWD]7# ]L[FFO^)[Z_<"T8F8);S]-Q(YQ9JCBA.49"^7V M[9>J?'0X,^TX.X+2J-:*@Q_3IQLW?0B4."]^:#R\L1KE7+M"=BHGW /^-N9^ M*^TAJ)\?'<>P>4 GN3*FLLW*'Z"0PHM^!/X2#]S++9^$O4H82U>NCX$N2[^4 M)V3M^L,!@+,ER9M3S#L:_2NER3^"C#SU:U)FS9?P45HB$E "#SV5%;#H(/\D]^<=,7+<]Q$N['4(DC0>!>5 ?!37DG;X4S#HY+Y(CF0 %M39KODAPYAE5%.M*"+#U!4U7+F*XMN^EOVP]D5/T0'7@%RD0 M_K9_56FM*@KG4;-&]&1X_^>98@O'?S6MS92#^GW2CXGPX%GON)*L$FQV0B1, MJ$'[:ACNAAKP"W3]ZVL:99:5?WHM\MH-$Q>&EWN$\7@+/W@N4GD0!^Z596?2 M+!X^ <3SX ?/RJGJ,CT!DF/OIJ@D>&BM V5/K^.27^&7GFE3[3"X$0QH?)8C@+0:$^03:]U/4+\+,>3X : MQP=4&AF^=M-_V=O@6=W,?S?+>./WO$#J28HT2P,TR/UB[^S?PFV#.B)*V_>T M_^:\ BY.;*&YWE?EDSN6NYFK!RH]5WVG:*-QTI=[5OSBZP22XK]W5W'_D26U M0BV5+]"7O_UM,O1L/+(GP")Q]\F)H4=GCJU[Z'JHH3%?I3(@CS#NMGR%,_4/!043TA #UU[AJSWWY=#,QP'7^ MK']&$W6FX%K=1YAV-"%2]#- &Q/!XWP&E,R+0/ MY.^Y.)^MPGC#MW;YS-7W# A5425O^)X _WI3X//U7U.ZFVLE1 )YO.YG]W91 M>?1X%PN393>0L!BX.VP<''68?$_&#?-6^KYM4!#8:Q39!:5IQ(_M*GMV24*F M=?7)_^21^H^XD6='ZR@'VC$2=_DS1IM&;W MM$+4>&5&$O5_D#J2WNE>Y;QRA4%/'US!EO4U]L"Z="E*MT17Q)V*PL),@#QQ MZB93[6%R""GUY![^T$.0Z0+FJ&9L9S'JGS20X*N4'WZW$C8@JUPG+.L9K8=3 MG.XB^_,#C3NW=_J0AG"Y;JS$S.4)- F$8'N"..= E%)8A:/^1M:)^7>N)1=< MH/[,;( F5+HO_N5$/^W*:R=] 7KSCU\;_*)[M$C.Q$=L"QZ3$4[_*J:8.-3J)DJLK M_Q3_PQTVT?A/09ESD/5?_T@H^4<:?.DRL?7JQ70+4N.\NN,9I-+_9!#XE^@9 MT\WF3< EO8ME\8?..-9!+KC\I7K0W=3'FMQQ4_J+EN4 V!B7%.(GTE@L=:=G MF>V<-A[;H+O-+7XCXZTELVF[L7#1U3BY\;*MQD&];4&Z#1ATC%V[4Z"Q\-I/ M^\>9U4_!NEMB \<0LBQIK?%?4PS+#Q93Q?MMF UUTU;3'!7@O.J$Y8Z 4C7* MB(F4T_"A(B^VD(>F%E][$)0^PM=XO%@#C;Y?\^_]8]L0<9)C/?U>W=:5/7X M(1G,;%D.O70N*W$>#,WDO<_@W&U.!<_P8)Z9<%=WZY,\+=HP:Y84']*X(>S@ M!%MY Z4UOB[<9NLBS;P>BQ+GPVV?W3:"JRD2H6/PTI&'8J?25VQ\]>[;U[A6 M[@06@W9465=?SZ#$=R;B4",IR62,6!MDYX9W"29H\ARYM$";ZOVI%?!171=W M(E?G1C/'^\U@$71/4>%KC"/S3/U= %9\3 YUDE,56PM[P8+]K7X/-Y+8.I;% M";6;[#Q__?].F?./D-XCJ@22B,J\Z@[%5Y8WT;66[,+?9%1=;18I;=JWBE\- M7-OKLD%W?=^F9IG$H1B&:_P-/)0UFES2#E_YW2@PKUV#D9/BM$[Z0IBJG_\3 MS%@Q?-IRQCGZ*+FFY<*W*J1)%\:+2^/$AKDO9/D MD-QD7(M)LE0X]K0MNL-+ISC8Q M\ [EP^#LJWMU&G2C):E"*DE-O!5]L6JQJ2Z:$5N)\UX W@S\,-\SY2M0.CG M]W%Y7T\9F0RK:)&I_#3C87].@ 2*^?U$"73X;,H,V9;E[R@FXY2(:7\X\9U#BZHRBC"OLNQ)CT%Z&XCTKI9-C-W:ML3(>"C>D"]+]_L@*3MU;[_& MW:QH++J\P&\)?F(CGLT=IP+(19\BB!+U" .0!OB3)=A"/KPDWIKXGE,IK9^R M?WS,A;+BUL[CG+H=!9%+M9MM.;%_?E?CB\_MA2*OFG.[E98I1AZW1@\71$\I M#KC]8,)FF>MB(9%+5,!GJZ$ZR_FVF7O0GYPE+OC.2HILKT(?$-JMOS(&P4H8 MO\$.9N5Y;;_W?,WS'2F5? MDFG>6>Q$#"''Z8CCM@)4"@]YC>WGH1[)FV\=7_)@ E]B5A]C[A)I\QA2^, !SFD%O[7B.6IQ MB?%=E:V-1XWHTMT?D]6WZE)?C'\-'(^JUYQ1>KV^([[]]J$IS>2-U:!J[@GP M^F"V/NSTJ"!9U.B+W-'G!"7*%]QQIXF7@IXO]P@!2Y*D@=5[!F'L'<0LXTX] M&E0\U(3Y1]-X,%_\M!_U\+B_#.A>-V M"ME"?M7A5W5UD=)<6JQ2K-?^D8"M(WZPCRV^_?R7,0,,]BS/KX2E/;(K9 BV MVY+H37&O+C+B&T4]J\9IX_OE7C)J-<. PNQ?;L+@4DZT1;V!]>654<>=%C4# M>0Z+'Q2G %&$.(LH$$7OX\MS>6]O87]W>X+/=UP]P#!@7S!764"@9[$)S&^( M*41%]&A&2N7:&NV5.$9?4)+ZUB;_E;XX7!$_4Y\U6;=-Y6<714I_'?=U^6P+ MO[E551)A/WU9*<<.@$Q/QV;EL/=] &VA0+RKJ?<7TP/KCDM"7J M (3+^C[I*C5:'RW54+:_!V9?[&($_%"W>PRN^<*$ *DG@4J$*Y%6' M:9C,\*-C(WZ72K$Q.TT-.]4Y4H\ ZWR$^NV@]6>0_!9]0WN^/-O)@?@]&B[7 MT+1-"Z6'^,+9< <]).2W<].SN6PP\'T1"^DEM3](:QPF ]:"<'+HJ?&C?W*7R7,<$SBEWE9%;N'FR'7_ MO;1BI\.MPM[%5F(19:KZ7NAPU$'+'Y-O^NK!7VBA6HJ\+[\I#I6E]W^ =*+H M3269K<]5]1>8PTY]:2+W>5"R>7@6E)Q8J[+(IP^=M*W1EWG>]U=K?HJEO4D&PPP M_4O-,LO_=N.FX6+^>-JP;(#@Y4LR57%NK:4^:%)^7:JG"-VDHK\[T8#<'1ZM M*=<]CI)S-IH^)KIIY,$N64Z6_$9C=+ 'A[S9?HRK1N>&N,32@Y",Y:*EU5O= MO5$>+&YGPPDT=L:H:^$CMIT0Q"IA0WL6GNN-^YN+^:2N&"5O-:?(RA=B M4%R>Z3#$P:U\T+FIP9\R[951<3;?ONY $#02"NP42-%AP&D+P MX,$M2(*E(;A+\.!.(+@3I'%W)Q :=VW<:;2QYO#LL]]WW[W''>.>>S_=ZC$_ MK*J:W?6O5;/J5ZM6/\P^K +/%63D90 4% ! >?P #PN %(#Y]"G&TR>8&!@8 M6%B8V+A$SW!Q<'#)"5_@$U%3T-)04U!1T3%QLM QL#-24;T2>,W^AIN/CX^6 M14A,D$>4DY>/YY\O0<'"PL+%P25[]HR,AYZ*GN?_=7KH @P@7943304!@"5 M 6- .6A!Z!];.<3E/](P'\F%%0T]"=/,3"QL'$>*]0^!U!1T-!0T=&>/$%' M?RSU?BP'T F>$-)S2SY]H6:"P6!/Q/,]-AN3\5UE)['ZV D3KZF#/Q8V"2D9 M.<5+9I97KUGY^-\*" H)2[V7EI&5DU?0^*BII:VCJV=F_OF+A:65M:.3LXNK MF[M'0&!0<$CHC["X^(3$I.2?*:DYN7GY!85%Q;^KJFMJZ^H;&INZNGMZ^_H' M!O^,3TQ.3<_,SLVOP=8W-K>V=W;WX*=GYQ>75XCKFW]TH0!H*/]*_[>Z"!YU MH:*CHZ%C_*,+!=7UGPH$Z$_HN9\22JIAF-B_8.#YCDGT+C:[LA.+D5?]A-C4 M80R;A(EO[27\'VG_H>S_3)C__R=E_Q;V7[KF 5PTE,>;AT8 @("KO5?4H[ M7,A88DT.:>- A/>%>BIHAG^E^F*F%SX$L(!S95K9G&[;P? M&VHIZ#Z-<3_..$SFN%.3N6 M250M@!M.!]DE--&L!H6(%:Y@(1$U^Z\A7.(41E)@5/*7L9"G!+),F7%^8D9A M\%"DP#[^6J.7Q#)&BE--AWYFW5W$0I>9B)C*KMZ-<0_TQ1Z!M#N7WV: DIN> MHXO=E)]$T/>^Q;/H:3^Q=X_>/D+6%MV[,/([4H:=/COZ+)OXRXX\X ;EN\"L7L++9ZAKTH M!GOW8; %S+H!?P!0B+MV5XA:##+HD".>2Z2Z00=,C58UB 62#<8WB\H8Z+C1 M'L!5&-MV)KZ7!OQ+O76\$@R*:W7*UV8\5YYE3[_A>.HO=#-9MT(D:N@+H];K M0(1W-QEHJ2?(MH<6Q:#*_I%QG+C(PL^RA)"']].(PFG#RD7YU_K&";U9 :YC M9IG7[-TH?_"&FNEP7?Z:6!M3M*B U]QC#P\YG ]!JK?4*T?U,JM/R=%$J8HQ M,O,!;PQIMQ=>6G#;E#(CJ[CEG:;Y!^ +U*&>PIJP0ECF"&N$AR>7[@9I[^8( M"PF[&/)T+X3;!;.;QQEF?F[\WM-J/TL M;5$VV'])P+^;1!2N$"?F(8L_/!O M9'IZ:1OMQ)%)75NCY6Q3M84+W@'N'H3KWIL]]+^$*<:26Q["W.-J#E\H3ZI M]P!T7K6;_Z"2-C]FO!O/,8^\%[>#$J$<\6G[S]^9P0UX=@B7N$+LLJ;,-6WT M&5GFZ=&_!U-&34"S(1Y9J&&O_L,P,V"8"S9_*2H.1E#R;@WK[^ZZ'P#OL&O% M]833PEZPO+JVVJ9DAREH,W4F[;Y@'>DY]%B<"MQ"#UU6SL[P[R]?_9<3@O=0 M@/9LV?CV8.SR5_3U,=?]I27:,:AVP1UPM.V\+ MVFYIOYK+PF]!SH ? -";!V#%-/I?/I \0G[!T!L\P%H^TMKU? 9)P^5OCB M)W[V7[\K_E^.;;BW2OUW5\G(6S[O_Y^V-I;:7'6@,^$*@Z$-\U^-Y;]8Z4RR M0.CF57.;W8[(0^&IP'%13ACPZM'@F1'+A-,MTC 5_"6K&Z;Y_/3? O-F41(I ME-\7TOQY4#:TR1X _!9CECNF$/F3I;[8O*6%G/)?+T=3\K_)O.G]P?1VJ3YD,O8#H=\Q6O/RW.6"*V5KO; 2Y>F M=RMNF>^3J*V7$4-H_-V1OYL5J(L65(;QU8R@=FC**+_R> &XT/PK< MUM>F?Y4CODQT$UI/7XV#YKCH8]]%#M6SB_\4%-RJY$ ^VQ^U-B*L;YG(;ZA= MI%1W^PR\*^-4V'CN0)H6=J,G1*@S+;=D2&;.D^8O7K,'7)?OKVV'G7NS]690 MUISC/)JI_9D=V,X4AVK^ ME[5THCR9Q>E5+,*TM>]_=]R_C&V[&8J)6._S>0.7@1 GD&A=R4USE^=$X$B. M*7C0)E#=I-X0A@'7IC-=XJ]GN$1I\_9I:"=S:R>V2&9>?&4+I?@DORC\B61[ MUVBI&/%V1@)A J,F?1>\I6%O)22W+,58747P/;,[[,@J;HB*((4YEE%R*MT/ M#N^_SS.H+^%3;A:W>9)ATSQWP/5ZA;?YL(]Y7.F8-%0)E%_.=M/YSLG$38DJH\F>.(.:SW:[KL_7]>BFK>O )RPOYM M:(&(RK5GBGUM+P*4QN=11%U_")W]LC[$[IZXSS:@:L<6-2ZU(7&]6I><>)+> M&,KY,R+8"\T/V3B"=7YH="P-N&D'^]#>29S4_60'UT"Q#+_3QRAZ4LK3L=0= M"<+JO9Z=M*U_@'.V%B%2ASZTA-T'=.6C-V.9JN *[AM52@/NS-FK*J1N=OUZ MR3^\\#G36:W]KB_KYU#(TN*XH^ZB/-=3M[F0F(C@[6Y>N]::ANGC6OS:)5ZA MCVK! QA4<3JICR2"UN=\'*0WE?SC0A^*<1^VHCA5^K*VJ=KE=$HQVZ (C0P] MF#;T6%.4=Q442D,V03]Q>-Z.N9CG0(X^8\\7=^IXU; [_\^@^.IYEW?&O06F MK#N'>FD4_=?L3M=B$U297D9@M"&SK%[9P17%XU.[>OD H'NI.:X9JMGQ;P8C M;S1$ZUBS;G)<2V](XF'2I M+? &FM7J8F?(MF?XY[RD3LR;H-W%HB)K0R**7@J11#BAN:IDE7U/,9@R^YJ; M7J'U(^F\1. 8H7<$:QQLRE%31S4-:IPDNB[E[ZU;J!QX"BHO0"AN*YJCM1Q\ M;MI=%';S.=)G-1L$GA34KPU\A4V7FNI< MD'EU%'/3]J9]BN/!7[595*V6R9^Q>8YEL(TQP;?W7Z-C(SHJ\U2+G^MF$P,9 MKG<6=N[[WZ__,Y*:C4- >) 6WQ)1N4-PH?Z9O6N]B#>QMP[2WT_P-]L.%/&E ME0L9+ *]PS"&0]X@URJA7:/XY8;MWU*L< MGOVDD22)MJ*A X1+BJ?]M)5BT(HL/-.P&UZE^U\UDX'4*H:-2>I")/! 55^J MU*2K2[NQO/!['(/68 D\T=FI3K$F4S_Q;U$"21^C^-F/WA51#^X:0D+;R&QH M*,=L^2G#2X3^YLHD5[P;-IK+ XJ^^N%)4HM9M?$A[&'X(?6JBTM/4D<'1'_- M\M9_VT 5+KY!$B]8M@G_ZB.Y"9JN+-!;L'(Q93O\ GOK8&=$1T)V(H_34$1& M+<&'LHFD/YE$4A@*<7$R""2[=&TI:F)X-]4OX2/'J-9K3;7K]\2Q)D05\^7+ MK5\8#Y;MZ;V?GVN*#)F#+?C3+T1UX\Q$:(>JHA@;WY$^ '&:>;X+*O>X,P/$ M%X^KN>_U2SW9^YH'8/0OX'JN)@T0_8<9M/^X YME8=362_G^/EA,BLGXZ.LA M-4:Z+T%Q,])=&'XI69:):[2O]Z4\N8FJ@.TG\HP$!?/\ZXEDOP=PJ M/?Q61.LS=&[#+LG8[5=%3MZG65PY_1?> /8A/1=UF]AD+LIBM+"]:/;#V$S"LJ2Y&U M)W/W#P C2 X^-;7]@_\5I]EWOF9+BU0A0"3%[!./=]/8FC&Y]?S=3)+V&TD; ME\L5J\K51.=!JC.HW71N \*"34_*#EQ2REIG;)[PRRL%Q7NS[8J<#ONGEZ - MSJW((:5>QCQLF9?<:G(8DY$*-P)/A=A?\PAR[]M-TRK_F3 P@4*IC,]#_\L# MT#OC4!>_GFZA._7U7(<].UPU2I8B0#@N-B?ML_O^O;U1N %U/Y_OXS MS=S)PZ54V!J,G5.*1M)PT]]XW)0 M/_DJIR&:Q$LB1"$*-O3^AS.U.G=()XU2H]B&USKH8)N_0"D::'Y;O@][;2&;B7JWN)4TOEZ UXU&,Q:R#.?!N(_-C,4 M95ME_-/5;$.NKP==/G5$2_>371*G] (>#T"W2ICQG(?GKO ^275M8(T 6K(J MYC4FDAY*MAUU<>AA5%:XK_7:LV"IU]GVGN8M=-4;OQ(2:5-\(E,-V1$N7' R MI6#_+LHS0"(4DOW8UYU48:Q/5R]0(:]QI#3C#;?0Q5\,] M6_:_N?3?5NFE!BMCZ[SAW?.HZ67 L)9I:2F[GZ+^:]_^',FUVX9G,5%SKB2E MT_^7S&ZI$WE-_0#,T>9['<.@%#;B?$WU#=,O9=V>Y[";6?OI9*3S#I"?H_J) MIYUH]XJA]9,ZZ,S].+2+50SE!)[,-*ICC0@.E,/:B";X*=,9->HFV3FW[K(TZNP"96"P!.;+=7+@WF:,+7 2 M2<5JVJ?EP"ALR4!5&"3.NQ:KA18Y&;BEJ3__*2:QWF*.HO MV!_O!!L8T$ M[GPYO!;,;.5V*,V)@\];1$B.&^$RR:2>?+G% Z )?HH3NQ2E@G-L0!N-%-:WXATJ<#-D:&E2 M25+LWWH%S8F&B=^+UZXNT\.?9L.\OX"U-9*'&Q->"=YF 4^! Y'UQ5&,&1]< M^'+X^B\L3KY&)EUZ.B6[-ZCOH5)^RI('-@604"\!F*%*ET?77NK'9<.N7&;* MQ$^2M&^.([8S5K5':?';!'01P6[G[<_SM"@"8BJ5"Y\/>PO=EMW0CON)>?Q? MQBE^G+BP[Z#.9/M^ NT-A\T(VQCROUW_L]*.CSJ)/ "$-EKSRBE827MK=44' MNU(?PGWD7QI.SI"X /"=RW;"H<^ABO%W:7;[F>'@TI.5'<%A"L9 M]C6#&S&8M2MLGF?I4I_YVDA\=$UEQ#O$!#&*T:K]]P&H2;Z+\&"Y]P A0XSE M_D>&!(W\VB')>H\/?>78H5OJD1H9"T+6$8&;V=4V>X(,,%E+QUN0GS A6.AH MH"GWK*;9N("D^5JD"W'>>3JZ(9A'_J9(7IB2@HHA199H(RW><%_9$_[3W;YY M0RFU>>JUR"[V3^>+_:*W*$HGH#XQC#X.^R==D6R@A8!-2*A1F5\LYDB07[X<%-2MD6AH26. MBT^'K=<<@\3;@?W38);BU6_"V@5>B@@V4!#[QK234%[+^/J66QYMBY^O)^,Q M5[O:\71+L!^_1L_\A@>;Y6")$6?JW--)!1BMI^@5'3WQCJ@O3W?;MB#>&F+=-(R*_= C63AW)//YA?G>U MAS+N]Y*Y8U0WX-MA\_MQ1(FAO>>P;0Y(!-9Y/_1G,]9Y1YXO- M*O#:VV*>->-CZLNZQ!H:_#"G=&7P)XKSP-MJ;A05,['(5[ZLTQH4:P'SV:I^ M(D:/N*7Z=$O1?(D%]IGZO8Q^JQN-61A+^ !@H^W);UPQU_ +,H=TUU?E9#,P M;K'A8=/0GC,AB9,$A'(/A%[ENXL8K.:'E*E7.=.$KEVTTDSQ+=A8'6:3&NG5 MG*(#*9A#M%#^ :4L61%P1*BYYJ8*:W\EK9%-,QP-YT=$T;7,IHZO\%;>#U/' M5PWBWZCL3 (.HT_*/U#K_K8Q5!G+]>L>"73/RLB<;AW1LJO?#>,PS'A)B&76 MN?H&^5(L>KPM!J$/VQ757O,R; "_&PSDS3CB/FV'\8AGS: 4[DQ['"7:%ZXP M=S,9F1.NO]2AL3]Z+,E4Z#VAR;9_W#3LFGEUZ!O"EF60A&1WT=?K9_P[:_8* M[7S@4I7X_M%@VN>[DDNTN7+DHG4W) M;5PQ&PX?-K>@=,G*"7S\2'329LSI9Y"A1>UAK>$] MF=*<_&K?E)NGI!C)0_@8K/)MFK[Z-&W0V!U^8+LN!95VR,S5;!_F7%Q _OZAJAY MDE'1G&4P(DF(Q9+IM'^YB99B7VF=ELK(,+=^=MT$EX5\@2(-#9&6V5>ZP*"K M5ZK6A\*"[7>JTHATCK1>3.6 :G ,M=4L%AP2(QX XY,^E\S<7?C >\CV8!J8 M$2>S$#&UOR\8-UM;RIV7B]V@MKA.S&<)GFR..?NSRFL&$<.H(*J/K&0TB\RP M/H+:RN!OW^T'C:BG'WDKB;ZD^/B2YF-FTGY=TUX[*OGY+]TLS(H^:I_=/J&K MWX1N.DO5M<4Z:;B8:=L9Z^+I(.$=!A4!@-O@G/$!@.@E"7NYG/W(;5CAY2GI M.R)KV.W8PQ^O3&+]F!0Q1!O4S>\NZ6,\<]&XM6(SY>39\&(X=7[K[]6[)0I0 M-G+W?-=8#<'84PR#8L];^[Y*B^9<(\T9:/5%ZZ3I:UDP.&FAH:]/_9L@Y?J4 MAMP^S1^4)(DQ09Q^XJN3V;W,U7+2E_NS;?+;[R7T(23;79#+:N5H+W-2G#YD M\AI7BW9V2-;)$0<&J0]+ .;Q\RUL?2M4',NP?:715$DPB=K1 M.A@BXM1CD5ZR=YU&8GKBN"L8[05VY*NPT6J#DH<> %0(_@F& MWTS/E9'S^;)2*NH0F: [?'>G[2*8D4 %7VFJZ"!6+3#_I"3MX'MMH4O5V'M; M?68Y\\1KT#+GW_O7*R>11ICAS3*8VY9"_ =E!4,TV30_\ENX%Z1>D">\1WU' M>72^F2>ZS@(X2)M8ZZG,!B@VOREZQ$3KBV]$1::O/16/W!\ ?:\[B-1?LU'F MAJ"M^A0F"3FCK#IA6+8^>:F_@8'.?0[)@*JN?YSPMBW^'MLXGQ*J[M=5@O[3 MA&<74/XQO3GF>'>J]KF99Z0@RUC8]8OH%@QUCXCIVHI)DR?,!Z_-A R32K=$ M">#N=QRH\_<1]T&8S*,?1GXY#D8TOJ1LX_EX2V.S97EQXH\G&,F MV$XW-^R6@Q!$R:(VT+F;>/]1.U*10*'$FK UZH_C=C1_J3>C-)%6;P:*0)BH M*DO",^L#8 .E>;E&5 @&(EATBU<.7M=JBB-MD';ZLA;L\=%A=RY#*AH&&H$@ M?+J'X'@9B%WAS.FV=QDF FJ.O84#3#_\L[%YWC?0NQ<4I7^B=YJ.TZW(S:;59KJ>*1;GM[9XGN<-T M^E?8XNN7F]Q$)QS?#FH?5*ZY/ND8&'D7K:*AOI+PUD%F^X>OB]A9K_T0L0!3 M[/DY#Q5/]NN_=5-78U:[$UOVIVZVA^R]?YJ$"9HM1][=3.)@C6?>"WR(VH@A M(V?Z]O/B"2;2>>7;#[]"P Q0WSGMIKJ,Z9S&8D MGE/7#I,F51HL*,1ULH9$O1?"+6BX?7 /:Z_;F3&B:$SFU:457F I_>!.&^"[8S0U$=BKT:NN:74 C4UP-X== MR=8^WJ)QN<=(13F5[5>Y9J-(OG<(>-PDE;GW>H#^1P9 ? X].,S3Z5V]_6OX MR;A>R6F4KS^^\EU,[JAYZG5J6S#B]7HFKIMKAX.N]4UO:_Y@:YPD5'% MQR4?RFZ;Z$E&[CH'D956*GR\+ ^T*\+1TI?BR>E:CE%T;, 5B$3#QT$4=.L_ M ($QB_=Q2DB561>[U0B+8<']7!HI7\/VV_?ANI8/ZD>HUW+7-C09ON#9*@ M%;E30HQ!=-P*CJ5/SBOG%N;:$YGZWD 9H]H]LS"B$L?N:!"518AFM!0]TLRBYBZR\ TR,,O!&_4I M:+VL"OBJ&;#UZ21GM+O-;#\AI0N:4)2%S$ MC6FFJ^D0,24J6;0"66ILC%,[9U<"+/XYX].>>0">/ ;B5:TEQ,/@!3_Z1-O MWQ-CI+Q6[ , !IWS2E#?_W-*YM@F *=PT^YR;X4Q? N7;P\9N1 M-F*$UZO'W1J-M8@\-@(C%#Q%][:#N:O&RI;P+_+;F&+U1^'P9W_%E3Q-_<;>872TI+;J,-D3?W MI\_4DKLE*_$GO3[-DPU3_4%I2&J2! M+T;P]90^*#KF+_;E-:.*-2&HY5]E M3$[?))AZSL01GTFAUW&YJ"0;5 M+/(T-U 5/"5".P#N;* 768+.RO$/CF ]M>FO0^[OF$=)Z>\?[S]_P7<^;:9W^JSN7+K^XRK] *V#0[.5LO^T%.Q>:BAM5_, O/4\K\;3LX^\E-N'D?W N&5H4 DW M8GZ,V:\Q';=V_*C@]7Y- Z_#:WM$V/&+(ZY1;3\OQ>9?/;Y$)N-TJ'('9@2_ M7P0MRFRQ3%0\ 'YA]_(@E^WOS(D+;TKOA#A3\B1?=K-ZE]CP.F&WVF<:30G$ MAG<*4\.;P+C"YK3;2.)=3'!M:.EZ0S"3/ZGV7'0:CWU-5!H5,E%;;71<\!%@0K32_KO&+H:.#410,<#H#"6@?5U\]2\GCXO,:RJX94["P12 M)Z*I7UE'3_\ )-F6^OB=W7QIQ512F!;;^A=R87K8XM"2V9Q +^KP MJ[W,A89$-Z_>N%:F0/K1Y;L$M$Z$P"#Q!P-<&\3V6O"<+AI>#I5*DBLU9Z.Y MGI9Y0AK;D(8T"# R,EVIMJ)*"9_>7'"UF=V(8PG=(W%4I!F56/X>VDFS;K=N M@!%5IF"T@,A5PB?N\3'H;%\2W'#Y+(BNG;=@6>=2R59C?U^6;S7OC&*89ZKH M.$-=N6O05_;&;R1>49\N^4 M,OL%/NY^#"*^.TFO1A 5]L90]J1A+63546]J_0% M\0"6_3#@Q"XT=18.[6D.BE*?=_YQ*RJM\N3CW;!XH>@-BCZ2H+%A8JW^EB?R M2IVC(2%*P]%$G\;/Y<9CAF,MG49R[?JS=_'6D0BT0,QF]$X@RYIA>>$PM S] MN^Y=>VS9ST\EJ!Y^$E>0M+_PCTL"Y/QFNSNJA2&=1L9$B?.5PW&Q6RI,C.5).O<8_V[$6X/D^EF MPP3++-(<;8-N@-_)+E=V9DX,[3&DD0V8A96W;9EE3B='/$X[^6^]2,33#&5- M.;"2AKJU- P(SMX7O@H,)%NUARI?6(_#G6U2Z">.Z"W"?Y"\_Z0MUD%G429; MH$BE)Y.:=F@92W2Q;4?[IY;O5O!IB?VW%SREU@O?^R8&^F&@F%*W +ZX@$(2 M*[]NUD3;,=QB<($LF+K:O5[/XQG\>P"3^:<('W*:=>K]$9^7LQQMA86(?@E* M3D8&JU1.'M7RF9NS@//R7/74^SM%T4MQ*5GBIEZ6E Q]>W N]8EUZ1C[H#MN MZ)]@XL;3:/"XA<$E%'#*KS)#15(QH*#V4!\,AEJ;7B2.-:]ETW+SJDW]0&W,XCR)V,<8,OR_^G#K MR[#;'67>L#07B] )Y>&SY(EJ1OCB5#I/]] 41R:MBX3UD#4!ADG0GK4-SLXR M$ATP;R"^UJ+)-RZ54JEIYYU/,DVC:)SY2%H?8W4I0%K/28C):,5D-BSY>4AX*@MS00(S>]NAT40M[SD8+#;T.T2=#' ;8"2N= @JY_KU[0'0(Z)I M0"&]B=>I'QV\M/WR18V!\(T098BOPF_"+;F+"8?JWH:+NG@E07D;_+A(;*Y-.R#'$$^&U8>ZAD=BH+VS- M?+^<^6/WZ19_V(J:[))M]\&5U&U$83 H [].C&WXF(467YQ-W^:MI7K'0!DK MET1TS*K/^[!C)]]#DHGR2_*,Z@C/K_+I]S+R-SP4?JI.&>VV,2[4_0Y"H:Y]:.[ MGR%8!L,?GVYB?UC\J5OL128Z-<_F8-.X^:T0U)C]-#.9[5S-*-,HN^C_$&#_ M.4 BGO%ZTU1?A4C,7EQ:E+9#=]S<3.QBC2PL%L7>L,S";VA?XSVIO\=M$D!B M]#X O=K0!Z"&I*Q@;QX9S?RK2,\H1Z^I6?]#U1.1&\(\6(M+&,"VHQ+\ %!S MJ'=1L_2.MSCTH$H7@=FI927IJ+97VCVNC\* VX*)GOEG=Z@V2C8JJ;QW\@XA M9]MA >KPZ.":4-SZFZ-,[.]IY).5-'_P5%;9UN9?H[\U@'$"J\DE?EU4 M+3SCM!2M%SR&FXSTKE(>'\ FZ1"U];&)JO-(7)@[PV3 ML=J.MRQBYN_6M9>)/IC3<8V;<*/ZBVJCH:+")-5;&"<3?GTY\0G^_K7C[0XI M_[,KDXX.BZ+1-"IQF*-H\@UE^NX$?SUL^09EG=P(U-64+G[SNI8RHOWF0I?Q M$17\\GP9$3-I[^"BS^T^LQ,HB\'UI_U4J-0J?2]^/^WK[!04O<<&O6I!5 M&O%&DRCO;O@!P#5^!H*)1SI3KBF-]]@O@L@>@/YVA9O4-HG)X@'0G[;ZRN:H!T"YKB5PZS5,5_4F&(C>-I)VMHX3V_%Z=19-N&>D$GIL MMG1EX+O#4#6A?3VS=<3&TB_ T[\.5M/.BO4]?U**>V9@(%4I)Z)HQS\Y-BF3[PH7)H=">^AJZ;NP:*#\99E&I)SJ9 MZJVB'/RD9=Q2_FSP?'TB;+ER^F5ME[%^BRQ5E<\IC^\R M6G0/-HQ/N]E5C?I:2X@.,QD7I=_'EX&MLJHQ3E7],Y8].4K'CNP7FOX'H$QW MZ]J98E+?\G1'N_A=/_H[=Y^2.++.K4>E]Z'HZ M/CH]*,A#/-^&9M$L%BWR]#MK_2ZG[9;,'G,H//%]XHR6AZ MB';!DGHM^N3]0H"WK\9Y1#WA9HA/9O;+D,&BKJCNK8CO&1L$J4= Y@B\H_>$&0(RY5MI;+([OT M!$7'M%GE^!%YDD7HWSAX$E=[W0%5[$59MSO[53RQIXVG)Q8)'13O+.ZWVP;8 M0#A*[-F7?=5P\B]-DUPF/#S VVSICU3G3)G]_-W!!HE$'N*9X]<96G@YCC/' M@BO!VOY#L!Y[F;FH4W*3U8WG3]<>@"R?VG,EK^IGIY8KA.?WLD\8]'_FF\KP M!*Y%PWB--;27QUP+,F,W89HE\NX5.6%L4L\A3^^S('IGFB=(O^@@\!6AI_DA M^OW3=:,S8_X[Z4F.;NCH>;@5>+R(9-=7X127U]? MY+C2ZFU2..Y;>",IM@[I!NH;&2S ?#J0(D%XJ6B)(J>;49:_ CRTA1:E8K_H M;<.PTD,AMF:QO+46/^2V'OES]<4$6KY^?>4X)&;(')VS$'=TBT5CI_O.IJ.X M&S_U2-M[Y/676@/WSTZ:S>,'G'IG!R?]-NQ8W_FK0F<)FT-%[&,COMEH]9CV M/:LL-1O2J)0!8$4X0GSN1^4%Z4=?CUQ2KEX](\B4>RF]N4? -S:RW!+E0:65UVY-Z&MM;$V2%,T0 M.CT5[V'&=,B1EG1%Y4E1Z5RF+R)EEF_X*D.V6YAYG1"0%XUP 2RFVVQYBY+9 M-8]G#$4>02-31=3!Z>!;O>TR.6(IR^BI"+-OE=R!@ZY<'ZL\=8UX*G9.XO.K.:$^WAC936/E^1'.,KH&XV9VZW6:=?ZK:VV! MR=TS.[.^A(2%.%%30_T7<@*^!$AG3\G)NR6?3@'OW4F?VDXH4[M5\A;R+=*Y M>$T[ 5&M\*3A5N&1)?=T;30_ELUD&S2[9]J=E]V!$7X +E]0,7 M[CR[C+1GO2I3/_'[VD(A*7R4B&,DNUNA+KC9[VA^9,Y&?-KW#+X\(J_ZG#KYM.44(HA,3&+<1-*&FKIH7"X()"*^)+ M$D]WLV>$3?Z_,;>C4O)#C,;SHR30)V09K^/HOL^B(4=[K7H+=F>2_+>58A;, MS?E+P%HW$)7Q=K$RUIKT/4/Q2S$#<7%U*[%H[JGS??.@>'M ME@-4-$*EMT6!,4,$JSRQJ3O\-J"#(KT_6^#+@XU>(12%N-ZZ>MM6_+6++6>< MP-,M3]=EK;>+I!G<,_SGLT*-O;HKPS<'Q'(R\7:_I[RO" 5X^$LRR@CLACGT M*B(_9[C! U?JT:(6IXQ996PT\ #-C=C8>K3HLUWM'-VR8X8XS)8)H=-+"]JW M6.B9'] RNYJL1:1G]XO%=1H5;\974G:UZIEGNAWE<=^I >IC4?F>05?]"G\5 MM5(OCRB'A!B#=WLJY2!Q4<^Y!&\+-S$:BL]?,"=U&.UI#=OBIS!QD+P1_BRW M'>$*75-I;$*.38I&BI_DO0K:3.)#/QK ;C2)UD!H_TB Y0?UMAEF&JK\/6LR M.'/0H^KO:DX:\WFSYV%F8C;),7N(X;?G8(\()CZG]NK$G; TIN:SXOR\TN9, M\XG2E?U7")WK8E];)J1A2^,J62,I_NKY(Q%2T#)Y.3T <97%OC.O0.=Z,VG: MN7?_/4,519J8B8#OBJ K[VFLO[^'>9HJNI-VD>P)6T\5PG];QE!*_O8]R:## MWZW!FA+>5\#!B$-AK6/_VDA=&_%D[;:-4[1*,XFC/N&R?;Q' ; 0,(1WCC*@ M9E2"WV%,.&B>?_&,E5IZ_4Q#V1V:JMWFUB'6*M:K-HK$003HCVIK"P?'FV E MR:5P?7$R-W<(I**GECR6H+&7]M!%T,*"X'QZC :[.?)EJ5MLF?S#RK\EZ)ZG M#"P*AV7#C(-2HX/.Y6L5(QW?-44Q:W+K&50/.-AWL+Y""\AIUH<$4]QG^C'" M(\K EQB:ODR\[G\B%J0(ZLEV5[*)/;M7,&O!KI*U4UM33JT\E#"M0:Z7](6V MLQV"4''D),IV@G;N+NC)G=3O\@(E9/P7OOUX,'=CNM_(%+@CB-$*5^CO)[?^ MCBL?'!MNY^)=UQ5K/.V#%^1OP0OIAY9 MOK..7 ZBLJWG[0?Q([+9+/P_?*W>%IK>TD>]C)63D*4CN/J!<7YO4$XG&V4 M_'(83I0?7 *=*.[4EZF4(K(L3"33)&=N\B;L,Z-+*4N_O!]KE*"YM^:@Z2/V M7Y;W,1TM:49)XQP;$6/+K6F(TZ0UK;WO$\S0J! 8-1.\@KCD6XX'+;R!:&ER M87)IZ=;6FSAR]!01I&OQ2SB\*U<1JTX2$RNA4.+G(MESHO\D3VX*14.CC/(6 ML* N>7?MC&9![TX?Y$862FHQV &DF8$B5<0:XF X_!)TH7:QP#I:D#$TLZO% MP[V46/$MU^\_W%MZ-"(PN6FVAAP)E]_5:%%9&U6Q&?DTH$?@-&4DB6)CHY"/6M' M!]GJ=\B_CK9NLE$,2^M*J@_ A/1C!9(*LY"K\'XX]E[+9QHOXV+:RYD'0)+X M!Y5QBW$11"9##?I$Q*[X9/9W78^2>_OP.7YX[,K@R?!]Z N*%B4G(O.??DC] MNOC#5#@$O1OL;6]O(2X)+H^> /UV3NO'7D68V V=R9#:_XP67\[/1FZGF6Q&$%K6$SI]# M6QU%U.?# [*:%XSC28(S'Z/X&JJ<@R6WI.EBJ A66!T*'P"(T1<6T4*M7VH> M5$XGO!$)A8VY-LY@/B&K]PZL;[#>O$(1S[MG2YKA"\SHLLC8+5<]<2'&B;._ M$\_8F%$ACY>+D&>*-YP_=XIYZB06*FKNLEUH ,N>/K1H'N-\WZ995?6#\M,# M\!%EA#=#OK\ H]4K4;@\W<>RE5(\&<=X;L+>.Y1O01#\^594C<0<[LD1= M/>O#G\U^]KYW?D0[YEG6=>C;:$DH\TNSA5L9NIHOFO*"[OVEG]R=].]G1]4F9*E[@Y<= M>[D[:10!1A@%SL?DKZK]A$\U&BL$Q5LVM"=<;&S=! M1&KZ,;*B@W9V3*<6YM:&E3M/E;Q,[(N'8+141M917HV<1TPIOG,CW\3]/FG/ M*XRX)+E^44JN\@Z-#(,UAZJ1%HU0^^V"N.A27J1/)PSE > P^S$BKW M]-B <:A=Q0KK2:X0DPNK!S*Q&!UX\;+YI[FH?^$F2'/'9D?(;LL]L:A/K[H] M4R?*$X.;&O9Q/L\52JS+OV_SA@.LX[P\ M%:I9B29 $+!W3,]RQMQ0LDIOE(HUD<:\$14ER])#LKC1:TS MH*]45(GOZ*;:3W,$[(3?R]_,^#O0 M]@?CZA>Q1C(TP/,F]0H_T&-AO_W9>6,^QM]Z#>O'."901KF38>N[TS!%LL&3 M0_C07$[E'3:&][OZ\BXT+[%5A)A;;[MH2*I.[$),QDJ-Y!DB4^;EN1OGHN0% M[]JQ]YP220]FI":[ZG:9H;@9M.<_?%= (S4M7"2B&OF9B@E(9]P_F9;)L5?0 MLS+:9[\?@"ZE@M4'8*C+5_AR.^%5YY\E_.!Q#CR>>]+VM15.U_P" MNTJWCD-0WE[9\ZE$9=&L+SI#?A[5O#C9AGE:U&=;$ZJ'FK-/ #4NZTKQ-X4 K$[-CF! MSSC=N8C M;_"@Z@)FN7O\5<]M?@/+J^,9Z\:I*C&W74*U>73=6#'U?5!).K?AC;-UJ<*5]GJLIA0S1/B95Q/#>TLZU2 M.9,_6[,TR25/#'M9G/$/IIBVIF[NW9)MD07))"8M?\U4#NQU+/VY\9J1#":O MG9Y')WB'M7MD'6YDL!?)9/5MNDHZ(386#28AUS^,V>]KY*EQS+^/H_/AK1)N M!-YD&)ZF/*A'%EN\UI Q]0_FUT_V+Q>/3D6C>)XJ;WMY*P-7Q$FZR9HE(*N7 M\RNQUULB9'ES&[3/GXQDPJAY=I>"'H"YW%19L_@M#-$;LRC@'/+[3JBDH'VM M540K4B&\V2FA&$DHRW@B!,G0Z.)&G,$VEZ/Y#P?J:VN?V@1UOY6@,LLB__K) M0WML7NN77:X52>KGG,3ZVB"3")H&M2CO_<-L&KG32VK:M0*#G##62)7_QU [A1,BO'E+V#L)> ME'0RM9O6ZGZ:H__ O31#[8&]OXD0RC.^ XTZ1W)BM2WOHU_%7I MR#CVYP-6B.BN:7$V> 6\K#ZR[*N3=@UEH?\J^]CSG_,87R\8(4RF*78P7[Q= M8W3=H]R '@*<:X5YP\7 I$^VE#85&]NY3A N1/5:JT"7D4"\PCAC')LDNL-7 M=YR['JI3FPD^4- R<>.);S!DXV2KL&C1^HW,#,^"(?AY$I#\2<<>:@T<Y/1@DACZ\C:7NGQCG^I$V>W]\(>KXOV_=2.O2[F>YD_2D$[4M!_:X>W/&]9$$B^U M[H6:5Z,TLB[\%+R=?2G[E6*SQ>PD7G:LC4K>M?#8[KE5K-3;G#:KKR7XOS9W M@/U,:7X;6839FF?A"<^0C3A_N/Q&2V_WLX/*$ES'?J;S+#RH9&97W:4X^T0- M6QE!65X[C6;K^:I^M3NW+?6@0< H03_Q^F-''&CAI'-N:G?;A\A&#XTQL0O2 M;2)H6KR?N4S8-.22&;?\!\'\ 3A5JHF^M'H#L5.!XYY]_O?DAFM?Z M9D3)KM[N-ATKV]4P8[P$1>!W9R*>N9Y'9$^6 !\CGGN& ==7'3.$*[K'-KFU M/N>6#4S1&AF)"W,&?ZT\[;DK4K)3F2BSNBL^1X.Y,@[/1@# S&^)DR]^L+EA_=Q65Z M2U1.M%-PKE\6E95X)1:N;8M_S!J,KS_S)-BZ[W@@B>-&<21Y^AFJ %VSHXP5 M%85T6\;FMLGI][)^-99C3?ZXWQV4\:M9-G7GRWJ$C1(=3GIB8R(K&56;,ZD^ MX7N<\*026TU=<=8)VT_1J^D44[?F47B7R#%&H<9&OY:@L8D!,&9VKZ>#%D\[ M*FNLJW@;(N@%!UG0,FT+9S^JEG_ED/W(G(O_BS#O5>E^ MY17U(IX;]<^9.5.KJ70Q%;RTG ++^;GC],^-,?*LIV%/B<4Z+JY ^1_A'RZ; MQ'\X>GY#J.8Q2:S_C3G':#SLK_PKM67%K=B8I9T6ESW.8Q ;)^'3N'JU3CRT M,.?;-0Q/H/#.X^G/U4F_TA AX=CCC8]8!]#V;#9V5FU4B,KG%1T7"U\I8-B? MF'5#"]R,#(TV[>U_@WYF1<5&-U^G91:PC>_&]%(]S^.FDUM7+?K]!J!^(MZ6 M5]TE:N^ZB9CY^.'\/Y]S^[JE/0#/RR=Z5_!%Y4O=(*J3[+EU;R>:$KC>XJ%^ MGZ#)J8Q?,P[7G/Q9]@83!(<_ -.0BN[U-_!=F M%!\F[XIH&JP^MREN=)&OR;DC2M=KRO,;DY$$^G,A#+J,GULMLWH&7B"X^0U- M=NLA=?V\ L8*.OSZ7#Q0NW!6GT_8R1'*E&GIHV/W4L8W$.\G[7@;&V]7_S.M M0G\.$-,,VC0342\4$%*;MXDR.EQK!$GU,G]%-U\&'&[S&TI+(V,Q?/9GA+[WB2ZE2\LQMDB&)P M(V:[BO:_;EL+'*/,>OD+RWE:DF.RT?%EW]IXYN^'("3;V^16SC@XL_K%-UH1 M;:3T[EGS&4?$;SVE%TET]OUB(-%X>2F(U#IT4'CD_KL.V^P+-T4R&LYRZP[) MDV7J7$_1Q'=5Z+\BYLVSV'A^Y8%CUW\C?+0HM:UJ;-B^ MF'E0)7\]&<(1^9VA52C"6[ZLRN]SEJ8YZ%'WU" M8S0/.<*G'.BDEZMIE [IFLS-9)"&&_]5X,'+3J'OST_,MN6^!;\%R)2.LFM\ M2T2IU0TTO39S"?,SG!701) M#16,X44:^>9P%MV5P#>F,G$%! MKPK-WJRWKR1JRI+P$;TTU^0EVI? IW+SF MZ4\[YC'_8,8X0]?S;@%1I8]^)=:)HX8?]SJ1^UNSWS"Y6QQN,L%]KNZV5FSPA72DK/;.PD2A!E@ M^*=!.@1UX[04?YCHE6DWIH.?\Y4=X1GZ/@3T(=?<["@JLH_P0AG4-]KYSTB7 M53AQ0TMW4E:7F>OL&S.4CS2)L]GQPQ+ FF'^H*/52TC3K&JT\,,@*KC3+4"E M>97?FJ?RII^Q/) 0:,F3H;U]9=V+XWU?M)ONG_[^=^;:5])PQ3*BB^]=1"C/ MR98@\IW4<7-S>0JMF292?BK\L<%;-S89XT._*Z %=!76VDD.2]Y.3ZJ#^'C0 M_@;3T6'P?O2G3<_KF]MH1!N257(N57:)VVJ7VO%OR3T/HO^LO>#M>WM3*(.+ MEXW!5T:W_OZG@[7&T?2UA/[O2$/9O&:C*.OOR8+W''2C].=63@[.JE6U.-9U M6J;U'JYS)O.4#7@ _8M$I%]V[YK6>EL^0D$=Q4[,/O?(8X[Y 03@2O]4&B82 M1[T,I-*I/[^MBM=ER]SPN/#U<%1N8U0/BA @29[Z[&9S3'^[?J$]+K.P@RE5 M(R^[K;GYK7D7>FA;)@)0#'5\-0_MF4 -D,U";'F35GS0766-8T_SRQ86_JKU MY3N/@K"LTST@7_.06RSY8?FRGZV#1<4B-Z"W"T>JZ5B@A3XS;S#6;$ MZ.X<7!HZZ^O1OVGM\'[RIL9-;3XQ9Z@?D>2WOC!9."U0C?D;->3<>!WR[T\D M0KQN>$>\RS/U^_PPQ>%[5+[() *.V<5ZS^DK@(2<^LWS./HL^GB1^(1\;>\M ME\A\__N36UE3ID?F:_AK_29N!NNRTF$*3-,Z'F@Q9'(%BG=>O2$95OMNIN#X M.#9 6S)Y7QN\;DK=A1@R,?GWH2%C_R-7+LVI:VY9/D?XVLZ]6C)].B^C+6D@ MRW>X*ERU?M8]^UL8"'_Q?=A"W8",]BTW9YCNR*N8]4E ]'(H[==X2TNY(%][/TVW>ZT-M M# 78#)UQ9T%;SQ:D<0*7QX!'RO%)T@/.!C("C#SC0"]&+X@.WJ)E-ZPZG=MX M3/$@?3&$06%HO?Z]*$AFW+)'EGE*Q/EAKYW6\P<+ 57;TRE,:H2V\ -H-H5T M4+5C$*F_5 E4#= T^XS;RY1%X1&SE*I+_81:F2IL?8S,H9%(-+WAP^S>AT/C MM_%3;C@'8!@S?6Z3*^6N]9MIYZ3S22D-[M4[:?A44ZC3ND5A:MSP$>N:3.9 MI+",6+^D3TV)DQ&D9Y\XQBI+IR %T,A9+=M457LGJB.U#V\!'V09!49=72WV M<25H$D&?L^^N'D?PFA_4L)YC\%U3T]1EXK(=BV MM!/7%^K9AN8]M\'O#@/*^RSZ]^5X?]5G^B^?(?)9@Z9F.Z+'O=MA _1B<:<' MM',Y4WL3O[38%*0C"3ITP'HOBV54UWA+)0,SJN%!W?/FOT)EM*7@W@]%6:L_ MLR[)/;Z1ZPF6?9.U!'/4A#P>H@HK>U/X!O=(U2+Y: &O7GD+N'&_"Y(\]>;T M__I-\!WH ED.;R*CZASK1E3X#H<&K2X2(U7TYZ(/T25GG9$T89JSA,D[[)T3 M OET)#(/\$Y!)%=/RY?FYG=%DTPM%@;<75E^##S?H'_PE57$$21C)9V6./+" MTJZSL^\9K8 R>VU"U].E;H>%>0 M[S^/6ZW"\95K%6GZ'MNPY^,>; 1*5!E==V53K*7Q4=?OYO2T:&8/KFP=5FXC M'CC-%F=#B(ST)DT#Y3;D!5:BYQ^G#JZHM+E*,WIVKU4H5[]Z->+]_AQNK==J M$"JXJ[8++TM=?H0+\O#)D$+8_*V]PP%..Z03F=GN)&0]25WO;2E?HAC[C:DM M":SP9=V^YSU,IZ4RH63B;['UHKHC*1/U6'Q3(.\Y*G&^'O2"C93&ZQ8X.IDMHLD6^C\XUQP+>"2X M)G1L>/'1AJ?L^^\9CE%6]+,QW^>Y/Z5-#<@ARBNMU<^'#,,E4I1 M#:DI53Q?*+AN+R;:W-&LP3J6%XY\;--0XUN?*6CY0OIED9*0ME\25QQ] M1OWBKT6\'#*W?RL*G[BX@^=KG,9!W7.["6RB1_AGMV6-E)V; -8WU9,M/"?+ M][%/KGN67DT+T-ND:2&L'S4+I $]$AZ< Z)/>4[ M_8%D-4=9T>^J.M]+VE;N X9B.TMD^GR?P]*18<5@KDLHC+?<1[SR<3))Q'5M=RSGGM&5"*[U@1;W4&J&4!J*AG M697O;;!_2=J4:"B_SW:^X=VG6CK_>MY3/A7-6 ML=5_RX908PF1V9IIW8J40 MQ=H7H"?(PGK"K3TD6\HMH"/RC#G6NC$RD/.W!FM]>.;J6TJXEX2E_*L[[H(N MW%LG@X)L#E-\+_-.1? #C)J:/H(_R;F6'->;T.,!0CI+9LI%D9TS(L])]Y3! 4*2WUG*V2Q;;[>TQ*#AU=@8]3Q"L)Y5N:?DG)K] M=<'&_IABIOA4_ L?$JZ\1"ME*AV".Q!1'O%VO82C%7Y3O*F'FK47;,4A\IF5 MKD"P+01O1JSD;@"G06/2LG[(SR'&KT+,1_B 9YM?EZE$1](/C%#M]>D1CAQ\^DYW\ZKZ:3Z);$;@%& MG\)2C5[(GZ]X&HDL/\ V=N]#C"87=&MB5@7X0MSC ]>WE?_F;RU2%^6E->F MH)KFI9#58&IM&"*02*IHPJF/#OPO-0XCG;[/X9QAHSRCZ2)!%!KGKJ3;:32:X%>?>P2:9>2$M)"% M#]#LQ;^H;);Z M0OWZT\:4OBMNN2?_GFP"+W,&BUO:LUOA_$$EQ0X#*%L1G5 M8;YTZ#J5#3LZK00#<31A6LV?C(\,2DMVE4A3?_QC):,2U*;ZYPQMT6QAP?D$ M+<<*5_K,FW0$B?O[L*'2VIHO;)0?@E"O=::HVGNB0N8^VS*_YF^^RE!- ?N& M8OFTEP_.6FP4?>!#Y,IL9K!JR*E_T>JD92_"[.G1?@OH>P@5>+R\H[M3J\E' M/?2/)L"C/$DPWH)'PS*JX0F:7BM\) /*G_\NF6V$ZQE=% $8E%_=[JF+$T;J M+GQKGU1NAB MTD_-7Y! \7+QNQZE:] Y3)O$FLT1U56=AM,XDRRF4DV@U9?IRGVJT!5"?8C^ M05\<\>*,Z\R$-0F6$2\L*8M!>8 [8/758I3T[F4S,G$MVMK$PYX_ _G]Q=)Z M*<@I'#0:3>O 6<(K*!8,_A"S*WY:Q=QM(=2 $)[:3^@YS(R+# -)K5<)74(F M9C8[9+"JUFN(B)E3WX@O562:98*, S??))G/(]?3# MAT?DNA9&$%,Z/F[V24@.%@H) M^4J)CEZS;SL2"ST0A1?_.'@!.[ZI%495$5TKA5T953;&MPD$L+EGA, '"9B MN0S9M !RY'&U&$62%:^64;$M[]=H>#K9K#.3]:*%Y?,7L_.^SR!L@\;KS/LQ M@7:YT0B- /!3GYB5UZ]KH7TIHRKC;PXNRC/ S%AU7BKH<(CP84G,I?O3$\$N MEBM0VZ12)?Q[O]*>!=DX>UV=''=[LTYTS@53Y&JR8=J?:3>7"Z&2\C6FRBLZ M"U'D1NB^%)==4W/+ES=0;S.FWN!\8+:%9/KI'3OJ)&/H216H<$)WFK5;_B,F M9Z\T^NL6 +_ =33@B ^+M0Z_+L^GG3"!S5Q,=W6/^\'FP;< H;&I0C]J/^IR MR?C!4RY=@]R?H=%<%5JA_]W/_[,=PG"$Z;0LYZ[84U-#3.\C*A8U*M*?[O1A M@]1;MX##C_!D?+!D&AXHA]6YS^<-N050^.L&.1:;WG'_(=C];-JX13XYC[^" M :-+[42F8W<>*_5FGQ),=Q[2W3&\>.QK:;4[BL*D<0L@R,9Q 3W T7C^Y%[' M:CZJ/(-:CO!^@[P&;2L2HA/Z0QV):IZM@:\ NY98TCN6*$\)DQ6:];YYJ#51O1FU M=[KZR=LX-+%?@K6:&J:#C5SC T,FO34^_=.!+.2"0MZ$8H#3[RMN ?_BV[^X M'BP)//+LJUP3P&PV-T@&-USS-#?H48BYK'@19IUE%^.4CU2RBW>?,L^#O9V# MZ.*\6F_.#4+)Q.P9*2>_W_GT^(CS!N M@+L?=)B/IR!_$C1.I'<+Z+*_D]N M#(.CK.\5-+YNFJ3V)+FU6M%7HEG M\N$T@+?KU[O4&S9@&18$X MFEHG^-./13*4]5+?)?)@"+F>=;8GY%?:_==@JOY+J F8/^)42[#5)LE&,S9J M_!N&1C;R^20OQ4$SR5#+_YP>=_X]B(R2VP:6!JT(W0+" 7\C_R]2BOROQJG/ M+'L8-#*8(_S,VU%/%%X=+#*6&4:.^H7),XW\YWF/_Y\@ ,10),">7O?(,DPO M!YR'%YO)>K9 ;:QQY4[1@"VK0YH/SH5/E%8KN1F];.LT;P$\R]&T.3&JI([T M9-'1@!ONT_]HGO\*H/F3UUR[%<4E5@DP$G0WB+HC;:3E<#]-.!*;-4.,-^Q4 M!EB98'E[YOT[G(LCZP;95O8U#(@NC=;*\L(-2?*# 5U4=?^MX?\-B*0JX>OR MAV<7VNEHX1B','S#.A7_U$#/HL]HEC;%ZE M;?Y$.!;ZHP%(??N+QUGM ,F:B)"7W% M8WH,<_2.)S?'IFZ MF#;!FTI?X(O$WS=%#OI)#[1^Y2^75#]I0.ZY2#OFH"\N/.IQ2.T+V,90P^)+ M0O=J9E&)#?L[BV35ZY9DVV)HVU(G]Q]N\NRBW]\1Y;X#QO=GE\%;E2>V0AE: MV^CRGT3$/BQ3T0;6,'NKK7.T=2R*E(HP@\RAP\7W0CV0.A8*FW3C-A_0QU5$ M%K""IL/I0.X)/N]AQ.!I*R\&)(5H(H7V=)&=?-MP9BWRS2';US*=E#%:UEPR MW5T33:%6D5?N-\[ZD27CA/'UCHRZ!7SGMT?:3MFW-G4VBE'D>.L[%_?Z%%L4 MUEH"JQ"0G,7(F38YL3D7$$U+ Q_A3S>#VC_@72Z@8O3AV='F]Y?C^T\W=4%) M'[US;_9^LOY K)]5IB /[OIHN=,%/68QW8D^-[3[[:>1A-Z"V!J!O^=&'8 S MV]6QTJ;PK!%O.R4V#T9K-C>"Q?%K?7_>2LMY>+)6_:R M"%HC(\':P371)O3/C6Z_*)X.=$J -H!(K !V0_KP%S"?M3+Y!TVN0RKZ+ M4;LNZ2AJSK[O1%]@(=$VZ<(Y\^A+C<:'3P8\MH]:Z2[]@'&?"7:$(13KL:HZ MDEN1IP]YM[[%ZWWY@!1<(B M H^U5MKO*MAAHB5;BUW>D0))XK=@ QS*)CZ#]CR'W+4"0V,^U:;T-S+=9M/A MJ1*%\;W!,ODUI<3(BE5'.,7LEA?#7Q; MR5GY>EI)$12;3Y$?M9_ P> ^UD.N79>FS$LO4(L7;;8M@(&25AT4@.B M4+V)\[]BKGWR[&6DKL*@04XS]8H^1(13W%UA%R#7LDG/D"_>OP70JW78CPS57[%J#",QASOSEMF7L)Z;= MS^N_(G?+!55N2!P?0\DR%!M/UO%K,VEGX*ZM'=;S-J)/HM;/63+ %-D): MZ'ZY>^'O;MOS-(0_,>??\EVK=/%0PT7Q" M*H/E3LP11A[4G0\333_/$JAH6V:KT=WLU=YLB/\JM?ZXCS-W55:;7?!SVY MM[.CMN%S>]\G'C-N/='440D9/U#*GY:+B"J,M.\JC//H:;%TTF6!V2#$'RYQ M"1^0X5E$1M7+L.*?/OHE))QDHO87U!7P\<*%\!9@"CAS&INH;WT4^ /3\J[? M6.R?"RK>071WE;W2Y!F3@/Z4?5K?@4^:FTOJY &,+H-N\:E@L-"!&5_C1^\" MK&_AHE*9&O5T^L2'7^ZQS8P4*(0.49.NA>>]I=Q55Z9;@*T9>LIBSMSQV%QJ M<:6^E=-HA4R2EDVL'L62:T?U#D&FTLW*P!'2 &9A:L) G5 M.>\E9;7(HN3JIH:#4;JYK. MB1\]OM"F$[CHP:8G\ MT4F^:QISX:GLEK>IP-[7]IZT1O/WJ D14?KN=L[] 7KE)P/T9<\!9?]^%0NH MN,:0_-";$;Y1V12%9=RW:WR[<8^S2OYNDQ0J@F$T"# N,J)UL)^;R?Z90#S4 M)]8>F.,F.=N1FV?J),GJL$?/(*H<4\#I.B@7.?=8T%18ATBN$BNEB:1_^J6* M1;#'>>QWP>\.UIC<\[5&JP@I.&L$^T-&)PHJ'\!;D@ J@M'JD%-"+2NCB>"9 M49<[4;,LQG9TLZ0FK;<(YWW=L":6V8*":O+9#; 3S5> M:RS3QH"%D:1_IA,O:GUWL! %98 -#,\PY:\!8Z2/T?8O7J:J:5:-;3>,?%ZV M@R<>K\-PG&A#E:0AG4>G%V0VOO'.OWS7&PN][D(AF ]_J#1^1MT9PL_1%*O> M@Q2JZU"_8N&,3O&GR"T*#\A_P'Y-?=KOBQQ]ER8^1"3![ 515@;8JJTNBFI! MP-/SG->&'U08?$[(J-]T#QY@9XFQYJNQB;W?S%_P+!1$N63;H#9;8=W?IET+-R7;?UVHI15; M&O6+WB[)(7,U/I2-K30O1/5L/DSYJ#@Y/SHAG'@+\*Z9UJ_VI\A9VC9*EZA[ MN6"2.=M/PW4D5F(U"@XRO5M(RD39/2\765W4_BW:RE-8D=LFU2ZAB4A"0B9@ M9WXK7'@D<'_V&#T6O;OP7 )3)-@Q->,A9?2'BN!3/A;R9MSYP'F/[[=5F_-4 M_N H[3I1=4FQ0Q;MI+1$;I6W1MO$*&CAR;L&TM1A"%SM@J= M)N09_>4>24N1](2XTO%M4D+SS67G:!EQ8=*>9EO1;4*EB_!T_(X_]Z,KL_XG MO)]@FV'N [@&1;>Y*X*N:OV\8/%8YM6S8MPS2;OXBG*1F=)746\_ERL_D[@T M]MRYA"CDP&%:ARA*52N&@TS?HG,0\4-ZKO MW'TTK:">%MSL89UBPS#3>5-A[= MAP\809E@]?F\8(E8FBY34'A)X5F+V8BTNA[04TK]F?YO@AUC60YL8/9AO&.+ M;+B-37V\+C1J/N*'2&^:(*UY59'CFY@S MA=:/BIN)[-U705\K)$G/L0\6V\=,;]ORFN&6P\^P(U5XM9_7(;(L?%S"E QN4 M9VD!]LX8?M^LTZ@X_R>?!D#JO^(M6UQ:%3HB*F%U &UH/_ MS[#:_QV";G__&U!+ P04 " "0B(%8.B<:D^$J !Z+ #0 &AY97@Q M,&M?-2YJ<&>=> 545%';[L#0(9+2(R$I(-T,B$A)=XD*2)> - ,HW2"@2 D( MTMTE'4K#T,@P=,=0 S-S\5OW^_[O_K'6O7>?]:QUUCKO.N<\[][O\SY[8^8P MJX#[:L]5GP.PL K+L+@%D$* ((\/#P\7 )\/'Q"0D)B$BH2$F(B4GH*"C) MJ)CH0 .CN/W&Q_C$ M_WM@80-Q5G=1ZTX1=*2$3S@):._A$')Q>_OX^GWX&!8>$1D5G9SR*34M M_?.7C+S\@N^%13^*2VIJZ^H;&IN:6[I[>OOZ!P:'AB>GIF>@LW/S"[ U^/K& MYM;VSN[)Z1GB_.+RZAKYEQ<6 (CUS_'?\B*_XX6-@P/$P?_+"PO;^V\ .0XN MBR >A8(._FMW2E:A$ *JITG?JKL(V81UCZG?O)L@HF$7@3TZ^4OM'\S^[XB% M_G\Q^Q>Q_^"U " !8MU-'I < 9<(KGR@HG^"PH'W2ESY.V 8RX=@G;W7XXY M4M>O'U *I2D!F-K=4PY,P,<="&$6A0('1LJQ7SLYIB=[8F2!WBS;UCDYH]73 MD(*AWKREN74S- ME6F+0*U127XP@MQ2(> Q^,09D;0="SZ!RS/%4>G(X_[?0M%ST6G+564.'5Y8 MX=K_\O%$&U]!\TPE;G-SW"1Y7?)(W2?)V,L:$31-=0AD;\ V8G^ MH%$/=*U\R*V$ W$!1^^(C!G>9X">,']%!:-3]SOQ95[G,1$M]KP]A]0'S!LK MUIT*9Y-I?B(Y+_EOD_P_X"PA!DQV#F*>VQG?N30<9S"A6QK)?B?8SSNQ!^I- MWAY031LPG7Y3T]BJQ[S5=+_Z?.&=)%(;?YA9_,JC^ J/0=+UL-R%9N>+T2#[ M:H(YE".A5+EHV.)@_E3P9\7>6G\8+(M^\06$=/<@X%0Z2G\%E6\'C-^BWD)Z MMI2H!/512OOAD,K'Y\B?!9BMJ3NSCA-P-+^AWHAU9K3-.+?$NF6"!@C (T5_ MM=YPOXJ4X+XO'?]69\P+S":<,)ZG &D?"Q7$80 M=LTYY1EGS^_"#_IM][V#4C51FF1=6[@\+YH+\#_#L:4_]O!I26RR/Q' IJ]7 M+.U(MK>82D5H= M ='IT_]:^MB;UVX23QHZN"XLN3*# MZO5O T\\E4GMB\2A8B!HTX.,5>Y+LM5"7N'QL0/<-?CDK ;H M8J2SO]F2]O895,:#M,RTS;#5^4L&^)':J=]61B^ZNPV]P76,@J'I<=^:'!^F MVQ8'YH]&W@8[+_0:V%?:3AQE.1L8,9*LSZI^F\OBAVI7Q&!!MA1V_F2^]@O.6@BB 6X-8'8!!N!H-E@NQ'/$U14$>2/%EH4 M'D/.2?V.&,_%FQ/^PE#6'6P'(M?HMD/ZW6R,G1=']'=2:UPZBR"0;*"]EY:D MG_)#W*)EPUXF:/KBWT)4KXB4C!&$<@(^?>@]4V5$,&C+U-2H_\!PN=MAP?.! MX%9Z!-?/0"FC=-4"\X?+U/O-EZ(&%?S.0>9NI(2>.][H;F('LM2?$1E]3DUXC+DU@0_5D:: M&@E()PAHC8PXED!'E N*>'[24<+^5TVMRSW:+5(]%MW+ITX.D/_("/I\A@1: M!/H.].="8 11$4IM3R$0PCZ48/BFS#Z-]\#UC*=E]7DG[==1Z6YIO+ M%'H._!,)O&8OUL1%6>KW+;<%;^)RO2NT-&:L8PA&$F4=OX?O\+,-9]O16=M" MLX7W##XVK677))@",F+I7Z6L9-,',VS0[#K$(F4\U#>?X$1/&A8=K@7SFBFL MB_6!K' <^_?X8!%)N^VVEPG&31Y;5M5ZO#HE@PJUR. MV: M2\Y^#>C6]EOPPE;V@>'K[$ADUY^,!?O6U\^GM('+Y_> M%06("EON#=3L?;QLII$$;^YT4"#U6#[0_+@@?(AZ4#3?YH?,"\FRK@RWM<\I M4E>5R3:COL4X<]N.::&P3^==Y2H"WF[+]E1.Q+%Z82O2,Z37C'ITD;EO6UZ2 MF=8#-=ZIA#Y(C&\UDB@[X%F0[)TULNG+ZA#_N+OOQX6<_687!$K1#Z-?L^2A MD%?WN3?^81Q>C!Q7M^6"2@6;HY)U9<,=[K0]NHHE0EN9M9W^IELJL&Z_87)H M,UZ>1-'JN,+?:.*1"6M]F_3O:S.SMM>I)UD)>SFFCPDS!S/?%L6_@.K6\M8T MDA3A[QDFFQ/AV?N&*)N6/QK5Q"I)-J?L=RB;Q>:*H90G_K'+2A")GV)>-E5; M*RAIM5+0TNP8I4XYX/!C((.<+X/^P6WX:R0ETJCLEB5AY"J%&#(F\0,_/85Y9I38 M,3ZT?OIP_!#_!@2MAK\7*XMSKY=?$UR:3M&NENJ^N#_&R,K!/_A3\.$JF6F[ M?>[7G/TC1'"G\V-\D#=UY@#ZT1/(K"WZ:;MX#S-91\MQ?$YI1_UWDY_[OUQF MW;,FJME?,9Z+*DH*PHS3S1)>I&L;KZ<"GR\2+FDYS$^A01B G9/80IY4M1?I M1M*9@,[UK*7S*AGYK^+?KJYUD2 M_50!>E;%0C+),2"T=-=/*RJ .]_4W/CE M3D96W$A7M.1!N$JR(IHU)!]; +C<?4XT.>S54;>83,F\0QJ1F$3M[3N(O9]"U#\GT6LPX/B\TL+P]7 MV)47@QAP]/I3\1 H[(W# G^^]RK+FG1_@\(6 3TY.04WOJME=].-K.Z-ALV- MR,;3K.&B1+(*+F)SA.V)ZWS%PN:%@5'LN[)W XO4*5YP'QGE,COHGN.%RIM, MD8J1R\5,RIV7$%^9V71=S)O5 M,>-"ABF %./TRW CKJ(-:K[S3:PX+8Z:F 2=IY1O!/N4U7Z3^;DH"=)G@&XA M@HC8V9H ;&;;6%%[<*MMP@BTS?+%&7C25*"-%7Y6Z8#*A',:SK*[MK'$0<0P M@#U=D.*VU+^OQ^;.2,+- +E9(SH,0-$#::1JC.:-58"C2N^PTL;*>UR=<]@3S0C,7R"CW4!Y.NW!MR7;*7\R'&C:G6,[@1;6_33 ^;\""(@"':.J"3]C["+ M2C(?6T4H^OZJGNSWRU&@V'S2@A_EDI%,TT M>5 O*[9BP?.[Q3YNDXS]51,<;+H6Q( *_]6UPC_S=HI/X%%M5K9H]I.>D*D= M^7A8@"H,3&UL:.GW[NM"D,TK R=-!/TJ\A/>/6GL25$/8K>0MOC_\JVSGN M*["SG$]1;-E@CR5L?#\G':VH3 UW)=_.&.BN3^[V]]EJ_L*9/&/N8@3V3RCW MJ>;1Q!J22T5T).5O_YF_>*F9CJU\L25?2;"$IX57+:/AF69T:J8L$!X+=HQF M<4HBJ_OQ&&R*]V4]!B9MQB='/$:QVSD/MM]<67IJG9I^LP$)<]B(/,8 PE]/ M"S@'*-/D>_"5=CE3/:D1JG5O2IG";B\R/AZ)KSXATYK),][(_NDK7B5'<#K_ M+NZ#/H+/=%9OMDVKZ-\ MVY9D/OFJLXBWV01USIR]]VYHS1?1.]/, ,YI_]F4 (/&:40"57.Z9MU4\BDC M!O"M8;N(:0XX/OY $H5]ZBA+_+(M.+=)Z2-;#1YO^A9=B?-:NUV\2PKZMNA* M/\.(F?H$?Y(,=:^E_4$/O=,*W21_/:G8@^33'?T1IGXBI6SUV'-9/.YD=\Y> M9"VS"R4:)7"E!X&Q3L^'[TR?@C>2,8 P[W)8'#;34S1#$U\>\6.=GS)0K ^V M1;*:^+*\POK'FW&.>>8C)"RZ7-2P%G% [6\S/*&.:9+^)BS1$>U@*B>]X">2 M@-FRH%'Y^J-(=C13-=GT;+)#^8:#:3$&\%80 XB/OK"<[P!?I>]-PLNJ2=!X MP;*3_ZRPOZ@]GSZ3D2WFO"RW 5WME!.5%I/L&'V XF, XQJ -E"L<5BO1EC M?6Q>2)5(N,[6X<\7%T4+61G?, #?B+."X3C)@06AQ6.6 :V 26O-BZ>-MZ&O M,8"*RMLPE\9X42",EXQL@$1'V4HBFS>,,VA5%31:E?"O$$.J85ELUUAZ1$M] M6AY?N:&Z70;G2Y7/S,VW)1W5)V#M:81Z.]//;O3"13R1[ M%0'>@=ZKR](]6H[8B\;#->RY6;\5QD0;W4_T##I.#%/7\&L;51%SL=P4M4YN M@8ZC5-,GC.[R;+,I<)8STFO:4IHJ5^=>=Y5RLF=U5]_**V/?GO LRM=J87?Q-7'^>M5.!DW1 MO(KX86^:7?]#V=;EU&'^S""JVSV>-^':2M-!:.-3]C36Y Z8P@5!2KLCO&-( MG_49(B32\N+SJ$<7\_EOG]9^^O38<_WV:1SW,M6-'AS%];A 7)N5!N/HHJ>4 MXB*=U]1M"H@/=\)7ZGY5JA$7XLQ=T%V(Y8:=RH@5/U]B^CAQJ-"A)2#FFA%KU;S@60.G"ANJ?L@'QP MX9_@&BH NIF-0V+),[^ZBD>(6-]D<4U?=':JZCV=/)';0:N9=*%EN(:7"5^DR-?ILF8%= MF#EXZX/^6]_7K7\NDMAC$E98QO:4SJL^+:88/IS[=9D:'OB<1XDT\]76%+6K M0BT=/D;$2HSBX[I_4%INH,@LJX/.8@#!!HU1 M!6P?&F>IJ^D)\H=HF:*HWYR76SU9,%6AAX(_@TL%MTY+3>L/XLXCYLL+I4XO V>?0M- M?K4J3,F9X2T0V 0_+@K,$SV^><81]VAI@&1#$UPN9^LGM6(/%_JBXJY/MWLM*[[(^>XAO@), >_BN3W[LM8U: MXCKYV.FVH[CAM*X&OIY70^MI\G*YZ?1B6-PCTA1^?\;[=L#XV=/9V'W5M^3) M6AX;Y8&$QUCO;^4^80!^)W>37IGC=7(S@4C )3* ^F.6<0"A$.J+RNLP3]R MR5[\I\T]<"V!L><"PKRG@^C;ST&2EWBGG4&LHDQY(7S6L)_7QZJ[_H@=LQRJ MU^2WJM"?M"-3XIN.&2WU;32%&XV!207=M[:]*(3F;7O'\?2'TPP^ M^F*-J\?DS;RLO*53D1 P/B352\^UG#3'_)$D U" 3ULJMOM@4_2UB&,./VQ% MW>=.$;U\G[CY64&+(IZWIUJS6%E\#"Z[XIWDM]#V5>U]-, M\K5C2_:YR,]KJ9+$84X-POE9H'TL5ERV>':Z5F]-:SK41L>1^#N"<8K'_CFN MHKY"Y7>2;=-+E-M=XA2I)TU\IG0SNI=I^KMRZQ*LV&N8)LE#R2IQ[O$">SH[ M$G1JQ8R\5=TIPF_$Q#D8)+?JS5SO_01ODE<$27,!E0)L2T:P?/?W'WWY8CQ\ MJ/PPN5- 4]@$61DG2K=?,%547Z^?)O1($$+WD'1^WX>:<)P% \@UO,M>O!ZD MZC7XC @*/ED R#P59/7/ ]VZ.^YHA;I?0XCKX*BMI,Z3W>LBR]3O273EZXTL M3Z_?H58!P)SACF]7RH01L*!HLI/G(]?-N?=6_KV!W8$L*4A J79-K&2E9@M1 MH8MZ<",F]J 5_3I22$[O3WQG0OM[#(#.:A&^K()LR;GU-*(LO9^6=E(^31&N MY$&?>R^"B; @7.^MZWY3T%L,P'09%?;X@;BZ\[HRK:?M,,47GC_[V0/?!3O7 MZ&;:F>XY:O/H7+PN%BL)=>5H$=O#S M6/'&E'F^NLG#CT]>%7@^M(JN)PG0IYGP7*M+EN%C'4Z.!9K4*K>*5@O9BC[U M_"D2W-5D;FV@-M[\4D.;#2_CT5XWB!)S]R?9XH1R- MJME"_\UL9WCBBCD<+?>/VW;GM2DO4OZ1Y#ZX"?_OX;PY[D^V++Z7.(;*T=Y% MX4=Q#3GK[+7YJAU4>.!/1]H]J#+/7!(P#;;+ZA#[5[LH3E27I6Z B)8 K.-C M)V*?;-=QTY7R*8-V)#.TZFYK4%_YXY;X0OR;I;.2YDB/!N%D5;Z-0@^ X @.0+9T*$AO *A3Y\^?@:\. M?"LJF3*,%T1T!VU]INN!0I.T18(W;7+02$0B)!;]7@ 0K*0=:=C M\L6-XD!;/\PE("%-2%.?^BBDWZ$HJXA)\M[&C2YW[+?8VZT@[ZTIQC=?F7.L M7X6:V,PSM/"J=W*F]9!V]+2;HX=K*$OXZ37B^]F> +&JBKR;MJBPM R3)^': M1K4/ORDMU[__X7+%G.HRS/1#UB$X]%%G*HOS!"_,K$+)4ZRA@,N>*MB/BS%# M4:E4A0Z]1B/771<00LOZG$CY]5 Q'SS5.3&VEY S02V#6S41]SKA'0K,@Z>7 MQA5*MMQ*(:3I9^@\TX*5K$9V$5G>O.48.?B00OJ>,*),/34JX:3X:"58L++< M2LG09*;15+E=QPNY*6B3T88;29YZ$QYX+>,+R M7UQ5[V2>IA,#,&>]\Z!]+R=O/;SSS4R_MZ>VCC@3ADI:#UVK'\KX(PI]K!F^ M%9M";$9\:I_FZ9"$B+VN(>1<*1_*E2_X ,N2!_G/%+*V'\5OM45S80"UJ['* M;K65OS6?+%9U9,ZHY]!H>'U;MD]P^&;;Y'M9BIH<8+=BG.D?7P6="5B2W?B; MNEZPTV( 27XW& V-%@TX'GSC#YDJ@R$Y'/W8/D"'\FXRV:Q_ M-;02+35MBA8]M:C1QP%8HW #E6'?%V'.W(%\?UDHL8LY3"A1]5+I* '^B8 _ M)\W@M8I,9'<$HE)X%G=A1\IO\-7-D[@7_IK&*=GM Y/M1O!0J[YGR,6B\TK0 M3-TU'ZRQV3:V(*D"NT%+;CIB?#@OFCM21\N ^5.7WC.AG]IX'5^(\JY')1BY MSD7'GQ?]MK=A#_6AV\, H"4Z6#7L<=H\,"W&!+^ICX$ENH)GME@W02+1 GAN M@P;Q!_G?S13I!S@S@6)2E4[3]PJ7YY^K;EO>%ZJU&7)-_9K#FD@N>;*7BCY)]G?BLD.2'_*<4KP:G&F MZ1*O-L5/30:VZ8SSL5\%F;$@[*NP%A7UN&CS\J),JTZE9*- PJ/V^$@^N^_@ M2=T"<_M&J?)GJVM_6Y\RD_)#=6IN[E<2;)S'Y5G$Z]70M@%I'19.N(-#Y2.. M7?3A"=^'?I0?U&^T"5T+?_4E% 1_&_$4,E?DC*H33Y,N+F=-'TW-5]QDX8Q- M6F0KJG?TV;Q8@."O]#W><9=L.V.Y8><051J[K3N7.)+_'1A871Z" 6@>0^Y4 MIEB$>AYV(!K(9_5WD@/2U]0[!7I'Z,:0,6[@HX59*%+\-OA.2I 7=VU7@2IQ M_GTT5^'#?WKM\6TILVRG_ &X60ODHTCQF@EN@8E 77R0I=]9NWCO M0E@9+W;9.WB8P.R.V470XQF3WY9O(]B2\?R-&'=F.A).9-2:7MB*?JJ[4\$$ M^<;CN.!GJ5:-/:ODHPI;E1N&\./ESYYZ3A_NW??WGV5R72-5/?@XL=A_3??0 M-E@:&NT3H7T_XLG#0?Q,M(B_5,X4U9//]:T8P%!\H2S1KP.*HL2OX1[H&349 M<:M/"8,)]UI181Z\:^I_>$=.X?V"V;XB\#7>N[J-DOE\Y5Q4287*TMK)(B:- M,NN\_;P-AM%.+7'?[PD?E3IG4E+B#'?*7A$5?#K1^)#DV#W3D-T/=59EPAHE MY$8X2E9O^+77NYJ% ])8_/XW^(D :=80!I-#P>S+)$0[>T./I1:_> M6A5U.7H[I4T4"%*QGX5DSBJ"HT0!L4>N($Z'\_59X?(1CU+S;ZU1K^WZ@?<^ M'V64N&5D.&\_IGGP0(M\3-HQ(Y9^Z:0O1TTU42Q-T) M>DESGXK3W?ASO_\KZT"IRS(F:3TS@48%F?M+BQ:LI6S-EBWOGB@IE&4^,?._)U^BBC?W0/%9$S&8HS)KC=@R 1\5Z M^C\W3'" M\3L-S!B]VXMWF^7_LB)_A)],980UVC1>%D/^CT;:7Z:B $TH^S) MOIE&;]\U0D.F+@J1*Q\?53[CVFVA7 M+Q 5$:-NU:GO4Y^NW^MNWL9U,KW=?A $M6R!?&>9I\?>V*@W>&2T)=LT(NG2 MT',S&!XPJK+OOJ,3'I7V+$E363H!__3[4KC0H]A$21*&'X4:B5/"%$0\DJ.P MH4%18O//4Q3]8I2)$3(Y.[I%# 7/L45WGZZB>#)KAU4?U?[!SW@LS5J_?O2X M)I>4_G)^ZKS"7Z>;FYCS\\CEU\7)^L-U7]7'$*R?98[UUQI 539FA0\ZC6H9 M"D9UY5),3QGBCAJ>\=;RA1R]2*%/#3I&SJI[P!9Y)$KX$OET\HX M!-I+VAT#T*"\CK[A$#CG1F\7A _\E[YQ=B/O7FGJOY" (IB-'+F\ZR_>R-E& M]#AOUKO?6VB+S@NKEVS@Y1C4U.T.2;F:U*3>)X\7SR82/AO.Y%XK677+.2PV MT.JHQM%K$TW$?+?M,B7/YN)JIIJ#34O!&<^+H7:L^ X/< *AHJKV" *3M_9X M3ZB5Y>LM!J@?"6X#Q5:]RDJ_G6;,-3$Y[S4 MS &]K.QPCU]5!$/DNR5!WGY_-T<.%\**;%(SM89XEG_5HN3'^,[K^ M[20&\#QN;LR)L;Y'\LT7%G62H"\E?BD+@[\O3MFB^$VFB$-+_,GE&:1LI?KN M'&!A\6U?8#H(68\DNIK]:RAF*E'O_R:[X"8&094XM_OO!\U_=Q"$5R<%8^ZE M]HU**HUV+_PQ@ 6K.F,"M ;90HNJ M\:%MX? +CYH,DT?,K$TDO=G.70-[\DB0E'<1UV;[BM9\@]O \ FC]?ME%^7S MDIJ@4:D6#*!DUFD1M3VGS=:?"Q*'F[U'X?IQH;)OE3X>!HQ]<\4&.CN],>G?QB9S<1B4*3875L_FYOS7G2A_-.;9\ MI^:=TY#N@A-!#"!' 0-PM@..%FT[_,0QGG9:='_D1O8J_*69?I76S38&H.87-&HZ=(/<2$2R@79> MI/DD':GE! ;EM4^"YQN.T,L!RUPXX M'"#K+'H45>9R4-BX];O1D2R//E/S)C>?N9+"F0 M"F)ZL,-2]=?S<.5% _Z!,H9.&N/YJ^&>'@I%R;;VD*)X)> OHN9!3LDQ_'JC MSI..K**KPD!L.WZ-WU+^NZ2L)?NGLY+ S$/XU$GNO8SHLSA>.$=,L;G]GEA* MV9SI+L6U6&.ZX4]%MBU:$MK+I=WA*Q?VF8&7$OVHS)<^C(O/VR0F_KX/X"=*W>=CM<;C4WBZ MPNM*Q=;NZNGKR\[L>0J9-3)4W-3B; M++7* 9YU1@*P' 8SGS2D/^5WAQ:;=<'K0M+G<[U]PK'Q*GL63SS?/*U)E@JV MPYHV$H4)4.=0J99]J[T1O_ Z6[#]O;SIC.;_ %*+Z4-+UQP']F<0W@%5S_QLR@O,S),-W2BV9P\!?,;1^TDI5BP MMG0NOYI#2.;BZ^B+!FIXMM\5IK8!)8,*LQ6MD\L"8;^_9\D*W2Q^9)MPX>X! M0:/CW+-0IIN&K0:?$8"3CA(5X Y8&\PB;8WC02)71B;3ZS0+CJ8:+B[6,&JT M"^W%+EAJN&V:3T;U1*N7/CM)RF+.Q,?![E'SQ\/89IPP$@D9T/AL]@N<"C>IZ?XEHSJEP:GQM3^RN0OK?J&!C=%11*>R/F]1#PNX"8Q\4#= ML678D594V;F'C5^R(BR%/N+YBG_QDI9[DU4&@L^U9ZL/3'EK].9CGX](J5F, MJG2?U&F$;#/\I%*W]K@RHFXOM;EFO.Z7_6Q!U0+KDUOY$4MU!HFC@@YU8\-# M)8*SR)_O=<9I=N5SR=BN3,H[(X/8KU*T,X2I?QF;*KM]M'+ZT6H.^2,_U6;Q MPZ'E3Y_/@6<@KM><)\-S2K.OWT,,34+H'B^!TF,#'6<.[KKI\.':(;1_@?AK MRI?-Z$=&GS" .OFA6WLH,C#U>U]?7WW!_3&WQ<)DB>ZZHIG(]9QR@ __IX7R ML:[.!U=29K8Q!I/LDO7WF#XJW5G3:1)QS>YVRBYFJ>.";.KQ_=R9H+9886,>9QB]3O8F+/CQLNL@CE1J&'OJ7^DNP-C4]'.%Y M3KT^H-'[#D(/.!8@7EKR2;OL[L!M->3+71[A.V8#%"B3?S@RS3CHKUWKC)1C M25$Y7MMK,'SO7( ]&X7=/2JT+QX(S]EX.>):8-^0/O7';.>B:GD,W>(#,_ % MK[P2@M '9F?9%!$JI6;2=!L)J;#$'&7 M=,:<@WC^@ M7ZW&>]W*$G,T?AY)7%*U+!\TAJ/%-7[L"1/S.BNJT5Q(?2PA<1N46L_&A^^] M3+"!69+9-ZI[67VS3YLEO+0)GR"/& _):/BI7*^3F. M'['HT]H[@@$05N2XKE6OX51/!NR9_7+TF;JG@E,Q6H#MGS%TY5ZD2A9]"_ZQ M_/VK40S\@0$931OGX]@72Z);=TOZKO0+GO+>U%:K,BGH_K8'F/8>5O3UN M\Y??R=L$%+G"IV4 90_CC)_(IK4"A '!_JXO4(+FD'#;CO'Z!,K%;:,,1_$+ MG)0\N]HA$5;YYP0KJD)8.Y;JYF9=WBX7ET\&1(1(*QFCZ8S][OO-\/+A*T]9 MFSSV+&4PH29YG=NHSZ(Z1 /5.;87:];V'G47\:^#TK MJ\'F=[1J%WZ15G_QK< K--\X_.3)+U(^AIXMB1C&HY]'G%>!O(OEM[)Y"PP? MG N,G[KHEVU*>UJ*,'^KD@290BXX4F,$45]L8_B=(6Z=31B 1T+Z<2XQXLZ] M0C#S_PM02P,$% @ D(B!6,T#*P==)P$ 6D(! T !H>65X,3!K7S8N M:G!G[+MW-%S_WR^Z$23:1.]&@N@D.L%(01 1(7I)0K11(HC!,$KT%@0)"4*T M:-&CC=ZC]]Y[FU$'8^;.]_<\YYSGCW//.?>NYZQ[_SA[UGO-K/WY[/W9K]>[ M[]D;/XE?!&YJJFFH 41$ $!$^ #X&> 1<)V,C)R,]#HY.?F-&]0D%,4DI23^ M.0G1C1LWJ"BI6*BI621N<=R2^'^\X9L VNO$920G)$2W 6):(A):(GP; "9< M)RG1OS;@WS7D'?0P."0T+ MCXA/^)R8E/SE:TIFUL_LG-R\_%]EY1655=5_:FI;6MO:.SJ[NGN&1T;'QBVT8='QR>G9YCSBW]P$0$D1/]E^^_BHB7@(KYVC>0:^3^X MB(@]_YE >XWTUCTRN@>ZY*]=Z6]+!%QG>!CWH[3Y!H_D"Q3CF_=#%$R\4DM\ MZ'^@_0O9_QJPP/]7R/XKL/^&:QJ@(B$B*(^$%H 9Q<"F?X4_U,I!+/-S1IA MA(UJ*Q,STX1M[%8M?OG:D7A'G/.W*N"!M@'FN5YH%I194HO.Y=6PT*+?[4II M<3JX(8HA;G;[C/X+:^G7=YLZ.:J KZKJ>PA-O5V:/*K6XS M/FSG9R_0L3$N]5X^6?;>8]UQ!UP"5K/ ]CL!DAT*X76?2T34!6FY S.SK X# MCYNC!QST3K@:HXY^L].>[)*YHQEXI>>N)]#YA?RY>A'@0\U !_!^([(4Q%PN MIX>]1>=DU*H5*35$27BY\EI;Q>0>98 *!(JA318\7((HF^^_F,ALHT2:/KB. ME_N);"=/R[;NS,PIK.WMZR8[AH\^)W=1A>&!)@0ME.O6B(>Q-/3<>5J>X58" M1DVX7]$73=EN(MLF^FQ^P"CM/HS__#;+-+"G M8;,EL(J#=T60%33&]_^GVD MN?O]?E9,9KWEBGH45O4';&,WQ:9(J;+Q4_1:SKT4X$(BH@?U]W .9ODTS8LJ M0<,Q:M^[E*?(89!(U0TG,S'1JGQSU./AC'7,[=MX (X27L<#U^ &: 9EJ9$9 M@[&$W6>QG_65M4!JA0X*ZP M-/)+[3T5SCG&(]*T4K1/!^UWG6?Q6T[AYT]?W4[/\1[/_8B[BXEMG>?1IN^( MJ^LP4SNX[11_VQOLJ@)6';+00XOKH''9OXQU%F=R37E VL]OVXH@93'5N?Y MQY0%84K<3K8&-1^?/8FE$[8%/U !&PY9WMW\#7^%IDF@RK:SRGC#V3,-VVOTX,!D$Z@K-M*'4&XDB[ZVH/J)5P+JZ3PHY&0F0XRRE MX)J8H&5!99Y9>Q.F?.EZVK*97X_5*(_O^"M_R2P_%H:F:E-T4'9/^WP.?ES6 M:.#X7AN&Z#@(\RY.6+[OQ/-XE+?RD&=./BK&Z)B!Z)B4<:WQ&MS68SF6VLS4 MP5!4^8>MX.S!V5<0-XY3^"QN],S=K@*C2L!E:))_V#Z55*/VU!_EB-JQ<# MY/" 9]$'2RIE";,=MLQ-+KZ76IWW7__IF.N[&N>,!GR<&'152/\EABEP?4RB M+PIGKN0D\JJ&6;/MJP9+Y["_DL@G,HTFQG27XBUF3\NWU:.[ZW^ZN?3="F0Y M8>32J4M.[UWH,&(SAFF,(5I?*!D>-2TC/3!&Y%BQI4Z-7%P%TGCEY2G/>O+-O&8GV+-.R7OJQ6A\H;+5J\]#6.!GSO MJ\(;O987(A"@XN544Z^W 3,L7\C43KM*?%'JD45PZ%*>M.G;R8VU%)&K3DY5 MP-U=5Q5@^$<,$[$&F!(\<-VB3UCK<>K+1%E)66&*4_[Y^NE^1%0:=[E"0^%$ M(!G[9WC^'Q^2<7_E[YE(! :!CC4.;7/%^+3WQA^LW?CZH=YE M-R'U71EQ^TBOO#J9=4ID.Q?\T&%;H2MBLSDNY!'))U5X.7H7A#':Z32B0R:A MSK"1WK97WIUX(","&,[,=SBL5Y#>+;UG3,?\]O7DXD2/-W^$,@\LW<17]LFX M\]L_YU\$/73]?3=)=E*$UY6>(:(LZ((N-2_6MXI6UKK>QJFMP@VU5^F>:+5^SV-\PQ$6_\%-Z/FF>&(>TLF#C<^VCA'KYF?GJ-M7O(= M#]C3X@%Z3I:SPYGS0?+!I+.;';;0.:F_=F'-I9I,<46G;D,FJ#% MZF Q^+W%OHDHI._.^8QN&?%I"<6(V-ZNGQQ[:GX\"\_H3W&>;Z2L2M!1B*VY MS>F9ZIC43KB%D>A/@[#2_MD3QE6=+-5E<&2R@OZAE.OL-AV/P@D'(KB](C8NEF?+4A7[]JN8,H-%'SN9AHQ$W"P;L-IHJ7'[*KEHR-P[>FO_M31[A_W>=ONSN$![FA;7&WN88D26AV;; _9Y6[L]Y=1 MYH)Z(BAQ/+,8-Z,W29YTU[]5JR ".L=_P?TVEEFX5]FM2QYC]A;="NRVEK58 M\,"(2#*]$T>]7V,P' \L@VGG,/%0C9)W-M4!KQ;F H_[ -^O2^+G#%*Q%R>Q MYP9]5C MG"HU#Z[!"O>RA#>208?GVVWBM@LB%2[J2U58@J,"(O0UXBL>&+Y# M,I(9L0+W6-3!J.&X8+;Z3S3-:O% ]DV%>VO:;DC1B7U%#33;@7X$6F=J&L]!<.%_+^>^@ MJ5!=S#BH8X=5:B!"#?WI7*_P?8'W2A$A$&8:/\K9-)#YL,TD\./E<_)*+T*= MYO+1?J7!9N%%Y'-309[(7L3Q 14[DNK!BBVI:(K>9TD(I;U,H[\_K3Z0";IW3>#P0ZTM_=8;3)UK MLN.!>/.?B-J%_@IE/CS0K3#>N#,[CFAN/.>;5K\LPNX\6K;$)A1!<0U] .SL M'V.X562+^\-_] M1P1P:D[J=(9S^W48'DB+7#AL-[M*;5R5+L0#$]=P M'EN-K(K*T@>AU<'T[J?I6[0K)81 ;XIJC%BJP[QT*>GCYM+^*LEQ-:X;"$F$ M@5N^"^FPP/5Q@[7L*\'3^R_4KVT$7(Q1"W.E,L;G\GZ+(5M]?KC+SY:$J_8M[";)>(GS\N_2M'T;2HY[R6]\@3YXY>)W M"([)MKV@KG=,PH2>]Y",DSDS=M2P".N.!I_*!EAT\+==!'F9>4R-3H3"(>B8 MNL6\XISA"E>/TT(;P_ 88/=Z!O5"J$D0!KS"V)%XGR'0/FWLJ&GG,.4B"2F M=F[X!>42(&3_D,.FR=DZ'B#OI9;XHX%A9 W*I@$<#N?)=0B;LG]-K'/627Z2 M0:5#X.AI)>*,_*A$X2K5;[\:#P EJI@&/,#;:X@'WB$4CDJFJO=W$"@*X*P@ M%G.2?-6*+5A!W(#%S[0@:&<,ZZ)70UBS2?7RNZ5/53NQWKVX)=S+0]G6(HE> M0TQ9E4EPH:?,@%1=UB=K+FW NQ,K91D*V63W.8\X42(Q"FU3($TJ<8[Z--?& MI^JI?BP9M@^@SB+\XTK MZ Y?O&R89G&.A"P9>93W1+NR73:JB.BSQ\Z9#:ZGAS;9II%>D M&I->4LR#3>B"-(3>+D5JARS[E\ET3^L[#3-!GG'D6U0Z-KD=#Y22].PT.=M+M><3N,5WGK' MG11;G@;C@3BF!1Q2_; 8VJ([P+^[5BCZY_[AZLJ((NXS48#K"H@#_A+]N-8O MP)6O*'.UT+6J77_W[WQ%/!0'P6B4F+87S"F-?.:'%M%&B XWE M:&X[II2QOEV#<4^!PGC-25:E7[_1&Q^[ 5A@*^^B'\;P;CHUV 3S.AMF9?J] M:*.B53X@B"H*G=Y1LWKU[?BQA\N>*?*Z$BD .0T=G5,$O[:GQVVOO]M]<-E$ M _EN>I5V/..# 'KS;H.4M]?&U3KE+(!?C> *8_:F).:;(>ZEB;H-GZ-LC_,A MM@TVPQO->IO+JLP&(^6?^>.+^E4!#Z18>G.:T+"8E+:I65FT9W2[\TU%1Y#C ML32XM1$$LVH99PN$>1K*CN\O:X1_MZ;]I%3K:F&%EEVB^?IC4Z$Z_,THO]=? MY*OPTD#C&G"1>).')PH1::!X<._3GY-).^+0"!PO++>32\P%A'FF\:J*CN63 M:JM&3&'G[\*K-^!P!.4\M>;&BR0MSU>47FEOZ*_&^\!$;P-!X?3J[Q_^':SM M8"_>/10>QREH7T-0.0\;/#\0>7/7.X' ZR 6@HY2ED75*Z1PQW@HFZ%CEURW M]LQU'-#@J1;!SM 38W;E1\^(+VPY)JH_9( ^>;Q1U$+7+->?9Z6_,/K"U4-S MS])HSM)^FN^SDY<;Z??:)<:?KR)WY4L2L"JY+0BVU;2])Q'4#VR[.9]_6T=^ M0B."I?! V#Q[595/A]:;'06M&^2>X"MO8*5>=0D<@N-'WQHO5M1@D'7NT6S^ MX,_$B6V%_"W1>\C&BCU/"8E)8?OZV39.(BHGQ? MX+@X=$]F"'].B93+>GANL!JPD''"D9C7ZZPA,P(:]" *OJ6QCGJV)%" M1"N>EE%2RE"KT]+(">::AIID3=;OO"N?9:Q]@1G@9R"*0Q_@-!40$]=*LNN5 M\,#M^51"B5R*!S9O(QTP9P2_XX3L!!H.([D(3N2B30@>1GC@F%8%- %9)4$0 MIAY@H^'5*!?]TF$_'J7^'YZ,A5QF0?"B@)2+!#,\\(D:#USY-!Y*'_*W'ER? M@4UTO+ W]*1[P&KHVR7?)45TK!Z%Y,5H3K0R;TIK0;OY@N-NA5J".W0H&\N8U_0^_44WD;BIS#L,%LWTC M-2NU?#S.4SF-+A)F!\DC,!OMRHIH\<@%%=1)T5IB6'*7L8$$\O5^>QW%.O:1 M$YI^R7H\Y>/%;'R[Y*N[GVJ3./:XQ_M+T>+M:??0O3#/E@2^CZ+"JAS^0">G M44HWIF#)DLE.F:OL#YH\@J: *F'/B"*NM"K-CF0&J[32ZZNU5(8I0U_3XA 9 M$Y/ISB,ONTLZOKV$V8E'N>J\Z65KDV%T MCTI?**JX MKIGFAWZ'*:-7F;9:7X_9P_JMDHBW?6-O-UAU4*/PP.5#VN6.$;]QGJO)6HC, M+*$&GXC'#:&O,ZRB"B0P]+KN/:QJ6*)%K;W*9D M)]\FGTD\D2@T3/,MV!D@QI1UML\S5(TZ577TI/)_1/3*D,0=9X"8T,DQ6-T5 M$+@Z6(JR_#5QWZH =44-IW&T_KC[0CB"VMG)>67,63SS\]%:PNW5#Z^@&6C+ MUB+*=C_!%$(Z4.:K"#*TD=!P ,>OY%]S+^14M\3\0/4;T51*S!M+.EE*A>LV ME$\.DB-A]\V3V]*8RT?W1=.FO9CIVEI97D^@BJ8WL,S+L;,8IXZJW3JLEHRG>F\.;/RD"Y,2:6ECP GI6M MK0K 2CIB0RYRPRLIJ=4?5AC;Z-_[FT79M,K6Z+NT0+^-!T@F'M:6X8'P>A\K MVJ3+G@8:Z/AF!D@ P[=$[=)BXI?+5 Y=E1H65I.UY:98\3@(00K58TKO5)*E ML;7-BV02 D@+R.3B3@008V251AZB#V+/-] ;#!HU[,6)8'B6!12U/*]"K?E' MOI^US)16<+EB#$<_/R>S#16U*47-?X>^J[L3,D<[,1C09PO;D_:"L^>9;GY8 M]SD?Z5'MOPNZAB.NU10@:<518:7&ZN6++;93KE+:<);) *^,QF5'0^%,TP,R MEB[(;D12!'#>C&/%5+?B ?I4XR'':U6Z<^>EOQW?WEA]T^"R3-YZ"0%OQK7* M7RIA'[G36]W7V ;E%0\3CHH!AR(8X;+(3HV:Y-VIQ69([SE78O62>,!TY7XE M5]$*^^_M0LX?H(95GG*N%F1 IC\[AST#E,.!D8'T)2? N)K.7L]>#*OB%'6' MZB@V_;4^+XV:*!Y2X8AMU>:Z5$$Q?<_9UO4R?!Y"\[5?OB!-?L3Y!$&ZG<1T M[SQ9\N%+9KGNXH@( &T9:$&&)O]8J?W,Z4UO5XQ=XO/]_B?2NQ,WU=V<>.GR M[%9?%(+>.1"H6+W26TR/-+2HC1ENTK#=2!V+'4@2$T8Q^AKF*^DQN,7GQ/P(GP$E K.*S6HE$F-WM*BOZ\ M>*@GGLI?H^07P?B^0TDH)^Y5CBA]+7AW_)GUZ O4_8!$C6^5#,[74^;MGJ M;I!)W&)[9V]L2;8W>2LD2&,).E0(?9_=_Q,REGE8"C8[D]ZI>$[^">N,LJE9 M'AWNB+;?.">-2I>YE[*' ]L;IO '5/0IX\2%MEE.:VWEY(O3"'9ST+I HZAK MA7;UJ(NDKB+>^RGAC*/SGAC\K*M"ZM78OA!:;2$_+)JN$V=P\3<^;(.H>5O2 M(HZ@$\^6 TKLP\%*P@6G/3DVRG1=E?(O?K)"7%Y/@MIHNQ!OOU=H:71]MW[* MJ+NNW);QF)&!: /"JBA9 ,MM>3=ESX2#[\B]K^DDM W!7,R-@_5D%\]J'.@T M>'W1"9_T)WX,J8#OPX(6T\..E3Q.+,GFW\HR1Y/LQBN>GC%R0&C\^&%E^Z1H MF@+1AHIG-!O)O%9_2!I\V54!@Y$][9AT%X<1#?F(NR$:-,:_%5+*51F(]/1& MG*2C)59TD&%:3@H,[DKM\),".#W:,E3:2QS.![>.E(]U3.75W?2%;E$0.(?& M_N--^@8SQG6(\K.C]7/$K?&&R*7&UBY%HI\Z+J&Q,5-[%ITKX&OVN+NHSE.E[GM?FF2.:)XZDA$59Q+4GKFPU-@. M)A\082-=8?>$>-]X!T*"-'?].+&R://8"/)P1>V"WHU@GFYC+5;)J8:&@JF\ M#! 1I@9UT#9_!YW7.%RHN.-*5[PWN6KXQVY0 YII-/.W[FW,-76NCP"U1::_ MX/;O;M>?%@]NSO%^*LL[X65##02#:; Z2XU_+2F#=(B0-E9C@V:%QBJ-[U3O73#4UCS;2QT#Q:^K=2N/X%CA6NBQ3XE M7XPMU=5%GW;:#5L'[_L*;YD(D/0C66 V>$ 'X\D?6O_HS>U>A<_\]^,*^BI! M'Y6E4#$UH@=!+L8_WC]D2( &'_,T^'(25CK(P'*@(6'81UP%*]"L-6'BS8&: M51*,;[ +U@[%5;-L?YPX6/CX]W2;%;>,S 7%:8H B?\P_*8'^..'-);Q)=I^ MT=,TG.GJ8L310LC\3?2"/]9@\\+S^\]9V437<#GAJ79?DG]"5Z0?"#KM&;[0 M9D%1>X-'/KEGKC++:H+\3V$!'B""OT"/#IK"(I9X*L/+J*+N*CTCU[-4'U)A M03*@UAJ#%67MLV;DW0.\W,92:XI^"6001_PG2X9L5<03V>?$"D'<^=9X0!\/ M[*>P0\N,;U MT3 (#[0J$@KJP0'9JT/HR!NT;4B]Q*D%^ZAT7M;H[1BYP"5+WM12#^KO8AR^\*MB5I-A]_F'>-B=>,?[NO'6M@1 MGQ@@1T6E>M5JD7^><%LV\'PC,L."Z10YW7Q/!>H?V$RPSE2[]:%V/ZU1SFO,B;G0Q:'V&>3(=D MOTL:+YWMLC#L)^<9;A!_A&:*6S:5J1LZL*H+,(4JD/C[RF=0:PH3=W8@.48K M:Z2@2@:L'M>[#0(>=/&4..I/+T1*@6D #]\7\X-I$7L#JX39*8%:,T^ PIH5U/)=/ACFJ6T<*DY\@1VTSG,U8-)SYRTP%486 M). +5G+7YA5[3DD5KB%5M\Z.>;8@,W,R;0O:_!#:<^KO;2L!(XR>9FBNN*4" MU=IQ\)XZ)BO/$MX3E9/\,X68U9K"6^!0J#VG&\9:C.T'UQL0.KRO=1 MOR6CUI]R4#TG.V%< E/@Q,T=:K_W54=ZA-'#7E;J,H ^"/69*RNUKUPJ//JBT:US8LA;'^/,DP5YW MIHJX;N2GI8GPAY=2D:QOH-UL*'86H#NL%S?KVNH4*NK>^$]5J5[PBB M^#R,^:[6&E)_O/&:E6,@VM*=?21)RS!4P_GPMURF5M@M;BTIUX01-Z*4\]!% MM08IRYMO*]-LWS:$(X]LUSDBAC#-'C*5:.C3H8P4E3R>A[_:WC_3!GQ9S@S0 MG[A@G],"OE&-5AY!.D;X8%S5_(W38CX_G!>)R8B_5J3C]?;^SQ9]Z3 MP;DD;K2O(]Q@ VN/9IOI/\;#AF)5;8&)/DJIUM-8_2/KF=-EF7VY30?+:#?- M=$;W-0WS!T9_#'@P>21;@F)%2]Q:BD^>=%$MZBDOV.(!R#O$0C-.>ATI@S&4 MC1'?K608YRVGG?[IPV"K=&3!6()1VWB,"0(%XX'*MPE_X^6P>VU6KH0FY3?= MX;@:1?+=L8LGLJ8"LZH'M+5]WMVE\#P:P/!#)Y M#:4S8&D+[4ABA0*@O5I6\IBS5$>"Q^MACSF%)9M;HJ\ZU^*7;"L78@1 M'J-?IB[!"L5B-*L#EQ><)?& :&F4GSO1#&7!AX1>XV4)]VD.V\/\@HW& 72 M^?)B"TSU"R]CW=G)H[:BJ_%WU%Z>[;%ALLHTJ+'@I"_-!+ON MF.@@5*;\.V9JT2AH&Y)O*'.\$G*SCW&OQ:LTJ_P><"CA\YQ\*"-00IZ1_M]- M8^ ?T_"'RZ*K&I9BV:L#L=KOCCJL[ZD=QFO*.M)/CKMT&-OH1*:\_UDF% >B M:$/9E?C@5B[\JMF;,'Z]SOVC4M9TY(BJ7Z3>$#0 M*K:.<-$-??4NI1OAA!!+*4>679+H)S]G9HK5=*,Z[#!@X('2!EE,H=([NE? M-U0WY!2BO]":B;O%1&,&R=^+.?U%/D_CX=?^T8$0^O2)B'>19AWY=O#.9]Q0 MV8^DA^E.B&37=@?X2[1?0R$,)TZV91AMY=+PQL9@JF&F1ODST3&%N6G7)1WL M:P-CL[0T?*,$SC:!O9>I462OS%W[IZ':\M[*P^;4"6>%":=%<29,M06*LU6I M+*?DU:7Q@94U7K!X( MD)$#?>;/ZIL%M24JVEXN>XR\<1B=I_>ZNOQ&_;8Z48/DI80HQR5KJ#>8WR75 M+?8J.+!7RDY'Y2\I#-PDSBF;RA]?W5?PJM1Y/Y*3.(D)G31J2.W<-O[-YJJE#+="Q\_C9(GN_['Y+UDXV(UU^RU4DN"ZGAT:B)IFK(33'Q M'[CQE)'=O*)F?GFY(@2#71H_1O;7I,7DSOL!%TEXC54(SZ^R0?+1]]H,PK7& MM,QC7XBT9>]>_YACUV:;=< "B8;E=G#:5Z9_3)$I8+7KZ\WZE,NQDCY>"(.V MO,"L+(8DY%(_U#*D\TJS6_U&WP[XD,_LXH&-?= E!M(16SU%:(MFP6FG*VEAE4WNI5[;"Z]3NCF3#W');!M$8.2R@XK29I[/H')OOVY%L MYM8$WLW16'D^&]A/YJ#R"- /!#T4W@#'5!UNW82]:1:SMG)Q6F.F4MOU+'DV MIFB"I,9HO?WUB6ME-^ZGT$+;&JP/\"P;H)([>ANC>#S;I!BPEAJ<=P;BW/E'I^\%.=*XKDO=[)W)HD$B#J6@Y/9.]H]8: M1]IC=@BA2Y<0NCS -I'!;R#1!5N4$ PZ"%=37OZ-[(Y=*^=GWA,3PXA?B#-M>&@&K$R<%/M\U,-^S_J/ M:HK^Y#*F2/,737PN%\4OA,D]3B 62['J9[Y:M')*=XJX(< O)WB<,;Q*D\6=RZ?1LI&PZ6S,*TJT<4&W MU22:=11!5BE >2&<8CBU*0X/6+4+0Z%T766$U%/T1N+!KA"U?K MY<>"GM=^\/3NWU&>@GQ__@=SD*>S%%;1(*Y1$VDQ>5N\_-T+N2Z+&H('R8;S M8<@](!%OCZ19?QI2_A9\K$1$T@"X3OK^8_WCQW2LI(*9V0U#A^" ![KT-9!N/Z_[4>WFJLHFQ5#^E M'?<7A2OA@82 T<:="CS07^;QPR4;:XFL1<]%C_4%:<[0T,SE[J^,^KQL#':; MG<-":_[45\N<27RU>!)V&>5CJ%H VS!%;40Z'^,!\-:-?+NIU\[+4T]((,(D M,; ]%6K41C!C=^Y\K;+#>++N("K M!M3R[FWGE-$;(ZB="\-(+,N(&%P'33R\CZGXO?5\38OFRV76409-Z(K:#]E0 M1)T$%IN9]2>A!- M>O*P9M!LG"+0I/T%2^RIE/DFCZP$]&WD;^EP&[JM%(&>32@*>J=$__GZ*G@M MBO[,2+#Y%YAJ/?ZH9?EBI770KIJ^YHY UB2G#X<'=B=W7#3EZ#&RZIF%$2># M3Z)/ M#N\8]>&39W?*D4RP'S@N3,[!L]'CWB#I$1%VE6:UN:C%$\::%5\>0Q1Y^W6L MU6LKOOYTR?/.-PF!ZG^+8CX3\;LC:\_O*@BRX!+[_?H53#7<"J%T^;RDP1QG _P7S\ED M.]&W,,&O;N$!T]4[ \6P(E@A4LY+HTPGV6[F*%?S+^8 #_"):Q'R8T$L'GC( M>!Q-Z (>X &SB?/GY-WSC-HFD.A3P6)$UQ-S'!Z(._L-]5QQP2;ZREY--AX+ M!2-65Y,)G2^X\YPM]5_[[P>=O2$TP80F0(L0J@DU73&44-#%@A'=3<:$3NDO M^*_A\#@"O>+RKR4,^Y25":[L7TY8OY,P]IQ\I/*PWL2IN/1299O-8_>-ED]D M/H^'\D?#,<8CIKATC+T&!H+&XH$>?Q&,Y8OT)<_HDU@*AS+&$7':MF=S1-Q[ M+IT_LC%$>(#GM"0H;K4:@A(ZP,E@V'%T.M3?#7I$MA5@HDUK*_O"_8VVK]2C M7)JO@5 MV%^86ZF6C\910=WH>FAKHZ*6D8ZL>" D=A.QH/.,@A'%4S[ MW<+(0-A@8EI\NJ==GS0<<3'D.IW9 "PTA#]DYS0,&NEU[5/WA_XHT#7:=N_8 MML:/D2N4[>/N!3]L"S* I"[C>R-Q@Y<3X7#^ZI21Y8Y4EW=1\9W"/ 4T#S@, M?5<^H*L#_&YQ^HV;SEPQ:<#;@XV_,G#EJ;L4 2_PP,?&942KBZCTS".?W!\D M\*!W/%?HX8;4%J1H&7HAF+=QI-G0VFXU./8>4H$-C0>8L(Y![DI+ 4J)VNID=)$%]ML!S!Z2E$!=5EFT_(]:-''A<40;B;VOJP(/T7$=-RU5Z%F;.0E:5/^2S'ZPTO M(H!.5%%B1^J2DT+_WH?91\0_([\M1AR!IF5QJIR2.$*Y'60Q8''O4@T/=&7G M(":&_N&>9, #3*F3"Y=!5<=(O;PW9RI^H:%C>]_T@BT?_:CM%"=6A]K/IP3= M*V*T?7H86Q=GL8%JZ5C0P\AF&\UU\ ;ZV*KKS3(YG.=V6##6H!!1-L/K!O=$ M C+@[[IT&(BVTKD:5\U1Z5>N>&!*U4>V=>&C@T2AQNBCK32 MM6/[ZDK#S=04:O=82>9K0)1PY_26>8ZJ(6ESBJ5])_J>J-AD;O& G%2%T/K'4&>I1PH+53N@PB4Z8GA;I4S;7#'%NLBWR M9?3$ UQNA G@],G.G)IAIP+7:1?EN&!S9?'S!&0U1?CD)T>ERM@8J#Q&AY8 M+=B&@^O$<<&6#V!9.%51*UQ]#H$D:@">A9IILQ!$7;4?8:#/+J%=_D]EG*>) MEBNS:M&$PI)UQMZD:%8F< %2.U-M!_8AJ3/4OI2QO50WV\%E0[[;8E\..\-) MT&(C[6PF$@]&Z)8;)! V94?2#;'# M ^?7-Q'[LD?YRO=8$4LO,/J@$V/M!?-O>O\^]@W\9Z&_[@K: D%]Q=XJ'0F(6 ]1V>Z&R-;2)%VI?KL6T0=K@;]/TT/*GV)9+9 M37 Z;H,_;760]" RY!&JMSG$[. PQ VW9@/UXZHAU'WU_"L-M!02:HWV4U-E M[W1*M\PM]T!.G.FA]1#H];9W-:ILT M.Y)FY!U,Q$B[A?B@!U3]FK8MZ$O#T-FWB(NJ 9RB$X&/%#P@A"DQ1ZTM!"LZ MNJ?^=&Q_AS2U"GF*4O7-)_2Z7#)XX*0/D0AHJS($_K?(?JFJL/FOKT_2*JXB%@7[X@J"G[4[46(H <9G]J>YL98_Q3.%>=^*;YYWH#OLS MIJ0).[KU><'/[G3X?5P[5 ;1'EJH!TG#F%0LC#N_I1@4+L4,K[MSO&AZ]3^AX(W:VY6'P9(0#\ M"M4<24'(%XH^K>D_HM@?F/@'LX*N*@.1@;9,AVF *U]BW5_(6M;C[$9%F]QX M@;6HSMO"/[8+)4!+.IG^PJ9;IP:.)M/]\V1*3W6%"*Y1KLH O-3-,1(=F%:- M_ITN?_18JTZYIL-AC(&(8_"1*VT$+-YHYI=""#E*:@9Z'RHE"'6ANOY,LRW@ M ?:7@P!QQ85']&BF::2PUT].MB>)8=@G!=S 73* T)@67*6^_A=;,WNL ZEK M8KM7KBG\(X7.-O1FQJ:] IN'CPO5EU5-,OT!@(4$>&DL-7/#F;0MR6! 3IY. M2M/(3ZZ/,$;Q2VJ&M$96^*VCV(V!E-OF4QWDAQWW_\=%.2]1&OC6@AA?9/1"@_X M;^$8?Q"(IKVM^F1,E^&54!0@U'CJ%#KM-W(J[ *1/X)GSZ472QKD_>N/ENO. M(GLN#*)]%9)YFWPJK2?9@=/SXTI)*'4*Q MX;OT B$A-,< 1/R*8-07B@$(R+PJ=MB_?AR9^G?0K>C;A4,J L+H[Y]%:7; M:6)9%3/K/]@6TOY9E:+]]_MHG(X0H#XUU;2#;?3SZ55QD?I M4H]_E)]T./3>KDWTH,K-X^$>'E)A6!EVG\P^LAK9HWM6-\Y(?M1N]N]W"(38 M4^^;MMWP<*+:IGG8$^"/W28H3NY5Q#1?Q/5X@8G@Q\\S?(&\8JD=]FZ2V:F9 M_ITF^S<&/$>,-A& ZO-?C"K .V#OIL.67_&CB0@GA'^K/>UJOT7Y2 M%64@,IG1*2L3<1(5711M/LRB3._2*W;\A^(Q L7RQ/I4Y!MZ0RJ,IMJE/F^K MH,(V <\,>.@2P2'W]!Y=DQFZGA%^.]J;UX$!U*1/\%!F&8/D'ZICA9+!FWQ1 M,A"%>(&L$.D8@7$I7?^\N^3_,OC92>-Y1EF#3\\,?R3=G<2V/PLKS7C\_%<6 M0.0O2+"4,QDFSX_L!4_X>7)361S]WOP,N>ZT0MM,]S@H,S,8_"F?8 %BCD7B M*LP&O_N9,_XYP_:3S)CKXW)91BNZP?HL)*A#7; M_'A?9OQCU/])SP;]'_D_\K\NZIJ 0)[V*+#RES4W_'E44'J+/UA5\J\EHB?V MGB\AJP.^# /_^J'8?H;-(SK6^^<[OSF(*B@%,/E?>M_V_Y\B65)L;GTXN$>2 MG[>7\V9!DDXPN1%]/+II)=='+*7_@^$@_I<@3P/$LX%$!/[YM0/RP-N\<]R? M?[J"L:GG&UN0ZTGVO*\=<9,\:W9.[BS#]O_PIJM0T25CE9Q<=[O)+^]8K$]L M$6"3L5ZQF.RP.'9=[TZ1E1.QZ'EF-P20B0_^CU\R>?I8/;[.^(?/]Y_& UK;LZGV>T-:;A$LO?-% MJ]^/GU5:]E%V&>_)AKV.,T#.F?7*"YTX[E(,S73[RMW1-,MRT_Z=[FNHA<0W MVQ=JU8LN5';SDE5HOJN^V6$>\T=2'SN::[A)5,"JNBE%N7.^U<^JZF:J^\.M M.W/4H!N-U+ /*YU@6L675FXE#DGY=FM+AV(L@)95CC>AN:\PC(?+H[G*3H*4PJS%VXT^^F[.\-7[V M@*NCGJ2M-J6ZRK2^LDEFQ9O/']UJ+1)TI!97[Y4'2[E*[[4,%\J\\/O].[?]K7& M=P/I#R+*L^!V@R?F)O,]/I27U_=3G2K[>M[(ZSBR <>_8NR7JL*ST_0CI->^ M3PJ 7T##T++MHN*MTZWV-XWFMU,"QY, MIM7X\>GUBLM# 9+1C#\AVXPI\W9KX;6*CBS@-OVOQ?2+!X0>B>>J%;M#OJSN MKWH06M:4=^S9N;G.E>Z_-E0-0^2CLFVF(V MK$IZ4N+I05U;VB31=9,>,]H4 @1>5PP4;E-6V)9)&0BHX%3KT14M:N_'S'JR ME-B,(%89[?& &3T>>,! !)4R[$\1"Q*/P@E@4EK.S$>+7E5]JGC#'D)RV.<. MIC[1-E3%?/T%DW$RT=;3#F2*XT^L9N#AH,<,DE<.6=C^@D,'"Z7E]YP*Q0\6 MJYRJF0W0ZW*Q\)39,20?S$<3-996LU'9QEQOTGF]MV?^RZX=R>_,/SK4<-T1 M^(."JCCE=)_L;5/*[(;I5W\Z8 46C)C0U\NEA>S0^V&(LJDDG;NQZ:Q;L=F M1S+S79.'-C4I4<00J1<,ZH^NAMBOI0=-[ M<]\+Q[>ET$S_Z\GB83_>AQP0-G\&CSMB4)[PG_76$!-]-^^G+[C(=214A_[ M++,^",=TIV&'_.I('2NB[3,.NEROOHBVY $7C2CY11R",$8I9X7@LSXPJE3Z MP ARD**<9=BE7/WTY$*X"[+T!CK_&[$@A6AIFVAXA0>0=H1#N2_F)"HN3(-QYUK8T/&C'?<#RO[=N;-[8(>C_RV6/Q$&8!:/1 M^@=O;=^]/LSV+0K>8"G1+A0:2N2W9]F.JCH_A4 MWTO"QEY1\0$/ATFE-H-ZNQ9?VC^S;K=K4ALD!:1:NB2_C3PX*7 YT[85J?E2 M!!AE!J@"QCI_!$='+P.__[)LG]C0DSXMYNHTE^JB^(,K?54L%S:3$N9(TN\E MQ/NBQ_T5']F4+X.F^E)@\P_>OF?CJ4X*?P9Y.M;( 2M0GT R;;*)??U0K1#5 M1W&=/ND%&8VZPP7Q?2U8D6KA.[6JI0_G#U3,O-^4.BI2+_F*OW!2ZWU<$;+[ M[?S7MXV987^IXS"N"=72ZL]OGA0-L7C?S&!#E81ZXQ()&,-QDNDOD1'CLKR" M<:5_0KN)D8'%+W:62H)<2GCK:@9%^=+4YO>GNI4;[$CZX,SOX1IHO;8TR?+J MN.,\;NOHB)7^6ZX!YX:2KLNI?6[-M2=_4T[3LTSW81VQUP"I1HMSZ>/OWX-S MOCM457T8>D <=7WE.>GKWD4PA;:O]&X*8ZK9T^MQ/;Z[)RO9@)>U"3F6%U+N M\>4C64W9(U>X".O65IQB9Y+2[Z."%2 ]5OMV]^/';WDP=H&52;_[P"BKH947YPZ-SGS%R@TXYQBZL,B9YJ4A\J:]0]JS;Q?,U;8R6YU(W5]!\ M@U]-P4 HCGY4&E0]9R?SWFQ#^?53ZRMR!J)U+GFT#V9BL>_TE_N4XZM+S9_* M5M8]1-O"H(XVA U<8@-S&P>UN,J#(33&I$IVZV:NORU=.6-IB?(5JISXJ CQ MY?SHJ6!&)QI"FN>(V^&\]W_Q]M9!=75=@^?%@EMP3X#@#A=WE^!RX6+!]>+N M3H(&#Q#!U6$ 4'1/Q@(C)A5>T5PC]/$GSH\E+S,/E<&M M M!5*>^2??PY'G;?OV2>KX##%ZY^'YSU,AN;0TN72(_U]HUM7"SJATM10G]$ M_ZV4?8H3BEVP/_8K8.OGX>KUP4Q+H94;&!CBQN_;K+O0RQ97)*;<5ET_75Y8 MTQIJWI#J-D#B8K0O2HK8N7K_J5[D>E9Y5V^U"]7;\X718Z(@C(^(^EZ!CO>^ M!52QSR^=E6.U;U0(+J@K?:_%M8=\J&KU0C;)!14_>.GMI6.I&+5(^3 SW7R3E2\Z/!%-3(C+^>R] M]3 W?K-",G$,+(LV7OE#=XT:6*_3Z\Y[6_K> ^Z/T\J8)TVP^1Q.$+53EK>0 M)=SO)XU!/Y@[5GC2SYV//KWM\?_JU/$26(,$@<*Q]OE#^:*S^,?M=!AN.=>D MLQ>4?<2]P2C9='"_<&$N#:+7\<[]>R@(=*.5+GJU==*XZWU;TB?:RKS78;NL M(!O^&&. V.XX1'1&TM:R(/YG_PQOLO"P6@BK>M-T>3EEV,5A:J'>]DOM]%EO M)'[[PI:7CT))\[%-4K_Q&[?MK+X#'K?'ENW=DK/7C;L-;NQ,[BQQRATX>;<:?6MOP0:>4*7. :<+O8?RMGB2!5;\N#&S=N*-,]$PH M$YXEEO4I!/_8 M-L3S/G"':_8^3[/V%(O+HR=30&= ]H)PLA]"9K0XR) MUKP WL2'BF(%+_5LUV"R%>BZZ:UH<".@LV+EQO03_X"W$C(A2)OM8>\Y<57F M+?X*\,PS4-ZP)AF#O[-0F?&O/;G2E:L4V2VCI7U001SSXBS/@O'1.'""%M-3 M?,.K.D>BN%-M?V_K4SJ4L&\PGXERM@16'$U,DVJ>7^I(Y0*05:RT62^MD$Z< M<&E.[$RM)RA++?QB&PP\%B57WUSL0+5)4PY#>\B?33@6LR@1YY$B63/ENRE^ M(MI05!6FI0DN7K9Z^2@LO34#V239)-S3!I54!C\)IA%.2"?8NJS)X6\[93]$ M72I/"#+F>$#T+!_TVS)? :TF;Q]@"6?\CRMIY>G)N@ >4%Q/M@W^MW;++PJ2 M*][S+%CVXMR(:V7!_UE-S.)9^%/T@_VSZTM8VY]6D3\4%SS['==S#\2W*!=5 MKP#B*R$TBLYG\0BZ"IQ?_[.Q\D3B=LDQ4]4VMTHOT%;2&F*3 S@L>%/.H:@2 MB>6'8QV@0V0S05QE6VC?-AE M*!=2B?G;U/785LK_J7D%Z.M^N[4DYJS#T%;/>0Q*][\-Y:=HI,.F)R(L^6#2 M8H>HE)M7U/72<):-RJ4J!??_6UA^MHKOWS]7[#\G?\OPW]HGG3[VXYN]/DB] MN1&,,X)GN1%T@-R( Q_F]=5Z_M7EHA/<'2Z17E^_))RTH!92XZVC*,F).A[1 M0S-Z-0X,^FHK_BAVKNH%V>(\IFZ72O#H.T2 6_DJUIO90+J^?7:NL-PP72ZW MWJ=N$*R(L,YD-!&=,-1I99#3];B/ZRAP'2@NJ\&MS.7\TI"Y?2.&VK\2P0E& M71_13Z$<.#\U2+*R@)@@A&@QV\B]"-5NF5;*LCP6YDWB1?N9Y:7X%2!BL&U"L8]Z37*T^'#ZC>X=Z>KP" MHKW(PS#7_'*D<$'(\__C_)&L+!Q- ,.]9[-YR>JVA*1)_$IM@D-8 'M%C.%Y M6;V%K7&Q\M +T LF!!>ICBG8J'P^QH*F0N$673W$[R$P)5P>+#89/!G +'.+ MP)\3)#K0(!B1]C\6DJ!M=X98K\3^X#*4+\^;)WV#_"IP<6Y0U7:[F6PO+?W= M%2X8@['3!' )#8+97XP.<,="@)1NP](,EXB#!@',XZ>@48Q=IG!D$!^BZFS\@#T^A[-F<6;M81MM ^\%B/?1R=QWL7C==-+%0. C$Z?PV:3BOB]YI MLV=Z0 HI75>@E#OH5$'TM2C^>X!D,+I#/^W*7N^H91,^>17-X(\%/A3&[ZB/ MF-& +F%E)8LMQO3F^^,>>A4\;_F137W,G!T9MN>Z@*QT%8,!QW05:JR$RCQA M_K4FDW;$=_)?N-.5)*X.GU>]@C!Q#KF)MZ/#VHH6NU.VRCG$:(ZA>],P?U7U M-.LATK!J-XCK#0>FP*!A+14 M%]D8%1%KD">S#>1RRMD4Z3!]&C4D;(5F336O./TE->0<.0TL,@F UZ4HT>5= MN$Q=:DZ6:D.,)*^9!2"B!>)J[XF4MF":S#D15\TX6%MXMN QU9VU^ HP'?CA MZ6])]+!1]X3YJ=QKI\.SD'L,LX1^K*,G^2DA;MPE@.U_4+(\_&NP+G<@][N>:J&"*NQY(\ M^XPFYDP8\D28U7W^D>0FJYLRY,_?=^TV\IWO9AZV*EO%7->?*0>1RXU\P<=/ MCJKA7)FJ(=&$;R91: 3@ M>C5@'H.4IJ.O!B0R-PE@Q.DB_\A_1("]I/N<]C"IS.#A_)-"]5C'__U&W!/S M3OAS-R=U0E\+N3%-:MI[]5= _\/OCZ2]<\ MOHN"=#,$_U-QT!9K?24/"-LY61EDY=XQ#>5XM\M+5!((;^I2*7#>DW=78Q#< MI=*O^2&THM#L:+63T?L/N*ZW;!UI2P7]"L7(U3DVPV,G@'5HPY>2V8PKP:WP M.D:P#G[S,N3-G00+WV3 M?*N&3)1%0RD2ZO\W&U,\MU'D[K/KX9#+J#00:(11_G M(G@OA5CQ:RMQZI\<6RS'J3,NF$55G06FA?P'I_9*"'K;7UKV[L=$C*79Z/]J M%?'6VYE> 7&5;^%T1=*)YK_VE@/N5G/ZHNZPH]]L:ZGGNA1>48[EA0W/BHJ MD9*IO9A<;=+\)U]L^RXO..LY,@57%P1QX9OU[#T-G.'9?[9F0332M ,&^ M%BPES'T?04*>I-!-<<%JZ#_'7U/D6+ 0_/LB5&ONMS!%&^"]3WO0K]C>-D6* M/Y[B/UELIELY39EJZ:39+J*/_.JV]Z)0WDFK:&.(D1W.0Q,__43A1^JL:%6? MH")FU!I\$\=FO^13VZC;]V1QI5$_Y[#:\>9."<=8M*1W6>Z ^XB6]^GV0Z/* MUL/_;"&7Y2%77DSP<\R<">6/CZA5S=](G_EAOMOCI1C?"\EKE.WE"6S<^'7Z MI%ELS>VDLR2%)7UXL19QU6,;\$\1.#_QYI-9KB3D%5![/,X4X4@'%R1DO:\1 MF91?1^-H93FJK-@^U27ME_XS4YM[R2.\/98QV8R MN854?>DW=SV3-7](<\;CTF".' "!#$"& ,J->"^G ]/PK^[0PS]$9,M^RO^P M\@IX@K>]^0+<\R(4"7P(Q575H_WRGR7B-=3UI! ?YE"SP,DU0$+)FK[,/P&? M^/,I_A"]!*4!D4G7C?N:@(!0*KUI")OZ102\9=G@YHZM+X-H]L^$M!&%!K@3 MXN_ZG[T^P7'U(H@)!GPD*EW<<1SH85\W)ZW*1G'RN0@0LI&F_A,1Q B!IC7G MP090F:W-2)'0[-0B;62GD:UM!) C405+J?UELB@IX.CG'T<(T[O 0.<9R<#$ MS(**LA"ZXG98D?7 ,C$?E=TF$GM,J_A>&5V5!GG,;W*] IA-2540YD^_? ^H M'"O0+I^':)!U.Z%;J;#]!W;]QU5^&"VUF9$K6]/0!"4>2P5DS(_#BU@W)S0: M9I<8HZWZ#CQ9O_N>$$+TH,:P=(TB!]T>C4YO-*:(B3U\W"?5#C*S[>=Y=!* M">#7(FJEI33CY]FI5>!_!Y(2BXN5KFA$CJ<97>('XM1:+TUQ-S_/4IT7AU2C M"(]WE8[#;WB'[-T_3$;+:XH(?GEFH#O!'L5\5X3]C@O&>F%-CUY /NY0?5J5 M3OJ#%TIR8.C_-2OF:5?FFJ_CH]N6HOL-_+?#+8-0^&]ERKV\F_&;.QMGLDYXKKX&+)A/-%%_)Y-OAAWRL122;%6Y+8S&X.BN_[FA?*LK> 5$(YM M3@SIS.1513GI4T%0.%+F5:K*$]QA6T9ZV%T\/4AGTQHX3)3>Q><[RWSQ$S4+N//^#W;[, M(*U&V;CVY;9,F'R.69!XH3"I_)O1=[W67[^B?J4J?S9I\Z)VZ$/J5BW%E"+, MCT>75'BBQY6_%5Y6+N[G M%N$%DW9 U,;9S=L:)9TDN8<8=&\B3<;: % ATD:>KB4NX%ZI@S:O99%8"CUG98\4N^*]?OW8F;&V9MZP3([)@2Y"7(]($ M$C/6E-*9'XANC2/&*'H7+/[]-!96-,T$#-I\^93-KOAW6Y:*L-*PULI@%+]1 MI89PNA_1O$\$RJO[A_H2GOWTY68B:S0_&Y-ZBK46%9/H+O;1B^[%,SS1+*#> M[Z?F\;MYZX6QKTKAJ+]SE\#W9_]O\D8&<3<)(_V9*[0F$PGOLN7E)UF MH-,D"^C,QL2;/+[R9B8K![;)Z-2VA;LX@:5'PG?O'-B#]0F^V:Y5GW$'VIBA M_]'M<\;O3C3K'#L'Y0%;6=97Z/[V23,@%PE:?8"9T(:+BTL#;/A8H-V VT,W M$$)WZJN<6/#>R9>\,&DRFV@VG&=6Y>E8_I'+:V@B(,!)9*@J/A[SNA*'@T6" M)^]-)V471XK@^GR]D&T>P+N*$?8*"(W;B-<,H$1[SRO"[#27!JE/V!32J6M9 M%N]=..\>5[8=QFX3Z_.Z_OTVDR$J(].! _GQA(7ZU;T50H3F 7P4L#K[[#+^ MK@4D^_A6[^Y/+A\G!:)N2C.%I!4-I5K:P^2NM$UIUK'E8%KPR7K#7&.Y&&5"JH*8ZN$N/5OWF"'1G;S0 MG>:^:&XF>0&'0_P3HXUA-_1+RUE?-.N5[E!XL^[5HX;SO;>8_0:I ^.X*CX0 M)0)/1O0=PCLN%M+<9#(2T@C 1CL%(W/?5QY&S*N;7FE.G7;\-)&ZNTJ)Q%K0 M'(^ZH&R_PZ 88+? BU_Z6\;7LH2$P*A)3W9DGS%FG]'TJK%=47+F O#>@U_, M@EM3\2%WRB^[Z&,3\\4/;Z2(P0<]'*)C*CK3P%?1^U0]/%S&-E1,)0+T4E_L MH@KWB/OI8IR=YBP=I5%-SS@>-QE ]J_5; 8D&V/WQ->8#_L&V_^MK3^/&?U MZC$62#BM*N55E(DW[X'Z['OZF'<_1P$&2S[XVAN5XG%G:SO[0!7Y>_=JPJNF@(WLTOR M%ZMS2W#@.BLBE7_H6=5/EO1;]GA60#<4VJQG/C3& #4AG5 7 ]19U6Q^TQ.X MDF')S+S)9@MY^?@.";H1OK07!LY8#+U[HN7>(]<>3\O%AGK&A50)>BT5,<(/ MM^5QZ]&D>IZK)B0U/RUB!Y.(![%K)$H4!Y;1SK*RWACUB,)R^6=&2_-&^>&B M_R]6=Y>+0S$-AE 5 "E $2_J0_FM>VH,78P_[Y]_D19$[VK+I[5@A,L<1'A M"Y3!/;B*D7QC-#CNIX^O "J_]%> OG].I4,EYK\E@]LP)1#/1%1R(QA# MCO[36+#(]:7)+\FI5-^_G$(>,-J40JH5VJKJ*;\H+5L>V76I!6>;W @? 4G_];U$$*7CP[VBQ6+P37(VNBO%)V65P*\'UO^6 M!6+D/J]OF4TR,WS>S8:?(F7WN7 &\XV86$5?\MY"0_=%T4P+3?!,B JK5> I M$]4$*+'(9A0<KS1 @ [?SBISNWD\N-7L>,KLH"KI4%1#J[XZZ8LAVT"$ Z;)H*^32R M"1.N?.C7?I6_U%[/]-,PV*'*UM'0.<2(*EE+.)8=$:8@(1OQZ1-537N-HR?K MY1_W"+#,E0^]#^K[D2]5[4%9__UZ41/4NT>YR%IEGQB28'@07W&.Q:MAJ"54 M5E"!(]KEHWJ.G/+L$,&6^K(-,)AJU?=(FR96ZBB,1(W\KMA2=B*'=)P%/LA/ MY@W@D"W&O(UAJ-L"^R0LUJT%#%;^^!QBRO,H?-UEY65K )R[+LLPVO9@VGT4 M:FONU]3 R-]L WA]=$5N_84ZQ[>1NMO5R)J6'BO6:#KWXWZ.WRU]XQGNF&/( MW@S+V\)MB/+7Z-*,=R4Z^.\3,%(_9F/OP&&Q?$C@\]^Q0LXH%<3R&@9Z\R_9 MKM0;<=0Q4DLQY>VE3HP!YQK@S(*\/9 ->L]LUG9^RKAN_9Q/,9 @+$5>7_RY MUOOP!R4W=&<_Y6,PH[^'>8 0EFQ4>M)T9;&@FN>$+>8.S:0#QGJP'F;(\E@7 M:J^%TWSZ#BUMFW,#N>DJTA47YR"4)N=]"DC@E_9M-N87'1-WNFHJM@,X6"ED M+K7W[R6-^4._.!H8;:RB+^XY[?,0:X[,U#: 4.T%OLFQ%%6JSY8?\$MUA+8: MK>].9EJ&+A723^0S49/?GXJ2U26MY- 4^>+-U*J"NV7B&-H58N[)2E\!"Q\' M8_D%&Y;OPX&[LS&O@+/XNW%['^8..,?.>V7Y@4D?1@OWLYDZJPJ6S./CWMI/$*GENAND0"DJK#69CRL=+?D/M/XC@3^;% M"WNAJ6D[.\DIWN>AY]3-VQ1*E2FPLG;C?HC) -9-$GQ+H8:5\FP(X5I4\(>Q M:8CKE=Q2QH;TG<0$X\(LWUF ?-6[Z@E2XB4;./N:$K'XQHQTJ4/AXP%D(YZ? MBD)M8[OP9IX.LXZ1UBY-?LA+_\$$8/PH>9*J''(LO#,8O="-@_@2I+M CED M<5T(=], U[S;,:H_EO6\2D;X6VM$6X*F>F=5[_SFU"*5&\535)>D'W%OOBA[ M72VVA-34I.V(PTJ&#@A/PPP=D/.&=?76-\,$NS@!J!O'L*OV1(@/R[K#BO(. MR'%G3BN =.J@IB8>MN#;!*-[F6U]MZ8-SXH7LK\&\\,F:4]]R(FNXDHDY]D8 MY^;?EG+EH[J*T9#Q,H'/3(>(\@2.S[]HGE./KRLNFUFD M;IF_CUD/;S/M6W_F><%O$?\B(-60%;U[N@L%N+,9&&88GY!$>IA418M%V+.9 MQ?K$S.3JP]HSP6X*U/1X/BR0*?<9?)I:D4$&QN>NQPXJ.^I 2I=6/7"4QR6C M@,AV/5$_[-.M,^6>V$7)BTVC35;TQ?T],NDU9Z8YV,R$D/CPMOVH.NK>(L1F M,E15@LH"'7"9)W?.M[AG7=*-6D%T-_7NN1NP#\]07JVQ;.@DV\5J(_PX8NY_ M5A$%"KNK>9%NDWAI!C7]2]L-;M,OG)QS31J(JVI0LOL/[R-'B#<5J8K&5*_V MO5N9I1/^0S*DTK0\FSLM:&E_=7\LW(TSHM_2X%)AB&M;-(@_ I!;]V&?2=#&UX8PY@#8J#H1^ZZV8UVX8?$50,YA<:@G3<^N MPX^[4L^L$7_@\((I2F0/DT MT-:) J8KQ7K[#+3_W64)AH*QA]]79:Y:F\^6#RKO@'M01M9KU*M2GJ'?0*^A M9_%G.MBU(G4I_@ <.YO(&4%?DWQ#/?"RZ."Y+);S;>"I/M0QD^K.UV9#R/8 M1Z'64XK;^X8+!O9)O(:5A(N$>>M[;PWG%\>5#,CF_*F9+)2)V(J:^=>[Q_E2 MSCM&Q: QA4F[2J-7@"3:2>5;4(D(!8W7^C+T'C ^^IJO*'B#S#YB*BXC /1C M-SC1N3=5FB>VPA:0!1L@:YZCFNFNWC1SFL9-+VC]Q]GCW-"ABN_*2/)6 ,.=L_/IHYSLM2FTI!V M*%KHUG\+I^)-[]\J>Q=UN9S] &LN_[K&&Y!93YYY8C>QM3LNT#;7T9)-V?[@ MMM.B2:*JX:*" !#@2E1/0#K7CO%56_&KMEH[X"+D8+BE\! MVQER_QXJFJUBIAZJU52^4QA'(.-\-GFV,?+24LID9\H"SY+1P6P6,'\HR,;@ MW(#4C3U19BUP?UPX54ZRH](XF!>,N+1'VV__D*[CK:BGO*6[H%!,OYORW4$$ MY?9/3J 6('@:6WN%H35![JR^H%@7:78#"55Z&%%5E)PSO["I?GPEG.V--9<\ M86#Z=^_:#HV%WJV<'';&Z^E^'G'$9U'2MB#CT8R,)3G,$EKNF)^<4XZ <\3) M7N9+J!"BK_:1G)8NO6$DQ !^"N.Y:-?X&A67V?N==.:)_[KAJ_UG5(<'R85. M:0-G(H,0;^+9,U=HVVX4D$11FN/S[?O<4ZW5X#TOXX*&NY32]GH7SP]?/[M2 MD=IO1U=W(RI7..HCAOK(%*]ZU-LPFW9!! @NH#Y1I'"_,5<",,/2-+MYTMJ6 MKZ84F'QX;>9[(;?$NS+JUP*ZWP6C/AJNT$:^J-YP'I"'%AQ,_]#'O+ MP5%TQ16]H/,2Z ,*X*=_N7UVT13B&SF@^/YW2Q)X0S;MA"V-LR9S7+K=M=-) M@@V7!/0,#VP5A;D$;"0)MC3*@NB]0JO<0HZBI-"4,*#NB-.BYCG>%6=;H6(K M_H$F7D>K\_2DOH<%:.HZO4VF*Z7^+'*2V(,%-VGY>3WF>EY5E-2%'"U3"!$4 M8=.3KCF#>S^')JSB#1!"T&T]6QX9"\ ,G_7H^5V/=9]/UD1V6)@;P*W@H)_])C6 MD_LGFYH28@=P87FYR\2">68H).P3RY$WC(I,F;8">GF9*_EBU0\.QQU?.CC& M[A>*QCD"12Q%4G_3)IUTC]$U 13@*>:2]<)LM#?N1*ZVX@[_+SZC8WT\7)C! MKG7OXFM[+/WTKX/6JK;1#D[AA#L%4X)\CF9K6N,&'@O.<#T[ +?MP-WKBN0( MP.6(A5BX_%EF./IL?GW*@S/#;Q>LQ-67N6Q@8O4!N"'6A55 O78Z$WUTH]_O MY&-,_L-TB44Q3_KP2]^G@4 M""_?0T%KBNO81-YFT9.))20,,_%4VM[0^K@X&\,:$T-/:HWU"$[0?/-HAY43 MT<[7.F,LV")%:O(]:D^PYN2T)P_ 3.X$Z0HX8=T\FI6KBQHMOOTAZB=Z7[QO MJ$YM<]C#)&.ZVS)N69,NF13 R(J;G.9E0C?#1+W!4E462U=:U.1 KDR88;(2 MV/8.PC_H$ECX47^)HBE3!J]:%I PKJDHH%XS TW;B4J"2UG8SFE:!QU^A MF(26;]03^Y8A;2(GH,0[L._K;5<&ZKLP*TLU-:E;,?=EF:OXC/_/V+ZJ-WFR%H44PMG'D9!T MM;]B9I8^+ACP2V])LHS-X!.^\[/VY#(FGCHJ\E101JW;%)V%IZJ1G "0XZQ4(U(_4GS[S+D M!=8GR[CR')9P%'IG,UL/T^"=2'>R^OR2;=XDI_BB'#QGB>HYHS2;:!O5"#<' M6 E8B.3M[L_9;2FR:1Q%:O;A6"9_7[QJT*'H^PE516>$IBA%!FE32#'AIN,5 M;M#)TC*)JJ"_)6K+T!*/R1PN#! /]Y9-%X%S."Y,0*/%A':RX-_1_W]Q;7^/ M+E\('6!?%*9_=%0A/)FMSSW.?FLM?1;]QX:QJ/8 +X^E>C,X9J8*?>;7))<4 M9R\1-4G8:Z6CL5V5= M[7$.GUO$5YVDW2$*5-\Y8?9=*&*MER%PH(E%67<[J==F#"O MR?T)JP6#-ALTKTCY0^Q+HM4M]3WZ1[G#BO:@;6F73"Q[!F=(L83@]ZA6D^(" M923,ZB[!A2B5;QI8A%IU%5 +=^Y*:WP2K=^+_/5H2:ZTH52O& 4O-/8^F01.OL- MX*3GF>U&"_U2HR.A4(+J_870^BQW_(+M6LR&$1'_?#F+CR54(@*^ MUA:-03:,JN@CWQ;R*/T<58\MC)LH/8^?2_\:#-@E, UF];:A:Y4U#WJ"NS=] ME!-^]MSZHQ3H.\Y0(3:^T4SG_S;-0/L>)J[*--]HQOJ9#H[_W$]=ZRC\1*ML M!2VGC-L$JW(R@!G%]=.;X*1DYQ=D8_+.78WH=C>/#'^WNM#-QTH$.;_\>M2" M.1NM=+5P.K>*->7.UT74^N)I?0V51FWYB@>AO3!%Y+LN12\\B)?D6=F0VA,[ M%"77=%\;L;9D@5+C#$]^#E'R>O9'D6UE+ ?O-]#[6KD*33N;$QGO"CK(GAID M-]L54G:M)'S86&!V!A=FMX'?(J3.5Y-EI=?(T3[D8HZALB:;JIV^<*BK>FD NZI1Q[11 M=U)DO\CZ]&7(OL4]COQH5\![BGP!+>PB;WE^,PUP^=?E%$7ZUP!SR.-&1D52 M^ K(KB,4LD=..+[>HN@U0N.YK;[=.BPGZK4YV8QC8Z?T&3M>2"M?4D.E.$?# M!>! !R-%MY."6TH'LT??FR2-@ NCMN53>\>/HA!WH8HX[3U.^><5\%^\.L&S MB2^"\'^?C7>8R.@@J%B<4@:?V(1]?@7\66I=>P7T\WGV ,0L-I6QK<<-A@KW M5/N3$_@%6ELD$*ZN@26O .29[#/CPQW$I9%M5,?I@9^0IX/8KM97P!?K)>R7 M5!Y5O3IHP? J^L?FAL =;G!Y0JNHTR!%)AUQX MR*+S\ZF$UG4E@?5L.QT_>5(^=*L7AJ%&KA:SI!R3Z*Y&?L[6Y8HCM;LXMM-CY%8#J98 AW,G71V8)NY.S$2TOL BA4IZ*W]3VD*SI->UVB'4K M<8G%3YU2"]:J?\0[^=FR&\6]!JJ!T\OZQO2^J^_2T!K44,]-X!"0HI4?0.B/ MJE%/S))2,G]XFKMRP#.GKNLIO;'[R7"<_E04M?PNW6!6D*1DI2*L+'_,[I T MS' %LM_X%DHUM#=43PKBX3;[@%BYW_-1!"/WJ6H4G+NEK:)7<*5CW[?:0+47%ZS='RB[ M\D?["[J;XGA=P.)=PPE6'YW:]N L0.?2.5;%?_?JN=G'RI0)T@8O(-& MPS&OIO5EKTNUQN:JZ=J;FO8Z*@]$)UZAZ=L*_QZ0%]XLU.H9:B_4RHS_"-'" MIZ(XVG(I:47U]W0LM=8:\&1^B<-8K5D>;C3VKO >1Y39$/*CP+3*LH[G3@8Y MDK)5ZI!>X85D,LUR#96I;I!]8H:P_)1.D&)YCO)Z=U7D(UK7R-UL7@3/S&%U M*VYEHAH/RN&]*<_"M9DU8*VIGK@2OP7AZ%$U:7R0S-Y*%BJ&Q23@+G,\1Y7] MQG1<@2T!K)9=97Q(,(CRFR#/]/F11P CK'T9NKQ_5<$#EJ#H]D?/&5C$B=I< M:&D&7(ZA'))_:C_'K[+WH_*VS.^.['A61@R]QDM:>];5KQFWGY*=?+]#R&KA M21VO&-@T2C ]VQ!V^J7ZO.'K$8MVG[,SRYUJXM,FXG?KOJZE-STC*MYZ4Q7G M-QU]%W ^DO+T\=RFEW:X:$C!\3;M\Z;]KF;VN4&52;%.3^4^O96]UR)E,I^[ MK=WO-L:(E^'FCCLC*^9J^573:0,=?/;PQ4S96[P\>'+B&=8C;-=E"]7T$9 L M*OY\5XMC#\ K]/3)0\]_CN9%NC7E=]4=YPNVC*_#7]]R!=;4G:K5Z#Z\0]!/ M[?_SA83?*2_HP5V*^ UD5:TXSIP=S*]='Z:-UNGFG UUHTT,)Z-3D5 GDOT1 MO"%/W&]%MZ -.')5Y%\>>6(O^!W],RD10SY.E,P^U%5G[<[9IL0Z:C&W@47_ MH3IJ+6U+D,.NUA!K_^%XLR-E ]^(CC;$?NU!*_9K7<$Y;:B++ZN\L$9S3;DM M;-92Z?-1K+7%5Q^*#9$[&5E?5Y;W?;83XO6+ 50&.:\ ?<:E MLG_MM<"<=TC$$IU1$4?056I<_HF@%V5RR$[80P#H31SGMLXR0W<0/=?W[('JC,C%GWB]Q]=HP(RX@V0JLI4N< MQ ]PI]J:ZO;+7.',=0P'Q/#$_F'@#=EY@_P6U-WB8I]/!3H'""8:Y^\/,DEC)K+3C_7L!#"F8KV@Z]%JS.0VR<;OI)5H^MI;;3A7):G'^I?1AL=&;8&B[8-H>9C&\S" M*W\4!&3M\CWUV"]_4SLO1%;B<]K@.RT\9X.[&S,I6[/^U-2![I(\L+3OO$:5 MP>M3)MLJZN- M%'D],GLM?F7:R&UD+F4EJ<3%BBE=\US@92M"UGVY]X%(-QRM3KC?(GU7>,NC M01+!RF?#.+6V#6&*%=W7.^5#&]K$4RH1?VD?)2>_4?ZYZH-*5-Q%D!G*!$T- M)ME-!ZU5>CEJ\B7=( Z8I,)FB.?MVO4N[\=8[L\V?WYCJFSSU7^M8EA_P7H% MQ'4HO@(J.L;G&D%)L7=S.7M?7A /W@)HAXS _^R !4T[D3G622CHXZ8]=L9[ MZ@B$D>XNE.5$KQEI%J5^Z[L??@J2A%M)DX(H':T_8 N\1ZRH[^7N))^&9*76,1'NR(9?\6-F"?'B. M,#64N.\R7N M3A2PV!L!R7!-+/ZY&/RM*BW'5:-(ULK,5(&':YI@ -E@Q1XH M'38*2:I3[WRY=C$ZNX R,D>53F]%/V349T!U#A9[6I[Z'32NA:]]0+&Z!B,F M3C6+32#U^[F"/?XC_I%?'T(S9$:S9NMZC,A8O00(U\])7XYN@?NBV2@>>-VN M$;G)*06X@*G)7W6*=F-R39*-/BT_(63A4.6*P^_[^%NPQ.OA_5G3LGR B"[L\"0BG2/7-<=?/5,[8& S_AL%.]?^5UT<\O'? MI*=L39&J6B:B."PXO<([T%P3YE>^*Z^#>QDO+CZ*]0]GFR[;R*H#;8,,&F1T MU_P)LN.XCN656J4X_:D,TOA!PV>#8K]Y*]7.9**#D:[:U)2\)-Z>J"-?6=BY MQ_/R& 1=&Y8*D;KDIC3@)I5<&$](2;B[HT?7+.GQRDZ["NTA%.OK2UC878ZN MJ\KLZI'G;*"6#6UGTK+G6]Q:BT U9H$#=9'QWY@+=7*<*HJ"]7=BRWI*Q6+P72DXO!XC M-(LO'B?F!T.]'Q-6+[D"BHKS8?/A8)MB_9C)YTO73[1]ONV?6.]/ M):>M#3:'R=7RY1\E]M=H&BP=L MS".U@9L._&XW9:[=/GS48(,*);@HE./#[DI%M>*U9@JQL-*#277?-Z4J5_RW MY:K4;9D=(FZ6"S9=THTLG
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end XML 100 hyex-20231231_htm.xml IDEA: XBRL DOCUMENT 0001630176 2023-01-01 2023-12-31 0001630176 2023-12-31 0001630176 2023-06-30 0001630176 2024-04-01 0001630176 2023-12-31 2023-12-31 0001630176 2022-12-31 2022-12-31 0001630176 2022-12-31 0001630176 2022-01-01 2022-12-31 0001630176 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001630176 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001630176 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001630176 2021-12-31 0001630176 us-gaap:CommonStockMember 2021-12-31 0001630176 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001630176 us-gaap:RetainedEarningsMember 2021-12-31 0001630176 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001630176 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001630176 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001630176 us-gaap:CommonStockMember 2022-12-31 0001630176 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001630176 us-gaap:RetainedEarningsMember 2022-12-31 0001630176 us-gaap:CommonStockMember 2023-12-31 0001630176 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001630176 us-gaap:RetainedEarningsMember 2023-12-31 0001630176 us-gaap:PatentsMember 2023-12-31 0001630176 us-gaap:PatentsMember 2022-12-31 0001630176 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001630176 us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-12-31 0001630176 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001630176 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-12-31 0001630176 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001630176 2014-12-19 2023-12-31 0001630176 fil:RelatedParty1Member 2023-01-01 2023-12-31 0001630176 fil:UnsecuredDebtAMember fil:RelatedParty1Member 2023-12-31 0001630176 fil:UnsecuredDebtAMember fil:RelatedParty1Member 2022-12-31 0001630176 fil:UnsecuredDebtHMember fil:RelatedParty1Member 2023-12-31 0001630176 fil:UnsecuredDebtHMember fil:RelatedParty1Member 2022-12-31 0001630176 fil:RelatedParty1Member 2023-12-31 0001630176 fil:RelatedParty1Member 2022-12-31 0001630176 us-gaap:NotesPayableOtherPayablesMember 2023-01-01 2023-12-31 0001630176 fil:UnsecuredDebt1Member us-gaap:NotesPayableOtherPayablesMember 2023-12-31 0001630176 fil:UnsecuredDebt1Member us-gaap:NotesPayableOtherPayablesMember 2022-12-31 0001630176 fil:SecuredDebt1Member us-gaap:NotesPayableOtherPayablesMember 2023-12-31 0001630176 fil:SecuredDebt1Member us-gaap:NotesPayableOtherPayablesMember 2022-12-31 0001630176 fil:UnsecuredDebt2Member us-gaap:NotesPayableOtherPayablesMember 2023-12-31 0001630176 fil:UnsecuredDebt2Member us-gaap:NotesPayableOtherPayablesMember 2022-12-31 0001630176 fil:SecuredDebt2Member us-gaap:NotesPayableOtherPayablesMember 2023-12-31 0001630176 fil:SecuredDebt2Member us-gaap:NotesPayableOtherPayablesMember 2022-12-31 0001630176 fil:SecuredDebt3Member us-gaap:NotesPayableOtherPayablesMember 2023-12-31 0001630176 fil:SecuredDebt3Member us-gaap:NotesPayableOtherPayablesMember 2022-12-31 0001630176 fil:SecuredDebt4Member us-gaap:NotesPayableOtherPayablesMember 2023-12-31 0001630176 fil:SecuredDebt4Member us-gaap:NotesPayableOtherPayablesMember 2022-12-31 0001630176 us-gaap:NotesPayableOtherPayablesMember 2023-12-31 0001630176 us-gaap:NotesPayableOtherPayablesMember 2022-12-31 0001630176 us-gaap:ConvertibleDebtMember 2023-01-01 2023-12-31 0001630176 fil:ConvertiblePromissoryNote1Member us-gaap:ConvertibleDebtMember 2023-12-31 0001630176 fil:ConvertiblePromissoryNote1Member us-gaap:ConvertibleDebtMember 2022-12-31 0001630176 fil:ConvertiblePromissoryNote2Member us-gaap:ConvertibleDebtMember 2023-12-31 0001630176 fil:ConvertiblePromissoryNote2Member us-gaap:ConvertibleDebtMember 2022-12-31 0001630176 fil:ConvertiblePromissoryNote3Member us-gaap:ConvertibleDebtMember 2023-12-31 0001630176 fil:ConvertiblePromissoryNote3Member us-gaap:ConvertibleDebtMember 2022-12-31 0001630176 fil:ConvertiblePromissoryNote4Member us-gaap:ConvertibleDebtMember 2023-12-31 0001630176 fil:ConvertiblePromissoryNote4Member us-gaap:ConvertibleDebtMember 2022-12-31 0001630176 us-gaap:ConvertibleDebtMember 2023-12-31 0001630176 us-gaap:ConvertibleDebtMember 2022-12-31 0001630176 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-01-01 2023-12-31 0001630176 fil:UponIssuanceMember 2023-01-01 2023-12-31 0001630176 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2022-01-01 2022-12-31 0001630176 fil:UponIssuanceMember 2022-01-01 2022-12-31 0001630176 srt:MinimumMember fil:UponIssuanceMember 2022-01-01 2022-12-31 0001630176 srt:MaximumMember fil:UponIssuanceMember 2022-01-01 2022-12-31 0001630176 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-12-31 0001630176 srt:MinimumMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-12-31 0001630176 srt:MaximumMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-12-31 0001630176 fil:UponIssuanceMember 2023-12-31 0001630176 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2022-12-31 0001630176 srt:MinimumMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2022-12-31 0001630176 srt:MaximumMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2022-12-31 0001630176 fil:UponIssuanceMember 2022-12-31 0001630176 srt:MinimumMember fil:UponIssuanceMember 2022-12-31 0001630176 srt:MaximumMember fil:UponIssuanceMember 2022-12-31 0001630176 2022-09-30 0001630176 2017-02-28 0001630176 us-gaap:SeriesAPreferredStockMember 2017-02-28 0001630176 2018-01-31 0001630176 2018-04-30 0001630176 us-gaap:SeriesAPreferredStockMember 2017-10-16 0001630176 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001630176 fil:WarrantsMember 2023-01-01 2023-12-31 0001630176 fil:WarrantsMember 2022-12-31 0001630176 fil:WarrantsMember 2022-12-31 2022-12-31 0001630176 fil:WarrantsMember 2023-12-31 2023-12-31 0001630176 fil:WarrantsMember 2023-12-31 0001630176 us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001630176 fil:OmnibusStockGrantAndOptionPlanMember 2023-01-01 2023-12-31 0001630176 fil:OmnibusStockGrantAndOptionPlanMember 2022-12-31 0001630176 fil:OmnibusStockGrantAndOptionPlanMember 2022-12-31 2022-12-31 0001630176 fil:OmnibusStockGrantAndOptionPlanMember 2023-12-31 2023-12-31 0001630176 fil:OmnibusStockGrantAndOptionPlanMember 2023-12-31 0001630176 fil:RestrictedStockUnitsMember 2022-12-31 0001630176 fil:RestrictedStockUnitsMember 2023-01-01 2023-12-31 0001630176 fil:RestrictedStockUnitsMember 2023-12-31 0001630176 fil:RestrictedStockUnitsMember 2023-10-01 2023-12-31 0001630176 fil:ShareOptionsUnitsAndWarrantsMember 2023-01-01 2023-12-31 0001630176 2023-10-01 2023-12-31 0001630176 2022-10-01 2022-12-31 0001630176 fil:March312023Member 2023-01-01 2023-12-31 0001630176 fil:ConsolidatedMember 2023-01-01 2023-12-31 0001630176 fil:BergametMember 2023-01-01 2023-12-31 0001630176 fil:UbnMember 2023-01-01 2023-12-31 0001630176 us-gaap:CorporateMember 2023-01-01 2023-12-31 0001630176 fil:ConsolidatedMember 2023-12-31 0001630176 fil:BergametMember 2023-12-31 0001630176 fil:UbnMember 2023-12-31 0001630176 us-gaap:CorporateMember 2023-12-31 0001630176 fil:March312022Member 2023-01-01 2023-12-31 0001630176 fil:ConsolidatedMember 2022-01-01 2022-12-31 0001630176 fil:BergametMember 2022-01-01 2022-12-31 0001630176 fil:UbnMember 2022-01-01 2022-12-31 0001630176 us-gaap:CorporateMember 2022-01-01 2022-12-31 0001630176 fil:ConsolidatedMember 2022-12-31 0001630176 fil:BergametMember 2022-12-31 0001630176 fil:UbnMember 2022-12-31 0001630176 us-gaap:CorporateMember 2022-12-31 pure iso4217:USD shares iso4217:USD shares 0001630176 --12-31 false 2023 FY 10-K true 2023-12-31 false 000-55572 Healthy Extracts Inc. NV 47-2594704 7375 Commercial Way Suite 125 Henderson NV 89011 720 463-1004 No No Yes Yes Non-accelerated Filer true false false false 18465134 2963906 BF Borgers CPA PC 5041 Lakewood, CO 19441 65651 30440 105794 1626283 1819128 151931 0 0 53015 71583 0 1899678 2043587 3306 5501 521881 521881 16890 16890 193260 193260 735336 737531 2635014 2781118 116842 91316 215069 94554 65229 0 9222 0 361093 275370 83366 866 608601 317284 64386 21387 2465 0 154150 102011 1680424 902788 0.001 0.001 75000000 75000000 0 0 0 0 0 0 0.001 0.001 50000000 50000000 2954104 2954104 2876437 2876437 354492 345172 18999770 17459899 -18399673 -15926742 954590 1878330 2635014 2781118 2485866 2251469 2485866 2251469 864055 879951 864055 879951 1621810 1371517 0 0 3865654 2283107 0 0 3865654 2283107 -176948 -64690 -52140 -9484 0 2643 -229088 -71531 -2472931 -983121 -2472931 -983121 -0.85 -0.34 2915410 2854290 2819868 338384 17075974 -14943620 2470738 -800267 -800 -53013 0 -53813 507917 508 24888 0 25396 6740000 6740 395360 0 402100 340621 341 16690 0 17031 0 0 0 -983121 -983121 80068 345173 17459899 -15926741 1878330 320000 320 15680 0 16000 0 0 298153 0 298153 0 0 785038 0 785038 9000000 9000 441000 0 450000 0 0 0 -2472931 -2472931 2954104 354492 18999770 -18399673 954590 -2472931 -983121 2195 878 1639191 402100 -52140 -9484 -75353 -27547 -192845 -138838 -151931 0 -53015 53015 -71583 0 0 -16890 25526 54048 120515 35291 42999 8337 2465 -14118 65229 0 9222 0 -415749 -390621 0 7987 0 2643 0 -5344 -90000 -11386 362963 463630 110535 318095 713283 275370 -657560 0 107500 0 25000 170000 68888 0 369539 239518 -46210 -156447 65651 222098 19441 65651 NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS Healthy Extracts Inc. (the “Company”) was incorporated in the State of Nevada on December 19, 2014 as Grey Cloak Tech Inc. On October 23, 2020, we changed our name from Grey Cloak Tech Inc. to Healthy Extracts Inc. to more accurately reflect our business. The Company has acquired BergaMet NA, LLC and Ultimate Brain Nutrients, LLC which market and sell health supplemental products. On January 13, 2023 the Company entered into definitive agreement to acquire nutraceutical manufacturer, Hyperion, and its digital marketing affiliate, Online Publishing and Marketing. The total purchase price for the acquisitions was $1,750,000 in cash, $1,300,000 in the form of secured promissory notes, which was due in twelve months once the purchase had occurred, and $1,250,000 worth of our common stock. NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying audited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying audited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of December 31, 2023 and the results of operations and cash flows for the periods presented. The results of operations for the year ended December 31, 2023 are not necessarily indicative of the operating results for the full fiscal year or any future period. These audited consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s form 10-K for the year ended December 31, 2022 filed with the SEC on March 31, 2023. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments. In regards to inventory write-offs and allowances, our Company determines the net realizable value by using the various factors as following: excess or slow-moving inventories (12 months or more of inventory on hand), expiration dates (within 12 months of the current reporting period), current and future product demand, production planning, and market conditions. If any of these factors are found in the reporting period, management will review each item and determine if any additional allowances or write-offs need to be made. A change in any of these variable’s factors could result in an adjustment to inventory. Management has provided for any risks in the current inventory allowance booked. As for revenue adjustments for discounts, allowances and refunds, we treat each of these items differently. When it comes to revenue discounts, we will create the invoice for the product sold which will include any discounts given. These discounts usually happen for a short period of time for sales that we will offer around holidays. Due to the revenue being recognized once the order has shipped, less any applicable discount, we book this transaction at the net order transaction amount. In regards to allowances and refunds for revenue adjustments, due to our refund percentage is less than 1% we decided the need for an estimated adjustment for allowances and refunds was not material. If we do receive any returned orders, we will directly book those orders as refunds the day we receive the call from the customer requesting the refund. We will book the credit memo at the full value of the customer original order. Cash Cash includes cash in banks, money market funds, and certificates of term deposits with maturities of less than three months from inception, which are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss in value. Accounts Receivables Accounts receivables are recorded at the invoice amount and do not bear interest. Inventory Inventories consist of health supplements held for sale in the ordinary course of business. The Company uses the weighted average cost method to value its inventories at the lower of cost and net realizable value. In pursuant to ASC 330-10-50-6, the components of inventory cost include raw materials, labor, and overhead. Additionally, the weighted average cost per unit is used as a basis to determine the cost amounts removed from inventory as the aggregate number of units expected to be delivered under each order. Finally, the net realizable value is determined by using the various factors as following: excess or slow-moving inventories (12 months or more of inventory on hand), expiration dates (within 12 months of the current reporting period), current and future product demand, production planning, and market conditions. If any of these factors are found in the reporting period, management will review each item and determine if any additional allowances or write-offs need to be made. A change in any of these variable’s factors could result in an adjustment to inventory. An allowance for inventory was established in 2018 and is evaluated each quarter to determine if all items are still sellable due to the factors listed above. As of December 31, 2023 and December 31, 2022, the total of inventory allowance was $1,611,257 and $1,914,891. The following are the classes held in inventory as of December 31, 2023 and December 31, 2022: <table style="border-collapse:collapse;width:479.5pt"><tr style="height:7.2pt"><td style="width:227pt" valign="middle"> </td><td style="width:13.55pt" valign="middle"> </td><td colspan="2" style="width:105.95pt" valign="middle">DECEMBER 31, </td><td style="width:13.5pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td colspan="2" style="width:106pt" valign="middle">DECEMBER 31, </td></tr> <tr style="height:7.2pt"><td style="width:227pt" valign="middle"></td><td style="width:13.55pt" valign="middle"> </td><td colspan="2" style="width:105.95pt;border-bottom:0.5pt solid #000000" valign="middle">2023 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td colspan="2" style="width:106pt;border-bottom:0.5pt solid #000000" valign="middle">2022 </td></tr> <tr style="height:7.2pt"><td style="width:227pt" valign="middle">Inventory </td><td style="width:13.55pt" valign="middle"> </td><td style="width:15.95pt" valign="middle"> </td><td style="width:90pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:18pt" valign="middle"> </td><td style="width:88pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="width:227pt" valign="middle"> </td><td style="width:13.55pt" valign="middle"> </td><td style="width:15.95pt" valign="middle"> </td><td style="width:90pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:18pt" valign="middle"> </td><td style="width:88pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:227pt" valign="middle">Inventory Classes: </td><td style="background-color:#CCFFCC;width:13.55pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:15.95pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:90pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:18pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:88pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="width:227pt" valign="middle"> Raw Materials </td><td style="width:13.55pt" valign="middle"> </td><td style="width:15.95pt" valign="middle">$ </td><td style="width:90pt" valign="bottom">2,998,683 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:18pt" valign="bottom">$ </td><td style="width:88pt" valign="bottom"> 3,398,655 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:227pt" valign="middle"> Finished Goods </td><td style="background-color:#CCFFCC;width:13.55pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:15.95pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:90pt" valign="bottom">225,567 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:18pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:88pt" valign="bottom"> 310,600 </td></tr> <tr style="height:7.2pt"><td style="width:227pt" valign="middle"> Work in process </td><td style="width:13.55pt" valign="middle"> </td><td style="width:15.95pt;border-bottom:0.5pt solid #000000" valign="middle"> </td><td style="width:90pt;border-bottom:0.5pt solid #000000" valign="bottom">13,290 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:18pt;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="width:88pt;border-bottom:0.5pt solid #000000" valign="bottom"> 24,764 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:227pt" valign="middle">Total inventory </td><td style="background-color:#CCFFCC;width:13.55pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:15.95pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:90pt" valign="bottom">3,237,540 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:18pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:88pt" valign="bottom"> 3,734,019 </td></tr> <tr style="height:7.2pt"><td style="width:227pt" valign="middle">Inventory allowance </td><td style="width:13.55pt" valign="middle"> </td><td style="width:15.95pt" valign="middle"> </td><td style="width:90pt" valign="bottom"> (1,611,257) </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:18pt" valign="bottom"> </td><td style="width:88pt" valign="bottom"> (1,914,891) </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:227pt" valign="middle">Total inventory, net </td><td style="background-color:#CCFFCC;width:13.55pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:15.95pt;border-bottom:3px double #000000" valign="middle">$ </td><td style="background-color:#CCFFCC;width:90pt;border-bottom:3px double #000000" valign="bottom">1,626,283 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:18pt;border-bottom:3px double #000000" valign="bottom">$ </td><td style="background-color:#CCFFCC;width:88pt;border-bottom:3px double #000000" valign="bottom"> 1,819,128 </td></tr> </table> Property and Equipment The Company’s property and equipment are recorded at cost and depreciated using the straight-line method over the useful lives of the assets, generally from three to seven years. Upon sale or disposal of property and equipment, the related asset cost and accumulated depreciation or amortization are removed from the respective accounts and any gain or loss is reflected in current operations. Indefinite-Lived Intangible Assets Indefinite-lived intangible assets established in connection with business combinations consist of patents, trademarks, and trade names. The impairment test for identifiable indefinite-lived intangible assets consists of a comparison of the estimated fair value of the intangible asset with it carrying value. If the carrying value exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. With the acquisition of Ultimate Brain Nutrients on April 3, 2020 the Company added a purchasing value of $315,604 in patents to its balance sheet. As of December 31, 2023, the Company believes that based upon qualitative factors, no impairment of indefinite-lived intangible assets is necessary. Goodwill In accordance with Goodwill and Other Intangible Assets, goodwill is defined as the excess of the purchase price over the fair value assigned to individual assets acquired and liabilities assumed and is tested for impairment at the reporting unit level on an annual basis in the Company's fourth fiscal quarter or more frequently if indicators of impairment exist. The performance of the test involves a two-step process. The first step of the impairment test involves comparing the fair value of the Company's reporting units with each respective reporting unit's carrying amount, including goodwill. The fair value of reporting units is generally determined using the income approach. If the carrying amount of a reporting unit exceeds the reporting unit's fair value, the second step of the goodwill impairment test is performed to determine the amount of any impairment loss. The second step of the goodwill impairment test involves comparing the implied fair value of the reporting unit's goodwill with the carrying amount of that goodwill. No goodwill impairment indicators were present, for the goodwill listed on the books as of December 31, 2023, after working through our analysis of goodwill during the year ended December 31, 2023. The Company has determined that the method applied represents the fair value of the asset group principally because the valuation of the intangibles with the asset group is based on the anticipated cash flows related to the revenue stream from its customers. The asset group excludes goodwill, long term non-operational assets and liabilities and cash. As such, the principal value from the asset group relates to the cash inflows from its customers and the cash outflows required to service these customers. The fair value for the asset group consists of the following: <kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt">·</kbd>Fair value of net revenues: computed using the income approach. The key input to these computations is the anticipated cash inflows from customers. These valuations include 100% of the cash inflows related to the customer base, and taking cash outflows into consideration. <kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt">·</kbd>Fair value of working capital (including accounts receivable, inventory, accrued expenses, and accounts payables). Due to the short-term nature of the working capital, book value has been determined to be fair value. These accounts represent either avoided future outflows (inventory, prepaids) or future cash flows (accrued expense, AP and AR) related to customer sales. <kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt">·</kbd>Fair value of five years of revenue (2023 to 2027): we discounted our cash flows to the anticipated cash projected to be received. We also projected the anticipated cash outflows required to service these customers. If the asset group was to be valued as a whole, we would expect an income approach based on the revenues being generated from the customers and expenses required to service those customers, appropriately adjusted for the working capital position. The sum of these values reasonably approximates this approach. The Company’s revenue streams align directly with the intangibles, which were recorded as a result of the BergaMet acquisition in fiscal 2019. For purposes of the Step 2 recoverability test under ASC 360 subsection 2.3., the net revenues from BergaMet customers base were used. The revenue stream fairly reflects anticipated future cash flows; accordingly, the intangibles associated with these revenue streams have been tested with the expected cash flows. Debt with Warrants In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations using the straight-line method. The offset to the contra-liability is recorded as either equity or liability in the Company’s consolidated balance sheets depending on the accounting treatment of the warrants. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. Convertible Debt – Derivative Treatment When the Company issues debt with a conversion feature, we must first assess whether the conversion feature meets the requirements to be treated as a derivative, as follows: (a) one or more underlying’s, typically the price of our common stock; (b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; (c) no initial net investment, which typically excludes the amount borrowed; and (d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both (a) indexed to its own stock; and (b) classified in stockholders’ equity in its balance sheet. If the conversion feature within convertible debt meets the requirements to be treated as a derivative, we estimate the fair value of the convertible debt derivative using a Black-Scholes Option-Pricing model upon the date of issuance. If the fair value of the convertible debt derivative is higher than the face value of the convertible debt, the excess is immediately recognized as interest expense. Otherwise, the fair value of the convertible debt derivative is recorded as a liability with an offsetting amount recorded as a debt discount, which offsets the carrying amount of the debt. The derivative is revalued at the end of each reporting period and any change in fair value is recorded as a gain or loss in the statement of operations. The debt discount is amortized through interest expense over the life of the debt using the straight-line method. Revenue Recognition The Company applies Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) topic 606, Revenue from Contracts with Customers (ASC 606). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes all of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASC 606 requires us to identify distinct performance obligations. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. When distinct performance obligations exist, the Company allocates the contract transaction price to each distinct performance obligation. The standalone selling price is used to allocate the transaction price to the separate performance obligations. The Company recognizes revenue when, or as, the performance obligation is satisfied. Mostly, revenues are recognized at the time of shipment to the customer with the price being fixed and determinable and collectability assured, provided title and risk of loss is transferred to the customer. Most of our shipping and handling costs are built into the transaction price, but if the customer asks for express shipping, the costs charged to customers are classified as sales, and the shipping and handling costs incurred are included in cost of sales. The Company’s subsidiary, BergaMet N.A., LLC, recognizes revenue from our main source – e-commerce revenue. Here is a list of all the sales channels which include the Company’s subsidiary website channel or any other selling channel like Amazon, doctors’ offices, and walk-in sales. All of our customer sales for Healthy Extracts, Inc. and Ultimate Brain Nutrients, LLC are recognized as revenue under the subsidiary of BergaMet N.A., LLC. All three divisions of the Company sell plant-based nutraceuticals to our end using customers. The Company evaluates the criteria pursuant to ASC 606-10-55. Some of the different considerations that we use because of their significance are as follows: Collectability - payment has to be made prior to shipment unless the customer has agreed upon terms. Guaranties – we offer a money back to customers if they are unhappy with our products. Principal versus Agent Considerations - currently we are the principal and have not engaged an agent at this time and we have not recognized any revenues under the agent considerations. Revenue is recognized when, or as, control of a promised merchandise or service is shipped to the customer, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for transferring title of those products or services and are recorded net of and discounts or allowances. Shipping costs paid by the customer are included in revenue. Merchandise sales are fulfilled with inventory held in our warehouse in Henderson, NV. Therefore, the Company’s contracts have a single performance obligation (shipment of product). If the Company receives a request for refund on a customer obligation, the Company will refund the full cost of the obligation due to our money back guarantee. Historically, we have done a valuation of our sales allowance account (customer returns). In 2023 our return percentage was 0.008% of sales and 2022 was 0.009% of sales. Due to the low refund percentage management decided there was not a need for an estimated adjustment for allowances and refunds due to materiality. Revenue recognition is evaluated through the following five-step process: <kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">6.</kbd>identification of the contract with a customer; <kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">7.</kbd>identification off the performance obligations in the contract; <kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">8.</kbd>determination of the transaction price; <kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">9.</kbd>allocation of the transaction price to the performance obligations in the contract; and <kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">10.</kbd>recognition of revenue when or as a performance obligation is satisfied. These steps are met when an order is received, a price agreed and the product shipped or delivered to that customer. Concentration There is no concentration of revenue for the year ended December 31, 2022 and for the year ended December 31, 2023 because the revenue was earned from multiple customers. Income Taxes The Company uses the liability method of accounting for income taxes under which deferred tax assets and liabilities are recognized for the future tax consequences of temporary differences between the accounting bases and the tax bases of the Company’s assets and liabilities. The deferred tax assets and liabilities are computed using enacted tax rates in effect for the year in which the temporary differences are expected to reverse. The Company's deferred income taxes include certain future tax benefits. The Company records a valuation allowance against any portion of those deferred income tax assets when it believes, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred income tax asset will not be realized. The Company has adopted ASC guidance regarding accounting for uncertainty in income taxes. This guidance clarifies the accounting for income taxes by prescribing the minimum recognition threshold an income tax position is required to meet before being recognized in the consolidated financial statements and applies to all income tax positions. Each income tax position is assessed using a two-step process. A determination is first made as to whether it is more likely than not that the income tax position will be sustained, based upon technical merits, upon examination by the taxing authorities. If the income tax position is expected to meet the more likely than not criteria, the benefit recorded in the consolidated financial statements equals the largest amount that is greater than 50% likely to be realized upon its ultimate settlement. At December 31, 2023 and 2022, there were no uncertain tax positions that required accrual. Fair Value Measurements The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The estimated fair value of certain financial instruments, including cash and cash equivalents are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 — quoted prices in active markets for identical assets or liabilities Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions) The derivative liability in connection with the conversion feature of the convertible debt, classified as a Level 3 liability, is the only financial liability measure at fair value on a recurring basis. If the convertible debt is viewed as short-term, management chooses to expense the full debt discount in the period incurred is recorded as a gain or loss in the consolidated statement of operations. The Company measures and reports certain financial instruments as liabilities at fair value on a recurring basis. The fair value of these instruments as of December 31, 2023 and December 31, 2022 was as follows: <table style="border-collapse:collapse;width:100%"><tr style="height:7.2pt"><td style="width:35.86%" valign="middle"> </td><td style="width:3.4%" valign="middle"> </td><td style="width:10.1%" valign="middle">Fair Value </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td colspan="2" style="width:12.44%" valign="middle">Level 1 </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td colspan="2" style="width:12.44%" valign="middle">Level 2 </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td colspan="2" style="width:12.98%" valign="middle">Level 3 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:35.86%" valign="middle">Fair Value at December 31, 2021 </td><td style="background-color:#CCFFCC;width:3.4%;border-bottom:0.5pt solid #000000" valign="middle"> $ </td><td style="background-color:#CCFFCC;width:10.1%;border-bottom:0.5pt solid #000000" valign="middle">92,527 </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.5%" valign="middle"> </td><td style="background-color:#CCFFCC;width:9.96%" valign="middle">- </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.5%" valign="middle"> </td><td style="background-color:#CCFFCC;width:9.96%" valign="middle">- </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:2.9%;border-bottom:0.5pt solid #000000" valign="middle">$ </td><td style="background-color:#CCFFCC;width:10.08%;border-bottom:0.5pt solid #000000" valign="middle">92,527 </td></tr> <tr style="height:7.2pt"><td style="width:35.86%" valign="middle">Derivative liability </td><td style="width:3.4%" valign="middle"> </td><td style="width:10.1%" valign="middle">102,011 </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.5%" valign="middle"> </td><td style="width:9.96%" valign="middle">- </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.5%" valign="middle"> </td><td style="width:9.96%" valign="middle">- </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="bottom"> </td><td style="width:2.9%" valign="middle"> </td><td style="width:10.08%" valign="middle">102,011 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:35.86%" valign="middle">Fair Value at December 31, 2022 </td><td style="background-color:#CCFFCC;width:3.4%;border-bottom:0.5pt solid #000000" valign="middle"> $ </td><td style="background-color:#CCFFCC;width:10.1%;border-bottom:0.5pt solid #000000" valign="middle">102,011 </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.5%" valign="middle"> </td><td style="background-color:#CCFFCC;width:9.96%" valign="middle">- </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.5%" valign="middle"> </td><td style="background-color:#CCFFCC;width:9.96%" valign="middle">- </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.9%;border-bottom:0.5pt solid #000000" valign="middle">$ </td><td style="background-color:#CCFFCC;width:10.08%;border-bottom:0.5pt solid #000000" valign="middle">102,011 </td></tr> <tr style="height:7.2pt"><td style="width:35.86%" valign="middle">Derivative liability </td><td style="width:3.4%" valign="middle"> </td><td style="width:10.1%" valign="middle">154,150 </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.5%" valign="middle"> </td><td style="width:9.96%" valign="middle">- </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.5%" valign="middle"> </td><td style="width:9.96%" valign="middle">- </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.9%;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="width:10.08%;border-bottom:0.5pt solid #000000" valign="middle">154,150 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:35.86%" valign="middle">Fair Value at December 31, 2023 </td><td style="background-color:#CCFFCC;width:3.4%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"> $ </td><td style="background-color:#CCFFCC;width:10.1%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">154,150 </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.5%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:9.96%" valign="middle">- </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.5%" valign="middle"> </td><td style="background-color:#CCFFCC;width:9.96%" valign="middle">- </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.9%;border-bottom:3px double #000000" valign="middle">$ </td><td style="background-color:#CCFFCC;width:10.08%;border-bottom:3px double #000000" valign="middle">154,150 </td></tr> </table> December 31, 2023 <table style="border-collapse:collapse;width:100%"><tr><td style="width:39.94%" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:11.94%;border-bottom:0.5pt solid #000000" valign="bottom">Level 1 </td><td style="width:0.98%;padding-bottom:1.5pt" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:12.14%;border-bottom:0.5pt solid #000000" valign="bottom">Level 2 </td><td style="width:0.98%;padding-bottom:1.5pt" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:11.94%;border-bottom:0.5pt solid #000000" valign="bottom">Level 3 </td><td style="width:0.98%;padding-bottom:1.5pt" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:12.28%;border-bottom:0.5pt solid #000000" valign="bottom">Total </td><td style="width:0.9%;padding-bottom:1.5pt" valign="bottom"> </td></tr> <tr><td style="background-color:#CCFFCC;width:39.94%" valign="bottom">Derivative liability </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:0.98%;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom">- </td><td style="background-color:#CCFFCC;width:0.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.18%;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom">- </td><td style="background-color:#CCFFCC;width:0.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:0.98%;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom"> 154,150 </td><td style="background-color:#CCFFCC;width:0.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.32%;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom"> 154,150 </td><td style="background-color:#CCFFCC;width:0.9%" valign="bottom"> </td></tr> </table> December 31, 2022 <table style="border-collapse:collapse;width:100%"><tr><td style="width:39.94%" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:11.94%;border-bottom:0.5pt solid #000000" valign="bottom">Level 1 </td><td style="width:0.98%;padding-bottom:1.5pt" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:12.14%;border-bottom:0.5pt solid #000000" valign="bottom">Level 2 </td><td style="width:0.98%;padding-bottom:1.5pt" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:11.94%;border-bottom:0.5pt solid #000000" valign="bottom">Level 3 </td><td style="width:0.98%;padding-bottom:1.5pt" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:12.28%;border-bottom:0.5pt solid #000000" valign="bottom">Total </td><td style="width:0.9%;padding-bottom:1.5pt" valign="bottom"> </td></tr> <tr><td style="background-color:#CCFFCC;width:39.94%" valign="bottom">Derivative liability </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:0.98%;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom">- </td><td style="background-color:#CCFFCC;width:0.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.18%;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom">- </td><td style="background-color:#CCFFCC;width:0.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:0.98%;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom"> 102,011 </td><td style="background-color:#CCFFCC;width:0.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.32%;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom"> 102,011 </td><td style="background-color:#CCFFCC;width:0.9%" valign="bottom"> </td></tr> </table> The details of derivative liability transactions for the year ended December 31, 2023 and December 31, 2022 are as follows: The change in Level 3 financial instrument fair value is as follows: <table style="border-collapse:collapse"><tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Balance, December 31, 2021 </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt;border-bottom:3px double #000000" valign="top">$ 92,527 </td></tr> <tr style="height:7.2pt"><td style="width:302.4pt" valign="top">Issued during the year ended December 31, 2022 </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt;border-top:3px double #000000" valign="top">264,952 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Derivative liabilities debt premium </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt" valign="top"> (43,269) </td></tr> <tr style="height:7.2pt"><td style="width:302.4pt" valign="top">Change in fair value recognized in operations </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt" valign="top">(212,199) </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Converted during the year ended December 31, 2022 </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt;border-bottom:0.5pt solid #000000" valign="top">(0) </td></tr> <tr style="height:7.2pt"><td style="width:302.4pt" valign="top">Balance, December 31, 2022 </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"> $ 102,011 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Issued during the year ended December 31, 2023 </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt" valign="top">145,067 </td></tr> <tr style="height:7.2pt"><td style="width:302.4pt" valign="top">Derivative liabilities debt discount </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt" valign="top">29,167 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Change in fair value recognized in operations </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt" valign="top">(83,923) </td></tr> <tr style="height:7.2pt"><td style="width:302.4pt" valign="top">Converted during the year ended December 31, 2023 </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt;border-bottom:0.5pt solid #000000" valign="top">(38,172) </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Balance, December 31, 2023 </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"> $ 154,150 </td></tr> </table> The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between levels during the year ending December 31, 2023 and December 31, 2022. The Company determines the fair value of the derivative liability based on Level 3 inputs using the Black-Scholes option pricing model. The significant unobservable input assumptions that can significantly change the fair value includes common share price; amount of principal and accrued interest convertible into shares as of the conversion date, and the number of shares issuable upon conversion; expected exercise price; expected term; volatility; and risk-free interest rate. Convertible Instruments Convertible debt – derivative treatment The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. If the conversion feature within convertible debt meets the requirements to be treated as a derivative, we estimate the fair value of the convertible debt derivative using the Black-Sholes option pricing model upon the date of issuance. If the fair value of the convertible debt derivative is higher than the face value of the convertible debt, the excess is immediately recognized as interest expense. Otherwise, the fair value of the convertible debt derivative is recorded as a liability with an offsetting amount recorded as a debt discount, which offsets the carrying amount of the debt. If the convertible debt is viewed as short-term, management chooses to expense the full debt discount in the period incurred is recorded as a gain or loss in the consolidated statement of operations. The convertible debt derivative is revalued at the end of each reporting period and any change in fair value is recorded as a gain or loss in the consolidated statement of operations. Convertible debt – beneficial conversion feature The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records when necessary, any discounts, if applicable, to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts, if applicable, under these arrangements are amortized over the term of the related debt to their stated date of redemption. Debt modifications and extinguishments The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded under change in fair value on derivative, in the consolidated operation statements, as a gain or loss on extinguishment of the two separate liabilities. During the year ended December 31, 2023, the Company issued $388,888 of convertible debt. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 amends the guidance for revenue recognition to replace numerous, industry specific requirements and converges areas under this topic with those of the International Financial Reporting Standards. The ASU implements of five–step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract cost, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The amendments in this ASU are effective for reporting period beginning after December 15, 2016, and early adoption is prohibited. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company’s revenues are recognized when control of the promised goods or services is transferred to our clients (upon shipment of goods) in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: (1) Identify the contract with a client; (2) Identify the performance obligations in the contract; (3) Determine the transaction price; (4) Allocate the transaction price to performance obligations in the contract; and (5) Recognize revenues when or as the Company satisfies a performance obligation. We adopted ASC 2014-09 on January 1, 2019. Although the new revenue standard is expected to have an immaterial impact, if any, on our ongoing net income, we did implement changes to our processes related to revenue recognition and the control activities with them. The Company leases its office and warehouse space under non-cancellable capital leases. The Company accounts for this lease in accordance with ASC 842. Right-of-use (“ROU”) assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Since our lease arrangements do not provide an implicit rate, we use our estimated incremental borrowing rate for the expected remaining lease term at commencement date in determining the present value of future lease payments. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. Capital lease expense is recognized on a straight-line basis over the lease term. Variable lease payments are not included in the lease payments to measure the lease liability and are expensed as incurred. Finance lease expense is comprised of both interest expense, which is recognized using the effective interest method, and amortization of the right-of-use assets. These expenses are presented consistently with the presentation of other interest expense and amortization or depreciation of similar assets. Common area maintenance fees (or CAMs) and other charges related to leases are expensed as incurred. See Note 5 — Right-of-Use Assets and Lease Liabilities for further discussion of the Company’s lease activities. Common Stock Purchase Warrants The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to our own stock as defined in ASC 815-40 (“Contracts in Entity's Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside our control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification is required. Basis of Presentation The accompanying audited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying audited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of December 31, 2023 and the results of operations and cash flows for the periods presented. The results of operations for the year ended December 31, 2023 are not necessarily indicative of the operating results for the full fiscal year or any future period. These audited consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s form 10-K for the year ended December 31, 2022 filed with the SEC on March 31, 2023. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments. In regards to inventory write-offs and allowances, our Company determines the net realizable value by using the various factors as following: excess or slow-moving inventories (12 months or more of inventory on hand), expiration dates (within 12 months of the current reporting period), current and future product demand, production planning, and market conditions. If any of these factors are found in the reporting period, management will review each item and determine if any additional allowances or write-offs need to be made. A change in any of these variable’s factors could result in an adjustment to inventory. Management has provided for any risks in the current inventory allowance booked. As for revenue adjustments for discounts, allowances and refunds, we treat each of these items differently. When it comes to revenue discounts, we will create the invoice for the product sold which will include any discounts given. These discounts usually happen for a short period of time for sales that we will offer around holidays. Due to the revenue being recognized once the order has shipped, less any applicable discount, we book this transaction at the net order transaction amount. In regards to allowances and refunds for revenue adjustments, due to our refund percentage is less than 1% we decided the need for an estimated adjustment for allowances and refunds was not material. If we do receive any returned orders, we will directly book those orders as refunds the day we receive the call from the customer requesting the refund. We will book the credit memo at the full value of the customer original order. Cash Cash includes cash in banks, money market funds, and certificates of term deposits with maturities of less than three months from inception, which are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss in value. Accounts Receivables Accounts receivables are recorded at the invoice amount and do not bear interest. Inventory Inventories consist of health supplements held for sale in the ordinary course of business. The Company uses the weighted average cost method to value its inventories at the lower of cost and net realizable value. In pursuant to ASC 330-10-50-6, the components of inventory cost include raw materials, labor, and overhead. Additionally, the weighted average cost per unit is used as a basis to determine the cost amounts removed from inventory as the aggregate number of units expected to be delivered under each order. Finally, the net realizable value is determined by using the various factors as following: excess or slow-moving inventories (12 months or more of inventory on hand), expiration dates (within 12 months of the current reporting period), current and future product demand, production planning, and market conditions. If any of these factors are found in the reporting period, management will review each item and determine if any additional allowances or write-offs need to be made. A change in any of these variable’s factors could result in an adjustment to inventory. An allowance for inventory was established in 2018 and is evaluated each quarter to determine if all items are still sellable due to the factors listed above. As of December 31, 2023 and December 31, 2022, the total of inventory allowance was $1,611,257 and $1,914,891. The following are the classes held in inventory as of December 31, 2023 and December 31, 2022: <table style="border-collapse:collapse;width:479.5pt"><tr style="height:7.2pt"><td style="width:227pt" valign="middle"> </td><td style="width:13.55pt" valign="middle"> </td><td colspan="2" style="width:105.95pt" valign="middle">DECEMBER 31, </td><td style="width:13.5pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td colspan="2" style="width:106pt" valign="middle">DECEMBER 31, </td></tr> <tr style="height:7.2pt"><td style="width:227pt" valign="middle"></td><td style="width:13.55pt" valign="middle"> </td><td colspan="2" style="width:105.95pt;border-bottom:0.5pt solid #000000" valign="middle">2023 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td colspan="2" style="width:106pt;border-bottom:0.5pt solid #000000" valign="middle">2022 </td></tr> <tr style="height:7.2pt"><td style="width:227pt" valign="middle">Inventory </td><td style="width:13.55pt" valign="middle"> </td><td style="width:15.95pt" valign="middle"> </td><td style="width:90pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:18pt" valign="middle"> </td><td style="width:88pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="width:227pt" valign="middle"> </td><td style="width:13.55pt" valign="middle"> </td><td style="width:15.95pt" valign="middle"> </td><td style="width:90pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:18pt" valign="middle"> </td><td style="width:88pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:227pt" valign="middle">Inventory Classes: </td><td style="background-color:#CCFFCC;width:13.55pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:15.95pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:90pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:18pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:88pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="width:227pt" valign="middle"> Raw Materials </td><td style="width:13.55pt" valign="middle"> </td><td style="width:15.95pt" valign="middle">$ </td><td style="width:90pt" valign="bottom">2,998,683 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:18pt" valign="bottom">$ </td><td style="width:88pt" valign="bottom"> 3,398,655 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:227pt" valign="middle"> Finished Goods </td><td style="background-color:#CCFFCC;width:13.55pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:15.95pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:90pt" valign="bottom">225,567 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:18pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:88pt" valign="bottom"> 310,600 </td></tr> <tr style="height:7.2pt"><td style="width:227pt" valign="middle"> Work in process </td><td style="width:13.55pt" valign="middle"> </td><td style="width:15.95pt;border-bottom:0.5pt solid #000000" valign="middle"> </td><td style="width:90pt;border-bottom:0.5pt solid #000000" valign="bottom">13,290 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:18pt;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="width:88pt;border-bottom:0.5pt solid #000000" valign="bottom"> 24,764 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:227pt" valign="middle">Total inventory </td><td style="background-color:#CCFFCC;width:13.55pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:15.95pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:90pt" valign="bottom">3,237,540 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:18pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:88pt" valign="bottom"> 3,734,019 </td></tr> <tr style="height:7.2pt"><td style="width:227pt" valign="middle">Inventory allowance </td><td style="width:13.55pt" valign="middle"> </td><td style="width:15.95pt" valign="middle"> </td><td style="width:90pt" valign="bottom"> (1,611,257) </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:18pt" valign="bottom"> </td><td style="width:88pt" valign="bottom"> (1,914,891) </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:227pt" valign="middle">Total inventory, net </td><td style="background-color:#CCFFCC;width:13.55pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:15.95pt;border-bottom:3px double #000000" valign="middle">$ </td><td style="background-color:#CCFFCC;width:90pt;border-bottom:3px double #000000" valign="bottom">1,626,283 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:18pt;border-bottom:3px double #000000" valign="bottom">$ </td><td style="background-color:#CCFFCC;width:88pt;border-bottom:3px double #000000" valign="bottom"> 1,819,128 </td></tr> </table> 1611257 1914891 <table style="border-collapse:collapse;width:479.5pt"><tr style="height:7.2pt"><td style="width:227pt" valign="middle"> </td><td style="width:13.55pt" valign="middle"> </td><td colspan="2" style="width:105.95pt" valign="middle">DECEMBER 31, </td><td style="width:13.5pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td colspan="2" style="width:106pt" valign="middle">DECEMBER 31, </td></tr> <tr style="height:7.2pt"><td style="width:227pt" valign="middle"></td><td style="width:13.55pt" valign="middle"> </td><td colspan="2" style="width:105.95pt;border-bottom:0.5pt solid #000000" valign="middle">2023 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td colspan="2" style="width:106pt;border-bottom:0.5pt solid #000000" valign="middle">2022 </td></tr> <tr style="height:7.2pt"><td style="width:227pt" valign="middle">Inventory </td><td style="width:13.55pt" valign="middle"> </td><td style="width:15.95pt" valign="middle"> </td><td style="width:90pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:18pt" valign="middle"> </td><td style="width:88pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="width:227pt" valign="middle"> </td><td style="width:13.55pt" valign="middle"> </td><td style="width:15.95pt" valign="middle"> </td><td style="width:90pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:18pt" valign="middle"> </td><td style="width:88pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:227pt" valign="middle">Inventory Classes: </td><td style="background-color:#CCFFCC;width:13.55pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:15.95pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:90pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:18pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:88pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="width:227pt" valign="middle"> Raw Materials </td><td style="width:13.55pt" valign="middle"> </td><td style="width:15.95pt" valign="middle">$ </td><td style="width:90pt" valign="bottom">2,998,683 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:18pt" valign="bottom">$ </td><td style="width:88pt" valign="bottom"> 3,398,655 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:227pt" valign="middle"> Finished Goods </td><td style="background-color:#CCFFCC;width:13.55pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:15.95pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:90pt" valign="bottom">225,567 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:18pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:88pt" valign="bottom"> 310,600 </td></tr> <tr style="height:7.2pt"><td style="width:227pt" valign="middle"> Work in process </td><td style="width:13.55pt" valign="middle"> </td><td style="width:15.95pt;border-bottom:0.5pt solid #000000" valign="middle"> </td><td style="width:90pt;border-bottom:0.5pt solid #000000" valign="bottom">13,290 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:18pt;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="width:88pt;border-bottom:0.5pt solid #000000" valign="bottom"> 24,764 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:227pt" valign="middle">Total inventory </td><td style="background-color:#CCFFCC;width:13.55pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:15.95pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:90pt" valign="bottom">3,237,540 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:18pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:88pt" valign="bottom"> 3,734,019 </td></tr> <tr style="height:7.2pt"><td style="width:227pt" valign="middle">Inventory allowance </td><td style="width:13.55pt" valign="middle"> </td><td style="width:15.95pt" valign="middle"> </td><td style="width:90pt" valign="bottom"> (1,611,257) </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:18pt" valign="bottom"> </td><td style="width:88pt" valign="bottom"> (1,914,891) </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:227pt" valign="middle">Total inventory, net </td><td style="background-color:#CCFFCC;width:13.55pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:15.95pt;border-bottom:3px double #000000" valign="middle">$ </td><td style="background-color:#CCFFCC;width:90pt;border-bottom:3px double #000000" valign="bottom">1,626,283 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:18pt;border-bottom:3px double #000000" valign="bottom">$ </td><td style="background-color:#CCFFCC;width:88pt;border-bottom:3px double #000000" valign="bottom"> 1,819,128 </td></tr> </table> 2998683 3398655 225567 310600 13290 24764 3237540 3734019 1611257 1914891 1626283 1819128 Property and Equipment The Company’s property and equipment are recorded at cost and depreciated using the straight-line method over the useful lives of the assets, generally from three to seven years. Upon sale or disposal of property and equipment, the related asset cost and accumulated depreciation or amortization are removed from the respective accounts and any gain or loss is reflected in current operations. Indefinite-Lived Intangible Assets Indefinite-lived intangible assets established in connection with business combinations consist of patents, trademarks, and trade names. The impairment test for identifiable indefinite-lived intangible assets consists of a comparison of the estimated fair value of the intangible asset with it carrying value. If the carrying value exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. With the acquisition of Ultimate Brain Nutrients on April 3, 2020 the Company added a purchasing value of $315,604 in patents to its balance sheet. As of December 31, 2023, the Company believes that based upon qualitative factors, no impairment of indefinite-lived intangible assets is necessary. 315604 315604 Goodwill In accordance with Goodwill and Other Intangible Assets, goodwill is defined as the excess of the purchase price over the fair value assigned to individual assets acquired and liabilities assumed and is tested for impairment at the reporting unit level on an annual basis in the Company's fourth fiscal quarter or more frequently if indicators of impairment exist. The performance of the test involves a two-step process. The first step of the impairment test involves comparing the fair value of the Company's reporting units with each respective reporting unit's carrying amount, including goodwill. The fair value of reporting units is generally determined using the income approach. If the carrying amount of a reporting unit exceeds the reporting unit's fair value, the second step of the goodwill impairment test is performed to determine the amount of any impairment loss. The second step of the goodwill impairment test involves comparing the implied fair value of the reporting unit's goodwill with the carrying amount of that goodwill. No goodwill impairment indicators were present, for the goodwill listed on the books as of December 31, 2023, after working through our analysis of goodwill during the year ended December 31, 2023. The Company has determined that the method applied represents the fair value of the asset group principally because the valuation of the intangibles with the asset group is based on the anticipated cash flows related to the revenue stream from its customers. The asset group excludes goodwill, long term non-operational assets and liabilities and cash. As such, the principal value from the asset group relates to the cash inflows from its customers and the cash outflows required to service these customers. The fair value for the asset group consists of the following: <kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt">·</kbd>Fair value of net revenues: computed using the income approach. The key input to these computations is the anticipated cash inflows from customers. These valuations include 100% of the cash inflows related to the customer base, and taking cash outflows into consideration. <kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt">·</kbd>Fair value of working capital (including accounts receivable, inventory, accrued expenses, and accounts payables). Due to the short-term nature of the working capital, book value has been determined to be fair value. These accounts represent either avoided future outflows (inventory, prepaids) or future cash flows (accrued expense, AP and AR) related to customer sales. <kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt">·</kbd>Fair value of five years of revenue (2023 to 2027): we discounted our cash flows to the anticipated cash projected to be received. We also projected the anticipated cash outflows required to service these customers. If the asset group was to be valued as a whole, we would expect an income approach based on the revenues being generated from the customers and expenses required to service those customers, appropriately adjusted for the working capital position. The sum of these values reasonably approximates this approach. The Company’s revenue streams align directly with the intangibles, which were recorded as a result of the BergaMet acquisition in fiscal 2019. For purposes of the Step 2 recoverability test under ASC 360 subsection 2.3., the net revenues from BergaMet customers base were used. The revenue stream fairly reflects anticipated future cash flows; accordingly, the intangibles associated with these revenue streams have been tested with the expected cash flows. Debt with Warrants In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations using the straight-line method. The offset to the contra-liability is recorded as either equity or liability in the Company’s consolidated balance sheets depending on the accounting treatment of the warrants. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. Convertible Debt – Derivative Treatment When the Company issues debt with a conversion feature, we must first assess whether the conversion feature meets the requirements to be treated as a derivative, as follows: (a) one or more underlying’s, typically the price of our common stock; (b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; (c) no initial net investment, which typically excludes the amount borrowed; and (d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both (a) indexed to its own stock; and (b) classified in stockholders’ equity in its balance sheet. If the conversion feature within convertible debt meets the requirements to be treated as a derivative, we estimate the fair value of the convertible debt derivative using a Black-Scholes Option-Pricing model upon the date of issuance. If the fair value of the convertible debt derivative is higher than the face value of the convertible debt, the excess is immediately recognized as interest expense. Otherwise, the fair value of the convertible debt derivative is recorded as a liability with an offsetting amount recorded as a debt discount, which offsets the carrying amount of the debt. The derivative is revalued at the end of each reporting period and any change in fair value is recorded as a gain or loss in the statement of operations. The debt discount is amortized through interest expense over the life of the debt using the straight-line method. Revenue Recognition The Company applies Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) topic 606, Revenue from Contracts with Customers (ASC 606). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes all of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASC 606 requires us to identify distinct performance obligations. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. When distinct performance obligations exist, the Company allocates the contract transaction price to each distinct performance obligation. The standalone selling price is used to allocate the transaction price to the separate performance obligations. The Company recognizes revenue when, or as, the performance obligation is satisfied. Mostly, revenues are recognized at the time of shipment to the customer with the price being fixed and determinable and collectability assured, provided title and risk of loss is transferred to the customer. Most of our shipping and handling costs are built into the transaction price, but if the customer asks for express shipping, the costs charged to customers are classified as sales, and the shipping and handling costs incurred are included in cost of sales. The Company’s subsidiary, BergaMet N.A., LLC, recognizes revenue from our main source – e-commerce revenue. Here is a list of all the sales channels which include the Company’s subsidiary website channel or any other selling channel like Amazon, doctors’ offices, and walk-in sales. All of our customer sales for Healthy Extracts, Inc. and Ultimate Brain Nutrients, LLC are recognized as revenue under the subsidiary of BergaMet N.A., LLC. All three divisions of the Company sell plant-based nutraceuticals to our end using customers. The Company evaluates the criteria pursuant to ASC 606-10-55. Some of the different considerations that we use because of their significance are as follows: Collectability - payment has to be made prior to shipment unless the customer has agreed upon terms. Guaranties – we offer a money back to customers if they are unhappy with our products. Principal versus Agent Considerations - currently we are the principal and have not engaged an agent at this time and we have not recognized any revenues under the agent considerations. Revenue is recognized when, or as, control of a promised merchandise or service is shipped to the customer, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for transferring title of those products or services and are recorded net of and discounts or allowances. Shipping costs paid by the customer are included in revenue. Merchandise sales are fulfilled with inventory held in our warehouse in Henderson, NV. Therefore, the Company’s contracts have a single performance obligation (shipment of product). If the Company receives a request for refund on a customer obligation, the Company will refund the full cost of the obligation due to our money back guarantee. Historically, we have done a valuation of our sales allowance account (customer returns). In 2023 our return percentage was 0.008% of sales and 2022 was 0.009% of sales. Due to the low refund percentage management decided there was not a need for an estimated adjustment for allowances and refunds due to materiality. Revenue recognition is evaluated through the following five-step process: <kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">6.</kbd>identification of the contract with a customer; <kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">7.</kbd>identification off the performance obligations in the contract; <kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">8.</kbd>determination of the transaction price; <kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">9.</kbd>allocation of the transaction price to the performance obligations in the contract; and <kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">10.</kbd>recognition of revenue when or as a performance obligation is satisfied. These steps are met when an order is received, a price agreed and the product shipped or delivered to that customer. Concentration There is no concentration of revenue for the year ended December 31, 2022 and for the year ended December 31, 2023 because the revenue was earned from multiple customers. Income Taxes The Company uses the liability method of accounting for income taxes under which deferred tax assets and liabilities are recognized for the future tax consequences of temporary differences between the accounting bases and the tax bases of the Company’s assets and liabilities. The deferred tax assets and liabilities are computed using enacted tax rates in effect for the year in which the temporary differences are expected to reverse. The Company's deferred income taxes include certain future tax benefits. The Company records a valuation allowance against any portion of those deferred income tax assets when it believes, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred income tax asset will not be realized. The Company has adopted ASC guidance regarding accounting for uncertainty in income taxes. This guidance clarifies the accounting for income taxes by prescribing the minimum recognition threshold an income tax position is required to meet before being recognized in the consolidated financial statements and applies to all income tax positions. Each income tax position is assessed using a two-step process. A determination is first made as to whether it is more likely than not that the income tax position will be sustained, based upon technical merits, upon examination by the taxing authorities. If the income tax position is expected to meet the more likely than not criteria, the benefit recorded in the consolidated financial statements equals the largest amount that is greater than 50% likely to be realized upon its ultimate settlement. At December 31, 2023 and 2022, there were no uncertain tax positions that required accrual. Fair Value Measurements The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The estimated fair value of certain financial instruments, including cash and cash equivalents are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 — quoted prices in active markets for identical assets or liabilities Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions) The derivative liability in connection with the conversion feature of the convertible debt, classified as a Level 3 liability, is the only financial liability measure at fair value on a recurring basis. If the convertible debt is viewed as short-term, management chooses to expense the full debt discount in the period incurred is recorded as a gain or loss in the consolidated statement of operations. The Company measures and reports certain financial instruments as liabilities at fair value on a recurring basis. The fair value of these instruments as of December 31, 2023 and December 31, 2022 was as follows: <table style="border-collapse:collapse;width:100%"><tr style="height:7.2pt"><td style="width:35.86%" valign="middle"> </td><td style="width:3.4%" valign="middle"> </td><td style="width:10.1%" valign="middle">Fair Value </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td colspan="2" style="width:12.44%" valign="middle">Level 1 </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td colspan="2" style="width:12.44%" valign="middle">Level 2 </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td colspan="2" style="width:12.98%" valign="middle">Level 3 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:35.86%" valign="middle">Fair Value at December 31, 2021 </td><td style="background-color:#CCFFCC;width:3.4%;border-bottom:0.5pt solid #000000" valign="middle"> $ </td><td style="background-color:#CCFFCC;width:10.1%;border-bottom:0.5pt solid #000000" valign="middle">92,527 </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.5%" valign="middle"> </td><td style="background-color:#CCFFCC;width:9.96%" valign="middle">- </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.5%" valign="middle"> </td><td style="background-color:#CCFFCC;width:9.96%" valign="middle">- </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:2.9%;border-bottom:0.5pt solid #000000" valign="middle">$ </td><td style="background-color:#CCFFCC;width:10.08%;border-bottom:0.5pt solid #000000" valign="middle">92,527 </td></tr> <tr style="height:7.2pt"><td style="width:35.86%" valign="middle">Derivative liability </td><td style="width:3.4%" valign="middle"> </td><td style="width:10.1%" valign="middle">102,011 </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.5%" valign="middle"> </td><td style="width:9.96%" valign="middle">- </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.5%" valign="middle"> </td><td style="width:9.96%" valign="middle">- </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="bottom"> </td><td style="width:2.9%" valign="middle"> </td><td style="width:10.08%" valign="middle">102,011 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:35.86%" valign="middle">Fair Value at December 31, 2022 </td><td style="background-color:#CCFFCC;width:3.4%;border-bottom:0.5pt solid #000000" valign="middle"> $ </td><td style="background-color:#CCFFCC;width:10.1%;border-bottom:0.5pt solid #000000" valign="middle">102,011 </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.5%" valign="middle"> </td><td style="background-color:#CCFFCC;width:9.96%" valign="middle">- </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.5%" valign="middle"> </td><td style="background-color:#CCFFCC;width:9.96%" valign="middle">- </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.9%;border-bottom:0.5pt solid #000000" valign="middle">$ </td><td style="background-color:#CCFFCC;width:10.08%;border-bottom:0.5pt solid #000000" valign="middle">102,011 </td></tr> <tr style="height:7.2pt"><td style="width:35.86%" valign="middle">Derivative liability </td><td style="width:3.4%" valign="middle"> </td><td style="width:10.1%" valign="middle">154,150 </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.5%" valign="middle"> </td><td style="width:9.96%" valign="middle">- </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.5%" valign="middle"> </td><td style="width:9.96%" valign="middle">- </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.9%;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="width:10.08%;border-bottom:0.5pt solid #000000" valign="middle">154,150 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:35.86%" valign="middle">Fair Value at December 31, 2023 </td><td style="background-color:#CCFFCC;width:3.4%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"> $ </td><td style="background-color:#CCFFCC;width:10.1%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">154,150 </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.5%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:9.96%" valign="middle">- </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.5%" valign="middle"> </td><td style="background-color:#CCFFCC;width:9.96%" valign="middle">- </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.9%;border-bottom:3px double #000000" valign="middle">$ </td><td style="background-color:#CCFFCC;width:10.08%;border-bottom:3px double #000000" valign="middle">154,150 </td></tr> </table> December 31, 2023 <table style="border-collapse:collapse;width:100%"><tr><td style="width:39.94%" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:11.94%;border-bottom:0.5pt solid #000000" valign="bottom">Level 1 </td><td style="width:0.98%;padding-bottom:1.5pt" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:12.14%;border-bottom:0.5pt solid #000000" valign="bottom">Level 2 </td><td style="width:0.98%;padding-bottom:1.5pt" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:11.94%;border-bottom:0.5pt solid #000000" valign="bottom">Level 3 </td><td style="width:0.98%;padding-bottom:1.5pt" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:12.28%;border-bottom:0.5pt solid #000000" valign="bottom">Total </td><td style="width:0.9%;padding-bottom:1.5pt" valign="bottom"> </td></tr> <tr><td style="background-color:#CCFFCC;width:39.94%" valign="bottom">Derivative liability </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:0.98%;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom">- </td><td style="background-color:#CCFFCC;width:0.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.18%;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom">- </td><td style="background-color:#CCFFCC;width:0.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:0.98%;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom"> 154,150 </td><td style="background-color:#CCFFCC;width:0.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.32%;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom"> 154,150 </td><td style="background-color:#CCFFCC;width:0.9%" valign="bottom"> </td></tr> </table> December 31, 2022 <table style="border-collapse:collapse;width:100%"><tr><td style="width:39.94%" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:11.94%;border-bottom:0.5pt solid #000000" valign="bottom">Level 1 </td><td style="width:0.98%;padding-bottom:1.5pt" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:12.14%;border-bottom:0.5pt solid #000000" valign="bottom">Level 2 </td><td style="width:0.98%;padding-bottom:1.5pt" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:11.94%;border-bottom:0.5pt solid #000000" valign="bottom">Level 3 </td><td style="width:0.98%;padding-bottom:1.5pt" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:12.28%;border-bottom:0.5pt solid #000000" valign="bottom">Total </td><td style="width:0.9%;padding-bottom:1.5pt" valign="bottom"> </td></tr> <tr><td style="background-color:#CCFFCC;width:39.94%" valign="bottom">Derivative liability </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:0.98%;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom">- </td><td style="background-color:#CCFFCC;width:0.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.18%;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom">- </td><td style="background-color:#CCFFCC;width:0.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:0.98%;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom"> 102,011 </td><td style="background-color:#CCFFCC;width:0.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.32%;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom"> 102,011 </td><td style="background-color:#CCFFCC;width:0.9%" valign="bottom"> </td></tr> </table> The details of derivative liability transactions for the year ended December 31, 2023 and December 31, 2022 are as follows: The change in Level 3 financial instrument fair value is as follows: <table style="border-collapse:collapse"><tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Balance, December 31, 2021 </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt;border-bottom:3px double #000000" valign="top">$ 92,527 </td></tr> <tr style="height:7.2pt"><td style="width:302.4pt" valign="top">Issued during the year ended December 31, 2022 </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt;border-top:3px double #000000" valign="top">264,952 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Derivative liabilities debt premium </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt" valign="top"> (43,269) </td></tr> <tr style="height:7.2pt"><td style="width:302.4pt" valign="top">Change in fair value recognized in operations </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt" valign="top">(212,199) </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Converted during the year ended December 31, 2022 </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt;border-bottom:0.5pt solid #000000" valign="top">(0) </td></tr> <tr style="height:7.2pt"><td style="width:302.4pt" valign="top">Balance, December 31, 2022 </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"> $ 102,011 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Issued during the year ended December 31, 2023 </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt" valign="top">145,067 </td></tr> <tr style="height:7.2pt"><td style="width:302.4pt" valign="top">Derivative liabilities debt discount </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt" valign="top">29,167 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Change in fair value recognized in operations </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt" valign="top">(83,923) </td></tr> <tr style="height:7.2pt"><td style="width:302.4pt" valign="top">Converted during the year ended December 31, 2023 </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt;border-bottom:0.5pt solid #000000" valign="top">(38,172) </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Balance, December 31, 2023 </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"> $ 154,150 </td></tr> </table> The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between levels during the year ending December 31, 2023 and December 31, 2022. The Company determines the fair value of the derivative liability based on Level 3 inputs using the Black-Scholes option pricing model. The significant unobservable input assumptions that can significantly change the fair value includes common share price; amount of principal and accrued interest convertible into shares as of the conversion date, and the number of shares issuable upon conversion; expected exercise price; expected term; volatility; and risk-free interest rate. <table style="border-collapse:collapse;width:100%"><tr style="height:7.2pt"><td style="width:35.86%" valign="middle"> </td><td style="width:3.4%" valign="middle"> </td><td style="width:10.1%" valign="middle">Fair Value </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td colspan="2" style="width:12.44%" valign="middle">Level 1 </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td colspan="2" style="width:12.44%" valign="middle">Level 2 </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td colspan="2" style="width:12.98%" valign="middle">Level 3 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:35.86%" valign="middle">Fair Value at December 31, 2021 </td><td style="background-color:#CCFFCC;width:3.4%;border-bottom:0.5pt solid #000000" valign="middle"> $ </td><td style="background-color:#CCFFCC;width:10.1%;border-bottom:0.5pt solid #000000" valign="middle">92,527 </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.5%" valign="middle"> </td><td style="background-color:#CCFFCC;width:9.96%" valign="middle">- </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.5%" valign="middle"> </td><td style="background-color:#CCFFCC;width:9.96%" valign="middle">- </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:2.9%;border-bottom:0.5pt solid #000000" valign="middle">$ </td><td style="background-color:#CCFFCC;width:10.08%;border-bottom:0.5pt solid #000000" valign="middle">92,527 </td></tr> <tr style="height:7.2pt"><td style="width:35.86%" valign="middle">Derivative liability </td><td style="width:3.4%" valign="middle"> </td><td style="width:10.1%" valign="middle">102,011 </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.5%" valign="middle"> </td><td style="width:9.96%" valign="middle">- </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.5%" valign="middle"> </td><td style="width:9.96%" valign="middle">- </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="bottom"> </td><td style="width:2.9%" valign="middle"> </td><td style="width:10.08%" valign="middle">102,011 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:35.86%" valign="middle">Fair Value at December 31, 2022 </td><td style="background-color:#CCFFCC;width:3.4%;border-bottom:0.5pt solid #000000" valign="middle"> $ </td><td style="background-color:#CCFFCC;width:10.1%;border-bottom:0.5pt solid #000000" valign="middle">102,011 </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.5%" valign="middle"> </td><td style="background-color:#CCFFCC;width:9.96%" valign="middle">- </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.5%" valign="middle"> </td><td style="background-color:#CCFFCC;width:9.96%" valign="middle">- </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.9%;border-bottom:0.5pt solid #000000" valign="middle">$ </td><td style="background-color:#CCFFCC;width:10.08%;border-bottom:0.5pt solid #000000" valign="middle">102,011 </td></tr> <tr style="height:7.2pt"><td style="width:35.86%" valign="middle">Derivative liability </td><td style="width:3.4%" valign="middle"> </td><td style="width:10.1%" valign="middle">154,150 </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.5%" valign="middle"> </td><td style="width:9.96%" valign="middle">- </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.5%" valign="middle"> </td><td style="width:9.96%" valign="middle">- </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.12%" valign="middle"> </td><td style="width:2.9%;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="width:10.08%;border-bottom:0.5pt solid #000000" valign="middle">154,150 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:35.86%" valign="middle">Fair Value at December 31, 2023 </td><td style="background-color:#CCFFCC;width:3.4%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"> $ </td><td style="background-color:#CCFFCC;width:10.1%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">154,150 </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.5%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:9.96%" valign="middle">- </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.5%" valign="middle"> </td><td style="background-color:#CCFFCC;width:9.96%" valign="middle">- </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.12%" valign="middle"> </td><td style="background-color:#CCFFCC;width:2.9%;border-bottom:3px double #000000" valign="middle">$ </td><td style="background-color:#CCFFCC;width:10.08%;border-bottom:3px double #000000" valign="middle">154,150 </td></tr> </table> December 31, 2023 <table style="border-collapse:collapse;width:100%"><tr><td style="width:39.94%" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:11.94%;border-bottom:0.5pt solid #000000" valign="bottom">Level 1 </td><td style="width:0.98%;padding-bottom:1.5pt" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:12.14%;border-bottom:0.5pt solid #000000" valign="bottom">Level 2 </td><td style="width:0.98%;padding-bottom:1.5pt" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:11.94%;border-bottom:0.5pt solid #000000" valign="bottom">Level 3 </td><td style="width:0.98%;padding-bottom:1.5pt" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:12.28%;border-bottom:0.5pt solid #000000" valign="bottom">Total </td><td style="width:0.9%;padding-bottom:1.5pt" valign="bottom"> </td></tr> <tr><td style="background-color:#CCFFCC;width:39.94%" valign="bottom">Derivative liability </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:0.98%;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom">- </td><td style="background-color:#CCFFCC;width:0.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.18%;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom">- </td><td style="background-color:#CCFFCC;width:0.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:0.98%;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom"> 154,150 </td><td style="background-color:#CCFFCC;width:0.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.32%;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom"> 154,150 </td><td style="background-color:#CCFFCC;width:0.9%" valign="bottom"> </td></tr> </table> December 31, 2022 <table style="border-collapse:collapse;width:100%"><tr><td style="width:39.94%" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:11.94%;border-bottom:0.5pt solid #000000" valign="bottom">Level 1 </td><td style="width:0.98%;padding-bottom:1.5pt" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:12.14%;border-bottom:0.5pt solid #000000" valign="bottom">Level 2 </td><td style="width:0.98%;padding-bottom:1.5pt" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:11.94%;border-bottom:0.5pt solid #000000" valign="bottom">Level 3 </td><td style="width:0.98%;padding-bottom:1.5pt" valign="bottom"> </td><td style="width:1.98%;padding-bottom:1.5pt" valign="bottom"> </td><td colspan="2" style="width:12.28%;border-bottom:0.5pt solid #000000" valign="bottom">Total </td><td style="width:0.9%;padding-bottom:1.5pt" valign="bottom"> </td></tr> <tr><td style="background-color:#CCFFCC;width:39.94%" valign="bottom">Derivative liability </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:0.98%;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom">- </td><td style="background-color:#CCFFCC;width:0.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.18%;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom">- </td><td style="background-color:#CCFFCC;width:0.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:0.98%;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom"> 102,011 </td><td style="background-color:#CCFFCC;width:0.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.98%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:1.32%;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#CCFFCC;width:10.96%;border-top:0.5pt solid #000000" valign="bottom"> 102,011 </td><td style="background-color:#CCFFCC;width:0.9%" valign="bottom"> </td></tr> </table> The details of derivative liability transactions for the year ended December 31, 2023 and December 31, 2022 are as follows: The change in Level 3 financial instrument fair value is as follows: <table style="border-collapse:collapse"><tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Balance, December 31, 2021 </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt;border-bottom:3px double #000000" valign="top">$ 92,527 </td></tr> <tr style="height:7.2pt"><td style="width:302.4pt" valign="top">Issued during the year ended December 31, 2022 </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt;border-top:3px double #000000" valign="top">264,952 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Derivative liabilities debt premium </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt" valign="top"> (43,269) </td></tr> <tr style="height:7.2pt"><td style="width:302.4pt" valign="top">Change in fair value recognized in operations </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt" valign="top">(212,199) </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Converted during the year ended December 31, 2022 </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt;border-bottom:0.5pt solid #000000" valign="top">(0) </td></tr> <tr style="height:7.2pt"><td style="width:302.4pt" valign="top">Balance, December 31, 2022 </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"> $ 102,011 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Issued during the year ended December 31, 2023 </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt" valign="top">145,067 </td></tr> <tr style="height:7.2pt"><td style="width:302.4pt" valign="top">Derivative liabilities debt discount </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt" valign="top">29,167 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Change in fair value recognized in operations </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt" valign="top">(83,923) </td></tr> <tr style="height:7.2pt"><td style="width:302.4pt" valign="top">Converted during the year ended December 31, 2023 </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt;border-bottom:0.5pt solid #000000" valign="top">(38,172) </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Balance, December 31, 2023 </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"> $ 154,150 </td></tr> </table> 92527 92527 102011 102011 102011 102011 154150 154150 154150 154150 154150 154150 102011 102011 92527 264952 -43269 -212199 0 102011 145067 29167 -83923 -38172 154150 Convertible Instruments Convertible debt – derivative treatment The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. If the conversion feature within convertible debt meets the requirements to be treated as a derivative, we estimate the fair value of the convertible debt derivative using the Black-Sholes option pricing model upon the date of issuance. If the fair value of the convertible debt derivative is higher than the face value of the convertible debt, the excess is immediately recognized as interest expense. Otherwise, the fair value of the convertible debt derivative is recorded as a liability with an offsetting amount recorded as a debt discount, which offsets the carrying amount of the debt. If the convertible debt is viewed as short-term, management chooses to expense the full debt discount in the period incurred is recorded as a gain or loss in the consolidated statement of operations. The convertible debt derivative is revalued at the end of each reporting period and any change in fair value is recorded as a gain or loss in the consolidated statement of operations. Convertible debt – beneficial conversion feature The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records when necessary, any discounts, if applicable, to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts, if applicable, under these arrangements are amortized over the term of the related debt to their stated date of redemption. Debt modifications and extinguishments The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded under change in fair value on derivative, in the consolidated operation statements, as a gain or loss on extinguishment of the two separate liabilities. During the year ended December 31, 2023, the Company issued $388,888 of convertible debt. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 amends the guidance for revenue recognition to replace numerous, industry specific requirements and converges areas under this topic with those of the International Financial Reporting Standards. The ASU implements of five–step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract cost, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The amendments in this ASU are effective for reporting period beginning after December 15, 2016, and early adoption is prohibited. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company’s revenues are recognized when control of the promised goods or services is transferred to our clients (upon shipment of goods) in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: (1) Identify the contract with a client; (2) Identify the performance obligations in the contract; (3) Determine the transaction price; (4) Allocate the transaction price to performance obligations in the contract; and (5) Recognize revenues when or as the Company satisfies a performance obligation. We adopted ASC 2014-09 on January 1, 2019. Although the new revenue standard is expected to have an immaterial impact, if any, on our ongoing net income, we did implement changes to our processes related to revenue recognition and the control activities with them. The Company leases its office and warehouse space under non-cancellable capital leases. The Company accounts for this lease in accordance with ASC 842. Right-of-use (“ROU”) assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Since our lease arrangements do not provide an implicit rate, we use our estimated incremental borrowing rate for the expected remaining lease term at commencement date in determining the present value of future lease payments. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. Capital lease expense is recognized on a straight-line basis over the lease term. Variable lease payments are not included in the lease payments to measure the lease liability and are expensed as incurred. Finance lease expense is comprised of both interest expense, which is recognized using the effective interest method, and amortization of the right-of-use assets. These expenses are presented consistently with the presentation of other interest expense and amortization or depreciation of similar assets. Common area maintenance fees (or CAMs) and other charges related to leases are expensed as incurred. See Note 5 — Right-of-Use Assets and Lease Liabilities for further discussion of the Company’s lease activities. Common Stock Purchase Warrants The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to our own stock as defined in ASC 815-40 (“Contracts in Entity's Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside our control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification is required. NOTE 3 – GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has generated minimal revenues from operations. Since its inception, the Company has been engaged substantially in financing activities and developing its business plan and incurring startup costs and expenses. As a result, the Company incurred accumulated net losses from Inception (December 19, 2014) through the year ended December 31, 2023 of $18,336,268. Due to our negative cash flow, the Company has substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. In addition, the Company’s development activities since inception have been financially sustained through equity financing. Management plans to keep seeking funding through debt and equity financing which are intended to mitigate the conditions that have raise substantial doubt about the entity’s ability to continue as a going concern. 18336268 NOTE 4 – RELATED PARTY For the year ended December 31, 2023 and December 31, 2022, the Company had expenses totaling $0 and $1,000 respectively, to an officer and director for salaries, which is included in general and administrative expenses on the accompanying consolidated statement of operations. <table style="border-collapse:collapse;width:549pt;margin-left:-40.5pt"><tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:108pt" valign="middle">Note </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:67.5pt" valign="middle">Issuance Date </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:54pt" valign="middle">Maturity Date </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt" valign="middle">Interest Rate </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">Original Principal Amount </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt" valign="middle">Balance at December 31, 2023 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:67.5pt" valign="middle">Balance at December 31, 2022 </td></tr> <tr style="height:7.2pt"><td style="width:108pt" valign="middle">Unsecured debt A </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:67.5pt" valign="middle">March 2019, March and June 2020 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:54pt" valign="middle">No due date </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="middle">0% </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">$866 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:63pt" valign="middle">$866 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:67.5pt" valign="middle">$866 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:108pt" valign="middle">Unsecured debt H </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:67.5pt" valign="middle">September 1, 2023 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:54pt" valign="middle">January 1, 2024 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt" valign="middle">10% </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt;border-bottom:1pt solid #000000" valign="middle">$82,500 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt;border-bottom:1pt solid #000000" valign="middle">$82,500 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:67.5pt;border-bottom:1pt solid #000000" valign="middle">$866 </td></tr> <tr style="height:7.2pt"><td style="width:108pt" valign="middle">Total notes payable </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:67.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:54pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">$83,366 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:63pt" valign="middle">$83,366 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:67.5pt" valign="middle">$866 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:108pt" valign="middle">Debt discount and deferred financing costs </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:67.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:54pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt;border-bottom:1pt solid #000000" valign="middle">- </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt;border-bottom:1pt solid #000000" valign="middle">- </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:67.5pt;border-bottom:1pt solid #000000" valign="middle">- </td></tr> <tr style="height:7.2pt"><td style="width:108pt" valign="middle">Total notes payable, net </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:67.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:54pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">$83,366 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:63pt" valign="middle">$83,366 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:67.5pt" valign="middle">$866 </td></tr> </table> Unsecured debt A: On March 2, 2020, the Company received an unsecured loan of $200 from a shareholder. Additionally, during in March and June 2019, the Company received an additional loan of $666 from another shareholder. Both of these notes are unsecured and do not have a payment due date at an interest rate of 0.00%. Unsecured debt H: On September 1, 2023, the Company received an unsecured line of credit in the principal of up to $82,500 with a loan origination fee in the amount of $7,500, which was amortized over the life of the line of credit. The net proceeds from this line of credit were $75,000. The loan is unsecured and is due for repayment on January 1, 2024. Interest will accrue at an interest rate of 10% per annum on any unpaid principal amount. If the Company defaults on the loan, the holder of the note can declare all or any portion of the unpaid balance with all accrued interest immediately due and payable. As of December 31, 2023, the outstanding principal balance of unsecured debt G totaled $75,000. 0 1000 <table style="border-collapse:collapse;width:549pt;margin-left:-40.5pt"><tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:108pt" valign="middle">Note </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:67.5pt" valign="middle">Issuance Date </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:54pt" valign="middle">Maturity Date </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt" valign="middle">Interest Rate </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">Original Principal Amount </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt" valign="middle">Balance at December 31, 2023 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:67.5pt" valign="middle">Balance at December 31, 2022 </td></tr> <tr style="height:7.2pt"><td style="width:108pt" valign="middle">Unsecured debt A </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:67.5pt" valign="middle">March 2019, March and June 2020 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:54pt" valign="middle">No due date </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="middle">0% </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">$866 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:63pt" valign="middle">$866 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:67.5pt" valign="middle">$866 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:108pt" valign="middle">Unsecured debt H </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:67.5pt" valign="middle">September 1, 2023 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:54pt" valign="middle">January 1, 2024 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt" valign="middle">10% </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt;border-bottom:1pt solid #000000" valign="middle">$82,500 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt;border-bottom:1pt solid #000000" valign="middle">$82,500 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:67.5pt;border-bottom:1pt solid #000000" valign="middle">$866 </td></tr> <tr style="height:7.2pt"><td style="width:108pt" valign="middle">Total notes payable </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:67.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:54pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">$83,366 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:63pt" valign="middle">$83,366 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:67.5pt" valign="middle">$866 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:108pt" valign="middle">Debt discount and deferred financing costs </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:67.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:54pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt;border-bottom:1pt solid #000000" valign="middle">- </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt;border-bottom:1pt solid #000000" valign="middle">- </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:67.5pt;border-bottom:1pt solid #000000" valign="middle">- </td></tr> <tr style="height:7.2pt"><td style="width:108pt" valign="middle">Total notes payable, net </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:67.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:54pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">$83,366 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:63pt" valign="middle">$83,366 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:67.5pt" valign="middle">$866 </td></tr> </table> 0 866 866 866 0.10 82500 82500 866 83366 83366 866 83366 83366 866 NOTE 5 – RIGHT-OF-USE ASSETS AND LEASE LIABILITIES In February 2022, the Company entered into a lease agreement for our warehouse facilities located at 7375 Commercial Way Suite 125, Henderson, Nevada 89011 with a term of 35 month 25 days and will expire in 2025. Prior to February 4, 2022 the company was leasing a warehouse facility on a month-to-month lease. The average monthly base rent for the first 12 months is approximately $5,333. For the next 24 months of the lease, the average monthly base rent will be approximately $5,694. As part of the agreement the Company will be responsible to share any property operating expenses estimated as $1,017 per month. Pursuant to ASC 842, the estimated operating expenses was included with the base rent and was included in the calculations of the right of use assets. The Company recorded operating lease right-of-use of $175,765 and lease liabilities for operating lease of $175,765. Supplemental statements of operations information related to leases are as follows: <table style="border-collapse:collapse;width:523pt;margin-left:-22.5pt"><tr style="height:7.2pt"><td rowspan="2" style="background-color:#CCFFCC;width:387pt" valign="middle"> </td><td rowspan="2" style="background-color:#CCFFCC;width:18pt" valign="middle"> </td><td colspan="2" style="background-color:#CCFFCC;width:118pt" valign="middle">Year Ended </td></tr> <tr style="height:7.2pt"><td colspan="2" style="background-color:#CCFFCC;width:118pt;border-bottom:0.5pt solid #000000" valign="middle">December 31, 2023 </td></tr> <tr style="height:7.2pt"><td style="width:387pt" valign="middle">Lease Cost </td><td style="width:18pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:104.5pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:387pt" valign="middle">Cash paid for amounts included in the measurement of lease liabilities for the first quarter 2022 </td><td style="background-color:#CCFFCC;width:18pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle">$ </td><td style="background-color:#CCFFCC;width:104.5pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:387pt" valign="middle">Weighted average remaining lease term – operating leases (in years) </td><td style="width:18pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:104.5pt" valign="middle">1.08 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:387pt" valign="middle">Average discount rate – operating leases </td><td style="background-color:#CCFFCC;width:18pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:104.5pt" valign="middle">9.80% </td></tr> <tr style="height:7.2pt"><td style="width:387pt" valign="bottom"> </td><td style="width:18pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:104.5pt" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:387pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:18pt" valign="middle"> </td><td colspan="2" style="background-color:#CCFFCC;width:118pt;border-bottom:0.5pt solid #000000" valign="middle">December 31, 2023 </td></tr> <tr style="height:7.2pt"><td style="width:387pt" valign="middle">Operating leases </td><td style="width:18pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:104.5pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:387pt" valign="middle">Right-of-use assets, net of amortization of $104,182 </td><td style="background-color:#CCFFCC;width:18pt" valign="top"> </td><td style="background-color:#CCFFCC;width:13.5pt;border-bottom:3px double #000000" valign="middle">$ </td><td style="background-color:#CCFFCC;width:104.5pt;border-bottom:3px double #000000" valign="middle">71,583 </td></tr> <tr style="height:7.2pt"><td style="width:387pt" valign="top"> </td><td style="width:18pt" valign="top"> </td><td style="width:13.5pt" valign="top"> </td><td style="width:104.5pt" valign="top"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:387pt" valign="middle">Short-term operating lease liabilities </td><td style="background-color:#CCFFCC;width:18pt" valign="top"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle">$ </td><td style="background-color:#CCFFCC;width:104.5pt" valign="middle"> (65,229) </td></tr> <tr style="height:7.2pt"><td style="width:387pt" valign="middle">Long-term operating lease liabilities </td><td style="width:18pt" valign="top"> </td><td style="width:13.5pt;border-bottom:0.5pt solid #000000" valign="middle"> </td><td style="width:104.5pt;border-bottom:0.5pt solid #000000" valign="middle"> (9,222) </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:387pt" valign="middle">Total operating lease liabilities </td><td style="background-color:#CCFFCC;width:18pt" valign="top"> </td><td style="background-color:#CCFFCC;width:13.5pt;border-bottom:3px double #000000" valign="middle">$ </td><td style="background-color:#CCFFCC;width:104.5pt;border-bottom:3px double #000000" valign="middle"> (74,452) </td></tr> </table> The following table summarizes the future undiscounted cash payments reconciled to the lease liability: <table style="border-collapse:collapse;width:504pt;margin-left:-18pt"><tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:382.5pt;border-bottom:0.5pt solid #000000" valign="middle">Year Ending </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td colspan="2" style="background-color:#CCFFCC;width:108pt;border-bottom:0.5pt solid #000000" valign="middle">Operating Leases </td></tr> <tr style="height:7.2pt"><td style="width:382.5pt" valign="middle">2022 (remaining eleven months) </td><td style="width:13.5pt" valign="middle"> </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:94.5pt" valign="bottom"> - </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:382.5pt" valign="middle">2023 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:94.5pt" valign="bottom"> - </td></tr> <tr style="height:7.2pt"><td style="width:382.5pt" valign="middle">2024 </td><td style="width:13.5pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:94.5pt" valign="bottom">69,635 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:382.5pt" valign="middle">2025 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:94.5pt" valign="bottom">5,822 </td></tr> <tr style="height:7.2pt"><td style="width:382.5pt" valign="middle">2026 and thereafter </td><td style="width:13.5pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:94.5pt;border-bottom:0.5pt solid #000000" valign="bottom"> - </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:382.5pt" valign="middle">Total lease payments </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle">$ </td><td style="background-color:#CCFFCC;width:94.5pt" valign="bottom">75,457 </td></tr> <tr style="height:7.2pt"><td style="width:382.5pt" valign="middle">Less: Imputed interest/present value discount </td><td style="width:13.5pt" valign="middle"> </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:94.5pt;border-bottom:0.5pt solid #000000" valign="bottom"> (1,005) </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:382.5pt" valign="middle">Present value of lease liabilities </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle">$ </td><td style="background-color:#CCFFCC;width:94.5pt;border-bottom:3px double #000000" valign="bottom">74,452 </td></tr> </table> 5333 5694 Supplemental statements of operations information related to leases are as follows: <table style="border-collapse:collapse;width:523pt;margin-left:-22.5pt"><tr style="height:7.2pt"><td rowspan="2" style="background-color:#CCFFCC;width:387pt" valign="middle"> </td><td rowspan="2" style="background-color:#CCFFCC;width:18pt" valign="middle"> </td><td colspan="2" style="background-color:#CCFFCC;width:118pt" valign="middle">Year Ended </td></tr> <tr style="height:7.2pt"><td colspan="2" style="background-color:#CCFFCC;width:118pt;border-bottom:0.5pt solid #000000" valign="middle">December 31, 2023 </td></tr> <tr style="height:7.2pt"><td style="width:387pt" valign="middle">Lease Cost </td><td style="width:18pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:104.5pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:387pt" valign="middle">Cash paid for amounts included in the measurement of lease liabilities for the first quarter 2022 </td><td style="background-color:#CCFFCC;width:18pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle">$ </td><td style="background-color:#CCFFCC;width:104.5pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:387pt" valign="middle">Weighted average remaining lease term – operating leases (in years) </td><td style="width:18pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:104.5pt" valign="middle">1.08 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:387pt" valign="middle">Average discount rate – operating leases </td><td style="background-color:#CCFFCC;width:18pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:104.5pt" valign="middle">9.80% </td></tr> <tr style="height:7.2pt"><td style="width:387pt" valign="bottom"> </td><td style="width:18pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:104.5pt" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:387pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:18pt" valign="middle"> </td><td colspan="2" style="background-color:#CCFFCC;width:118pt;border-bottom:0.5pt solid #000000" valign="middle">December 31, 2023 </td></tr> <tr style="height:7.2pt"><td style="width:387pt" valign="middle">Operating leases </td><td style="width:18pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:104.5pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:387pt" valign="middle">Right-of-use assets, net of amortization of $104,182 </td><td style="background-color:#CCFFCC;width:18pt" valign="top"> </td><td style="background-color:#CCFFCC;width:13.5pt;border-bottom:3px double #000000" valign="middle">$ </td><td style="background-color:#CCFFCC;width:104.5pt;border-bottom:3px double #000000" valign="middle">71,583 </td></tr> <tr style="height:7.2pt"><td style="width:387pt" valign="top"> </td><td style="width:18pt" valign="top"> </td><td style="width:13.5pt" valign="top"> </td><td style="width:104.5pt" valign="top"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:387pt" valign="middle">Short-term operating lease liabilities </td><td style="background-color:#CCFFCC;width:18pt" valign="top"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle">$ </td><td style="background-color:#CCFFCC;width:104.5pt" valign="middle"> (65,229) </td></tr> <tr style="height:7.2pt"><td style="width:387pt" valign="middle">Long-term operating lease liabilities </td><td style="width:18pt" valign="top"> </td><td style="width:13.5pt;border-bottom:0.5pt solid #000000" valign="middle"> </td><td style="width:104.5pt;border-bottom:0.5pt solid #000000" valign="middle"> (9,222) </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:387pt" valign="middle">Total operating lease liabilities </td><td style="background-color:#CCFFCC;width:18pt" valign="top"> </td><td style="background-color:#CCFFCC;width:13.5pt;border-bottom:3px double #000000" valign="middle">$ </td><td style="background-color:#CCFFCC;width:104.5pt;border-bottom:3px double #000000" valign="middle"> (74,452) </td></tr> </table> The following table summarizes the future undiscounted cash payments reconciled to the lease liability: <table style="border-collapse:collapse;width:504pt;margin-left:-18pt"><tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:382.5pt;border-bottom:0.5pt solid #000000" valign="middle">Year Ending </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td colspan="2" style="background-color:#CCFFCC;width:108pt;border-bottom:0.5pt solid #000000" valign="middle">Operating Leases </td></tr> <tr style="height:7.2pt"><td style="width:382.5pt" valign="middle">2022 (remaining eleven months) </td><td style="width:13.5pt" valign="middle"> </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:94.5pt" valign="bottom"> - </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:382.5pt" valign="middle">2023 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:94.5pt" valign="bottom"> - </td></tr> <tr style="height:7.2pt"><td style="width:382.5pt" valign="middle">2024 </td><td style="width:13.5pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:94.5pt" valign="bottom">69,635 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:382.5pt" valign="middle">2025 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:94.5pt" valign="bottom">5,822 </td></tr> <tr style="height:7.2pt"><td style="width:382.5pt" valign="middle">2026 and thereafter </td><td style="width:13.5pt" valign="middle"> </td><td style="width:13.5pt" valign="middle"> </td><td style="width:94.5pt;border-bottom:0.5pt solid #000000" valign="bottom"> - </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:382.5pt" valign="middle">Total lease payments </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle">$ </td><td style="background-color:#CCFFCC;width:94.5pt" valign="bottom">75,457 </td></tr> <tr style="height:7.2pt"><td style="width:382.5pt" valign="middle">Less: Imputed interest/present value discount </td><td style="width:13.5pt" valign="middle"> </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:94.5pt;border-bottom:0.5pt solid #000000" valign="bottom"> (1,005) </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:382.5pt" valign="middle">Present value of lease liabilities </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle">$ </td><td style="background-color:#CCFFCC;width:94.5pt;border-bottom:3px double #000000" valign="bottom">74,452 </td></tr> </table> 0 P1Y29D 0.0980 71583 65229 9222 74452 0 0 69635 5822 75457 1005 74452 NOTE 6 – NOTES PAYABLE As of December 31, 2023, the Company had the following: <table style="border-collapse:collapse;width:549pt;margin-left:-45pt"><tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:90pt;border-bottom:1pt solid #000000" valign="middle">Note </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt;border-bottom:1pt solid #000000" valign="middle">Issuance Date </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt;border-bottom:1pt solid #000000" valign="middle">Maturity Date </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt;border-bottom:1pt solid #000000" valign="middle">Interest Rate </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt;border-bottom:1pt solid #000000" valign="middle">Original Principal Amount </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:67.5pt;border-bottom:1pt solid #000000" valign="middle">Balance at December 31, 2023 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:81pt;border-bottom:1pt solid #000000" valign="middle">Balance at December 31, 2022 </td></tr> <tr style="height:7.2pt"><td style="width:90pt" valign="middle">Unsecured debt B </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:63pt" valign="middle">February 22, 2022 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">February 15, 2023 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="middle">10% </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:58.5pt" valign="middle">200,000 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:67.5pt" valign="middle">- </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:81pt" valign="middle">75,370 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:90pt" valign="middle">Secured debt C </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt" valign="middle">October 7, 2022 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">October 7, 2023 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt" valign="middle">12.99% </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">200,000 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:67.5pt" valign="middle">- </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:81pt" valign="middle">200,000 </td></tr> <tr style="height:7.2pt"><td style="width:90pt" valign="middle">Unsecured debt D </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:63pt" valign="middle">March 20, 2023 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">August 17, 2024 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="middle">10% </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">330,000 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:67.5pt" valign="middle">166,486 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:81pt" valign="middle">- </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:90pt" valign="middle">Secured debt E </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt" valign="middle">May 19, 2023 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">May 18, 2024 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt" valign="middle">12.99% </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">131,000 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:67.5pt" valign="middle">- </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:81pt" valign="middle">- </td></tr> <tr style="height:7.2pt"><td style="width:90pt" valign="middle">Secured debt F </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:63pt" valign="middle">July 26, 2023 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">May 18, 2024 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="middle">12.99% </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">196,000 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:67.5pt" valign="middle">110,399 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:81pt" valign="middle">- </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:90pt" valign="middle">Secured debt G </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt" valign="middle">December 19, 2023 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">December 18, 2024 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt" valign="middle">10% </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">94,600 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:67.5pt" valign="middle">92,526 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:81pt" valign="middle">- </td></tr> <tr style="height:7.2pt"><td style="width:90pt" valign="middle">Total notes payable </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:63pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:58.5pt;border-top:1pt solid #000000" valign="middle">1,151,600 </td><td style="width:13.5pt;border-top:1pt solid #000000" valign="bottom"> </td><td style="width:67.5pt;border-top:1pt solid #000000" valign="middle">369,411 </td><td style="width:13.5pt;border-top:1pt solid #000000" valign="bottom"> </td><td style="width:81pt;border-top:1pt solid #000000" valign="middle">$275,370 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:90pt" valign="middle">Debt discount and deferred financing costs </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">- </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:67.5pt" valign="middle">- </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:81pt" valign="middle">- </td></tr> <tr style="height:7.2pt"><td style="width:90pt" valign="middle">Total notes payable, net </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:63pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:58.5pt;border-top:1pt solid #000000" valign="middle">1,151,600 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:67.5pt;border-top:1pt solid #000000" valign="middle">369,411 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:81pt;border-top:1pt solid #000000" valign="middle">$275,370 </td></tr> </table> Unsecured debt B: On February 22, 2022, the Company received an unsecured loan in the principal of $200,000 with a loan origination fee in the amount of $20,000, which was fully expensed as interest expense in this period. The net proceeds from this loan were $180,000. The loan is unsecured and the initial payment of $17,804 was due on April 22, 2022. There will be ten monthly payments due on the 22nd day of each following month, beginning on May 22, 2022 through Feb 15, 2023. During fourth quarter of 2022, the note holder agreed to forgo two months of payments and add them to the back end of the note, which extended the due date of the note to April 25, 2023. Interest will accrue at an interest rate of 10% per annum on any unpaid principal amount. If the Company defaults on the loan, the default interest will increase to 16% per annum. During 2022, the Company made a total in principal payments of $124,630 towards unsecured debt B. During 2023, the Company has made additional principal payments towards unsecured debt B totaling $75,370 which settled the entire principal balance in full. As of December 31, 2023, the principal balance of the note was paid off. Secured debt C: On October 7, 2022, the Company agreed to a secured loan by any consigned inventory held at fulfillment centers and any rights, title or interest in their account. The principal loan amount was $200,000 and will have a loan term of twelve months with an annual interest rate of 12.99%, with a default rate of 14.99%. The first three months of payment will be interest only payments of $2,165 and the remaining nine payments will be principal and interest payments of $23,442. Interest payments will begin November 8, 2022 and Installment payments, including principal and interest, will begin February 8, 2023. During 2023, the Company has made principal payments totaling $200,000 towards the secured debt C which settled the entire principal balance in full. As of December 31, 2023 the principal balance of secured debt C was paid off. Unsecured debt D: On March 20, 2023, the Company received an unsecured loan in the principal of $330,000 with a loan origination fee in the amount of $30,000, which was fully expensed as interest expense in this period. The net proceeds from this loan were $300,000. The loan is unsecured and the initial payment of $23,359 will be due on June 17, 2023. There will be fourteen monthly payments due on the 17th day of each following month, beginning on July 17, 2023 through August 17, 2024. Interest will accrue at an interest rate of 10% per annum on any unpaid principal amount. If the Company defaults on the loan, the default interest will increase to 16% per annum. During 2023, the Company made a total in principal payments of $163,514 towards the unsecured debt D. As of December 31, 2023, the outstanding principal balance of unsecured debt D totaled $166,486. Secured debt E: On May 19, 2023, the Company agreed to a secured loan by any consigned inventory held at fulfillment centers and any rights, title or interest in their account. The principal loan amount was $131,000 and will have a loan term of twelve months with an annual interest rate of 12.99%, with a default rate of 14.99%. The first payment of principal and interest will be $11,700 and will be due June 19, 2023 with an additional eleven payments due each 19th of the month. During 2023, the Company has made principal payments totaling $10,282 towards the secured debt E. As of December 31, 2023 the principal balance of secured debt E was paid off. Secured debt F: On July 26, 2023, the Company agreed to a secured loan by any consigned inventory held at fulfillment centers and any rights, title or interest in their account. The principal loan amount was $196,000 and will have a loan term of twelve months with an annual interest rate of 12.99%, with a default rate of 14.99%. The first payment of principal and interest will be $17,505 and will be due August 26, 2023 with an additional eleven payments due each 26th of the month. During 2023, the Company has made principal payments totaling $85,601 towards the secured debt F. As of December 31, 2023 the principal balance of secured debt E was $110,399. Secured debt G: On December 19, 2023, the Company agreed to a secured loan by any rights, title or interest in their account. The principal loan amount was $86,000 and will have a loan term of twelve months. The note has a cost of funds equal to 10% of the loan amount or $8,600 and will be due upon acceptance of the loan amount. A total of $283 of the interest has been expensed in 2023. Payment will be made daily at a repayment rate of 14% of daily sales. and will be due December 21, 2023 and will continue until full amount owed is paid. During 2023, the Company has made principal payments totaling $2,074 towards the secured debt E. As of December 31, 2023 the principal balance of secured debt E was $92,526. <table style="border-collapse:collapse;width:549pt;margin-left:-45pt"><tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:90pt;border-bottom:1pt solid #000000" valign="middle">Note </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt;border-bottom:1pt solid #000000" valign="middle">Issuance Date </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt;border-bottom:1pt solid #000000" valign="middle">Maturity Date </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt;border-bottom:1pt solid #000000" valign="middle">Interest Rate </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt;border-bottom:1pt solid #000000" valign="middle">Original Principal Amount </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:67.5pt;border-bottom:1pt solid #000000" valign="middle">Balance at December 31, 2023 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:81pt;border-bottom:1pt solid #000000" valign="middle">Balance at December 31, 2022 </td></tr> <tr style="height:7.2pt"><td style="width:90pt" valign="middle">Unsecured debt B </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:63pt" valign="middle">February 22, 2022 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">February 15, 2023 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="middle">10% </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:58.5pt" valign="middle">200,000 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:67.5pt" valign="middle">- </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:81pt" valign="middle">75,370 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:90pt" valign="middle">Secured debt C </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt" valign="middle">October 7, 2022 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">October 7, 2023 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt" valign="middle">12.99% </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">200,000 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:67.5pt" valign="middle">- </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:81pt" valign="middle">200,000 </td></tr> <tr style="height:7.2pt"><td style="width:90pt" valign="middle">Unsecured debt D </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:63pt" valign="middle">March 20, 2023 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">August 17, 2024 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="middle">10% </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">330,000 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:67.5pt" valign="middle">166,486 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:81pt" valign="middle">- </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:90pt" valign="middle">Secured debt E </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt" valign="middle">May 19, 2023 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">May 18, 2024 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt" valign="middle">12.99% </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">131,000 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:67.5pt" valign="middle">- </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:81pt" valign="middle">- </td></tr> <tr style="height:7.2pt"><td style="width:90pt" valign="middle">Secured debt F </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:63pt" valign="middle">July 26, 2023 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">May 18, 2024 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="middle">12.99% </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">196,000 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:67.5pt" valign="middle">110,399 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:81pt" valign="middle">- </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:90pt" valign="middle">Secured debt G </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt" valign="middle">December 19, 2023 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">December 18, 2024 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt" valign="middle">10% </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">94,600 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:67.5pt" valign="middle">92,526 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:81pt" valign="middle">- </td></tr> <tr style="height:7.2pt"><td style="width:90pt" valign="middle">Total notes payable </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:63pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:58.5pt;border-top:1pt solid #000000" valign="middle">1,151,600 </td><td style="width:13.5pt;border-top:1pt solid #000000" valign="bottom"> </td><td style="width:67.5pt;border-top:1pt solid #000000" valign="middle">369,411 </td><td style="width:13.5pt;border-top:1pt solid #000000" valign="bottom"> </td><td style="width:81pt;border-top:1pt solid #000000" valign="middle">$275,370 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:90pt" valign="middle">Debt discount and deferred financing costs </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">- </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:67.5pt" valign="middle">- </td><td style="background-color:#CCFFCC;width:13.5pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:81pt" valign="middle">- </td></tr> <tr style="height:7.2pt"><td style="width:90pt" valign="middle">Total notes payable, net </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:63pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:58.5pt;border-top:1pt solid #000000" valign="middle">1,151,600 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:67.5pt;border-top:1pt solid #000000" valign="middle">369,411 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:81pt;border-top:1pt solid #000000" valign="middle">$275,370 </td></tr> </table> 0.10 200000 0 75370 0.1299 200000 0 200000 0.10 330000 166486 0 0.1299 131000 0 0 0.1299 196000 110399 0 0.10 94600 92526 0 1151600 369411 275370 1151600 369411 275370 NOTE 7 – CONVERTIBLE DEBT As of December 31, 2023, the Company had the following convertible debt outstanding: <table style="border-collapse:collapse;width:533.1pt;margin-left:-45pt"><tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:94.5pt;border-bottom:1pt solid #000000" valign="middle">Note </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt;border-bottom:1pt solid #000000" valign="middle">Issuance Date </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt;border-bottom:1pt solid #000000" valign="middle">Maturity Date </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt;border-bottom:1pt solid #000000" valign="middle">Interest Rate </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt;border-bottom:1pt solid #000000" valign="middle">Original Principal Amount </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt;border-bottom:1pt solid #000000" valign="middle">Balance at December 31, 2023 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:69.6pt;border-bottom:1pt solid #000000" valign="middle">Balance at December 31, 2022 </td></tr> <tr style="height:7.2pt"><td style="width:94.5pt" valign="middle">Convertible promissory note #1 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">July 28, 2016 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">January 19, 2017 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="middle">8% </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:58.5pt" valign="middle">15,000 </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:63pt" valign="middle">6,750 </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:69.6pt" valign="middle">6,750 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:94.5pt" valign="middle">Convertible promissory note #2 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">May 25, 2022 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">August 5, 2023 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt" valign="middle">10% </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">154,000 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt" valign="middle">- </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:69.6pt" valign="middle">110,535 </td></tr> <tr style="height:7.2pt"><td style="width:94.5pt" valign="middle">Convertible promissory note #3 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">May 12, 2022 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">May 1, 2023 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="middle">12% </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">200,000 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:63pt" valign="middle">200,000 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:69.6pt" valign="middle">200,000 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:94.5pt" valign="middle">Convertible promissory note #4 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">January 24, 2023 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">April 24, 2024 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt" valign="middle">0% </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt;border-bottom:1pt solid #000000" valign="middle">388,888 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt;border-bottom:1pt solid #000000" valign="middle">401,851 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:69.6pt;border-bottom:1pt solid #000000" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:94.5pt" valign="middle">Total notes payable </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:58.5pt" valign="middle">757,888 </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:63pt" valign="middle">608,601 </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:69.6pt" valign="middle">317,285 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:94.5pt" valign="middle">Debt discount and deferred financing costs </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle"> - </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt" valign="middle"> - </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:69.6pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:94.5pt" valign="middle">Total notes payable, net </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:58.5pt;border-top:1pt solid #000000" valign="middle">757,888 </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:63pt;border-top:1pt solid #000000" valign="middle">608,601 </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:69.6pt;border-top:1pt solid #000000" valign="middle">317,285 </td></tr> </table> Convertible promissory note #1: On July 28, 2016, the Company executed the convertible promissory note #1 in the principal amount of $15,000, which is in default but management has not been able to make contact with this party, due to them living out of the country. The due date for this note was January 19, 2017 at an interest rate of 8%, with a default interest rate of 18%. We have calculated the derivative liability as if it is in default (but the note’s default interest rate stays the same at 8%) and will still accrue appropriate interest until the note is fully satisfied or converted into the Company’s common stock. The conversion option for this note coverts at a 54% discount to the market price based on the lowest trading prices in the last 20 days trading period. The outstanding balance on convertible promissory note #1 as of December 31, 2023 was $6,750. The fair value of the derivative as of December 31, 2023 was determined to be $21,185 using the Black-Scholes option pricing model based on the following assumptions: common share price of $0.06 per share; expected exercise price of $0.0169 per share; volatility of 133%; expected dividend yield of zero; and annual risk-free interest rate of 5.44%. The derivatives are classified as liabilities as they represent an obligation to deliver a variable number of shares of common stock in the future and are therefore required to be initially and subsequently measured at fair value each reporting period. The Company originally recorded a derivative liability in the amount of $9,649. The fair value of the derivative liability is remeasured each reporting period using the Black-Scholes option pricing model, and the change in fair value is recorded as an adjustment to the derivative liabilities account with the unrealized gains or losses reflect in other income – change in fair value on derivative. Convertible promissory note #2: On May 25, 2022, the Company executed the convertible promissory note #2 in the principal amount of $154,000 with a loan origination fee in the amount of $15,400, which was fully expensed as interest expense in this period. The net proceeds from this note were $138,600. The loan is unsecured and the initial repayment of $14,488 was due on October 5, 2022. There will be ten additional monthly payments due on the 5th day of each following month, beginning on November 5, 2022 through August 5, 2023. Interest will accrual at an interest rate of 10% per annum on any unpaid principal amount. If the Company defaults on the loan, the default interest will increase to 16% per annum. During 2022, the Company has made principal payments totaling $43,465 towards the outstanding balance on convertible promissory note #2. During 2023, the Company has made additional principal payments towards convertible promissory note #2 totaling $110,535 which settled the entire principal balance in full. As of December 31, 2023, the principal balance of the note was paid off the principal balance of the note was paid off. The fair value of the derivative was determined to be $0, due to being paid off, using the Black-Scholes option pricing model based, prior to the note being paid off, on the following assumptions: common share price of $0.06 per share; expected exercise price of $0.05 per share; volatility of 133%; expected dividend yield of zero; and annual risk-free interest rate of 5.44%. The derivatives are classified as liabilities as they represent an obligation to deliver a variable number of shares of common stock in the future and are therefore required to be initially and subsequently measured at fair value each reporting period. The Company originally recorded a derivative liability in the amount of $89,895. The fair value of the derivative liability is remeasured each reporting period using the Black-Scholes option pricing model, and the change in fair value is recorded as an adjustment to the derivative liabilities account with the unrealized gains or losses reflect in other income – change in fair value on derivative. Convertible promissory note #3: On May 12, 2022, the Company executed the convertible promissory note #3 in the principal amount of $200,000. The loan is unsecured and the principal and any unpaid accrued interest shall be due and payable on May 12, 2023. Interest shall accrue at the rate of 12% per annum. The outstanding balance on convertible promissory note #3 as of December 31, 2023 was $200,000. At any time on or after July 24, 2023, the holder shall have the right, at his option, to convert the principal amount of the note, or any portion of such principal amount, plus accrued but unpaid interest into shares of the Company’s common stock. The Company has been advised the holder of convertible promissory note #3 will be converting the full value of the outstanding principal and interest in the near future. The conversion price shall be $0.05 per share. The fair value of the derivative was determined to be $76,919 using the Black-Scholes option pricing model based on the following assumptions: common share price of $0.06 per share; expected exercise price of $0.05 per share; volatility of 133%; expected dividend yield of zero; and annual risk-free interest rate of 5.44%. The derivatives are classified as liabilities as they represent an obligation to deliver a variable number of shares of common stock in the future and are therefore required to be initially and subsequently measured at fair value each reporting period. The Company originally recorded a derivative liability in the amount of $184,011. The fair value of the derivative liability is remeasured each reporting period using the Black-Scholes option pricing model, and the change in fair value is recorded as an adjustment to the derivative liabilities account with the unrealized gains or losses reflect in other income – change in fair value on derivative. Convertible promissory note #4: On January 24, 2023, the Company executed the convertible promissory note #4 in the principal amount of $388,888 with a loan origination fee in the amount of $38,888, which was fully expensed as interest expense in this period, additionally there were $12,500 of legal costs and $31,500 of agent fees in which were also fully expenses in this period. The net proceeds from this loan were $306,000. The loan is unsecured and the principal and any unpaid accrued interest shall be due and payable on October 24, 2023 with an interest rate of 0%. Any unpaid balance at that time will start to accrue interest at a default rate of 20% per annum. On October 31, 2023 the note was extended to April 24, 2024 for an additional fee in the amount of $38,889. The additional fee will be amortized over the six month and in 2023 $12,962 was expensed. The outstanding balance on convertible promissory note #4 as of December 31, 2023 was $401,851. The holder shall have the right, at his option, to convert the principal amount of the note, or any portion of such principal amount, plus accrued but unpaid interest into shares of the Company’s common stock. The conversion price means ninety percent (90%) of the lowest VWAP of our common stock for the five (5) consecutive Trading Days immediately preceding the date of the issuance of a Conversion Election. The fair value of the derivative was determined to be $56,047 using the Black-Scholes option pricing model based on the following assumptions: common share price of $0.06 per share; expected exercise price of $0.0425 per share; volatility of 133%; expected dividend yield of zero; and annual risk-free interest rate of 5.44%. The derivatives are classified as liabilities as they represent an obligation to deliver a variable number of shares of common stock in the future and are therefore required to be initially and subsequently measured at fair value each reporting period. The Company originally recorded a derivative liability in the amount of $174,234. The fair value of the derivative liability is remeasured each reporting period using the Black-Scholes option pricing model, and the change in fair value is recorded as an adjustment to the derivative liabilities account with the unrealized gains or losses reflect in other income – change in fair value on derivative. <table style="border-collapse:collapse;width:533.1pt;margin-left:-45pt"><tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:94.5pt;border-bottom:1pt solid #000000" valign="middle">Note </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt;border-bottom:1pt solid #000000" valign="middle">Issuance Date </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt;border-bottom:1pt solid #000000" valign="middle">Maturity Date </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt;border-bottom:1pt solid #000000" valign="middle">Interest Rate </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt;border-bottom:1pt solid #000000" valign="middle">Original Principal Amount </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt;border-bottom:1pt solid #000000" valign="middle">Balance at December 31, 2023 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:69.6pt;border-bottom:1pt solid #000000" valign="middle">Balance at December 31, 2022 </td></tr> <tr style="height:7.2pt"><td style="width:94.5pt" valign="middle">Convertible promissory note #1 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">July 28, 2016 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">January 19, 2017 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="middle">8% </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:58.5pt" valign="middle">15,000 </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:63pt" valign="middle">6,750 </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:69.6pt" valign="middle">6,750 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:94.5pt" valign="middle">Convertible promissory note #2 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">May 25, 2022 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">August 5, 2023 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt" valign="middle">10% </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">154,000 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt" valign="middle">- </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:69.6pt" valign="middle">110,535 </td></tr> <tr style="height:7.2pt"><td style="width:94.5pt" valign="middle">Convertible promissory note #3 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">May 12, 2022 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">May 1, 2023 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="middle">12% </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="middle">200,000 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:63pt" valign="middle">200,000 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:69.6pt" valign="middle">200,000 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:94.5pt" valign="middle">Convertible promissory note #4 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">January 24, 2023 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle">April 24, 2024 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt" valign="middle">0% </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt;border-bottom:1pt solid #000000" valign="middle">388,888 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt;border-bottom:1pt solid #000000" valign="middle">401,851 </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:69.6pt;border-bottom:1pt solid #000000" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:94.5pt" valign="middle">Total notes payable </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:58.5pt" valign="middle">757,888 </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:63pt" valign="middle">608,601 </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:69.6pt" valign="middle">317,285 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:94.5pt" valign="middle">Debt discount and deferred financing costs </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:49.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:58.5pt" valign="middle"> - </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:63pt" valign="middle"> - </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:69.6pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:94.5pt" valign="middle">Total notes payable, net </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:58.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:49.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:58.5pt;border-top:1pt solid #000000" valign="middle">757,888 </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:63pt;border-top:1pt solid #000000" valign="middle">608,601 </td><td style="width:13.5pt" valign="middle">$ </td><td style="width:69.6pt;border-top:1pt solid #000000" valign="middle">317,285 </td></tr> </table> 0.08 15000 6750 6750 0.10 154000 0 110535 0.12 200000 200000 200000 0 388888 401851 0 757888 608601 317285 757888 608601 317285 NOTE 8 – DERIVATIVE LIABILITY The Company evaluated the notes under the requirements of ASC 480 “Distinguishing Liabilities From Equity” (ASC 480) and concluded that the notes do not fall within the scope of ASC 480. The Company next evaluated the notes under the requirements of ASC 815 “Derivatives and Hedging Activities” and determined that the scope exception to ASC 815’s derivative accounting provisions does not apply. The Company then evaluated the embedded derivative criteria in ASC 815, and concluded that the conversion features meet all the embedded derivative criteria in ASC 815, and therefore, the conversion features meet the definition of an embedded derivative that should be separated from the notes and accounted for as a derivative liability. The derivative liabilities were valued using a Black-Scholes option pricing model with the following average assumptions: <table style="border-collapse:collapse;width:519.55pt;margin-left:-13.5pt"><tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:107.25pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:90.2pt;border-bottom:1pt solid #000000" valign="middle">December 31, 2023 </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:94.35pt;border-bottom:1pt solid #000000" valign="middle">Upon Issuance 2023 </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:90.2pt;border-bottom:1pt solid #000000" valign="middle">December 31, 2022 </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:94.35pt;border-bottom:1pt solid #000000" valign="middle">Upon Issuance 2022 </td></tr> <tr style="height:7.2pt"><td style="width:107.25pt" valign="middle">Stock Price </td><td style="width:90.2pt" valign="middle">$0.06 </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:94.35pt" valign="middle">$0.048 </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:90.2pt" valign="middle">$0.04 </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:94.35pt" valign="middle">$ 0.043-0.066 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:107.25pt" valign="middle">Exercise Price </td><td style="background-color:#CCFFCC;width:90.2pt" valign="middle">$ 0.017-0.05 </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:94.35pt" valign="middle">$0.045 </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:90.2pt" valign="middle">$ 0.0224-0.05 </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:94.35pt" valign="middle">$ 0.0224-0.05 </td></tr> <tr style="height:7.2pt"><td style="width:107.25pt" valign="middle">Expected Life </td><td style="width:90.2pt" valign="middle">0 </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:94.35pt" valign="middle">0.75 </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:90.2pt" valign="middle">0 - 0.59 </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:94.35pt" valign="middle">1.0 - 1.2 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:107.25pt" valign="middle">Volatility </td><td style="background-color:#CCFFCC;width:90.2pt" valign="middle">133% </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:94.35pt" valign="middle">145% </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:90.2pt" valign="middle">168% </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:94.35pt" valign="middle">194.52 - 197.12% </td></tr> <tr style="height:7.2pt"><td style="width:107.25pt" valign="middle">Dividend Yield </td><td style="width:90.2pt" valign="middle">0% </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:94.35pt" valign="middle">0% </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:90.2pt" valign="middle">0% </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:94.35pt" valign="middle">0% </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:107.25pt" valign="middle">Risk-Free Interest Rate </td><td style="background-color:#CCFFCC;width:90.2pt" valign="middle">5.44% </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:94.35pt" valign="middle">4.57% </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:90.2pt" valign="middle">4.02% </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:94.35pt" valign="middle">0.53 - 0.61% </td></tr> <tr style="height:7.2pt"><td style="width:107.25pt" valign="middle">Convertible Notes </td><td style="width:90.2pt" valign="bottom"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt">595,638</kbd> </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:94.35pt" valign="bottom"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt">388,888</kbd> </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:90.2pt" valign="bottom"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt">317,285</kbd> </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:94.35pt" valign="bottom"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt">356,000</kbd> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:107.25pt" valign="middle">Total Fair Value </td><td style="background-color:#CCFFCC;width:90.2pt" valign="bottom"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt">154,153</kbd> </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:94.35pt" valign="bottom"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt">174,234</kbd> </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:90.2pt" valign="bottom"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt">102,011</kbd> </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:94.35pt" valign="bottom"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt">273,906</kbd> </td></tr> </table> The expected life of the note was based on the remaining contractual term of the instruments. The Company uses the historical volatility of its Common Stock to estimate the future volatility for its Common Stock. The expected dividend yield was based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future. The risk-free interest rate was based on rates established by the Federal Reserve Bank. Consolidated Statement of Operations – Change in fair value on derivative During the year ended December 31, 2022, , the following transactions were recorded in the account “change in fair value on derivative”: (i) as a result of the issuance of convertible notes, the Company recorded derivative liabilities of $(264,952); (ii) the Company viewed the convertible debt derivatives as short term and thus chose to record as other income the debt premium associated with the derivative liabilities incurred during this period in the amount of $43,269; and (iii) the change in the fair value of these derivative liabilities for the year ended December 31, 2022 resulted in a gain of $212,199. During the year ended December 31, 2023, the following transactions were recorded in the account “change in fair value on derivative”: (i) as a result of the issuance of convertible notes, the Company recorded derivative liabilities of $(145,067); (ii) the Company viewed the convertible debt derivatives as short term and thus chose to expense the debt discounts associated with the derivative liabilities incurred during this period in the amount of $(29,167); (iii) the changes in the fair value of these derivative liabilities for the year ended December 31, 2023 resulted in a gain of $83,920; and (iv) the Company recorded a gain on debt extinguishment of $38,172 to account for the extinguishment of derivative liabilities associated with the settlement or the conversion of the convertible debt accounted for as a derivative liability. The details of derivative liability transactions for the period ended December 31, 2023 and December 31, 2022 are as follows: The change in Level 3 financial instrument fair value is as follows: <table style="margin:0 auto;border-collapse:collapse"><tr><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Balance, December 31, 2021 </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt;border-bottom:3px double #000000" valign="top">$ 92,527 </td></tr> <tr><td style="width:302.4pt" valign="top">Issued during the year ended December 31, 2022 </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt;border-top:3px double #000000" valign="top">264,952 </td></tr> <tr><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Derivative liabilities debt premium </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt" valign="top"> (43,269) </td></tr> <tr><td style="width:302.4pt" valign="top">Change in fair value recognized in operations </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt" valign="top">(212,199) </td></tr> <tr><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Converted during the year ended December 31, 2022 </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt;border-bottom:0.5pt solid #000000" valign="top">(0) </td></tr> <tr><td style="width:302.4pt" valign="top">Balance, December 31, 2022 </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"> $ 102,011 </td></tr> <tr><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Issued during the year ended December 31, 2023 </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt" valign="top">145,067 </td></tr> <tr><td style="width:302.4pt" valign="top">Derivative liabilities debt discount </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt" valign="top">29,167 </td></tr> <tr><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Change in fair value recognized in operations </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt" valign="top">(83,923) </td></tr> <tr><td style="width:302.4pt" valign="top">Converted during the year ended December 31, 2023 </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt;border-bottom:0.5pt solid #000000" valign="top">(38,172) </td></tr> <tr><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Balance, December 31, 2023 </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"> $ 154,150 </td></tr> </table> <table style="border-collapse:collapse;width:519.55pt;margin-left:-13.5pt"><tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:107.25pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:90.2pt;border-bottom:1pt solid #000000" valign="middle">December 31, 2023 </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:94.35pt;border-bottom:1pt solid #000000" valign="middle">Upon Issuance 2023 </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:90.2pt;border-bottom:1pt solid #000000" valign="middle">December 31, 2022 </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:94.35pt;border-bottom:1pt solid #000000" valign="middle">Upon Issuance 2022 </td></tr> <tr style="height:7.2pt"><td style="width:107.25pt" valign="middle">Stock Price </td><td style="width:90.2pt" valign="middle">$0.06 </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:94.35pt" valign="middle">$0.048 </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:90.2pt" valign="middle">$0.04 </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:94.35pt" valign="middle">$ 0.043-0.066 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:107.25pt" valign="middle">Exercise Price </td><td style="background-color:#CCFFCC;width:90.2pt" valign="middle">$ 0.017-0.05 </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:94.35pt" valign="middle">$0.045 </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:90.2pt" valign="middle">$ 0.0224-0.05 </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:94.35pt" valign="middle">$ 0.0224-0.05 </td></tr> <tr style="height:7.2pt"><td style="width:107.25pt" valign="middle">Expected Life </td><td style="width:90.2pt" valign="middle">0 </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:94.35pt" valign="middle">0.75 </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:90.2pt" valign="middle">0 - 0.59 </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:94.35pt" valign="middle">1.0 - 1.2 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:107.25pt" valign="middle">Volatility </td><td style="background-color:#CCFFCC;width:90.2pt" valign="middle">133% </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:94.35pt" valign="middle">145% </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:90.2pt" valign="middle">168% </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:94.35pt" valign="middle">194.52 - 197.12% </td></tr> <tr style="height:7.2pt"><td style="width:107.25pt" valign="middle">Dividend Yield </td><td style="width:90.2pt" valign="middle">0% </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:94.35pt" valign="middle">0% </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:90.2pt" valign="middle">0% </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:94.35pt" valign="middle">0% </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:107.25pt" valign="middle">Risk-Free Interest Rate </td><td style="background-color:#CCFFCC;width:90.2pt" valign="middle">5.44% </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:94.35pt" valign="middle">4.57% </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:90.2pt" valign="middle">4.02% </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:94.35pt" valign="middle">0.53 - 0.61% </td></tr> <tr style="height:7.2pt"><td style="width:107.25pt" valign="middle">Convertible Notes </td><td style="width:90.2pt" valign="bottom"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt">595,638</kbd> </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:94.35pt" valign="bottom"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt">388,888</kbd> </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:90.2pt" valign="bottom"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt">317,285</kbd> </td><td style="width:14.4pt" valign="bottom"> </td><td style="width:94.35pt" valign="bottom"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt">356,000</kbd> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:107.25pt" valign="middle">Total Fair Value </td><td style="background-color:#CCFFCC;width:90.2pt" valign="bottom"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt">154,153</kbd> </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:94.35pt" valign="bottom"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt">174,234</kbd> </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:90.2pt" valign="bottom"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:72pt">102,011</kbd> </td><td style="background-color:#CCFFCC;width:14.4pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:94.35pt" valign="bottom"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt">273,906</kbd> </td></tr> </table> 0.06 0.048 0.04 0.043 0.066 0.017 0.05 0.045 0.0224 0.05 0.0224 0.05 P0Y P0Y9M P0Y P1Y 1.33 1.45 1.68 1.9452 1.9712 0 0 0 0 0.0544 0.0457 0.0402 0.0053 0.0061 595638 388888 317285 356000 154153 174234 102011 273906 212199 83920 38172 The change in Level 3 financial instrument fair value is as follows: <table style="margin:0 auto;border-collapse:collapse"><tr><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Balance, December 31, 2021 </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt;border-bottom:3px double #000000" valign="top">$ 92,527 </td></tr> <tr><td style="width:302.4pt" valign="top">Issued during the year ended December 31, 2022 </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt;border-top:3px double #000000" valign="top">264,952 </td></tr> <tr><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Derivative liabilities debt premium </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt" valign="top"> (43,269) </td></tr> <tr><td style="width:302.4pt" valign="top">Change in fair value recognized in operations </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt" valign="top">(212,199) </td></tr> <tr><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Converted during the year ended December 31, 2022 </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt;border-bottom:0.5pt solid #000000" valign="top">(0) </td></tr> <tr><td style="width:302.4pt" valign="top">Balance, December 31, 2022 </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"> $ 102,011 </td></tr> <tr><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Issued during the year ended December 31, 2023 </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt" valign="top">145,067 </td></tr> <tr><td style="width:302.4pt" valign="top">Derivative liabilities debt discount </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt" valign="top">29,167 </td></tr> <tr><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Change in fair value recognized in operations </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt" valign="top">(83,923) </td></tr> <tr><td style="width:302.4pt" valign="top">Converted during the year ended December 31, 2023 </td><td style="width:16.8pt" valign="top"> </td><td style="width:89.8pt;border-bottom:0.5pt solid #000000" valign="top">(38,172) </td></tr> <tr><td style="background-color:#CCFFCC;width:302.4pt" valign="top">Balance, December 31, 2023 </td><td style="background-color:#CCFFCC;width:16.8pt" valign="top"> </td><td style="background-color:#CCFFCC;width:89.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"> $ 154,150 </td></tr> </table> 92527 264952 -43269 -212199 0 102011 145067 29167 -83923 -38172 154150 NOTE 9 – INCOME TAXES The effective income tax rate for the years ended December 31, 2023 and 2022 differs from the U.S. Federal statutory rate due to the following: <table style="border-collapse:collapse"><tr style="height:7.2pt"><td style="width:270pt" valign="bottom"></td><td style="width:13.5pt" valign="bottom"> </td><td style="width:85.5pt;border-bottom:0.5pt solid #000000" valign="middle">December 2023 </td><td style="width:13.1pt" valign="bottom"> </td><td style="width:85.9pt;border-bottom:0.5pt solid #000000" valign="middle">December 2022 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:270pt" valign="middle">Federal statutory income tax rate </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:85.5pt" valign="middle"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">678,297 </kbd> </td><td style="background-color:#CCFFCC;width:13.1pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:85.9pt" valign="middle"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">(166,169)</kbd> </td></tr> <tr style="height:7.2pt"><td style="width:270pt" valign="middle">Change in valuation allowance </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:85.5pt;border-bottom:0.5pt solid #000000" valign="middle"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">(678,297)</kbd> </td><td style="width:13.1pt" valign="bottom"> </td><td style="width:85.9pt;border-bottom:0.5pt solid #000000" valign="middle"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">166,169 </kbd> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:270pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:85.5pt;border-bottom:3px double #000000" valign="middle"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">- </kbd> </td><td style="background-color:#CCFFCC;width:13.1pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:85.9pt;border-bottom:3px double #000000" valign="middle"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">- </kbd> </td></tr> </table> The components of the deferred tax assets and liabilities at December 31, 2023 and 2022 are as follows: <table style="border-collapse:collapse"><tr style="height:7.2pt"><td style="width:270pt" valign="bottom"></td><td style="width:13.5pt" valign="bottom"> </td><td style="width:85.5pt;border-bottom:0.5pt solid #000000" valign="middle">December 2023 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:85.5pt;border-bottom:0.5pt solid #000000" valign="middle">December 2022 </td></tr> <tr style="height:7.2pt"><td style="width:270pt" valign="middle">Long-term deferred tax assets: </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:85.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:85.5pt" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:270pt" valign="middle"> Federal net operating loss carryforwards </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:85.5pt" valign="middle"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">678,297 </kbd> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:85.5pt" valign="middle"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">166,169 </kbd> </td></tr> <tr style="height:7.2pt"><td style="width:270pt" valign="middle"> Valuation allowance </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:85.5pt;border-bottom:0.5pt solid #000000" valign="middle"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">(678,297)</kbd> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:85.5pt;border-bottom:0.5pt solid #000000" valign="middle"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">(166,169)</kbd> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:270pt" valign="middle">Net long-term deferred tax assets </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:85.5pt;border-bottom:3px double #000000" valign="middle"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">- </kbd> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:85.5pt;border-bottom:3px double #000000" valign="middle"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">- </kbd> </td></tr> </table> <table style="border-collapse:collapse"><tr style="height:7.2pt"><td style="width:270pt" valign="bottom"></td><td style="width:13.5pt" valign="bottom"> </td><td style="width:85.5pt;border-bottom:0.5pt solid #000000" valign="middle">December 2023 </td><td style="width:13.1pt" valign="bottom"> </td><td style="width:85.9pt;border-bottom:0.5pt solid #000000" valign="middle">December 2022 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:270pt" valign="middle">Federal statutory income tax rate </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:85.5pt" valign="middle"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">678,297 </kbd> </td><td style="background-color:#CCFFCC;width:13.1pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:85.9pt" valign="middle"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">(166,169)</kbd> </td></tr> <tr style="height:7.2pt"><td style="width:270pt" valign="middle">Change in valuation allowance </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:85.5pt;border-bottom:0.5pt solid #000000" valign="middle"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">(678,297)</kbd> </td><td style="width:13.1pt" valign="bottom"> </td><td style="width:85.9pt;border-bottom:0.5pt solid #000000" valign="middle"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">166,169 </kbd> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:270pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:85.5pt;border-bottom:3px double #000000" valign="middle"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">- </kbd> </td><td style="background-color:#CCFFCC;width:13.1pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:85.9pt;border-bottom:3px double #000000" valign="middle"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">- </kbd> </td></tr> </table> 678297 -166169 -678297 166169 0 0 <table style="border-collapse:collapse"><tr style="height:7.2pt"><td style="width:270pt" valign="bottom"></td><td style="width:13.5pt" valign="bottom"> </td><td style="width:85.5pt;border-bottom:0.5pt solid #000000" valign="middle">December 2023 </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:85.5pt;border-bottom:0.5pt solid #000000" valign="middle">December 2022 </td></tr> <tr style="height:7.2pt"><td style="width:270pt" valign="middle">Long-term deferred tax assets: </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:85.5pt" valign="bottom"> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:85.5pt" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:270pt" valign="middle"> Federal net operating loss carryforwards </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:85.5pt" valign="middle"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">678,297 </kbd> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:85.5pt" valign="middle"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">166,169 </kbd> </td></tr> <tr style="height:7.2pt"><td style="width:270pt" valign="middle"> Valuation allowance </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:85.5pt;border-bottom:0.5pt solid #000000" valign="middle"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">(678,297)</kbd> </td><td style="width:13.5pt" valign="bottom"> </td><td style="width:85.5pt;border-bottom:0.5pt solid #000000" valign="middle"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">(166,169)</kbd> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:270pt" valign="middle">Net long-term deferred tax assets </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:85.5pt;border-bottom:3px double #000000" valign="middle"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">- </kbd> </td><td style="background-color:#CCFFCC;width:13.5pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:85.5pt;border-bottom:3px double #000000" valign="middle"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:68pt">- </kbd> </td></tr> </table> 678297 166169 678297 166169 0 0 NOTE 10 – STOCKHOLDERS’ EQUITY Authorized Stock The Company has authorized 75,000,000 common shares with a par value of $0.001 per share. Each common share entitles the holder to one vote on any matter on which action of the stockholders of the corporation is sought. During February 2017, the Company increased the authorized number of shares to 500,000,000. Also, the Company increased the authorized preferred stock to 75,000,000 shares and designated 25,000,000 shares of preferred stock to Series A Convertible Preferred Stock. During January 2018, the Company increased its authorized number of common shares to 1,000,000,000. During April 2018, the Company increased its authorized number of common shares to 2,500,000,000. The Board of Directors, in the future, has the authority to increase the authorized capital up to 4,000,000,000 shares based on shareholder approval. On December 29, 2023 the Company decreased its authorized number of common shares to 50,000,000. The Company effectuated a reverse stock split of 120-for-1 as of December 29, 2023. On October 16, 2017, the Company filed an Amended and Restated Certificate of Designation of the Rights, Preferences, Privileges and Restrictions of the Series A Convertible Preferred Stock (the “Amended Certificate”) with the Secretary of State of the State of Nevada. The Amended Certificate reduces the number of preferred shares designated as Series A Preferred Stock from 25,000,000 shares to 1,333,334 shares. The Amended Certificate also changes the conversion and voting rights of the Series A Preferred Stock. The Series A Preferred Stock is now convertible into the number of shares of our common stock equal to 0.00006% of our outstanding common stock upon conversion. The voting rights of the Series A Preferred Stock are now equal to the number of shares of common stock into which the Series A Preferred Stock may convert. As of December 31, 2023, there are no outstanding shares of preferred stock. All the preferred stock was converted in common stock on February 4, 2019. Common Share Issuances During the months ended March 31, 2023, the Company issued 320,000 shares of common stock. During the months ended June 30, 2023, the Company did not issue any shares of common stock. During the months ended September 30, 2023, the Company issued 9,000,000 shares of common stock for the Restricted Stock Units which were executed. The holders paid the Company $0.01 for each share of common stock and the value of each share was $0.05. There were no shares issued during the fourth quarter 2023. There were no shares issued during the fourth quarter 2022. During the third quarter 2022, the Company issued 340,000 shares of common stock for consulting fees along with issuing 340,621 shares of common stock to convert an outstanding note payable to a shareholder. On May 19, 2022, the Company issued 4,400,000 shares of common stock for broker and consulting fees. On April 22 and 25, 2022, the Company issued 2,000,000 shares of common stock for broker and funding fees. On February 4, 2022, the Company issued 507,917 shares of common stock in a direct security purchase agreement. On January 10, 2022, the Company cancelled 200,267 shares of common stock. Further, on March 4, 2022, the Company cancelled 600,000 shares of common stock. Warrant Issuances During the month ending March 31, 2023, the Company issued 61,846 warrants to 2 unrelated parties at a per share price of $5.6592. On February 2, 2022, the Company issued 16,667 warrants to an individual at a per share price of $6.00. As of December 31, 2023, there were 195,180 warrants outstanding, of which 195,180 warrants are fully vested. <table style="border-collapse:collapse;width:496pt"><tr style="height:7.2pt"><td style="width:237pt" valign="bottom"> </td><td style="width:57pt" valign="bottom"> </td><td style="width:66pt" valign="bottom"> </td><td style="width:70pt" valign="middle">Weighted- </td><td style="width:66pt" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="width:237pt" valign="bottom"> </td><td style="width:57pt" valign="bottom"> </td><td style="width:66pt" valign="middle">Weighted- </td><td style="width:70pt" valign="middle">Average </td><td style="width:66pt" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="width:237pt" valign="bottom"> </td><td style="width:57pt" valign="bottom"> </td><td style="width:66pt" valign="middle">Average </td><td style="width:70pt" valign="middle">Remaining </td><td style="width:66pt" valign="middle">Aggregate </td></tr> <tr style="height:7.2pt"><td style="width:237pt" valign="bottom"> </td><td style="width:57pt" valign="bottom"> </td><td style="width:66pt" valign="middle">Exercise </td><td style="width:70pt" valign="middle">Contractual </td><td style="width:66pt" valign="middle">Intrinsic </td></tr> <tr style="height:7.2pt"><td style="width:237pt" valign="bottom"> </td><td style="width:57pt;border-bottom:0.5pt solid #000000" valign="middle">Warrants </td><td style="width:66pt;border-bottom:0.5pt solid #000000" valign="middle">Price </td><td style="width:70pt;border-bottom:0.5pt solid #000000" valign="middle">Life (Years) </td><td style="width:66pt;border-bottom:0.5pt solid #000000" valign="middle">Value </td></tr> <tr style="height:7.2pt"><td style="width:237pt" valign="bottom"> </td><td style="width:57pt" valign="bottom"> </td><td style="width:66pt" valign="bottom"> </td><td style="width:70pt" valign="bottom"> </td><td style="width:66pt" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:237pt" valign="middle">Outstanding at December 31, 2022 </td><td style="background-color:#CCFFCC;width:57pt" valign="middle">133,333 </td><td style="background-color:#CCFFCC;width:66pt" valign="middle">$7.22 </td><td style="background-color:#CCFFCC;width:70pt" valign="middle">2.17 </td><td style="background-color:#CCFFCC;width:66pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:237pt" valign="middle">Granted </td><td style="width:57pt" valign="middle">61,846 </td><td style="width:66pt" valign="middle">6.00 </td><td style="width:70pt" valign="middle">1.11 </td><td style="width:66pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:237pt" valign="middle">Forfeited </td><td style="background-color:#CCFFCC;width:57pt" valign="middle"> - </td><td style="background-color:#CCFFCC;width:66pt" valign="middle"> - </td><td style="background-color:#CCFFCC;width:70pt" valign="middle"> - </td><td style="background-color:#CCFFCC;width:66pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:237pt" valign="middle">Exercised </td><td style="width:57pt;border-bottom:0.5pt solid #000000" valign="middle"> - </td><td style="width:66pt;border-bottom:0.5pt solid #000000" valign="middle"> - </td><td style="width:70pt;border-bottom:0.5pt solid #000000" valign="middle"> - </td><td style="width:66pt;border-bottom:0.5pt solid #000000" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:237pt" valign="middle">Outstanding at December 31, 2023 </td><td style="background-color:#CCFFCC;width:57pt;border-bottom:3px double #000000" valign="middle">195,180 </td><td style="background-color:#CCFFCC;width:66pt;border-bottom:3px double #000000" valign="middle">$6.83 </td><td style="background-color:#CCFFCC;width:70pt;border-bottom:3px double #000000" valign="middle">1.17 </td><td style="background-color:#CCFFCC;width:66pt;border-bottom:3px double #000000" valign="middle"> $ - </td></tr> <tr style="height:7.2pt"><td style="width:237pt" valign="bottom"> </td><td style="width:57pt" valign="bottom"> </td><td style="width:66pt" valign="bottom"> </td><td style="width:70pt" valign="bottom"> </td><td style="width:66pt" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:237pt" valign="middle">Vested and expected to vest at December 31, 2023 </td><td style="background-color:#CCFFCC;width:57pt;border-bottom:3px double #000000" valign="middle">195,180 </td><td style="background-color:#CCFFCC;width:66pt;border-bottom:3px double #000000" valign="middle">$6.83 </td><td style="background-color:#CCFFCC;width:70pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:66pt;border-bottom:3px double #000000" valign="middle"> $ - </td></tr> <tr style="height:7.2pt"><td style="width:237pt" valign="bottom"> </td><td style="width:57pt" valign="bottom"> </td><td style="width:66pt" valign="bottom"> </td><td style="width:70pt" valign="bottom"> </td><td style="width:66pt" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:237pt" valign="middle">Exercisable at December 31, 2023 </td><td style="background-color:#CCFFCC;width:57pt;border-bottom:3px double #000000" valign="middle">195,180 </td><td style="background-color:#CCFFCC;width:66pt;border-bottom:3px double #000000" valign="middle">$6.83 </td><td style="background-color:#CCFFCC;width:70pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:66pt;border-bottom:3px double #000000" valign="middle"> $ - </td></tr> </table> At December 31, 2023, the intrinsic value of these stock warrants was $0 as the exercise price of these stock warrants were greater than the market price. Stock Issued for Services On March 6, 2023, the Company issued 320,000 shares of common stock for consulting fees at a per share price of $0.05. On September 13, 2022, the Company issued 340,000 shares of common stock for consulting fees at a per share price of $0.05. During the period ending June 30, 2022, the Company issued 6,400,000 shares of common stock for broker, consulting, and funding fees at a per share price of $0.05. Share Conversion Agreements All of the holders of the Company’s Series A Convertible Preferred Stock (the “Preferred Holders”) entered into a Preferred Stock Conversion Agreement. Pursuant to the Conversion Agreements, the Preferred Holders converted their shares of preferred stock into common stock, effective as of the Exchange. As a result, no shares of the Company’s Series A Convertible Preferred Stock are outstanding. An aggregate of 15,592,986 shares of common stock were issued to the Preferred Holders. The Preferred Holders agreed to convert each share of Series A Convertible Preferred Stock into eighteen (18) shares of common stock and agreed to retire a total of 467,057 shares of Series A Convertible Preferred Stock. The Company cancelled the retired shares. Omnibus Stock Grant and Option Plan On December 31, 2021, the Company approved stock option agreements in the amount of 7,500,000 shares with a strike price of $0.05 to twenty-one individuals. These options are immediately vest and will expire in five years. The following summary of options activity for the year ended December 31, 2023 is presented below: <table style="border-collapse:collapse;width:100%"><tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:48.78%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.72%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.02%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:14.64%" valign="middle">Weighted- </td><td style="background-color:#CCFFCC;width:12.84%" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:48.78%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.72%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.02%" valign="middle">Weighted- </td><td style="background-color:#CCFFCC;width:14.64%" valign="middle">Average </td><td style="background-color:#CCFFCC;width:12.84%" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:48.78%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.72%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.02%" valign="middle">Average </td><td style="background-color:#CCFFCC;width:14.64%" valign="middle">Remaining </td><td style="background-color:#CCFFCC;width:12.84%" valign="middle">Aggregate </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:48.78%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.72%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.02%" valign="middle">Exercise </td><td style="background-color:#CCFFCC;width:14.64%" valign="middle">Contractual </td><td style="background-color:#CCFFCC;width:12.84%" valign="middle">Intrinsic </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:48.78%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.72%;border-bottom:0.5pt solid #000000" valign="middle">Options </td><td style="background-color:#CCFFCC;width:13.02%;border-bottom:0.5pt solid #000000" valign="middle">Price </td><td style="background-color:#CCFFCC;width:14.64%;border-bottom:0.5pt solid #000000" valign="middle">Life (Years) </td><td style="background-color:#CCFFCC;width:12.84%;border-bottom:0.5pt solid #000000" valign="middle">Value </td></tr> <tr style="height:7.2pt"><td style="width:48.78%" valign="bottom"> </td><td style="width:10.72%" valign="bottom"> </td><td style="width:13.02%" valign="bottom"> </td><td style="width:14.64%" valign="bottom"> </td><td style="width:12.84%" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:48.78%" valign="middle">Outstanding at December 31, 2022 </td><td style="background-color:#CCFFCC;width:10.72%" valign="middle">32,083 </td><td style="background-color:#CCFFCC;width:13.02%" valign="middle">$6.00 </td><td style="background-color:#CCFFCC;width:14.64%" valign="middle">2.13 </td><td style="background-color:#CCFFCC;width:12.84%" valign="middle">38,500 </td></tr> <tr style="height:7.2pt"><td style="width:48.78%" valign="middle">Granted </td><td style="width:10.72%" valign="middle">6,250 </td><td style="width:13.02%" valign="middle">6.00 </td><td style="width:14.64%" valign="middle">3.42 </td><td style="width:12.84%" valign="middle">7,500 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:48.78%" valign="middle">Forfeited </td><td style="background-color:#CCFFCC;width:10.72%" valign="middle"> - </td><td style="background-color:#CCFFCC;width:13.02%" valign="middle"> - </td><td style="background-color:#CCFFCC;width:14.64%" valign="middle"> - </td><td style="background-color:#CCFFCC;width:12.84%" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:48.78%" valign="middle">Exercised </td><td style="width:10.72%;border-bottom:0.5pt solid #000000" valign="middle"> - </td><td style="width:13.02%;border-bottom:0.5pt solid #000000" valign="middle"> - </td><td style="width:14.64%;border-bottom:0.5pt solid #000000" valign="middle"> - </td><td style="width:12.84%;border-bottom:0.5pt solid #000000" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:48.78%" valign="middle">Outstanding at December 31, 2023 </td><td style="background-color:#CCFFCC;width:10.72%;border-bottom:3px double #000000" valign="middle">38,333 </td><td style="background-color:#CCFFCC;width:13.02%;border-bottom:3px double #000000" valign="middle">$6.00 </td><td style="background-color:#CCFFCC;width:14.64%;border-bottom:3px double #000000" valign="middle">2.34 </td><td style="background-color:#CCFFCC;width:12.84%;border-bottom:3px double #000000" valign="middle">$46,000 </td></tr> <tr style="height:7.2pt"><td style="width:48.78%" valign="bottom"> </td><td style="width:10.72%" valign="bottom"> </td><td style="width:13.02%" valign="bottom"> </td><td style="width:14.64%" valign="bottom"> </td><td style="width:12.84%" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:48.78%" valign="middle">Vested and expected to vest at December 31, 2023 </td><td style="background-color:#CCFFCC;width:10.72%;border-bottom:3px double #000000" valign="middle">38,333 </td><td style="background-color:#CCFFCC;width:13.02%;border-bottom:3px double #000000" valign="middle">$6.00 </td><td style="background-color:#CCFFCC;width:14.64%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:12.84%;border-bottom:3px double #000000" valign="middle">$46,000 </td></tr> <tr style="height:7.2pt"><td style="width:48.78%" valign="middle">Exercisable at December 31, 2023 </td><td style="width:10.72%;border-bottom:3px double #000000" valign="middle">38,333 </td><td style="width:13.02%;border-bottom:3px double #000000" valign="middle">$6.00 </td><td style="width:14.64%" valign="bottom"> </td><td style="width:12.84%;border-bottom:3px double #000000" valign="middle">$46,000 </td></tr> </table> At December 31, 2023, the intrinsic value of these stock options was $46,000 as the exercise price of these stock options were less than the market price. On December 26, 2022, the Company canceled 101,250 stock options with a strike price of $6.00. The following summary of restricted stock units’ activity for the three months ended December 31, 2023 is presented below: <table style="border-collapse:collapse;width:468.2pt"><tr style="height:7.2pt"><td style="width:224.65pt" valign="middle"> </td><td style="width:58.85pt" valign="middle"> </td><td colspan="2" style="width:68.7pt" valign="middle"> </td><td style="width:17.7pt" valign="middle"> </td><td style="width:20.3pt" valign="middle"> </td><td colspan="2" style="width:78pt" valign="middle">Weighted- </td></tr> <tr style="height:7.2pt"><td style="width:224.65pt" valign="middle"> </td><td style="width:58.85pt" valign="middle"> </td><td colspan="2" style="width:68.7pt" valign="middle"> </td><td style="width:17.7pt" valign="middle"> </td><td style="width:20.3pt" valign="middle"> </td><td colspan="2" style="width:78pt" valign="middle">Weighted- </td></tr> <tr style="height:7.2pt"><td style="width:224.65pt" valign="middle"> </td><td style="width:58.85pt" valign="middle"> </td><td colspan="2" style="width:68.7pt" valign="middle"> </td><td style="width:17.7pt" valign="middle"> </td><td style="width:20.3pt" valign="middle"> </td><td colspan="2" style="width:78pt" valign="middle">Average </td></tr> <tr style="height:7.2pt"><td style="width:224.65pt" valign="middle"> </td><td style="width:58.85pt" valign="middle"> </td><td colspan="2" style="width:68.7pt" valign="middle"> </td><td style="width:17.7pt" valign="middle"> </td><td style="width:20.3pt" valign="middle"> </td><td colspan="2" style="width:78pt" valign="middle">Grant Date </td></tr> <tr style="height:7.2pt"><td style="width:224.65pt" valign="middle"> </td><td style="width:58.85pt" valign="middle"> </td><td colspan="2" style="width:68.7pt;border-bottom:0.5pt solid #000000" valign="middle">Shares </td><td style="width:17.7pt" valign="middle"> </td><td style="width:20.3pt" valign="middle"> </td><td colspan="2" style="width:78pt;border-bottom:0.5pt solid #000000" valign="middle">Fair Value </td></tr> <tr style="height:7.2pt"><td style="width:224.65pt" valign="middle"> </td><td style="width:58.85pt" valign="middle"> </td><td colspan="2" style="width:68.7pt" valign="middle"> </td><td style="width:17.7pt" valign="middle"> </td><td style="width:20.3pt" valign="middle"> </td><td colspan="2" style="width:78pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:224.65pt" valign="middle">Non-vested at December 31, 2022 </td><td style="background-color:#CCFFCC;width:58.85pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:11.8pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:56.9pt" valign="middle">- </td><td style="background-color:#CCFFCC;width:17.7pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:20.3pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:19.3pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:58.7pt" valign="middle">- </td></tr> <tr style="height:7.2pt"><td style="background-color:#FFFFFF;width:224.65pt" valign="middle">Granted </td><td style="background-color:#FFFFFF;width:58.85pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:11.8pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:56.9pt" valign="middle">133,125 </td><td style="background-color:#FFFFFF;width:17.7pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:20.3pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:19.3pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:58.7pt" valign="middle">6.00 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:224.65pt" valign="middle">Vested </td><td style="background-color:#CCFFCC;width:58.85pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:11.8pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:56.9pt" valign="middle">(74,167) </td><td style="background-color:#CCFFCC;width:17.7pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:20.3pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:19.3pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:58.7pt" valign="middle">6.00 </td></tr> <tr style="height:7.2pt"><td style="background-color:#FFFFFF;width:224.65pt" valign="middle">Forfeited </td><td style="background-color:#FFFFFF;width:58.85pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:11.8pt;border-bottom:0.5pt solid #000000" valign="middle"> </td><td style="background-color:#FFFFFF;width:56.9pt;border-bottom:0.5pt solid #000000" valign="middle">- </td><td style="background-color:#FFFFFF;width:17.7pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:20.3pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:19.3pt;border-bottom:0.5pt solid #000000" valign="middle"> </td><td style="background-color:#FFFFFF;width:58.7pt;border-bottom:0.5pt solid #000000" valign="middle">- </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:224.65pt" valign="middle">Non-vested at December 31, 2023 </td><td style="background-color:#CCFFCC;width:58.85pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:11.8pt;border-bottom:3px double #000000" valign="middle"> </td><td style="background-color:#CCFFCC;width:56.9pt;border-bottom:3px double #000000" valign="middle">58,958 </td><td style="background-color:#CCFFCC;width:17.7pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:20.3pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:19.3pt;border-bottom:3px double #000000" valign="middle"> </td><td style="background-color:#CCFFCC;width:58.7pt;border-bottom:3px double #000000" valign="middle">6.00 </td></tr> </table> The total fair value of restricted stock units vested during the three months ended September 30, 2023 was $445,000 and is included in selling, general and administrative expenses in the accompanying consolidation statements of operations. As of December 31, 2023, the amount of unvested compensation related to issuances of restricted stock units’ fair value was $423,910. This amount will be amortized and expensed over the life of the contract and will be included in selling, general and administrative expenses in the accompanying consolidation statements of operations. The fair value of share options, units, and warrants are estimated using the Black-Scholes option pricing method based on the following weighted-average assumptions: <table style="margin:0 auto;border-collapse:collapse;width:385pt"><tr style="height:7.2pt"><td style="width:146.55pt" valign="middle"> </td><td style="width:13.3pt" valign="middle"> </td><td colspan="6" style="width:206pt;border-bottom:0.5pt solid #000000" valign="middle">Year Ending December 31, </td><td style="width:19.15pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="width:146.55pt" valign="middle"></td><td style="width:13.3pt" valign="middle"> </td><td colspan="2" style="width:84.95pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="middle">2023 </td><td style="width:19.15pt" valign="middle"> </td><td style="width:13.3pt" valign="middle"> </td><td colspan="2" style="width:88.6pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="middle">2022 </td><td style="width:19.15pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:146.55pt" valign="middle">Risk-free interest rate </td><td style="background-color:#CCFFCC;width:13.3pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:15.65pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:69.3pt" valign="middle">5.18 </td><td style="background-color:#CCFFCC;width:19.15pt" valign="middle">% </td><td style="background-color:#CCFFCC;width:13.3pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:15.25pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:73.35pt" valign="middle">2.75 </td><td style="background-color:#CCFFCC;width:19.15pt" valign="middle">% </td></tr> <tr style="height:7.2pt"><td style="background-color:#FFFFFF;width:146.55pt" valign="middle">Average expected term (years) </td><td style="background-color:#FFFFFF;width:13.3pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:15.65pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:69.3pt" valign="middle">4.7 years </td><td style="background-color:#FFFFFF;width:19.15pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:13.3pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:15.25pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:73.35pt" valign="middle">4.75 years </td><td style="background-color:#FFFFFF;width:19.15pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:146.55pt" valign="middle">Expected volatility </td><td style="background-color:#CCFFCC;width:13.3pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:15.65pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:69.3pt" valign="middle">106.5 </td><td style="background-color:#CCFFCC;width:19.15pt" valign="middle">% </td><td style="background-color:#CCFFCC;width:13.3pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:15.25pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:73.35pt" valign="middle">194.8 </td><td style="background-color:#CCFFCC;width:19.15pt" valign="middle">% </td></tr> <tr style="height:7.2pt"><td style="background-color:#FFFFFF;width:146.55pt" valign="middle">Expected dividend yield </td><td style="background-color:#FFFFFF;width:13.3pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:15.65pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:69.3pt" valign="middle">- </td><td style="background-color:#FFFFFF;width:19.15pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:13.3pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:15.25pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:73.35pt" valign="middle">- </td><td style="background-color:#FFFFFF;width:19.15pt" valign="middle"> </td></tr> </table> 75000000 0.001 0.001 500000000 75000000 25000000 1000000000 2500000000 50000000 50000000 The Company effectuated a reverse stock split of 120-for-1 as of December 29, 2023 25000000 1333334 0 320000 340000 340621 4400000 507917 -200267 -600000 61846 16667 195180 195180 <table style="border-collapse:collapse;width:496pt"><tr style="height:7.2pt"><td style="width:237pt" valign="bottom"> </td><td style="width:57pt" valign="bottom"> </td><td style="width:66pt" valign="bottom"> </td><td style="width:70pt" valign="middle">Weighted- </td><td style="width:66pt" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="width:237pt" valign="bottom"> </td><td style="width:57pt" valign="bottom"> </td><td style="width:66pt" valign="middle">Weighted- </td><td style="width:70pt" valign="middle">Average </td><td style="width:66pt" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="width:237pt" valign="bottom"> </td><td style="width:57pt" valign="bottom"> </td><td style="width:66pt" valign="middle">Average </td><td style="width:70pt" valign="middle">Remaining </td><td style="width:66pt" valign="middle">Aggregate </td></tr> <tr style="height:7.2pt"><td style="width:237pt" valign="bottom"> </td><td style="width:57pt" valign="bottom"> </td><td style="width:66pt" valign="middle">Exercise </td><td style="width:70pt" valign="middle">Contractual </td><td style="width:66pt" valign="middle">Intrinsic </td></tr> <tr style="height:7.2pt"><td style="width:237pt" valign="bottom"> </td><td style="width:57pt;border-bottom:0.5pt solid #000000" valign="middle">Warrants </td><td style="width:66pt;border-bottom:0.5pt solid #000000" valign="middle">Price </td><td style="width:70pt;border-bottom:0.5pt solid #000000" valign="middle">Life (Years) </td><td style="width:66pt;border-bottom:0.5pt solid #000000" valign="middle">Value </td></tr> <tr style="height:7.2pt"><td style="width:237pt" valign="bottom"> </td><td style="width:57pt" valign="bottom"> </td><td style="width:66pt" valign="bottom"> </td><td style="width:70pt" valign="bottom"> </td><td style="width:66pt" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:237pt" valign="middle">Outstanding at December 31, 2022 </td><td style="background-color:#CCFFCC;width:57pt" valign="middle">133,333 </td><td style="background-color:#CCFFCC;width:66pt" valign="middle">$7.22 </td><td style="background-color:#CCFFCC;width:70pt" valign="middle">2.17 </td><td style="background-color:#CCFFCC;width:66pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:237pt" valign="middle">Granted </td><td style="width:57pt" valign="middle">61,846 </td><td style="width:66pt" valign="middle">6.00 </td><td style="width:70pt" valign="middle">1.11 </td><td style="width:66pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:237pt" valign="middle">Forfeited </td><td style="background-color:#CCFFCC;width:57pt" valign="middle"> - </td><td style="background-color:#CCFFCC;width:66pt" valign="middle"> - </td><td style="background-color:#CCFFCC;width:70pt" valign="middle"> - </td><td style="background-color:#CCFFCC;width:66pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:237pt" valign="middle">Exercised </td><td style="width:57pt;border-bottom:0.5pt solid #000000" valign="middle"> - </td><td style="width:66pt;border-bottom:0.5pt solid #000000" valign="middle"> - </td><td style="width:70pt;border-bottom:0.5pt solid #000000" valign="middle"> - </td><td style="width:66pt;border-bottom:0.5pt solid #000000" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:237pt" valign="middle">Outstanding at December 31, 2023 </td><td style="background-color:#CCFFCC;width:57pt;border-bottom:3px double #000000" valign="middle">195,180 </td><td style="background-color:#CCFFCC;width:66pt;border-bottom:3px double #000000" valign="middle">$6.83 </td><td style="background-color:#CCFFCC;width:70pt;border-bottom:3px double #000000" valign="middle">1.17 </td><td style="background-color:#CCFFCC;width:66pt;border-bottom:3px double #000000" valign="middle"> $ - </td></tr> <tr style="height:7.2pt"><td style="width:237pt" valign="bottom"> </td><td style="width:57pt" valign="bottom"> </td><td style="width:66pt" valign="bottom"> </td><td style="width:70pt" valign="bottom"> </td><td style="width:66pt" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:237pt" valign="middle">Vested and expected to vest at December 31, 2023 </td><td style="background-color:#CCFFCC;width:57pt;border-bottom:3px double #000000" valign="middle">195,180 </td><td style="background-color:#CCFFCC;width:66pt;border-bottom:3px double #000000" valign="middle">$6.83 </td><td style="background-color:#CCFFCC;width:70pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:66pt;border-bottom:3px double #000000" valign="middle"> $ - </td></tr> <tr style="height:7.2pt"><td style="width:237pt" valign="bottom"> </td><td style="width:57pt" valign="bottom"> </td><td style="width:66pt" valign="bottom"> </td><td style="width:70pt" valign="bottom"> </td><td style="width:66pt" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:237pt" valign="middle">Exercisable at December 31, 2023 </td><td style="background-color:#CCFFCC;width:57pt;border-bottom:3px double #000000" valign="middle">195,180 </td><td style="background-color:#CCFFCC;width:66pt;border-bottom:3px double #000000" valign="middle">$6.83 </td><td style="background-color:#CCFFCC;width:70pt" valign="bottom"> </td><td style="background-color:#CCFFCC;width:66pt;border-bottom:3px double #000000" valign="middle"> $ - </td></tr> </table> 133333 7.22 P2Y2M1D 0 61846 6.00 1.11 0 195180 6.83 P1Y2M1D 0 195180 6.83 0 195180 6.83 0 320000 340000 6400000 15592986 467057 The following summary of options activity for the year ended December 31, 2023 is presented below: <table style="border-collapse:collapse;width:100%"><tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:48.78%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.72%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.02%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:14.64%" valign="middle">Weighted- </td><td style="background-color:#CCFFCC;width:12.84%" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:48.78%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.72%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.02%" valign="middle">Weighted- </td><td style="background-color:#CCFFCC;width:14.64%" valign="middle">Average </td><td style="background-color:#CCFFCC;width:12.84%" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:48.78%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.72%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.02%" valign="middle">Average </td><td style="background-color:#CCFFCC;width:14.64%" valign="middle">Remaining </td><td style="background-color:#CCFFCC;width:12.84%" valign="middle">Aggregate </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:48.78%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.72%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:13.02%" valign="middle">Exercise </td><td style="background-color:#CCFFCC;width:14.64%" valign="middle">Contractual </td><td style="background-color:#CCFFCC;width:12.84%" valign="middle">Intrinsic </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:48.78%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:10.72%;border-bottom:0.5pt solid #000000" valign="middle">Options </td><td style="background-color:#CCFFCC;width:13.02%;border-bottom:0.5pt solid #000000" valign="middle">Price </td><td style="background-color:#CCFFCC;width:14.64%;border-bottom:0.5pt solid #000000" valign="middle">Life (Years) </td><td style="background-color:#CCFFCC;width:12.84%;border-bottom:0.5pt solid #000000" valign="middle">Value </td></tr> <tr style="height:7.2pt"><td style="width:48.78%" valign="bottom"> </td><td style="width:10.72%" valign="bottom"> </td><td style="width:13.02%" valign="bottom"> </td><td style="width:14.64%" valign="bottom"> </td><td style="width:12.84%" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:48.78%" valign="middle">Outstanding at December 31, 2022 </td><td style="background-color:#CCFFCC;width:10.72%" valign="middle">32,083 </td><td style="background-color:#CCFFCC;width:13.02%" valign="middle">$6.00 </td><td style="background-color:#CCFFCC;width:14.64%" valign="middle">2.13 </td><td style="background-color:#CCFFCC;width:12.84%" valign="middle">38,500 </td></tr> <tr style="height:7.2pt"><td style="width:48.78%" valign="middle">Granted </td><td style="width:10.72%" valign="middle">6,250 </td><td style="width:13.02%" valign="middle">6.00 </td><td style="width:14.64%" valign="middle">3.42 </td><td style="width:12.84%" valign="middle">7,500 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:48.78%" valign="middle">Forfeited </td><td style="background-color:#CCFFCC;width:10.72%" valign="middle"> - </td><td style="background-color:#CCFFCC;width:13.02%" valign="middle"> - </td><td style="background-color:#CCFFCC;width:14.64%" valign="middle"> - </td><td style="background-color:#CCFFCC;width:12.84%" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:48.78%" valign="middle">Exercised </td><td style="width:10.72%;border-bottom:0.5pt solid #000000" valign="middle"> - </td><td style="width:13.02%;border-bottom:0.5pt solid #000000" valign="middle"> - </td><td style="width:14.64%;border-bottom:0.5pt solid #000000" valign="middle"> - </td><td style="width:12.84%;border-bottom:0.5pt solid #000000" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:48.78%" valign="middle">Outstanding at December 31, 2023 </td><td style="background-color:#CCFFCC;width:10.72%;border-bottom:3px double #000000" valign="middle">38,333 </td><td style="background-color:#CCFFCC;width:13.02%;border-bottom:3px double #000000" valign="middle">$6.00 </td><td style="background-color:#CCFFCC;width:14.64%;border-bottom:3px double #000000" valign="middle">2.34 </td><td style="background-color:#CCFFCC;width:12.84%;border-bottom:3px double #000000" valign="middle">$46,000 </td></tr> <tr style="height:7.2pt"><td style="width:48.78%" valign="bottom"> </td><td style="width:10.72%" valign="bottom"> </td><td style="width:13.02%" valign="bottom"> </td><td style="width:14.64%" valign="bottom"> </td><td style="width:12.84%" valign="bottom"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:48.78%" valign="middle">Vested and expected to vest at December 31, 2023 </td><td style="background-color:#CCFFCC;width:10.72%;border-bottom:3px double #000000" valign="middle">38,333 </td><td style="background-color:#CCFFCC;width:13.02%;border-bottom:3px double #000000" valign="middle">$6.00 </td><td style="background-color:#CCFFCC;width:14.64%" valign="bottom"> </td><td style="background-color:#CCFFCC;width:12.84%;border-bottom:3px double #000000" valign="middle">$46,000 </td></tr> <tr style="height:7.2pt"><td style="width:48.78%" valign="middle">Exercisable at December 31, 2023 </td><td style="width:10.72%;border-bottom:3px double #000000" valign="middle">38,333 </td><td style="width:13.02%;border-bottom:3px double #000000" valign="middle">$6.00 </td><td style="width:14.64%" valign="bottom"> </td><td style="width:12.84%;border-bottom:3px double #000000" valign="middle">$46,000 </td></tr> </table> 32083 6.00 P2Y1M17D 38500 6250 6.00 3.42 7500 38333 6.00 P2Y4M2D 46000 38333 6.00 46000 38333 6.00 46000 <table style="border-collapse:collapse;width:468.2pt"><tr style="height:7.2pt"><td style="width:224.65pt" valign="middle"> </td><td style="width:58.85pt" valign="middle"> </td><td colspan="2" style="width:68.7pt" valign="middle"> </td><td style="width:17.7pt" valign="middle"> </td><td style="width:20.3pt" valign="middle"> </td><td colspan="2" style="width:78pt" valign="middle">Weighted- </td></tr> <tr style="height:7.2pt"><td style="width:224.65pt" valign="middle"> </td><td style="width:58.85pt" valign="middle"> </td><td colspan="2" style="width:68.7pt" valign="middle"> </td><td style="width:17.7pt" valign="middle"> </td><td style="width:20.3pt" valign="middle"> </td><td colspan="2" style="width:78pt" valign="middle">Weighted- </td></tr> <tr style="height:7.2pt"><td style="width:224.65pt" valign="middle"> </td><td style="width:58.85pt" valign="middle"> </td><td colspan="2" style="width:68.7pt" valign="middle"> </td><td style="width:17.7pt" valign="middle"> </td><td style="width:20.3pt" valign="middle"> </td><td colspan="2" style="width:78pt" valign="middle">Average </td></tr> <tr style="height:7.2pt"><td style="width:224.65pt" valign="middle"> </td><td style="width:58.85pt" valign="middle"> </td><td colspan="2" style="width:68.7pt" valign="middle"> </td><td style="width:17.7pt" valign="middle"> </td><td style="width:20.3pt" valign="middle"> </td><td colspan="2" style="width:78pt" valign="middle">Grant Date </td></tr> <tr style="height:7.2pt"><td style="width:224.65pt" valign="middle"> </td><td style="width:58.85pt" valign="middle"> </td><td colspan="2" style="width:68.7pt;border-bottom:0.5pt solid #000000" valign="middle">Shares </td><td style="width:17.7pt" valign="middle"> </td><td style="width:20.3pt" valign="middle"> </td><td colspan="2" style="width:78pt;border-bottom:0.5pt solid #000000" valign="middle">Fair Value </td></tr> <tr style="height:7.2pt"><td style="width:224.65pt" valign="middle"> </td><td style="width:58.85pt" valign="middle"> </td><td colspan="2" style="width:68.7pt" valign="middle"> </td><td style="width:17.7pt" valign="middle"> </td><td style="width:20.3pt" valign="middle"> </td><td colspan="2" style="width:78pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:224.65pt" valign="middle">Non-vested at December 31, 2022 </td><td style="background-color:#CCFFCC;width:58.85pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:11.8pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:56.9pt" valign="middle">- </td><td style="background-color:#CCFFCC;width:17.7pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:20.3pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:19.3pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:58.7pt" valign="middle">- </td></tr> <tr style="height:7.2pt"><td style="background-color:#FFFFFF;width:224.65pt" valign="middle">Granted </td><td style="background-color:#FFFFFF;width:58.85pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:11.8pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:56.9pt" valign="middle">133,125 </td><td style="background-color:#FFFFFF;width:17.7pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:20.3pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:19.3pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:58.7pt" valign="middle">6.00 </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:224.65pt" valign="middle">Vested </td><td style="background-color:#CCFFCC;width:58.85pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:11.8pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:56.9pt" valign="middle">(74,167) </td><td style="background-color:#CCFFCC;width:17.7pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:20.3pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:19.3pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:58.7pt" valign="middle">6.00 </td></tr> <tr style="height:7.2pt"><td style="background-color:#FFFFFF;width:224.65pt" valign="middle">Forfeited </td><td style="background-color:#FFFFFF;width:58.85pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:11.8pt;border-bottom:0.5pt solid #000000" valign="middle"> </td><td style="background-color:#FFFFFF;width:56.9pt;border-bottom:0.5pt solid #000000" valign="middle">- </td><td style="background-color:#FFFFFF;width:17.7pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:20.3pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:19.3pt;border-bottom:0.5pt solid #000000" valign="middle"> </td><td style="background-color:#FFFFFF;width:58.7pt;border-bottom:0.5pt solid #000000" valign="middle">- </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:224.65pt" valign="middle">Non-vested at December 31, 2023 </td><td style="background-color:#CCFFCC;width:58.85pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:11.8pt;border-bottom:3px double #000000" valign="middle"> </td><td style="background-color:#CCFFCC;width:56.9pt;border-bottom:3px double #000000" valign="middle">58,958 </td><td style="background-color:#CCFFCC;width:17.7pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:20.3pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:19.3pt;border-bottom:3px double #000000" valign="middle"> </td><td style="background-color:#CCFFCC;width:58.7pt;border-bottom:3px double #000000" valign="middle">6.00 </td></tr> </table> 0 0 133125 6.00 74167 6.00 58958 6.00 445000 423910 <table style="margin:0 auto;border-collapse:collapse;width:385pt"><tr style="height:7.2pt"><td style="width:146.55pt" valign="middle"> </td><td style="width:13.3pt" valign="middle"> </td><td colspan="6" style="width:206pt;border-bottom:0.5pt solid #000000" valign="middle">Year Ending December 31, </td><td style="width:19.15pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="width:146.55pt" valign="middle"></td><td style="width:13.3pt" valign="middle"> </td><td colspan="2" style="width:84.95pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="middle">2023 </td><td style="width:19.15pt" valign="middle"> </td><td style="width:13.3pt" valign="middle"> </td><td colspan="2" style="width:88.6pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="middle">2022 </td><td style="width:19.15pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:146.55pt" valign="middle">Risk-free interest rate </td><td style="background-color:#CCFFCC;width:13.3pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:15.65pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:69.3pt" valign="middle">5.18 </td><td style="background-color:#CCFFCC;width:19.15pt" valign="middle">% </td><td style="background-color:#CCFFCC;width:13.3pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:15.25pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:73.35pt" valign="middle">2.75 </td><td style="background-color:#CCFFCC;width:19.15pt" valign="middle">% </td></tr> <tr style="height:7.2pt"><td style="background-color:#FFFFFF;width:146.55pt" valign="middle">Average expected term (years) </td><td style="background-color:#FFFFFF;width:13.3pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:15.65pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:69.3pt" valign="middle">4.7 years </td><td style="background-color:#FFFFFF;width:19.15pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:13.3pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:15.25pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:73.35pt" valign="middle">4.75 years </td><td style="background-color:#FFFFFF;width:19.15pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:146.55pt" valign="middle">Expected volatility </td><td style="background-color:#CCFFCC;width:13.3pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:15.65pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:69.3pt" valign="middle">106.5 </td><td style="background-color:#CCFFCC;width:19.15pt" valign="middle">% </td><td style="background-color:#CCFFCC;width:13.3pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:15.25pt" valign="middle"> </td><td style="background-color:#CCFFCC;width:73.35pt" valign="middle">194.8 </td><td style="background-color:#CCFFCC;width:19.15pt" valign="middle">% </td></tr> <tr style="height:7.2pt"><td style="background-color:#FFFFFF;width:146.55pt" valign="middle">Expected dividend yield </td><td style="background-color:#FFFFFF;width:13.3pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:15.65pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:69.3pt" valign="middle">- </td><td style="background-color:#FFFFFF;width:19.15pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:13.3pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:15.25pt" valign="middle"> </td><td style="background-color:#FFFFFF;width:73.35pt" valign="middle">- </td><td style="background-color:#FFFFFF;width:19.15pt" valign="middle"> </td></tr> </table> 0.0518 0.0275 P4Y8M12D P4Y9M 1.065 1.948 0 0 NOTE 11 – BUSINESS SEGMENT INFORMATION As of December 31, 2023, the Company operated in two reportable segments (Corporate and Health Supplements) supported by a corporate group which conducts activities that are non-segment specific. The following table presents selected financial information about the Company’s reportable segments for the year ended December 31, 2023. <table style="border-collapse:collapse;width:464.15pt"><tr style="height:7.2pt"><td style="width:153pt" valign="bottom"> </td><td style="width:94.5pt" valign="middle">CONSOLIDATED </td><td colspan="2" style="width:138.45pt" valign="middle">HEALTH SUPPLEMENTS </td><td style="width:78.2pt" valign="middle">CORPORATE </td></tr> <tr style="height:7.2pt"><td style="width:153pt" valign="middle"></td><td style="width:94.5pt" valign="middle"></td><td style="width:92.65pt" valign="middle">BergaMet </td><td style="width:45.8pt" valign="middle">UBN </td><td style="width:78.2pt" valign="middle"></td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:153pt" valign="middle">Revenue </td><td style="background-color:#CCFFCC;width:94.5pt" valign="middle">2,485,866 </td><td style="background-color:#CCFFCC;width:92.65pt" valign="middle">2,485,866 </td><td style="background-color:#CCFFCC;width:45.8pt" valign="middle"> - </td><td style="background-color:#CCFFCC;width:78.2pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:153pt" valign="middle">Cost of Revenue </td><td style="width:94.5pt" valign="middle">813,614 </td><td style="width:92.65pt" valign="middle">813,614 </td><td style="width:45.8pt" valign="middle"> - </td><td style="width:78.2pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:153pt" valign="middle">Long-lived Assets </td><td style="background-color:#CCFFCC;width:94.5pt" valign="middle">732,030 </td><td style="background-color:#CCFFCC;width:92.65pt" valign="middle">193,260 </td><td style="background-color:#CCFFCC;width:45.8pt" valign="middle">538,771 </td><td style="background-color:#CCFFCC;width:78.2pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:153pt" valign="middle">Gain (Loss) Before Income Tax </td><td style="width:94.5pt" valign="middle"> (2,422,489) </td><td style="width:92.65pt" valign="middle"> (219,975) </td><td style="width:45.8pt" valign="middle"> (5,113) </td><td style="width:78.2pt" valign="middle"> (2,197,401) </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:153pt" valign="middle">Identifiable Assets </td><td style="background-color:#CCFFCC;width:94.5pt" valign="middle">1,676,724 </td><td style="background-color:#CCFFCC;width:92.65pt" valign="middle">1,676,724 </td><td style="background-color:#CCFFCC;width:45.8pt" valign="middle"> - </td><td style="background-color:#CCFFCC;width:78.2pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:153pt" valign="middle">Depreciation and Amortization </td><td style="width:94.5pt" valign="middle">2,195 </td><td style="width:92.65pt" valign="middle">2,195 </td><td style="width:45.8pt" valign="middle"> - </td><td style="width:78.2pt" valign="middle"> - </td></tr> </table> As of December 31, 2022, the Company operated in two reportable segments (Corporate and Health Supplements) supported by a corporate group which conducts activities that are non-segment specific. The following table presents selected financial information about the Company’s reportable segments for the year ended December 31, 2022. <table style="border-collapse:collapse;width:464.15pt"><tr style="height:7.2pt"><td style="width:153pt" valign="bottom"> </td><td style="width:90pt" valign="middle">CONSOLIDATED </td><td colspan="2" style="width:142.95pt" valign="middle">HEALTH SUPPLEMENTS </td><td style="width:78.2pt" valign="middle">CORPORATE </td></tr> <tr style="height:7.2pt"><td style="width:153pt" valign="bottom"></td><td style="width:90pt" valign="middle"></td><td style="width:97.15pt" valign="middle">BergaMet </td><td style="width:45.8pt" valign="middle">UBN </td><td style="width:78.2pt" valign="middle"></td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:153pt" valign="middle">Revenue </td><td style="background-color:#CCFFCC;width:90pt" valign="middle">2,251,469 </td><td style="background-color:#CCFFCC;width:97.15pt" valign="middle">2,251,469 </td><td style="background-color:#CCFFCC;width:45.8pt" valign="middle"> - </td><td style="background-color:#CCFFCC;width:78.2pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:153pt" valign="middle">Less Selling Fees </td><td style="width:90pt" valign="middle"> </td><td style="width:97.15pt" valign="middle"> </td><td style="width:45.8pt" valign="middle"> </td><td style="width:78.2pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:153pt" valign="middle">Cost of Revenue </td><td style="background-color:#CCFFCC;width:90pt" valign="middle">783,141 </td><td style="background-color:#CCFFCC;width:97.15pt" valign="middle">783,141 </td><td style="background-color:#CCFFCC;width:45.8pt" valign="middle"> - </td><td style="background-color:#CCFFCC;width:78.2pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:153pt" valign="middle">Long-lived Assets </td><td style="width:90pt" valign="middle">732,030 </td><td style="width:97.15pt" valign="middle">193,260 </td><td style="width:45.8pt" valign="middle">538,771 </td><td style="width:78.2pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:153pt" valign="middle">Gain (Loss) Before Income Tax </td><td style="background-color:#CCFFCC;width:90pt" valign="middle"> (983,121) </td><td style="background-color:#CCFFCC;width:97.15pt" valign="middle"> (164,625) </td><td style="background-color:#CCFFCC;width:45.8pt" valign="middle"> (358) </td><td style="background-color:#CCFFCC;width:78.2pt" valign="middle"> (818,138) </td></tr> <tr style="height:7.2pt"><td style="width:153pt" valign="middle">Identifiable Assets </td><td style="width:90pt" valign="middle">1,819,128 </td><td style="width:97.15pt" valign="middle">1,819,128 </td><td style="width:45.8pt" valign="middle"> - </td><td style="width:78.2pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:153pt" valign="middle">Depreciation and Amortization </td><td style="background-color:#CCFFCC;width:90pt" valign="middle">878 </td><td style="background-color:#CCFFCC;width:97.15pt" valign="middle">878 </td><td style="background-color:#CCFFCC;width:45.8pt" valign="middle"> - </td><td style="background-color:#CCFFCC;width:78.2pt" valign="middle"> - </td></tr> </table> Currently, all of our customers are located in the United States of American and Canada. Our revenues to our customers are not material to our overall total sales. Our largest customers, Natural Grocers and Emerson Ecologics, LLC, account for less than 1% of our total sales in the year ending 2023 and 2022. <table style="border-collapse:collapse;width:464.15pt"><tr style="height:7.2pt"><td style="width:153pt" valign="bottom"> </td><td style="width:94.5pt" valign="middle">CONSOLIDATED </td><td colspan="2" style="width:138.45pt" valign="middle">HEALTH SUPPLEMENTS </td><td style="width:78.2pt" valign="middle">CORPORATE </td></tr> <tr style="height:7.2pt"><td style="width:153pt" valign="middle"></td><td style="width:94.5pt" valign="middle"></td><td style="width:92.65pt" valign="middle">BergaMet </td><td style="width:45.8pt" valign="middle">UBN </td><td style="width:78.2pt" valign="middle"></td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:153pt" valign="middle">Revenue </td><td style="background-color:#CCFFCC;width:94.5pt" valign="middle">2,485,866 </td><td style="background-color:#CCFFCC;width:92.65pt" valign="middle">2,485,866 </td><td style="background-color:#CCFFCC;width:45.8pt" valign="middle"> - </td><td style="background-color:#CCFFCC;width:78.2pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:153pt" valign="middle">Cost of Revenue </td><td style="width:94.5pt" valign="middle">813,614 </td><td style="width:92.65pt" valign="middle">813,614 </td><td style="width:45.8pt" valign="middle"> - </td><td style="width:78.2pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:153pt" valign="middle">Long-lived Assets </td><td style="background-color:#CCFFCC;width:94.5pt" valign="middle">732,030 </td><td style="background-color:#CCFFCC;width:92.65pt" valign="middle">193,260 </td><td style="background-color:#CCFFCC;width:45.8pt" valign="middle">538,771 </td><td style="background-color:#CCFFCC;width:78.2pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:153pt" valign="middle">Gain (Loss) Before Income Tax </td><td style="width:94.5pt" valign="middle"> (2,422,489) </td><td style="width:92.65pt" valign="middle"> (219,975) </td><td style="width:45.8pt" valign="middle"> (5,113) </td><td style="width:78.2pt" valign="middle"> (2,197,401) </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:153pt" valign="middle">Identifiable Assets </td><td style="background-color:#CCFFCC;width:94.5pt" valign="middle">1,676,724 </td><td style="background-color:#CCFFCC;width:92.65pt" valign="middle">1,676,724 </td><td style="background-color:#CCFFCC;width:45.8pt" valign="middle"> - </td><td style="background-color:#CCFFCC;width:78.2pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:153pt" valign="middle">Depreciation and Amortization </td><td style="width:94.5pt" valign="middle">2,195 </td><td style="width:92.65pt" valign="middle">2,195 </td><td style="width:45.8pt" valign="middle"> - </td><td style="width:78.2pt" valign="middle"> - </td></tr> </table> 2485866 2485866 0 0 813614 813614 0 0 732030 193260 538771 0 -2422489 -219975 -5113 -2197401 1676724 1676724 0 0 2195 2195 0 0 <table style="border-collapse:collapse;width:464.15pt"><tr style="height:7.2pt"><td style="width:153pt" valign="bottom"> </td><td style="width:90pt" valign="middle">CONSOLIDATED </td><td colspan="2" style="width:142.95pt" valign="middle">HEALTH SUPPLEMENTS </td><td style="width:78.2pt" valign="middle">CORPORATE </td></tr> <tr style="height:7.2pt"><td style="width:153pt" valign="bottom"></td><td style="width:90pt" valign="middle"></td><td style="width:97.15pt" valign="middle">BergaMet </td><td style="width:45.8pt" valign="middle">UBN </td><td style="width:78.2pt" valign="middle"></td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:153pt" valign="middle">Revenue </td><td style="background-color:#CCFFCC;width:90pt" valign="middle">2,251,469 </td><td style="background-color:#CCFFCC;width:97.15pt" valign="middle">2,251,469 </td><td style="background-color:#CCFFCC;width:45.8pt" valign="middle"> - </td><td style="background-color:#CCFFCC;width:78.2pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:153pt" valign="middle">Less Selling Fees </td><td style="width:90pt" valign="middle"> </td><td style="width:97.15pt" valign="middle"> </td><td style="width:45.8pt" valign="middle"> </td><td style="width:78.2pt" valign="middle"> </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:153pt" valign="middle">Cost of Revenue </td><td style="background-color:#CCFFCC;width:90pt" valign="middle">783,141 </td><td style="background-color:#CCFFCC;width:97.15pt" valign="middle">783,141 </td><td style="background-color:#CCFFCC;width:45.8pt" valign="middle"> - </td><td style="background-color:#CCFFCC;width:78.2pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="width:153pt" valign="middle">Long-lived Assets </td><td style="width:90pt" valign="middle">732,030 </td><td style="width:97.15pt" valign="middle">193,260 </td><td style="width:45.8pt" valign="middle">538,771 </td><td style="width:78.2pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:153pt" valign="middle">Gain (Loss) Before Income Tax </td><td style="background-color:#CCFFCC;width:90pt" valign="middle"> (983,121) </td><td style="background-color:#CCFFCC;width:97.15pt" valign="middle"> (164,625) </td><td style="background-color:#CCFFCC;width:45.8pt" valign="middle"> (358) </td><td style="background-color:#CCFFCC;width:78.2pt" valign="middle"> (818,138) </td></tr> <tr style="height:7.2pt"><td style="width:153pt" valign="middle">Identifiable Assets </td><td style="width:90pt" valign="middle">1,819,128 </td><td style="width:97.15pt" valign="middle">1,819,128 </td><td style="width:45.8pt" valign="middle"> - </td><td style="width:78.2pt" valign="middle"> - </td></tr> <tr style="height:7.2pt"><td style="background-color:#CCFFCC;width:153pt" valign="middle">Depreciation and Amortization </td><td style="background-color:#CCFFCC;width:90pt" valign="middle">878 </td><td style="background-color:#CCFFCC;width:97.15pt" valign="middle">878 </td><td style="background-color:#CCFFCC;width:45.8pt" valign="middle"> - </td><td style="background-color:#CCFFCC;width:78.2pt" valign="middle"> - </td></tr> </table> 2251469 2251469 0 0 783141 783141 0 0 732030 193260 538771 0 -983121 -164625 -358 -818138 1819128 1819128 0 0 878 878 0 0 NOTE 12 – SUBSEQUENT EVENTS The key terms for the 15,975,000 RSU are as follows: the effective grant date for all RSU’s is April 28, 2023. Each of the RSU’s will have a purchase price of $0.01 (prior to the reverse split). 8,900,000 of the RSU’s had an expiration date of June 30, 2023 and are all immediately vested once granted. All of the 8,900,000 shares of common stock were issued on July 5, 2023. 7,075,000 of the RSU’s will have an expiration date of March 31, 2024 and will vest on January 1, 2024. Any of the RSU will be forfeited without any payment or consideration by the holder. The RSU’s comply with Section 409A. The Company has verbally agreed with the borrower of unsecured debt H to extend the due date to July 1, 2024. The definitive agreement to be acquired for Hyperion, and its digital marketing affiliate, Online Publishing and Marketing expired on the anniversary date of the agreement. When new funding is acquired, further discussions will occur. The Company evaluated its December 31, 2023 financial statements for subsequent events through March 11, 2024, the date the financial statements were available to be issued.

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2023	Apr. 01, 2024	Jun. 30, 2023
Details
Registrant CIK	0001630176
Fiscal Year End	--12-31
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	000-55572
Entity Registrant Name	Healthy Extracts Inc.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	47-2594704
Entity Address, Address Line One	7375 Commercial Way
Entity Address, Address Line Two	Suite 125
Entity Address, City or Town	Henderson
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89011
City Area Code	720
Local Phone Number	463-1004
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Document Financial Statement Error Correction	false
Entity Shell Company	false
Entity Public Float			$ 18,465,134
Entity Common Stock, Shares Outstanding		2,963,906
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Auditor Name	BF Borgers CPA PC
Auditor Firm ID	5041
Auditor Location	Lakewood, CO

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash	$ 19,441	$ 65,651
Accounts receivable	30,440	105,794
Inventory, net	1,626,283	1,819,128
Offering costs	151,931	0
Prepaid acquisition costs	0	53,015
Right of use asset, net	71,583	0
Total current assets	1,899,678	2,043,587
Fixed assets	3,306	5,501
Patents/Trademarks	521,881	521,881
Deposit	16,890	16,890
Goodwill	193,260	193,260
Total other assets	735,336	737,531
TOTAL ASSETS	2,635,014	2,781,118
LIABILITIES
Accounts payable	116,842	91,316
Accrued liabilities	215,069	94,554
Lease liabilities - current	65,229	0
Lease liabilities - long-term	9,222	0
Notes payable	361,093	275,370
Notes payable - related party	83,366	866
Convertible debt, net of discount	608,601	317,284
Accrued interest payable	64,386	21,387
Accrued interest payable - related party	2,465	0
Derivative liabilities	154,150	102,011
Total current and total liabilities	1,680,424	902,788
STOCKHOLDERS' EQUITY
Preferred stock, $0.001 par value, 75,000,000 shares authorized, none and none shares issued and outstanding, respectively	0	0
Common stock, $0.001 par value, 50,000,000 shares authorized, 2,954,104 shares issued and outstanding as of December 31, 2023, and 2,876,437 shares issued and outstanding as of December 31, 2022, respectively	354,492	345,172
Additional paid-in capital	18,999,770	17,459,899
Accumulated deficit	(18,399,673)	(15,926,742)
Total stockholders' equity	954,590	1,878,330
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 2,635,014	$ 2,781,118

CONSOLIDATED BALANCE SHEETS - Parenthetical - $ / shares	Dec. 31, 2023	Dec. 31, 2022
CONSOLIDATED BALANCE SHEETS
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	75,000,000	75,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	50,000,000	50,000,000
Common Stock, Shares, Issued	2,954,104	2,876,437
Common Stock, Shares, Outstanding	2,954,104	2,876,437

CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
REVENUE
Revenue	$ 2,485,866	$ 2,251,469
Net revenue	2,485,866	2,251,469
COST OF REVENUE
Cost of goods sold	864,055	879,951
Total cost of revenue	864,055	879,951
GROSS PROFIT	1,621,810	1,371,517
OPERATING EXPENSES
Direct cost of revenue	0	0
General and administrative	3,865,654	2,283,107
Impairment of assets	0	0
Total operating expenses	3,865,654	2,283,107
OTHER INCOME (EXPENSE)
Interest expense, net of interest income	(176,948)	(64,690)
Change in fair value on derivative	(52,140)	(9,484)
Gain on sale of asset	0	2,643
Total other income (expense)	(229,088)	(71,531)
Net income/(loss) before income tax provision	(2,472,931)	(983,121)
NET INCOME/(LOSS)	$ (2,472,931)	$ (983,121)
Income/(Loss) per share - basic and diluted	$ (0.85)	$ (0.34)
Weighted average number of shares outstanding - basic and diluted	2,915,410	2,854,290

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Common Stock	Additional Paid-in Capital	Retained Earnings	Total
Equity, Attributable to Parent, Beginning Balance at Dec. 31, 2021	$ 338,384	$ 17,075,974	$ (14,943,620)	$ 2,470,738
Shares, Outstanding, Beginning Balance at Dec. 31, 2021	2,819,868
Cancelation of common stock for debt	$ (800)	(53,013)	0	(53,813)
Cancelation of common stock for debt	(800,267)
Issuance of common stock for cash	$ 508	24,888	0	25,396
Issuance of common stock for cash	507,917
Issuance of common stock for services	$ 6,740	395,360	0	402,100
Issuance of common stock for services	6,740,000
Issuance of common stock - Note Conversion	$ 341	16,690	0	17,031
Issuance of common stock-Note Conversion, shares	340,621
Net Income/(Loss)	$ 0	0	(983,121)	(983,121)
Equity, Attributable to Parent, Ending Balance at Dec. 31, 2022	$ 345,173	17,459,899	(15,926,741)	1,878,330
Shares, Outstanding, Ending Balance at Dec. 31, 2022	80,068
Cancelation of common stock for debt	(200,267)
Issuance of common stock for cash	507,917
Issuance of common stock for services	$ 320	15,680	0	16,000
Issuance of common stock-Note Conversion, shares	340,621
Net Income/(Loss)	$ 0	0	(2,472,931)	(2,472,931)
Equity, Attributable to Parent, Ending Balance at Dec. 31, 2023	$ 354,492	18,999,770	(18,399,673)	954,590
Shares, Outstanding, Ending Balance at Dec. 31, 2023	2,954,104
Issuance of common stock for services	320,000
Fair value of restricted stock units	$ 0	298,153	0	298,153
Fair value of options and warrants issued	0	785,038	0	785,038
Issuance of common stock-restricted stock units issued	$ 9,000	$ 441,000	$ 0	$ 450,000
Issuance of common stock-restricted stock units issued	9,000,000

CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)	12 Months Ended		108 Months Ended
CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023
Cash Flows from Operating Activities
Net Income/(Loss)	$ (2,472,931)	$ (983,121)	$ 18,336,268
Adjustments to reconcile net loss to net cash
Depreciation and amortization	2,195	878
Warrants issued for services	1,639,191	402,100
Change in fair value on derivative liability	52,140	9,484
Changes in operating assets and liabilities
Accounts receivable	75,353	27,547
Inventory	192,845	138,838
Offering Costs	(151,931)	0
Cost in acquisition of Hyperion/OP&M	53,015	(53,015)
Right of use asset, net	(71,583)	0
Deposits	0	(16,890)
Accounts payable	25,526	54,048
Accrued liabilities	120,515	35,291
Accrued interest payable	42,999	8,337
Accrued interest payable - related party	2,465	(14,118)
Lease liability - current	65,229	0
Lease liability - long-term	9,222	0
Net Cash used in Operating Activities	(415,749)	(390,621)
Cash Flows from Investing Activities
Purchase of fixed assets	0	(7,987)
Gain on sale of asset	0	2,643
Cash flows provided by (used in) Investing Activities	0	(5,344)
Cash Flows from Financing Activities
Proceeds from issuance of common stock	(90,000)	(11,386)
Proceeds from issuance of convertible debt	362,963	463,630
Payments for repayment of convertible debt	(110,535)	(318,095)
Proceeds from issuance of noted payable	713,283	275,370
Payments for repayment of notes payable	(657,560)	0
Proceeds from issuance of noted payable - related party	107,500	0
Payments for repayment of noted payable - related party	(25,000)	(170,000)
Loan origination fees	68,888	0
Net Cash provided by Financing Activities	369,539	239,518
Increase (decrease) in cash	(46,210)	(156,447)
Cash at beginning of period	65,651	222,098
Cash at end of period	$ 19,441	$ 65,651	$ 19,441

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory: Schedule of Inventory (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Details
Raw Materials	$ 2,998,683	$ 3,398,655
Finished Goods	225,567	310,600
Work in process	13,290	24,764
Total inventory	3,237,540	3,734,019
Inventory allowance	(1,611,257)	(1,914,891)
Inventory, net	$ 1,626,283	$ 1,819,128

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Indefinite-Lived Intangible Assets (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Patents/Trademarks	$ 521,881	$ 521,881
Patents
Patents/Trademarks	$ 315,604	$ 315,604

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Inputs, Level 3
Derivative liabilities	$ 154,150	$ 102,011	$ 92,527
Increase (Decrease) in Derivative Liabilities	154,150	102,011
Derivative liabilities	154,150	102,011	$ 92,527
Increase (Decrease) in Derivative Liabilities	154,150	102,011
Convertible Debt, Issued	145,067	264,952
Derivative liabilities debt premium	29,167	(43,269)
Convertible Debt, Change In Fair Value Recognized In Operations	(83,923)	(212,199)
Convertible Debt, Converted	$ (38,172)	$ 0

NOTE 3 - GOING CONCERN (Details) - USD ($)	12 Months Ended		108 Months Ended
NOTE 3 - GOING CONCERN (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023
Details
Net Income/(Loss)	$ (2,472,931)	$ (983,121)	$ 18,336,268

NOTE 4 - RELATED PARTY (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Details
Salary and Wage, Excluding Cost of Good and Service Sold	$ 0	$ 1,000

NOTE 4 - RELATED PARTY: Schedule of Debt (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Notes payable	$ 361,093	$ 275,370
Related Party
Original Principal Amount	83,366
Due to Related Parties	83,366	866
Notes payable	$ 83,366	866
Unsecured Debt A \| Related Party
Debt Instrument, Interest Rate, Effective Percentage	0.00%
Original Principal Amount	$ 866
Due to Related Parties	$ 866	866
Unsecured Debt H \| Related Party
Debt Instrument, Interest Rate, Effective Percentage	10.00%
Original Principal Amount	$ 82,500
Due to Related Parties	$ 82,500	$ 866

NOTE 5 - RIGHT OF USE ASSETS AND LEASE LIABILITIES (Details)	Dec. 31, 2023 USD ($)
Details
Average monthly base rent, first 12 months	$ 5,333
Average monthly base rent, next 24 months	$ 5,694

NOTE 8 - DERIVATIVE LIABILITY (Details) - USD ($)	12 Months Ended
NOTE 8 - DERIVATIVE LIABILITY (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Details
Gain (Loss) on Derivative Liabilities	$ 83,920	$ 212,199
Gain (Loss) on Extinguishment of Debt	$ 38,172

NOTE 9 - INCOME TAXES: Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2023	Sep. 30, 2022
Details
Federal net operating loss carryforwards	$ 678,297	$ 166,169
Valuation allowance	(678,297)	(166,169)
Net long-term deferred tax assets	$ 0	$ 0

NOTE 10 - STOCKHOLDERS' EQUITY (Details) - USD ($)	3 Months Ended		12 Months Ended
NOTE 10 - STOCKHOLDERS' EQUITY (Details) - USD ($)	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Apr. 30, 2018	Jan. 31, 2018	Oct. 16, 2017	Feb. 28, 2017
Preferred Stock, Shares Authorized	75,000,000		75,000,000	75,000,000				75,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.001		$ 0.001	$ 0.001
Common Stock, Shares Authorized	50,000,000		50,000,000	50,000,000	2,500,000,000	1,000,000,000		500,000,000
Stockholders' Equity, Reverse Stock Split			The Company effectuated a reverse stock split of 120-for-1 as of December 29, 2023
Preferred Stock, Shares Outstanding	0		0	0
Warrants Issued				61,846
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	195,180		195,180
Warrants Fully Vested	195,180		195,180
General and administrative			$ 3,865,654	$ 2,283,107
Unvested compensation related to issuances of restricted stock units fair value	$ 423,910		$ 423,910
Restricted Stock Units
General and administrative	$ 445,000
Common Stock
Issuance of common stock for services		320,000	320,000
StockIssued During Period Shares Issued For Services4			340,000	340,000
Issuance of common stock-Note Conversion, shares			340,621	340,621
StockIssued During Period Shares Issued For Services3			4,400,000
Issuance of common stock for cash			507,917	507,917
Cancelation of common stock for debt			(200,267)	(800,267)
Cancelation Of Common Stock For Deb tShares2			(600,000)
StockIssued During Period Shares Issued For Services2				16,667
StockIssued During Period Shares Issued For Services5				6,400,000
Preferred Stock
Issuance of common stock-Share Conversion Agreements			15,592,986
Issuance of common stock-Share Conversion Agreements, Retired			467,057
Series A Preferred Stock
Preferred Stock, Shares Authorized							1,333,334	25,000,000

NOTE 10 - STOCKHOLDERS' EQUITY: Schedule of Share-based Compensation, Stock Options, Activity (Details)			12 Months Ended
	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number \| shares	195,180		195,180
Warrants
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number \| shares	195,180	133,333	195,180
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 6.83	$ 7.22	$ 6.83
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	1 year 2 months 1 day	2 years 2 months 1 day
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value \| $	$ 0	$ 0	$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures \| shares			61,846
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 6.00
Weighted Average Remaining Contractual Life (Years)			1.11
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value	$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number \| shares	195,180		195,180
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 6.83		$ 6.83
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value \| $	$ 0		$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number \| shares	195,180		195,180
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 6.83		$ 6.83
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value \| $	$ 0		$ 0
Omnibus Stock Grant and Option Plan
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number \| shares	38,333	32,083	38,333
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 6.00	$ 6.00	$ 6.00
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	2 years 4 months 2 days	2 years 1 month 17 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value \| $	$ 46,000	$ 38,500	$ 46,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures \| shares			6,250
Weighted Average Remaining Contractual Life (Years)	3.42
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value	$ 7,500
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number \| shares	38,333		38,333
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 6.00		$ 6.00
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value \| $	$ 46,000		$ 46,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number \| shares	38,333		38,333
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 6.00		$ 6.00
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value \| $	$ 46,000		$ 46,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 6.00